"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05003960","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism",,"Recruiting","No Results Available","Autism","Biological: AlloRx","Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-8-02","September 2021","September 2025","September 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003960"
2,"NCT02649959","An Open Label Study of CM-AT for the Treatment of Children With Autism",,"Active, not recruiting","No Results Available","Autism","Drug: CM-AT","Aberrant Behavioral Checklist: Subscale of Irritability / Agitation (ABC-I) at fecal chymotrypsin (FCT) levels less than or equal to 12.6|Aberrant Behavior Checklist: Subscale of Lethargy / Social Withdrawal (ABC-L) at fecal chymotrypsin (FCT) levels less than or equal to 12.6","Curemark","All","3 Years to 17 Years   (Child)","Phase 3","405","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00104/Open Label-Autism","October 2015","December 2021","June 2022","January 8, 2016",,"January 26, 2021","Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Advent Health -Lake Mary Pediatrics, Orange City, Florida, United States|A.P.G. Research, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Newburgh, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Barbara Enright, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Cneter, Autism & Obsessive Compulsive Spectrum Program, Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic Autism Center, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt Universtiy Med.Center-Treatment&Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston-Behavioral & Biomedical Sciences, Houston, Texas, United States|Focus Center of Clinical Research, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02649959"
3,"NCT02410902","A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)",,"Completed","No Results Available","Autism","Drug: CM-AT|Drug: PLACEBO","Primary outcome measurements to determine efficacy of treatment with CM-AT versus placebo for changes in the Aberrant Behavior Checklist subscale for Irritability / Agitation (ABC-I) between baseline and Week 12/Termination visit|Secondary Outcome measurements of changes in the Aberrant Behavior Checklist Checklist subscale for Lethargy / Social Withdrawal (ABC-L) between baseline and Week 12/Termination visit","Curemark","All","3 Years to 8 Years   (Child)","Phase 3","335","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00103","May 2015","December 22, 2017","December 22, 2017","April 8, 2015",,"April 30, 2021","Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe RESEARCH CENTERS, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Florida Hospital Medical Group-Lake Mary Pediatrics, Orange City, Florida, United States|Kaley Kildahl, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Evansville, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Children'S Specialized Hospital, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Center, Autism & Obsessive Compulsive Spectrum Prog., Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic, Center For Autism Research, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt University Med.Center -Treatment & Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston Dept. of Psychiatry and Behavioral Sciences, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02410902"
4,"NCT02998684","Learning Enhancement Through Neurostimulation in Autism","LENS","Completed","Has Results","Autism","Device: Active Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation|Behavioral: PEERS Social Skills Training","Test of Adolescent Social Skills Knowledge (TASSK)|Social Responsiveness Scale (SRS)","Medical University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Not Applicable","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00056912","July 2016","July 2017","July 2017","December 20, 2016","September 4, 2018","September 4, 2018","Medical Univeristy of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02998684/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02998684"
5,"NCT02195401","The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism",,"Completed","No Results Available","Autism","Other: Cleanroom","Change in blood and hair elemental concentrations|Change of xenobiotic chemical concentrations","The Children's Institute|Duquesne University|Health Resources and Services Administration (HRSA)","All","3 Years to 21 Years   (Child, Adult)",,"10","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-131","May 2010","October 2010","October 2010","July 21, 2014",,"July 21, 2014","The Children's Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02195401"
6,"NCT03982290","Psychophysiological Effects of Lactobacillus Plantarum PS128 in Preschool Children With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism","Other: Probiotic, Lactobacillus plantarum PS128|Other: Placebo, microcrystalline cellulose","Changes from baseline of anxiety subscale in Children's Behavior Checklist (CBCL)/Achenbach System of Empirically Based Assessment (ASEBA) at week 8 and week 16|Changes from hyperactivity subscale of Attention-Deficit/Hyperactivity Disorder Test (ADHDT) at week 8 and week 16|Gastrointestinal symptoms recorded by using GI Severity Index (6-GSI) at week 8 and week 16|Change of total scores at week 8 and week 16 from baseline of Changes of Childhood Asperger Syndrome Test (CAST)|Change of total scores at week 8 and week 16 from baseline of Penn Interactive Peer Play Scale, (PIPPS)|Change of total scores at week 8 and week 16 from baseline of Social Interaction Assessment Scale|Comparison of Microbiota composition between week 8 and baseline","Mackay Memorial Hospital","All","30 Months to 7 Years   (Child)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17MMHIS193e","October 1, 2018","December 2019","December 2020","June 11, 2019",,"June 11, 2019","Department of Pediatric Neurology, MacKay Children's Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03982290"
7,"NCT01724047","Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools","AIR-B II","Completed","No Results Available","Autism","Behavioral: Playground Intervention|Behavioral: STAT Intervention","Playground Intervention: Playground Peer Engagement|Playground Intervention: Social Network Salience|STAT Intervention: Teacher Behaviors and Student's Engagement in the Classrooms|Playground Intervention: Teachers Ratings of Intervention Implementation|Playground Intervention: Teacher's Perceptions of Intervention|STAT Intervention: Teacher Nominated Target Behaviors|Playground Intervention Teacher's Perceptions of Intervention|Playground Intervention: Coach Ratings of Aide Implementation|Playground Intervention: Observer Ratings of Aide Implementation|Playground Intervention: Observer Ratings of Aides Implementation|STAT Intervention: Coach Rated Teacher Implementation|STAT Intervention: Teacher Ratings of Implementation|Playground Intervention: Aides Ratings of Effectiveness of Intervention|STAT Intervention: Teachers Ratings of Effectiveness of Intervention","Health Resources and Services Administration (HRSA)|University of Rochester|University of Pennsylvania","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","250","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","12-001120","November 2012","June 2014","June 2014","November 9, 2012",,"September 25, 2014","UCLA Semel Institute, Los Angeles, California, United States|University of Rochester Medical Center, Rochester, New York, United States|UPENN Map Center for Mental Health Policy and Services Research, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01724047"
8,"NCT01098383","Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders",,"Unknown status","No Results Available","Autism","Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements|Drug: Indistinguishable placebo tablets, matching both donepezil and choline","Core autistic symptoms (ATEC)|Side effects and adverse events questionnaire|Linguistic performance (CELF-4)|Adaptive functioning (Vineland-II)|Comorbid behaviors (CSI-4 questionnaire)|Executive functions (BRIEF questionnaire)","Sheba Medical Center|The Israeli Society of Clinical Pediatrics (HIPAK)","All","10 Years to 18 Years   (Child, Adult)","Phase 4","84","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHEBA-09-7151-LG-CTIL","March 2010","December 2017","December 2017","April 2, 2010",,"October 14, 2016","Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT01098383"
9,"NCT01836562","A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism","BMCA","Unknown status","No Results Available","Autism","Biological: STEM CELL THERAPY","Improvement in childhood autism rating scale|Improvement in perfusion of brain with PET scan report","Chaitanya Hospital, Pune","All","3 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00105","September 2014","June 2016","June 2016","April 22, 2013",,"September 17, 2014","Chaitanya Hospital, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01836562"
10,"NCT03723876","Basic Body Awareness Therapy for Persons With Autism",,"Enrolling by invitation","No Results Available","Autism","Behavioral: Body awareness therapy","Change of experienced health problem from Numeric rating scale|Change of results of Body Awareness Scale Movement Quality and Experiences, BAS MQ-E","Lund University|Vastra Gotaland Region","All","15 Years to 30 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ingrid Bertilsson","May 1, 2018","May 2022","May 2022","October 30, 2018",,"February 8, 2021","Vuxenhabiliteringen, Vaxjo, Kronoberg, Sweden|Habiliteringen Vastra Gotalandsregionen, Skovde, Vastra Gotaland, Sweden",,"https://ClinicalTrials.gov/show/NCT03723876"
11,"NCT00881452","A Trial of CM-AT in Children With Autism","CM-AT","Completed","No Results Available","Autism","Drug: CM-AT|Drug: Placebo","Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism","Curemark","All","3 Years to 8 Years   (Child)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00101","May 2009","June 2011","September 2011","April 15, 2009",,"April 19, 2018","Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University Health Science Center, Shreveport, Louisiana, United States|Saint Peters University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma University Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Westside Medical, Clinton, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00881452"
12,"NCT00912691","A Trial of CM-AT in Children With Autism- Open Label Extension Study","CM-AT","Completed","No Results Available","Autism","Drug: CM-AT","Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism","Curemark","All","9 Years to 12 Years   (Child)","Phase 3","165","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00102/Autism","January 2010","February 2016","February 2016","June 3, 2009",,"March 1, 2019","Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University, Shreveport, Louisiana, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, Manhattan, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma State University, Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research Center, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00912691"
13,"NCT03786744","Allogenic Cord Blood Transfusion in Patients With Autism",,"Completed","Has Results","Autism Spectrum Disorder|Autism","Biological: ASD CB-MNC injection.|Other: Standard therapy.","A Number of Participants With Non-serious and Serious Adverse Events 24 Hrs Post-transfusion|Autism Treatment Evaluation Checklist (ATEC).|Cytokine Analysis.|Immune Status as Determined by Percentage of Peripheral Blood Cells|Immune Status as Determined by Absolute Cell Count of Peripheral Blood Cells","State-Financed Health Facility ""Samara Regional Medical Center Dinasty""","All","3 Years to 15 Years   (Child)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12112018","October 12, 2018","October 12, 2019","December 12, 2019","December 26, 2018","November 19, 2020","November 19, 2020","Medical Centre Dinasty, Samara, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03786744/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03786744"
14,"NCT02807766","Brain Plasticity of Autism in Response to Early Behavioral Intervention: A Multimodal MRI Study",,"Recruiting","No Results Available","Autism","Behavioral: Behavior modification|Behavioral: Behavior modification and sensory integration training|Behavioral: Behavior modification and applied behavioral analysis|Behavioral: Behavior modification and TEACCH","Brain structural and functional change under behavioral intervention at 6 months in children with autism|Prediction model of intervention effect based on multimodal multivariate pattern analysis methods","University of Electronic Science and Technology of China","All","2 Years to 8 Years   (Child)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","UESTC-chenhuafulab-001","May 2016","December 2022","December 2022","June 21, 2016",,"January 18, 2020","Department of Children's and Adolescent Health, Public Health College of Harbin Medical University, Harbin, Heilongjiang, China|Center for Information in BioMedicine, Key laboratory for NeuroInformation of Ministry of Education, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT02807766"
15,"NCT03368001","Investigating Social Competence in Youth With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: SENSE Theatre|Behavioral: Tackling Teenage Together","NEPSY Memory for Faces Delayed|Incidental Face Memory (IFM) Event-Related Potential (ERP) task|Social Responsiveness Scale (SRS)|Adaptive Behavior Scales for Children (ABAS)|Contextual Assessment of Social Skills (CASS)|Child Behavior Checklist (CBCL)","Vanderbilt University Medical Center","All","8 Years to 16 Years   (Child)","Not Applicable","405","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","171153","November 22, 2017","January 2023","January 2023","December 11, 2017",,"August 30, 2021","University of Alabama, Tuscaloosa, Alabama, United States|Stony Brook University, Stony Brook, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03368001/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03368001"
16,"NCT03152383","Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism",,"Completed","No Results Available","Autism","Behavioral: Training trials|Behavioral: Progressive Ratio Session|Behavioral: Re-test|Behavioral: Pairing Protocol","Breakpoint achieved for each stimulus|Change in breakpoints","Emory University|National Institute of Mental Health (NIMH)","All","2 Years to 6 Years   (Child)","Not Applicable","64","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00056563|R21MH108873","June 22, 2012","December 31, 2020","December 31, 2020","May 15, 2017",,"March 1, 2021","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03152383"
17,"NCT04533607","Modular Approach for Autism Programs in Schools","MAAPS","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: MAAPS","Change in score for Developmental Disability-Clinical Global Assessment Scale (DD-CGAS)|Change in rating for Teacher Nominated Target Problems (TNTP)|Change in score for Social Skills Improvement System (SSIS)|Change in score for Children's Communication Checklist, Second Edition (CCC-2)|Change in score for Children's Yale-Brown Obsessive-Compulsive Scales-ASD (CYBOCS-ASD)|Change in engaged time measured by Academic Engaged Time (AET)|Change in score for Adaptive Behavior Assessment System, Third Edition (ABAS-3)|Usage Rating Profile-Intervention, Revised (URP-IR)","May Institute|University of South Florida|University of Rochester","All","5 Years to 12 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R324A200154","November 4, 2020","June 2024","June 2024","August 31, 2020",,"February 24, 2021","University of South Florida, Tampa, Florida, United States|May Institute, Randolph, Massachusetts, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT04533607"
18,"NCT01911442","Lurasidone Pediatric Autism Study",,"Completed","Has Results","Autism","Drug: Lurasidone 20 mg daily|Drug: Lurasidone|Drug: Placebo","Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6|Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)|Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)|Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6|Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.","Sunovion","All","6 Years to 17 Years   (Child)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1050325","August 2013","November 2014","November 2014","July 30, 2013","February 25, 2016","February 25, 2016","Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Newport Beach Clinical Research Associates, Newport Beach, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Palm Springs Research Institute Inc, Hialeah, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida, Tampa, Florida, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Capstone Clinical Research, Inc., Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|NeuroScientific Insights, Rockville, Maryland, United States|Neurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Childrens Specialized Hospital, Toms River, New Jersey, United States|Montefiore Medical Center PRIME, Bronx, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Chapel Hill Neurology, Chapel Hill, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Cyn3rgy Research & Development, Gresham, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Segal Institute for Clinical Research, Charleston, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|CRI Lifetree, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic, Roanake, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01911442"
19,"NCT01388179","Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.",,"Terminated","No Results Available","Autism","Device: Transcranial Magnetic Stimulation","CGI-I(clinical global impression-I) as a measure for social functioning|ASRS (Adult ADHD Self Report Scale) as a measure for social awareness and social motivation|Facial recognition test as a measure for preference to faces vs. objects|PLS-4(Preschool Language Scale - 4 ) as a measure for language impairment.|BASC (Behavior Assessment System for Children) as a measure for anxiety|ABC (Autism Behavior Checklist)as a measure for repetitive behaviors","Brainsway|Hadassah Medical Organization","All","10 Years to 18 Years   (Child, Adult)","Phase 2","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TMS-AUTISM","January 23, 2013","December 31, 2016","December 31, 2016","July 6, 2011",,"April 17, 2018","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01388179"
20,"NCT04631432","Choice Switching and Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Diagnostic Test: Pre-screening|Behavioral: Task session","Mean run size|Advantageous selections","Technion, Israel Institute of Technology","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","109171|Technion institute 109171","January 1, 2021","October 2021","October 2021","November 17, 2020",,"September 9, 2021","Technion, Israel Institute of Technology, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04631432"
21,"NCT03467464","The Efficacy of EMDR in Youngsters With Autism","EYE-catcher","Unknown status","No Results Available","Autism Spectrum Disorder","Other: Eye Movement Desensitization and Reprocessing (EMDR)","Change in autism symptoms|Change in disease severity|Change in experienced stress|Change in general well-being|Change in working memory capacity","Karakter Kinder- en Jeugdpsychiatrie|Fonds Psychische Gezondheid","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL6002609116","December 1, 2017","December 2018","December 2018","March 16, 2018",,"March 16, 2018","Karakter kinder- en jeugdpsychiatrie, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03467464"
22,"NCT03413241","Pain in Autism Spectrum Disorder",,"Recruiting","No Results Available","High-functioning Autism",,"Pain processing and modulation mechanisms underlying the pain sensitivity profile of adults with HF-ASD","Rambam Health Care Campus","All","18 Years to 45 Years   (Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ASD 0496-17-RMB","May 6, 2018","January 1, 2022","October 1, 2022","January 29, 2018",,"May 20, 2021","The lab of clinical neurophysiology, the faculty of medicine, Technion and Rambam Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT03413241"
23,"NCT04861740","Autism Access Link for Early Referral and Treatment","Autism ALERT","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Autism ALERT|Other: Screening Intervention","Change in satisfaction with Care Coordination in general and for autism in particular|Change in Parent stress|Change in Parenting stress|Change in Family Empowerment|Change in Family Centered and Coordinated Care|Family Satisfaction with Program|% referred to program who complete an ASD educational evaluation within 6 months|Time from EI/ECSE referral to ASD treatment in EI/ECSE, among children with ASD|Family self-reported ASD knowledge|Change in provider self-efficacy about autism management|Change in provider autism paperwork burden|Time from EI/ECSE referral to evaluation among children with ASD|Age of EI/ECSE educational determination, among children with ASD|% with ASD determination receiving ASD services 6 months after enrollment|monthly service hours among children with ASD 6 months after enrollment|age of ASD medical diagnosis among children on Medicaid|% with ASD medical diagnosis receiving ASD therapy 6 months after enrollment, among children on Medicaid","Oregon Health and Science University|Boston Medical Center|Providence Health & Services","All","12 Months to 54 Months   (Child)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","00001","March 18, 2021","May 31, 2022","May 31, 2022","April 27, 2021",,"July 21, 2021","Ohsu Cdrc, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04861740"
24,"NCT04766177","Role of Bumetanide in Treatment of Autism",,"Recruiting","No Results Available","Autism","Drug: Bumetanide|Drug: Placebo","Number of patients with improved CARS score","Sherief Abd-Elsalam|Tanta University","All","3 Years to 12 Years   (Child)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","autism","January 1, 2021","December 1, 2030","December 1, 2030","February 23, 2021",,"February 23, 2021","Sherief Abd-Elsalam, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04766177"
25,"NCT04246398","FMT in Children With Autism and Gastrointestinal Symptoms",,"Not yet recruiting","No Results Available","Children With Autism","Other: FMT|Other: FMT - placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])|Significant change in GI symptoms [efficiency]|Change in food selection [efficiency]|Improving ASD symptoms [efficiency]|Diversity and variability of the gut microbiome","Assaf Harofeh MC|Assaf-Harofeh Medical Center","All","7 Years to 20 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0052-19-ASF","February 2020","December 2022","December 2022","January 29, 2020",,"February 5, 2020","Assaf-HarofehMC, Zerifin, Israel",,"https://ClinicalTrials.gov/show/NCT04246398"
26,"NCT04199507","Physical Fitness in Autism",,"Completed","No Results Available","Autism","Other: physical fitness assessment","Physical fitness|Posture analysis|Physical activity level|Family Anxiety Level","Hacettepe University","All","7 Years to 17 Years (Child)",,"36","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","GO18/905","December 16, 2019","April 16, 2020","April 16, 2020","December 16, 2019",,"August 11, 2020","Hacettepe University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04199507"
27,"NCT02842671","Autism Spectrum Ambassador Program","ASAP","Completed","No Results Available","Autism Spectrum Disorder","Other: Assigned Ambassador","Patient Satisfaction Survey (questionnaire)|Medical Student Satisfaction Survey (questionnaire)|Medical Student Career Interest (questionnaire)|Medical Student Comfort Level (questionnaire)","Milton S. Hershey Medical Center","All","30 Months to 17 Years   (Child)","Not Applicable","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","00004103","December 1, 2016","November 25, 2019","November 25, 2019","July 25, 2016",,"June 18, 2021","Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02842671"
28,"NCT04068688","Tailoring Treatment Targets for Early Autism Intervention in Africa",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model (ESDM)","Supported joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Coordinated joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Symbol-infused joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Fluency and connectedness measured by the Joint Engagement Rating Inventory (JERI)|Shared routines and rituals measured by the Joint Engagement Rating Inventory (JERI)|Scaffolding measured by the Joint Engagement Rating Inventory (JERI)|Following in on a child's focus measured by the Joint Engagement Rating Inventory (JERI)|Caregiver affect measured by the Joint Engagement Rating Inventory (JERI)|Initiation of joint attention measured by the Early Social Communication Scales (ESCS)|Response to joint attention measured by the Early Social Communication Scales (ESCS)|Language and Communication developmental quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Personal-Social-Emotional developmental quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Socialization subscale standard score on the Vineland Adaptive Behavior Scales - Socialization subscale standard score on the Vineland Adaptive Behavior Scales - 3rd edition (VABS-3)|Communication subscale standard score on the Vineland Adaptive Behavior Scales - 3rd edition (VABS-3)|Affective response measured by the SenseToKnow App|Social referencing measured by the SenseToKnow App|Gaze patterns measured by the SenseToKnow App|Postural sway measured by the SenseToKnow App","Duke University|University of Cape Town","All","18 Months to 72 Months   (Child)","Not Applicable","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00103045","September 1, 2019","July 31, 2021","July 31, 2021","August 28, 2019",,"August 6, 2020","University of Cape Town, Cape Town, West Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04068688"
29,"NCT04666493","Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum","Screen for Child Anxiety Related Emotional Disorders (SCARED), Parent version|Screen for Child Anxiety Related Emotional Disorders (SCARED), Child version","Evdokia Anagnostou|Anagnostou, Evdokia, M.D.","All","8 Years to 13 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0240","December 4, 2020","November 30, 2021","November 30, 2021","December 14, 2020",,"December 14, 2020","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04666493"
30,"NCT02222662","Parent-delivered Massage for Children With Autism - Ages 6 to 11",,"Completed","No Results Available","Autism","Other: Parent massage tx group|Other: Parent massage wait-list control group","Change in severity of autism|Change in developmental skills","Western Oregon University|HRSA/Maternal and Child Health Bureau","All","6 Years to 11 Years   (Child)","Not Applicable","35","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R40MC24945(2)","June 2014","February 2016","February 2016","August 21, 2014",,"April 29, 2016","Various locations in Portland, Salem, Albany/Corvallis and Eugene, Portland, Salem, Albany, Corvallis, Eugene, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02222662"
31,"NCT05031364","CBT for Youth With Autism and Emotional/Behavioral Needs in Community Care Settings","CYAN","Recruiting","No Results Available","Autism","Behavioral: Behavioral Interventions for Anxiety in Children with Autism (BIACA)|Behavioral: Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)","Change in Aberrant Behavior Checklist-2 Irritability Subscale (ABC-2)|Change in Pediatric Anxiety Rating Scale (PARS)|Change in Social Responsiveness Scale II (SRS-II)|Consumer Satisfaction Parent Questionnaire","University of California, Los Angeles|Virginia Commonwealth University|United States Naval Medical Center, San Diego|Westside Regional Center","All","6 Years to 14 Years   (Child)","Not Applicable","100","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AR200108","July 1, 2021","March 1, 2025","June 30, 2025","September 1, 2021",,"September 1, 2021","Westside Regional Center, Culver City, California, United States|Naval Medical Center San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT05031364"
32,"NCT01343511","Safety and Efficacy of Stem Cell Therapy in Patients With Autism",,"Completed","No Results Available","Autism","Biological: human cord blood mononuclear cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells","Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event","Shenzhen Beike Bio-Technology Co., Ltd.|Shandong Jiaotong Hospital|Association for the Handicapped Of Jinan","All","3 Years to 12 Years   (Child)","Phase 1|Phase 2","37","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-AUTISM-1.0(2009)","March 2009","June 2010","May 2011","April 28, 2011",,"October 14, 2011","Shandong Jiaotong Hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01343511"
33,"NCT02192749","Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism",,"Completed","No Results Available","Autism","Biological: Umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC)","Translational Biosciences","All","6 Years to 16 Years   (Child)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-UCMSC-ASD001","July 2014","August 2017","August 2017","July 17, 2014",,"October 13, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02192749"
34,"NCT04209452","Improving Working Memory of Children With Autism",,"Terminated","No Results Available","Autism","Behavioral: Rehearsal strategy|Behavioral: Reinforcement|Behavioral: Rehearsal strategy and reinforcement","Change in percent recall|Change in percent strategy used.","Arizona State University|Shanghai Xuhui Clover Children Healthy Garden|Jingdezhen Kindkids Autism Rehabilitation and Training Center|Sunshine Special Education Center","All","4 Years to 8 Years   (Child)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00010960","January 15, 2020","November 10, 2020","November 10, 2020","December 24, 2019",,"November 12, 2020","Jingdezhen Kindkids Autism Rehabilitation and Training Center, Jingdezhen, Jiangxi, China|Sunshine Special Education Center, Taizhou, Zhejiang, China|Shanghai Xuhui Clover Children Healthy Garden, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04209452"
35,"NCT02111551","Phase I Nicotinic Agonist Treatment Trial for Autism",,"Terminated","No Results Available","Autism","Drug: DMXB-A 150 mg|Other: placebo|Drug: DMXB-A 75 mg","Difference between drug and placebo on theTotal Scale Score on the repeatable Battery for the Assessment of neuropsychological Status at 2 hours after administration|Difference between drug and placebo on the CPT at 30 minutes after administration|Difference between the P50 auditory evoked potential test/conditioning ratio 1 hour after administration|Difference between placebo and drug on the Social Responsiveness scale 2 hours after administration","University of Colorado, Denver","All","18 Years to 50 Years   (Adult)","Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-0614","June 2015","May 2016","May 2016","April 11, 2014",,"June 16, 2016","University of Colorado Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02111551"
36,"NCT01801696","Parent-delivered Massage for Children With Autism",,"Completed","No Results Available","Autism","Other: Parent massage tx group|Other: Parent massage wait-list control group","Severity of autism|Developmental skills","Western Oregon University|HRSA/Maternal and Child Health Bureau","All","2 Years to 5 Years   (Child)","Phase 2|Phase 3","103","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R40MC24945(1)","September 2012","November 2014","March 2016","March 1, 2013",,"April 29, 2016","Various locations in Albany and Corvallis, Corvallis, Oregon, United States|Various locations in Eugene, Oregon, Eugene, Oregon, United States|Various locations in Portland, Oregon, Portland, Oregon, United States|Various locations in Salem, Oregon, Salem, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01801696"
37,"NCT03569176","Examining the Efficacy of a Mobile Therapy for Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Device: Autism Glass","Change in socialization subscale scores of the Vineland Adaptive Behavior Scales, 2nd Edition (VABS-II) from baseline to week 6.|Change in Parent Rated Social Responsiveness Scale 2 (SRS-2) from baseline to week 6|Change in NEPSY-II, Affect Recognition subscale scores from baseline to week 6|Change in Emotion Guessing Game (EGG) scores from baseline to week 6|Change in ASD symptoms as measured by Brief Observation of Social Communication Change (BOSCC) from baseline to week 6|Change in adaptive social and personal skills as measured by Vineland Adaptive Behavior Scales, 2nd edition (VABS-II) Full Scale from baseline to week 6.|Change in child's emotional, behavioral, and social problems from Baseline (week 0) to Week 6 as measured by Child Behavior Checklist (CBCL).","Dennis Paul Wall|Stanford University","All","6 Years to 12 Years   (Child)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-34059","November 1, 2016","April 11, 2018","April 15, 2018","June 26, 2018",,"July 17, 2018",,,"https://ClinicalTrials.gov/show/NCT03569176"
38,"NCT04302753","Autistic Women's Experiences of Self Compassion and Receiving Their Diagnosis in Adulthood",,"Completed","No Results Available","Autism",,"Experience of receiving ASD diagnosis in adulthood based on semi structured interviews|Experience of self-compassion before and after receiving ASD diagnosis based on semi structured interviews","University of Sheffield","Female","18 Years to 99 Years   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","164845","August 12, 2019","December 1, 2020","March 29, 2021","March 10, 2020",,"May 6, 2021","DClin Univeristy of Sheffield, Sheffield, Yorkshire And Humber, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04302753"
39,"NCT02627508","Pilot Trial of Pregnenolone in Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Drug: Pregnenolone|Drug: Placebo","Change from baseline in parent rated Aberrant Behavior Checklist Irritability (ABC-I) score during treatment|Change from baseline in parent rated Aberrant Behavior Checklist (ABC) scores during treatment|Change from baseline in parent rated Sensory Profile Questionnaire (SPQ) scores during treatment|Change from baseline in Vineland Adaptive Behavior Scales Second Edition (VABS-II)|Change from baseline in Clinical Global Impression (CGI) scores during treatment|Change from baseline in levels of pregnenolone and its related neurosteroids in peripheral blood|Change from baseline on the Autism Diagnostic Observation Schedule (ADOS)|Change from baseline in laboratory based eye-gaze measures|Change from baseline in laboratory based electroencephalography (EEG) measures|Change from baseline in laboratory clinical lab values including complete metabolic panel, complete blood count with differential, cholesterol panel and routine urinalysis.|Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) scores during treatment","Stanford University|Simons Foundation","All","14 Years to 25 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-34762","January 29, 2016","April 2023","April 2023","December 11, 2015",,"May 3, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02627508"
40,"NCT02037022","Pivotal Response Treatment Package for Young Children With Autism","PRT-P","Completed","No Results Available","Autism Spectrum Disorder (ASD)|Autism","Behavioral: Pivotal Response Treatment Package (PRT-P)","Change from Baseline in communication during parent-child and clinician-child interactions at 6, 12, and 24 weeks|Change from Baseline on the Preschool Language Scale, 5th Edition (PLS-5) at 12, and 24 weeks|Change from Baseline on the Sensory Profile Questionnaire at 6, 12, and 24 weeks|Change from Baseline on the Social Responsiveness Scale (SRS) at 6, 12, and 24 weeks|Change from Baseline on the MacArthur-Bates Communication Development Inventory at 6, 12, and 24 weeks|Change from Baseline on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) at 6, 12, and 24 weeks|Change from Baseline on the Behavior Rating Inventory of Executive Function, Preschool (BRIEF-P) at 6, 12, and 24 weeks|Change from Baseline on the Parenting Stress Index (PSI) at 6, 12, and 24 weeks|Change from Baseline on the Family Empowerment Scale (FES) at 6, 12, and 24 weeks|Change from Baseline on the Clinical Global Impression Scale at 6, 12, and 24 weeks|Change from Baseline on the Social attention and word-learning eye tracking task at 12, and 24 weeks","Stanford University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","2 Years to 5 Years   (Child)","Not Applicable","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-28314|R21DC013689","December 4, 2013","July 28, 2017","July 28, 2017","January 15, 2014",,"February 25, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02037022"
41,"NCT00498173","Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism",,"Completed","Has Results","Autism","Drug: Atomoxetine|Drug: Placebo","ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase)|ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Randomized Phase)|Aberrant Behavior Checklist (ABC) (Randomized Phase)|Social Responsiveness Scale (SRS) (Randomized Phase)|Vineland Adaptive Behavior Scales (VABS) Composite Score (Randomized Phase)|Pediatric Quality of Life Inventory (Randomized Phase)|Pediatric Anxiety Rating Scale, 5-Item Total (Randomized Phase)|Odds of Clinical Global Impression-Improvement Scale, Very Much or Much Improved (1 or 2) (Randomized Phase)|Change in ADHD Rating Scale (ADHDRS)-Home Version Total Score (Open-label Trial)|Change in ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Open-label Trial)|Change in Aberrant Behavior Checklist (ABC) (Open-label Trial)|Change in Social Responsiveness Scale (SRS) (Open-label Trial)|Change in Vineland Adaptive Behavior Scales (VABS) Composite Score (Open-label Trial)|Change in Pediatric Quality of Life Inventory (Open-label Trial)|Change in Pediatric Anxiety Rating Scale, 5-item Total (Open-label Trial)","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","5 Years to 15 Years   (Child)","Phase 3","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01MH077600|DDTR B2-NDA","July 2007","October 2015","October 2015","July 9, 2007","August 14, 2017","August 14, 2017","Christian Sarkine Autism Treatment Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Lurie Center - MassGeneral Hospital, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00498173"
42,"NCT03517163","Boston Outcomes of Autism in Toddlers Study","BOAT","Recruiting","No Results Available","Autism Spectrum Disorder|Autism",,"ASD Symptomatology|Cognitive Level|Language Level|Adaptive Functioning","Boston Children's Hospital","All","5 Years to 7 Years   (Child)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P00026909","June 1, 2018","May 2022","February 2024","May 7, 2018",,"September 8, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03517163"
43,"NCT03887754","Therapeutic Issues for Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Risperidone|Device: hyperbaric oxygen therapy|Drug: Non specific Multivitamin","Childhood Autism Rating Scale version 2 (CARS2)measured after one year and after two years to compare the effect of hyperbaric oxygen therapy, Risperidone, both of them and the placebo effect","Minia University","All","5 Years to 7 Years   (Child)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Autism Spectrum Disorder","January 2016","January 2018","December 2018","March 25, 2019",,"March 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03887754"
44,"NCT04349644","Enhancing Social Competence in Adults With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: SENSE Theatre","Change in Incidental Face Memory|Change in Contextual Assessment of Social Skills|Change in Social Responsiveness Scale - Self (SRS)|Change in Social Responsiveness Scale - Parent (SRS)|Cambridge Face Memory Test|Wechsler Memory Scale Face Memory Delay Test|Wechsler Memory Scale Face Memory Test|Adaptive Behavior Assessment System (ABAS) - Self-Report|Adaptive Behavior Assessment System (ABAS) - Parent-Report|State-Trait Anxiety Inventory (STAI) Scale|The Adult Self Report (ASR)|The Adult Behavior Checklist (ABCL)","Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)","All","18 Years to 35 Years   (Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","192271|1R33MH120149-01A1","October 21, 2020","April 1, 2023","April 1, 2023","April 16, 2020",,"February 11, 2021","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04349644/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04349644"
45,"NCT02947048","Safety of L1-79 in Autism",,"Completed","No Results Available","Autism","Drug: L1-79|Drug: Placebo","Adverse event frequency|Change from baseline in CGI|Change from Baseline in Vineland Adaptive Behavior Scales - 2nd Edition|Change from Baseline in the Autism Diagnostic Observation Schedule (ADOS)|Change from baseline in Aberrant Behavior Checklist - Community|Change from baseline in the Social Responsiveness Scale - 2nd edition (SRS-2)|Changes from baseline in the Repetitive Behavior Scale - Revised (RBS-R).|Plasma concentrations of L1-79","F Peter Halas|Yamo Pharmaceuticals LLC","Male","13 Years to 21 Years   (Child, Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HT 02-121","October 2016","December 2017","February 1, 2018","October 27, 2016",,"February 10, 2020","Eric Bartky MD, Bartky Health Care Center, Livingston, New Jersey, United States|F. Peter Halas MD, Sea Girt Pediatrics, Sea Girt, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02947048"
46,"NCT01502488","Adipose Derived Stem Cell Therapy for Autism",,"Withdrawn","No Results Available","Autism","Procedure: Fat Harvesting and Stem Cell Injection","Improvement in the Childhood Autism Rating Scale，CARS|Improvement in the Clinical Global Impression Scale, CGI|Improvement in the Aberrant Behavior Checklist, ABC","Ageless Regenerative Institute|Instituto de Medicina Regenerativa","All","3 Years to 12 Years   (Child)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADI-AT-001","October 2016","November 2017","January 2018","December 30, 2011",,"July 21, 2017","Ageless Regenerative Institute LLC, Aventura, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01502488"
47,"NCT00549562","Study of Paliperidone ER in Adolescents and Young Adults With Autism",,"Completed","Has Results","Autism","Drug: Paliperidone ER","The Clinical Global Impression-Improvement(CGI-I)|The Aberrant Behavior Checklist|The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders|The Social Responsiveness Scale|The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain","Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University","All","12 Years to 21 Years   (Child, Adult)","Phase 3","25","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0709-24|R076477-AUT-4002","November 2007","September 2010","September 2010","October 26, 2007","May 16, 2017","May 16, 2017","Riley Child & Adolescent Psychiatry Clinic- Riley Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00549562"
48,"NCT01677663","Neuropsychopathological Study of Autism",,"Unknown status","No Results Available","Autism",,,"National Taiwan University Hospital|National Taiwan University","All","3 Years to 25 Years   (Child, Adult)",,"350","Other","Observational","Observational Model: Family-Based","201103003RB","August 2011",,"July 2016","September 3, 2012",,"September 3, 2012","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01677663"
49,"NCT00252603","Galantamine Versus Placebo in Childhood Autism",,"Completed","No Results Available","Autism|Childhood Autism","Drug: Galantamine","Autism Diagnostic Observation Schedule-Generic (ADOS-G)- Change from Baseline to Final Visit|Clinical Global Impression Improvement (CGI)- Change from Baseline to Final Visit|Aberrant Behavior Checklist (ABC) (hyperactivity/irritability sections)- Change from Baseline to Final Visit|Vineland Adaptive Behavior Scale- Change from Baseline to Final Visit|MacArthur Communicative Development Inventory (MCDI)- Change from Baseline to Final Visit|Conners' Parent Rating Scale-Revised: Long form (CPRS-R:L)- Change from Baseline to Final Visit","University of Medicine and Dentistry of New Jersey|National Alliance for Autism Research|Rutgers, The State University of New Jersey","All","5 Years to 17 Years   (Child)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","4682","April 2004",,"April 2007","November 11, 2005",,"January 29, 2007","UMDNJ Robert Wood Johnson Medical School - Dept of Psychiatry, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00252603"
50,"NCT04679974","Melodic-based Communication Therapy for Promoting Spoken Language Development in Individuals With Nonverbal Autism","MBCT","Completed","No Results Available","Nonverbal and Low Verbal Autism","Behavioral: Melodic-based Communication Therapy","Number of spoken words|Frequency of repetitive and stereotypical behaviors","Loma Linda University","All","3 Years to 10 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5170235","June 17, 2018","August 16, 2018","August 30, 2018","December 22, 2020",,"December 22, 2020","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT04679974"
51,"NCT03751930","Intestinal Microbiota, Tryptophan and Autism","MTA","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Samples","Urinary concentrations of tryptophan metabolites|Faecal concentrations of tryptophan metabolites|Characterization of gut microbiota|Correlation of metabolic profiles of tryptophan and microbiotic profiles","University Hospital, Tours","All","3 Years to 12 Years   (Child)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DR180136|2018-A01086-49","January 2, 2019","January 2022","January 2022","November 23, 2018",,"April 28, 2021","Child psychiatry department, University Hospital, Tours, Tours, France|Clinical investigation center, University Hospital, Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT03751930"
52,"NCT02086110","Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism",,"Completed","Has Results","Autism","Dietary Supplement: Synbiotic|Dietary Supplement: Prebiotic","Stool Microbiota Composition Change During Prebiotic Only Treatment|Stool Microbiota Composition Change During Synbiotic Treatment|Serum Immune Profile Change During Prebiotic Only Treatment","University of California, Davis","All","2 Years to 11 Years   (Child)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","450072","June 6, 2014","November 16, 2015","November 16, 2015","March 13, 2014","August 1, 2019","August 1, 2019","UC Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02086110"
53,"NCT02591459","Android Mobile Devices to Assist Routine Anticipation for Autistic Children",,"Unknown status","No Results Available","Autism","Other: Using the app to assist routine anticipation","Increase in verbal communication","University of Mogi das Cruzes","All","3 Years to 9 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","49354415.0.0000.5497","October 2015","October 2015","December 2015","October 29, 2015",,"October 29, 2015","Centro de inclusão e Apoio ao Autista de Guarulhos (CIAAG), Guarulhos, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02591459"
54,"NCT04501588","Parent Telehealth Intervention for Children With Autism",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Responsive training with no video feedback|Behavioral: Responsive training with video feedback","Parent Use of Language Support Strategies (Mother-child interaction)|MacArthur-Bates Communicative Development Inventory (MCDI) (Child)","Northwestern University","All","18 Months to 48 Months   (Child)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STU00201708","March 6, 2020","June 30, 2021","September 30, 2021","August 6, 2020",,"July 7, 2021","Northwestern University, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04501588"
55,"NCT03179787","Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism",,"Completed","Has Results","Autism","Drug: Aripiprazole oral product","Mean Changes of Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale Scores From Baseline.","Otsuka Pharmaceutical Co., Ltd.","All","6 Years to 17 Years   (Child)",,"528","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","031-101-00116","April 1, 2017","March 17, 2020","July 6, 2020","June 7, 2017","September 16, 2021","September 16, 2021","Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03179787/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03179787/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03179787"
56,"NCT01716845","SynapDx Autism Gene Expression Analysis Study","SAGA","Completed","No Results Available","Autism",,"RNA gene expression in peripheral blood","SynapDx","All","18 Months to 5 Years   (Child)",,"660","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12001","October 2012","December 2014","December 2014","October 30, 2012",,"December 17, 2014","Children's Hospital Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01716845"
57,"NCT00166621","Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy",,"Completed","No Results Available","Autism","Drug: Buspirone","Safety will be measured by obtaining clinical laboratory tests, vital signs and evaluating probably or definitely related adverse events.|Population pharmacokinetics will be conducted to measure plasma concentrations in relation to the drug responses to buspirone.|The primary efficacy outcome will be the overall severity score from the Clinical Global Impressions assessment obtained from two raters, (parent and examiner)|Comparisons of allele, and genotype frequencies between responders and non-responders will be done for each polymorphism using Fisher's exact test to best predict response to buspirone.","Chugani, Diane C.","All","2 Years to 6 Years   (Child)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","PPRU 10659s","March 2004",,"August 2005","September 14, 2005",,"July 20, 2011","PET Center/Children's Hospital of Michigan, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00166621"
58,"NCT02632773","Parent Language Intervention for Autism",,"Completed","No Results Available","Autism","Behavioral: Responsive Intervention|Behavioral: Directive Intervention","Parent Use of Language Support Strategies (Mother-child interaction)|Expressive vocabulary of the child as measured by transcribing and coding a 20 minute video of a therapist-child interaction in the clinic with a standard set of age-appropriate toys.|MacArthur-Bates Communicative Development Inventory (MCDI) (Child)","Northwestern University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","18 Months to 48 Months   (Child)","Not Applicable","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","1R01DC014709-01","August 2015","March 2020","March 2020","December 17, 2015",,"July 16, 2021","Northwestern University, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02632773"
59,"NCT03164746","Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism With Severe Injurious Behavior.","PACKING","Completed","No Results Available","Autism Spectrum Disorder","Other: Dry sheet Therapeutic body wraps|Other: WET sheet Therapeutic body wraps","Aberrant Behavior Checklist (ABC) irritability score|ABC hyperactivity score|ABC lethargy score|ABC inappropriate speech score|ABC stereotypic behavior score|ABC Total score|Child Autism Rating Scale (CARS)|Clinical Global Impression-Improvement (CGI-I)|Clinical Global Impression-Severity (CGI-S)","University Hospital, Lille|Ministry of Health, France","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2007/0715|2007-A01376-47|DGS 2008-0070","December 2007","December 2014","December 2014","May 24, 2017",,"May 24, 2017","Centre de Santé Mentale Angevin, Angers, France|Centre Hospitalier d'Arras, Arras, France|Centre Hospitalier Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Montfavet, Avignon, France|Institut Départemental Albert Calmette, Camiers, France|Centre Hospitalier de Douai, Douai, France|Etablissement Public de Santé Roger Prévot, Gennevilliers, France|Centre Hospitalier de Lens, Lens, France|Hôpital Fontan, CHRU, Lille, France|Institut Médico-éducatif, Montigny-en-Ostrevent, France|Etablissement de Santé Maison Blanche, Paris, France|Groupe Hospitalier Pitier-Salpêtrière, Paris, France|Etablissement Public de Santé Mentale Val de Lys-Artois, Saint-Venant, France",,"https://ClinicalTrials.gov/show/NCT03164746"
60,"NCT01676389","Osteopathic Manual Medicine Treatment in Autism","OMMA","Completed","No Results Available","Autism Spectrum Disorders","Other: Sham OMM|Other: Osteopathic Manual Medicine (Body Therapy)","Autism Behavior Checklist (ABC)|Salivary IgA and Salivary Cortisol|WeeFIM measurement of child's functional abilities","New York Institute of Technology","All","3 Years to 11 Years   (Child)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BHS-760","January 2013","October 2014","May 2015","August 30, 2012",,"January 21, 2016","Family Care Center - New York Institute of Technology College of Osteopathic Medicine, Central Islip, New York, United States|Academic Health Care Center at Old Westbury, Old Westbury, New York, United States",,"https://ClinicalTrials.gov/show/NCT01676389"
61,"NCT02236650","Primary Care Stepping Stones Triple P for Children With Autism",,"Completed","No Results Available","Autism","Behavioral: Primary Care Stepping Stones Triple P (PC-SS Triple P)|Other: Treatment as Usual","Change from Baseline in Eyberg Child Behavior Inventory Score at 4 weeks|Change from Baseline in Connor-Davidson Resilience Scale Score at 4 weeks|Change from Baseline in Parent Stress Index - Short Form Score at 4 weeks|Change from Baseline in Family Assessment Device score at 4 weeks|Change from Baseline in Aberrant Behavior Checklist Score at 4 weeks|Change from Baseline in The Parenting Scale Score at 4 weeks|Change from Baseline in the Parenting Sense of Competence Scale Score at 4 weeks","St. Louis University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLUBM_24272","July 2014","December 2015","December 2015","September 10, 2014",,"December 17, 2015","Saint Louis University, Knights of Columbus Developmental Center, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02236650"
62,"NCT02968225","Using Serious Game Technology to Improve Sensitivity to Eye Gaze in Autism","SAGA","Completed","No Results Available","Autism","Behavioral: Computer Game","Static Eye Gaze Following Task|Dynamic Eye Gaze Following Task|Social/Visual Attention Task|Social Responsiveness Scale|Social Skills Inventory System - Child version|Social Skills Inventory System - Adult version|Treatment as Usual","Penn State University|National Institute of Mental Health (NIMH)","All","10 Years to 18 Years   (Child, Adult)","Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R61MH110624","August 2016","October 2018","October 2018","November 18, 2016",,"March 5, 2021","Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02968225"
63,"NCT00577447","Docosahexaenoic Acid in the Treatment of Autism",,"Completed","No Results Available","Autism","Dietary Supplement: docosahexaenoic acid (DHA)|Dietary Supplement: Placebo","Clinical Global Impressions-Improvement Scale|Child Development Inventory|Behavior Assessment Scale for Children|Aberrant Behavior Checklist","Mayo Clinic|DSM Nutritional Products, Inc.","All","3 Years to 10 Years   (Child)","Not Applicable","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","398-05","October 2005","September 2007","November 2007","December 20, 2007",,"April 28, 2015","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00577447"
64,"NCT04936048","Music for Autism (M4A)","M4A","Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Music Therapy|Behavioral: Play therapy","Children's Communication Checklist-2|Brain connectivity of frontotemporal regions|Child and Adolescent Scale of Participation|Beach Center Family Quality of Life Scale|Peabody Picture Vocabulary Test- 4th edition|Social Responsiveness Scale|Vineland Adaptive Behavior Scales|Hair cortisol concentration|Grey and white matter volume (Structural brain changes)","NORCE Norwegian Research Centre AS|University of Bergen|University of Vienna","All","6 Years to 12 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","M4A","August 1, 2021","June 30, 2023","June 30, 2023","June 23, 2021",,"August 25, 2021","University of Vienna, Vienna, Austria|NORCE Norwegian Research Centre, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT04936048"
65,"NCT04078061","Comparative Effectiveness of EIBI and Adaptive ABA for Children With Autism","ISOLDE","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: MABA|Behavioral: EIBI","Change in Vineland Adaptive Behavior Scale (VABS-3)|Change in ASD symptoms using the Ohio Autism Clinical Impressions Scale (OACIS)","University of Rochester|The Cleveland Clinic|May Institute|Nationwide Children's Hospital|Vanderbilt University Medical Center|University of Michigan|University of Virginia","All","18 Months to 5 Years   (Child)","Not Applicable","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","W81XWH-18-1-0790","August 22, 2019","August 2022","August 2022","September 4, 2019",,"March 16, 2021","May Institute, Jacksonville, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|May Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04078061"
66,"NCT04283045","Community-based Adaptive Autism Intervention for Toddlers","CAIT","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: JASPER|Behavioral: jasPEER|Behavioral: Structured Teaching","Change in social communicative utterances (SCU) using Short Play and Communication Evaluation (SPACE)|Change in social communicative utterances (SCU) using JASPER Deployment Project Treatment Fidelity Checklist (TCX)|Change in play levels/types using the Short Play and Communication Evaluation (SPACE)|Change in joint engagement using the JASPER Deployment Project Treatment Fidelity Checklist (TCX)","University of California, Los Angeles|National Institutes of Health (NIH)","All","24 Months to 36 Months   (Child)","Not Applicable","350","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-000197","February 1, 2021","June 30, 2025","August 31, 2025","February 25, 2020",,"September 27, 2021","New York Center for Infants and Toddlers, Inc., New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04283045"
67,"NCT04739982","Evaluating Efficacy of GuessWhat Mobile App Therapy for Children With Autism",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Device: GuessWhat Mobile App","Change in parent reported socialization based on the Vineland Adaptive Behavior Scales 3rd Edition (VABS-3) Parent/Caregiver Socialization Subscale, from baseline to week 4|GuessWhat App Usage Data|Parent reported feedback|Change in Parental Stress Scale - from baseline to week 4|Change in Emotion Recognition from baseline to week 4","Stanford University","All","3 Years to 12 Years   (Child)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","60181","June 14, 2021","December 31, 2021","March 1, 2022","February 5, 2021",,"June 16, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04739982"
68,"NCT01944046","Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors","SOARS-B","Completed","Has Results","Autism Spectrum Disorders","Drug: Double blind phase Placebo Nasal Spray|Drug: double Blind Oxytocin Nasal Spray|Drug: Open Label intranasal oxytocin","Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity|Change in Sociability Factor (SF)|Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score|Change in Stanford Binet-5th Edition (SB-5) IQ Score","Linmarie Sikich|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","3 Years to 17 Years   (Child)","Phase 2","290","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00063950|1U01HD073984|13-0593","August 1, 2014","November 30, 2017","November 30, 2017","September 17, 2013","January 5, 2021","June 18, 2021","Lurie Center for Autism, Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai School of Medicine, New York, New York, United States|Center for Autism and the Developing Brain, White Plains, New York, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Duke University , Genetics Center, Durham, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Seattle Children's Hospital Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01944046/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01944046"
69,"NCT02536365","Sensory Integration Therapy in Autism: Mechanisms and Effectiveness",,"Recruiting","No Results Available","Autism","Behavioral: Sensory Integration Therapy|Behavioral: Applied Behavioral Analysis","The Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) Daily Living|The Assessment of Motor and Process Skills (AMPS)|Repetitive Behavior Scale-Revised (RBS-R)","Albert Einstein College of Medicine|Thomas Jefferson University|Queens College, The City University of New York","All","6 Years to 102 Months   (Child)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2014-3795","September 2015","December 2021","December 2021","August 31, 2015",,"January 15, 2021","Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT02536365"
70,"NCT03634761","Early Intervention and Autism: Transformation From Research to Practice Through a Competency Based Model","AUT-TID","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Competency based model|Behavioral: Comprehensive program","Change in overall program quality measured by the Autism Program Environment Rating Scale (APERS-P-SE)|Ethics, Values and Allegiance (EVA)|Evidence Based Practices (EBP)|Autism Knowledge Questionnaire (AKQ)|Self-Efficacy and Stress Questionnaire (SESQ)|Goal Attainment Scale (GAS)|Clinical Global Impression-autism (CGI-AUT)|Children's Engagement Questionnaire (CEQ)|Vineland Adaptive Behavior Scales - Second Edition (Vineland-II) - Teacher ratings","Stockholm University|Karolinska Institutet","All","2 Years to 5 Years   (Child)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","VR 2015-01212","May 15, 2017","May 30, 2019","May 30, 2019","August 16, 2018",,"September 20, 2019","BanyanCenter, Stockholm, Sweden|Autismcenter för Små Barn, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03634761"
71,"NCT02508922","Trial of Vitamin D3 Supplementation in Paediatric Autism",,"Completed","No Results Available","Autism","Dietary Supplement: Vitamin D3|Dietary Supplement: Placebo","Change from baseline in stereotypic behaviour from the aberrant behaviour checklist|Change from baseline in serum 25-hydroxyvitamin D levels|Change from baseline in serum calcium levels, corrected for albumin|Change from baseline in aberrant behaviour checklist|Change from baseline in cytokines|Change from baseline in autoimmune markers|Change from baseline in behaviour Assessment System for Children - Second Edition|Change from baseline in repetitive behavior Scale - Revised|Change from baseline in Social Responsiveness Scale|Change from baseline in Developmental Disabilities-Children's Global Assessment Scale|Change from baseline in Vitamin D and Sun Questionnaire","University of Dublin, Trinity College|The National Children's Hospital, Tallaght","All","3 Years to 12 Years   (Child)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","NCHVitDASD","September 2015","June 2016","July 2016","July 27, 2015",,"October 25, 2016","Linn Dara and BeechPark, Dublin, Ireland|National Children's Hopsital, Dublin, Ireland|Trinity College Dublin, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT02508922"
72,"NCT02712281","Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Autism MEAL Plan|Behavioral: Parent Education","Change in Clinical Global Impression - Improvement scale (CGI-I) score|Change in Parenting Stress Index- Short Form (PSI) score|Parent Satisfaction Rating|Change in Brief Autism Mealtime Behavior Inventory (BAMBI) scores|Change in Food Preference Inventory (FPI) scores|Change in nutritional intake|Change in Aberrant Behavior Checklist (ABC) scores|Change in rapid acceptance during 10 minute meal observation|Change in rapid swallowing during 10-minute meal observation|Change in disruptions during 10-minute meal observation|Change in crying during 10-minute meal observation|Change in volume of food consumed during 10-minute meal observation|Weight|Height|Body Mass Index","Emory University|Children's Healthcare of Atlanta","All","3 Years to 8 Years   (Child)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00085811","July 2016","March 2018","April 2018","March 18, 2016",,"December 19, 2018","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02712281"
73,"NCT03300128","Incredible Years Program for Parents of Children With Autism","IY-ASD","Terminated","No Results Available","Autism Spectrum Disorder","Behavioral: Incredible Years - ASD|Other: Circle of Parents","Change in child behavior|Change in parent stress|Change in coping mechanisms|Change in parenting practices|Change in depression, anxiety, and stress|Satisfaction survey|Weekly IY-ASD evaluation","University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00074617","June 1, 2017","May 31, 2018","December 10, 2018","October 3, 2017",,"January 2, 2020","Onslow County Partnership for Children, Jacksonville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03300128"
74,"NCT00406159","Effects of Hyperbaric Oxygen Therapy on Children With Autism",,"Completed","No Results Available","Autism","Device: Hyperbaric Oxygen Therapy","Standardized Measures|In addition to the direct measures of behavior described above, standardized intelligence and adaptive assessments will be conducted prior to the initiation of HBOT. These will include:|ADI/ADOS|WPPSI-III (2-6 years) /WASI (6+ years)|Vineland Adaptive Behavior Scale (VABS)|Subjective Questionnaires|Aberrant Behavior Checklist|Clinical Global Impression|ATEC|Selected sections of the APEQ|BRIEF|Parenting Stress Index|Repetitive Behavior Scale|A side effect questionnaire|Thoughtful House Caregiver diary","Thoughtful House","All","2 Years to 10 Years   (Child)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06.10.0004","November 2006",,"September 2007","December 4, 2006",,"August 7, 2009","Medical Center at Thoughtful House, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00406159"
75,"NCT02654743","Open Label of Clinical Trial of Sulforaphane in Children With Autism",,"Completed","No Results Available","Autism","Dietary Supplement: Sulforaphane","Urinary metabolites|Behavior Measures","University of California, San Francisco","All","5 Years to 22 Years   (Child, Adult)","Phase 3","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SF15-17002","January 2016","May 2016","September 2016","January 13, 2016",,"March 6, 2019",,,"https://ClinicalTrials.gov/show/NCT02654743"
76,"NCT04031755","A Proof-of-Concept Study of Minocycline in Autism",,"Completed","No Results Available","Autism Spectrum Disorder|Autism","Drug: Minocycline|Drug: Placebos","Subject weight will be compared pre- and post-treatment in the drug versus placebo conditions|Aberrant Behavior will be evaluated pre- and post-treatment in the drug versus placebo conditions|Incidence of liver toxicity will be evaluated in the pre- and post-treatment setting in the drug versus placebo conditions","Children's Hospital Medical Center, Cincinnati","All","12 Years to 22 Years   (Child, Adult)","Phase 1","53","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIN001 - Minocycline in ASD","April 19, 2019","October 30, 2020","October 30, 2020","July 24, 2019",,"December 8, 2020","Thompson Center for Autism & Neurodevelopmental Disorders - University of Missouri, Columbia, Missouri, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Center for Autism and Developmental Disorders - University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04031755"
77,"NCT01810341","SynapDx Autism Gene Expression Analysis Study (STORY)","STORY","Completed","No Results Available","Autism",,"RNA gene expression in peripheral blood|Metabolites, lipids and DNA variation in peripheral blood","SynapDx","All","18 Months to 60 Months   (Child)",,"880","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12002","March 2013","July 2014","December 2014","March 13, 2013",,"December 17, 2014","Melmed Center, Scottsdale, Arizona, United States|Miller Children's Hospital, Long Beach, California, United States|UC Davis MIND Institute, Sacramento, California, United States|Emory University, Decatur, Georgia, United States|Rush Medical Center, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Lurie Center Massachusetts General Hospital, Lexington, Massachusetts, United States|Mount Sinai School of Medicine/Seaver Center, New York, New York, United States|Institute for Behavioral Research on Staten Island, Staten Island, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States|Seattle Children's, Seattle, Washington, United States|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01810341"
78,"NCT03677089","Extension for Community Healthcare Outcomes Autism Replication Evaluation","ECHO Autism","Completed","Has Results","Autism Spectrum Disorder","Behavioral: 12 ECHO Autism telehealth clinics","Longitudinal Pattern of ASD Screening in PCP Charts|Longitudinal Pattern of Reported Co-occurring Medical Conditions Correctly Treated in PCP Charts|Longitudinal Pattern of Scores on Provider ASD Knowledge Assessment|Longitudinal Pattern of Scores on Provider ASD Self-Efficacy Assessment|Longitudinal Pattern of the Number of Perceived Barriers to Care|Participant Satisfaction With ECHO Autism Program|PCP ECHO Program Attendance|Number of Co-morbidities in Children With ASD","Massachusetts General Hospital|University of Toronto|Children's Hospital of Philadelphia|University of Pittsburgh|University of Rochester|Children's Hospital Medical Center, Cincinnati|University of Arkansas|Nationwide Children's Hospital|Vanderbilt University Medical Center|University of California, Irvine|University of Missouri-Columbia","All","Child, Adult, Older Adult","Not Applicable","148","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2016P000415|UA3MC11054","September 1, 2016","November 27, 2018","November 27, 2018","September 19, 2018","April 30, 2020","April 30, 2020",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03677089/Prot_000.pdf|""Statistical Analysis Plan: Original"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03677089/SAP_001.pdf|""Statistical Analysis Plan: Amendment 1"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03677089/SAP_002.pdf|""Statistical Analysis Plan: Amendment 2"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03677089/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03677089"
79,"NCT01154777","Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism",,"Unknown status","No Results Available","Autism","Behavioral: Neurofeedback training","Level of normalization of brainwaves based upon QEEG","Institute for Personal Excellence, P.A.|Life Quality Resources|National Institute of Mental Health (NIMH)","All","6 Years to 18 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFB6-18Autism","July 2011","June 2016","December 2016","July 1, 2010",,"October 5, 2010","Institute for Personal Excellence, P.A., Raleigh, North Carolina, United States|Life Quality Resources, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01154777"
80,"NCT04696133","Sensory Integration Versus Fine Motor Intervention in Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: fine motor skills|Other: sensory integration","Gilliam autism rating scale|Bruininks-Oseretsky Test Of Motor Proficiency|Pediartic Quality of life Inventory Scale","Cairo University","All","8 Years to 12 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Autism spectrum","March 15, 2021","December 30, 2021","December 30, 2021","January 6, 2021",,"August 5, 2021","faculty of physical therapy, Cairo university, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04696133"
81,"NCT01780883","Melatonin Dose-effect Relation in Childhood Autism","MELADOSE","Completed","No Results Available","Childhood Autism","Drug: melatonin|Drug: Placebo","Severity of autistic disorder|Severity of autistic impairments|Sleep problems|Excretion of the urinary metabolite of melatonin","Rennes University Hospital|Centre Hospitalier Guillaume Régnier, RENNES","Male","6 Years to 8 Years   (Child)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANSM A91245-56","February 2013","July 2013","September 2013","January 31, 2013",,"September 5, 2013","Service de Psychiatrie de l'Enfant et de l'Adolescent - Hôpital de la Pitié-Salpêtrière, Paris, France|Centre Hospitalier Spécialisé Henri Laborit, Poitiers, France|Service de Psychothérapie de l'Enfant et de l'Adolescent - Hôpital Robert Debré, Reims, France|Pôle de Psychiatrie de l'Enfant et de l'Adolescent - Centre Hospitalier Guillaume Régnier, Rennes, France",,"https://ClinicalTrials.gov/show/NCT01780883"
82,"NCT02140112","Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder",,"Terminated","No Results Available","Autism","Biological: Trichuris suis ova|Other: Placebo","Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks","Coronado Biosciences, Inc.","All","5 Years to 17 Years   (Child)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CNDO 201-101","May 2014","April 2015","April 2015","May 16, 2014",,"November 4, 2015","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Baber Research Group, Naperville, Illinois, United States|Montefiore Medical Center Dept. of Psychiatry, Child Annex, Bronx, New York, United States|Red Oak Psychiatry, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02140112"
83,"NCT00490802","Intranasal Oxytocin in the Treatment of Autism",,"Completed","Has Results","Autism","Drug: Oxytocin|Drug: Placebo","Clinical Global Impressions Scale - Improvement - Social|Repetitive Behavior Scale - Revised|Diagnostic Analysis of Nonverbal Accuracy, Paralanguage Test|Yale-Brown Obsessive-Compulsive Scale|Social Responsiveness Scale","Evdokia Anagnostou|Icahn School of Medicine at Mount Sinai|Anagnostou, Evdokia, M.D.","All","18 Years to 60 Years   (Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-0230 0001 02 PS","June 2006","September 2011","April 2012","June 25, 2007","November 5, 2014","October 23, 2015","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00490802"
84,"NCT00367107","Autism in Adult Patients and the Effects on Caregivers",,"Unknown status","No Results Available","Autism",,,"Sheba Medical Center","All","30 Years to 45 Years   (Adult)",,"240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SHEBA-06-4169-RG-CTIL","August 2008","August 2009",,"August 22, 2006",,"February 6, 2008","Sheba Medical Center, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00367107"
85,"NCT04623398","Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)","Lisphem","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: Lithium Carbonate|Drug: Placebo","Score social responsiveness scale|score of autism diagnosis observation scale|Score of attention deficit hyperactivity disorder|score of child's sleep disorder rating scale|Score of Dunn Sensory Profile|Score of Aberrant Behavior checklist scale|score of global functioning|Score of Vineland Adaptive Behavior Composite|Score of surrounding constraints|score of Columbia Suicide Severity Rating Scale","Assistance Publique - Hôpitaux de Paris","All","7 Years to 18 Years   (Child, Adult)","Phase 3","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P160914","September 2021","September 2023","September 2023","November 10, 2020",,"September 16, 2021","Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT04623398"
86,"NCT01999894","Open-label Study of Safety and Tolerability of Memantine in Children With Autism",,"Completed","Has Results","Autism|Pediatric Autism","Drug: Memantine HCl","Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)","Forest Laboratories|Merz Pharmaceuticals GmbH","All","6 Years to 18 Years   (Child, Adult)","Phase 2","102","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEM-MD-67","November 2009","February 2013","February 2013","December 3, 2013","March 18, 2014","March 18, 2014","Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 003, Sacramento, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 020, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 024, Jacksonville Beach, Florida, United States|Forest Investigative Site 007, St. Petersburg, Florida, United States|Forest Investigative Site 014, Hoffman Estates, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 010, Indianapolis, Indiana, United States|Forest Investigative Site 025, Cambridge, Massachusetts, United States|Forest Investigative Site 011, Toms River, New Jersey, United States|Forest Investigative Site 006, Voorhees, New Jersey, United States|Forest Investigative Site 017, Manhasset, New York, United States|Forest Investigative Site 013, Cleveland, Ohio, United States|Forest Investigative Site 015, Cleveland, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01999894"
87,"NCT04295746","Improving Daily Living Skills in People With Autism Spectrum Disorder Through a Personalised Serious Game",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Other: Serious Game ShopAut","change from baseline in a specific evaluation form based on the International Classification of Functioning, Disability and Health: children and youth version (ICF-CY) at 11 weeks|change from baseline in Vineland Adaptive Behavior Scale II (VABS-II) at 6 months|Vineland Adaptive Behavior Scale II (VABS-II) at 12 months|a specific evaluation form based on the International Classification of Functioning, Disability and Health: children and youth version (ICF-CY) at 12 months","Federico II University","All","8 Years to 16 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9820","March 1, 2019","November 30, 2019","September 30, 2021","March 4, 2020",,"July 23, 2020","University of Naples Federico II - Centro Medico Riabilitativo Pompei, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04295746"
88,"NCT02059577","Nutritional and Dietary Treatment Study for Children/Adults With Autism",,"Completed","No Results Available","Autism","Dietary Supplement: Nutritional and Dietary Interventions","Childhood Autism Rating Scale|Reynolds Intellectual Assessment Scales|Vineland Adaptive Behavior Scale","Arizona State University|Autism Research Instittute","All","30 Months to 60 Years   (Child, Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NutritionDietAutism","November 2011","April 2013","April 2013","February 11, 2014",,"February 11, 2014","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02059577"
89,"NCT03601468","Association Between Autism and Iron Deficiency",,"Unknown status","No Results Available","Autism in Children",,"Aggressive autism picture","Assiut University","All","2 Years and older   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Assiut university 2018","September 1, 2018","August 30, 2019","September 1, 2019","July 26, 2018",,"July 26, 2018",,,"https://ClinicalTrials.gov/show/NCT03601468"
90,"NCT00211796","Divalproex Sodium ER in Adult Autism",,"Completed","No Results Available","Autism","Drug: Divalproex Sodium ER","the Clinical Global Improvement and Severity scales (CGI-I and CGI-S)|Overt Aggression Scale-Modified (OAS M)|Affective Lability Scale (ALS).|Global Assessment of Functioning Scale (GAF)|Aggression Questionnaire (AQ)|the Hamilton Depression (Ham-D) Scale|Yale Brown Obsessive Compulsion Scale (YBOCS)|Compulsion sub-scale|Aberrant Behavior Checklist (ABC)|Barratt Impulsiveness Scale|Version11 (BIS-11).","Montefiore Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO#04-1106","April 2005","April 2007","April 2007","September 21, 2005",,"May 31, 2018","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00211796"
91,"NCT04660669","Early Intervention in Remote Autism (IPAAD)","IPAAD","Not yet recruiting","No Results Available","Early Intervention in Remote Autism","Other: ESDM intervention|Other: MOOC","The gain in developmental quotient measured using the Mullen Scales of Early Learning (MSEL)|Assessment of child autism symptoms and change in autism symptoms using ADOS-2|Assessment of child behavioral adaptation using The Vineland Adaptive Behavior Scales second version (VABS-2)|Assessment of sensory reactivity using The Dunn's Sensory Profile for toddlers|Assessment of the parent burden and quality of life using the CareQuol-7D","University Hospital, Brest","All","15 Months to 36 Months   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IPAAD (29BRC19.0279)","December 2020","December 2021","December 2024","December 9, 2020",,"December 9, 2020","CH Réné-Dubos, Cergy-Pontoise, France|CHU Le Havre, Le Havre, France|CH Limoges, Limoges, France|CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04660669"
92,"NCT00872898","Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism",,"Completed","Has Results","Autism","Drug: Memantine - Extended Release (ER)|Drug: Placebo","Extent of Absorption of Memantine (Part One)|Change in Total Raw Score of Social Responsiveness Scale|Core Autism Treatment Scale-Improvement: Total Score|Core Autism Treatment Scale-Improvement: Social Interaction|Core Autism Treatment Scale-Improvement: Communication|Change in Children's Communication Checklist-2 (CCC-2) - Speech Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Context Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Interests Subscale","Forest Laboratories|Merz Pharmaceuticals GmbH","All","6 Years to 18 Years   (Child, Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MEM-MD-57A","April 2009","August 2012",,"March 31, 2009","January 14, 2014","January 14, 2014","Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Sacramento, California, United States|Forest Investigative Site, San Francisco, California, United States|Forest Investigative Site, Santa Ana, California, United States|Forest Investigative Site, Stanford, California, United States|Forest Investigative Site, Jacksonville Beach, Florida, United States|Forest Investigative Site, St Petersburg, Florida, United States|Forest Investigative Site, Hoffman Estates, Illinois, United States|Forest Investigative site, Naperville, Illinois, United States|Forest Investigative Site, Indianapolis, Indiana, United States|Forest Investigative Site, Cambridge, Massachusetts, United States|Forest Investigative Site, Toms River, New Jersey, United States|Forest Investigative Site, Voorhees, New Jersey, United States|Forest Investigative Site, Manhasset, New York, United States|Forest Investigative Site, Cleveland, Ohio, United States|Forest Investigative Site, Columbus, Ohio, United States|Forest Investigative Site, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT00872898"
93,"NCT03494088","Mycobiome Evaluation in Children With Autism & GI Symptoms",,"Unknown status","No Results Available","Autism|Gastrointenstinal Symptoms",,"Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species|Presence of fungal species Candida tropicalis|Presence of fungal species Candida albicans|Presence of fungal species Saccharomyces cerevisiae|Gastrointentinal (GI) symptoms as assessed by the GI Symptoms Severity Index|Behavioral problems as assessed by the Aberrant Behavior Checklist (ABC)|Behavioral problems as assessed by the Social Responsiveness Scale-2 (SRS-2)|Oral Mycobiome Composition as assessed by sequencing of oral fungal species|Gut inflammation as assessed by fecal calprotectin levels|Antifungal immunity as assessed by serum dectin 1 levels","The University of Texas Health Science Center, Houston|Baylor College of Medicine","All","4 Years to 16 Years   (Child)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSC-MS-17-1015","March 22, 2018","May 1, 2019","May 1, 2019","April 11, 2018",,"May 14, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03494088"
94,"NCT00873834","Fluoxetine Essay in Children With Autism","FAIR","Withdrawn","No Results Available","Autism","Drug: fluoxetine|Drug: placebo","Subscores of Autism Diagnostic Interview (ADI-R)at each visit of the protocol (LECOUTER et RUTTER, 1989)|Sides effect scale (FSEC)|Aberrant Behavior Checklist (Aman et al., 1985)|Clinical Global Impressions (CGI) severity and improvement (NIMH.1985)","Assistance Publique - Hôpitaux de Paris","All","5 Years to 12 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P030901|AOM 98082","September 2009","November 2010","November 2011","April 2, 2009",,"January 10, 2012",,,"https://ClinicalTrials.gov/show/NCT00873834"
95,"NCT04271774","Genome Environment Microbiome and Metabolome in Autism Study","GEMMA","Recruiting","No Results Available","Autism Spectrum Disorder",,"Use of microbiome/metagenomics/metatrancriptomic analysis to identify through our proposed prospective study and validate through large existing microbiome projects multi-omic biomarker predictors of ASD in at-risk infants.","Massachusetts General Hospital|Azienda Sanitaria Locale Salerno|National University of Ireland, Galway, Ireland","All","up to 6 Months   (Child)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018P002109","July 1, 2019","December 2025","December 2025","February 17, 2020",,"September 1, 2021","Massachusetts General Hospital for Children, Boston, Massachusetts, United States|National University of Ireland Galway, Galway, Ireland|The Azienda Sanitaria Locale Salerno, Salerno, Italy",,"https://ClinicalTrials.gov/show/NCT04271774"
96,"NCT04517799","Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Drug: Epidiolex|Drug: placebo oral solution","Total Score on Repetitive Behavior Scale-Revised (RBS-R)|Total Score on Child Behavior Checklist (CBCL)|Autism Diagnostic Observation Scale- 2 (ADOS-2)|Total Score on Aberrant Behavior Checklist (ABC)|Total Score on Self Harm Inventory|Total Score on Social Responsiveness Scale|Total Score on Peabody Picture Vocabulary test (PPVT-4)|Total Score on Expressive One Word Picture Vocabulary test, Fourth Edition (EOWPVT-4)|Total Score on Children's Sleep Habits Questionnaire (CSHQ)","University of California, San Diego|Wholistic Research and Education Foundation","Male","7 Years to 14 Years   (Child)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","181455","June 1, 2020","February 28, 2022","December 31, 2022","August 18, 2020",,"September 5, 2021","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT04517799"
97,"NCT04288986","The Impact of Group Based Activity Programmes on Children Who Have Autism and Their Families in Staffordshire",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Keep Achieving","Social Skills Improvement System Rating Scales - Parent (SSIS; Gresham & Elliott (2007).|Social Skills Improvement System Rating Scales - Child (SSIS; Gresham & Elliott (2007).|Social Connectedness Scale Revised (SCS-R; Lee, Draper & Lee 2001)|Self Image Profile (SIP; Butler)|The Short Warwick-Edinburgh Mental Wellbeing Scales (SWEMWBS; Stewart-Brown et al., 2009)|Goal Based Outcomes (GBOs)","Midlands Psychology CIC","All","5 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MP/KA-3","March 15, 2020","January 1, 2021","January 1, 2021","February 28, 2020",,"February 28, 2020","The Hates, Stafford, Staffs, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04288986"
98,"NCT00208559","Ziprasidone in Children With Autism: A Pilot Study",,"Completed","No Results Available","Autism","Drug: Ziprasidone","Clinical Global Impressions|Children's Psychiatric Rating Scale","Drexel University College of Medicine|Drexel University","All","12 Years to 18 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00936","February 2002","June 2005","August 2006","September 21, 2005",,"June 17, 2010","Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00208559"
99,"NCT01740869","Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders","Autism","Unknown status","No Results Available","Autism|Autism Spectrum","Other: Stem cells","IDEA Improvement|CARS improvement","Hospital Universitario Dr. Jose E. Gonzalez","All","5 Years to 15 Years   (Child)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE12-021|Autism uanl","November 2012","November 2016","December 2016","December 4, 2012",,"June 4, 2015","Hematology Service, Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT01740869"
100,"NCT01603225","Transcranial Direct Current Stimulation and Autism",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders","Procedure: Transcranial Direct Current Stimulation (tDCS)","Picture naming accuracy|Picture naming speed","Johns Hopkins University","All","14 Years to 79 Years   (Child, Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NA_00042345","October 2015","October 2024","October 2024","May 22, 2012",,"November 2, 2020","Department of Neurology; Cognitive Neurology/Neuropsychology, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01603225"
101,"NCT01770548","Neurophysiological Molecular and Developmental Analysis of the Glutamate Synapse in Autism","NMDA-Autism","Completed","No Results Available","Autism","Genetic: analysis of the glutamate synapse in autism|Genetic: DNA collection|Other: Auditory evoked potentials","screening of about 50 genes encoding proteins of the NMDA receptor complex, chosen according to their chromosomal localisation located in hotspots depicted by genome-wide screens in large population of autistic patients","University Hospital, Tours","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","497","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","AORT08-FBB/NMDA-Autism|2008-A01162-53","January 2009","January 2011","June 2014","January 17, 2013",,"January 16, 2017","CHRU - Centre de Ressources Autisme (CRA), Brest, France|CHS du ROUVRAY, Rouen, France|Chru - Cic, Tours, France|CHRU - Pédopsychiatrie, Tours, France",,"https://ClinicalTrials.gov/show/NCT01770548"
102,"NCT04766970","Telehealth Autism Assessment for Adults",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: ADOS-2 Module 4|Behavioral: Adapted Telehealth ADOS-2 Module 4","Concurrent validity","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","202427","November 1, 2021","December 31, 2025","December 31, 2025","February 23, 2021",,"October 6, 2021",,,"https://ClinicalTrials.gov/show/NCT04766970"
103,"NCT02090829","Intranasal Oxytocin and Learning in Autism",,"Withdrawn","No Results Available","Autism Spectrum Disorders","Drug: Syntocinon (synthetic oxytocin)|Other: Placebo","Change from Baseline to Post-testing on the The Part/Whole Identity Test|Change from Baseline to Post-testing on the Reading the Mind in the Eyes Task|Change from Baseline to Post-testing on measures of social attention, reward/motivation, perception and cognition","University of Minnesota|Children's Hospital of Philadelphia","Male","12 Years to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1402M48250","March 2014","March 2018","March 2018","March 18, 2014",,"November 1, 2019","Center for Neurobehavioral Development, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02090829"
104,"NCT01727466","Treatment for Children With Autism and Anxiety",,"Completed","No Results Available","Autism","Behavioral: Facing Your Fears","Change in Clinical Global Impression Scale - Improvement and Severity (CGIS-S; CGIS-I)|Anxiety Disorders Interview Survey for Children-Parent Version (ADIS-P)","University of Colorado, Denver|Autism Speaks","All","8 Years to 14 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","03-0245","August 2006","September 2009","December 2009","November 16, 2012",,"November 16, 2012",,,"https://ClinicalTrials.gov/show/NCT01727466"
105,"NCT01630811","Nuedexta for the Treatment of Adults With Autism","Nuedexta","Completed","Has Results","Autism","Drug: Nuedexta|Other: Placebo","Change in Maladaptive Behaviors|Primary Safety Endpoints|Change in Aggressive Behavior","Sutter Health","All","18 Years to 60 Years   (Adult)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHKI-Nued0911","January 24, 2012","December 15, 2015","December 15, 2015","June 28, 2012","December 8, 2017","December 8, 2017","Sutter Pediatric Neurology, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01630811"
106,"NCT02154828","Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)","AUTISM","Completed","No Results Available","Autism","Behavioral: Integrative practices","Developmental evolution in the Psycho Educative-Profil 3 (PEP 3) scale between Month 0 and Month 12|Global evolution of children by ECA-R scale|Global evolution thanks to CARS scale","Nantes University Hospital","All","3 Years to 6 Years   (Child)",,"103","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC14_0029","September 2014","December 2016","March 2018","June 3, 2014",,"December 12, 2018","CHI Robert Ballanger, Aulnay sous bois, France|Daumezon hospital, Bouguenais, France|Brest University Hospital, Brest, France|Brive Hospital, Brive, France|CH du Vinatier, Bron, France|Inercomunal Center, Créteil, France|Fondation Vallée, Gentilly, France|CH Gonesse, Gonesse, France|HDJ Les Marmousets, Haguenau, France|ARSEAA - Centre de guidance, Labege, France|CH Saint-Marie, Le Puy-en-Velay, France|Lille University Hospital, Lille, France|EPSM de l'agglomération Lilloise, Mons en Baroeul, France|Nantes University Hospital, Nantes, France|Niort Hospital, Niort, France|HDJ La Pomme, Paris, France|Hôpitaux de St Maurice, Paris, France|Unité de soins précoces HJ René Diatkine ASM13, Paris, France|Saint-Nazaire Hospital, Saint-Nazaire, France|Centre Hospitalier CESAME, Sainte-Gemmes sur Loire, France|Rouvray Hospital, Sotteville les Rouen, France",,"https://ClinicalTrials.gov/show/NCT02154828"
107,"NCT01474993","Sulforaphane-rich Broccoli Sprout Extract for Autism",,"Completed","Has Results","Autism","Drug: Sulforaphane-rich Broccoli Sprout Extract|Drug: Placebo","Change From Screening/Baseline in Social Responsiveness Scale (SRS) at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Change From Screening/Baseline in Aberrant Behavior Checklist (ABC) at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S) Scale at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) (or CGI-I Scores) Scores at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Liver Function Tests [Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT)] at 4 Weeks, 18 Weeks and 22 Weeks|Renal Function Tests (Serum Creatinine) at 4 Weeks, 18 Weeks and 22 Weeks|Thyroid Stimulating Hormone (TSH) at 4 Weeks, 18 Weeks and 22 Weeks|Red Blood Cell (RBC) Count at 4 Weeks, 18 Weeks and 22 Weeks|White Blood Cell (WBC) Count at 4 Weeks, 18 Weeks and 22 Weeks|Platelet Count at 4 Weeks, 18 Weeks and 22 Weeks|Change From Screening and Baseline in Urinary Isoprostane F2α-VI Levels at 24 Hours After First Dose, at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Change From the Screening Visit in Heat Shock Protein Gene Expression (Relative Maximum Gene Expression) at 24 Hours After First Dose, 18 Weeks and 22 Weeks","Andrew Zimmerman|Johns Hopkins University|University of Massachusetts, Worcester","Male","13 Years to 30 Years   (Child, Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011P002221","December 2011","November 2013","November 2013","November 18, 2011","November 24, 2014","September 12, 2018","Lurie Center for Autism, MassGeneral Hospital for Children, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01474993"
108,"NCT00211757","Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism",,"Completed","Has Results","Autism","Drug: Divalproex sodium|Drug: Placebo","Number of Participants Reporting Improvement on the Clinical Global Impression|Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores","Montefiore Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)","All","5 Years to 17 Years   (Child)","Phase 2","27","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-0294|1R21NS043979","September 2002","July 2008","July 2008","September 21, 2005","December 6, 2018","December 6, 2018","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00211757"
109,"NCT00584701","Pharmacogenomics in Autism Treatment","PG","Completed","Has Results","Autism","Drug: Risperidone","Percent Change of ABC - Irritability Subscale Score|Exon Expression Positively or Negatively Correlated With Percentage Improvement in ABC-I","University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)","All","4 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","49","Other|Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200715817-1|R21MH080026","January 2008","May 2009","May 2009","January 2, 2008","July 24, 2012","July 24, 2012","UC San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00584701"
110,"NCT00211770","Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.",,"Completed","No Results Available","Autism","Behavioral: Behavioral Assessment",,"Icahn School of Medicine at Mount Sinai","All","5 Years to 18 Years   (Child, Adult)",,"144","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GCO # 04-0629","February 2005","December 2005","December 2012","September 21, 2005",,"June 12, 2013","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00211770"
111,"NCT03971578","Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: No Intervention Provided","ABR Peak Latency and Amplitude","Intelligent Hearing Systems|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","42 Months to 54 Months   (Child)",,"100","Industry|NIH","Observational","Observational Model: Case-Control|Time Perspective: Other","ASDCLAD001","February 1, 2020","May 2022","August 2022","June 3, 2019",,"August 25, 2021","University of Miami Department of Psychology, Coral Gables, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03971578"
112,"NCT01638819","Autologous Cord Blood Stem Cells for Autism",,"Completed","Has Results","Autism","Biological: Autologous Cord Blood Stem Cells|Biological: Placebo","Change in Language (Total Standard Score, Range 40 - 160)|Change in Behavior/Learning (Standard Score, Range 40 - 160 for Each Subtest)|Change in Knowledge and Fluid Reasoning (Scaled Score, Range 1-19 for Each Subtest)","Sutter Health","All","2 Years to 7 Years   (Child)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CB2011Chez","August 2012","December 2015","December 2016","July 12, 2012","August 20, 2018","August 20, 2018","Sutter Pediatric Neurology, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01638819"
113,"NCT04939974","Probiotic in Autism",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Dietary Supplement: probiotic","change in childhood autism rating scale at 24 weeks as compared to baseline","All India Institute of Medical Sciences, New Delhi","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","probiotic autism","August 1, 2021","August 1, 2022","August 1, 2022","June 25, 2021",,"June 25, 2021",,,"https://ClinicalTrials.gov/show/NCT04939974"
114,"NCT00655174","Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?",,"Completed","No Results Available","Autism","Drug: fluvoxamine|Drug: sertraline|Drug: Placebo","The severity of the autistic child's behaviour or condition (assessed by parents)|Weight and vital signs|Blood count and liver function studies","The Hospital for Sick Children","All","3 Years to 10 Years   (Child)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0019990290","June 1999","September 2006","January 2007","April 9, 2008",,"April 9, 2008","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00655174"
115,"NCT01624194","Intranasal Oxytocin Treatment for Social Deficits in Children With Autism",,"Completed","Has Results","Autism","Drug: Oxytocin nasal spray|Drug: Placebo","Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment.|Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment|Change From Baseline in Height.|Clinical Global Impression-Improvement (CGI-I) Score at Week 4|Parent Rated Aberrant Behavior Checklist (ABC) Irritability Scores at Baseline and Week 4|Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.|Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition - Social and Communication Subscales During Treatment.|Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.|Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.|Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.|Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.|Change From Baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Affect Recognition Scores During Treatment.|Change From Baseline in Plasma Oxytocin Levels During Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale- Revised (RBS-R) Scores During Treatment.|Change From Baseline in Weight|Change From Baseline in Heart Rate|Change From Baseline in Blood Pressure","Stanford University","All","6 Years to 12 Years   (Child)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-12132011-8827","June 2012","May 2016","May 2016","June 20, 2012","June 6, 2018","July 15, 2019","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01624194"
116,"NCT00208533","Aripiprazole in Children With Autism: A Pilot Study",,"Completed","No Results Available","Autism","Drug: Aripiprazole","Clinical Global Impressions","Drexel University College of Medicine|Drexel University","All","12 Years to 18 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02841","February 2004","November 16, 2011","November 16, 2011","September 21, 2005",,"July 30, 2018","Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00208533"
117,"NCT02720900","Prebiotic Intervention for Autism Spectrum Disorders",,"Completed","No Results Available","Autism","Dietary Supplement: B-GOS|Dietary Supplement: Maltodextrin","effect on faecal microbiota composition using pyrosequencing|effect on faecal microbiota activity using nuclear magnetic resonance spectroscopy|questionnaire as a measure of bowel function|questionnaire as a measure of mood|questionnaire as a measure of behaviour","Clasado Limited|University of Reading","All","5 Years to 10 Years   (Child)","Not Applicable","41","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASD2015","September 2015","September 2016","May 2017","March 28, 2016",,"February 15, 2018","University of Reading, Reading, Berks, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02720900"
118,"NCT00378157","Joint Attention Intervention and Young Children With Autism",,"Completed","No Results Available","Autism","Behavioral: Joint attention intervention","childrens score on measures of joint attention|score on measures of joint engagement -child and mother|childrens score on measures of language|parents and service providers perception of the intervention","Ullevaal University Hospital|Centre for Child and Adolescent Mental Health|Oslo University Hospital","All","24 Months to 60 Months   (Child)","Phase 1|Phase 2","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UUS 29560105","September 2006","December 2009","January 2010","September 19, 2006",,"February 23, 2011","Ullevaal University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00378157"
119,"NCT04841525","Autism Biomarker Consortium for Clinical Trials (ABC-CT): Follow-up Study","ABC-CT","Enrolling by invitation","No Results Available","Autism Spectrum Disorder",,"N170 Latency to Upright Human Faces|Oculomotor Index of Gaze to Human Faces (OMI)|VABS: Vineland Adaptive Behavior Scales- III Socialization","Yale University|Boston Children's Hospital|Duke University|University of California, Los Angeles|University of Washington|Food and Drug Administration (FDA)|National Institute of Mental Health (NIMH)","All","6 Years to 11 Years   (Child)",,"399","Other|U.S. Fed|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1509016477_b|U01FD006888|U19MH108206","April 9, 2021","June 1, 2026","June 1, 2026","April 12, 2021",,"April 21, 2021","Yale University Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04841525"
120,"NCT03015272","Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Autism","Behavioral: Auditory-Motor Mapping Training|Behavioral: Speech-Repetition Therapy","Change in approximately correct Consonant-Vowel Syllables between Best-Baseline and Post-25-session assessment|Change in approximately correct Consonant-Vowel Syllables between Best-Baseline and Post-4-week follow-up assessment","Beth Israel Deaconess Medical Center|Boston University","All","66 Months to 120 Months   (Child)","Phase 2|Phase 3","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2012P000344","November 2014","September 2019","December 2019","January 10, 2017",,"May 19, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Boston University, Autism Center of Excellence, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03015272"
121,"NCT04551313","Effectiveness of Social Skills Training Group for Children With Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: social skill group","GAS (Goal attainment scale)|Vineland Adaptive Behavior Scale","National Taiwan University Hospital","All","5 Years to 6 Years   (Child)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","202006158RINA","October 5, 2020","October 2023","October 2023","September 16, 2020",,"September 16, 2020","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04551313"
122,"NCT04275063","Autism, Sport and Society: Conversations With Parents",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder",,"Child Physical Activity and Parent Attitudes to Sport: Parent Questionnaire","Midlands Psychology CIC","All","Child, Adult, Older Adult",,"30","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","MP/KA-2","March 1, 2020","August 1, 2020","August 1, 2020","February 19, 2020",,"February 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04275063"
123,"NCT03033784","Autism Oxytocin Brain Project",,"Completed","Has Results","Autism|Autism Spectrum Disorder","Drug: 8 International Units (IU) of Oxytocin|Drug: 24IU of Oxytocin|Drug: 48IU of Oxytocin|Drug: Placebo","Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex)|Blood Oxygen Level Dependent (BOLD) Activity in Response to Social Cues|Percent Change in Blood Oxygen Level Dependent (BOLD) Activity During Ball-Game Task|Oxytocin Plasma Concentration|Rate of Smiling During Global Clinical Interview|Milliseconds of Visual Fixation|Social Learning Test (SLT) Reaction Time","Emory University|National Institute of Mental Health (NIMH)","Male","18 Years to 45 Years   (Adult)","Phase 2","51","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00093455|P50MH100023","May 10, 2017","October 3, 2018","October 3, 2018","January 27, 2017","January 12, 2021","January 12, 2021","Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03033784"
124,"NCT04472780","Hyperbaric Oxygen Treatment in Autism Spectrum Disorders",,"Recruiting","No Results Available","Child Autism","Device: Hyperbaric oxygen Therapy HBOT","clinical severity assesement|dosage of Inetreleukine 6|dosage of TNFα|Oxidatif stress profil|dosage of Glutathione peroxidase","General Administration of Military Health, Tunisia|Military Hospital of Tunis","All","4 Years to 14 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Autism spectrum disorder","June 1, 2019","October 1, 2021","October 1, 2021","July 15, 2020",,"September 22, 2021","HBOT Department Military Hospital, Tunis, Montfleury, Tunisia",,"https://ClinicalTrials.gov/show/NCT04472780"
125,"NCT02871349","Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Propranolol|Drug: Placebo|Device: Magnetic Resonance Imaging (MRI)","Change in General Social Outcomes Measure (GSOM) Assessment|Change in Social Responsiveness Scale (SRS-2)|Change in score on Anagrams test|Change in Semantic fluency test results|Change Clinical Global Impression surveys|Change in Autism Impact Measure (AIM)|Change in Clinical Evaluation of Language Fundamentals (CELF-5) assessment|Change in Vineland Adaptive Behavior Scales (VABS-2) assessment|Change in score on Aberrant Behavior Checklist (ABC)|Change in gastrointestinal symptomology","University of Missouri-Columbia|United States Department of Defense","All","7 Years to 24 Years   (Child, Adult)","Early Phase 1","69","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2005213","August 2016","August 2020","August 2020","August 18, 2016",,"October 8, 2020","Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02871349/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02871349"
126,"NCT04484077","hCT-MSC Infusion in Adults With Autism Spectrum Disorder","AIMs","Not yet recruiting","No Results Available","Autism Spectrum Disorder|Autism","Biological: hCT-MSC","Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Repetitive Behavior Scale Revised - parent/guardian questionnaire|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years to 35 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00104691","September 2021","March 2023","March 2023","July 23, 2020",,"June 29, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04484077"
127,"NCT01625299","Pilot Study of Diet and Behavior in Children With Autism",,"Completed","No Results Available","Autism","Dietary Supplement: Gluten and dry milk|Dietary Supplement: Placebo","Intestinal Permeability|Psychometric testing|Gastrointestinal symptoms","The University of Texas Health Science Center, Houston","All","3 Years to 12 Years   (Child)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","HSC-MS-07-0223","October 2008","March 2011","March 2011","June 21, 2012",,"June 21, 2012","The University of Texas Health Science Center At Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01625299"
128,"NCT03005431","Parents of Newly Diagnosed Preschool Children With Autism Spectrum Disorder:",,"Unknown status","No Results Available","Autism","Behavioral: Parent training and support","Change in the Parent's Knowledge of ASD and Early Home Intervention Questionnaire.|Change in the Early Intervention Techniques Parent Rating Scale.|Change in Parent/Child Joint Engagement|Change in Expressive Communication Measure|Change in the Parenting Stress Index-Short Form|Change in the Family Support Scale","University of Manitoba","All","up to 59 Months   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HS20295 (H2016:427)","January 2017","April 2018","April 2018","December 29, 2016",,"October 3, 2017",,,"https://ClinicalTrials.gov/show/NCT03005431"
129,"NCT01225198","Vitamin/Mineral Supplement for Children and Adults With Autism",,"Completed","No Results Available","Autism","Dietary Supplement: Multi-Vitamin/Mineral Supplement|Other: Liquid Placebo","Oxidative Stress|Parent Global Impressions - Revised","Arizona State University|Autism Research Institute|Legacy Foundation","All","3 Years to 60 Years   (Child, Adult)","Phase 2","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AutismVitaminStudy2008","May 2008","February 2009","February 2009","October 20, 2010",,"October 20, 2010","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01225198"
130,"NCT04654117","Examining the Active Ingredients of Consultation to Improve Implementation of a Parent-mediated Intervention for Children With Autism in the Community Mental Health System",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: Consultee-centered administrative consultation","Treatment adherence|Parent-mediated intervention competence|Case penetration|Ratings of feasibility, acceptability, and appropriateness of each consultation phase|Ratings of feasibility, acceptability, and appropriateness of Project ImPACT|Child social communication skills","Michigan State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","R40MC27705","May 2021","July 2021","April 2022","December 4, 2020",,"March 25, 2021","Michigan State University, East Lansing, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04654117"
131,"NCT01018407","Interventions for Communication in Autism Network","ICAN","Completed","No Results Available","Autism","Behavioral: Discrete Trial Training|Behavioral: Interpersonal Developmental Approach","Reynell Developmental Language Scale|McArthur-Bates Communicative Development Inventory (Word and Gestures Inventory and/or Words and Sentences Inventory)|Caregiver-child Interaction|Early Social Communication Scale|Structured Play Assessment","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","33 Months to 54 Months   (Child)","Not Applicable","192","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01MH084864-01A109|1R01MH084864|DDTR B2-MBA","December 2009","June 2015","June 2015","November 23, 2009",,"June 8, 2015","University of California, Los Angeles, Los Angeles, California, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01018407"
132,"NCT03866668","A Study of Esomeprazole in Children With Autism",,"Suspended","No Results Available","Autism|Autism Spectrum Disorder","Drug: Esomeprazole","Change from Baseline on the Social Responsiveness Scale, 2nd Edition (SRS-2)|Change from Baseline on the Aberrant Behavior Checklist, 2nd Edition (ABC-2)","Stanford University|SPARK (Stanford University)","All","2 Years to 6 Years   (Child)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-44589","May 29, 2019","December 2022","December 2022","March 7, 2019",,"May 4, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03866668"
133,"NCT02903732","Autism Registry for French Guiana","REGUYAUT","Unknown status","No Results Available","Autism Spectrum Disorder","Other: observational","autism spectrum disorder","Centre Hospitalier de Cayenne","All","8 Years to 8 Years   (Child)",,"400","Other","Observational","Time Perspective: Cross-Sectional","REGUYAUT","September 2015","September 2015","December 2020","September 16, 2016",,"September 16, 2016","Centre Hospitalier de Cayenne, Cayenne, French Guiana, France",,"https://ClinicalTrials.gov/show/NCT02903732"
134,"NCT01768806","Randomized Controlled Trial of the P.L.A.Y. (Play and Language for Autistic Youngsters) Project Intervention for Autism","PLAY","Completed","No Results Available","Autism|Autism Spectrum Disorder","Behavioral: PLAY Project Intervention for Autism|Behavioral: Special education pre-school","Reduction in autism severity as measured by the Autism Diagnostic Observation Scale (ADOS)|Language as measured by the MacArthur-Bates Communicative Developmental Inventories|Vineland Adaptive Behavior Scale","Richard Solomon MD, Plc|Michigan State University|National Institute of Mental Health (NIMH)","All","3 Years to 5 Years   (Child)","Not Applicable","112","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3125511|2R44MH078431-02A1","September 2009","June 2012","December 2012","January 15, 2013",,"January 17, 2013","Ann Arbor Center for Developmental and Behavioral Pediatrics, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01768806"
135,"NCT00917683","Investigation of Neuroserpin as an Autism Candidate Gene",,"Terminated","No Results Available","Autism",,"Determine SERPIN1 gene sequence variation in autistic subjects.","State University of New York - Upstate Medical University","All","1 Year and older   (Child, Adult, Older Adult)",,"5","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB#5811","June 2009","April 2012","April 2012","June 10, 2009",,"April 19, 2016","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT00917683"
136,"NCT04069676","Emotional Proactive Brain Study in Adults With Autism Spectrum Condition","PREDEMAUT","Recruiting","No Results Available","Autism Spectrum Disorder","Other: EEG","Differences between autistic and typically developed participants in evoked potentials related to prediction mechanisms during visual processing|Differences between autistic and typically developed participants in behavioral responses related to prediction mechanisms during visual processing|Differences between groups in oscillatory activity|Difference between groups in cerebral connectivity|Differences between groups in autonomous activity|Sex differences","University Hospital, Grenoble|Laboratoire de Psychologie et NeuroCognition","All","18 Years to 50 Years   (Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC19.131|2019-A01145-52","September 17, 2020","September 16, 2023","September 16, 2023","August 28, 2019",,"March 29, 2021","Chu Grenoble Alpes, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04069676"
137,"NCT01260961","Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial",,"Active, not recruiting","No Results Available","Autism","Dietary Supplement: Placebo|Dietary Supplement: Docosahexanoic Acid","Amelioration of phenotypic features of autism|oxidative stress biomarkers","Rutgers, The State University of New Jersey","All","5 Years to 17 Years   (Child)","Not Applicable","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0220080189","November 2010","July 2015","December 2021","December 15, 2010",,"December 7, 2020","Rutgers, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01260961"
138,"NCT01040221","Trichuris Suis Ova in Autism Spectrum Disorders","TSO","Completed","No Results Available","Autism","Drug: Trichuris Suis Ova","Yale-Brown Obsessive Compulsive Scale (YBOCS): to measure repetitive behaviors|Aberrant Behavior Checklist (ABC): to measure aggression and irritability|Clinical Global Impression - Improvement (CGI-I): to measure global functioning|Repetitive Behavior Scale-Revised.","Montefiore Medical Center|Simons Foundation","All","18 Years to 35 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-11-384","November 2012","June 2014","July 2014","December 29, 2009",,"April 3, 2018","Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01040221"
139,"NCT00938054","Identification of Characteristics Associated With Symptom Remission in Autism",,"Completed","No Results Available","Autism Spectrum Disorders|Autism",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","7 Years to 17 Years   (Child)",,"37","NIH","Observational","Time Perspective: Other","090171|09-M-0171","June 25, 2009",,"October 9, 2012","July 13, 2009",,"October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00938054"
140,"NCT00819364","Early Intervention Program for Children With Autism (BCRI Model)",,"Unknown status","No Results Available","Autism|Autism Spectrum Disorder","Behavioral: BCRI intervention program|Behavioral: Standard community care","Psychoeducational Profile-3rd Edition(PEP-3)|SRS(social response scale) scores and/or C-WYCSI scores at 2-year follow-up. SRS(social response scale) scores and/or C-WYSC scores at 5-year follow-up.","Sun Yat-sen University","All","up to 30 Months   (Child)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2007024","August 2009","August 2013","August 2016","January 9, 2009",,"August 11, 2009",,,"https://ClinicalTrials.gov/show/NCT00819364"
141,"NCT02586935","Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders","TIDE","Completed","No Results Available","Autism Spectrum Disorders","Drug: Tideglusib|Other: Placebo","Effect of tideglusib vs. placebo on measures of social engagement/withdrawal|Efficacy of tideglusib vs. placebo on measures of repetitive behaviours|Efficacy of tideglusib vs. placebo on measures of social function|Safety and tolerability of tideglusib in adolescents with ASD|Pharmacokinetic (PK) parameters in this age group","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|University of Western Ontario, Canada|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.","All","12 Years to 17 Years   (Child)","Phase 2","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TIDE-06-2015","February 10, 2016","February 25, 2018","February 25, 2018","October 27, 2015",,"May 31, 2018","McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada|University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02586935"
142,"NCT04859998","Effects of Animal-assisted Therapy on the Physical Function and Communication of Adults With Autism",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: dog-assisted therapy","Changes in walking performance (10m)|Changes in walking performance (6m)|Changes in balance and risk of falling|Changes in communication without dog|Changes in communication with dog|Changes in the ability to climb and descend stairs|Changes in step length (6m)|Changes in step length (10m)|Changes in cadence (6m)|Changes in cadence (10m)|Changes in duration of phases in the gait cycle (6m)|Changes in duration of phases in the gait cycle (10m)","Daniel Collado-Mateo|Asociación de Padres de Personas Con Autismo (APNA)|Asociación Nuevo Horizonte|Federación Autismo Madrid|King Juan Carlos University","All","40 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","AATinAutism","April 26, 2021","July 15, 2021","July 15, 2021","April 26, 2021",,"April 26, 2021","King Juan Carlos University, Móstoles, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04859998"
143,"NCT02579109","Multisensorial Information's Treatment in Autism Spectrum Disorder",,"Completed","No Results Available","Autism","Other: memory test","rate of reminder after 30 minutes between the group autistic and the group witness( %)|Difference of the scores of reminders words (%)","Centre Hospitalier Universitaire de Nice","All","7 Years to 13 Years   (Child)","Not Applicable","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13AOI09","February 2014","February 2014","August 2014","October 19, 2015",,"October 19, 2015",,,"https://ClinicalTrials.gov/show/NCT02579109"
144,"NCT04549506","Autism, Emotional Processing, and the Amygdala",,"Completed","No Results Available","Autism Spectrum Disorder",,"Age|Anxiety scores|Severity of Austism-Spectrum Disorders|Color identification task|Detection task|fMRI response","Yawei Cheng|National Yang Ming University","All","13 Years to 40 Years   (Child, Adult)",,"51","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","YM102035","April 19, 2014","September 21, 2016","June 16, 2017","September 16, 2020",,"September 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04549506"
145,"NCT01451983","Genetics, Brain Structure and Thinking Skills in Autism",,"Completed","Has Results","Autism Spectrum Disorders",,"Total Brain Volume","The Cleveland Clinic|National Institutes of Health (NIH)|National Center for Research Resources (NCRR)","All","2 Years to 50 Years   (Child, Adult)",,"138","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CCF 09-624|UL1RR024989","May 2010","August 2014","August 2014","October 14, 2011","January 14, 2015","January 14, 2015","Cleveland Clinic Center for Autism, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01451983"
146,"NCT01912378","Triadic Interactions of Families With Autism and Oxytocin","TAO","Withdrawn","No Results Available","Autism Disorder","Drug: Oxytocin|Drug: Placebo nasal spray","Parental social behavior|Child and Parent Physiological Synchrony|Child social behavior","University of California, San Francisco","All","7 Years to 60 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TAO","August 2013","May 2015","May 2015","July 31, 2013",,"January 16, 2019","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01912378"
147,"NCT04186364","Autism Spectrum Ambassador Program (ASAP) in the ED",,"Withdrawn","No Results Available","Autism Spectrum Disorder","Behavioral: Assigned Ambassador","Patient Satisfaction Survey (Questionnaire)|Medical Student Satisfaction Survey (Questionnaire)|Medical Student Career Interest (Questionnaire)|Medical Student Comfort Level (Questionnaire)","Milton S. Hershey Medical Center","All","30 Months to 17 Years   (Child)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","00002020","April 1, 2021","April 8, 2021","April 8, 2021","December 4, 2019",,"April 13, 2021","Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04186364"
148,"NCT04576559","Effect of Modified Dental Visual Aids on Behavior Management During Dental Treatment in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Child Autism","Other: Modified dental visual aids|Other: Regular dental visual aids","Plaque Index Scoring|Anxiety Scale for Children with Autism Spectrum Disorder (ASC-ASD)|The Observational Scale of Behavioral Distress (OSBD)","King Abdulaziz University","All","6 Years to 10 Years   (Child)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","KingAbdulazizUni","September 1, 2019","July 1, 2021","August 30, 2021","October 6, 2020",,"February 23, 2021","King Abdulaziz University, Jeddah, Select A State Or Province, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04576559"
149,"NCT04845776","Vitamin/Mineral Supplement for Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Dietary Supplement: ANRC Essentials Plus","Parent Global Impressions of Autism","Arizona State University|Southwest College of Naturopathic Medicine","All","3 Years to 17 Years   (Child)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00013694","May 4, 2021","April 20, 2022","April 20, 2023","April 15, 2021",,"May 6, 2021","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04845776"
150,"NCT04744428","Trial of Autism Parent Navigator Program","APN","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Autism Parent Navigators|Behavioral: Peer mentoring","Weekly Count of Service Navigation Behaviors|Parenting Scale (Arnold)|CES-Depression|Coparenting Relationship Scale (Feinberg, Brown, & Kan, 2012)|Family Empowerment Scale - FES|PDD-BI","Penn State University|University of South Carolina|Family Connections","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","APN-RT01","March 25, 2021","July 1, 2024","July 1, 2025","February 9, 2021",,"May 11, 2021","Family Connections, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04744428"
151,"NCT03690661","Using Serious Games to Improve Social Skills in Autism","SAGA","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Intervention Video Game|Behavioral: Placebo Control Game","Primary Target Eye Gaze Mechanisms - Performance Accuracy|Primary Target Eye Gaze Mechanisms - Visual Fixation|Social Symptoms - Social Skills Inventory System (SSIS)|Autism Behaviors - Social Responsiveness Scale 2nd Edition (SRS-2)|Intermediate Face Processing Mechanisms - Face Identity (CFMT)|Intermediate Face Processing Mechanisms - Object Identity (CBMT)|Intermediate Face Processing Mechanisms - Face Expression Identification - (CAM)|Intermediate Face Processing Mechanisms - Face Expression Identification - (RMET)|Face-to-Face Social Interactions - Visual Fixations","Penn State University|National Institute of Mental Health (NIMH)","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","11","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","R33MH110624","December 1, 2019","July 31, 2022","July 31, 2022","October 1, 2018",,"April 19, 2021","Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03690661"
152,"NCT02272192","Intervention Effects of Intensity and Delivery Style for Toddlers With Autism","TADPOLE","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model (ESDM)|Behavioral: Early Intensive Behavioral Intervention (EIBI)","Expressive Communication Composite Score|Autism Severity Composite Score|Receptive Language Composite Score|Nonverbal Development Composite Score","University of California, Davis|University of Washington|Vanderbilt University|University of California, Los Angeles","All","15 Months to 30 Months   (Child)","Not Applicable","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","406188","March 2013","July 1, 2019","July 1, 2019","October 22, 2014",,"January 6, 2020","UC Davis MIND Institute, Sacramento, California, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Washington Autism Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02272192"
153,"NCT03693313","The Effect of CrossFit Kids on Social Skills in Children With Autism Spectrum Disorder (CrossFit KAMP)","CrossFit KAMP","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: CrossFit Kids exercise program","Improvement in social skills in children with ASD|Improvement in behavioral symptoms in children with ASD|Improvement in repetitive behaviors in children with ASD","University of California, Davis","All","8 Years to 11 Years   (Child)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1235533","September 4, 2018","August 30, 2019","September 30, 2019","October 2, 2018",,"October 31, 2019","UC Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03693313"
154,"NCT04165655","Keep Achieving:The Impact of Group Based Activity Programmes on Children Who Have Autism and Their Families",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Keep Achieving (KA)","Change in Social Skills Improvement System Rating Scales - Parent (Social Skills Improvement System; Gresham & Elliott (2007).|Change in Social Skills Improvement System Rating Scales - Child (Social Skills Improvement System; Gresham & Elliott (2007).|Social Connectedness Scale Revised (SCS-R; Lee, Draper & Lee 2001)|Self Image Profile (SIP; Butler)|The Short Warwick-Edinburgh Mental Wellbeing Scales (SWEMWBS; Stewart-Brown et al., 2009)|Goal Based Outcomes (GBOs)","Midlands Psychology CIC","All","8 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MP/KA-1","February 1, 2020","April 2020","May 2020","November 18, 2019",,"March 2, 2020","The Hayes, Stafford, Staffordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04165655"
155,"NCT04832152","Telehealth Intervention for Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: OT4ASD","Daily Living Skills Change Score - Pediatric Evaluation of Disabilities Inventory|Autism Behaviors Pervasive Developmental Disorders Behavioral Inventory T Score|Goal Attainment Scale T Score|Sensory Processing Measure","Thomas Jefferson University|Montefiore Medical Center","All","4 Years to 12 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","412579-19406","May 1, 2021","April 30, 2022","June 30, 2022","April 5, 2021",,"April 9, 2021",,,"https://ClinicalTrials.gov/show/NCT04832152"
156,"NCT02094651","Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium",,"Withdrawn","No Results Available","Autism","Drug: divalproex sodium|Other: Placebo","effect of drug vs placebo on reduction in epileptiform EEG discharges in children with ASD|behavior changes in drug vs placebo.","Boston Children's Hospital|University of Louisville","All","4 Years to 10 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","P00005744","April 2014","October 2016","October 2016","March 24, 2014",,"October 21, 2016","University of Louisville, Louisville, Kentucky, United States|Boston Childrens Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02094651"
157,"NCT04107064","Achieving Steady Work Among Adults With Autism Through Specialized Employment Program",,"Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: NaW|Behavioral: NaW-DS","Job Retention Rates|Duration of Sustained Employment|Costs of Employee Turnover|Rates of Job Offers|World Health Organization Quality of Life Assessment [WHOQOL-100]|Maslach's Burnout Measure|Meyer and Allen's Affective Commitment Measure|Eisenberger's Perceived Organizational Support|Morgensen and Humphrey's Job Characteristics (WDQ)|Judge's Global Job Satisfaction|MOAQ Subscale: Intent to Turnover|Work Motivation and Engagement (UWES)|ANZ Financial Well-being Scale","Lawrence Fung|3R Behavioral Solutions|Rangam Consultants|Stanford University","All","18 Years to 55 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","50268","September 30, 2019","March 2024","December 2025","September 27, 2019",,"September 21, 2021","Stanford University School of Medicine, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04107064"
158,"NCT02560415","Gaming Open Library for Intervention in Autism at Home (GOLIAH /MICHELANGELO)","MICHELANGELO","Completed","No Results Available","Autism Spectrum Disorder","Device: Experimental|Behavioral: Comparator","change from baseline in Autism Diagnostic Observation Schedule (ADOS) at 6 months|change from baseline in Vineland II at 6 months|change from baseline in Child Behavior Check List at 6 months|change from baseline in Wechsler Intelligence scale at 6 months|change from baseline in Social Communication Questionnaire at 6 months|change from baseline in Parental Stress Index at 6 months","Assistance Publique - Hôpitaux de Paris|European Commission","All","5 Years to 8 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDRCB2014-A-00170-47 - P120914|EU: FP7-ICT-2011-7 (n°288241)","September 2014","June 2015","June 2015","September 25, 2015",,"September 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02560415"
159,"NCT02996669","Autism Biomarker Consortium for Clinical Trials","ABC-CT","Completed","No Results Available","Autism Spectrum Disorder",,"NEPSY-II|Video Tracking|Aberrant Behavior Checklist (ABC)|Autism Impact Measure (AIM) Frequency|Autism Impact Measure (AIM) Impact|Child and Adolescent Symptom Inventory 5 (CASI-5)|PDD Behavior Inventory (PDD-BI)|Social Responsiveness Scale 2 (SRS-2) Total Score|Cognitive Assessment|Resting State EEG|Faces EEG|Visual Evoked Potentials (VEPs) EEG|Biological Motion EEG|Eye-tracking (ET) Biological Motion Task|Eye-tracking (ET) Activity Monitoring Task|Eye-tracking (ET) Interactive Social Task (IST)|Eye-tracking (ET) Pupillary Light Reflex Task|Eye-tracking (ET) Visual Search/Static Social Scenes Task","Yale University|Boston Children's Hospital|Duke University|University of California, Los Angeles|University of Washington|Food and Drug Administration (FDA)|National Institute of Mental Health (NIMH)","All","6 Years to 11 Years   (Child)",,"399","Other|U.S. Fed|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1509016477|U01FD006888|U19MH108206","October 2016","May 13, 2019","May 13, 2019","December 19, 2016",,"March 5, 2020","Yale University Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02996669"
160,"NCT00786799","Omega-3 Fatty Acids for Autism Treatment",,"Completed","Has Results","Autism","Dietary Supplement: Omega-3 Fatty Acids","Group-specific and Comparison of Change in Aberrant Behavior Checklist-Hyperactivity Subscale Score (Active Omega-3 Group Only, Placebo Group Only and Comparison Between Groups)|Change in Percentage of Serum Omega-3 Fatty Acids|Change in Serum TNFα (Cytokine) Level","University of California, San Francisco|Autism Speaks","All","3 Years to 8 Years   (Child)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200816175-1","August 2008","September 2009","September 2009","November 6, 2008","August 31, 2012","August 31, 2012","UC San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00786799"
161,"NCT03771560","Folinic Acid in Autism",,"Completed","Has Results","Autism Spectrum Disorder","Drug: folinic acid","Aberrant Behavior Checklist (ABC) - Parent Reported Change|Aberrant Behavior Checklist (ABC) - Teacher Reported Change|Social Responsiveness Scale (SRS) - Parent Reported Change|Social Responsiveness Scale (SRS) - Teacher Reported Change|Pediatric Quality of Life (PedsQL) - Parent Reported Change","University of California, San Francisco","All","5 Years to 25 Years   (Child, Adult)","Phase 2|Phase 3","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Folinic acid","February 15, 2018","June 30, 2018","June 30, 2018","December 11, 2018","December 3, 2019","December 3, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03771560/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03771560"
162,"NCT03215394","Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Suspected Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Attention Training Program|Behavioral: Social ABCs|Other: Treatment As Usual|Behavioral: Sham Attention Training","Improved Attentional Flexibility|Improved Attentional Control|Increased Social Orienting to Parent|Increased Child Smiling|Increased Child Responsivity to Parent Prompt|Parent Fidelity of Implementation|Receptive Language|Expressive Language|Joint Attention","Holland Bloorview Kids Rehabilitation Hospital|IWK Health Centre|Dalhousie University|University of Alberta|University of East London|University of London","All","12 Months to 30 Months   (Child)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-666","April 1, 2017","August 30, 2020","August 30, 2020","July 12, 2017",,"January 27, 2021","University of Alberta - Autism Research Centre, Edmonton, Alberta, Canada|IWK Health Centre / Dalhousie University, Halifax, Nova Scotia, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada|University of East London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03215394"
163,"NCT00467753","Oxcarbazepine Versus Placebo in Childhood Autism",,"Completed","Has Results","Autism","Drug: Oxcarbazepine|Other: Placebo/sugar pill","Vineland Adaptive Behavior Scales|Aberrant Behavior Checklist|Autism Diagnostic Observation Schedule|Clinical Global Impression Improvement (CGI-AD)","University of Medicine and Dentistry of New Jersey|National Alliance for Research on Schizophrenia and Depression|Rutgers, The State University of New Jersey","All","5 Years to 17 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0220055339","April 2006","December 2011","December 2011","May 1, 2007","December 16, 2013","January 13, 2021","Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00467753"
164,"NCT03202303","Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Cannabidivarin|Drug: Matched Placebo","Aberrant Behavior Checklist-Irritability Subscale (ABC-I)|Repetitive Behavior Scale-Revised (RBS-R)|Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW)|Pediatric Quality of Life Inventory (PedsQL) Family Impact Module|Vineland Adaptive Behavior Scale-3 (Vineland 3)|Clinical Global Impressions-Improvement (CGI-I)|Montefiore Einstein Rigidity Scale-Revised (MERS-R)","Montefiore Medical Center|United States Department of Defense|GW Pharmaceuticals Ltd.","All","5 Years to 18 Years   (Child, Adult)","Phase 2","100","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017-8538|AR160104|G32379","April 12, 2019","October 6, 2021","October 6, 2021","June 28, 2017",,"August 5, 2021","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03202303"
165,"NCT02235467","Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: ABA parent training","Acquisition from baseline of new behaviors at 8 weeks|Acquisition from baseline of new behaviors at 16 weeks|Acquisition from baseline of new behaviors at 21 weeks|Change from baseline in Eye-tracking at 21 weeks|Change from baseline in Vineland Scale at 21 weeks|Change from baseline in SON-R 2½-7 at 21 weeks|Change from baseline in Zaritt Burden Interview at 21 weeks|Change from baseline in OERA at 21 weeks","Federal University of São Paulo|Mackenzie Presbiterian University, São Paulo, Brazil|University of Sao Paulo","All","3 Years to 7 Years   (Child)","Phase 4","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","U1111-1157-8984|2012/51584-0","February 2014","December 2014","December 2014","September 10, 2014",,"April 2, 2015","Federal University of São Paulo Department of Psychiatry, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02235467"
166,"NCT04710810","UCB Stem Cells for Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Other: umbilical cord blood mononuclear stem cells","Incidence of Treatment Emergent Adverse Events|Changes in severity of autistic symptoms from baseline at 3d and 6th month (measured by Checklist for Autism Spectrum Disorders (CASD)|Changes in severity of autistic symptoms from baseline at 3d and 6th month (measured by Autism Treatment Evaluation Checklist (ATEC)|""Digit Span"" subscale of Wechsler Intelligence Scale for Children (WISC)|""Picture completion"" subscale of Wechsler Intelligence Scale for Children (WISC)|""Block design"" subscale of Wechsler Intelligence Scale for Children (WISC)|""Coding"" subscale of Wechsler Intelligence Scale for Children (WISC)","St. Petersburg Bekhterev Research Psychoneurological Institute","All","3 Years to 11 Years   (Child)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA1512","November 4, 2019","January 31, 2021","July 31, 2021","January 15, 2021",,"August 4, 2021","St.-Petersburg Bekhterev Reserach Psychoneurological Institute, Saint Petersburg, Санкт-Петербург, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04710810"
167,"NCT04660552","Transcranial Photobiomodulation for Reducing Autism Symptoms in Children","TPBMASD","Recruiting","No Results Available","Autism Spectrum Disorder","Device: Cognilum TM: Light Treatment Condition","Change in Autism symptoms|EEG - 1|EEG - 2","JelikaLite LLC","All","2 Years to 6 Years   (Child)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","19751975","November 15, 2020","December 31, 2022","December 30, 2023","December 9, 2020",,"December 9, 2020","Dr. Steingold Psychology PC, Brooklyn, New York, United States|Dr. Steingold Psychology PC, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04660552"
168,"NCT01945957","Brain Imaging of Intranasal Oxytocin Treatment in Autism",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Oxytocin","Aim 1a. fMRI Activation Analysis/Connectivity|Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking)|Plasma Oxytocin (OT) levels in aim 1b. and 2b.|Salivary Oxytocin (OT) levels for all aims.|SRS-Social Responsiveness Scale|Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV)|ABC-lethargy/social withdrawal subscale","University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 18 Years   (Child, Adult)","Phase 1","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","12-2622|U54HD079124-01","September 2014","January 2017","January 2017","September 19, 2013",,"April 25, 2017","The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01945957"
169,"NCT00463164","Functional MRI of Cognitive Control in Autism",,"Unknown status","No Results Available","Autism",,,"UMC Utrecht","All","6 Years to 12 Years   (Child)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","06-179","December 2007",,,"April 20, 2007",,"April 20, 2007","Dept. of Child and Adolescent Psychiatry, UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00463164"
170,"NCT04381195","Adult Functioning Scale in Autism (AFS)","AFS","Recruiting","No Results Available","Autism Spectrum Disorder","Diagnostic Test: AFS Development|Diagnostic Test: AFS Testing","Adult Functioning Scale","University of Pittsburgh|Autism Speaks","All","18 Years and older   (Adult, Older Adult)",,"1300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","STUDY19080355|11923","June 28, 2021","February 28, 2023","February 28, 2023","May 8, 2020",,"July 7, 2021","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04381195"
171,"NCT03514498","Autism & Anesthetic Exposure Study",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Procedure: Dental surgery","Current language and behaviour skills|Regression in language and behaviour skills|Metabolic make-up|Metabolic changes|Current non-specific behaviour skills|Regression in non-specific behaviour skills|Current sleep habits|Regression in sleep habits|Current social communication skills|Regression in social communication skills|Current social responsiveness skills|Regression in social responsiveness skills|Posthospitalization Behaviours|Changes in posthospitalization behaviours","The Hospital for Sick Children","All","4 Years to 12 Years   (Child)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1000057105","March 28, 2018","May 31, 2020","December 31, 2021","May 2, 2018",,"February 2, 2021","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03514498"
172,"NCT00494754","Clinical and Genetic Study of Autism Spectrum Disorder",,"Completed","No Results Available","Autism",,,"National Taiwan University Hospital|National Science Council, Taiwan","All","3 Years to 18 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Family-Based|Time Perspective: Other","9561709027","May 2007","April 2011","April 2011","July 2, 2007",,"May 7, 2021","National Taiwan University Hospital, Taipei, Taiwan|Taipei City Psychiatric Center, Taipei, Taiwan|Chang Gung Children's Hospital, Taoyuan, Taiwan|Taoyuan Mental Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00494754"
173,"NCT03778827","A Center Based Study of Pivotal Response Treatment for Preschoolers With Autism","PRT-C","Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Intensive Center-Based Pivotal Response Treatment (PRT-C)","Mean Change from baseline on the Social Responsiveness Scale-2 Total Score at 12 Weeks|Mean change from baseline on the Brief Observation of Communication Change (BOSCC) total score at 12 Weeks|Mean change from baseline on the frequency if the child's functional utterances on the structured lab observation at 12 Weeks|Mean change from baseline on the Vineland Adaptive Behavior Scales 3rd Edition Socialization subscale at 12 Weeks|Mean change from baseline on the MacArthur-Bates Communication Development Inventory at 12 Weeks","Stanford University|John & Marcia Goldman Foundation","All","2 Years to 3 Years   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-49033","May 8, 2019","May 2023","May 2023","December 19, 2018",,"May 24, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03778827"
174,"NCT04562688","Care Improving Cognition for ADolescents on the Autism Spectrum","CICADAS","Recruiting","No Results Available","Autism Spectrum Disorder","Other: CICADAS and then PEERS|Other: PEERS + CICADAS and then no-contact|Other: PEERS + Active Comparator and then no-contact","Digital Assessment Completion Rate|NB-SCT Program Adherence|Post-Study Usability Ratings|Reported Number of Adverse Effects|Total number of participants who complete the intervention","Posit Science Corporation|University of Minnesota","All","11 Years to 18 Years   (Child, Adult)","Not Applicable","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSC-0909-20","June 11, 2021","December 1, 2022","December 1, 2022","September 24, 2020",,"August 9, 2021","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04562688"
175,"NCT01064973","An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders",,"Terminated","No Results Available","Autism Spectrum Disorders","Drug: arbaclofen","Irritability subscale of the Aberrant Behavior Checklist","Seaside Therapeutics, Inc.","All","6 Years to 17 Years   (Child)","Phase 2","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22007","February 2010","December 2012","December 2012","February 9, 2010",,"December 20, 2012","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01064973"
176,"NCT03575429","Autism Adaptive Community-based Treatment to Improve Outcomes Using Navigators (ACTION) Network",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Engagement Intervention|Behavioral: Engagement + Coaching Intervention","Parent contingent responsiveness change over time|Observation of DSM-5 features of autism spectrum disorder change over time|Child social communication change over time|Autism Diagnostic Observation Schedule (ADOS)|Mullen Scales of Early Learning (MSEL)|Vineland Adaptive Behavior Scales (VABS-3)","Florida State University|Boston Medical Center|University of Miami|University of Massachusetts, Boston|Kaiser Permanente|Children's Hospital of Philadelphia|Boston University","All","12 Months to 24 Months   (Child)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","R01HD093055","January 1, 2019","December 2021","June 2022","July 2, 2018",,"September 17, 2018","University of Miami, Coral Gables, Florida, United States|Florida State University Autism Institute, Tallahassee, Florida, United States|Boston Medical Center Corporation, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03575429"
177,"NCT04089579","hCT-MSC in Children With Autism Spectrum Disorder","IMPACT","Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion","Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","4 Years to 11 Years   (Child)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00102894","October 12, 2020","October 1, 2022","May 1, 2023","September 13, 2019",,"March 18, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04089579"
178,"NCT00065962","Secretin for the Treatment of Autism",,"Completed","No Results Available","Autism","Drug: secretin, synthetic porcine|Drug: secretin, biologically derived porcine",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","3 Years to 12 Years   (Child)","Phase 3","85","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","5P01HD035465|NICHD-23|57-937|Supplement CRC99-3|3P01HD035468","June 1999",,"May 2000","August 5, 2003",,"June 24, 2005","Children's Hospital, Denver, Colorado, United States|Center on Human Development and Disability, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00065962"
179,"NCT00449566","Magnetic Resonance Imaging of Brain Development in Autism",,"Unknown status","No Results Available","Autism",,,"UMC Utrecht","All","6 Years to 18 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","METC 05/208-K","January 2006",,,"March 20, 2007",,"March 20, 2007","Dept. of Child and Adolescent Psychiatry, UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00449566"
180,"NCT03994757","Effects of Routines-Based Early Intervention in Children With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: MRBI|Behavioral: Control","Goal Attainment Scale(GAS)|Comprehensive Developmental Inventory for Infants and Toddlers(CDIIT)|Childhood Asperger Syndrome Test(CAST)|The Children Autism Rating Scale Second Edition(CARS-2)|Clancy Behavior Scale|Social Responsiveness Scale(SRS)|Theory of Mind Inventory-2(ToMI-2)|The Berry-Buktenica Developmental Test of Visual-Motor Integration(VMI)|Preschool Language Impaired Scale(PLS)/ Language Impaired Scale(LS)|Peabody Picture Vocabulary Test-Revised(PPVT-R)|Assessment of preschool children's participation(APCP) / Children Assessment of Participation and Enjoyment andPreferences for Activity of Children(CAPE)|Functional Independence Measure for Children(WeeFIM)|TNO-AZL Preschool children Quality of Life(TAPQOL)/TNO-AZL Quality of Life Questionnaire(TACQOL)|Sensory Profile(SP)|Parenting Stress Index(PSI)|Swanson, Nolan, and Pelham Questionnaire(SNAP)","Chang Gung Memorial Hospital","All","3 Years to 9 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201602004A3","August 1, 2017","September 2019","September 2019","June 21, 2019",,"August 1, 2019","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03994757"
181,"NCT04321915","Intestinal Dysbiosis and BBB Integrity in Autism","LEDA","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Analysis of intestinal microbiota in autism spectrum desorder|Other: Analysis of neuroinflammation markers in autism spectrum desorder","Intestinal microbiota assessment|Measuring the severity of ASD|Evaluation of the level of social interaction|Behavioural disorders|Quality of life of children with ASD|Developmental trajectory of children with ASD|IQ (Intellectual Quotient)|Assessment of stools aspect|Repetitive and stereotypical behaviours|Intensity of GI disorders|Measurement of neuroinflammation|Intestinal permeability|Intestinal inflammation|TH1/TH2 immune response|Metabolome analysis","University Hospital, Montpellier|Inserm1047, CHU Nîmes|LBPC, Inserm 1183, IRMB CHU Montpellier|UMR 5203, InsermU1191, IGF, Montpellier","All","6 Years to 16 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RECHMPL18_0197","April 26, 2021","April 26, 2023","August 26, 2023","March 25, 2020",,"April 29, 2021","Centre de Ressources Autisme, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04321915"
182,"NCT02878499","Do Sleep and Circadian Rhythm Disturbances Impact the Cognitive and Behavioural Development of Children With Autism?",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: polysomnography","Change in sleep latency at 1 year follow-up and 2 year follow-up compared to baseline|Change in sleep fragmentation index at 1 year follow-up and 2 year follow-up compared to baseline|Change in nocturnal melatonin secretion at 1 year follow-up and 2 year follow-up compared to baseline|Change in amplitude of the day-night melatonin secretion at 1 year follow-up and 2 year follow-up compared to baseline|Change in non-verbal index (INV, derived from the Kaufmann-Assessment Battery fir Children II (K-ABC II)) at 1 year follow-up and 2 year follow-up compared to baseline|Change in verbal intelligence quotient (IQ) at 1 year follow-up and 2 year follow-up compared to baseline|Change in Raven performance IQ at 1 year follow-up and 2 year follow-up compared to baseline|Change in Autism Diagnostic Observation Schedule (ADOS), module 1-3: part 'D' et 'E' (repetitive and abnormal behaviour) at 1 year follow-up and 2 year follow-up compared to baseline|Change in aberrant Behaviour Checklist (ABCL) global score at 1 year follow-up and 2 year follow-up compared to baseline|presence of an intrinsic sleep disorders (e.g. obstructive or central sleep apnea syndrome, restless legs syndrome and periodic limb movements during sleep…)|Total sleep time (TST)|Time and percentage of TST spent in different sleep stages (slow wave sleep, rapid eye movement (REM) sleep)|Sleep spindle density in light slow wave sleep|Density of rapid eye movements in REM sleep|Spectral analysis of the sleep electro-encephalogram (EEG)|24h urinary 6-sulfatoxymelatonin levels (ng/ml)|Inter-daily stability (IS) and intra-daily variability (IV) of circadian rhythms (actigraphy derived)|Circadian phase of body temperature|Level of ferritin in plasma","University Hospital, Strasbourg, France","All","3 Years to 8 Years   (Child)","Not Applicable","105","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","5060","December 19, 2012","December 2021","December 2021","August 25, 2016",,"August 12, 2020","CHRU de Lille - Hôpital Roger Salengro, Lille, France|CHU de Lyon - CHS Le Vinatier, Lyon, France|CHU Gui de Chaulhiac, Montpellier, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|CHU de TOURS - Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT02878499"
183,"NCT04873674","A Deep Learning Algorithm Platform to Predict Autism Diagnosis and Subtypes",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: ASD diagnosis|Other: Psychiatric diagnosis","Autism diagnostic interview (ADI-R)|Neuropsychological functions: Continuous Performance Test(CPT)|Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)","National Taiwan University Hospital","All","4 Years to 25 Years   (Child, Adult)",,"420","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","202002086RIND","May 1, 2020","April 2024","April 2024","May 5, 2021",,"May 5, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04873674"
184,"NCT03583684","Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism","PRT-I","Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Pivotal Response Treatment Program (PRT-P)","Change in Number of Child Utterances During a Structured Lab Observation (SLO)|Change on MacArthur-Bates Communication Development Inventory (CDI)","Stanford University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","2 Years to 4 Years   (Child)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB-46131","December 7, 2018","November 30, 2022","November 30, 2023","July 11, 2018",,"August 11, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03583684"
185,"NCT04574206","Testing a Novel Parenting Intervention for Children With Autism","PAREint","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Elaborative Reminiscence (ER)|Behavioral: Present Tense Talk (PTT)","Trial recruitment feasibility|Feasibility of training procedures|Training enactment|Implementation fidelity (actual dosage)|Implementation fidelity (frequency of intervention delivery)|Intervention acceptability|Memory test|Memory elaborations|Mental state understanding|Self-concept","City, University of London","All","7 Years to 11 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","GRY190053860","December 1, 2020","August 2022","October 2022","October 5, 2020",,"January 28, 2021","City University of London, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04574206"
186,"NCT03131635","Effectiveness of a Developmental Reciprocity Treatment Program in Autism","DRTP","Suspended","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Developmental Reciprocity Treatment Program (DRT-P)","Change from Baseline on the Social Responsiveness Scale (SRS) at 6, 12, and 24 weeks|Change from Baseline on the Brief Observation of Social Communication Change (BOSCC) at 24 weeks|Change from Baseline on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) at 12, and 24 weeks|Change from Baseline on the Stanford Social Dimensions Scale (SSDS) Questionnaire.","Stanford University","All","2 Years to 5 Years   (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 40026","July 26, 2017","May 2022","May 2022","April 27, 2017",,"May 4, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03131635"
187,"NCT04644003","Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: STP1|Drug: Placebo","Safety and Tolerability|Plasma concentration of STP1 (PK)","Stalicla SA","All","18 Years to 40 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STP1-C004","December 7, 2020","November 30, 2021","December 31, 2021","November 25, 2020",,"June 18, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04644003"
188,"NCT04628715","Biofeedback Intervention in Adolescents With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: RSA biofeedback","Change in Root Mean Square of Successive Differences between normal heart beats (RMSSD) as a measure of cardiac vagal modulation.|Change in Logarithm of High-Frequency Heart Rate Variability (LnHF-HRV) as a measure of cardiac vagal modulation.|Change in Heart rate|Change in Breathing frequency|Change in Skin conductance|Change in Fingertip temperature|Change in Cortisol level|Autism Spectrum Quotient - Adolescent Version (AQ)|Change on Social Responsiveness Scale - 2nd edition (SRS-2)|Change on Repetitive Behavior Scale - Revised (RBS-R)|Change on Strengths and Difficulties Questionnaire - parent report (SDQ-PR)|Change on Strengths and Difficulties Questionnaire - adolescent self-report (SDQ-SR)|Change on Perceived Stress Scale - Adolescent version (PSS)|Change on Depression Anxiety and Stress Scale-21 items version|Change on Physical Activity Vital Sign|Change on Visual Analogue Scale (VAS) for sensory hyper-responsivity|Change on Visual Analogue Scale for perceived stress","Universitaire Ziekenhuizen Leuven","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","s64219","November 26, 2020","December 2021","August 2023","November 13, 2020",,"April 5, 2021","KU Leuven, Leuven, Vlaams Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT04628715"
189,"NCT04727489","Study of the Genetic Factors Involved in Autism and Related Disorders","Gene&autism","Recruiting","No Results Available","Autism Spectrum Disorder","Genetic: DNA from subjects will be stored in the biobank of our study.","Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder|Prevalence of the deleterious mutations in the major biological pathways in Autism Spectrum Disorder","Institut National de la Santé Et de la Recherche Médicale, France","All","24 Months to 70 Years   (Child, Adult, Older Adult)",,"3800","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","C16-89","March 30, 2021","December 21, 2022","December 31, 2037","January 27, 2021",,"May 5, 2021","Albert Chenevier Hospital, Creteil, Ile De France, France|Robert Debré Hospital, Paris, Ile De France, France|CIC, CHU Bordeaux, Bordeaux, France|CRA, Hopital Charles Perrens, Bordeaux, Bordeaux, France|CIC, H. Mondor, Creteil, Créteil, France|Centre de rehabilitation psychosociale, Hopital Saint Egreve, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04727489"
190,"NCT01168284","A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum: A Feasibility Study",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Coping Effectiveness Training","Feasibility of the intervention","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Other","999910160|10-HG-N160","July 5, 2010","April 4, 2011","May 6, 2011","July 23, 2010",,"December 17, 2019","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01168284"
191,"NCT00584480","Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism","HBOT","Completed","Has Results","Autism","Other: Hyperbaric Oxygen Treatment (HBOT)","Number of Participants With the Given Clinical Global Impression Scale - Improvement (CGI-I) Score","University of California, San Francisco|University of California, Davis","All","3 Years to 8 Years   (Child)","Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200715202-1","October 2007","September 2009","September 2009","January 2, 2008","April 13, 2012","August 7, 2012",,,"https://ClinicalTrials.gov/show/NCT00584480"
192,"NCT01529580","School-Age Children With Autism With Limited Expressive Language Skills",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Non-Verbal School Aged Children with Autism (NVSACA) Intervention","Change in Baseline Spontaneous Language|Change in Baseline Autism Diagnostic Observation Schedule|Change in Baseline Reynell|Changes in Baseline Early Social Communication Scales (ESCS)|Changes in Baseline Structured Play Assessment","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute of Mental Health (NIMH)","All","48 Months to 95 Months   (Child)","Not Applicable","13","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA_00049467|3R01MH085048-03S1","January 2012","December 2013","December 2013","February 9, 2012",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01529580"
193,"NCT04773548","Feasibility and Safety of a Virtual-Reality Based Job Interview Training Tool in Teenagers With High-Functioning Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Other: VR-JIT","Change in mock job interview","Kessler Foundation","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-1036-18","October 24, 2018","October 24, 2020","October 24, 2020","February 26, 2021",,"February 26, 2021","Kessler Foundation, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04773548"
194,"NCT04482088","Piloting an Enhanced Protocol of Occupational Therapy in an Equine Environment for Youth With Autism",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Occupational Therapy in an Equine Environment|Behavioral: Occupational Therapy in a Clinic (OTC)","Change in Goal Performance using Goal Attainment Scaling|Change in Aberrant Behavior Checklist- Community|Change in Social Responsiveness Scale, Second Edition|Change in Pediatric Disability Inventory Computer Adaptive Test for Autism Spectrum Disorders|Change in World Health Organization Quality of Life- BREF|Change in Emotional Dysregulation Inventory","Colorado State University|Hearts and Horses Therapeutic Riding Center","All","6 Years to 13 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-10140H","January 20, 2020","December 2021","December 2021","July 22, 2020",,"May 12, 2021","Temple Grandin Equine Center Colorado State University, Fort Collins, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04482088"
195,"NCT03427138","Training Early Social Language in Autism","TESLA","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Jasper|Behavioral: Parent Education","Change in EEG Frequency Data- Resting State|Change in EEG Frequency Data- Grasping Objects|Change in EEG Frequency Data- Observing actions|Change in joint attention measured with the Early Social and Communication scales (ESCS)|Change in play level measured with the Structured Play Assessment (SPA)|Change in imitation measured with the Elicited Imitation Battery (adapted from Rogers et al., 2003)|Change in language measured with the Elicitation of Language Sample Assessment-Toddler version (ELSA-T)|Change in parent-child interactions|Change in predictive gaze measured with eye-tracking","Boston University Charles River Campus|University of Maryland, College Park|University of Chicago|Centre National de la Recherche Scientifique, France|University of California, Los Angeles|Boston Medical Center","All","18 Months to 59 Months   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","4190E","July 1, 2016","August 31, 2021","August 31, 2021","February 9, 2018",,"February 5, 2021","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03427138"
196,"NCT04017793","Mindfulness-Associated Brain Changes in Adults With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Mindfulness Based Stress Reduction|Behavioral: Relaxation Group","Beck Depression Inventory - II|Beck Depression Inventory - 2|State-Trait Anxiety Inventory|World Health Organization Quality of Life","Arizona State University|Southwest Autism Research and Resource Center (SARRC)|Banner Alzheimer's Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB # STUDY00007227","May 6, 2019","December 31, 2021","December 31, 2021","July 12, 2019",,"September 20, 2021","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04017793"
197,"NCT04259671","Exploring the Efficacy and Usability of the My Autism Passport (MAP).",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: My Autism Passport (MAP) Application","Number of services contacted at 6 months|Number of services contacted at 12 months|Number of services contacted at 18 months|Parental Stress Scale at 6 months|Parental Stress Scale at 12 months|Parental Stress Scale at 18 months|Parent Empowerment and Efficacy Measure at 6 months|Parent Empowerment and Efficacy Measure at 12 months|Parent Empowerment and Efficacy Measure at 18 months","Unity Health Toronto|Autism Speaks","All","1 Month to 6 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","REB 18-168","March 1, 2020","November 1, 2021","February 1, 2022","February 6, 2020",,"March 23, 2020","Unity Health Toronto, St.Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04259671"
198,"NCT04024111","Social Groups for Australian Children on the Autism Spectrum",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: KONTAKT(c)|Other: Art group","Change in the Goal Attainment Scale (GAS)|Change in the Emotion Regulation Checklist (ERC)|Change in the Negative Incidents and Effects of Psychological Treatment (NEQ)|Change in the Child Health Utility 9D (CHU9D)|Change in Treatment Inventory of Costs in Patients (TIC-P)|Treatment Satisfaction Scale|Change in the Social responsiveness scale - Second Edition (SRS-2)|International classification of functioning (ICF) - Autism coreset|Junior Temperament and characteristic Inventory (JTCI)|Motivation to participate|Change in the LERID friendship questionnaire|Change in the Social Interaction anxiety scale (SIAS)|Change in Social Skills Assessment Questionnaire (SSAQ)","Curtin University|Autism Association of Western Australia|Stan Perron charitable trust|Karolinska Institutet","All","8 Years to 12 Years   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HRE2017-0245-34","December 1, 2019","May 1, 2022","May 1, 2022","July 18, 2019",,"August 3, 2021","Curtin University, Bentley, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04024111"
199,"NCT02897687","Facebook for Social Skills Training in Autism: Project Rex Connect","FBREX","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Facebook Group|Behavioral: Book Club Group","Improvements in social skills as assessed by Social Responsiveness Scale.|Improvements in social skills as assessed by Social Skills Improvement System.|Improvements in social skills as assessed by the Project Rex Parent Survey.|Participant satisfaction as assessed by the Project Rex Connect Participant Survey.","Medical University of South Carolina","All","12 Years to 20 Years   (Child, Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00021530","April 2013","June 2014","August 2016","September 13, 2016",,"May 9, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02897687"
200,"NCT02007447","Oxytocin in Adolescents With Autism Spectrum Disorders","OXYASD","Terminated","No Results Available","Autism Spectrum Disorder","Drug: OCYTOCINA - SPRAY NASAL","SOCIAL SKILLS|REPETITIVE BEHAVIOR","University of Sao Paulo General Hospital","Male","12 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE 10922213.7.0000.0068","June 2015","August 2015","May 4, 2018","December 10, 2013",,"October 28, 2019","Institute os Psychiatry, Clinical Hospital at São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02007447"
201,"NCT00183404","Long-Term Olanzapine Treatment in Children With Autism",,"Completed","No Results Available","Autism","Drug: Olanzapine","Children's Psychiatric Rating Scale|Aberrant Behavior Checklist|Clinical Global Impressions|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale","Drexel University|National Institute of Mental Health (NIMH)","All","3 Years to 12 Years   (Child)","Phase 2|Phase 3","32","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH073524|DDTR B2-NDA","September 2004","July 2011","October 2011","September 16, 2005",,"August 15, 2014","Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00183404"
202,"NCT00935701","Acupressure and Acupuncture as an Intervention With Children With Autism II",,"Completed","Has Results","Autism Spectrum Disorder","Device: Acupressure and Acupuncture","Proportions of Children Completing Acupressure and Acupuncture Treatment.|Change in Conners' Rating Scales|Change in Children's Sleep Habits Questionnaire|Change in Parenting Stress Index","Johns Hopkins University|Autism Speaks","All","3 Years to 10 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00026158|2949","July 2009","February 2011","February 2011","July 9, 2009","September 26, 2014","April 18, 2017","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00935701"
203,"NCT03827941","Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: 1 Hz Auricular transcutaneous electrical nerve stimulation|Other: 20 Hz Auricular transcutaneous electrical nerve stimulation","Change in Sleep Quality Assessment (PSQI)|Change in Autism Treatment Evaluation Checklist (ATEC)|Change in Aberrant Behavior Checklist (ABC)|Change in Clinical Global Impression-Improvement (CGI-I)|Change in PROMIS Sleep Disturbance Short Form|Change in Penn State Worry Questionnaire","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2017P000894","July 1, 2021","January 28, 2022","January 28, 2022","February 4, 2019",,"September 2, 2020",,,"https://ClinicalTrials.gov/show/NCT03827941"
204,"NCT03392870","Evaluation of a Clinical Transitional Program in Autism","TAVA","Unknown status","No Results Available","Autism Spectrum Disorder (ASD)","Other: Integrative interventional programme|Other: As usual","Change in Quality of life.|Change in: Asperger Symptoms.|Change in: Depressive symptoms|Change in: Anxiety Symptoms.|Change in: Obsessive-compulsive symptoms.|Change in: ASD symptoms evaluated by parents/caregiver.|Change in: ASD symptoms.|Change in: Social phobia symptoms.|Change in: Evaluation of support needs.|Change in: Caregiver's burden associated with the disorder.|Change in: Evaluation of the level of autonomy, self-regulation, self-empowerment, self-knowledge.","Corporacion Parc Tauli","All","18 Years to 21 Years   (Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CSPT04_TAVA","March 1, 2017","March 2019","April 2019","January 8, 2018",,"January 8, 2018","Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03392870"
205,"NCT03376373","Neurotherapy to Promote Emotion Recognition in Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: neurofeedback","facial emotion recognition (RMET)","Virginia Polytechnic Institute and State University","Male","16 Years to 29 Years   (Child, Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MH100268","September 1, 2016","December 31, 2019","December 31, 2019","December 18, 2017",,"September 16, 2020","Child Study Center, Blacksburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03376373"
206,"NCT01425918","Social Cognitive Development in Young Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Social Enhancement Intervention|Behavioral: Parent Education","Change in Baseline Eye Tracking Tasks|Change in Baseline Communication and Symbolic Behavior Scale Developmental Profile|Change in Baseline Spontaneous Imitation Task|Change in Baseline Autism Diagnostic Observation Schedule|Change in Baseline Mullen Scales of Early Learning|Change in Baseline Action/intention understanding taks","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Autism Speaks","All","24 Months to 42 Months   (Child)","Not Applicable","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA_00050400","January 2012","April 2015","April 2015","August 30, 2011",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01425918"
207,"NCT02160119","Emotional and Change-related Attention in Autism","AUTATTEN","Completed","No Results Available","Autism Spectrum Disorders","Other: MRI-based techniques|Other: EEG","Neural responses to neutral and emotional stimuli","Institut National de la Santé Et de la Recherche Médicale, France","All","5 Years to 45 Years   (Child, Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","C13-26|2013-A01315-40","May 27, 2014","May 2018","May 27, 2018","June 10, 2014",,"August 30, 2021","University Hospital, Tours, France",,"https://ClinicalTrials.gov/show/NCT02160119"
208,"NCT01996800","Study of Chiropractic and Neuromuscular Reeducation as a Treatment for Autism Symptoms",,"Terminated","No Results Available","Autism","Procedure: Spinal Manipulative Therapy (SMT)|Procedure: SMT and Neuromuscular Reeducation","Assessing change using the Autism Treatment Evaluation Checklist","Southern California University of Health Sciences","All","5 Years to 15 Years   (Child)","Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCU-AUT-01","August 2013","August 2014","August 2014","November 27, 2013",,"October 4, 2016","Southern California University of Health Sciences, Whittier, California, United States",,"https://ClinicalTrials.gov/show/NCT01996800"
209,"NCT03842332","Building Resilience and Appropriate Independence in Young Adults With Autism",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Life Skills and Resilience Program","Change in Baseline Resilience at 3-6 months|Change in Baseline General Family Functioning at 3-6 months|Change in Baseline Self Efficacy at 3-6 months|Change in Baseline Pediatric Quality of Life at 3-6 months|Change in Baseline Satisfaction with Social Roles at 3-6 months and Activities (v2.0)|Change in Baseline Employment Status","University of California, San Francisco|National Institutes of Health (NIH)|Golden Gate Regional Center|The Arc San Francisco|National Institute of Mental Health (NIMH)","All","18 Years to 26 Years   (Adult)","Not Applicable","42","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P0527544|R21MH115375","January 25, 2019","May 31, 2021","May 31, 2021","February 15, 2019",,"April 28, 2021","The Arc, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03842332"
210,"NCT04278898","Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: N-Acetylcysteine","Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)|Change in Gamma band amplitude and synchronization measured by electroencephalography","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 2","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-54931","February 12, 2021","August 2022","January 2023","February 20, 2020",,"August 12, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04278898"
211,"NCT03117530","Measuring Brain Inflammation in Autism",,"Suspended","No Results Available","Autism Spectrum Disorder","Drug: Minocycline","Evaluate differences in CNS microglial activation in adults with ASD versus healthy volunteers via in vivo CNS binding of [11C]-DAA1106|Evaluate the effect of 12-weeks of minocycline exposure on CNS microglial activation in adults with ASD by measuring change in [11C]-DAA1106 binding pre- and post- treatment|Effect of minocycline exposure on cognition across seven cognitive domains before and after low dose intervention and regular dose intervention as measured by MCCB (MATRICS Consensus Cognitive Battery) subdomain scores|Effect of minocycline exposure on self-rated anxiety and emotion regulation as measured by ADAMS (Anxiety and Depression Mood Scale)|Effect of minocycline exposure on peripheral inflammatory cytokine profiles as measured by DNA and RNA expression in blood samples","University of California, Los Angeles","Male","18 Years to 35 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-001784","April 11, 2017","December 2022","December 2022","April 18, 2017",,"August 10, 2020","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03117530"
212,"NCT03513419","The AMOR Method: Resilience Training for Parents of Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: The AMOR Method","Change in Connor-Davidson Resilience Scale (CDRISC) from Baseline to week 8|Change in Acceptance and Action Questionnaire-II (AAQ-II) from Baseline to week 8|Change in Mindful Attention Awareness Scale (MAAS) from Baseline to week 8|Change in Life Orientation Test Revised (LOT-R) from Baseline to week 8","Stanford University","All","Child, Adult, Older Adult","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","45774","May 25, 2018","February 29, 2020","February 29, 2020","May 1, 2018",,"May 7, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03513419"
213,"NCT02299700","Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder","Mentis","Completed","No Results Available","Autism Spectrum Disorder","Other: No Intervention","Stage 1: Usability of the Janssen Autism Knowledge Engine (JAKE) in Measuring Clinical Symptoms of Autism Spectrum Disorder (ASD)|Stage 2: Usability of the Janssen Autism Knowledge Engine (JAKE) in Measuring Clinical Symptoms of ASD|Utility of JAKE Symptom Tracker in Measuring Clinical Symptoms of ASD|Correlation Between Key Biosensors and ASD Symptoms|Ease of use and Utility of JAKE for use in Prospective Clinical Trials|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","Janssen Research & Development, LLC","All","3 Years and older   (Child, Adult, Older Adult)",,"34","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR104919|ASD-001","September 30, 2014","April 24, 2015","April 24, 2015","November 24, 2014",,"October 23, 2017","Boston, Massachusetts, United States|Toms River, New Jersey, United States|Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02299700"
214,"NCT03204786","Intranasal Vasopressin Treatment in Children With Autism",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder|ASD","Drug: Vasopressin (USP) Injectable Solution [Vasostrict]|Drug: Placebo","Change from baseline in parent rated Social Responsiveness Scale, Second Edition Total Scores (SRS-2) total scores during treatment.|Change from baseline in Clinical Global Impression (CGI) scores during treatment.|Change from baseline on Reading the Mind in the Eyes Test (RMET) during treatment.|Change from baseline on the Facial Emotion Recognition Test during treatment.|Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.|Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.|Change from baseline on electrocardiogram (EKG) (P Duration, PR Interval, QRS Interval, QT Interval) during treatment.|Change from baseline on clinical labs (Sodium, Potassium, Chloride) during treatment.|Change from baseline on blood pressure (systolic and diastolic) during treatment.|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) during treatment.|Change from baseline in Overt Aggression Scale (OAS) during treatment.|Baseline vasopressin concentration predicting primary and secondary behavioral outcome measures.","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","Phase 2|Phase 3","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-39972|1R01HD091972","February 20, 2018","April 1, 2024","July 1, 2024","July 2, 2017",,"October 5, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03204786"
215,"NCT03597477","Procedure Sedation With Dexmedetomidine in Children With Autism Spectrum Disorders During Magnetic Resonance Imaging",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Dexmedetomidine","The 50% and 95% effective doses of intranasal dexmedetomidine|sedation induction time|Wake -up time","Guangzhou Women and Children's Medical Center","All","2 Years to 12 Years   (Child)",,"136","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Intranasal dexmedetomidine","July 16, 2018","September 17, 2020","September 18, 2020","July 24, 2018",,"February 25, 2021","Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03597477"
216,"NCT03556826","Social Value Training in Toddlers With Elevated Autism Symptoms","SVT","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Social Value Learning Training","Proportion of looking at faces during the laboratory and real-world tests|Proportion of looking at the scene during laboratory and real-world tests","Yale University|National Institute of Mental Health (NIMH)","All","15 Months to 21 Months   (Child)","Not Applicable","48","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000021541|P50MH115716","December 13, 2019","August 31, 2023","August 31, 2024","June 14, 2018",,"June 18, 2021","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03556826"
217,"NCT00999778","Optimizing Social and Communication Outcomes for Toddlers With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Caregiver-Mediated Intervention|Behavioral: Caregiver-Education Intervention","Cognitive Assessment - Mullen Scales of Early Learning (MSEL)|Language Assessment - Reynell Developmental Language Scales|Language Sample - The Caregiver Child Interaction will be coded at each timepoint to obtain a 10 minute sample of the child's language transcription will yield a measure of lexical density, type-token ration and mean length of utterances|Early Social-Communication Scales; frequencies of initiating and responses of joint attention behaviors to toys and l interaction - sessions will be video taped|MacArthur Communicative Development Inventories|Parent Expectancy/Belief in the Intervention - assesses caregiver beliefs that the intervention is appropriate and working for the child|ADOS - The Autism Diagnostic Observation Schedule - semi-structured, standardized assessment of communication, social interaction, play and imaginative use of materials|Generalization of skills to classroom - Observational measure to determine whether child show generalization of skill to the classroom,and in interaction with teachers & peers|Coding of child behaviors in classroom - using time sampling procedure, four different contexts; direct instruction, structure play, circle-time, unstructured play|Caregiver-child interaction - A 10-minute interaction between parent and child|ADI-R Clinical diagnostic instrument for assessing autism in children|Parenting Stress - The Parenting Stress Index (PSI) measuring parents reported stress associated with the care of autistic child","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Autism Speaks","All","18 Months to 36 Months   (Child)","Not Applicable","86","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","1P50HD055784","July 2008","July 2012","August 2012","October 22, 2009",,"August 16, 2012","University of California Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00999778"
218,"NCT02940899","Syracuse University Fit Families Program: Autism","SUFFP","Completed","No Results Available","Autism Spectrum Disorders","Other: Intervention: Syracuse University Fir Families Program (SUFFP)","Physical Activity|Motor skills of Parents and Children|Adaptive behavior|Reported Behavior Problems|Sensory Processing|Quality of Life of Parents of Children with Autism Spectrum Disorders|Physical Activity Experiences|Cardiovascular Health","Syracuse University|Texas Woman's University","All","5 Years to 11 Years   (Child)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","28491","January 2015","November 30, 2018","December 30, 2018","October 21, 2016",,"April 4, 2019","Syracuse University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT02940899"
219,"NCT01918787","rTMS for Adults With Autistic Spectrum Disorder",,"Unknown status","No Results Available","Autism","Device: repetitive TMS","continuous performance test|Yale-Brown Obsessive Compulsive Scale","Chang Gung Memorial Hospital","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100-2985C|NSC 100-2314-B-182A-075","April 2012","April 2015","April 2015","August 8, 2013",,"August 8, 2013","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01918787"
220,"NCT00811083","Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity",,"Completed","No Results Available","Autism","Drug: DMSA - dimercaptosuccinic acid","Determine the effect of DMSA therapy on the symptoms of autism|Determine the safety of DMSA therapy by pre/post assessment of complete blood count, standard chem panel including liver/kidney function, and excretion of essential minerals|Determine if the initial severity of autism correlates with the excretion of toxic metals","Southwest College of Naturopathic Medicine","All","3 Years to 8 Years   (Child)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DMSA","May 2005","April 2007","April 2007","December 18, 2008",,"December 18, 2008","Southwest College of Naturopathic Medicine, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00811083"
221,"NCT01881737","A Study of Pregnenolone in the Treatment of Individuals With Autism",,"Completed","Has Results","Autistic Disorder","Drug: Pregnenolone","Number of Participants With Adverse Events According to Dosage Record and Treatment Emergent Symptom (DOTES) as Assessed at All Follow-up Visits (2, 4, 6, 8, 10, 12, and 16 Weeks)|Social Responsiveness Scale (SRS) Total Score|Sensory Profile Questionnaire Total Score|Vineland Adaptive Behavior Scale|Repetitive Behavior Scale|Pregnenolone Level in Peripheral Blood as Measured at Baseline and After 12 Weeks","Stanford University","All","18 Years to 45 Years   (Adult)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-08092011-8246","July 2011","September 2013","September 2013","June 20, 2013","March 29, 2017","March 29, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01881737"
222,"NCT02977962","Treatment of Anxiety in Late Adolescents With Autism","TALAA","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Cognitive-Behavior Therapy|Other: Treatment as Usual","Change from Baseline in anxiety severity on the Hamilton Anxiety Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Clinical Global Impressions Scale after 16 weeks of treatment.","University of South Florida|Johns Hopkins All Children's Hospital","All","16 Years to 21 Years   (Child, Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","USF-ACH 001","January 2017","April 2021","August 2021","November 30, 2016",,"April 24, 2020","Rothman Center for Neuropsychiatry, University of South Florida, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02977962"
223,"NCT01372449","A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Memantine|Drug: Placebo","Developmental Neuropsychological Assessment (NEPSY) Apraxia and Repetition of Nonsense Words Subtests|Expressive Vocabulary Test (EVT)|Vineland Adaptive Behavior Scale - Revised|Safety Monitoring Uniform Research Form","Evdokia Anagnostou|Icahn School of Medicine at Mount Sinai|Rush University Medical Center|Nationwide Children's Hospital|Anagnostou, Evdokia, M.D.","All","6 Years to 12 Years   (Child)","Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","111576","December 2011","October 2015","October 2015","June 14, 2011",,"March 20, 2017","Rush University Medical Center, Chicago, Illinois, United States|Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01372449"
224,"NCT00090428","Diet and Behavior in Young Children With Autism",,"Completed","No Results Available","Autism|Autistic Disorder","Behavioral: Gluten- and casein-free diet|Behavioral: Placebo controlled diet","Safety and efficacy of the gluten free casein free diet","University of Rochester|National Institute of Mental Health (NIMH)","All","30 Months to 54 Months   (Child)","Phase 1","21","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","U54MH066397|DDTR BD-DD","January 2004","October 2008","February 2009","August 27, 2004",,"February 1, 2013","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00090428"
225,"NCT04600882","Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder",,"Withdrawn","No Results Available","Autism Spectrum Disorder",,"Prevalence of non-behavioral phenotypical traits in sub-populations with Autism Spectrum Disorder (ASD)","Stalicla SA","All","4 Years to 10 Years   (Child)",,"0","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","STP1-C002","November 30, 2020","March 31, 2021","April 30, 2021","October 23, 2020",,"June 24, 2021","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04600882"
226,"NCT00698997","Intensive Intervention for Toddlers With Autism (EARLY STEPS)",,"Completed","Has Results","Autism|Autism Spectrum Disorder","Behavioral: Early Start Denver Model|Behavioral: Standard community care","Language Age Equivalent|Overall Developmental Quotient (DQ)|Adaptive Behavior Age Equivalent Scores|Autism Severity","University of California, Davis|University of Washington|University of Michigan|National Institutes of Health (NIH)|University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","12 Months to 24 Months   (Child)","Not Applicable","118","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","200816233|1R01MH081757","April 2008","July 2013","December 2013","June 17, 2008","February 17, 2020","February 17, 2020","UC Davis Mind Institute, Sacramento, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT00698997/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT00698997"
227,"NCT01248728","Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)",,"Completed","Has Results","Autism Spectrum Disorder","Dietary Supplement: Omega-3 Fatty Acids|Dietary Supplement: Placebo","Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score|Change From Baseline in the Behaviour Assessment System for Children (BASC-2) - Externalizing Problems Composite|Number of Participants Classified as Responders by the Clinical Global Impression - Improvement (CGI-I)|Change From Baseline in the Vineland Adaptive Behavioral Scales (VABS) - Adaptive Functioning Composite|Change From Baseline in the Preschool Language Scale (PLS-4) - Total Language","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|The Hospital for Sick Children|Anagnostou, Evdokia, M.D.","All","2 Years to 5 Years   (Child)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-018","November 2010","December 2013","June 2014","November 25, 2010","May 18, 2016","May 18, 2016","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01248728"
228,"NCT01171937","Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior","ProjectV","Completed","No Results Available","Autism","Drug: Risperidone|Drug: Placebo","Aberrant Behavior Checklist","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 16 Years   (Child)","Phase 2","41","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-06-033|P50HD055784","September 2008","September 2016","December 2016","July 29, 2010",,"May 3, 2017","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01171937"
229,"NCT02708901","Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters",,"Completed","No Results Available","Autism Spectrum Disorder","Dietary Supplement: Vivomixx®|Dietary Supplement: Placebo","Changes in severity level of ASD symptomatology|Changes in GI symptomatology|Changes in Electroencephalogram (EEG) power|Changes in EEG coherence|Changes in EEG asymmetry|Changes in levels of serum Lipopolysaccharide|Changes in levels of serum Leptin|Changes in levels of serum Resistin|Changes in levels of serum Tumor Necrosis Factor - alfa|Changes in levels of serum Interleukin-6 (IL-6)|Changes in levels of serum Plasminogen Activator Inhibitor-1 (PAI-1)|Changes in levels of fecal calprotectin|Changes in global ASD symptomatology assessed by Childhood Autism Rating Scale|Changes in ASD symptomatology: repetitive behaviors|Changes in ASD symptomatology: sensory profiles|Changes in global ASD symptomatology assessed by Social Communication Questionnaire|Changes in Developmental Quotient|Changes in Adaptive Functioning|Changes in Behavioral Profiles|Changes in Parental Stress","IRCCS Fondazione Stella Maris|Ministry of Health, Italy|Istituto di Fisiologia Clinica CNR","All","18 Months to 72 Months   (Child)","Not Applicable","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GR-2011-02348280","November 2015","August 2018","September 2018","March 15, 2016",,"February 18, 2019","IRCCS Stella Maris Foundation, Calambrone, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT02708901"
230,"NCT04452045","SweetDreams Sleep Study for Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Insomnia","Device: SweetDreams","Change in Children's Sleep Habits Questionnaire (CSHQ)|Change in Pittsburgh Sleep Quality Index (PSQI)","University of California, San Francisco","All","12 Months to 60 Months   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UL1TR001872","September 1, 2020","December 30, 2021","December 31, 2021","June 30, 2020",,"August 17, 2021","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04452045"
231,"NCT03573128","Development and Pilot Testing of the Students With Autism Accessing General Education (SAAGE) Model","SAAGE","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Students with Autism Accessing General Education|Other: Enhanced Services As Usual","Mean change in student function as measured by the Developmental Disability-Clinical Global Assessment Scale|Mean change in social communication and interaction as rated by child's teacher using the 30 item Social Skills Subscale of the Social Skills Improvement System|Mean change in restricted and repetitive behavior as measured by the Children's Yale-Brown Obsessive-Compulsive Scales - PDD|Change in teacher-nominated target behaviors|Change in on-task behavior during instruction|School-related adaptive functioning|Social skills and behavior regulation|Class placement","University of Rochester|May Institute|University of South Florida","All","Child, Adult, Older Adult","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R324A150032","August 1, 2017","August 28, 2018","August 28, 2018","June 29, 2018",,"November 16, 2018","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03573128"
232,"NCT03286621","Development of Eye-tracking Based Markers for Autism in Young Children",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Administration of five eye-tracking paradigms","Global eye-gaze characteristics|Feature-specific eye-gaze characteristics|Global eye-gaze characteristics and associations with symptom severity|Feature-specific eye-gaze characteristics and associations with symptom severity","University of Electronic Science and Technology of China","All","12 Months to 10 Years   (Child)",,"70","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","UESCT_neuSCAN_41","September 9, 2017","February 28, 2018","February 28, 2018","September 18, 2017",,"October 29, 2018","School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03286621"
233,"NCT00263796","An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism",,"Completed","No Results Available","Autism","Drug: Oxytocin|Drug: Placebo","Change in BOLD with oxytocin infusion","Anagnostou, Evdokia, M.D.","All","18 Years to 50 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO # 04-0749 (2)","March 2006","October 2010","September 2012","December 9, 2005",,"April 30, 2014","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00263796"
234,"NCT03493347","A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Equine-assisted Occupational Therapy","Change in Visual Analog Scale (VAS) ratings of individualized occupational performance goals|Change in Irritability|Change in Hyperactivity|Change in Social Functioning|Change in Canadian Occupational Performance Measure","Colorado State University","All","5 Years to 14 Years   (Child)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-7112H","July 24, 2017","December 18, 2017","December 31, 2018","April 10, 2018",,"April 12, 2019","Hearts and Horses Therapeutic Riding Center, Loveland, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03493347"
235,"NCT02928068","Telehealth Coaching for Families of Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Occupational Performance Coaching (OPC)","Parent Sense of Competence Scale|Canadian Occupational Performance Measure","University of Kansas Medical Center","All","12 Months to 84 Months   (Child)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00002264","April 2015","June 2017","June 2017","October 7, 2016",,"November 17, 2017","Occupational Therapy Education, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02928068"
236,"NCT01881750","Pivotal Response Group Treatment for Parents of Young Children With Autism","PRTG","Completed","Has Results","Autistic Disorder","Behavioral: Pivotal Response Training (PRT)|Behavioral: Parent Education Group (PEG)","Change From Baseline in Communication During Structured Lab Observation (SLO) at 12 Weeks|Parenting Stress Index Total Score|Family Empowerment Scale Total Score|Behavior Rating Inventory of Executive Function- Preschool Global Executive Composite Score|Repetitive Behavior Scale- Revised Total Score|Sensory Profile Questionnaire Sensory Seeking Raw Score|Pediatric Quality of Life Scale Scaled Total Mean Score","Stanford University|Autism Speaks","All","2 Years to 6 Years   (Child)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-11022010-7151","July 2010","June 2012","July 2012","June 20, 2013","August 16, 2019","August 16, 2019","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01881750"
237,"NCT01784744","Hyperthermia and the Amelioration of Autism Symptoms",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Hydroworx Pool at 98 degrees Fahrenheit|Other: Hydroworx Pool at 102 degrees Fahrenheit","Aberrant Behavior Checklist|Social Responsiveness Scale|Clinical Global Impression Scale - Improvement","Montefiore Medical Center|Simons Foundation","All","5 Years to 17 Years   (Child)",,"15","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12-10-113-01","November 2012","November 2013","December 2013","February 6, 2013",,"January 24, 2017","Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01784744"
238,"NCT03361787","A Multi-dimensional Program for Parents of Adolescents With High-functioning Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: ""Parentship""- a multi dimensional intervention program to improve parental resilience","Canadian Occupational Performance Measure (COPM)|Autism: Parenting Questionnaire (APQ)|Clinical Assessment of Therapeutic Responses (CATR)","Hadassah Medical Organization|Hebrew University of Jerusalem","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0269-17-HMO-CTIL","January 15, 2018","August 15, 2019","September 24, 2019","December 5, 2017",,"February 12, 2021","Hadassah medical organization, Jerusalem Israel, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT03361787"
239,"NCT02940574","Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Syntocinon (Oxytocin)|Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water))","Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 4 Weeks of Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After a Single Dose of Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 4 Weeks of Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/Reaction Time) After a Single Dose of Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 4 Weeks of Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 8 Weeks (Including 4 Weeks Without Nasal Spray)|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 52 Weeks (Including 48 Weeks Without Nasal Spray)|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 4 Weeks of Nasal Spray|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Scores on Questionnaire Assessing Mood After a Single Dose of Nasal Spray","KU Leuven|The Branco Weiss Fellowship|Research Foundation Flanders","Male","18 Years to 40 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S56327|2014-000586-45","April 2015","December 2016","December 2019","October 21, 2016","February 13, 2020","February 10, 2021",,,"https://ClinicalTrials.gov/show/NCT02940574"
240,"NCT04607616","Interactive Guidance Therapy With Video Feed-back of Parent and Child With Autism Spectrum Disorder","GIETSA","Not yet recruiting","No Results Available","Autism Spectrum Disorders","Behavioral: Baseline sessions TAU|Behavioral: Interactive guidance therapy|Diagnostic Test: Developmental and diagnostic assessments|Behavioral: Developmental assessment -Parental scales|Behavioral: Qualitative analysis","Percentage of time spent in a joint attention situation|Parent-child interactive features/ joint attention|Parent-child interactive features / DCMA scale|Parent-child interactive features / Parental synchrony|Parent-child interactive features / Communication|Parent-child interactive features / Initiation of communication|Child development / MSEL|Child development / CDI|Child development / IFDC|Autistic Symptoms / CARS|Autistic Symptoms ECAR|Autistic Symptoms ADOS-2|Autistic Symptoms ADIR|Adaptive behavior of the child|Change process|Content analysis of guidance session by parent","Assistance Publique - Hôpitaux de Paris|Ville Evrard Hospital","All","18 Months to 3 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","APHP180671|2019-A02707-50","December 2020","November 2023","May 2024","October 29, 2020",,"October 29, 2020","Hôpital Necker Enfants Malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT04607616"
241,"NCT03570372","Internet-based Treatment for Adults With Autism Spectrum Disorder","MILAS","Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Internet-based treatment for adults with autism spectrum|Behavioral: Psychoeducation about autism spectum disorder","Change in life quality|Change in depressive and anxiety symptoms|Change in knowledge of ASD|Subjective experience of ICBT|Content of communication|Correlation between schizotypal traits using SPQ and effect in quality of Life using BBQ","Örebro County Council|Susanne Bejerot, professor, MD","All","16 Years to 55 Years   (Child, Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17RS4920","August 1, 2018","May 30, 2020","May 30, 2020","June 27, 2018",,"October 8, 2019","Region Örebro County, Örebro, Örebro County, Sweden",,"https://ClinicalTrials.gov/show/NCT03570372"
242,"NCT03819439","Microbiome and Mycobiome Registry of Volunteers With and Without Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Microbiome and Autism Questionnaire","Characterize the microbiome [bacteria and fungal community]","University Hospitals Cleveland Medical Center","All","2 Years and older   (Child, Adult, Older Adult)",,"74","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","03/18/29","January 30, 2019","July 23, 2019","July 23, 2019","January 28, 2019",,"July 30, 2019","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03819439"
243,"NCT02773303","Neurofeedback Therapy for Children Diagnosed With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Device: Mente Autism™|Device: Sham","Changes in qEEG|Changes in Stability Score|Changes in Questions about Behavioural Function (QABF) test|The Behavior Rating Inventory of Executive Function (BRIEF)|Changes in Social Responsiveness Scale (Second Edition) SRS-2|Changes in Autism Behaviour Checklist (ABC)","Carrick Institute for Graduate Studies","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CI-IRB-20160321001","May 2016","December 13, 2017","December 13, 2017","May 16, 2016",,"July 24, 2018","Plasticity Brain Centers, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02773303"
244,"NCT02277756","Pain in Adults With Autism Spectrum Disorder","DOUPA","Terminated","No Results Available","Autism|Pain","Device: thermode","Pain as assessed by Computerized Visual analog scale|salivary cortisol|Behavioral response to thermal stimulation assessed by an inspired EDM-DI behavior scale|heart rate variability","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DOUPA (RB 14.035)","May 29, 2015","April 5, 2017","April 5, 2017","October 29, 2014",,"October 12, 2017","CHRU Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT02277756"
245,"NCT03294668","KONTAKT Australia a Social Skills Group Training for Adolescents on the Autism Spectrum",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: KONTAKT Australia|Other: Super Chef","Change in the Goal Attainment Scale (GAS)|Change in the Emotion Regulation and Social Skills Questionnaire (ERSSQ)|Mind Reading Battery|Change in the Circumplex Scale of Interpersonal Efficacy (CSIE)|Change in the Paediatric Quality of life Inventory- 4th edition (PedQL-4.0)|Change in the Perth Loneliness Scale (PALs)|Change in the Negative Incidents and Effects of Psychological Treatment (NEQ)|Change in the Child Health Utility 9D (CHU9D)|Change in Emotions via Experience Sampling (ESM)|Change in Social Interaction Anxiety Scale (SIAS)|Change in Treatment Inventory of Costs in Patients (TIC-P)|Change in social functioning|Treatment Satisfaction Scale|Change in the Social responsiveness scale - Second Edition (SRS-2)","Curtin University|Autism Association of Western Australia|Karolinska Institutet","All","12 Years to 17 Years   (Child)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HRE2017-0245","February 1, 2017","October 6, 2019","October 25, 2020","September 27, 2017",,"January 27, 2020","Curtin University, Bentley, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03294668"
246,"NCT04294290","Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder","TACT","Recruiting","No Results Available","Autism Spectrum Disorder","Biological: hCT-MSC infusion","Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG","Duke University|The Marcus Foundation","All","18 Months to 48 Months   (Child)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00104460","February 24, 2021","December 1, 2022","December 1, 2022","March 4, 2020",,"March 19, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04294290"
247,"NCT00065910","Improving Attention Skills of Children With Autism",,"Completed","No Results Available","Autism","Behavioral: Caregiver joint attention intervention",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","12 Months to 36 Months   (Child)","Phase 1|Phase 2","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21MH064927","September 2001",,"January 2006","August 5, 2003",,"July 2, 2007","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00065910"
248,"NCT01887132","A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism",,"Terminated","Has Results","Autism Spectrum Disorders","Drug: Donepezil|Drug: Placebo","Nonverbal Developmental Quotient (NVDQ)|REM Percentage at Baseline, 6, 12 and 18 Months","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","24 Months to 50 Months   (Child)","Phase 2","5","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","130164|13-M-0164","June 2013","December 2015","December 2015","June 26, 2013","September 25, 2017","September 25, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01887132"
249,"NCT02695693","RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: TeachTown|Behavioral: Discrete Trial Training|Behavioral: Pivotal Response Training|Behavioral: Teaching in Functional Routines","Differential Abilities Scale, 2nd Edition|Bracken School Readiness Assessment, 3rd Edition","University of Pennsylvania|National Institute of Mental Health (NIMH)|The School District of Philadelphia","All","5 Years to 9 Years   (Child)","Not Applicable","212","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH106175","April 2015","June 2017","June 15, 2018","March 1, 2016",,"April 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02695693"
250,"NCT01908205","Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)","OXY-R","Completed","Has Results","Autism Spectrum Disorder","Drug: Intranasal Oxytocin|Drug: Placebo","Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Function|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Cognition|Number of Participant Considered Social Responders|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Repetitive Behaviors|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Anxiety|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Quality of Life|Number of Participant Considered Overall Responders|Safety and Tolerability of Intranasal Oxytocin in Children and Adolescents With ASD","Evdokia Anagnostou|United States Department of Defense|Anagnostou, Evdokia, M.D.","All","10 Years to 17 Years   (Child)","Phase 2","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OXY-R07-2013","September 2013","September 2015","March 2016","July 25, 2013","November 16, 2020","November 16, 2020","University of Minnesota, Minneapolis, Minnesota, United States|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01908205"
251,"NCT02627131","Autologous Bone Marrow Stem Cell Therapy for Autism",,"Completed","No Results Available","Autistic Disorder","Biological: Autologous Bone Marrow Mononuclear Cells","Change in Total Score of Childhood Autism Rating Scale (CARS)|Number of adverse events","Vinmec Healthcare System","All","3 Years to 16 Years   (Child)","Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBG 003","April 2014","December 2015","December 2015","December 10, 2015",,"December 10, 2015","Vinmec International Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT02627131"
252,"NCT02374541","Screening and Linkage to Services for Autism","SaLSA","Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Patient Navigation","Completion of developmental evaluation / eligibility determination|Individualized Family Service Plan (IFSP) development|Age at Individualized Family Service Plan (IFSP) development|Time to Individualized Family Service Plan (IFSP) development|Initiation of indicated early intervention (EI) services|Age at initiation of indicated early intervention services|Time to initiation of indicated early intervention services|Referral for developmental evaluation / eligibility determination|Time to referral for and implementation of developmental evaluation / eligibility determination|Age at referral for and implementation of developmental evaluation / eligibility determination","University of Colorado, Denver|Denver Health and Hospital Authority|Rocky Mountain Human Services|El Grupo Vida","All","16 Months to 32 Months   (Child)","Not Applicable","305","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","14-1728|R40MC27702","February 16, 2015","May 31, 2018","November 21, 2018","March 2, 2015",,"April 6, 2020","Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Denver Health and Hospital Authority, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02374541"
253,"NCT03538431","Improving Driving in Young People With Autism Spectrum Disorders",,"Completed","Has Results","Autism Spectrum Disorder","Drug: Buspirone","Driving Performance - Measured by Mean Off-Road Glance Duration|Heart Rate","Massachusetts General Hospital|Massachusetts Institute of Technology","All","18 Years to 24 Years   (Adult)","Phase 4","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018-P-000900","October 31, 2018","December 16, 2019","December 16, 2019","May 29, 2018","March 18, 2021","March 18, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03538431/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03538431"
254,"NCT01614275","Using Web-based Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families",,"Unknown status","No Results Available","Autism Spectrum Disorders","Behavioral: Technology-Enhanced Parent Training|Behavioral: Technology-Enhanced Tutor Training|Behavioral: Technology-enhanced Early Intensive Behavioral Intervention|Behavioral: No-Intervention","Intelligent Quotient: Differential Abilities Scales, Second Edition|Parent Training: Behavioral Implementation Skills for Play Activities|Tutor Training: Behavioral Implementation of Work Activities","University of Nebraska|State University of New York - Upstate Medical University","All","18 Months to 48 Months   (Child)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","059-11|W81XWH-11-1-0444","May 30, 2012","July 1, 2017","July 1, 2018","June 7, 2012",,"February 7, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01614275"
255,"NCT02751957","Pilot Study to Improve Access to Early Intervention for Autism in Africa",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model","The Griffiths Scales of Mental Development: Change in developmental quotient and language subdomain developmental quotient|The Vineland Adaptive Behavior Scales: Changes in communication and socialization standard scores","Duke University|University of Cape Town","All","18 Months to 72 Months   (Child)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00064533","July 1, 2016","July 2020","July 2020","April 26, 2016",,"August 25, 2020","University of Cape Town, Cape Town, Western Cape Province, South Africa",,"https://ClinicalTrials.gov/show/NCT02751957"
256,"NCT00319722","EEG Studies of Sensory Processing in Autistic Children",,"Unknown status","No Results Available","Autism",,"EEG and ERP abnormalities|Characteristic and severity of autistic behaviors","Massachusetts General Hospital|CURE Foundation|The Commonwealth Fund|National Alliance for Autism Research|Nancy Lurie Marks Family Foundation","All","3 Months to 8 Years   (Child)",,"130","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2005-P-000868/3","February 2006","March 2011","March 2011","April 27, 2006",,"May 4, 2010","MGH LADDERS Clinic, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00319722"
257,"NCT02508259","University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial","SAT1","Completed","Has Results","Autism Spectrum Disorders","Drug: Suramin|Drug: Saline","Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2)|Expressive Language|Aberrant Behavior Checklist (ABC)|Autism Treatment Evaluation Checklist (ATEC)|The Clinical Global Impression - Improvement Scale (CGI-I)|Repetitive Behavior Questionnaire","University of California, San Diego","Male","4 Years to 17 Years   (Child)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-0134","May 2015","March 2016","April 2016","July 24, 2015","July 16, 2019","July 16, 2019","University of California, San Diego School of Medicine, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02508259"
258,"NCT01780090","Handheld Technology for Speech Development in Students With Autism",,"Completed","No Results Available","Autism Spectrum Disorders","Other: iPad software","Learning of software|Usability of software|Student engagement in treatment|Software effectiveness","Yale University|Handhold Adaptive","All","4 Years to 19 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1208010627|ED-IES-12-R-0007","September 2012","December 2012","January 2013","January 30, 2013",,"January 30, 2013","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01780090"
259,"NCT01417026","Intranasal Oxytocin and Learning in Autism",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Intranasal Oxytocin (Trade name: Syntocinon)","Change From Baseline to Post-testing (After Max. 12 Days) on the Part/Whole Identity Test (LFI Skills Battery)|Change From Baseline to Post-testing (After Max. 12 Days) on the Reading the Mind in the Eyes Test (Child Version)|Changes From Baseline to Post-testing (After Max. 12 Days) on the ""Happy Faces"" Measure of Social Attention","Robert Schultz|Children's Hospital of Philadelphia","Male","12 Years to 17 Years   (Child)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-008241","September 2011","April 2015","April 2015","August 16, 2011","March 30, 2017","March 30, 2017","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01417026"
260,"NCT03232775","Use of a Visual Pedagogy and Structure With Children With Autism for Routine Physical Exams",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Treatment: Physical Exam with Visual Pedagogy and Structure|Other: Control: Physical Exam without Visual Pedagogy and Structure","Change from baseline on the Aberrant Behavior Checklist-Community measure ( irritability and stereotypy subscales)|Number of study exam items completed during study exams|Change from baseline in Cooperation likert-scale rating form","University of Colorado, Denver|Children's Hospital Colorado","All","4 Years to 10 Years   (Child)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","07-0362","September 2007","August 2011","August 2011","July 28, 2017",,"July 28, 2017",,,"https://ClinicalTrials.gov/show/NCT03232775"
261,"NCT02668991","Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort",,"Completed","No Results Available","Autism Spectrum Disorder",,"Utility of Autism Behavior Inventory(ABI) in Measuring Clinical Symptoms of Autism Spectrum Disorder (ASD)|Usability of the Janssen Autism Knowledge Engine (JAKE) in Measuring Clinical Symptoms of ASD|Correlation Between Key Biosensors and Autism Spectrum Disorder (ASD) Symptoms|Correlation Between Genomic Characteristics and Autism Phenotypes|Usability of the JAKE System to detect changes in response to standard|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Normative data on the JAKE Biosensor Array (Continuous and Periodic)|Normative data on the JAKE Task Battery|Ease of use of JAKE for use in Prospective Clinical Trials|Utility of JAKE for use in Prospective Clinical Trials","Janssen Research & Development, LLC","All","6 Years and older   (Child, Adult, Older Adult)",,"186","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR106701|MENTIS-ASD002","July 2015","October 2016","October 2016","January 29, 2016",,"December 19, 2016","Phoenix, Arizona, United States|San Francisco, California, United States|New Haven, Connecticut, United States|Worcester, Massachusetts, United States|Toms River, New Jersey, United States|Orangeburg, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02668991"
262,"NCT01974973","Stem Cell Therapy in Autism Spectrum Disorders",,"Withdrawn","No Results Available","Autism Spectrum Disorders","Procedure: Autologous bone marrow mononuclear cell transplantation","Improvement in the scales for Autism spectrum disorders|Positron Emission Tomography- computed tomography to study change in brain metabolism","Neurogen Brain and Spine Institute","All","6 Months to 40 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NGBSI-02","August 2009","January 2016","May 2016","November 3, 2013",,"October 25, 2018","Neurogen brain and spine institute, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01974973"
263,"NCT03791385","Effectiveness of Picture Exchange Communication System on Gingival Health of Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Picture Exchange Communication System (PECS)","Gingival index score|Plaque index score|Parents' rating of PECS difficulty|PECS usefulness","Jordan University of Science and Technology","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","37","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20110011","April 2011","October 2011","October 2011","January 2, 2019",,"January 2, 2019","Jordan University of Science and Technology, Irbid, Jordan",,"https://ClinicalTrials.gov/show/NCT03791385"
264,"NCT02811627","Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Memantine|Device: Magnetic Resonance Imaging","Clinical Global Impressions - Improvement|Social Responsiveness Scale (SRS)|General Social Outcomes Measure (GSOM)|Aberrant Behavior Checklist (ABC)|Test of Language Competence","University of Missouri-Columbia","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2004983HS","June 2016","April 2021","April 2021","June 23, 2016",,"April 14, 2021","University of Missouri, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02811627/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02811627"
265,"NCT02472860","Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder","MGHTCT","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Targeted Cognitive Training (TCT)|Other: Youth Appropriate Online Games","Cambridge Neuropsychological Test Automated Battery (CANTAB)","Massachusetts General Hospital|Deborah Munroe Noonan Memorial Research Fund","All","13 Years to 17 Years   (Child)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015P000610","June 2015","August 2, 2017","August 2, 2017","June 16, 2015",,"March 27, 2018",,,"https://ClinicalTrials.gov/show/NCT02472860"
266,"NCT03724552","Photobiomodulation in Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Device: Transcranial LED Therapy","Reduction in ASD Symptoms (SRS)|Reduction in ASD Symptoms (CGI)","Massachusetts General Hospital","All","18 Years to 59 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P002826","April 13, 2017","August 2022","August 2022","October 30, 2018",,"September 22, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03724552"
267,"NCT04878718","Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder",,"Available","No Results Available","Autism Spectrum Disorder|Autism","Biological: Fecal Microbiota Transplant; Vancomycin",,"ProgenaBiome|Topelia Therpeutics","All","2 Years and older   (Child, Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients",,"19343",,,,"May 7, 2021",,"September 5, 2021","Ventura Clinical Trials, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04878718"
268,"NCT02595697","Communication Intervention for Toddlers With Autism","J-EMT","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: J-EMT for Toddlers with Autism","Number of spontaneous social communication attempts made as assessed by a 20 minute lanugage sample.","Vanderbilt University|Northwestern University","All","24 Months to 36 Months   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R324A150094","July 2015","December 2019","June 2020","November 3, 2015",,"October 6, 2020","Northwestern University, Evanston, Illinois, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02595697"
269,"NCT03640156","Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Oxytocin|Other: Placebo","Change from baseline in socially adaptive mirroring as measured by TMS|Change from baseline in mirroring of others' actions as measured by TMS|Change from baseline in corticospinal excitability as measured by TMS|Change from baseline in total fixation duration towards the eye region of the model.","KU Leuven","Male","18 Years to 35 Years   (Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","S56327c","July 26, 2018","December 19, 2019","December 19, 2019","August 21, 2018",,"February 5, 2020","Katholieke Universiteit Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03640156"
270,"NCT00503191","NeuroModulation Technique Treatment of Autism","NMT","Completed","No Results Available","Autism|Neurodevelopmental Disorder","Behavioral: NeuroModulation Technique","Primary efficacy outcome measures include mean change from start of treatment to end of treatment on the PDDBI Autism Composite Index, the ABC-C Total Score, and the ATEC Total Score.|Secondary outcome measures include mean change from start of treatment to end of treatment on the remaining subscales of the PDDBI, the ABC-C, and the ATEC.","NeuroModulation Technique Research Institute","All","5 Years to 10 Years   (Child)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMTRI001-01","July 2007","February 2009","February 2009","July 18, 2007",,"January 22, 2014","Robert H. Weiner, Ph.D., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00503191"
271,"NCT02714101","Equine-assisted Occupational Therapy for Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Equine assisted occupational therapy","Rater coding of engagement|Rater coding of enjoyment","University of Alberta","All","3 Years to 8 Years   (Child)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00031008","June 2012","December 2012","September 2013","March 21, 2016",,"March 21, 2016",,,"https://ClinicalTrials.gov/show/NCT02714101"
272,"NCT01646866","Early Detection of Autism Spectrum Disorder in Children",,"Completed","No Results Available","Autism Spectrum Disorder",,"Percentage of Children with a High Risk Genetic Score on the ARISK Genetic Test who have a Diagnosis of Autism Spectrum Disorders (ASD) at 24 Months|Percentage of Children who failed the Red Flags for Communication (RFC) Scale at 12 months who have a Diagnosis of ASD at 24 months","St. Louis University|IntegraGen SA","All","6 Months to 36 Months   (Child)",,"37","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15861","December 2010","December 2015","December 2015","July 20, 2012",,"March 6, 2017","Knights of Columbus Developmental Center, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01646866"
273,"NCT03830541","Oral Health Care in Autism Spectrum Disorder","CREASED","Unknown status","No Results Available","Autism Spectrum Disorder|Autism","Other: Oral care delivery analysis in participants with ASD","Oral Health Status as measured by number of subjects with missing teeth|Oral Health Status as measured by untreated dental decay|Oral health care delivery analysis|Tooth loss in institutionalised participants|Tooth loss in general anaesthesia","University of Novi Sad","All","3 Years to 80 Years   (Child, Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","01789/2019","March 20, 2019","July 20, 2019","December 20, 2019","February 5, 2019",,"March 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03830541"
274,"NCT02675933","Satisfaction Rates Among Parents of Children With Autism in the ED","ASD","Terminated","No Results Available","Autism Spectrum Disorder","Behavioral: Questionnaire","Satisfaction Scores|Length of Stay|Admission rate|Number of PIV attempts|Sedating medications needed for procedures","Seton Healthcare Family","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CR-15-162","February 2016","January 6, 2017","January 6, 2017","February 5, 2016",,"August 2, 2018","Dell Children's Medical Center of Central Texas, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02675933"
275,"NCT02456298","Comparing Behavioral Assessments Using Telehealth for Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Standard FA+FCT|Behavioral: Pragmatic FA+FCT","Percent Reduction in Problem Behavior","Matthew J O'Brien, PhD, BCBA-D|University of Houston|Emory University|Children's Healthcare of Atlanta|National Institute of Mental Health (NIMH)|University of Iowa","All","18 Months to 83 Months   (Child)","Not Applicable","152","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB#201501781|R01MH104363","June 2015","May 31, 2020","May 31, 2020","May 28, 2015",,"October 8, 2020","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02456298"
276,"NCT03235596","Effects of Cathodal tDCS on Executive Functions in Autism","TRANSFEX","Unknown status","No Results Available","Autism Spectrum Disorder","Device: tDCS","Cognitive dysexecutive functions|Score changes in the tDCS adapted version of the Udvalg pour Kliniske Undersøgelser (UKU) Side Effect Rating Scale|Behavioral dysexecutive functions|Trail Making Test A and B|Stroop Test|Verbal Fluency Test","Centre Hospitalier du Rouvray","All","20 Years to 50 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-A00805-46","December 2016","August 2017","August 2017","August 1, 2017",,"August 1, 2017","Centre Hospitalier du Rouvray, Sotteville-lès-Rouen, France",,"https://ClinicalTrials.gov/show/NCT03235596"
277,"NCT02493426","Single Dose Intranasal Oxytocin and Cognitive Effects in Autism",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders","Drug: Intranasal Oxytocin|Drug: Placebo","Social Cognition Tasks|Cognitive Rigidity Tasks|Brain Body Physiology measures","University of Minnesota","All","5 Years to 40 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","INOT Challenge","May 2014","December 31, 2020","December 31, 2020","July 9, 2015",,"January 9, 2020","Center for Neurobehavioral Development, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02493426"
278,"NCT04890717","Biomarkers for Autism and ADHD in Children",,"Recruiting","No Results Available","Autism|ADHD",,"To identify the microbial species in stool in suspected and confirmed ASD and/or ADHD children|To confirm different microbial species in stool in suspected and confirmed ASD and/or ADHD children across 2 years|To confirm different microbial species in stool at different age groups in suspected and confirmed ADS and/or ADHD children across 2 years|To correlate the changes in microbial species in stool with different diet habits in ASD and/or ADHD children across 2 years|To correlate the changes in microbial species in stool between the suspected and confirmed ASD and/or ADHD children with their siblings, parent or typically developed children at baseline|To correlate the changes in microbial species in stool with different food additives levels in all subject groups at baseline","Chinese University of Hong Kong","All","up to 18 Years   (Child, Adult)",,"320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mic_ASDADHD","May 15, 2021","May 14, 2024","December 31, 2024","May 18, 2021",,"July 28, 2021","Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04890717"
279,"NCT04468620","A Peer-mediated Vocational Social Skills Program for Young Adults With Autism",,"Completed","No Results Available","Autism Spectrum Disorder High-Functioning","Behavioral: Assistive Soft Skills & Employment Training (ASSET)","Baseline Social Functioning|Change in Social Functioning|Baseline General Self-efficacy|Change in General Self-efficacy|Baseline Perceived Empathic Self-efficacy|Change in Perceived Empathic Self-efficacy|Baseline Perceived Social Self-efficacy|Change in Perceived Social Self-efficacy|Baseline Depression|Change in Depression|Baseline Anxiety|Changes in Anxiety","Florida Gulf Coast University","All","18 Years to 29 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-11","September 16, 2019","April 15, 2020","June 30, 2020","July 13, 2020",,"February 3, 2021","Florida Gulf Coast University, Fort Myers, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04468620"
280,"NCT00953095","Social and Communication Outcomes for Young Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Joint Attention Intervention","Early Social Communication Scale|Mullen Scales of Early Learning","Health Resources and Services Administration (HRSA)|University of California, Los Angeles|University of Washington|University of Michigan|Florida State University|Johns Hopkins University","All","24 Months to 60 Months   (Child)","Not Applicable","112","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","G09-02-016-01|UA3MC11055","April 2009","December 2011","December 2011","August 6, 2009",,"September 25, 2014","University of California, Los Angles, Los Angeles, California, United States|Florida State University, Tallahassee, Florida, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00953095"
281,"NCT00467818","Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders",,"Completed","Has Results","Autism","Drug: Omega 3 fatty acids|Other: Placebo","Clinical Global Impression Scale(CGI)- Improvement|Aberrant Behavior Checklist (ABC)|Vineland Adaptive Behavior Scale|Overt Aggression Scale-Modified|Parental Stress Index","University of Medicine and Dentistry of New Jersey|National Center for Complementary and Integrative Health (NCCIH)|Rutgers, The State University of New Jersey","All","5 Years to 17 Years   (Child)","Not Applicable","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0220060238|5R21AT002927","January 2007","December 2010","December 2010","May 1, 2007","December 16, 2020","January 26, 2021","University Behavioral Health Care Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00467818"
282,"NCT04630847","Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders",,"Not yet recruiting","No Results Available","Autism|Autism Spectrum Disorder","Biological: Fecal Microbiota Transplant","Adverse Events|Serious Adverse Events|ATEC|CARS-2|QoLA|SRS-II|Shannon Diversity Index","ProgenaBiome|Ventura Clinical Trials","All","2 Years and older   (Child, Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCT-1","December 2021","June 2024","December 2024","November 16, 2020",,"September 5, 2021","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04630847"
283,"NCT03434366","Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: ketamine and dexmedetomidine|Drug: ketamine|Drug: Saline","Autism Diagnostic Interview Revised (ADI-R)|Autism Diagnostic Observation Schedule (ADOS)|autism behavior checklist (ABC)|magnetic resonance spectroscopy(MRS)|Childhood Autism Rating Scale (CARS)","Guangzhou Women and Children's Medical Center","All","2 Years to 15 Years   (Child)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","intranasal ketamine","January 20, 2018","December 30, 2023","December 30, 2023","February 15, 2018",,"May 26, 2020","Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03434366"
284,"NCT02477904","Ketogenic Diet Therapy for Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Ketogenic Diet","Change from baseline in core symptoms of ASD|Change from baseline in the number of medications used for ASD management|Change from baseline in the dosage of medications used for ASD management|Change from baseline in the number of lab tests ordered for ASD management|Change from baseline in the number of emergency room or hospital visits for ASD management|Change from baseline in subject/family satisfaction with the ketogenic diet|Change from baseline in biochemical profiles due to the ketogenic diet","Shriners Hospitals for Children|University of Hawaii","All","2 Years to 21 Years   (Child, Adult)","Not Applicable","119","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HON1403","March 2015","April 28, 2017","April 28, 2017","June 23, 2015",,"September 20, 2019","Shriners Hospitals for Children - Honolulu, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT02477904"
285,"NCT04652388","Impact of Nutritional Counselling in Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Nutritional counseling","Adherence to Mediterranean Diet|Change in food selectivity|Change in eating habits","Federico II University","All","24 Months to 48 Months   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","353/20","September 1, 2020","September 1, 2020","September 1, 2022","December 3, 2020",,"December 3, 2020","University of Naples Federico II, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04652388"
286,"NCT01970345","A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: IGF-1|Drug: Placebo/saline","Aberrant Behavior Checklist - Social Withdrawal Subscale|Social|Language|Repetitive Behavior|Overall Functional Outcomes|Caregiver Strain","Icahn School of Medicine at Mount Sinai|Autism Science Foundation","All","5 Years to 12 Years   (Child)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 13-1206","May 2014","May 2022","May 2022","October 28, 2013",,"July 15, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01970345"
287,"NCT01749670","Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder",,"Exosomal microRNA expression patterns","State University of New York - Upstate Medical University","All","4 Years to 17 Years   (Child)",,"45","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","346301-1","January 2013","September 2014","September 2014","December 17, 2012",,"November 26, 2014","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01749670"
288,"NCT02360332","A Collaborative Public/Private Employment Training and Placement Model ASD Transition Age Youth With Autism Spectrum Disorder (ASD)","ProjSEARCH1","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Project SEARCH plus ASD Supports","Change in Employment Status across 3 points in time (Employed or not employed)|Change in Hours worked weekly across 3 points in time|Change in Hourly wage earned across 3 points in time|Change in Intensity of work support required across 3 points in time","Virginia Commonwealth University|Henrico County Public Schools|Virginia Department of Aging and Rehabilitative Services|Chesterfield County Public Schools","All","18 Years to 21 Years   (Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIDDRDRRP09-13","October 2009","September 2013","January 2015","February 10, 2015",,"February 10, 2015",,,"https://ClinicalTrials.gov/show/NCT02360332"
289,"NCT02302911","Swiss Early Intervention Project in Autism: An Evaluation of Early Intervention Outcome","SwissEIPA","Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Early intensive behavioral intervention|Behavioral: Early intensive eclectic intervention|Other: Treatment as usual","Autism Diagnostic Observation Schedule-2 (ADOS-2)|Positive Gain Scale|General Positive Affect Scale|Questionnaire on Resources and Stress|Hospital anxiety and Depression scale|Strengths and Difficulties Questionnaire|Vineland Adaptive Behavior Scales II (VABS)|Snijders-Oomen nicht-verbaler Intelligenztest 2 1/2 - 7 (SON-R)|Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III)","University of Zurich","All","up to 5 Years   (Child)",,"90","Other","Observational","Observational Model: Other|Time Perspective: Prospective","SWEIPA","January 2013","December 2018","December 2018","November 27, 2014",,"October 2, 2017","Autismuszentrum GSR, Aesch, Basel Stadt, Switzerland|Association Objectif Vaincre l'Autisme, Gland, Vaud, Switzerland|University of Zurich, Department of Child and Adolescent Psychiatry, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02302911"
290,"NCT02291172","Comprehensive Communication Intervention for Minimally Verbal Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Intervention JEP","Spontaneous communicative utterances","Vanderbilt University","All","36 Months to 54 Months   (Child)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","141453","September 2014","December 2017","March 2018","November 14, 2014",,"July 12, 2018","Metro Nashville Schools, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02291172"
291,"NCT00036244","Synthetic Human Secretin in Children With Autism",,"Completed","No Results Available","Autism","Drug: RG1068 (Synthetic Human Secretin)",,"Repligen Corporation","All","32 Months to 59 Months   (Child)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","RG1068-04","April 2002",,"January 2004","May 9, 2002",,"August 5, 2005","Southwest Autism Research Center, Phoenix, Arizona, United States|UCLA Pediatric Neurology, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|1st Allergy & Clinical Research Center, Centennial, Colorado, United States|Alachua Family Psychiatry, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Riley Children's Hospital, Indianapolis, Indiana, United States|The Clinical Trials Center:A Division of Children's Hospital, Metairie, Louisiana, United States|Hardy Healthcare Associates, Hingham, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|The Ohio State University, Columbus, Ohio, United States|Children's Biomedical Center of Utah, Sandy, Utah, United States|Puget Sound Neurology, Edmonds, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00036244"
292,"NCT02353130","Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment",,"Withdrawn","No Results Available","Autism Spectrum Disorders","Drug: Memantine-XR","cortical metrics (a mathematical plot of tactile responsivity in 3 dimensions)|Clinical Global Impressions - Improvement Score.|PDD-BI SV change 0-8|ABC-SW subscale score 0-8","University of North Carolina, Chapel Hill","Male","8 Years to 12 Years   (Child)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-1996","July 2015","December 2015","December 2015","February 2, 2015",,"May 8, 2017",,,"https://ClinicalTrials.gov/show/NCT02353130"
293,"NCT04923854","Phenotypic Exploration of Autism Spectrum Disorders Retrospective and Prospective Data","EXPECT","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: No intervention","The main objective is to better understand the phenotypic heterogeneity of Autism Spectrum Disorder (ASD).","Assistance Publique - Hôpitaux de Paris","All","1 Year to 18 Years   (Child, Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP191023","July 1, 2021","July 1, 2026","July 1, 2027","June 11, 2021",,"June 11, 2021","Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT04923854"
294,"NCT04992169","Clinicianless Training in Autism Treatment: An Adaptive Online Parent Education Program",,"Recruiting","No Results Available","Autism Spectrum Disorder|Parents","Behavioral: Smartphone-App Parent Training in Pivotal Response Treatment","Change from Baseline in Parent Fidelity of Implementation of Pivotal Response Treatment (PRT) during Behaviorally Coded Parent-Child Intervention Videos at 8 weeks, 16 weeks|Change from Baseline in Frequency of Child Vocalizations/Word Use during Behaviorally Coded Parent-Child Intervention Videos at 8 weeks, 16 weeks.|Change from Baseline in Percentage of Child Positive Affect during Behaviorally Coded Parent-Child Intervention Videos at 8 weeks, 16 weeks.|Change from Baseline in MacArthur-Bates Communicative Development Inventory (CDI), Level I Short Form (Total Score) at 16 weeks|Change from Baseline in Vineland Adaptive Behavior Scales, Third Edition (Standard Score on Communication Domain) at 16 weeks|Change from Baseline in Vineland Adaptive Behavior Scales, Third Edition (Standard Score on Socialization Domain) at 16 weeks|Change from Baseline in Social Responsiveness Scale, Second Edition (SRS-2; Total T-Score) at 16 weeks","University of California, Santa Barbara","All","12 Months to 54 Months   (Child)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","24-21-0034","August 23, 2021","June 30, 2022","August 30, 2022","August 5, 2021",,"September 28, 2021","University of California, Santa Barbara, Santa Barbara, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04992169/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04992169/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04992169/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04992169"
295,"NCT05013528","Balance Auditory Vision Training (Bal-A-Vis-X) and Aerobic Training in Children With Autism Spectrum Disorder","Bal-A-Vis-X","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Bal-A-Vis-X training|Other: Aerobic Training Group","Bruininks- Oseretsky Test of Motor Proficiency-2 (BOT-2)|Childhood Executive Functioning Inventory|Color Trail Test","Riphah International University","All","4 Years to 12 Years   (Child)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","REC00826/ Mahnoor Zia","August 1, 2021","October 30, 2021","October 30, 2021","August 19, 2021",,"September 2, 2021","Child Dream Center, Faisalabad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05013528"
296,"NCT04658043","Early Socioemotional Intervention for Children With Autism Spectrum Disorder in Hong Kong and Mainland China",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: Intervention on socioemotional functioning","Change in Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)|Change in the Autism Spectrum Quotient (AQ)|Change in Dyadic Parent-Child Interaction Coding System (DPICS system)|Change in Parenting Stress Index, Fourth Edition Short Form (PSI-4-SF)|Change in Self-Efficacy in Nurturing Role Questionnaire|Change in Classroom Observation Scale (COS)|Change in Social Responsiveness Scale, Second Edition (SRS-2)","The University of Hong Kong|Shenzhen University|Guangdong Province, Department of Science and Technology","All","3 Years to 6 Years   (Child)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EA1811014","September 22, 2019","August 31, 2022","August 31, 2022","December 8, 2020",,"December 8, 2020","Shenzhen University, Shenzhen, China|University of Hong Kong, Hong Kong, Hong Kong","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT04658043/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04658043"
297,"NCT04274127","Early Screening of Autism Spectrum Disorder in General and Pediatric Practices","KitCAT","Recruiting","No Results Available","Autism Spectrum Disorder","Diagnostic Test: early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)","number of children with a confirmed ASD diagnosis","Hôpital le Vinatier","All","16 Months to 24 Months   (Child)","Not Applicable","1700","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-A00823-46","April 9, 2018","January 2024","January 2024","February 18, 2020",,"August 9, 2021","Centre Hospitalier Le Vinatier, Bron, Rhône, France",,"https://ClinicalTrials.gov/show/NCT04274127"
298,"NCT04706364","Investigation of Brain Plasticity in Autism Spectrum Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Neuropsychological Testing|Genetic: (Optional) Saliva Collection|Device: Sensory Testing|Device: Electroencephalogram (EEG)|Device: Transcranial Magnetic Stimulation","Textured novel object recognition test (NORT) and mechanical detection threshold (MDT) with von Frey hairs|Somatosensory temporal discrimination threshold (STDT) and PAS-induced modulation of motor-evoked potentials (MEPs)","Boston Children's Hospital|National Institute of Mental Health (NIMH)|Simons Foundation Autism Research Initiative (SFARI)","All","6 Years to 18 Years   (Child, Adult)",,"60","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB-P00027556|R21MH120438","June 10, 2019","May 2022","May 2022","January 12, 2021",,"February 21, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04706364"
299,"NCT03338530","Efficacy of a Comprehensive School-based Intervention for High-functioning Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Comprehensive School-Based Intervention","Change from Baseline Cambridge Mindreading Face-Voice Battery for Children (CAM-C) Scores at Follow-up|Change from Baseline Social Responsiveness Scale, 2nd Edition, School Age Form (SRS-2) Scores at Follow-up|Change from Baseline Adapted Skillstreaming Checklist (ASC) Scores at Follow-up|Change from Baseline Woodcock-Johnson III Tests of Achievement (WJ III ACH) Scores at Follow-up|Change from Baseline Social Interaction Observation Scale (SIOS) Scores at Follow-up","Canisius College|U.S. Department of Education","All","6 Years to 12 Years   (Child)","Not Applicable","103","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2012-13#142RENEWAL-Ammend","August 1, 2013","July 31, 2017","July 31, 2017","November 9, 2017",,"November 9, 2017",,,"https://ClinicalTrials.gov/show/NCT03338530"
300,"NCT04498078","Creatine Supplementation in Autism Spectrum Disorder","CREATOR","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Dietary Supplement: Creatine","Brain creatine change|Brain N-acetylaspartate change|Autism Treatment Evaluation Checklist (ATEC) score","University of Novi Sad, Faculty of Sport and Physical Education","All","10 Years and older   (Child, Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ABL-21-AUCR","January 15, 2021","January 15, 2022","February 14, 2022","August 4, 2020",,"April 28, 2021","FSPE Applied Bioenergetics Lab, Novi Sad, Vojvodina, Serbia",,"https://ClinicalTrials.gov/show/NCT04498078"
301,"NCT05045339","Ball Exercises and Stereotypic Behavior in Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Procedure: Ball Exercises","Stereotypic Behaviors","University of Faisalabad","All","4 Years to 16 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","TUF/DR/DPT/157","February 6, 2018","April 20, 2018","May 28, 2018","September 16, 2021",,"October 6, 2021","The University of Faisalabad, Faisalābad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05045339"
302,"NCT04651972","Measurement of vanilloïd Compounds in Urin of Autistic vs Control Patients, as Potential Biomarkers","DIADAUVEDA","Not yet recruiting","No Results Available","Autism Spectrum Disorder",,"measurements of vanilloid compound in urins","Central Hospital, Nancy, France","Male","2 Years to 14 Years   (Child)",,"140","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","2020PI116","December 15, 2020","July 30, 2022","July 30, 2022","December 3, 2020",,"December 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04651972"
303,"NCT04010409","Mindreading in Adults With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Other: no intervention","eye tracking indicators","National Taiwan University Hospital","All","20 Years to 50 Years   (Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201809069RINA","January 8, 2019","November 2019","November 2019","July 8, 2019",,"July 8, 2019","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04010409"
304,"NCT05063656","Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: Gabapentin","Right Anterior Insula GABA level","David Cochran|Eagles Autism Foundation|University of Massachusetts, Worcester","All","13 Years to 17 Years   (Child)","Phase 4","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Gabapentin ASD Trial","November 2021","November 2023","November 2023","October 1, 2021",,"October 1, 2021","University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05063656"
305,"NCT00036231","Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction",,"Terminated","No Results Available","Autism","Drug: RG1068 (Synthetic Human Secretin)",,"Repligen Corporation","All","32 Months to 59 Months   (Child)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","RG1068-03","April 2002",,,"May 9, 2002",,"November 21, 2005",,,"https://ClinicalTrials.gov/show/NCT00036231"
306,"NCT05067582","A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Autism","Drug: L1-79","Vineland Adaptive Behavior Scale, Third Edition (Vineland-3), Average of the Growth Scale Value (GSV) score of the three Socialization Subdomains (combined)|Brief Observation of Social Communication Change (BOSCC)|Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization|Clinical Global Impression of Change (CGI-C) weighted for socialization|Percent of subjects showing a statistically significant improvement in GSV on 2 of the Socialization Subdomains|Caregiver Global Impression of Change of 3 Most Bothersome Symptoms of ASD (CGI-3P)|Social Responsiveness Scale, Second Edition (SRS-2) Social-Communication and Interaction - DSM-5 Composite T-score|Social Responsiveness Scale, Second Edition (SRS-2) Total T-score|Social Responsiveness Scale, Second Edition (SRS-2) Social Motivation T-score|Vineland-3 Socialization Domain, Standard Score|Parent-rated Anxiety Scale for ASD (PRAS-ASD)|Child's Sleep Habits Questionnaire (CSHQ)","Yamo Pharmaceuticals LLC","All","12 Years to 21 Years   (Child, Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Y202","October 2021","February 2023","March 2023","October 5, 2021",,"October 5, 2021",,,"https://ClinicalTrials.gov/show/NCT05067582"
307,"NCT00695812","The Development of Younger Siblings of Children With Autism Now at 10 Years of Age",,"Unknown status","No Results Available","Autism Spectrum Disorders",,,"Shaare Zedek Medical Center|Hebrew University of Jerusalem","All","10 Years to 11 Years   (Child)",,"104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Siblings Autism.ctil","September 2008","September 2011","September 2011","June 12, 2008",,"June 12, 2008",,,"https://ClinicalTrials.gov/show/NCT00695812"
308,"NCT01962870","The Role of Vasopressin in the Social Deficits of Autism",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Vasopressin|Drug: Placebo","Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.|Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment.|Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.|Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.|Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.|Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment|Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.|Change From Baseline in Heart Rate After Treatment.|Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment.|Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment.|Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment.|Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment.|Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.|Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.|Change From Baseline in Blood Pressure After Treatment|Change From Baseline in Body Weight After Treatment.|Change From Baseline in Body Temperature After Treatment|Change From Baseline in the Awareness of Social Inference Test Revised (TASIT-R) Scores During Treatment.|Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment.|Change From Baseline in Plasma Vasopressin Levels During Treatment.","Stanford University|National Institute of Mental Health (NIMH)","All","6 Years to 12 Years   (Child)","Phase 2","68","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB-26034|R21MH100387-01","December 2013","May 30, 2017","May 30, 2017","October 14, 2013","May 24, 2019","May 24, 2019","Stanford University School of Medicine; Psychiatry and Behavioral Sciences, Stanford, California, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01962870"
309,"NCT04719923","Dietetic Pattern in Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Children with autism spectrum disorders","Adverse food reactions|Eating habits|Nutritional status|Composition of gut microbiota|Function of gut microbiota","Federico II University","All","18 Months to 7 Years   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","312/17","October 1, 2017","October 1, 2020","October 1, 2020","January 22, 2021",,"January 22, 2021","University of Naples Federico II, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04719923"
310,"NCT01850459","Extracellular Signal-Related Kinase Biomarker Development in Autism","ERK","Completed","No Results Available","Autism Spectrum Disorders",,"ERK activation","Children's Hospital Medical Center, Cincinnati","All","3 Years to 25 Years   (Child, Adult)",,"213","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CIN001- ERK in Autism","January 2013","August 2015","August 2015","May 9, 2013",,"April 19, 2017","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01850459"
311,"NCT04442061","Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus","STIMAUT","Not yet recruiting","No Results Available","Autism Spectrum Disorders","Device: Transcranial magnetic stimulation|Device: MRI|Device: Neuronavigation|Device: Eye-tracking|Genetic: Salivary samples|Other: Clinical scales","Changes gaze pattern to the eyes|Autistic Behavior Checklist (ABC) scale at v1|Autistic Behavior Checklist (ABC) scale at v2|Autistic Behavior Checklist (ABC) scale at v3|Autistic Behavior Checklist (ABC) scale at v4|""Evaluation des comportements Autistiques révisée"" (ECA-R) scale at v1|""Evaluation des comportements Autistiques révisée""(ECA-R) scale at v2|""Evaluation des comportements Autistiques révisée"" (ECA-R) scale at v3|""Evaluation des comportements Autistiques révisée"" (ECA-R) scale at v4|Clinical Global Impression (CGI) scale at v1|Clinical Global Impression (CGI) scale at v2|Clinical Global Impression (CGI) scale at v3|Clinical Global Impression (CGI) scale at v4|Changes in rest brain fonctionning at v1|Changes in rest brain fonctioning at v2|Changes in rest brain fonctioning at v3|Changes in rest brain fonctioning at v4|BDNF/COMT polymorphisms","Assistance Publique - Hôpitaux de Paris|Fondation de France|Fondation Malakoff Médéric","Male","18 Years to 25 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APHP191009","October 2021","January 2024","June 2024","June 22, 2020",,"September 23, 2021","Hôpital Necker Enfants Malades - Service de radiologie pédiatrique, Paris, France",,"https://ClinicalTrials.gov/show/NCT04442061"
312,"NCT04358744","The Real World Study of Autism Spectrum Disorder in China",,"Recruiting","No Results Available","Autism Spectrum Disorder",,"Behaviour assessment","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Months to 18 Years   (Child, Adult)",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XH-20-005","April 13, 2019","September 2024","September 2024","April 24, 2020",,"June 16, 2020","ShanghaiXinhua, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04358744"
313,"NCT01197131","Urinary Steroid Metabolites in Autism",,"Unknown status","No Results Available","Autism|Autism Spectrum Disorder",,"difference in hormone formation and androgen precursors|difference in hormone formation in gender and age","Intersci Research Association, Austria","All","5 Years to 15 Years   (Child)",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","protocol 1.0/18/06/2010","September 2010","July 2011","April 2019","September 9, 2010",,"February 19, 2019","Intersci Research Association, Leibnitz, Steiermark, Austria",,"https://ClinicalTrials.gov/show/NCT01197131"
314,"NCT03369431","Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder","VIVO-ASD","Completed","No Results Available","Autism Spectrum Disorder","Dietary Supplement: Vivomixx|Dietary Supplement: Placebo","A change in the Autism Treatment Evaluation Checklist (ATEC) total score compared to baseline.|A change in the frequency of gastrointestinal symptoms compared to baseline, as measured by the Gastrointestinal History (GIH) questionnaire.|A change in the Aberrant Behaviour Checklist (ABC) total score compared to baseline.|A change in the Autism Parenting Stress Index (APSI) score compared to baseline.","University College, London","All","3 Years to 16 Years   (Child)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17/0148","February 1, 2018","October 2, 2020","January 29, 2021","December 12, 2017",,"April 29, 2021","University College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03369431"
315,"NCT04798274","Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: Transcranial Magnetic Stimulation","MEG|MRS|DTI|fcMRI|Behavioral Measures","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","14 Years to 25 Years   (Child, Adult)","Not Applicable","106","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","200159|20-M-0159","June 15, 2021","June 1, 2023","June 1, 2023","March 15, 2021",,"September 29, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04798274"
316,"NCT02617342","Robot-Mediated Intervention for Children With Autism Spectrum Disorders",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Robot-mediated Intervention","Change in baseline emotions accurately identified on the Transporters Quiz|Change in baseline Social Responsiveness Scale Score|Number of prompt-free intervals during the treatment sessions|Change in baseline parent report of child's emotion recognition","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Aetna, Inc.","All","4 Years to 8 Years   (Child)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00067744","November 2015","March 2022","March 2022","November 30, 2015",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02617342"
317,"NCT05038748","A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected Siblings",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Psychiatric diagnosis|Other: ASD diagnosis","Autism Diagnostic Interview-Revised (ADI-R)|Autism Diagnostic Observation Scale (ADOS)","National Taiwan University Hospital","All","7 Years to 25 Years   (Child, Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201810048RIND","January 1, 2019","December 31, 2020","December 31, 2020","September 9, 2021",,"September 16, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05038748"
318,"NCT04936009","Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Transcranial Magnetic Stimulation (TMS)","right hemisphere N170 latency|proportion of visual attention to the eye region of the face","Yale University|United States Department of Defense","All","18 Years to 30 Years   (Adult)","Not Applicable","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2000030576|Proposal No. AR200174","September 1, 2021","July 1, 2024","July 1, 2024","June 23, 2021",,"August 24, 2021","Yale University Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04936009"
319,"NCT04446442","Cerebellar tDCS in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: tDCS","Incidence of tDCS associated side effects assessed by tDCS Safety Assessment|Change in Autism Spectrum Disorder Symptoms assessed by NEPSY-2 Subtests|Change in Autism Spectrum Disorder Symptoms assessed by Reading the Mind in the Eyes|Change in Autism Spectrum Disorder Symptoms assessed by Triangle Animations/Social Perception Task|Change in Autism Spectrum Disorder Symptoms assessed by Cyberball/Social Ball Throwing Task|Change in Autism Spectrum Disorder Symptoms assessed by Dimensional Change Card Sort|Change in Autism Spectrum Disorder Symptoms assessed by Autism Spectrum Rating Scale","University of Texas Southwestern Medical Center|United States Department of Defense","All","4 Years to 17 Years   (Child)","Not Applicable","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","UTSW 022017-071","June 4, 2019","December 2023","July 2024","June 25, 2020",,"June 23, 2021","Children's Medical Center, Dallas, Texas, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04446442"
320,"NCT03625999","A Novel Intervention for Training Auditory Attention in Adolescents With Autism Spectrum Disorder",,"Withdrawn","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: video game training exercise","Child Behavioral Assessment: ADOS|Child Behavioral Assessment: Leiter-3|Child Behavioral Assessment: PPVT-5|Child Behavioral Assessment: EVT-3|Parent Questionnaire: SCQ|Parent Questionnaire: VABS-3|Parent Questionnaire: RBS-R|Parent Questionnaire: SSP|Parent Questionnaire: CASI-5|Post-test EEG","Boston University Charles River Campus|Carnegie Mellon University","All","13 Years to 20 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","4875E","August 1, 2021","September 30, 2021","September 30, 2021","August 10, 2018",,"April 9, 2021","Center for Autism Research Excellence, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03625999"
321,"NCT01288716","Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Arbaclofen","Aberrant Behavior Checklist-Social Withdrawal Subscale","Seaside Therapeutics, Inc.","All","5 Years to 21 Years   (Child, Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","209AS208","May 2011","August 2012","September 2012","February 2, 2011",,"July 31, 2013","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01288716"
322,"NCT04655326","Probiotic Therapy for Children and Adults With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Biological: Flore","Parent Global Impressions of Autism|Social Responsiveness Scale|Gastrointestinal Symptom Rating Scale","Arizona State University|Sun Genomics","All","30 Months to 75 Years   (Child, Adult, Older Adult)","Early Phase 1","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00012299","October 15, 2020","October 15, 2022","March 15, 2023","December 7, 2020",,"December 7, 2020","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04655326"
323,"NCT03195244","Aquatic Therapy and Autism Spectrum Disorders","AT&ASD","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Aquatic Physical Therapy","Change in PedsQL Score","Sloan W. Rush, MD|Panhandle Eye Group, LLP","All","3 Years to 17 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AT&ASD","June 12, 2017","February 12, 2023","February 12, 2023","June 22, 2017",,"March 10, 2021","Turn Center, Amarillo, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03195244"
324,"NCT04772898","Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Hippotherapy","Social Responsiveness Scale (SRS)|Postural control, center of pressure measures (range, root mean square, sway path, sample entropy)|Coherence and Cross Sample Entropy between the movement sensors and heart rate sensors of the horse and rider|Correlation between horse temperament and therapeutic outcomes|Aberrant Behavior Checklist","Creighton University","All","5 Years to 10 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5R03HD101115-02","September 7, 2021","February 2023","February 2023","February 26, 2021",,"September 17, 2021","Hearthland Equine Therapeutic Riding Academy, Gretna, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04772898"
325,"NCT01643720","Emotion Regulation in Preschoolers With Autism and Their Parents",,"Completed","No Results Available","Autism Spectrum Disorders",,"Emotion regulation(ER)strategies during emotion eliciting episodes|Salivary hormone levels: Cortisol and Oxytocin of both parent and child","Meir Medical Center","All","3 Years to 6 Years   (Child)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MMC1013010kCTIL","November 2010","May 2011","May 2011","July 18, 2012",,"April 8, 2015","Brill Mental Health Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01643720"
326,"NCT04440852","Randomized, Controlled Trial of an Intervention for Preschool Children With Autism: TEACCH",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: TEACCH","Chinese Version of Psycho-educational Profile-3rd edition (CPEP-3)","Wuhan Mental Health Centre|Wuhan University","All","36 Months to 90 Months   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","KY2016(53)","January 1, 2018","December 31, 2019","March 30, 2020","June 22, 2020",,"June 22, 2020","Wuhan Mental Health Centre, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04440852"
327,"NCT01366859","Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior",,"Completed","No Results Available","Autism Spectrum Disorders","Dietary Supplement: Whey Protein|Dietary Supplement: Rice Protein (Placebo)","Behavioral Analysis|Safety Analysis|Intracellular Glutathione & Antioxidant Capacity","Nova Southeastern University|Immunotec Inc.","All","3 Years to 5 Years   (Child)","Phase 2","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","01291001F","May 2011","October 2016","October 2016","June 6, 2011",,"November 3, 2016","Nova Southeastern University Clinic, Fort Lauderdale, Florida, United States|Nova Southeastern University, College of Pharmacy, Fort Lauderdale, Florida, United States|Mailman Segal Center, Ft. Lauderdale, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01366859"
328,"NCT04987749","The Therapeutic Effects of Intermittent Theta Burst Stimulation in Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: intermittent theta burst stimulation","Changes of total scores of Social Responsiveness Scale|Changes of total scores of Repetitive Behavior Scale-Revised|Changes of total scores of Emotional Dysregulation Inventory|Changes of total scores of Adaptive Behavior Assessment System|Changes in accuracy of Frith-Happe animation|Changes in accuracy of Eyes task|Changes in accuracy of Wisconsin Card Sorting Test|Changes of total scores of Behavior Rating Inventory of Executive Function|Raven's Progressive Matrices|Autism Diagnostic Observation Schedule - Generic|MRI T1|functional MRI (resting-state/biological motion task) - BOLD signal|Diffusion Tensor Imaging (DTI) - FA|Electroencephalography","Chang Gung Memorial Hospital","All","8 Years to 30 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","201900713A0","November 5, 2019","August 2023","November 2023","August 3, 2021",,"August 3, 2021","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04987749"
329,"NCT04987541","The Therapeutic Effect of TBS Stimulation on Emotion Regulation in Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Device: intermittent theta burst stimulation","Changes of total scores of Emotional Dysregulation Inventory|Changes of total scores of Aberrant Behavior Checklist|Changes of total scores of Child Behavior Checklist|Changes of total scores of Social Responsiveness Scale|Changes of total scores of Repetitive Behavior Scale-Revised|Changes of total scores of Adaptive Behavior Assessment System|Changes in accuracy of Frith-Happe animation|Changes in accuracy of Eyes task|Changes in accuracy of Wisconsin Card Sorting Test|Changes of total scores of Behavior Rating Inventory of Executive Function|Raven's Progressive Matrices|Autism Diagnostic Observation Schedule - Generic|MRI T1|functional MRI (resting-state/biological motion task) - BOLD signal|Diffusion Tensor Imaging (DTI) - FA|Electroencephalography","Chang Gung Memorial Hospital","All","8 Years to 30 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","202002498A0","August 2022","September 2025","December 2025","August 3, 2021",,"August 3, 2021","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04987541"
330,"NCT04993144","The Therapeutic Effects of Continuous Theta Burst Stimulation in Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: continuous theta burst stimulation","Changes of total scores of Social Responsiveness Scale|Changes of total scores of Repetitive Behavior Scale-Revised|Changes of total scores of Emotional Dysregulation Inventory|Changes of total scores of Adaptive Behavior Assessment System|Changes of total scores of Vineland Adaptive Behavior Scales|Changes in accuracy of Frith-Happe animation|Changes in accuracy of Eyes task|Changes in accuracy of Wisconsin Card Sorting Test|Changes of total scores of Behavior Rating Inventory of Executive Function|Raven's Progressive Matrices|Autism Diagnostic Observation Schedule - Generic|MRI T1|functional MRI (resting-state/biological motion task) - BOLD signal|Diffusion Tensor Imaging (DTI) - FA","Chang Gung Memorial Hospital","All","8 Years to 30 Years   (Child, Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","201802246A0","December 10, 2019","January 2022","March 2022","August 6, 2021",,"August 6, 2021","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04993144"
331,"NCT01647295","Social Interactions: Ocular Explorations and Pupillometry in Autism","ISEOP","Completed","No Results Available","Autism Spectrum Disorders",,"Total time spent on pictures|Interest zones","Institut National de la Santé Et de la Recherche Médicale, France","All","3 Years to 12 Years   (Child)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","C11-60|2012-A00520-43","February 25, 2013","June 2019","June 18, 2019","July 23, 2012",,"August 26, 2021","CHRU Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT01647295"
332,"NCT04950517","Physical Activity and Cardiorespiratory Fitness in Adolescents With Autism Spectrum Disorder","PAASD","Not yet recruiting","No Results Available","Autism Spectrum Disorder",,"Concurrent validity of the Physical Activity Vital Sign (questionnaire) and an Online Physical Activity Logbook (m-Path app) by using accelerometry (Actigraph model wGT3X-BT) as the criterion measure in adolescents with Autism Spectrum Disorder|Concurrent validity of a submaximal cardiorespiratory fitness test in adolescents with Autism Spectrum Disorder|The test-retest reliability of a submaximal cardiorespiratory fitness test in adolescents with Autism Spectrum Disorder|Determination of (interactions between) intrapersonal correlates of physical activity in adolescents with Autism Spectrum Disorder by using a comprehensive assessment protocol with standardized assessment tools|Exploration of the barriers and facilitators adolescents with Autism Spectrum Disorder experience with regard to physical activity participation","Universitaire Ziekenhuizen Leuven","All","12 Years to 18 Years   (Child, Adult)",,"154","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","S65474","November 2021","October 2024","October 2024","July 6, 2021",,"July 6, 2021","Anke Arkesteyn, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT04950517"
333,"NCT03676673","Deciphering the Autism Spectrum Disorder Beyond Genomics",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: Psychiatric diagnosis","ASD-associated transcriptome profiles","National Taiwan University Hospital","All","3 Years to 20 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201801044RINC","August 1, 2018","December 2021","December 2021","September 19, 2018",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03676673"
334,"NCT04273087","Characterization of a Clinical Subpopulation With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: Observation","Prevalence of non-behavioral phenotypical traits in sub-populations with Autism Spectrum Disorder (ASD)","Stalicla SA","All","10 Years to 40 Years   (Child, Adult)",,"250","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","STP1-C003","June 4, 2020","December 2021","December 2021","February 17, 2020",,"November 3, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04273087"
335,"NCT02611921","Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Ketamine|Drug: Placebo","Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)|Change in the Clinician-rated CGI Improvement scale (CGI-I)","Children's Hospital Medical Center, Cincinnati|Roivant Sciences, Inc.|Cures Within Reach","All","12 Years to 30 Years   (Child, Adult)","Phase 1","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015-2494","December 22, 2015","May 7, 2018","May 7, 2018","November 23, 2015",,"October 12, 2018","Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02611921"
336,"NCT04737707","Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders","Autisemo","Recruiting","No Results Available","Autism Spectrum Disorders","Other: Dialectical Behavior Therapy (DBT)","Difficulties in Emotion Regulation Scale (DERS)","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8108","April 16, 2021","September 1, 2024","September 1, 2024","February 4, 2021",,"September 20, 2021","Service de psychiatrie, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04737707"
337,"NCT04980963","Cognitive Support Technology for Postsecondary Students With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Cognitive Support Technology (CST)","Grade Point Average (GPA)|Current academic standing|Post-Secondary Enrollment Status|Satisfaction with current living status and transportation access|Satisfaction with Social Support|Current Employment Status|% of Participants Receiving Disability Benefits|Depression Symptoms|Overall Health Status|Perceived Stress|Acceptance of Disability|Quality of Life (QoL)","Kent State University|Virginia Commonwealth University","All","Child, Adult, Older Adult","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","20-069","March 1, 2020","June 30, 2024","June 30, 2024","July 28, 2021",,"July 28, 2021","Kent State University, Kent, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04980963"
338,"NCT02573428","Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder","EYE","Completed","No Results Available","Autism Spectrum Disorders",,"Percentage of correctly discriminated ASD and non-ASD cases using the autism risk index.|Area under the ROC curve of the prognostic algorithm in discriminating non-verbal cognitive disability.|Number of regions of interest with significant dwell time differences between ASD-affected and non-ASD participants.|Natural Interaction, Monologue with Directed Attention Stimulus - Dwell time in Upper Face Region of Interest (ROI) from 0.5-24 seconds|Natural Interaction, Monologue with Directed Attention Stimulus - Dwell time in Desk picture and Cup/Phone Regions of Interest (ROI) from 0.5-24 seconds|Natural Interaction, Joke 1 Stimulus - Dwell time in the Upper and Lower Face ROIs from 0.5-5.5 seconds|Natural Interaction, Joke 1 Stimulus - Dwell time in Body and Toys ROIs from 0.5-6.88 seconds|Natural Interaction, Joke 2 Stimulus - Dwell time in Upper Face ROI and Lower Face ROI from 0.5-8.0 seconds|Natural Interaction, Joke 2 Stimulus - Dwell time in Upper Face ROI from 4.3-5.0 seconds|Natural Interaction, Joke 2 Stimulus - Dwell time in Distractor 1, Distractor 2, Distractor 3 and Body ROIs from 0.2-10.34 seconds|Joint Attention, Gaze Middle Stimulus - Dwell time in Face ROI from 0.3-1.1 seconds|Joint Attention, Gaze Middle Stimulus - Dwell time in Target Toy, Distractor Right and Distractor Left ROIs from 1.0-2.3 seconds|Joint Attention, Gaze Right Stimulus - Dwell time in Face A and Face B ROIs from 3.3-3.7 seconds|Joint Attention, Gaze Right Stimulus - Dwell time in Target Toy and Distractor Toy ROIs from 1.0-2.3 seconds|Joint Attention, Gaze Right 2 Stimulus - Dwell time in Face ROI from 2.0-3.0|Joint Attention, Gaze Right 2 Stimulus - Dwell time in Left Distractor, Middle Distractor and Right Target from 0.9-1.6 seconds|Joint Attention, Gesture Middle 1 Stimulus - Left Distractor, Right Distractor and Middle Target from 1.5-3.5 seconds|Joint Attention, Gesture Right 1 Stimulus - Target Toy, Distractor Middle and Distractor Left ROIs from 0.8-3.5 seconds|Joint Attention, Gesture Right 2 Stimulus - Target Toy and Distractor Toy ROIs from 1.3-2.4 seconds|Joint Attention, Gesture Left 1 Stimulus - Target Toy, Distractor Middle and Distractor Right ROIs from 1.4-3.4 seconds|Joint Attention, Gesture Left 2 Stimulus - Target Toy and Distractor Right ROIs from 1.2-2.7 seconds|Joint Attention - Gesture Left 3 Stimulus - Left Target, Middle Distractor and Right Distractor ROIs from 0.7-2.3 seconds","The Cleveland Clinic","All","18 Months to 18 Years   (Child, Adult)",,"389","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","14-620","June 2015","December 2016","December 2016","October 9, 2015",,"March 14, 2017","Cleveland Clinic Center for Autism, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02573428"
339,"NCT02791789","SEMATIC Pilot Study in Children With Autism Spectrum Disorder Using an Innovative Edutainment Software","sematic","Completed","No Results Available","Autism Spectrum Disorder","Other: Autism Spectrum Disorder","measure learning words and phrases while using SEMATIC in children with ASD and non-readers without functional language|Evaluate the impact of learning words and phrases on the acquisition of the lexicon (speech and language test ELO)|Evaluate the duration of the game necessary to learning|Assess the number of sessions necessary to learning|Assess the technical performance and usability of the game platform|Evaluate the satisfaction of organizing the SEMATIC survey of parents and educators","Fondation Lenval","All","6 Years to 12 Years   (Child)","Not Applicable","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","14-HPNCL-10","October 2013","February 2015","February 2015","June 7, 2016",,"June 7, 2016","Fondation LENVAL - Hôpitaux Pédiatriques de Nice CHU-LENVAL, Nice, France",,"https://ClinicalTrials.gov/show/NCT02791789"
340,"NCT01836965","Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Social Skills Intervention","Change from Baseline Social Responsiveness Scale Score after Intervention|Video recording of Social Interaction|Change from Baseline Strengths and Difficulties Questionnaire (SDQ) after Intervention|Change from Baseline Loneliness Scale after Intervention|Change from Baseline Multidimensional Anxiety Scale for Children after Intervention|Change from Baseline Strengths and Difficulties Questionnaire (parent form)after Intervention|Change from Baseline Strengths and Difficulties Questionnaire at 3 month Follow Up|Change from Baseline Loneliness Scale at 3-month Follow Up|Change from Baseline Multidimensional Anxiety Scale for Children at 3 month Follow Up|Change from Baseline Strengths and Difficulties Questionnaire (parent form)at 3 Month Follow Up","Milton S. Hershey Medical Center","All","13 Years to 17 Years   (Child)","Not Applicable","155","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","42565EP","March 2013","April 9, 2018","April 9, 2018","April 22, 2013",,"March 13, 2019","Penn State Hershey Psychiatry Clinic, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01836965"
341,"NCT02212275","Cortical Metrics in Intervention Trials With Autism Spectrum Disorders",,"Withdrawn","No Results Available","Autism Spectrum Disorders","Drug: Dextromethophan","The difference in the Cortical Metric before and after acute exposure to dextromethorphan (DXM)|Change in the cortical metric|The Cortical Metric|Aberrant Behavior Checklist (ABC) Total Score|Pervasive Developmental Disorders Behavior Inventory - Screening Version Score (PDDBI-SV) Social Deficit Score|Social Responsiveness Scale, Version 2 Total Score (SRS)","Duke University|North Carolina Translational and Clinical Sciences Institute","Male","8 Years to 12 Years   (Child)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","Pro00065239|14-1141","August 2015","July 2016","July 2016","August 8, 2014",,"August 25, 2016","University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02212275"
342,"NCT04043351","Diagnostic Performance of Exome Sequencing in Autism Spectrum Disorders","REDIA","Recruiting","No Results Available","Autism Spectrum Disorder",,"Proportion of unrelated index cases","University Hospital, Rouen","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018/0417/HP","June 12, 2019","June 2020","June 2023","August 2, 2019",,"August 2, 2019","DRCI, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04043351"
343,"NCT01648868","Transcranial Magnetic Stimulation (rTMS) and Autism.","TMSAUTISME","Completed","No Results Available","Autism Spectrum Disorder","Device: Transcranial Magnetic Stimulation (rTMS)","Fixation time in eyes, mouth and face areas|Eye-tracking or voice human perception correlation|Fractional anisotropy covariation|Fractional anisotropy comparison","Assistance Publique - Hôpitaux de Paris","All","18 Years to 30 Years   (Adult)","Not Applicable","97","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 081232|2009-A01025-52","April 6, 2011","September 27, 2017","May 13, 2019","July 24, 2012",,"March 23, 2021","Hôpital Necker-Enfants Malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT01648868"
344,"NCT02363673","The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Individualised homoeopathic remedy in aqua distilla","Childhood Autism Rating Scale|Autism Treatment Evaluation Checklist|Case notes","University of Johannesburg","All","3 Years to 6 Years   (Child)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CGoodwin201006636|REC-01-128-2014","February 2015","July 2015","July 2015","February 16, 2015",,"May 19, 2016","University of Johannesburg Doornfontein Campus, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT02363673"
345,"NCT04802434","Strengthening Skills Behavioral Intervention for Adults With Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Strengthening Skills Program|Behavioral: PEERS Social Skills Program","Mean Change from Baseline in Adaptive Functioning on the Adaptive Behavior Assessment System, Third Edition (ABAS-3)|Mean Change from Baseline in Self-reported Quality of Life on the WHOQOL-BREF|Mean Change from Baseline in Prospective Memory on the Royal Prince Alfred Prospective Memory Test","Southwest Autism Research & Resource Center|Arizona State University|Mayo Clinic","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00011585|W81XWH-20-1-0171","April 2021","June 2022","December 2022","March 17, 2021",,"March 17, 2021",,,"https://ClinicalTrials.gov/show/NCT04802434"
346,"NCT03912896","Taekwondo for Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Taekwondo","Subject response to taekwondo","Loma Linda University","All","7 Years to 11 Years   (Child)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","5180418","June 11, 2019","November 20, 2019","February 10, 2020","April 11, 2019",,"March 6, 2020","Loma LInda University Health, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT03912896"
347,"NCT04293783","Randomized Double-blind Clinical Trial With L.Reuteri Supplementation in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Dietary Supplement: L.Reuteri|Dietary Supplement: Placebo","Changes in severity level of ASD symptomatology|Changes in Microbiome Profile|Changes in GI symptoms|Changes in ASD symptomatology: problematic behaviors|Changes in ASD symptomatology: repetitive behaviors|Changes in Adaptive Functioning|Changes in global ASD symptomatology|Changes in Behavioral Profiles|Changes in Parental Stress|Changes in Metabolomic Profile|Changes in Inflammatory Profile","University of Rome Tor Vergata|University of Bari","All","18 Months to 8 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Reg. Sperim. 244/19","February 1, 2020","October 30, 2020","August 30, 2021","March 3, 2020",,"March 3, 2020","University of Bari, Bari, BA, Italy|University of Rome Tor Vergata, Rome, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04293783"
348,"NCT03267095","Use Music Therapy In Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: music therapy sessions .","The Arabic Language test","Assiut University","All","3 Years to 7 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MTH ASD","October 1, 2019","October 1, 2020","November 1, 2021","August 30, 2017",,"July 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03267095"
349,"NCT04838912","Testing a CBT Program for Anxiety in Teenagers With Autism: A Feasibility Study",,"Not yet recruiting","No Results Available","Anxiety|Autism","Behavioral: Cool Kids (Chilled) Anxiety program adapted to children and youths with anxiety disorders (ASA)","The Experience of Service Questionnaire|Anxiety Disorders Interview Schedule for DSM-IV: Parent & Child interview schedule (ADIS C/P)|Spence Children's Anxiety Scale (SCAS)|Children's Anxiety Life Inference Scale (CALIS)|Children's Automatic Thoughts Scale (CATS)","University of Aarhus","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-16-02-37-21","June 2021","May 2022","May 2022","April 9, 2021",,"April 19, 2021","Auhus University Hospital, Psychiatry, Aarhus N, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04838912/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04838912"
350,"NCT04220086","Pediatric Massage for Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Procedure: Pediatric massage therapy|Procedure: Usual care|Other: No intervention","Changes in the Autism Behavior Checklist (ABC)|Changes in the Childhood Autism Rating Scale (CARS)|Changes in the Social Responsiveness Scale - Second Edition (SRS-2)|Changes in the Children's Sleep Habits Questionnaire (CSHQ)|Changes in the Eysenck Personality Questionnaire (EPQ) - adult version|Changes in electroencephalography (EEG)|Changes in functional near-infrared spectroscopy (fNIRS) of the brain|Number of participants with non-serious and serious adverse events (AEs)|Number of participants with abnormal laboratory values in blood routine examination.|Changes in the Autism Treatment Evaluation Checklist (ATEC).","The University of Hong Kong|Shenzhen Children's Hospital","All","3 Years to 10 Years   (Child)","Not Applicable","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TNASD1","May 30, 2021","June 30, 2022","December 31, 2022","January 7, 2020",,"September 29, 2021","Shenzhen Children's Hospital, Shenzhen, Guangdong, China|Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04220086"
351,"NCT01333072","Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)","BAART","Completed","Has Results","Autistic Disorder","Drug: Aripiprazole|Drug: Risperidone","Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks","Medical University of South Carolina","All","6 Years to 17 Years   (Child)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","R01HD062550-01A1","July 2011","August 2015","August 2015","April 11, 2011","September 26, 2018","September 26, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01333072"
352,"NCT01493609","A Clinical Trial of a New Computer Based Intervention for Children With Autism.","Click-East","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Click-East app","Autism Diagnostic Observation Schedule - Change (ADOS-C)","University of Edinburgh|NHS Lothian|Newcastle University","All","15 Months to 6 Years   (Child)","Early Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010/C/PMLD/03|NCF/36343","February 2012","June 2013","June 2013","December 16, 2011",,"November 25, 2013","University of Edinburgh, Edinburgh, Midlothian, United Kingdom|Clinical Research Facility, Royal Hospital for Sick Children, Edinburgh, Midlothian, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01493609"
353,"NCT04875481","Precise Objective Automated Assessment System of Autism Spectrum Disorder From an Existing Big Cohort",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: Psychiatric diagnosis|Other: ASD diagnosis","Autism diagnostic interview (ADI-R)|Neuropsychological functions: Continuous Performance Test(CPT)|Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)","National Taiwan University Hospital","All","4 Years to 25 Years   (Child, Adult)",,"550","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201801038RINB","August 1, 2018","July 2022","July 2022","May 6, 2021",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04875481"
354,"NCT04108312","Age-related Changes in Myeloarchitectonics Across Adulthood in Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Diagnostic Test: Anatomical MRI Scan","Anatomical MRI Scan","San Diego State University","All","40 Years to 65 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","11736","May 2015","June 2021","October 2021","September 30, 2019",,"March 25, 2021","San Diego State University, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04108312"
355,"NCT04292522","Care Pathway for Children With Autism Spectrum Disorder Included in the ELENA Cohort","ELENA-SNDS","Recruiting","No Results Available","Autism Spectrum Disorder",,"Care pathway|Clinical characteristics","University Hospital, Montpellier","All","2 Years and older   (Child, Adult, Older Adult)",,"903","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL19_0443-UF7969","February 27, 2020","June 30, 2021","December 31, 2021","March 3, 2020",,"March 5, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04292522"
356,"NCT04612647","Fit Families Program: Fundamental Motor Skill Intervention in Children With Autism Spectrum Disorders and Their Parents",,"Completed","No Results Available","Autism Spectrum Disorder","Other: 12-week FMS Intervention|Behavioral: Physical Activities & Activity Booklets","Change in Gross Motor Development as Measured by TGMD-3|Number of Participants Whose Perceptions Qualitatively Improve as measured via semi-structured interview|Fidelity of Intervention reported as Number of Parents who Implements the Intervention as Intended|Change in Social Communication Questionnaire (SCQ)","University of Wisconsin, Madison","All","4 Years to 11 Years   (Child)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2019-1256|A176000|EDUC/KINESIOLOGY/KINESIO","January 2, 2020","May 24, 2020","May 24, 2020","November 3, 2020",,"November 3, 2020","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04612647"
357,"NCT03310775","The Effect of Korean Version of PEERS Social Skills Training for Young Adults (PEERS-YA-K) With Autism Spectrum Disorder",,"Completed","Has Results","Autism Spectrum Disorder|Autism","Behavioral: Parent-assisted social skills training program for young adult with ASD","Change From Baseline in Autism Diagnostic Observation Schedule(ADOS) at 4 Month|Change From Baseline in Test of Young Adult Social Skills Knowledge(TYASSK) at 4 Month|Change From Baseline in Korean Version of the Social Skills Rating System (K-SSRS) at 4 Month|Change From Baseline in Social Responsiveness Scale-2 (SRS-2) at 4 Month|Korean Version of the Vineland Adaptive Behavior Scale, Second Edition|Change From Baseline in Beck Depression Inventory (BDI) at 4month","Seoul National University Hospital","All","18 Years to 35 Years   (Adult)","Not Applicable","47","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","B-1611-371-303","November 9, 2016","October 30, 2018","October 30, 2018","October 16, 2017","September 9, 2020","September 9, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03310775/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03310775"
358,"NCT03672344","Computer-based Social Skills Training for Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Device: BioStream Training|Device: Alternative Game","Intervention's Efficacy in Improving Eye Contact - Primary Outcome Measure 1|Intervention's Efficacy in Improving Eye Contact - Primary Outcome Measure 2|Intervention's Efficacy in Improving Emotion Recognition - Primary Outcome Measure 3|Intervention's Efficacy in Improving Attention - Primary Outcome Measure 4|Intervention's Efficacy in Improving Eye Contact and Emotion Recognition - Primary Outcome Measure 5|Gaze Pattern Based Assessment Capability|Game Performance Based Assessment Capability|Intervention's Efficacy in Improving Joint Attention","BioStream Technologies, LLC","All","4 Years to 14 Years   (Child)","Not Applicable","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08012018A","August 25, 2018","January 31, 2022","January 31, 2022","September 14, 2018",,"July 20, 2021","Milestones Behavioral Services, Orange, Connecticut, United States|Els for Autism Foundation, Jupiter, Florida, United States|Positive Behavior Supports Corporation, Melbourne, Florida, United States|Positive Behavior Supports Corporation, Miami, Florida, United States|Positive Behavior Supports Corporation, West Palm Beach, Florida, United States|Nashoba Learning Group, Inc., Bedford, Massachusetts, United States|Y.A.L.E. School, Cherry Hill, New Jersey, United States|Connect Plus Therapy, Inc., Cherry Hill, New Jersey, United States|Partners in Learning, Inc., Clementon, New Jersey, United States|Mary E. Keefe, Point Pleasant Beach, New Jersey, United States|The Pathway School, Jeffersonville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03672344"
359,"NCT03678129","GABA Pathways in Autism Spectrum Disorder (ASD)",,"Unknown status","No Results Available","Autism Spectrum Disorder","Drug: AZD7325_10|Drug: AZD7325_20|Drug: Placebo","Neurochemical response to GABAergic stimulation.|Functional connectivity measures using resting state functional magnetic resonance imaging.|Brain oscillations under sensory stimulation","King's College London","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","REC 18/WM/0208","December 7, 2018","February 15, 2020","September 14, 2021","September 19, 2018",,"February 26, 2019","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03678129"
360,"NCT03864289","Parent Skills Training for Families of Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Parent skills training","Change from baseline average score of the Interaction Fidelity Rating System at 8 weeks|Change from baseline correct answer rate of the Questionnaire on Awareness and Knowledge of Interventions about Autism at 8 weeks","Children's Hospital of Fudan University","All","18 Months to 54 Months   (Child)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDEK-PST-2019","March 15, 2019","August 14, 2021","December 14, 2021","March 6, 2019",,"February 4, 2021","Children's hospital of Fudan University, Shanghai, Shanghai, China|Children's hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03864289"
361,"NCT02550912","A Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children",,"Completed","No Results Available","Autism","Drug: Vitamin D3|Other: Placebo","Effect of vitamin D on changes in behavioral measures (Childhood autism rating scale)|Effect of vitamin D on changes in behavioral measures (autism treatment evaluation checklist)|Effect of vitamin D on calcium level|Effect of vitamin D on phosphorous level|Effect of vitamin D on alkaline phosphatase level|Effect of vitamin D on parathyroid hormone level|Effect of vitamin D on liver function test (alanine transaminase and aspartate transaminase)|Effect of vitamin D on kidney function test (Blood urea nitrogen and serum creatinine)","Ain Shams University","All","2 Years to 15 Years   (Child)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PhD(NO.18)","August 2015","February 2016","March 2016","September 16, 2015",,"July 12, 2016","Faculty of Pharmacy AinShams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02550912"
362,"NCT04054349","The Effect of the Low Fodmap Diet in Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Low FODMAP diet","Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Module-Parent Report|Assessment of stool consistency|Assessment of stool frequency|Assessment of behavioral problems|Energy and Nutrient Intake","Ohio State University","All","6 Years to 17 Years   (Child)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018H0543","January 3, 2019","July 30, 2019","July 30, 2019","August 13, 2019",,"August 13, 2019","The Ohio State University Nisonger Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04054349"
363,"NCT03466671","A Trial of TTA-121 on Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Drug: TTA-121","Efficacy on autism spectrum social core symptom assessed by social reciprocity score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by communication score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by revised algorithm score of social affect on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by revised algorithm of repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4|Efficacy assessed by Clinical Global Impression-Improvement|Efficacy assessed by Clinical Global Impression-Severity|Efficacy assessed by Global Assessment of Functioning|Efficacy assessed by gaze fixation time on social region|Efficacy assessed by quantitative analysis of facial expression","Hamamatsu University|Japan Agency for Medical Research and Development","Male","18 Years to 54 Years   (Adult)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UMIN000031412","February 27, 2018","March 16, 2020","March 30, 2020","March 15, 2018",,"December 20, 2019","Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03466671"
364,"NCT04097457","Group Based Parent Training for Children With Autism and Disruptive Behaviors",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: ""Parent training for disruptive behaviors"" manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)","The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects (Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J.,1985)|Home Situations Questionnaire (HSQ) (Barkley & Murphy, 1998)|Social Responsiveness Scale (SRS) (Constantino & Gruber, 2005)|Adaptive Behavior Assessment System (ABAS-II)|Parenting Stress Index Short Version (PSI-SR) (Abidin, 1990)","Hebrew University of Jerusalem","All","4 Years to 8 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GroupPT ASD","October 2, 2017","September 2, 2020","January 2, 2021","September 20, 2019",,"September 20, 2019","The Hebrew university, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT04097457"
365,"NCT04427150","Affective Prosody Recognition and Auditory Intervention for Children With Autism Spectrum Disorders (ASD)",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Auditory Training|Behavioral: Non-auditory training","Change in Accuracy of Affective Prosody Recognition|Change in Ability in Discriminating Pitch Differences|Change in Accuracy in Processing Rapid Presentation of Two Tones","Hong Kong Baptist University|The Hong Kong Polytechnic University|Education University of Hong Kong","All","8 Years to 14 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HKBU 12604418","September 25, 2020","December 2021","December 2021","June 11, 2020",,"August 27, 2021","Centre of Learning Science, Kowloon Tong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04427150"
366,"NCT03865719","Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder","ACORN-ASD","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Healthy Habits for Life","Change in Body Mass Index (BMI) z-score|Inflammation as indicated by change in circulating high sensitivity C-reactive protein (hs-CRP)|Implementation effectiveness|Change in Waist circumference|Change in Blood pressure|Change in Lipid Panel Lab Values|Change in Glucose Serum|Change in Insulin|Change in HOMA-IR|Change in aberrant behaviors|Change in emotional dysregulation|Change in parenting stress|Change in weight loss behaviors|Change in physical activity habits","University of Pittsburgh|Massachusetts General Hospital","All","8 Years to 26 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY18120156","August 7, 2019","August 2021","August 2021","March 7, 2019",,"April 27, 2021","Autism Treatment Network Site at Merck Child and Adolescent Outpatient Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03865719"
367,"NCT04722783","Effect of ESDM and PCIT-A in Autism Spectrum Disorder","TAFF","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|Behavioral: Early Start Denver Model (ESDM) intervention|Behavioral: 1-hour ESDM|Behavioral: Early special needs education (ESNE)","Disruptive behavior change (for PCIT-A analysis)|Autism symptoms change (for ESDM analysis)|Disruptive behavior long-term change (for PCIT-A analysis)|Autism symptoms change (for PCIT-A analysis)|Developmental level change (for PCIT-A analysis)|Non-verbal Intelligence change (for PCIT-A analysis)|Adaptive behavior change (for PCIT-A analysis)|Social-emotional competence change (for PCIT-A analysis)|Parenting stress change (for PCIT-A analysis)|Autism symptoms long-term change (for ESDM analysis)|Disruptive behavior change (for ESDM analysis)|Developmental level change (for ESDM analysis)|Non-verbal intelligence change (for ESDM analysis)|Adaptive behavior change (for ESDM analysis)|Social-emotional competence change (for ESDM analysis)|Parenting stress change (for ESDM analysis)","Bruno Rhiner|West Virginia University|University of Arkansas|Psychiatrische Dienste Thurgau","All","24 Months to 59 Months   (Child)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Protocol_PDT_010_TAFF|2020-02787 (EKOS 20/223)","January 14, 2021","October 31, 2022","October 31, 2023","January 25, 2021",,"February 8, 2021","Psychiatric Services of Thurgovia, Münsterlingen, Thurgau, Switzerland",,"https://ClinicalTrials.gov/show/NCT04722783"
368,"NCT04520685","CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr","CASCADE","Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Oral cannabidiol 100mg/mL|Drug: Placebo","Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Lethargy/Social Withdrawal subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Stereotypic Behavior subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Inappropriate Speech subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Hyperactivity/Noncompliance subscale|Anxiety, Depression, and Mood Scale (ADAMS): Total Score|Anxiety, Depression, and Mood Scale (ADAMS): General Anxiety subscale|Anxiety, Depression, and Mood Scale (ADAMS): Social Avoidance subscale|Social Responsiveness Scale - 2nd Edition (SRS-2): total T-score|Ohio Autism Clinical Impressions Scale - Severity (OACIS-S) scale|Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) scale|Autism Screening Instrument for Educational Planning - 3rd Edition (ASIEP - 3): Interaction Assessment Autism Interaction Score|Repetitive Behavior Scale - Revised (RBS-R)|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Global Executive Functioning Score|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): ADHD score|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Index scores|Sleep Clinical Global Impressions - Severity Scale (Sleep CGI-S)|Sleep Clinical Global Impressions - Improvement Scale (Sleep CGI-I)|Autism Family Experience Questionnaire (AFEQ)|NIH Toolbox Scales: Satisfaction with Social Roles and Activities - Short Form 4a|NIH Toolbox Scales: Life Satisfaction - Short Form 8b|NIH Toolbox Scales: Positive Affect - Short Form 4a|Pediatric Quality of Life Inventory (PedsQL) - Core Scale|Pediatric Quality of Life Inventory (PedsQL) - Cognitive Functioning Scale","University of Colorado, Denver","All","5 Years to 17 Years   (Child)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","19-2168","November 30, 2021","June 1, 2023","June 1, 2023","August 20, 2020",,"July 23, 2021","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04520685"
369,"NCT03984487","Daily Living Skills Intervention for Adolescents With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Surviving and Thriving in the Real World|Behavioral: Program for the Education and Enrichment of Relational Skills","Vineland Adaptive Behavior Scales, 3rd Edition","Children's Hospital Medical Center, Cincinnati|United States Department of Defense","All","15 Years to 22 Years   (Child, Adult)","Not Applicable","72","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CIN-DUNCAN-2018-2886","May 17, 2018","June 30, 2022","August 31, 2023","June 13, 2019",,"May 12, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03984487"
370,"NCT01788072","INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders","INOXT","Completed","No Results Available","Autism Spectrum Disorder","Drug: Intranasal Oxytocin|Drug: Placebo","Efficacy of intranasal oxytocin vs. placebo on social function in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social cognition in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social function in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social responsiveness in adults with ASD|Safety and tolerability of intranasal oxytocin in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on quality of life|Efficacy of intranasal oxytocin vs. placebo on anxiety","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|Unity Health Toronto|Anagnostou, Evdokia, M.D.","All","18 Years to 45 Years   (Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INOXT-10-2013","June 2014","August 2017","October 2017","February 11, 2013",,"January 25, 2018","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01788072"
371,"NCT00725556","The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist",,"Completed","No Results Available","Autism|Asperger Syndrome","Other: Speech Therapy","To evaluate the process of development of autistic children, in a direct and indirect intervention context from mother´s response in Autism Behavior Checklist.","Federal University of São Paulo","All","3 Years to 12 Years   (Child)","Phase 1|Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ana Carina Tamanaha","March 2006","March 2007","December 2007","July 30, 2008",,"August 1, 2008","Ana Carina Tamanaha, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT00725556"
372,"NCT04242355","Transcranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder","TMSinASD","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Transcranial Magnetic Stimulation (TMS)","right lateralized N170 latency to upright faces|proportion of visual attention to the eye region of the face|The Benton Face Recognition Task","Yale University","All","18 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000021846","July 1, 2019","July 2024","July 2025","January 27, 2020",,"April 20, 2021","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04242355"
373,"NCT03853265","The Effect Of Virtual Reality Glasses On The Behavior Of Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Simulated dental office visit","Change in heart rate|Change in 5-point Venham Anxiety Scores|Change in 5-point Venham Uncooperative Behavior Scores","Virginia Commonwealth University","All","5 Years to 25 Years   (Child, Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HM20015131","October 23, 2019","February 17, 2020","February 17, 2020","February 25, 2019",,"November 9, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03853265"
374,"NCT03725644","Parent Training Program for Preschool Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: parent-training program|Behavioral: traditional program","Change Scores of Functional Emotional Assessment Scale|Change Scores of Chinese Version of Psychoeducational Profile - Third Edition|Change Scores of Vineland Adaptive Behavior Scales","National Cheng Kung University","All","36 Months to 71 Months   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","B-BR-103-065","January 29, 2015","September 30, 2017","September 30, 2017","October 31, 2018",,"October 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03725644"
375,"NCT00095420","Relationship Training for Children With Autism and Their Peers",,"Completed","No Results Available","Autism|Autistic Disorder","Behavioral: Social skills training targeting children with autism|Behavioral: Social skills training of peers without autism|Behavioral: Combination treatment of social skills/education about autism|Behavioral: Usual training","Social network involvement of autistic children","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","6 Years to 11 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","U54MH068172|DDTR BD-DD","September 2003","June 2008","June 2008","November 5, 2004",,"May 14, 2013","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00095420"
376,"NCT03849456","Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder",,"Terminated","No Results Available","Autism Spectrum Disorder","Drug: GWP42006","Number of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)|Change from Baseline in Children's Communication Checklist-2 (CCC-2)|Change from Baseline in Social Responsiveness Scale-2 (SRS-2)|Change from Baseline in Vineland Adaptive Behavior Scales, 3rd Edition (Vineland-3)|Change from Baseline in National Institutes of Health (NIH) Toolbox Cognition Battery|Change from Baseline in Repetitive Behavioral Scale - Revised (RBS-R)|Change from Baseline in Children's Sleep Habits Questionnaire (CSHQ)|Change from Baseline in Aberrant Behavior Checklist (ABC)|Clinical Global Impressions-Improvement (CGI-Improvement)","GW Research Ltd","All","4 Years to 18 Years   (Child, Adult)","Phase 2","1","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GWND18089","January 7, 2020","May 26, 2020","May 26, 2020","February 21, 2019",,"May 27, 2021","Clinical Trial Site, Louisville, Kentucky, United States|Clinical Trial Site, Lexington, Massachusetts, United States|Clinical Trial Site, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03849456"
377,"NCT04745026","Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: GWP42003-P|Drug: Placebo","Change from Screening in Aberrant Behavior Checklist (ABC) Subscale Scores|Change from Day 1 in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores|Change from Day 29 in Clinical Global Impression Improvement (CGI-I) Scores|Change from Screening in Clinical Global Impression Severity (CGI-S) Scores|Number of Participants with Severe Treatment-emergent Adverse Events|Number of Participants with Clinically Significant Clinical Laboratory Parameter Values|Number of Participants with Clinically Significant Vital Sign Values|Number of Participants with Clinically Significant Physical Examination Procedure Findings|Number of Participants with Clinically Significant 12-lead Electrocardiogram Findings|Number of Participants with a Positive Response to Questions Regarding Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)","GW Research Ltd","All","6 Years to 17 Years   (Child)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GWND19189|2020-002819-21","May 4, 2021","February 28, 2023","March 30, 2023","February 9, 2021",,"June 11, 2021","Clinical Trial Site, Scottsdale, Arizona, United States|Clinical Trial Site, Orlando, Florida, United States|Clinical Trial Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04745026"
378,"NCT03254992","Real and Virtual Environments in Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Device: ASD - Abstract task|Device: ASD - Tangible task|Device: TD - Abstract task|Device: TD - Tangible task","Change in performance, measured by coincident timing task","University of Sao Paulo","All","7 Years to 15 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","55498016.1.0000.5390","November 2, 2016","October 20, 2017","November 20, 2017","August 21, 2017",,"November 27, 2017","Escola de Artes,Ciencias e Humanidades da Universidade d Sao Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03254992"
379,"NCT03835117","Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Wide-spectrum nutritional supplement|Other: Placebo","Change in mitochondrial activity in study patients|Change in the Childhood Autism Rating Scale (CARS) score|Change in the Clinical Global Impression scale (CGI) score|Change in the Children's Yale-Brown Obsessive Compulsive Scale modified for Autism Spectrum Disorder (CYBOCS-ASD) score|Change in the Aberrant Behavior Checklist (ABC) scores|Change in the Parent-rated Anxiety Scale for ASD (PRAS-ASD) score|Change in the Caregiver Strain Questionnaire (CGSQ) score|Change in the Vineland III Caregiver score|Evaluate intervention safety|Evaluate intervention effect on cellular regulatory pathways known to be implicated in ASD|Examine the change in attention to social stimuli|Examine the change in cognitive ability","Phoenix Children's Hospital","All","2 Years to 17 Years   (Child)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MITO","February 1, 2020","April 2022","April 2022","February 8, 2019",,"March 15, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03835117"
380,"NCT03152838","The Role of Epigenetic Modifications in Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Genetic: DNA methylation and Real-time Polymerase Chain Reaction Analysis|Diagnostic Test: Gilliam Autism Rating Scale Arabic version","The difference of percentage of DNA methylation of Brain derived neurotrophic factor gene and glial fibrillary acidic protein gene between the two groups|The relation between the severity of autistic symptoms and percentage of Brain derived neurotrophic factor gene and glial fibrillary acidic protein gene methylation in Autism cases group","Assiut University","All","2 Years to 6 Years   (Child)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HRM","September 1, 2017","September 1, 2018","March 1, 2019","May 15, 2017",,"May 15, 2017",,,"https://ClinicalTrials.gov/show/NCT03152838"
381,"NCT03537950","Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Drug: PLC|Drug: CBD|Drug: CBDV","Brain biochemistry response to pharmacological stimulation|Measurement of low frequency brain activity using resting state fMRI|Measurement of brain functional connectivity using resting state fMRI","King's College London","Male","18 Years to 50 Years   (Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HR15-162744","August 22, 2016","February 16, 2017","April 27, 2019","May 25, 2018",,"May 25, 2018","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03537950"
382,"NCT00614198","ScanBrit Dietary Intervention in Autism","ScanBrit","Completed","Has Results","Autism|Autism Spectrum Disorder (ASD)","Other: Gluten- and casein-free diet","Change in Diet Groups Scores on One of Several Measures Used Against Pre-defined Statistical Thresholds as Evidence of Improvement.|Changes to Appearance of Multiple Compounds in Urine Samples","Center for Autisme, Denmark|Norway: Bo Nils og Seim Family Settlement|The Robert Luff Foundation, United Kingdom|Eric Birger Christensen Fond, Denmark|Norsk Proteinintolerance, Norway","All","4 Years to 11 Years   (Child)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","KA 0503g","April 2006","October 2008","October 2008","February 13, 2008","October 1, 2010","October 1, 2010",,,"https://ClinicalTrials.gov/show/NCT00614198"
383,"NCT02202421","T-ABA Group Based Early Intervention For Parents of Children With ASD","T-ABA","Terminated","No Results Available","Autism","Behavioral: Targeted Applied Behavior Analysis (T-ABA)","Increase in child utterances|Child communication|Autism and other behavioral symptoms|Language Scores|Adaptive Behavior|Eye Tracking|Global Functioning|Quality of Life","The Cleveland Clinic|O'Neill Foundation|CVS Caremark","All","24 Months to 71 Months   (Child)","Not Applicable","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCF IRB 14-429","January 2015","April 2017","April 2017","July 29, 2014",,"October 24, 2017","Cleveland Clinic Center for Autism, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02202421"
384,"NCT01322022","Treatment of Sleep Disturbances in Young Children With Autism",,"Completed","Has Results","Autism|Autism Spectrum Disorders","Behavioral: ParentTraining|Other: Parent Education","Modified Simond & Parraga Sleep Questionnaire (MSPSQ) - Composite Sleep Index|Actigraphy - Sleep Efficiency|Actigraphy - Sleep Latency|Actigraphy - Total Sleep Time","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","24 Months to 72 Months   (Child)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO09070340|R34MH082882","December 2009","November 2012","January 2013","March 24, 2011","February 2, 2015","August 25, 2015","Children's Hospital of Pittsburgh Autism Cetner, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01322022"
385,"NCT03180112","The Association Between Herpes Simplex Viruses and Autism",,"Unknown status","No Results Available","Autism Spectrum Disorder","Genetic: enzyme linked immunosorbent assay and polymerase chain reaction","relationship between herpes simplex viruses infections and development of autism.","Assiut University","All","6 Months to 5 Years   (Child)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HA","August 1, 2017","August 1, 2018","February 1, 2019","June 8, 2017",,"June 8, 2017",,,"https://ClinicalTrials.gov/show/NCT03180112"
386,"NCT02385799","A Trial of Sertraline in Young Children With Autism Spectrum Disorder","Sert2","Completed","Has Results","Autism Spectrum Disorder","Drug: Sertraline Liquid Placebo|Drug: Sertraline","Change in Mullen Scales of Early Learning - Expressive Language Raw Score|Change in Mullen Scales of Early Learning - Combined Age Equivalent Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score|Preschool Anxiety Scale-Revised - Total Score|Preschool Language Scale-Fifth Edition - Total Language Raw Score|Sensory Processing Measure-Preschool - Social Participation Raw Score|Clinical Global Impression Scale-Severity (CGI-S)|Clinical Global Impression Scale-Improvement (CGI-I)|Visual Analog Scale - Language/Communication Score","Randi J. Hagerman, MD|Health Resources and Services Administration (HRSA)|University of California, Davis","All","24 Months to 72 Months   (Child)","Phase 2","58","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","663866","April 2015","July 2018","July 2018","March 11, 2015","May 9, 2019","October 22, 2019","UC Davis MIND Institute, Sacramento, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02385799/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02385799"
387,"NCT03621189","The Impacts of Theta-burst Stimulation on Children and Adolescents With Autism Spectrum Disorder",,"Completed","Has Results","Autism Spectrum Disorder","Device: intermittent theta burst stimulation","Changes of Total Scores of Social Responsiveness Scale|Changes of Total Scores of Repetitive Behavior Scale-Revised|Changes in Accuracy of Frith-Happe Animation|Changes in Accuracy of Eyes Task|Functional MRI (Biological Motion Task)|Resting State fMRI|Diffusion Tensor Imaging","Chang Gung Memorial Hospital","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","201509413A0","November 2, 2016","April 17, 2019","April 17, 2019","August 8, 2018","August 27, 2021","August 27, 2021","Chang Gung Memorial Hospital, Taoyuan, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03621189/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03621189"
388,"NCT04298164","Evaluating the Effectiveness of an Acceptance and Commitment Therapy-based Group Intervention for Parents of Children With a Diagnosis of Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: START programme|Behavioral: Treatment as Usual","Change in psychological flexibility|Parenting stress|Mental wellbeing|Parent relationship","University College Dublin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","START1","November 25, 2019","March 30, 2021","March 30, 2021","March 6, 2020",,"May 3, 2021","HSE Donegal, Donegal, Ireland|HSE Longford/Westmeath, Longford, Ireland",,"https://ClinicalTrials.gov/show/NCT04298164"
389,"NCT03177525","Parent Training to Enhance Social Success for Children With Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Social SUCCESS|Behavioral: Wait List","Change in Visual Analog Scale Rating from Baseline to Week 12|Change in frequency of child initiations|Change in parent fidelity of implementation|Social Responsiveness Scale, Second Edition|Social Skills Improvement System","Stanford University","All","4 Years to 6 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","41867","August 9, 2017","December 31, 2021","December 31, 2022","June 6, 2017",,"January 8, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03177525"
390,"NCT00996931","Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders",,"Completed","Has Results","Autism","Drug: lenalidomide","Change in TNF-alpha Levels|Change in Childhood Autism Rating Scale (CARS)Value From Baseline to 6 Weeks","Sutter Medical Foundation","Male","6 Years to 16 Years   (Child)","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-ASD-CHEZ-0329","February 2009","December 2009","December 2009","October 16, 2009","May 29, 2013","May 29, 2013",,,"https://ClinicalTrials.gov/show/NCT00996931"
391,"NCT01039792","Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism","B12","Completed","Has Results","Autistic Disorder","Drug: Methyl B12|Dietary Supplement: Placebo","Clinical Global Impression-Improvement (CGI-I)","University of California, San Francisco|University of California, Davis|Arkansas Children's Hospital Research Institute","All","3 Years to 7 Years   (Child)","Phase 2|Phase 3","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Autism Speaks 3031","January 2010","October 2013","November 2013","December 25, 2009","February 24, 2017","February 24, 2017","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01039792"
392,"NCT04049578","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder",,"Terminated","Has Results","Autism Spectrum Disorder","Drug: Balovaptan","Area Under the Curve at Steady State (AUCss) of Balovaptan|Plasma Concentration of Balovaptan|Plasma Concentration of M2 Metabolite, as Applicable|Plasma Concentation of M3 Metabolite|Plasma Concentration Ratio of M2 to Balovaptan, as Applicable|Plasma Concentration Ratio of M3 to Balovaptan|Number of Participants With Adverse Events","Hoffmann-La Roche","All","2 Years to 4 Years   (Child)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WP40877","December 19, 2019","April 23, 2020","May 6, 2020","August 8, 2019","October 14, 2020","October 14, 2020","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04049578/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04049578"
393,"NCT03594552","Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)",,"Unknown status","No Results Available","Autism Spectrum Disorder","Drug: Arbaclofen_15|Drug: Arbaclofen_30|Drug: Placebo","Neurochemical response to GABAergic stimulation.|Functional connectivity measures using resting state functional magnetic resonance imaging.|Brain oscillations under sensory stimulation","King's College London","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HR16-17 4081","February 1, 2018","September 30, 2019","February 2, 2020","July 20, 2018",,"July 20, 2018","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03594552"
394,"NCT02584972","Postural Control During Walking and Standing Among Children With Autism Spectrum Disorder","PCASD","Completed","No Results Available","Autism Spectrum Disorder","Other: no intervention required","postural stability measures|6 meter Narrow Path Walking Test","Soroka University Medical Center","All","6 Years to 12 Years   (Child)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Sor 274-13 CTIL","November 2015","October 2017","October 2017","October 23, 2015",,"July 30, 2021","Ben-guion University of the Negev,, Beer-Sheva, Israel|Soroka University Medical Center, Beer-Sheva, Israel",,"https://ClinicalTrials.gov/show/NCT02584972"
395,"NCT03606343","Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting","TASK-R21","Completed","Has Results","Autism Spectrum Disorder","Behavioral: Teaching Academic Skills to Kids","Children's Organizational Skills Scale|Behavior Rating Inventory of Executive Function - Second Edition|Homework Problem Checklist|Woodcock Johnson Tests of Achievement - Third Edition Basic Writing Subtest|Classroom Performance Survey|Academic Performance Rating System|Parenting Relationship Questionnaire - Communication Subscale","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 14 Years   (Child)","Not Applicable","21","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21HD090334-01A1","September 1, 2017","August 31, 2020","August 31, 2020","July 30, 2018","November 24, 2020","December 17, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03606343/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03606343"
396,"NCT02720588","Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder",,"Psychiatric Interview","National Taiwan University Hospital","All","18 Years to 35 Years   (Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201505142RINC","January 2016","December 31, 2016","December 31, 2016","March 28, 2016",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02720588"
397,"NCT03468959","Maternal Polyunsaturated Fatty Acids in Association With Child Autism Spectrum Disorder in the MARBLES Study",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Maternal Supplemental PUFA Intake","autism spectrum disorder group (ASD)|A group of typically development (TD) people","University of California, Davis","All","3 Years and older   (Child, Adult, Older Adult)",,"252","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","225645","January 2006","June 30, 2016","June 30, 2016","March 19, 2018",,"March 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03468959"
398,"NCT03020277","Use of a Smartphone© Application to Study Autism Spectrum Disorders (ASD)","SMARTAUTISM","Unknown status","No Results Available","Autism Spectrum Disorders","Other: Ecological Momentary Assessment with Smartphone© Application","Filling rate of the application|child behavior with pairs|child sleep disorders|child eating disorders|child general behavior|Visual Analogic scale quotation about parental self esteem|Visual Analogic scale quotation about parental anxiety|Visual Analogic scale quotation about parental sleep|Visual Analogic scale quotation about parental mood|Visual Analogic scale quotation about parental stress|Visual Analogic scale quotation about parental pain|Visual Analogic scale quotation about parental professional life|Visual Analogic scale quotation about parental personal life|Visual Analogic scale quotation about parental social life|Visual Analogic scale quotation about parental support and resources|the duration of use|the time of use|rate of complete filling","Nantes University Hospital|Institut de Recherche en Santé Publique, France","All","3 Years to 16 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","RC16_0185","January 2017","January 2018","January 2018","January 13, 2017",,"January 13, 2017","Nantes CHU, France, Nantes, France|Angers CHU, Angers, France",,"https://ClinicalTrials.gov/show/NCT03020277"
399,"NCT03589898","Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Gabapentin","Cortical GABA in Anterior Cingulate Cortex|Cortical GABA in Right Anterior Insula|Cortical Glx in Anterior Cingulate Cortex|Cortical Glx in Right Anterior Insula","University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)|Johns Hopkins University","All","13 Years to 17 Years   (Child)","Early Phase 1","42","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","H00012656|1K23MH113008-01A1","September 14, 2017","August 31, 2022","August 31, 2022","July 18, 2018",,"September 23, 2021","University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03589898"
400,"NCT03195465","The Effect of High Antioxidant Cacao on Behaviors in Children With Autism Spectrum Disorder",,"Terminated","Has Results","Autism Spectrum Disorder","Dietary Supplement: Dark Chocolate","Aberrant Behavior Checklist 2nd Edition","Loma Linda University","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","5170206","November 14, 2017","April 1, 2018","April 1, 2018","June 22, 2017","May 13, 2021","June 2, 2021","Loma Linda University Health, Loma Linda, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03195465/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03195465"
401,"NCT03003221","Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: AIR-P Dental Toolkit|Behavioral: Parent Training","Frequency of tooth brushing at home|Child oral health according to standardized measures from visual exam|Child behavior during tooth brushing at home according to questionnaire|Observed child anxiety and behavior at the dental office visit as indexed by observer ratings on the Venham Anxiety and Behavior Scales (aggregate composite)|Dentist-reported child behavioral compliance during dental office visit as indexed by questionnaire|Completion of dental visit procedures according to questionnaire","University of California, Irvine|Massachusetts General Hospital|Nationwide Children's Hospital|California State University, Fullerton|Healthy Smiles for Kids of Orange County","All","3 Years to 13 Years   (Child)","Not Applicable","119","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016-3043","December 2016","June 2019","June 2019","December 26, 2016",,"April 14, 2021","University of California Irvine, Irvine, California, United States|Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03003221"
402,"NCT02280746","Gluten for Autism Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorders","Other: Gluten challenge","The extent of autistic symptoms based on the Autism Diagnostic Observation Schedule - 2 (ADOS-2)|The severity of symptoms based on a Social Communication Questionnaire (SCQ)|Presentation of gastrointestinal (GI) functional disorders (evaluation based on a parent-report form - Rome III diagnostic questionnaire|The extent of adaptive level of functioning on Vineland Adaptive Behavior Scale (VABS)|The extent of functioning on Autism Spectrum Rating Scale (ASRS)|Anthropometry|Intelligence test Leiter International Performance Scale","Medical University of Warsaw|Nutricia Foundation","All","3 Years to 6 Years   (Child)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG 8/2013","September 2014","December 2015","December 2015","October 31, 2014",,"October 31, 2014","Medical University of Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT02280746"
403,"NCT03254264","Impact of Early Interventions on Neurocognitive Profile of Children With Autism Spectrum Disorder","IDEAEYE","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model|Behavioral: 'as-usual' intervention","The primary outcome will be the time spent on biological motion in the task of visual preference stimuli.|Average proximity from pattern eyes norm in complex social scene task|Difference of saccadic latencies between overlap and gap condition|Time spent on unpredictable stimuli","Hôpital le Vinatier","All","15 Months to 36 Months   (Child)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2015-A00696-43","May 29, 2017","May 31, 2021","May 31, 2021","August 18, 2017",,"October 5, 2020","Hopital Vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT03254264"
404,"NCT03156153","A Study of Bumetanide for the Treatment of Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Bumetanide|Drug: Placebo","Childhood Autism Rating Scale(CARS)|Clinical Global Impressions Scale (CGI)|Social Responsiveness Scale (SRS)|Autism Diagnostic Observation Schedule (ADOS)|Short Sensory Profile Report|Symbolic Play Test|Chinese Communicative Development Inventory","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Jiao Tong University School of Medicine","All","3 Years to 6 Years   (Child)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XH-16-048","May 24, 2017","July 8, 2019","July 10, 2019","May 17, 2017",,"March 1, 2021","Xinhua Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03156153"
405,"NCT00947700","Early Connections, Early Detection and Intervention in Infants at Risk for Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Assessment, Monitoring & Intervention","Autism Symptoms|Mullen Receptive Language Scale|Communication and Symbolic Behavior Scale|Parent Child Interaction|Parent quality of life","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)|Autism Speaks|Washington State Department of Social and Health Services|Autism Science Foundation","All","5 Months to 12 Months   (Child)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","32400|P50HD055782|P30ES007033","January 2008","June 2013","June 2013","July 28, 2009",,"April 20, 2017","Center on Human Development and Disabilities, University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00947700"
406,"NCT00106210","School- and Home-Based Early Intervention for Toddlers With Autism",,"Completed","No Results Available","Autistic Disorder|Autism","Behavioral: Early intervention blending several tx approaches, w/ focus|Behavioral: Early intervention blending several treatment approaches","Receptive language skills|Expressive language skills|Social cognitive skills|Social emotional functioning|Play skills","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute of Mental Health (NIMH)","All","18 Months to 33 Months   (Child)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U54MH066417|DDTR BD-DD","May 2003","September 2007","September 2007","March 22, 2005",,"July 8, 2013","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00106210"
407,"NCT01706523","Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders",,"Terminated","No Results Available","Autism Spectrum Disorders","Drug: STX209 (arbaclofen)","Safety and tolerability of STX209|Aberrant Behavior Checklist","Seaside Therapeutics, Inc.","All","5 Years to 21 Years   (Child, Adult)","Phase 3","165","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","209AS209","November 2011","July 2013","July 2013","October 15, 2012",,"July 31, 2013","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|UCDavis M.I.N.D Insitute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|NYS Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|UNC Chapel Hill Department of Psychiatry, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01706523"
408,"NCT03504917","A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension",,"Terminated","Has Results","Autism Spectrum Disorder","Drug: Balovaptan|Drug: Placebo","Change From Baseline at Week 24 on the Vineland Adaptive Behavior Scales (Vineland-II) Two-domain Composite (2DC) Score.|Change From Baseline at Week 12 on the Vineland-II 2DC Score|Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores|Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score|Change From Baseline at Week 12 and 24 on the Vineland-II Socialization Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Communication Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Daily Living Skills Domain Standard Score|Change From Baseline in Severity of Clinical Impressions as Measured by Clinical Global Impression-Severity (CGI-S)|Improvements in Clinical Impressions, as Measured by Clinical Global Impression-Improvement (CGI-I)|Change From Baseline at Weeks 12 and 24 in the Hamilton Anxiety Rating Scale (HAM-A) Total and Domain Scores|Proportion of Subjects With a >=6-point Improvement in Vineland-II 2DC Score|Percentage of Participants With Adverse Events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN39434","August 8, 2018","March 4, 2020","July 1, 2020","April 20, 2018","May 7, 2021","September 23, 2021","Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|University of California , Los Angeles (UCLA); Child, Adolescent Psychiatry, Los Angeles, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Uni of Chicago; Centre For Advanced Medicine, Chicago, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Hapworth Research Inc., New York, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center; Department of Psychiatry, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Seattle Children's Hospital, Seattle, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|University of Western Ontario, London, Ontario, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Hopital Charles Perrens; Centre de Ressources Autisme Aquitaine, Bordeaux, France|Hospices Civils de Lyon; Centre d'Investigation Clinique Pédiatrique, LYON Cedex, France|Centre hospitalier du Rouvray; CRAHN Centre de Ressources Autisme Haute-Normandie, Sotteville Les Rouen, France|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|AUSL di Piacenza; Psichiatria di Collegamento, Piacenza, Lombardia, Italy|ASL TO2; Centro Pilota Regione Piemonte - Dip. Salute Mentale, Torino, Piemonte, Italy|A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti, Catania, Sicilia, Italy|Hospital Mutua de Terrassa; Departamento de Psiquiatria, Terrassa, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Psiquiatria del niño y del adolescente, Madrid, Spain|Hospital Universitario Rio Hortega; Departamento de Psiquiatria, Valladolid, Spain|Western General Hospital; Wellcome Trust CRF, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|Kings College Hospital; Kings Clinical Research Facility, London, United Kingdom|RE:Cognition Health; RE:Cognition Health, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03504917/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03504917"
409,"NCT02445625","BCI (Brain Computer Interface) Intervention in Autism","BCIAUT","Completed","Has Results","Autism Spectrum Disorder","Device: BCI to train joint attention in ASD","JAAT_NoFace|JAAT_Face|ATEC - Autism Treatment Evaluation Checklist|VABS - Vineland Adaptive Behaviour Scale","University of Coimbra","All","16 Years to 30 Years   (Child, Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBILI-VB-2015-01","February 2016","November 2017","September 2018","May 15, 2015","February 18, 2019","February 18, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02445625/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02445625/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02445625"
410,"NCT01366885","Vitamin D to Prevent Autism in Newborn Siblings",,"Completed","Has Results","Autistic Disorder","Drug: Vitamin D3","Number of Children Who Developed Autism|Number of Mothers Who Developed Side Effects From Vitamin D","Oregon Health and Science University","Female","20 Years to 44 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","OHSU-AS-11-1-11","February 2008","February 2016","February 2016","June 6, 2011","June 14, 2016","June 14, 2016","Evergreen Center, Oregon City, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01366885"
411,"NCT03055533","Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Headsprout reading program","Change in Kaufman Test of Educational Achievement score (KTEA-3)|Change in the Dynamic Indicators of Basic Early Literacy Skills (DIBELS) assessment score","University of Nebraska","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","278-18","October 1, 2018","December 31, 2021","December 31, 2021","February 16, 2017",,"April 5, 2021","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03055533"
412,"NCT02628808","Susceptibility Genes in Autism Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorders",,"Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder|Identification of biological pathways in Autism Spectrum Disorders","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Months to 70 Years   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","C07-33|2008-A00019-46","August 2008","August 2016","August 2018","December 11, 2015",,"December 11, 2015","Albert Chenevier Hospital, Creteil, Ile de France, France|Robert Debré Hospital, Paris, Ile de France, France",,"https://ClinicalTrials.gov/show/NCT02628808"
413,"NCT02561481","Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)",,"Completed","Has Results","Autism Spectrum Disorder","Drug: Sulforaphane|Drug: Placebo","Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline|OACIS-I Response Rate on Aberrant Behaviors Subscale|OACIS-I Response Rate on Social Communication Subscale|Change in Total Aberrant Behavior Checklist Score From Baseline|Change in Total SRS-2 Score From Baseline|Dithiocarbamate Plasma Concentration Detected by Cyclocondensation at Each Visit|Comparison of Free Reduced Glutathione (GSH), Total GSH, Oxidized Glutathione (GSSG) at Week 0 and 15|Free GSH:GSSG and Total GSH:GSSG Ratios at Week 15","University of Massachusetts, Worcester|Congressionally Directed Medical Research Programs|Johns Hopkins University","All","3 Years to 12 Years   (Child)","Phase 1|Phase 2","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H00007832|AR140087","December 2015","December 2018","January 2020","September 28, 2015","November 25, 2020","December 17, 2020","University of Massachusetts Medical School, Worcester, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02561481/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02561481/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02561481"
414,"NCT03611075","A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)",,"Completed","Has Results","Autism Spectrum Disorder","Other: No Intervention","Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD) - Total Score|Montefiore Einstein Rigidity Scale (MERS-R)|Repetitive Behavior Scale-Revised (RBS-R)|Repetitive Behavior Questionnaire for Children (RBQ-2)|Restricted Behavior Questionnaire for Adults (RBQ-2A)|Childhood Routines Inventory-Revised (CRI-R)|Adult Routines Inventory (ARI)|Clinical Global Impression Scales (CGI)|Child's Sleep Habits Questionnaire (CSHQ)|Pittsburg Sleep Quality Index (PSQI)|Reading the Mind in the Eyes Test -R (RMET-R)|Reading the Mind in the Eyes Test Child -C (RMET-C)|Hamilton Anxiety Rating Scale (HAM-A)|Parent Rated Anxiety Scale for ASD (PRAS-ASD)|Beck Anxiety Index (BAI)|Digital Biomarkers|Behaviour Rating Inventory of Executive Function for Children (BRIEF)|Behaviour Rating Inventory of Executive Function for Adults (BRIEF-A)|Short Sensory Profile (SSP)|Vineland(TM)-II Survey|Pediatric Quality of Life Inventory (PedsQL) Family Impact Scale|PedsQL Core Functioning Scale|PedsQL Cognitive Functioning Scale","Hoffmann-La Roche","All","5 Years to 45 Years   (Child, Adult)","Phase 1","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","BP40331|2019-003524-20","August 13, 2018","May 21, 2020","May 21, 2020","August 2, 2018","July 23, 2021","July 23, 2021","Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|PCSD Feighner Research, San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Clinical Neuroscience Solutions Inc; Jacksonville Clinic, Jacksonville, Florida, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research Ltd, San Antonio, Texas, United States|Northwest Clinical Research Center - ClinEdge - PPDS, Bellevue, Washington, United States|Seattle Children's Hospital - PIN; Investigational Drug Services, Seattle, Washington, United States|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|Gartnavel Royal Hospital; Mental Health & Wellbeing, Glasgow, United Kingdom|Kings College London, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03611075/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03611075"
415,"NCT03270306","Eating Behaviours, Diet and Gastrointestinal Symptoms in Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder",,"Mealtime behaviours|Gastrointestinal symptoms|Gut microbiota profile","Chinese University of Hong Kong","All","3 Years to 6 Years   (Child)",,"130","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2016.607","November 4, 2017","May 31, 2019","May 31, 2019","September 1, 2017",,"July 30, 2019","Chinese University of Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT03270306"
416,"NCT02358317","Motor Learning and Brain Changes in Autism",,"Completed","No Results Available","Autistic Disorder","Behavioral: Video Game Motor Training|Behavioral: Sedentary Video Game Training","Balance Time|Postural Stability|White matter microstructure of the Corticospinal tract|Adaptive Daily Living Skills|Social Responsiveness","University of Wisconsin, Madison|Brain & Behavior Research Foundation","All","13 Years to 17 Years   (Child)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2014-1499","March 2015","May 2019","May 24, 2019","February 6, 2015",,"June 11, 2019","Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02358317"
417,"NCT00609531","Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Citalopram|Drug: Placebo","Functional Magnetic Resonance Imaging|Clinicians Global Improvement Scale|Childrens Yale-Brown Obsessive Compulsive Scale","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","All","10 Years to 55 Years   (Child, Adult)","Phase 1","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","04-0975|NIH/NCRR K12 RR023248|The Dana Foundation|K23MH081285","January 2007","August 2009","August 2009","February 7, 2008",,"October 8, 2012","UNC-Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00609531"
418,"NCT03469986","A Multi-site Comparison of Social Visual Engagement to Clinical Diagnosis for Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Device: Marcus Autism Center Investigational Device","Presence of Autism Spectrum Disorder|Social disability index|Verbal Ability Index|Nonverbal Ability Index","EarliTec Diagnostics, Inc","All","16 Months to 30 Months   (Child)",,"505","Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S-DTD-2014-301","April 7, 2018","June 30, 2019","September 1, 2021","March 19, 2018",,"March 30, 2021","Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California San Francisco, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03469986"
419,"NCT02700074","Brain Mechanisms for Language Processing in Adolescents With Autism Spectrum Disorder","BSL","Completed","No Results Available","Autism Spectrum Disorders","Other: No Intervention","Autism Spectrum Diagnosis|Adaptive Behaviors|Cognitive Abilities|Language Abilities|Social Behavior|Repetitive Behavior|Sensory Behavior|Atypical Behavior|Psychopathology|Emotion Regulation|Handedness|Brain measures of structural and functional connectivity in key nodes of the speech production network|Electrophysiological measures and neural oscillatory patterns of the perception, organization and analysis of auditory scenes.|Indices of social attention deployment measured by unobtrusively recording participants' eye-movements during the passive viewing of brief realistic video-clips.|Indices of electrodermal activity (EDA) measured wirelessly with the Q sensor (a small wearable device designed to work in real-world environments in an untethered, unobtrusive way).","Boston University Charles River Campus|National Institutes of Health (NIH)|Massachusetts General Hospital|Northeastern University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","14 Years to 21 Years   (Child, Adult)",,"88","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","3077E|P50DC013027","February 2015","May 31, 2019","August 30, 2019","March 7, 2016",,"January 27, 2020","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02700074"
420,"NCT02493699","Martial Arts Therapy in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Other: physical exercise- based intervention (Karate techniques training)","Raw score of communication subscale of Gilliam Autism Rating Scale-Second Edition (GARS-2) as the measure of communication deficit","University of Isfahan","All","5 Years to 16 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14/02/2011","May 2011","August 2011","September 2011","July 9, 2015",,"July 9, 2015",,,"https://ClinicalTrials.gov/show/NCT02493699"
421,"NCT03664232","A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder","Envision","Recruiting","No Results Available","Autism Spectrum Disorder","Drug: JNJ-42165279|Drug: Placebo","Change from Baseline in the Autism Behavior Inventory (ABI) Core Domain Score to Day 85|Change from Baseline in ABI Social Communication Domain Score to Day 85|Change from Baseline in ABI Repetitive/Restrictive Behavior (RRB) Domain Score to Day 85|Change from Baseline in the ABI Mood and Anxiety Domain Score to Day 85|Change from Baseline in the ABI Challenging Behavior Domain Score|Change from Baseline in the ABI Self-Regulation Domain Score|Change from Baseline in the Aberrant Behavior Checklist (ABC) Subscales|Change from Baseline in the Autism Behavior Inventory-Short Form (ABI-S) Scale Domains|Change from Baseline in the Autism Behavior Inventory-Clinician Interview (ABI-C) Domains|Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score|Change from Baseline in the Repetitive Behavior Scale - Revised (RBS-R) Scale Score|Change from Baseline in the Zarit Burden Interview (ZBI) Scale Score|Change from Baseline in the Child Adolescent Symptom Inventory - Anxiety (CASI-Anx) Scale Score|Change from Baseline in the Social Responsiveness Scale 2 (SRS-2) Score|Change from Baseline in the Caregiver Global Impression of Severity (Caregiver GI-S)|Caregiver Assessment of Treatment Score|Self Global Impression of Improvement (Self GI-I) Score|Clinical Global Impression-Improvement (CGI-I)","Janssen Research & Development, LLC","All","13 Years to 35 Years   (Child, Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108275|42165279AUT2001","November 7, 2018","March 28, 2022","June 24, 2022","September 10, 2018",,"September 20, 2021","Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|APG Research, LLC, Orlando, Florida, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|New York Presbyterian Hospital, New York, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03664232"
422,"NCT02551380","Folinic Acid in Children With Autism Spectrum Disorders","EFFET","Unknown status","No Results Available","Autism Spectrum Disorder","Drug: FOLINORAL|Other: Placebo","Evaluation of severity of autistic symptoms with standardized scale ADOS (Autism Diagnosis Observation Scale)|Evaluation of the reduction of autistic symptom perceived by parents with a heteroevaluation scale : SRS (social responsiveness scale)|evaluate the constancy of auto antibodies anti-FRα","Central Hospital, Nancy, France","All","3 Years to 10 Years   (Child)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015-000955-25","October 2015","January 2018","January 2018","September 16, 2015",,"April 7, 2017","CHU Nancy-Hopital Brabois Enfants, Vandoeuvre les Nancy, France",,"https://ClinicalTrials.gov/show/NCT02551380"
423,"NCT02733120","Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder","ASD","Unknown status","No Results Available","Autism Spectrum Disorder","Other: stable isotope infusion","Tryptophan turnover|leucine turnover|Whole body myofibrillar protein breakdown rate (reflecting muscle protein breakdown)|glutathione turnover|hydroxyproline breakdown (reflecting collagen breakdown)|glutamate turnover|taurine turnover|urea production|Group differences in state of mood as measured by the Hospital Anxiety and Depression Scale (HADS),|Group differences in learning and memory as measured by Auditory Verbal Learning Test (AVLT)|Group differences in learning and memory as measured by Controlled Oral Word Association Test (COWAT),|Group differences in learning and memory as measured by Digit Span|Group differences in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)|Group differences in attention and executive functions as measured by Trail Making Test (TMT),|Group differences in attention and executive functions as measured by Stroop Color-Word Test (SCWT),|Adolescent/Adult Sensory Profile|Group differences in attention and executive functions as measured by Brief-A|Group differences in attention and executive functions as measured by PASAT","Texas A&M University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2015-0542","October 2015","September 2020","September 2020","April 11, 2016",,"January 16, 2019","Texas A&M University-CTRAL, College Station, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02733120"
424,"NCT02488226","Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder","ASD","Completed","No Results Available","Autism Spectrum Disorder","Other: Gaze-contingent eye-tracking technology","Gaze behavior during eye tracking tasks measured by standard eye-tracking analysis protocols|Behavior during real-world interactions measured by coding of video recordings","Yale University","All","18 Months to 60 Months   (Child)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","1306012246","June 2015","October 2016","December 2016","July 2, 2015",,"March 6, 2020","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02488226"
425,"NCT02382172","Social Cognition and Interaction Training for Autism","SCIT-A","Completed","No Results Available","Autism|Social Behavior","Behavioral: Social Cognition and Interaction Training for Autism (SCIT-A)|Other: Treatment as Usual (TAU)","Change in visual attention from baseline as measured by the Tobii Eye Tracking Paradigm|Change in patient social skills as measured by the Social Responsiveness Scale (SRS)|Change in patient social cognition as measured by the Hinting Task|Change in patient social cognition as measured by the Penn Emotion Recognition Task-40 (ER40)","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute|Carolina Institute for Developmental Disabilities","All","10 Years to 69 Years   (Child, Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","14-2804","January 2015","January 2017","January 2017","March 6, 2015",,"April 25, 2017","Carolina Institute for Developmental Disabilities, Carrboro, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02382172"
426,"NCT05067361","Effectiveness of Aerobic Exercises on the Autistic Children",,"Completed","No Results Available","Autism Spectrum Disorder","Procedure: Aerobic Exercise|Procedure: Ball Exercises","Repetitive behavior scale revised (RBS-R)|Jebsen Hand Function Test (JHFT)","University of Faisalabad","All","6 Years to 20 Years   (Child, Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","TUF/DR/MSPP/173","March 3, 2020","August 8, 2020","October 26, 2020","October 5, 2021",,"October 5, 2021","University of Faisalabad, Faisalābad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05067361"
427,"NCT02719067","A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder",,"Structural neuroimaging|Neuropsychological functions","National Taiwan University Hospital","All","12 Years to 20 Years   (Child, Adult)",,"140","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201602058RIN","January 1, 2016","December 31, 2016","December 31, 2016","March 25, 2016",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02719067"
428,"NCT00789932","Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial","BIACA-2","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: cognitive behavioral therapy|Behavioral: Usual community care","ADIS-C/P (Anxiety Disorder Interview Schedule for Children and Parents)|Behavioral observations of social responsiveness","University of California, Los Angeles|Organization for Autism Research","All","7 Years to 11 Years   (Child)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OAR-UCLA-2009","September 2008","December 2011","December 2011","November 13, 2008",,"February 5, 2013","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00789932"
429,"NCT00910559","Phenotypic and Genetic Factors in Autism Spectrum Disorders",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders",,"genotype-phenotype correlation","Boston Children's Hospital|National Institute of Mental Health (NIMH)","All","18 Months and older   (Child, Adult, Older Adult)",,"1500","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","04-05-075|R01MH085143|R01MH083565","July 2008","February 2022","February 2024","June 1, 2009",,"July 29, 2021","Children's Hospital Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00910559"
430,"NCT02747056","Study of the Personal Identity in Adults With Autism Spectrum Disorder Without Intellectual Deficiency","TSASDI","Completed","No Results Available","Autism Spectrum Disorders","Other: clinical, psychological and neuropsychological assessment|Other: Autobiographical memories Assessment|Other: Autobiographical memories assessment characteristics","The number of details in the memory (A)/The specificity of the memory (B)|Study A and B: Autistic symptoms questionnaire 1|Study A and B: Autistic symptoms questionnaire 2|Study A and B: Autistic symptoms questionnaire 3|Study A and B:Executives functions, test 1|Study Aand B:Executives functions test 2|Study A and B:Executives functions test 3|Study A and B: The self concept, questionnaire 1|Study A and B: The self concept, questionnaire 2|Study A and B: The self concept, questionnaire 3|Study A: the number of remember/ know/ guess responses, the perspective in recollection and the subjective temporal distance in the memory|Study B:The importance for the self of the memory test1|Study B:The importance for the self of the memory test 2|Study B:The importance for the self of the memory test 3|Study B:The importance for the self of the memory test 4","University Hospital, Strasbourg, France","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","6282","June 2016","August 2019","August 2019","April 21, 2016",,"August 21, 2019","Hôpitaux universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT02747056"
431,"NCT01028820","FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders","AripfMRI","Completed","Has Results","Autism Spectrum Disorder","Drug: Aripiprazole","Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version|Total Repetitive Behavior Scale - Revised (RBS_R)","University of North Carolina, Chapel Hill|Duke University|National Institute of Mental Health (NIMH)","All","10 Years to 55 Years   (Child, Adult)","Phase 4","13","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090795|K23MH081285","August 2009","January 2011","January 2011","December 9, 2009","March 11, 2014","March 11, 2014","University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01028820"
432,"NCT02608333","Efficiency of Early Intervention for Autism Spectrum Disorder","IDEA","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: ESDM-12|Behavioral: control group","Developmental quotient at the Mullen Scale of Early Learning|Severity of autism symptoms is measured with ADOS 2|Adaptive behavior score is measured by the composite score of Vineland adaptative behavior scale 2|Productive language level assessed with a standardized French productive language developmental scale|Costs associated with interventions|Developement of communication and symbolic behavior|Parent child naturalistic interaction during play|Sensorial profil|Change at the Brief Observation of Social Communication Change (BOSCC)","Hôpital le Vinatier|University Hospital, Strasbourg, France|Versailles Hospital|Centre hospitalier Saint Jean de Dieu - ARHM|Hospices Civils de Lyon","All","15 Months to 36 Months   (Child)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2015-A00124-45","September 9, 2015","June 30, 2021","June 30, 2021","November 18, 2015",,"July 9, 2021","Hopital Vinatier, Bron, Aura, France",,"https://ClinicalTrials.gov/show/NCT02608333"
433,"NCT02625116","ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders","ELENA","Recruiting","No Results Available","Autism Spectrum Disorders",,"Adaptive behavior scores obtained using the three sub-scales of the Vineland Adaptive Behavior Scale","University Hospital, Montpellier|Caisse Nationale de Solidarité pour l'Autonomie","All","2 Years to 16 Years   (Child)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","8852-2","September 2012","September 2024","October 2025","December 9, 2015",,"May 21, 2018","CHU Montpellier-Hôpital La Colombière, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02625116"
434,"NCT02487082","Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders",,"Terminated","No Results Available","Autism Spectrum Disorder","Drug: Melatonin and Donepezil|Other: Placebo","Lethargy/Social Withdrawal|Stereotypic Behavior|Sleep quality|Clinician Global improvement|Parent Global improvement","Stony Brook University","All","4 Years to 17 Years   (Child)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","65708","June 2015","December 31, 2020","January 29, 2021","July 1, 2015",,"April 28, 2021","Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT02487082"
435,"NCT01308749","A Study of Oxytocin in Children and Adolescents With Autistic Disorder","Oxytocin","Completed","Has Results","Autism","Drug: Oxytocin|Drug: Placebo","Number of Participants Who Could Tolerate Twice Daily Oxytocin|Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase|Change in Mean Weight|Change in Mean Total Social Social Responsiveness Scale (SRS) T-score|Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score|Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods|Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods|Change in Mean Systolic Blood Pressure During Period 1|Mean Change in Prolactin Levels Over Period 1|Mean Change in Temperature During Period 1","University of North Carolina, Chapel Hill|Autism Speaks","All","3 Years to 17 Years   (Child)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-0493","March 2011","April 2013","April 2013","March 4, 2011","July 17, 2017","July 17, 2017","University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01308749"
436,"NCT01582256","Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without CNVs",,"Completed","No Results Available","Autism",,,"National Taiwan University Hospital","All","10 Years to 25 Years   (Child, Adult)",,"132","Other","Observational","Observational Model: Other|Time Perspective: Other","201201006RIB","August 1, 2012","July 31, 2015","July 31, 2015","April 20, 2012",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01582256"
437,"NCT03805828","Effectiveness of Educational Program on Parenting Stress and Coping Mechanism Among Parents of Children With Autism Spectrum Disorder in Amman, Jordan",,"Unknown status","No Results Available","Autism Spectrum Disorder","Other: Educational program on parenting stress and coping mechanism","parenting stress|coping mechanism","Universiti Putra Malaysia","All","20 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","University Putra Malaysia","March 1, 2019","August 1, 2019","August 1, 2019","January 16, 2019",,"January 16, 2019","Centers for the treatment of Autistic Disorder, Amman, Jordan|Ministry of Social Development, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03805828"
438,"NCT04672967","MAP Autism Prediction Study","MAP","Not yet recruiting","No Results Available","Autism Spectrum Disorder|Developmental Delay","Diagnostic Test: BioROSA MAP test","Autism Diagnostic Observation Scale (ADOS)|Vineland Adaptive Behavior Scale (VABS)|Mullen Scales of Early Learning (MSEL)|Modiﬁed Checklist for Autism in Toddlers (M-CHAT)","BioROSA Technologies Inc|Melmed Center|Rensselaer Polytechnic Institute","All","18 Months to 60 Months   (Child)",,"130","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1320036","May 2021","May 2022","October 2022","December 17, 2020",,"December 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04672967"
439,"NCT02439671","Transition Support Program for Young Adults With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: McGill Transition Support Program","Change in Social problem-solving task (Channon & Crawford, 2010)|Change in Arc's Self-Determination Scale (SDS; Wehmeyer & Kelchner, 1995)|Change in Quality of Life Questionnaire (Shalock & Keith, 1993)|Curriculum-specific workbook questions|Participant Program Evaluation Survey (Flanagan & Nadig, 2012)|Parent Program Evaluation Survey (Flanagan & Nadig, 2012)|Questionnaire on vocational, educational and living situation outcomes|Communication task (Nadig, Vivanti, & Ozonoff, 2009)","McGill University","All","18 Years to 30 Years   (Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Max Bell / McGill x-209094","May 2012","July 2015","July 2016","May 12, 2015",,"May 9, 2017","McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02439671"
440,"NCT01985308","A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Device: MRT-Active|Device: MRT-SHAM","Childhood Autism Rating Scale (CARS)","Wave Neuroscience","All","4 Years to 12 Years   (Child)","Not Applicable","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MRT-001","November 2013","April 2014","April 2014","November 15, 2013",,"April 16, 2014","Brain Treatment Center, Newport Beach, California, United States|Brain Treatment Center of Atlanta, Buford, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01985308"
441,"NCT02646696","Reliability Study Using Electrodermal Activity to Measure Sensory Processing in Children With and Without Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Sensory Challenge Protocol","Electrodermal Activity in response to sensation","Barpak Geriatric Health Services, Inc. d/b/a Barpak Occupational Therapy","Male","4 Years to 11 Years   (Child)",,"32","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Barpak-01-EDA","January 2013","April 2014","May 2014","January 6, 2016",,"January 6, 2016",,,"https://ClinicalTrials.gov/show/NCT02646696"
442,"NCT02228876","A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder",,"Diagnosis of autism|Diagnosis of psychiatric disorders","National Taiwan University Hospital","All","3 Years and older   (Child, Adult, Older Adult)",,"360","Other","Observational","Observational Model: Other|Time Perspective: Other","201403019RINA","August 1, 2014","July 31, 2017","July 31, 2017","August 29, 2014",,"September 5, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02228876"
443,"NCT02233348","Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder",,"Diagnosis of autism","National Taiwan University Hospital","All","10 Years to 25 Years   (Child, Adult)",,"523","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201403109RINC","January 1, 2015","December 31, 2019","December 31, 2019","September 8, 2014",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02233348"
444,"NCT02445105","Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Autism Navigator Enhanced Practice|Behavioral: Family Engagement plus Autism Navigator","Number of children screened by community service provider|Child age at screening by community service provider|Child age at referral for evaluation by community service provider|Child age at entry into intervention|Child autism symptoms measured with the Autism Diagnostic Observation Schedule|Child developmental level measured with the Mullen Scales of Early Learning|Child adaptive behavior measured with the Vineland Adaptive Behavior Scales|Family measure of resources measured with Family Resource Scale completed by parent|Family measure of stress measured with Parenting Stress Index completed by parent|Family measure of access to community activities measured with Home and Community Activities Survey completed by parent","Florida State University|Emory University|Weill Medical College of Cornell University|Drexel University|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Not Applicable","72474","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","MH104423|1R01MH104423-01","December 2015","June 2020","June 2020","May 15, 2015",,"February 7, 2020","Florida State University, Tallahassee, Florida, United States|Emory University, Atlanta, Georgia, United States|Weill Cornell Medical College, White Plains, New York, United States|Drexel University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02445105"
445,"NCT02360449","Social Motivation Intervention for Children With Autism Spectrum Disorder: Improving Peer Initiation",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Social Initiation Motivation Intervention","Initiation Frequency (observational rating of the frequency of child initiations to peers measured from video recording during free play sessions)","Stanford University","All","4 Years to 6 Years   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","31420","January 2015","July 19, 2017","November 5, 2020","February 10, 2015",,"January 8, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02360449"
446,"NCT03708614","A Study Looking at How Well Children With Autism Spectrum Disorder on Medications Like Having More Protein",,"Unknown status","No Results Available","Autism Spectrum Disorder","Other: Controlled energy diet with elevated protein intake","Caloric and protein intake|Pre- (at time of study enrolment) and post-intervention anthropometric measurements|Post-intervention interview with participants and family|Study feasibility (designs, methods, processes)","Holland Bloorview Kids Rehabilitation Hospital","All","6 Years to 17 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","REB 18-781","December 7, 2018","April 2020","June 2020","October 17, 2018",,"August 26, 2019","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03708614"
447,"NCT01987037","Neuropsychomotor Functions in Children With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: neuropsychomotor assessment","results to the NP-MOT tests battery","Centre Hospitalier Esquirol","All","4 Years to 11 Years   (Child)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013-A00644-41","October 2013","February 2016","February 2016","November 19, 2013",,"August 3, 2015","Centre de Ressources Autisme Limousin, Limoges, France|Centre Hospitalier esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01987037"
448,"NCT04895215","AB-2004 in Treatment of Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Drug: AB-2004|Drug: Placebo","The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 High Dose|The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 Low Dose|The mean change in the Clinical Global Impression-Severity (CGI-S) from Baseline to Week 8 for AB-2004 High Dose and AB-2004 Low Dose|Number of participants who reported treatment emergent adverse events (TEAEs)","Axial Therapeutics, Inc.","All","13 Years to 17 Years   (Child)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AXL-2004-002","August 2, 2021","December 2022","June 2023","May 20, 2021",,"August 20, 2021","Axial Therapeutics, Woburn, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04895215"
449,"NCT02496819","Metacognitive Self-regulated Learning and Sensory Integrative Approaches for Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Meta-cognitive self-regulated learning intervention|Other: Sensory integration intervention|Other: Activity-based intervention","Adaptive behaviour on the Vineland Adaptive Behaviour Scales - change from baseline after the intervention|Adaptive behaviour on the Vineland Adaptive Behaviour Scales - change from baseline at one month after the intervention completed|Executive function behaviours on the Behaviour Rating Inventory of Executive Function - change from baseline after the intervention|Executive function behaviours on the Behaviour Rating Inventory of Executive Function - change from baseline at one month after the intervention completed|School-related task performance on the School Function Assessment - change from baseline after the intervention|School-related task performance on the School Function Assessment - change from baseline at one month after the intervention completed|Social skills on the Walker Mc-Connell scale - change from baseline after the intervention|Social skills on the Walker Mc-Connell scale - change from baseline at one month after the intervention completed|Sensory processing difficulties on the Sensory Processing Measures - change from baseline after the intervention|Sensory processing difficulties on the Sensory Processing Measures - change from baseline at one month after the intervention completed|Sensory processing patterns and effects on functional performance on the Sensory Profile - change from baseline after the intervention|Sensory processing patterns and effects on functional performance on the Sensory Profile - change from baseline at one month after the intervention completed","University of Western Sydney|National University of Malaysia","All","6 Years to 12 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SR-Autism","June 2015","December 2016","March 2017","July 14, 2015",,"November 6, 2017","National University of Malaysia, Bangi, Selango, Malaysia",,"https://ClinicalTrials.gov/show/NCT02496819"
450,"NCT02901431","A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)",,"Terminated","Has Results","Autism Spectrum Disorder","Drug: Placebo|Drug: RO5285119","Change From Baseline in Vineland™-II Adaptive Behavior Scale Two Domain Composite (2DC) Score at Week 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Composite Standard Score After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Adaptive Behavior Scale Communication, Socialization, and Daily Living Skills Domain Standard Scores at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Proportion of Subjects With >=6 Points Improvement in the Vineland-II 2DC Score for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Ohio Autism Clinical Impressions Scale-Severity (OACIS-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Clinical Global Impressions- Improvement (CGI-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Ohio Autism Clinical Impressions Scale- Improvement (OACIS-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Patient-Reported Pediatric Quality of Life (PedsQL) v4.0 Generic Core Scale After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Composite Standard Score in Adolescents and Children Independently at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Adaptive Behavior Scale 2DC Score at Week 12 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Percentage of Participants With Adverse Events for Treatment With Balovaptan","Hoffmann-La Roche","All","5 Years to 17 Years   (Child)","Phase 2","339","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP30153","November 21, 2016","April 15, 2020","June 30, 2020","September 15, 2016","February 8, 2021","February 8, 2021","Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital of Colorado, Aurora, Colorado, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Segal trials, North Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|USF Rothman Center, Saint Petersburg, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|UMASS Medical School, Worcester, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Midwest Childrens Health Research Institute, Lincoln, Nebraska, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia;Allergy/Immunology Department, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Core Clinical Research, Everett, Washington, United States|Seattle Children's Research Institute; Psychiatry and Behavioral Medicine, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02901431"
451,"NCT03252392","/Autism Spectrum Disorder(ASD)Hearing Abnormalities Study",,"Unknown status","No Results Available","Autism Spectrum Disorder",,"Number of autistic participants suffering from hearing abnormalities.","Assiut University","All","3 Years to 12 Years   (Child)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IRB17200055","October 1, 2017","October 1, 2020","October 1, 2020","August 17, 2017",,"August 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03252392"
452,"NCT02311751","rTMS for Executive Function Deficits in Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Device: Repetitive Transcranial Magnetic Stimulation","Change in accuracy on the Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Task|Change in scores on Behaviour Rating Inventory of Executive Functioning (A) (BRIEF) (A)","Centre for Addiction and Mental Health|Academic Health Science Centres","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","119/2013","October 2014","May 4, 2018","May 4, 2018","December 8, 2014",,"March 6, 2019","Centre for Addictions and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02311751"
453,"NCT02176317","Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Autism Spectrum Disorder","Biological: Autologous Umbilical Cord Blood","Number of participants with non-serious and serious adverse events.|The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II","Duke University|The Marcus Foundation|PerkinElmer, Inc.","All","24 Months to 72 Months   (Child)","Phase 1","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00052449","June 2014","December 2015","December 2015","June 27, 2014",,"December 3, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02176317"
454,"NCT04811885","The Effects of Covid-19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder","ASD","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Cardiovascular Health","Other: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder","The Effects of Covid-9 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder","Institute of Technology, Carlow","All","4 Years to 18 Years   (Child, Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Institute Technology Carlow","October 14, 2019","October 14, 2021","October 14, 2021","March 23, 2021",,"March 24, 2021","Institute of Technology Carlow, Carlow, Lenister, Ireland",,"https://ClinicalTrials.gov/show/NCT04811885"
455,"NCT04010422","Ocular Function in Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism|Ocular Surface Disease","Diagnostic Test: no intervention","cornea innervation|visual function","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201904121RINC","May 15, 2019","December 31, 2020","December 31, 2020","July 8, 2019",,"July 8, 2019","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04010422"
456,"NCT02428452","Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: Trial of a Parent-Mediated Intervention",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Social ABCs parent-mediated intervention program","Change from Baseline in Child Vocal Responsivity at 12 and 24 weeks|Change from Baseline in Child Vocal Initiations at 12 and 24 weeks|Change from Baseline in Parent-Child Shared Smiling at 12 and 24 weeks|Change from Baseline in Parent Fidelity of Implementation at 12 and 24 weeks","Jessica Brian|IWK Health Centre|Holland Bloorview Kids Rehabilitation Hospital","All","12 Months to 30 Months   (Child)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-192|1005465","May 2011","March 2015","March 2015","April 28, 2015",,"July 13, 2017","IWK Health Centre, Halifax, Nova Scotia, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02428452"
457,"NCT05013164","Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Folinic Acid","To determine the role of folinic acid in improving the speech and adaptive skills among children with autism spectrum disorders|To dertermine improvement of stereotype movements and hyperactivity in children with autism spectrum disorders","Nishtar Medical University","All","3 Years to 14 Years   (Child)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICHMultan","October 1, 2020","March 30, 2021","March 30, 2021","August 19, 2021",,"August 24, 2021","Children's Hospital and Institute of Child Health, Multan, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05013164"
458,"NCT02879110","A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Dietary Supplement: Sulforaphane|Other: Placebo","The change of social impairments of children with autism spectrum disorder|The change of rigid interests and behaviors of children with autism spectrum disorder|The change of clinical symptoms of children with autism spectrum|The change of other behavioral problems of children with autism spectrum|The change of adaptive behaviors of children with autism spectrum|The change of clinical general impression of children with autism spectrum|The change of heart rate as measured by stopwatch|The change of weight as measured by weighing-machine|The change of height as measured by Height measurement tools|The change of blood routine test as tested by clinical laboratory|The change of fasting blood-glucose as tested by clinical laboratory|The change of blood lipid as tested by clinical laboratory|The change of liver function as tested by clinical laboratory|The change of kidney function as tested by clinical laboratory|The change of thyroid function as tested by clinical laboratory|The change of HBV test as tested by clinical laboratory|The change of helicobacter pylori test as tested by clinical laboratory|The change of urine routine test as tested by clinical laboratory|Number of participants with treatment-related adverse events as assessed by Systematic Assessment for Treatment Emergent Effects","Central South University|Davis family funding|University of California|University of Illinois at Chicago","All","3 Years to 15 Years   (Child)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASD201512","August 2016","July 2019","July 2019","August 25, 2016",,"July 30, 2019","Guangzhou Huiai Hospital, Guangzhou, Guangdong, China|The second Xiangya hospital of central south university, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT02879110"
459,"NCT03873831","Effects of Therapy Dogs on Social Behavior in Group Social Skills Instruction With Children With Autism",,"Unknown status","No Results Available","Autism Spectrum Disorder|Social Skills","Behavioral: Animal-assisted intervention|Behavioral: Social skills group","Verbal utterances|Direction of utterances|Quality of utterance|Unwanted behavior|Social behavior|Heart Rate|Electrodermal activity|Salivary cortisol|Quality of instruction: correct and timely feedback|Quality of instruction: adherence to the program script|Quality of instruction: attention to children","Texas Tech University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 17 Years   (Child)","Not Applicable","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Therapy Dogs Group Autism|R21HD095206","May 15, 2019","December 31, 2020","December 31, 2020","March 14, 2019",,"September 6, 2019","Texas Tech University, Lubbock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03873831"
460,"NCT01695200","Omega-3 Fatty Acids in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Dietary Supplement: Omega-3 fatty acids","Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment|Change from baseline in parent rated Child Behavior Checklist (CBCL) scores during treatment|Change from baseline in teacher rated Teacher Report (TRF) scores during treatment|Change from baseline in teacher rated Social Responsiveness Scale (SRS) scores during treatment|Change from baseline in clinician rated Clinical Global Impression (Severity and Improvements) scores during treatment|Change from baseline in clinician rated Global Assessment of Functioning (GAF) scores during treatment|Children's Yale-Brown Obsessive Compulsive Scale modified for Pervasive Developmental Disorders (CYBOCS-PDD)","National Healthcare Group, Singapore","All","5 Years to 18 Years   (Child, Adult)","Phase 4","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSRB: 2011/00028","September 2011","January 2013","January 2013","September 27, 2012",,"May 1, 2013","Institute of Mental Health, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01695200"
461,"NCT02160691","Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Device: Anxiety Meter","Proportion of responders|Change in heart rate|Change in self-reported anxiety level","Holland Bloorview Kids Rehabilitation Hospital","All","8 Years to 18 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANXMT_RCT1","October 2015","August 2020","August 2020","June 11, 2014",,"January 16, 2019","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02160691"
462,"NCT01579669","Partnering With Autistic Adults to Improve Healthcare",,"Completed","Has Results","Autism Spectrum Disorder","Behavioral: Use of toolkit","Patient Satisfaction|Provider Satisfaction|Patient Use of Toolkit Components|Change in Patient Satisfaction With Healthcare|Change in Patient's Perceived Barriers to Healthcare|Change in Patient Healthcare Self-Efficacy","Oregon Health and Science University|National Institute of Mental Health (NIMH)|Syracuse University|Indiana University|Autistic Self Advocacy Network|Portland State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","237","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R34MH092503","September 2013","August 2014","August 2014","April 18, 2012","December 7, 2015","December 7, 2015","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01579669"
463,"NCT02081027","Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Riluzole|Other: placebo","Clinical Global Impression-Improvement|Aberrant Behavior Checklist- Irritability","Children's Hospital Medical Center, Cincinnati","All","12 Years to 25 Years   (Child, Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","CIN001- Riluzole in Autism","September 19, 2013","April 2015","May 2015","March 7, 2014",,"January 14, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02081027"
464,"NCT03177590","Recording Facial and Vocal Emotional Productions in Children With Autism as Part of the JEMImE Project",,"Completed","No Results Available","Autism|Pervasive Developmental Disorder","Other: Recordings of facial and vocal emotional productions","Record facial and vocal emotional productions of children of an imitation situation|Record facial and vocal emotional productions of children in a situation of mime on written request|Record facial and vocal emotional productions of children in a situation of mime on presentation of an image","Fondation Lenval","All","6 Years to 12 Years   (Child)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-HPNCL-02","May 10, 2016","July 10, 2017","July 10, 2017","June 6, 2017",,"July 31, 2018","Fondation Lenval Hôpitaux Pédiatriques de Nice CHU-LENVAL, Nice, France|Hôpital de La Salpétrière - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT03177590"
465,"NCT01435733","Parenting a Child With Autism Spectrum Disorder and Marital Status",,"Suspended","No Results Available","Autism Spectrum Disorder",,"lower or higher levels of divorce","Sheba Medical Center","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SHEBA-11-8552-LG-CTIL","September 1, 2011","January 1, 2020","January 1, 2020","September 19, 2011",,"July 2, 2018","Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT01435733"
466,"NCT01691066","Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Infant Toddler Years PRT","Feasibility of a novel behavioral treatment|Acceptability of a novel behavioral treatment","Yale University|National Institute of Mental Health (NIMH)","All","12 Months to 15 Months   (Child)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1110009256|R03MH092617","September 2012","February 27, 2017","February 27, 2017","September 24, 2012",,"June 26, 2020","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01691066"
467,"NCT00846547","Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Arbaclofen","Irritability Subscale of the Aberrant Behavior Checklist, Community Version","Seaside Therapeutics, Inc.","All","6 Years to 17 Years   (Child)","Phase 2","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22003","February 2009","June 2010","September 2010","February 18, 2009","June 14, 2013","June 14, 2013","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00846547"
468,"NCT02200679","National Study on Autism Spectrum Disorder in China",,"Completed","No Results Available","Autism Spectrum Disorders",,"prevalence of autism spectrum disorder|ASRS|ADI-R|ADOS","Fudan University|National Health and Family Planning Commission, P.R.China","All","6 Years to 12 Years   (Child)",,"143755","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","201302002","January 2014","December 2016","December 2016","July 25, 2014",,"May 16, 2017","Capital Institute of Pediatrics, Beijing, Beijing, China|Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The Third Affiliated Hosptial,Sun Yat-Sen University, Guangzhou, Guangdong, China|Harbin Medical University, Harbin, Heilongjiang, China|Central South University, ChangSha, Hunan, China|Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China|Sichuan University, Chengdu, Sichuan, China|The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02200679"
469,"NCT02414503","Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: 8IU intranasal oxytocin|Drug: 24IU intranasal oxytocin|Drug: Placebo|Device: OptiNose Breath Powered Bi","Performance on an emotion sensitivity test|Performance on a facial emotion morphing task|Performance on the reading the mind in the eyes test|Performance on an emotional dot probe task|Heart rate variability|Eyetracking","OptiNose AS|Oslo University Hospital|University of Oslo","Male","18 Years to 35 Years   (Adult)","Phase 1|Phase 2","17","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","SMR-2728|2014-005452-26","April 2015","February 2016","February 2016","April 10, 2015",,"September 27, 2016","NORMENT, KG Jebsen Centre for Psychosis Research - TOP Study, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02414503"
470,"NCT04258839","Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148",,"Enrolling by invitation","No Results Available","Irritability Associated With Autism Spectrum Disorder","Drug: Brexpiprazole","Adverse Events|Aberrant Behavior Checklist (ABC-I)|Clinical Global Impression (CGI-S)","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","5 Years to 17 Years   (Child)","Phase 3","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-201-00191","January 17, 2020","August 20, 2022","August 20, 2022","February 6, 2020",,"May 28, 2020","For additional information regarding sites, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04258839"
471,"NCT02255565","Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study",,"Completed","Has Results","ADHD|Autism","Drug: Very Low Dose Quillivant XR|Drug: Low Dose Quillivant XR|Drug: Moderate Dose Quillivant XR","ADHD Rating Scale - IV|Clinical Global Impressions-ADHD - Severity|Clinical Global Impression - Improvement (CGI-I)","Seattle Children's Hospital|Pfizer","All","5 Years to 16 Years   (Child)","Phase 4","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","WI185890","September 2014","September 2016","October 2016","October 2, 2014","June 5, 2017","August 1, 2017","Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02255565"
472,"NCT04174365","Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder","Anchor","Recruiting","No Results Available","Irritability Associated With Autism Spectrum Disorder (ASD)","Drug: Brexpiprazole|Drug: Placebo","The mean change from baseline to Week 8 in the Aberrant Behavior Checklist- Irritability subscale score (ABC-I)|The mean change from baseline to Week 8 in the Clinical Global Impression- Severity of Illness Scale (CGI-S) score pertaining to irritability","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","5 Years to 17 Years   (Child)","Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-201-00148","October 30, 2019","February 23, 2022","February 23, 2022","November 22, 2019",,"May 28, 2020","For additional information regarding sites, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04174365"
473,"NCT02226458","An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder","Autism","Withdrawn","No Results Available","Autism Spectrum Disorder","Drug: EPI-743","Primary Efficacy|Secondary Endpoint|Safety Endpoint","Edison Pharmaceuticals Inc","All","3 Years to 14 Years   (Child)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI743-14-025","October 2014","November 2015","January 2016","August 27, 2014",,"March 10, 2015",,,"https://ClinicalTrials.gov/show/NCT02226458"
474,"NCT00572741","Treating Oxidative Stress and the Metabolic Pathology of Autism",,"Completed","No Results Available","Autistic Disorder","Dietary Supplement: B12|Dietary Supplement: Placebo|Dietary Supplement: folate|Dietary Supplement: B complex|Dietary Supplement: vitamin C|Dietary Supplement: cod liver oil|Dietary Supplement: Mineral complex|Dietary Supplement: carnitine","Behavioral test scores|Plasma metabolic profile","Arkansas Children's Hospital Research Institute","All","3 Years to 7 Years   (Child)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","59538","June 2008","April 2016","April 2016","December 13, 2007",,"May 5, 2016","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00572741"
475,"NCT00468130","Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","Abilify","Completed","No Results Available","Autism","Drug: Aripiprazole|Drug: Placebos","Clinical Global Impression Improvement (CGI-AD)|Aberrant Behavior Checklist","University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey","All","5 Years to 17 Years   (Child)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0220055441","May 2006","November 2009","November 2009","May 2, 2007",,"March 2, 2021","Department of Child and Adolescent Psychiatry, University Behavioral Health Care Building, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00468130"
476,"NCT02069977","Study to Evaluate the Efficacy and Safety of Aripiprazole",,"Unknown status","No Results Available","Autism","Drug: Aripiprazole","irritability subscale of the aberrant behavior checklist|Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech|Change of CGI-S, CGI-I from baseline|Change of Behavioral problems from baseline|Change of Adaptive Skills from baseline|Change of Parental stress from baseline","Yoo-Sook Joung|Korea Otsuka International Asia Arab|Samsung Medical Center","All","6 Years to 17 Years   (Child)","Phase 4","79","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","031OTC1301","February 2014","February 2016","February 2016","February 24, 2014",,"March 11, 2014","Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Medical City, Pasig, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Siriraj Hospital Mahidol University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02069977"
477,"NCT01612897","Study of the Effectiveness of a Computer Decision Support System to Improve Physicians' Screening for Autism","CAAC","Completed","No Results Available","Healthy Children Undergoing Routine Care|Children With Autism","Other: Computer based care reminders","Structure autism screening instrument administered|Are appropriate diagnostic studies conducted among children who screen positive for autism.","Indiana University","All","17 Months to 4 Years   (Child)","Not Applicable","368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","R01HS018453","September 2009","July 2014","July 2014","June 6, 2012",,"March 24, 2015","Wishard (Eskenazi) Healthcare clinics, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01612897"
478,"NCT01966679","Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial","FAST-AS","Completed","No Results Available","Autism Spectrum Disorder","Drug: AZD7325|Drug: Placebo","EEG","University of California, Los Angeles","All","18 Years to 35 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HHS-NIH-DA-12-241","October 2013","July 2015","July 2015","October 21, 2013",,"October 22, 2015","UCLA, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Seattle Children's Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01966679"
479,"NCT01914939","A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Oxytocin|Behavioral: Social Skills focused CBT|Behavioral: Stress management/relaxation training|Drug: placebo drug","Changes in the Autism Diagnostic Observation Schedule (ADOS)|Clinical Global Impression Scale (CGI)|Social Responsiveness Scale (SRS)|Reading the Mind in the Eyes Test (RMET)|Social Ball Tossing Task","Massachusetts General Hospital|Massachusetts Institute of Technology","Male","18 Years to 40 Years   (Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","W81XWH-12-1-0543|Clinical Trial Award","April 2014","November 2017","November 2017","August 2, 2013",,"January 27, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts Institute of Technology Martinos Imaging Center, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01914939"
480,"NCT04523805","Adapted Judo for Children With Autistic Spectrum Disorders","AUTJUDO","Enrolling by invitation","No Results Available","Autism Spectrum Disorder","Behavioral: Adapted judo programme","Change from Pre-intervention in psycho-social and behavioural scores|Change from Pre-intervention in motor skills scores|Change from Baseline in psycho-social and behavioural scores|Change from Baseline in motor skills scores","University Ramon Llull|Myriam Guerra|Cristina Curto Luque","All","8 Years to 15 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","01-autjudo","July 1, 2019","July 1, 2020","July 1, 2021","August 24, 2020",,"August 24, 2020","Jose Morales, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04523805"
481,"NCT04299464","A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Drug: Placebo|Drug: RO7017773","Change from Baseline to Week 12 in the Adaptive Behavior Composite score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants Discontinuing Treatment due to AEs|Change from Baseline Over Time in Suicide Risk Using the Columbia-Suicide-Severity Rating Scale (C-SSRS)|Change from Baseline to Week 12 in Behavior/Symptoms as Measured by all Domains of the Repetitive Behavior Scale-Revised (RBS-R)|Change from Baseline to Week 12 on the Vineland-3 Socialization Domain|Change from baseline to Week 12 on the Vineland-3 Communication domains","Hoffmann-La Roche","All","15 Years to 45 Years   (Child, Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BP41316|2019-003524-20","March 31, 2021","September 30, 2023","September 30, 2023","March 6, 2020",,"October 7, 2021","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Core Clinical Research, Kirkland, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Janeway Childrens Health; and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|London Health Sciences Centre; Victoria Hospital, London, Ontario, Canada|AOU Policlinico Tor Vergata, Università Roma Tor Vergata, Roma, Lazio, Italy|Ist. G. Gaslini; UOC Neuropsichiatria Infantile, Genova, Liguria, Italy|Istituto Scientifico Medea; U.O Psicopatologia età evolutiva, Bosisio Parini (LC), Lombardia, Italy|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti, Catania, Sicilia, Italy|IRCCS Fondazione Stella Maris; U.O. Complessa NPI 3 - Psichiatria dello sviluppo, Calambrone (PI), Toscana, Italy|Hospital Santa Caterina; Servicio de Psiquiatría, Salt, Girona, Spain|IGAIN (Instituto Global de Atención Integral al Neurodesarrollo), Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital Universitario Infanta Leonor; Servicio de Psiquiatría, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04299464"
482,"NCT04261595","Dates as a Functional Food for Autism",,"Active, not recruiting","No Results Available","Autistic Spectrum Disorder","Other: Dates fruit as functional Food|Behavioral: behavioral modification and stimulation|Other: nutritional Guidance","Dates' ability to change the oxidative stress of ASD|change on the pathogenic microbiota of the autistic children as detected by traditional stool analysis through DNA extraction (quantitative PCR) of the fecal samples|change on the useful microbiota of the autistic children ( probiotics)|Dates' effect on the change of the behavioral rating assessed by an Observation Checklist using the ""Bailey Scales of Infant and Toddler Development|Dates' effect on the change of the mental development assessed by an Observation Checklist using the ""Bailey Scales of Infant and Toddler Development""|Dates' effect on the change of the Psychomotor abilities assessed by the observational checklist using the ""Bailey Scales of Infant and Toddler Development|Dates' effect on the changes of the level of the autism as assessed by the 5th edition of the DSM-V|Dates' effect on the changes of the severity of the autism as assessed by Childhood Autism Rating Scale (CARS) measure|Dates' effect on the change on the dietary intake using the Food frequency questionnaire, 24-hour dietary recall, Dietary record","National Research Centre, Egypt","All","3 Years to 12 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","12060158","December 15, 2019","December 15, 2022","December 15, 2022","February 10, 2020",,"March 5, 2021","National Research Centre, Giza, Al Jizah, Egypt",,"https://ClinicalTrials.gov/show/NCT04261595"
483,"NCT03183674","Oxytocin in Spectrum Autism Disorders","OxytocinASD","Completed","No Results Available","Autistic Disorder","Drug: Oxytocin|Other: placebo","Eye tracking|Nepsy","University of Sao Paulo General Hospital","All","3 Years to 16 Years   (Child)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","10922213.7.0000.0068-2","July 15, 2016","July 20, 2017","May 15, 2018","June 12, 2017",,"October 28, 2019","Instituto de Psiquiatria, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03183674"
484,"NCT01501058","Parent-supported Social Skills Training for Teens With Autism Spectrum Disorders (PEERS-K)",,"Unknown status","No Results Available","Autism Spectrum Disorders","Behavioral: parent-assisted social skills training program for adolescents with autism spectrum disorder|Behavioral: Delayed intervention","Change from baseline in Test of Adolescent Social Skills Knowledge(TASSK) at 3month|Change from baseline in Social Skills Rating Scale (SSRS) at 3 month|Change from baseline in Friendship Qualities Scale (FQS) at 3month","Seoul National University Hospital","All","11 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PEERSK2011","December 2011","June 2012","September 2013","December 29, 2011",,"May 29, 2013","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01501058"
485,"NCT02832557","A Salivary miRNA Diagnostic Test for Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Developmental Delay","Other: Salivary collection|Other: Vineland Adaptive Behavior Scale-III Assessment|Other: Medical history questionaire|Other: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|Other: Mullen Scales of Early Learning","Salivary miRNA profile|Measures of adaptive function|Measures of early intellectual development|Measure of autistic behavior","State University of New York - Upstate Medical University|National Institute of Mental Health (NIMH)|Quadrant Biosciences Inc.|Milton S. Hershey Medical Center|University of Missouri-Columbia|Children's Hospital Medical Center, Cincinnati|Baylor College of Medicine","All","24 Months to 48 Months   (Child)",,"750","Other|NIH|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","346301|R41MH111347|R42MH111347","November 1, 2015","August 31, 2021","August 31, 2021","July 14, 2016",,"August 27, 2020","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT02832557"
486,"NCT00263367","Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism",,"Completed","No Results Available","Autism|Oxidative Stress","Other: Hyperbaric Oxygen","glutathione","The International Child Development Resource Center","All","5 Years to 12 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICDRC-22.2005","October 2005","January 2006","February 2006","December 8, 2005",,"June 22, 2011","ICDRC, Melbourne, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00263367"
487,"NCT01263756","Autism Spectrum Disorders (ASD) Driving Study",,"Completed","No Results Available","Autism Spectrum Disorder",,"Simulated driving performance of adolescents and adults with ASDs.|Questionnaire measures of driving history and behavior of adolescents and adults with ASDs.","Massachusetts General Hospital|Massachusetts Institute of Technology","All","16 Years to 50 Years   (Child, Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2010-P-000173","March 2010","March 2011","March 2011","December 21, 2010",,"December 8, 2011","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01263756"
488,"NCT01793441","A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: Placebo|Drug: RG7314","Change From Baseline in Social Communication Deficits as Measured by Social Responsiveness Scale 2 (SRS-2)|Percentage of Participants with Suicidality, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants With Adverse Events|Change From Baseline in Behavior/Symptoms as Measured by Aberrant Behavior Checklist (ABC)|Change From Baseline in Behavior/Symptoms as Measured by Repetitive Behavior Scale-Revised (RBS-R)|Change From Baseline in Behavior/Symptoms as Measured by Anxiety, Depression and Mood Scale (ADAMS)|Measure: Change From Baseline in Behavior/Symptoms as Measured by State-Trait Anxiety Inventory (STAI)|Change From Baseline in Clinical Global Impressions as Measured by Clinical Global Impressions Improvement (CGI-I) Scale|Change From Baseline in Adaptive Functioning and Skills as Measured by Vineland-II Adaptive Behavior Scale (VABS)|Plasma Concentration of RG7314|Plasma Concentration of RG7314 Metabolite M3|Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Concentration (AUClast) of RG7314|AUClast of RG7314 Metabolite M3|Maximum Observed Plasma Concentration (Cmax) of RG7314|Cmax of RG7314 Metabolite M3|Percentage of Participants With Clinical Response, Defined as At Least 25% Improvement in the SRS-2 Score With a CGI-I Score of 1 or 2","Hoffmann-La Roche","Male","18 Years to 45 Years   (Adult)","Phase 2","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP28420|2012-005597-55","September 2013","September 2016","September 2016","February 15, 2013",,"February 3, 2017","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Sacramento, California, United States|PCSD Feighner Research, San Diego, California, United States|San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Stanford, California, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Centennial, Colorado, United States|Yale University; Yale Child Study Center, New Haven, Connecticut, United States|New Haven, Connecticut, United States|Neurology offices of south florida, Delray Beach, Florida, United States|Delray Beach, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Oakland Park, Florida, United States|Compass Research, Orlando, Florida, United States|Orlando, Florida, United States|Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States|Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Chicago, Illinois, United States|The Kennedy Krieger Institute, Baltimore, Maryland, United States|Baltimore, Maryland, United States|Neuroscientific Insights, Rockville, Maryland, United States|Rockville, Maryland, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Lexington, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Montefiore Medical Center; Departments of Psychiatry & Biobehavioral Science, Bronx, New York, United States|Bronx, New York, United States|Mount Sinai School of Medicine; Seaver Autism Center, New York, New York, United States|New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Orangeburg, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Cleveland, Ohio, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Nashville, Tennessee, United States|Road Runner Research, San Antonio, Texas, United States|San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Bothell, Washington, United States|Seattle Children's Research Institute, Seattle, Washington, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01793441"
489,"NCT03459625","Mindfulness for Parents of Children With Autism Spectrum Disorder Autism Spectrum Disorder","ASD","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Mindfulness-Based Stress Reduction (MSBR)|Behavioral: Psychoeducational Support Group (PE)","Child externalizing behavior problems as evidenced by reductions in the Externalizing scores on a standardized parent-report questionnaire.|Child externalizing behavior problems as evidenced by reductions in the Externalizing score on a standardized parent-report questionnaire.|Parenting Stress","Loma Linda University|California State University, Fullerton","All","3 Years to 5 Years   (Child)","Not Applicable","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","5110264","July 21, 2018","May 2022","May 2022","March 9, 2018",,"April 23, 2021","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT03459625"
490,"NCT01972074","Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder",,"Completed","Has Results","Autism Spectrum Disorder","Drug: Memantine|Other: Placebo","Treatment Responder","Massachusetts General Hospital|Mclean Hospital","All","8 Years to 17 Years   (Child)","Phase 3","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013-P-001826","February 17, 2015","May 7, 2018","May 7, 2018","October 30, 2013","September 11, 2019","September 11, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01972074/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01972074"
491,"NCT04099381","Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility.","ASD-HLA2019","Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Biological: ASD CB-MNC infusion low level HLA compatibility.|Biological: ASD CB-MNC infusion high level HLA compatibility.|Other: Standard therapy.","Number of participants with non-serious and serious adverse events.|The Childhood Autism Rating Scale (CARS2).|Autism Treatment Evaluation Checklist (ATEC).|Evaluation of the survival of donor cells in the host body without immune responses|The correlation of the concentration of T-regulatory cells (CD4/CD25/FoxP3) in the sample of umbilical cord blood and the treatment effectiveness degree|The correlation of the concentration of T-regulatory cells (CD4/CD25/FoxP3) in the patient depending on the severity of the disease.|The correlation of the concentration of CD34+ cells in the cord blood sample and the treatment effectiveness degree","State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|INBIO, LLC","All","3 Years to 14 Years   (Child)","Phase 1|Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASD-HLA2019","August 10, 2019","December 26, 2021","May 26, 2022","September 23, 2019",,"March 2, 2020","Medical Centre Dinasty, Samara, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04099381"
492,"NCT02708069","e-Unstuck:Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder","e-Unstuck","Completed","No Results Available","Autistic Disorder","Other: e-Unstuck|Other: Unstuck and On Target","Change from baseline in ratings of top three child EF difficulties interference with daily functioning as measured on the Top Executive Functioning Difficulties.|Change from baseline in child executive function using the Behavior Rating of Executive Function-II (BRIEF-II).|Change from baseline in parental self-efficacy on the Parenting Sense of Competence Scale.|Change from Baseline in parental perceptions of caregiving as measured on the Caregiver Questionnaire","3-C Institute for Social Development|Children's National Health System","All","Child, Adult, Older Adult","Not Applicable","97","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1R44MH109193","March 1, 2017","February 28, 2018","February 28, 2018","March 15, 2016",,"July 31, 2018","Children's National Health System, Rockville, Maryland, United States|3C Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02708069"
493,"NCT01337687","Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders","INOT","Completed","Has Results","Autism Spectrum Disorders","Drug: Intranasal Oxytocin|Drug: Placebo","Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale|Change in Obsessive- Compulsive Behavior Based on Yale Brown Obsessive Compulsive Scale (YBOCS)|Change in Repetitive Behavior Based Repetitive Behavior Scale - Revised (RBS-R)|Change in Facial Emotion Recognition Based on Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2)","Montefiore Medical Center|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 55 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-10-303","October 2009","December 2013","December 2013","April 19, 2011","February 27, 2020","February 27, 2020","Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01337687"
494,"NCT00801554","Autism Spectrum Disorders (ASD) Characterization Study",,"Completed","No Results Available","Autism Spectrum Disorders",,"Overall level of functioning of children and adults with autism spectrum disorders (ASD) compared to individuals without ASD.","Massachusetts General Hospital","All","6 Years to 60 Years   (Child, Adult)",,"26","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2007-P-001951","October 2008","April 2010","April 2010","December 3, 2008",,"October 22, 2013","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00801554"
495,"NCT01322984","Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Pictures|Behavioral: Startle eliciting noise","The eyeblink of the Startle reflex is measured.","University of Tromso|The Royal Norwegian Ministry of Health","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010/238","March 2011","January 2013",,"March 25, 2011",,"October 25, 2012","Department of Psychology, University of Tromso, Tromso, Troms, Norway",,"https://ClinicalTrials.gov/show/NCT01322984"
496,"NCT04276571","EMPATIA@Lecco- Balance Rehabilitation of Autistic Children With Virtual rEality","BRAVE","Recruiting","No Results Available","Autism Spectrum Disorder","Device: exergames with GRAIL virtual immersive reality environment","experimental balance assessment|Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007).|Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007).|assessment of balance in response to perturbation applied by accelerating the dual-belt treadmill the dominant side at toe-off|assessment of overground balance using GSENSOR (BTS Bioengineering), a medical device for motion analysis|evaluation of gait features using the GRAIL (Motekforce Link)","IRCCS Eugenio Medea","All","7 Years to 14 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIP-679","October 18, 2019","October 31, 2020","October 31, 2020","February 19, 2020",,"February 21, 2020","Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy",,"https://ClinicalTrials.gov/show/NCT04276571"
497,"NCT03422016","Electroretinogram in Autistic Spectrum Disorders","ERG in ASD","Unknown status","No Results Available","Autism Spectrum Disorder","Diagnostic Test: electroretinogram (ERG)","light adapted electroretinogram","Great Ormond Street Hospital for Children NHS Foundation Trust|Flinders University|Yale University|Swinburne University of Technology","All","4 Years to 25 Years   (Child, Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","17PP33","September 3, 2018","September 2019","April 2020","February 5, 2018",,"September 6, 2019","Yale University, New Haven, Connecticut, United States|Flinders University, Adelaide, South Australia, Australia|Swinburne University of Technology, Melbourne, Australia|Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03422016"
498,"NCT04066673","Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.",,"Unknown status","No Results Available","Autism Spectrum Disorder","Diagnostic Test: Stanford-Binet Intelligence Scale, 5th Edition","Intelligence Quotient assessment in autistic children by the Stanford-Binet Intelligence Scales, 5th Edition","Assiut University","All","3 Years to 18 Years   (Child, Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","IQ in Autism","September 2019","September 2020","October 2020","August 26, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04066673"
499,"NCT03374072","Engaging Siblings of Adults With Autism in Future Planning",,"Completed","No Results Available","Autistic Disorder","Behavioral: Siblings FORWARD program|Behavioral: Information Only Condition","Change in Quality of Sibling Plan of Action|Sibling Future Planning Actions|Social Problem-Solving Skills Inventory-Revised|Family Communication about Future Planning|Future Planning Self-Efficacy|Sibling Barriers to Future Planning|Sibling Knowledge of Adult Services|Sibling Knowledge of Family Future Plan","Boston University Charles River Campus|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","4366E|R34MH111489","February 1, 2017","January 31, 2021","January 31, 2021","December 15, 2017",,"May 28, 2021","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03374072"
500,"NCT03008889","A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder","NAC","Completed","Has Results","Autism Spectrum Disorder","Drug: N-acetylcysteine|Drug: Placebo","Percentage of Participants Randomized|Attrition Rate|Study Medication Compliance|Successful Collection of Outcome Measures|Parent Satisfaction Rating|Positive Predictive Value of Screening Method of Classifying Self-injurious Behavior (SIB) by Type.|Aberrant Behavior Checklist Irritability Subscale Score at Baseline and 9 Weeks Post-intervention|Number of Self-Injurious Behavior Events|Change in Clinical Global Impression (CGI-I) Scale at 9 Weeks Post-intervention|Change in Biomarkers and Possible Mechanisms of Action of NAC in Children With ASD.","Emory University","All","5 Years to 12 Years   (Child)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00088115","July 5, 2018","September 12, 2019","September 12, 2019","January 4, 2017","December 16, 2020","January 26, 2021","Marcus Autism Center, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03008889/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03008889"
501,"NCT02839915","Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Folinic Acid|Other: Placebo","Change in Clinical Evaluation of Language Fundamentals 4 (CELF-4) Score.|Change in Clinical Evaluation of Language Fundamentals Preschool (CELF-P) score|Change in Clinician Global Impression for Improvement (CGI-I) Score","Phoenix Children's Hospital|Emory University|Harvard University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Aprofol","All","5 Years to 12 Years   (Child)","Phase 2","134","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00089662|R01HD088528","August 13, 2020","July 1, 2023","July 1, 2024","July 21, 2016",,"August 24, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Healtcare of Atlanta, Atlanta, Georgia, United States|Harvard University, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02839915"
502,"NCT04270708","Intranasal Dexmedetomidine vs Oral Triclofos Sodium for EEG in Children With Autism",,"Not yet recruiting","No Results Available","Autistic Disorder","Drug: Dexmedetomidine|Drug: Triclofos 100 MG/ML","Maximal Sedation Depth|Technician satisfaction from sedation|Neurologist satisfaction from EEG motion artifact|Compliance with IN vs Oral Delivery|Resistance to drug administration (1-10 scale)|Achieving sedation following single dose|Achieving sedation following rescue dose|Sedation onset, duration and recovery periods|Adverse Events","Rabin Medical Center","All","3 Years to 19 Years   (Child, Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","0090-20-RMC","March 1, 2020","March 1, 2022","August 1, 2022","February 17, 2020",,"February 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04270708"
503,"NCT00335790","A Controlled Trial of the Clinical Effects of Hyperbaric Therapy in Autistic Children",,"Completed","No Results Available","Autism","Procedure: Hyperbaric Therapy","Blinded Therapist Autism Diagnostic Observation Schedule (ADOS)|Blinded Therapist Aberrant Behavior Checklist (ABC-C)|Blinded Physician Clinical Global Impression Severity Score (CGI)|Parental Autism Treatment Evaluation Checklist (ATEC)","International Hyperbarics Association","All","2 Years to 7 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","HBA-2","June 2006",,"March 2007","June 12, 2006",,"April 10, 2007","Center for Autism Research and Education, Phoenix, Arizona, United States|International Child Development Resource Center, Melbourne, Florida, United States|Blue Ridge Spectrum Center, Charlottesville, Virginia, United States|Advocates for Children, Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00335790"
504,"NCT00936182","Study of Fluconazole in Children With Autism Spectrum Disorder",,"Unknown status","No Results Available","Autism Spectrum Disorder","Drug: Fluconazole","PDD Behavior Inventory","The Center for Autism and Related Disorders|The International Child Development Resource Center|Thoughtful House","All","3 Years to 10 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C0901","July 2009","July 2010","July 2011","July 9, 2009",,"July 9, 2009","Center for Autism and Related Disorders, Tarzana, California, United States|International Child Development Resource Center, Melbourne, Florida, United States|Thoughtful House, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00936182"
505,"NCT01333865","A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Memantine","Number of Participants With Reduction in ASD Symptom Severity as Defined by the Social Responsiveness Scale (SRS)|Number of Participants With Reduction in ASD Symptom Severity as Defined by the NIMH Clinical Global Impression for Pervasive Developmental Disorders (CGI-PDD) Improvement Score","Massachusetts General Hospital","All","18 Years to 50 Years   (Adult)","Phase 4","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-P-000016","January 2010","July 2014","July 2014","April 12, 2011","October 6, 2014","March 24, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01333865"
506,"NCT01011764","Study of Peer Relationships at School","HRSAII","Completed","No Results Available","Autism","Behavioral: SKILLS vs ENGAGE","The Friendship Survey|Friendship Qualities Scale","Health Resources and Services Administration (HRSA)|Florida State University|Johns Hopkins University|University of Michigan|University of Washington","All","7 Years to 12 Years   (Child)","Not Applicable","200","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","G09-04-021-01A|UA3MC11055","September 2009","June 2012","August 2012","November 11, 2009",,"August 16, 2012","University of California, Los Angeles, Los Angeles, California, United States|Florida State University, Tallahassee, Florida, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01011764"
507,"NCT00404846","Effects of Hyperbaric Oxygenation Therapy on Adaptive, Aberrant and Stereotyped Behaviors in Children With Autism",,"Unknown status","No Results Available","Autism","Procedure: Hyperbaric Oxygenation Therapy","Direct Behavioral Observations|The Vineland Adaptive Behavior Scales: Expanded Edition (VABS)|Peabody Picture Vocabulary Test (PPVT)|Test of Visual-Perceptual Skills (TVPS)|The Beery-Buktenica Developmental Test of Visual-Motor Integration (VMI)|Autism Diagnostic Observation Schedule (ADOS)|The Behavior Rating Inventory of Executive Functioning (BRIEF)|Aberrant Behavior Checklist|Clinical Global Impression Scale","The Center for Autism and Related Disorders|The International Child Development Resource Center","All","2 Years to 14 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","906001","November 2006","September 2007","December 2007","November 29, 2006",,"May 5, 2009","Center for Autism and Related Disorders, Tarzana, California, United States",,"https://ClinicalTrials.gov/show/NCT00404846"
508,"NCT01093768","Brain Imaging Study of Adults With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Oxytocin|Drug: Vasopressin","Changes in brain activations|Performance scores and reaction time on behavioral tasks","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 40 Years   (Adult)","Phase 1","38","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Diagnostic","100068|10-M-0068","February 19, 2010","April 11, 2013","April 11, 2013","March 26, 2010",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01093768"
509,"NCT01361503","Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders",,"Structural and neurochemical profiles of adolescents with ASD","Massachusetts General Hospital|Mclean Hospital","All","6 Years to 17 Years   (Child)",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2010-P-000185","April 2010","September 2014","September 2014","May 26, 2011",,"July 9, 2021","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01361503"
510,"NCT03715153","Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Drug: BUMETANIDE/S95008|Drug: PLACEBO","Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Scale II (VABS II)|Adverse Event and Pediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|Columbia-Suicide severity scale Children's version (C-SSRS-C)|Acceptability and palatability questionnaires|Paediatric Quality of Life Inventory (PedsQL) questionnaire","Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier","All","2 Years to 6 Years   (Child)","Phase 3","211","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL3-95008-002|2017-004420-30","October 4, 2018","June 15, 2021","September 20, 2022","October 23, 2018",,"January 20, 2021","Richmond Behavioral Associates, Staten Island, New York, United States|Liverpool Hospital, Liverpool, Australia|The Royal Children's Hospital Melbourne, Parkville, Australia|Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio-Universidade Federal do Ceará, Fortaleza, Brazil|Clínica Neurológica e Neurocirúrgica de Joinville, Joinville, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de psiquiatra, São Paulo, Brazil|University hospital of Ostrava, Department of Psychiatry, Poruba, Ostrava, Czechia|University Hospital Brno, Department of Child Neurology, Brno, Czechia|Institute of Neuropsychiatric Care, Department of Child Psychiatry, Praha, Czechia|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron Cedex, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Ile De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Magyar Református Egyház Bethesda Gyermekkórháza, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale ""Autismo 0-90"" A.O.U. Policlinico ""Gaetano Martino"", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|""Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|National Institute of Children Diseases, Department of Child Psychiatry, Bratislava, Slovakia|EPAMED, s.r.o., Košice, Slovakia|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Colchester Hospital, Colchester, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre 195-197 Hathersage Road, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03715153"
511,"NCT03514784","Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder|Gastrointestinal Symptoms","Drug: BB-12 with LGG (Higher Dose)|Drug: Placebo|Drug: BB-12 with LGG (Lower Dose)","Effects of BB-12+LGG at different doses on adverse events (safety)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors with Aberrant Behavior Checklist (ABC)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors measured with the Social Responsiveness Scale-2","The University of Texas Health Science Center, Houston|Texas Higher Education Coordinating Board|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 16 Years   (Child)","Phase 1|Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HSC-MS-17-0995|R01HD095158-02","May 2016","September 2025","September 2025","May 2, 2018",,"November 17, 2020","UTHealth, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03514784"
512,"NCT00106652","Childhood Autism Risks From Genetics and the Environment (The CHARGE Study)",,"Completed","No Results Available","Autism|Developmental Disabilities",,,"National Institute of Environmental Health Sciences (NIEHS)|University of California, Davis|University of California, Los Angeles","All","24 Months to 60 Months   (Child)",,"2000","NIH|Other","Observational","Time Perspective: Other","11269-CP-001|200210574-4","September 2001","September 2017","September 2017","March 29, 2005",,"September 25, 2017","University of California, Davis, California, United States",,"https://ClinicalTrials.gov/show/NCT00106652"
513,"NCT04881656","Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: Help is in Your Hands","Parent Stress Index 4th Edition, Short Form|Parent Sense of Competence|Telehealth Usability Questionnaire","University of California, Davis|National Center for Advancing Translational Science (NCATS)|National Institute of Mental Health (NIMH)","All","6 Months to 99 Years   (Child, Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1749700","September 1, 2021","May 31, 2023","May 31, 2033","May 11, 2021",,"August 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04881656"
514,"NCT03234608","Health System Integration of Tools to Improve Primary Care for Autistic Adults",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: AASPIRE Healthcare Toolkit","Barriers to healthcare checklist|Patient-provider communication scale|Healthcare Self-Efficacy|Visit preparedness scale|Clinic use of accommodations scale","Portland State University|Oregon Health and Science University|Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","241","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1R34MH111536-01","August 24, 2017","March 15, 2019","July 30, 2020","July 31, 2017",,"April 30, 2020","Kaiser Permanente Northern California, Oakland, California, United States|Legacy Health System, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03234608"
515,"NCT04899544","Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism","PRT-C vs PRT-H","Not yet recruiting","No Results Available","Autism|Autism Spectrum Disorder|ASD","Behavioral: Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Behavioral: Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)","Change in Number of Child Utterances during the Parent-Child portion of the Structured Lab Observation (SLO).|Change on MacArthur-Bates Communication Development Inventory (CDI) Scores|Change From Baseline in Parent Rated Vineland Adaptive Behavior Scale- 3 (VABS-3) Scores|Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) Score|Change From Baseline in Parent Rated Stanford Social Dimension Scale (SSDS) Scores|Change on the Brief Observation of Social Communication Change (BOSCC) direct child observation assessment.|Change on the Clinical Global Impressions (CGI) Scale.","Stanford University|Anonymous Donor","All","2 Years to 5 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB-61427","January 15, 2022","January 15, 2026","January 15, 2026","May 24, 2021",,"May 25, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04899544"
516,"NCT04909658","The Effect of Acceptance and Commitment Therapy","ASDMatrix","Completed","No Results Available","Autism, Infantile","Behavioral: ACT Matrix|Behavioral: PT Protocol","Acceptance and Action Questionnaire (AAQ-II)|Home Situation Questionnaire (HSQ-ASD)|Valued Living Questionnaire (VLQ)|Mindful Attention Awareness Scale (MAAS)|Parental Stress Index/Short Form (PSI/SF)","S.Anna Rehabilitation Institute|Istituto per la Ricerca e l'Innovazione Biomedica","All","3 Years to 13 Years   (Child)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CNR-AMMCEN 54444/2018","January 7, 2018","December 30, 2019","December 30, 2020","June 2, 2021",,"June 2, 2021","Institute for Biomedical Research and Innovation (IRIB), Messina, Italy",,"https://ClinicalTrials.gov/show/NCT04909658"
517,"NCT02712853","Improving Autism Screening With Brain-Related miRNA",,"Completed","No Results Available","Autism Spectrum Disorder|Developmental Delay","Other: Saliva collection|Other: Vineland Adaptive Behavior Scale-II Assessment","salivary miRNA profile|Measures of adaptive function|Measure of autistic behavior","Milton S. Hershey Medical Center","All","18 Months to 6 Years   (Child)",,"304","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Study00003658","November 2015","August 2018","August 2018","March 18, 2016",,"August 22, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02712853"
518,"NCT04293627","Access to Tailored Autism Integrated Care Pilot Study","ATTAIN","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Mental Health Issue","Behavioral: ATTAIN","Feasibility and acceptability of ATTAIN|Acceptability of Intervention Measure|Feasibility of Intervention Measure|ASD + Mental Health Comfort and Knowledge Questionnaire|Measure of Innovation-Specific Implementation Intentions (MISII)|ATTAIN Uptake|Caregiver Perceptions of ATTAIN","University of California, San Diego|Kaiser Permanente|San Ysidro Health Center|Rady Children's Hospital, San Diego","All","4 Years to 16 Years   (Child)",,"45","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","UC San Diego","November 13, 2019","August 31, 2021","March 30, 2022","March 3, 2020",,"August 9, 2021","University of California, San Diego, La Jolla, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04293627/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04293627"
519,"NCT02947880","Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology","BUMAUTEP","Withdrawn","No Results Available","Autistic Disorder","Drug: Bumetanide|Drug: Placebo","Change (evolution) between day 0 and day 99 of the result of the scale CARS (Childhood Autism Rating Scale).|CARS (Childhood Autism Rating Scale) between D0 and D99 and between D99 and D190 which will be describe by etiology","University Hospital, Limoges","All","5 Years to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","I14039","December 2016","December 2019","June 2020","October 28, 2016",,"June 2, 2021",,,"https://ClinicalTrials.gov/show/NCT02947880"
520,"NCT01813318","Study of Acamprosate in Autism",,"Completed","No Results Available","Autistic Disorder","Drug: Acamprosate|Drug: Placebo","Change from baseline to week 10 on the Social WIthdrawal subscale of ABC|Change Clinical Global Impression- Improvement|Change in ABC subscales: Irritability, Stereotypy, Hyperactivity, and Inappropriate Speech from baseline to week 10","Children's Hospital Medical Center, Cincinnati|Autism Speaks","All","5 Years to 17 Years   (Child)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CIN001-Acamprosate in Autism","July 2, 2013","September 7, 2017","September 7, 2017","March 18, 2013",,"February 3, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01813318"
521,"NCT00382382","Diffusion Tensor Imaging in Autism",,"Withdrawn","No Results Available","Autistic Disorder","Other: diffusion tensor imaging (DTI)","RBS-R scores, including both total and subset scores","University of Florida","Male","8 Years to 12 Years   (Child)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1R03HD051656","July 2008","July 2009","July 2009","September 29, 2006",,"March 13, 2015","McKnight Brain Institute of the University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00382382"
522,"NCT01005953","Comprehensive Collection, Charting, and Communication System","CCCCSys","Unknown status","No Results Available","Autism",,,"SymTrend Inc.|University of Washington|National Institute of Mental Health (NIMH)","All","22 Years to 70 Years   (Adult, Older Adult)",,"70","Industry|Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1R41MH086153-01","October 2009","August 2011","August 2011","November 1, 2009",,"June 7, 2011","SymTrend, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01005953"
523,"NCT00409747","Minocycline to Treat Childhood Regressive Autism",,"Completed","Has Results","Autism|Minocycline|Regressive Autism","Drug: Minocycline","z Score|Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","3 Years to 12 Years   (Child)","Phase 4","11","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070024|07-M-0024","November 2006","June 2010","April 2011","December 11, 2006","December 11, 2015","December 11, 2015","Childrens National Medical Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00409747"
524,"NCT04382885","Cariprazine Pediatric ASD PK Study",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Cariprazine","Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Percentage of participants with potentially clinically significant values in clinical laboratory assessments|Percentage of participants with potentially clinically significant values in vital signs assessments|Percentage of participants with potentially clinically significant values in ECG assessments|Percentage of participants who have suicidal ideation or suicidal behaviors in C-SSRS assessments|Percentage of participants with treatment-emergent parkinsonism in SAS assessments|Percentage of participants with treatment-emergent akathisia in BARS assessments|Percentage of participants with potentially clinically significant values in ocular examination parameters|Pharmacokinetics: Maximum plasma concentrations (Cmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Area under the plasma concentration-time curve during the dosing interval (AUC0-tau) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Terminal elimination half-life (T1/2) of cariprazine and its metabolites DCAR and DDCAR|Pharmacokinetics: Minimum plasma concentrations (Cmin) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Average plasma concentrations (Cavg) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Apparent total clearance of cariprazine from plasma (CL/F) on Day 42|Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of cariprazine","Allergan","All","5 Years to 17 Years   (Child)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000-103-009","June 26, 2020","September 30, 2021","September 30, 2021","May 11, 2020",,"July 29, 2021","Neuropsychiatric Research Center of Orange County /ID# 233663, Orange, California, United States|Atlanta Center for Medical Research /ID# 233576, Atlanta, Georgia, United States|iResearch Atlanta, LLC /ID# 233614, Decatur, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04382885"
525,"NCT00695136","The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism",,"Completed","Has Results","Autism|Cognition Disorder","Drug: Donepezil hydrochloride|Behavioral: Increase REM sleep percentage","Change in Percentage of Time That Subjects With Autism Spend in REM Sleep.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","2 Years to 10 Years   (Child)","Phase 1|Phase 2","17","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","080154|08-M-0154","June 2008","January 2011","January 2011","June 11, 2008","April 24, 2013","April 24, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00695136"
526,"NCT02184390","Parenting Your Young Child With Autism: A Web-Based Tutorial",,"Completed","No Results Available","Autistic Disorder","Other: On LIne Parent Training Tutorial","System Usability Scale|Autism Knowledge Test","Center for Psychological Consultation|National Institute of Mental Health (NIMH)","All","18 Months to 6 Years   (Child)","Not Applicable","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R44MH086936","May 2013","May 2015","September 2015","July 9, 2014",,"February 3, 2016","Center for Psychological Consulation, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02184390"
527,"NCT02275455","Design Of WELL Being Monitoring Systems, Application in Autism","Do Well B","Unknown status","No Results Available","Autistic Disorder","Behavioral: real life situations","Heart Rate Variability from holter electrocardiogram|Heart Rate Variability from the heart rate transmitter belt","University Hospital, Clermont-Ferrand","All","12 Years to 25 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHU-0213|2014-A00611-46","October 2014","December 2016","December 2018","October 27, 2014",,"July 26, 2016","University Hospital of Clermont-Ferrand (CHU), France, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT02275455"
528,"NCT01258465","Research in Autism: Parent Intervention",,"Completed","No Results Available","Autistic Disorder","Behavioral: Pivotal Response Training|Behavioral: Picture Exchange Communication System","Mullen Scales of Early Learning|Vineland Adaptive Behavior Scales","University of California, San Diego","All","24 Months to 47 Months   (Child)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH39434","January 2005","December 2009","December 2009","December 13, 2010",,"December 13, 2010","University of California, San Diego Psychology Department, La Jolla, California, United States|University of California, Santa Barbara, School of Education, Department of Clinical, Counseling, and School Psychology, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT01258465"
529,"NCT02004236","Transcranial Random Noise Stimulation (tRNS) Over Fronto-temporal Cortex Improves Verbal Fluency and Empathy in Autism Children","tRNS25112013","Completed","Has Results","Autism|ASD","Device: tRNS Fronto-temporal cortex|Device: tRNS over fusiform temporal cortex|Device: tRNS with sham","Verbal Fluency|Sociability|Ratio Theta/Beta Before tRNS|Theta Amplitude in T5 Before tRNS|Ratio Theta/Beta After tRNS|Theta Amplitude in T5 After tRNS|Reaction Time in ECPT Before tRNS|Omission Errors Before tRNS|Commission Errors Before tRNS|P3b Wave Amplitude Before tRNS|Reaction Time After tRNS|Ommision Errors After tRNS|Commission Errors After tRNS|P3b Wave Amplitude After tRNS","Spanish Foundation for Neurometrics Development","All","5 Years to 12 Years   (Child)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Autism and tRNS","January 2014","August 2014","September 2014","December 9, 2013","October 16, 2014","May 4, 2021","General Elche Hospital, Elche, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT02004236"
530,"NCT00889538","Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems",,"Completed","No Results Available","Autism|Severe Behavior Disorder","Drug: placebo|Drug: glutathione|Drug: glutathione, vit C and NAC","Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.|Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio","University of Louisville|Cumberland Pharmaceuticals|Norton Healthcare","All","5 Years to 16 Years   (Child)","Not Applicable","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glutathione-KCPCRU-01","April 2009","September 2012","September 2012","April 29, 2009",,"December 7, 2016","KCPCRU, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00889538"
531,"NCT00755430","Structural and Functional Connectivity in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder",,,"National Taiwan University Hospital|National Science Council, Taiwan","All","3 Years to 15 Years   (Child)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Other","200807036R","January 1, 2009","December 31, 2012","December 31, 2012","September 19, 2008",,"September 5, 2021","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00755430"
532,"NCT00090415","Early Characteristics of Autism",,"Completed","No Results Available","Autism|Autistic Disorder","Behavioral: Intensive behavioral therapy","Communication and social behavior scales; an early development interview; observations of parent/child interaction; and neuropsychological, cognitive, and adaptive behavioral measures","University of Washington|National Institute of Mental Health (NIMH)","All","18 Months to 30 Months   (Child)","Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U54MH066399|DDTR BD-DD","April 2003","April 2008",,"August 27, 2004",,"June 19, 2012","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00090415"
533,"NCT04725383","Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Repetitive Compulsive Behavior","Drug: amitriptyline","Clinical Global Impressions scale-Improvement of Much Improved (2) or Very Much Improved (1)|Child Yale Brown Obsessive Compulsive Scale- Pervasive Developmental Disorders (CYBOCS-PDD)|Repetitive Behavior Scale-revised","University of Missouri, Kansas City","All","6 Years to 17 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015984|17-055","June 1, 2021","June 1, 2024","December 20, 2024","January 26, 2021",,"May 11, 2021",,,"https://ClinicalTrials.gov/show/NCT04725383"
534,"NCT02465086","Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population",,"Unknown status","No Results Available","Autism Spectrum Disorder","Other: Training of linguistic recursion","Performance on second-order false-belief tasks","Roskilde University","All","7 Years to 15 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Protocol-01/2015","September 2015","May 2017","May 2017","June 8, 2015",,"April 6, 2016","School Ellebaekskolen, Koege, Denmark",,"https://ClinicalTrials.gov/show/NCT02465086"
535,"NCT00211783","Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism",,"Completed","No Results Available","Autism|Asperger's Syndrome","Procedure: fMRI","BOLD","Icahn School of Medicine at Mount Sinai","All","18 Years to 50 Years   (Adult)",,"71","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GCO# 04-0749","November 2004","November 2011","June 2012","September 21, 2005",,"June 28, 2012","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00211783"
536,"NCT02222311","Influence of Vitamin D Deficiency on the Development of Autism",,"Unknown status","No Results Available","Autism","Other: Blood Samples","Level of Vitamin D|Effect of environment on Vitamin D level","Hillel Yaffe Medical Center","All","6 Years to 12 Years   (Child)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0038-14-HYMC","November 2014","November 2017","April 2018","August 21, 2014",,"August 21, 2014","Hillel Yaffe Medical Center, Hadera, Israel",,"https://ClinicalTrials.gov/show/NCT02222311"
537,"NCT01248130","Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders",,"Terminated","Has Results","Autism Spectrum Disorder (ASD)","Drug: Omega-3 Fatty Acid","Change in Social Responsiveness Scale (SRS) Total Raw Score|Change in NIMH Clinical Global Impression Scale for Pervasive Developmental Disorders (CGI-PDD) Improvement Scores","Massachusetts General Hospital","All","6 Years to 17 Years   (Child)","Phase 2","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2009-P-001593","November 2009","April 2013","April 2013","November 25, 2010","September 22, 2014","November 6, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01248130"
538,"NCT03847337","Can Novel Telemedicine Tools Reduce Disparities Related to Early Identification of Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Developmental Delay","Other: Telehealth-Screening Tool for Autism in Toddlers (STAT)|Other: Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)","Accurate diagnosis of autism via telemedicine|Accurate diagnosis of developmental delay via telemedicine","Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)","All","15 Months to 3 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","190152|1R21MH118539-01","March 4, 2019","November 1, 2021","November 1, 2021","February 20, 2019",,"June 11, 2021","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03847337"
539,"NCT00005014","Treatment of Autism in Children and Adolescents",,"Completed","No Results Available","Autistic Disorder","Drug: Risperidone",,"National Institute of Mental Health (NIMH)","All","5 Years to 17 Years   (Child)","Phase 3","101","NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","N01 MH70001|N01 MH70009|N01 MH80011|N01 MH70010|DSIR CT","October 1997",,"February 2001","April 3, 2000",,"April 17, 2014","UCLA, Los Angeles, California, United States|Yale Univ, New Haven, Connecticut, United States|Indiana Univ / Riley Hosp for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State Univ, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00005014"
540,"NCT03489811","The Effect of Aroma on Anxiety Among Children With Autism.",,"Recruiting","No Results Available","Anxiety|Autism Spectrum Disorder","Other: Test Essential Oil Blend|Other: Active Essential Oil Blend|Other: Control Blend","39-Question Spence Children's Anxiety Scale (SCAS)","Franklin School of Integrative Health Sciences","All","6 Years to 11 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","17-2100","July 24, 2017","August 31, 2021","September 21, 2021","April 6, 2018",,"April 29, 2020","Franklin Institute of Wellness, Franklin, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03489811"
541,"NCT03785327","Improving Social Interaction for Adolescents With Autism During the Transition to Adulthood",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder|Typical Development","Device: tDCS|Behavioral: Autism Training","Objective Social Interaction Quality|Subjective Social Interaction Quality|Social Cognition","The University of Texas at Dallas","Male","18 Years to 21 Years   (Adult)","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","1806799","January 18, 2019","July 2022","July 2022","December 24, 2018",,"September 30, 2021","The University of Texas at Dallas, Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03785327"
542,"NCT00515320","Study of Fluoxetine in Autism","SOFIA","Completed","No Results Available","Autistic Disorder","Drug: Fluoxetine|Drug: Placebo","The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.|The time and dose related course of therapeutic effects|The inter-relationship between these effects in the context of global clinical changes.|The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment.|Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests.","Neuropharm|Autism Speaks","All","5 Years to 17 Years   (Child)","Phase 3","158","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPL-2008-4-AUTUS-004","August 2007","January 2009","January 2009","August 13, 2007",,"April 27, 2012","Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|University of Florida, Department of Psychiatry, Gainesville, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00515320"
543,"NCT02469870","ASD Parent Trainer: Online Coaching for Parents of Children With Autism","APT","Completed","Has Results","Autism Disorder","Behavioral: Autism Parent Trainer (APT)|Behavioral: Teaching Routines (Control)","Child Behavior Measured by Strengths and Difficulties Questionnaire (Goodman, 1997)|Family Quality of Life as Measured by Family Quality of Life Survey (Summers et al., 2005)|Parenting Scale (Arnold, O'Leary, Wolff, & Aker, 1993)|Scales of Independent Behavior-Revised (SIB-R; Bruininks, Woodcock, Weatherman, & Hill, 1996)|Knowledge About Applied Behavior Analysis and Acceptance Commitment Training Measured by Questionnaire|Consumer Satisfaction Questionnaire","IRIS Media Inc","All","18 Years and older   (Adult, Older Adult)","Not Applicable","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2R44MH102845-02","August 2016","October 2017","October 30, 2017","June 12, 2015","February 5, 2020","February 5, 2020","IRIS Educational Media, Eugene, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02469870/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02469870"
544,"NCT02708290","Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD",,"Completed","Has Results","Autistic Disorder|Autism|ASD","Other: MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time","Improvement of Language as Measured by Autism Therapy Evaluation Checklist (ATEC) and Mental Synthesis Evaluation Checklist (MSEC).","ImagiRation, LLC","All","2 Years to 12 Years   (Child)",,"6454","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MITA001","September 2015","July 1, 2020","July 1, 2020","March 15, 2016","December 20, 2019","November 27, 2020","ImagiRation LLC, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02708290/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02708290"
545,"NCT03924973","3 Year Follow up Study of the IDEA Population","IDEA2SCOLA","Recruiting","No Results Available","Autism","Behavioral: ESDM followed by treatment as usual","ADOS (Autism Diagnostic Observation Schedule )|Wechsler (Wechsler Intelligence Scale for Children)|VABS (Vineland Adaptive Behavior Scales)|PPVT ( Peabody Picture Vocabulary Test )|Parental self-assentiment","Hôpital le Vinatier","All","39 Months to 60 Months   (Child)","Not Applicable","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2017-A02446-47","April 17, 2019","December 31, 2022","December 31, 2025","April 23, 2019",,"February 9, 2021","Hopital Vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT03924973"
546,"NCT02077985","Sensory Adapted Dental Environment to Enhance Oral Care for Children With ASD","SADE","Completed","No Results Available","Autism","Behavioral: Sensory Adapted Dental Environment","Electrodermal activity (EDA)|Children's Dental Behavioral Rating Scale (CDBRS)|Number of hands used to restrain child|Frankl Scale|The Anxiety and Cooperation Scale (A & C Scale)|Time","University of Southern California|Children's Hospital Los Angeles","All","6 Years to 12 Years   (Child)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5R34DE022263-02","October 2012","June 2013","June 2013","March 4, 2014",,"March 4, 2014",,,"https://ClinicalTrials.gov/show/NCT02077985"
547,"NCT03108976","Build-up of Action Representation in Autism Spectrum Disorders","ASD-BARN","Unknown status","No Results Available","Healthy|Autism Spectrum Disorder","Other: Behavioral assessments|Other: Magnetoencephalography (MEG)|Other: Magnetic Resonance Imaging (MRI)","Changes of cerebral oscillations in three frequency bands (alpha, beta, gamma) during sensori-motor learning.|Correlation between oscillatory measures and learning performance.","Hospices Civils de Lyon","All","7 Years to 12 Years   (Child)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL16_0677","April 10, 2015","March 10, 2019","April 10, 2019","April 11, 2017",,"August 31, 2018","CH le Vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT03108976"
548,"NCT00004486","Randomized Study of Fluoxetine in Children and Adolescents With Autism",,"Completed","No Results Available","Autism","Drug: fluoxetine",,"Icahn School of Medicine at Mount Sinai|FDA Office of Orphan Products Development","All","5 Years to 17 Years   (Child)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","199/14266|MTS-FDR001520|MTS-GCO-96-713","September 1998",,"December 2002","October 19, 1999",,"March 25, 2015","Albert Einstein College of Medicine, Bronx, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00004486"
549,"NCT00576732","A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder",,"Completed","Has Results","Autistic Disorder|Autism","Drug: Placebo|Drug: Risperidone high dose|Drug: Risperidone low dose","Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale|Number of Participants Who Had at Least 25% Improvement in ABC-I|Change in Clinical Global Impression Severity (CGI-S)|Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.|Change in Fasting Glucose (mg/dL) at 6 Weeks|Change in Insulin Resistance (IR) at 6 Weeks|Change in Fasting Glucose (mg/dL) at 6 Months|Change in Insulin Resistance (IR) at 6 Months","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","5 Years to 17 Years   (Child)","Phase 4","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR014740|RISAUT4002","December 2007","September 2009","March 2010","December 19, 2007","September 28, 2010","May 9, 2014","Dothan, Alabama, United States|Phoenix, Arizona, United States|Sacramento, California, United States|Santa Ana, California, United States|Boca Raton, Florida, United States|Miami, Florida, United States|Smyrna, Georgia, United States|Hoffman Estates, Illinois, United States|Naperville, Illinois, United States|Lake Charles, Louisiana, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|Staten Island, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Portsmouth, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00576732"
550,"NCT02914951","Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability",,"Active, not recruiting","No Results Available","Autism|Intellectual Disability","Behavioral: Cognitive-Behavioral Therapy|Other: Functional magnetic resonance imaging (fMRI)","Modified Overt Aggression Scale (MOAS)|Aberrant Behavior Checklist - Irritability Scale (ABC-I)|Home Situations Questionnaire (HSQ)","Yale University","All","8 Years to 16 Years   (Child)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0102012121-D","October 2016","December 2021","December 2021","September 26, 2016",,"March 1, 2021","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02914951"
551,"NCT01183221","The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders",,"Completed","Has Results","Autism|ASD","Drug: Syntocinon|Drug: Placebo","Empathic Accuracy Performance|Fmri BOLD Response During Empathic Accuracy Task","Alexander Kolevzon|Icahn School of Medicine at Mount Sinai","All","18 Years to 45 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","GCO 09-0857","June 18, 2010","April 25, 2014","April 25, 2014","August 17, 2010","April 15, 2021","April 15, 2021","Mount Sinai School of Medicine - Seaver Autism Center for Research and Treatment, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01183221"
552,"NCT04244721","Effectiveness of a Parent-mediated Intervention With PACT on Children With ASD","iPACT","Recruiting","No Results Available","Autism Spectrum Disorder","Other: Preschool Autism Communication Therapy (PACT)|Other: Treatment As Usual (TAU)","Autism symptoms|Social Interactions of the child|Parent-child synchrony and initiative in communication|Number of words produced by the child|Adaptative behavior|Autism Family Experience|Characteristics of the parents","Hôpital le Vinatier","All","18 Months to 36 Months   (Child)","Not Applicable","238","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018-A02516-49","June 30, 2020","June 2023","February 2024","January 28, 2020",,"July 9, 2021","Hopital Vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT04244721"
553,"NCT05047224","Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Tele-assessment + in-person assessment|Behavioral: Tele-assessment only","Diagnostic accuracy of the TAP|Validity of the TAP|Family perceptions of tele-assessment|Family satisfaction with diagnostic services|Family empowerment|Child service access and utilization","Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)","All","18 Months and older   (Child, Adult, Older Adult)","Not Applicable","720","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Diagnostic","210760|1R01MH127228-01","January 30, 2022","December 31, 2025","June 30, 2026","September 17, 2021",,"September 17, 2021","UC Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT05047224"
554,"NCT00004449","Randomized Study of Intensive One-on-one Behavioral Treatment for Preschool Aged Children With Autism",,"Completed","No Results Available","Autistic Disorder","Behavioral: intensive one-on-one behavioral treatment|Behavioral: Individualized in home parent training","Wechsler Preschool and Primary Scales of Intelligence, 3rd ed.|Bayley Scales of Infant Development|Merrill-Palmer Scale of Mental Tests|Reynell Developmental Language Scales|Vineland Adaptive Behavior Scales - Survey Edition","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","2 Years to 3 Years   (Child)","Not Applicable","102","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH048863|UCLA-HSPC-G930506611","May 1998","September 2004","April 2006","October 19, 1999",,"May 27, 2015",,,"https://ClinicalTrials.gov/show/NCT00004449"
555,"NCT00247156","An Autism Study Using Nambudripad's Food Allergy Elimination Treatments",,"Completed","No Results Available","Autism|Food Allergies","Procedure: Acupressure treatments and NAET treatments","Improvement in speech and communication|Elimination or reduction of commonly seen autistic traits","Nambudripad's Allergy Research Foundation","All","3 Years to 10 Years   (Child)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","narfoundationautismstudy|narffoundation 101","November 2004",,"November 2005","November 1, 2005",,"June 26, 2008","PNIB Research Center, Buena Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00247156"
556,"NCT01395953","Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders",,"Withdrawn","No Results Available","Autism Spectrum Disorder (ASD)","Drug: Buspirone|Drug: Placebo","Reduction in Pediatric Anxiety Rating Scale (PARS) Score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score","Massachusetts General Hospital","All","6 Years to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2011-P-000703","November 2011","July 2013","July 2013","July 18, 2011",,"July 9, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01395953"
557,"NCT00850070","Sapropterin as a Treatment for Autistic Disorder",,"Completed","Has Results","Autistic Disorder","Drug: sapropterin|Drug: Placebo","Clinical Global Impression -- Improvement (CGI-I) Scale|Clinical Global Impression -- Severity (CGI-S) Scale|Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months.|Vineland Adaptive Behavior Scale-II.|Children's Yale Brown Obsessive Compulsive Scale (C-YBOCS)|Connor's Preschool ADHD Questionnaire|Adverse Events Scale|Aberrant Behavior Checklist (ABC) - Inappropriate Speech|Social Responsiveness Scale (SRS)|Parent Global Assessment (PGA) Scale","The Children's Health Council|BioMarin Pharmaceutical","All","3 Years to 6 Years   (Child)","Phase 2","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHC-0901","March 2009","August 2011","October 2011","February 24, 2009","February 28, 2014","May 1, 2018","The Children's Health Council, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00850070"
558,"NCT02504554","Beneficial Bacteria Treatment for Autism","BBT","Completed","Has Results","Gastrointestinal Problems|Autism Spectrum Disorders","Drug: oral Vancomycin|Drug: MoviPrep|Drug: Prilosec|Biological: human fecal material; processed, frozen administered orally|Biological: human fecal material; processed, frozen; administered orally and rectally","Gastrointestinal Symptom Responsiveness Scale (GSRS)|Parent Global Impressions-Revised (PGI-R)|Blood Safety Markers (Assessment of Blood Chemistry Panel and Complete Blood Count)|Childhood Autism Rating Scale (CARS)|Social Responsiveness Scale (SRS)|Short Sensory Profile|Vineland Adaptive Behavior Scale (VABS)|Daily Stool Record (DSR)","Arizona State University|Northern Arizona University|University of Arizona|University of Minnesota","All","7 Years to 17 Years   (Child)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001053","July 2014","April 2016","April 2016","July 22, 2015","December 18, 2019","December 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02504554"
559,"NCT02997566","Autonomic Modulation and Facial Expression in Autism Spectrum Disorder",,"Completed","No Results Available","Autistic Disorder|Autism Spectrum Disorder","Other: Autonomic evaluation","Autonomic evaluation|Childhood Autism Rating Scale (CARS)|Autistic Behavior Checklist","Universidade Estadual Paulista Júlio de Mesquita Filho","All","3 Years to 14 Years   (Child)",,"55","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","57347916.5.0000.5402","August 2016","June 2017","December 2017","December 20, 2016",,"June 4, 2020","Universidade Estadual Paulista Júlio de Mesquita Filho, Presidente Prudente, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02997566"
560,"NCT02862340","Study of the Involvement of 15q11 - q13 Chromosome Region and CYFIP1 Gene in Autism. Attempt a Genotype-phenotype Correlation",,"Completed","No Results Available","Autistic Disorder","Genetic: Genetic test","presence or absence of abnormality in 15q11q13 gene|phenotype","Centre Hospitalier Universitaire de Nice","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","07-PP-01","January 2008","January 2008","February 2012","August 11, 2016",,"August 11, 2016","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT02862340"
561,"NCT00057408","A Controlled Study of Olanzapine in Children With Autism",,"Completed","No Results Available","Autistic Disorder","Drug: olanzapine (Zyprexa)|Drug: Placebo","Children's Psychiatric Rating Scale|Clinical Global Impressions|Aberant Behavior Checklist|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale","FDA Office of Orphan Products Development|National Institute of Mental Health (NIMH)","All","3 Years to 12 Years   (Child)","Phase 2","78","U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2190","May 2003",,"September 2005","April 2, 2003",,"March 25, 2015","Drexel University College of Medicine c/o Friends Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00057408"
562,"NCT00873509","Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder","B-ACE","Completed","No Results Available","Autistic Disorder","Drug: Buspirone|Drug: Placebo","To evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children 2-6 years measuring the change from baseline in ADOS (Autism Diagnostic Observation Schedule) Composite Total scores compared to placebo at 6 months.|To evaluate the effects of twice-daily oral buspirone on the ADOS Composite calibrated severity score, social behavior, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there are age group differences in the effects of buspirone on social interaction, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there is a difference in the incidence of side effects and long term safety between the buspirone and placebo groups, and between the different dose groups.|To determine whether the whole brain PET measure of serotonin synthesis capacity is a predictor of buspirone effect.|To determine whether blood serotonin concentration is a predictor of buspirone effect.","Chugani, Diane C.|National Institute of Neurological Disorders and Stroke (NINDS)","All","2 Years to 6 Years   (Child)","Phase 2|Phase 3","166","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10888|5U01NS061264","May 2009","January 2015","January 2015","April 1, 2009",,"July 26, 2016","University California Davis M.I.N.D. Institute, Sacramento, California, United States|Children's Hospital of Michigan Wayne State University, Detroit, Michigan, United States|New York University Langone Medical Center, New York, New York, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00873509"
563,"NCT01043822","Pain and Emotional Expression in Children With Autism or Mental Retardation",,"Unknown status","No Results Available","Autism|Mental Retardation",,,"University Hospital, Montpellier","All","18 Months to 6 Years   (Child)",,"138","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","UF8481","December 2009","June 2011","July 2011","January 7, 2010",,"October 29, 2010","Montpellier University Hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT01043822"
564,"NCT01400269","An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism",,"Completed","No Results Available","Autistic Disorder","Behavioral: Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention","Social Responsiveness Scale|Repetitive Behavior Scale|Family Empowerment Scale|Caregiver Strain questionnaire|Pediatric Quality of Life Inventory|Sensory Profile Questionnaire","Stanford University","All","18 Months to 6 Years   (Child)","Not Applicable","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-11022010-7169","September 2010","January 2014","January 2014","July 22, 2011",,"September 22, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01400269"
565,"NCT00273650","Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism",,"Completed","No Results Available","Autistic Disorder","Drug: methylcobalamin|Other: saline placebo","Primary measure is the Clinical Global Impression Scale -Improvement supplemented by videos taken at all visits and rated blindly to measure executive function, speech, and language, and socio-economic development.|Secondary measures:NEPSY, ABC, PPVT, SB:V, PDRF, MCDI, PIA-CV, and CARS.","University of California, San Francisco","All","3 Years to 8 Years   (Child)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB12-AUT","July 2005","June 2009","August 2009","January 9, 2006",,"October 9, 2019","UC Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00273650"
566,"NCT04948814","Application of Fecal Microbiota Transplantation in Children With ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder","Biological: Fecal microbiota transplantation|Drug: Vancomycin","Change in Autism Diagnostic Observation Scale (ADOS) in ASD children|Changes in the Autism Behavior Checklist (ABC) in ASD children|Changes in the Childhood Autism Rating Scale (CARS) in ASD children|Change in Social Responsiveness Scale (SRS) in ASD children|Change in Autism Treatment Evaluation Checklist (ATEC) in ASD children|Change in gastrointestinal symptoms among children with ASD|Evaluate the difference of the gut microbe composition between children with ASD and healthy children by sequencing faecal metagenome.","Tongji Hospital","All","3 Years to 18 Years   (Child, Adult)","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F616|2018B030335001","July 1, 2021","September 1, 2023","September 1, 2023","July 2, 2021",,"July 2, 2021","Tongji Hospital, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04948814"
567,"NCT03438994","Early Assessment of Autism Through Smart Tablet Gameplay",,"Unknown status","No Results Available","Autism Spectrum Disorder|Other Neurodevelopmental Disorder","Diagnostic Test: Play.Care","Diagnostic accuracy of Play.Care to detect ASD|Ability of Play.Care to distinguish ASD from OND","University of Strathclyde|Harimata|University of Glasgow|University of Aberdeen|Göteborg University","All","30 Months to 5 Years   (Child)","Not Applicable","760","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","UEC17/49","January 10, 2018","July 30, 2019","November 30, 2019","February 20, 2018",,"September 23, 2019","Gillberg Neuropsychiatry Centre, Gothenburg, Sweden|University of Strathclyde, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03438994"
568,"NCT02003820","Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Dental Caries","Behavioral: video modeled social story","Measure of video intervention use|Plaque index|Caregiver survey","Yale University","All","5 Years to 14 Years   (Child)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pedidentalautism","July 2014","June 2015","July 2015","December 6, 2013",,"August 8, 2016","Yale New Haven Hospital Pediatric Dental Center, New Haven, Connecticut, United States|Yale Pediatric Dental Center Suite 403, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02003820"
569,"NCT04245306","Pilot Evaluation of a New Computerized Test for Pragmatic Inferences in Children With ASD","TIPI","Recruiting","No Results Available","Autism Spectrum Disorder","Other: computerized test for pragmatic inferences","Discrimination power of the measure assessed by the dissociation of the developmental trajectories of children with ASD compared to TD children in the composite score of the TIPi.|Sensitivity of the TIPi composite score (measuring pragmatic inferencing) to typical development in the targeted age range: 8 to 12 years oldin the targeted age range: 8 to 12 years old|The TIPi composite score provides additional information compared to other cognitive assessments typically provided in the global assessment of children with ASD|Discrimination power of the measure assessed by the dissociation of the developmental trajectories of children with ASD compared to children with DLD in the composite score of the TIPi.","Hôpital le Vinatier","All","8 Years to 12 Years   (Child)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2019-A01721-56","February 7, 2020","February 2022","March 2023","January 28, 2020",,"July 9, 2021","Ch Le Vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT04245306"
570,"NCT00054730","Effects of CX516 on Functioning in Fragile X Syndrome and Autism",,"Completed","No Results Available","Fragile X Syndrome|Autism","Drug: CX516 (Ampalex®)",,"RespireRx|FRAXA Research Foundation","All","18 Years to 50 Years   (Adult)","Phase 2",,"Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CORX-CX516-013","June 2002",,,"February 11, 2003",,"June 24, 2005","UC Davis-MIND Institute, Sacramento, California, United States|RUSH-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00054730"
571,"NCT01116388","A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders","GFCF","Completed","No Results Available","Autism|Gastrointestinal Symptoms","Other: GFCF product with GFCF diet|Other: product containing gluten and casein (milk protein) with GFCF diet","A study to assess the role of a gluten free-casein free diet in the dietary management of autism associated gastrointestinal disorders","Massachusetts General Hospital|Nutricia North America","All","2 Years to 17 Years   (Child)","Not Applicable","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2008-P-002385","April 2010","April 2015","April 2015","May 5, 2010",,"April 8, 2015","Massachusetts General Hospital, Boston, Massachusetts, United States|Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01116388"
572,"NCT00541346","A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms",,"Completed","Has Results","Autism|Attention Deficit Hyperactivity Disorder","Drug: Methylphenidate Transdermal System","Change in Attention Deficit Hyperactivity Disorder Rating Scale - IV (ADHD-RS-IV) Total Score From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Hyperactivity Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Irritability Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Lethargy Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Stereotypy Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Inappropriate Speech Scores From Baseline to 8-week Follow-up Visit|Change in Lifetime Participation Scale (LPS) Total Scores From Baseline to 8-week Follow-up Visit|Change in Family III General Scale Summed Score From Baseline to 8-week Follow-up Visit|Change in Pediatric Evaluation Disability Inventory (PEDI) Caregiver Assistance: Self-Care From Baseline to 8-week Follow-up Visit|Change in Pediatric Evaluation Disability Inventory (PEDI) Social Function From Baseline to 8-week Follow-up Visit|Change in Attention Deficit Hyperactivity Disorder Rating Scale IV: Teacher Assessment Total Scores From Baseline to 8-week Follow-up Visit","University of Oklahoma|Mark L. Wolraich, M.D.","All","6 Years to 11 Years   (Child)","Phase 3","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPD485-420-Lock","September 2007","May 2009","February 2010","October 10, 2007","February 6, 2014","February 6, 2014","OU Child Study Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT00541346"
573,"NCT05018169","Behavioral Activation for Treatment of Depression in Adolescents With Autism","BA-A","Not yet recruiting","No Results Available","Depression|Autism","Behavioral: BA-A","Children's Depression Inventory, Second Edition, Parent Report|Children's Depression Inventory, Second Edition, Self Report|Children's Depression Rating Scale, Revised|Spence Children's Anxiety Scale, Self Report|Spence Children's Anxiety Scale, Parent Report|Social Skills Improvement System, Parent Report","University of Virginia","All","12 Years to 17 Years   (Child)","Not Applicable","23","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSR200385","August 2021","August 2022","August 2022","August 24, 2021",,"August 24, 2021",,,"https://ClinicalTrials.gov/show/NCT05018169"
574,"NCT00198120","Safety and Effectiveness of D-Cycloserine in Children With Autism",,"Completed","No Results Available","Autistic Disorder","Drug: D-cycloserine|Drug: Placebo","Change in Clinical Global Impressions (CGI) Global Improvement|Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC)","Indiana University|National Institute of Mental Health (NIMH)|National Alliance for Research on Schizophrenia and Depression|Indiana University School of Medicine","All","3 Years to 12 Years   (Child)","Phase 3","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K23MH068627|0305-30|DDTR BK-TKND","February 2004","September 2007","August 2010","September 20, 2005",,"April 12, 2016","Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00198120"
575,"NCT02414451","Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response",,"Withdrawn","No Results Available","Autism","Drug: Propranolol|Drug: Placebo","Change in General Social Outcome Measure (GSOM)|Change in Social Responsiveness Scale (SRS)|Change in Anagrams task|Change in Verbal fluency for categories task|Change in Spence Children's Anxiety Scale (SCAS)|Vertical attention task|Change in Clinical Global Impression of Change (CGIC) scale|Change in Autism Impact Measure (AIM)|Change in Vineland Adaptive Behavior Scales-II (VABS)|Change in Aberrant Behavior Checklist (ABC)|Change in Clinical Global Impression of Severity (CGIS) scale","University of Missouri-Columbia","All","15 Years to 30 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","200089","September 2016","September 2016","September 2016","April 10, 2015",,"October 4, 2016",,,"https://ClinicalTrials.gov/show/NCT02414451"
576,"NCT00676195","An Open-Label Study of N-Acetyl Cysteine in Children With Autism",,"Completed","Has Results","Autistic Disorder","Drug: N-Acetyl Cysteine","Number of Participants With Adverse Events Reported on the Dosage Record and Treatment Emergent Symptom Scale (DOTES)|Social Responsiveness Scale (SRS)|Sensory Profile Questionnaire (SPQ)|Irritability Subscale of the Aberrant Behavior Checklist (ABC)|Glutathione Metabolism Intermediates in Peripheral Blood Measured by High-performance Liquid Chromatography","Stanford University","All","3 Years to 12 Years   (Child)","Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-05062008-1139","June 2008","June 2010","June 2010","May 12, 2008","March 29, 2017","March 29, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00676195"
577,"NCT03419611","Word Learning in Children With Autism",,"Unknown status","No Results Available","Autistic Disorders Spectrum","Behavioral: Multi-Modal|Other: Treatment as Usual|Behavioral: High Intensity Multi-Modal","Expressive Word Acquisition|Change in Expressive Word Acquisition|Receptive Word Acquisition|Change in Receptive Word Acquisition|Communication Complexity Scale|Change in Communication Complexity Scale","University of Kansas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 10 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00140285|U54HD090216","November 1, 2016","May 31, 2021","May 31, 2021","February 5, 2018",,"April 29, 2019","University of Kansas, Lawrence, Kansas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03419611/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03419611"
578,"NCT00943579","Open-Label Extension Study of Kuvan for Autism",,"Completed","Has Results","Autistic Disorder","Drug: Kuvan®","Clinical Global Impressions Scale|Vineland Adaptive Behavior Scale, 2nd Edition|Children's Yale Brown Obsessive Compulsive Scale|Parental Global Assessment|Preschool Language Scale, 4th Edition (PLS-4)|Connor's Preschool ADHD Questionnaire|Aberrant Behavior Checklist (ABC)|Adverse Events Reporting","The Children's Health Council|BioMarin Pharmaceutical","All","3 Years to 6 Years   (Child)","Phase 2|Phase 3","41","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHC-0902","August 2009","December 2011","March 2012","July 22, 2009","July 4, 2013","May 2, 2018","The Children's Health Council, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00943579"
579,"NCT01800539","Improving Services and Outcomes for Children With Autism Spectrum Disorder (ASD)",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders","Behavioral: Provider Education Model (PEM)","Change in Provider Delivery Service Practices|Change in Baseline Mullen Scales of Early Learning|Change in Baseline Autism Diagnostic Observation Schedule|Change in Caregiver Interaction with Child","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Health Resources and Services Administration (HRSA)","All","12 Months to 42 Months   (Child)","Not Applicable","80","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA_00023642","February 2014","June 2022","June 2022","February 27, 2013",,"September 1, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01800539"
580,"NCT04095585","Molecular Characterization of Patients Affected by Williams Syndrome and Autism.","WBA","Completed","No Results Available","Williams Beuren Syndrome|Autism Spectrum Disorder","Genetic: chromosomal microarray analysis (CMA) and whole exome sequencing (WES)","Possible presence of pathogenic chromosomal|Possible presence of gene variants","Hospices Civils de Lyon","All","Child, Adult, Older Adult",,"6","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","2019-WBA","September 2014","November 2015","December 2015","September 19, 2019",,"September 27, 2019",,,"https://ClinicalTrials.gov/show/NCT04095585"
581,"NCT00065884","Valproate Response in Aggressive Autistic Adolescents",,"Unknown status","No Results Available","Autism","Drug: Valproate",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","6 Years to 21 Years   (Child, Adult)","Phase 3","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","P30HD002528|K08MH001516",,,,"August 5, 2003",,"June 24, 2005","Outpatient MR/Autism Clinic, University of Kansas, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00065884"
582,"NCT00627705","A Study of N-Acetyl Cysteine in Children With Autism",,"Completed","Has Results","Autistic Disorder","Drug: N-Acetyl Cysteine|Other: Placebo - sugar pill","Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES)|The Clinical Global Rating Scale (CGRS) Improvement Subscale Score|Glutathione (GSH) Levels in Peripheral Blood, Measured by State-of-the-art High-performance Liquid Chromatography (HPLC)|Irritability Subscale of the Aberrant Behavior Checklist (ABC)|The Aberrant Behavior Checklist Total Score (ABC)|Social Responsiveness Scale (SRS)|Sensory Profile Questionnaire (SPQ)|Glutathione (GSH) Metabolism Intermediates in Peripheral Blood","Stanford University","All","3 Years to 12 Years   (Child)","Phase 2","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-02012008-995|10142","February 2008","September 2010","September 2010","March 3, 2008","May 18, 2017","May 18, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00627705"
583,"NCT00086645","Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)",,"Completed","No Results Available","Autistic Disorder","Drug: citalopram hydrobromide|Other: placebo","Clinical Global Improvement|Safety Monitoring Uniform Research Form (SMURF)|Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS)|Repetitive Behavior Scale-Revised (RBS-R)|Parent Chief Complaint|Aberrant Behavior Checklist|Child and Adolescent Symptom Inventory: Anxiety and Depression scales|Behavioral Activation|Caregiver Strain Questionnaire|Vineland","Boston University|National Institute of Mental Health (NIMH)","All","5 Years to 17 Years   (Child)","Phase 2","149","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U54MH066398","April 2004","October 2006","April 2007","July 13, 2004",,"March 10, 2017","UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore - Long Island Jewish Hospital, Great Neck, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00086645"
584,"NCT02279680","Associative Memory in Adults With an Autism Spectrum Disorder","MEM-T2A","Unknown status","No Results Available","Autistic Disorder","Device: Electroencephalography|Behavioral: Neuropsychological assesments","The associative memory index|theta and gamma oscillations during the associative memory task","University Hospital, Caen","All","18 Years to 30 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2013-AO1800-45","June 2014","December 2015","December 2016","October 31, 2014",,"October 31, 2014","UMR1077 Inserm/EPHE/UCBN, Caen, France",,"https://ClinicalTrials.gov/show/NCT02279680"
585,"NCT03487770","Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder",,"Completed","No Results Available","Autistic Disorder","Drug: Aripiprazole Oral Solution|Drug: Placebo Oral Solution","Changes from Baseline to Week 8 (or endpoint) in the ABC-I score|Clinician-rated CGI-I score at Week 8 (or endpoint)|Change in ABC subscale scores from Baseline to Week 8 (or endpoint)|Response Rate at Week 8 (or endpoint) (or endpoint)","Otsuka Beijing Research Institute","All","6 Years to 17 Years   (Child)","Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","031-403-00106","April 9, 2018","April 21, 2020","April 21, 2020","April 4, 2018",,"December 29, 2020","6th affiliated hospital, Peking University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03487770"
586,"NCT00692315","Treating Oxidative Stress in Children With Autism",,"Completed","No Results Available","Autistic Disorder","Drug: Methylcobalamin (methylB12)","Glutathione redox status (GSH/GSSG)|Vineland Adaptive Behavior Scales","Arkansas Children's Hospital Research Institute","All","3 Years to 7 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","28839","September 2006","June 2007","December 2007","June 6, 2008",,"April 15, 2016","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00692315"
587,"NCT02225808","Neural Mechanisms of CBT for Anxiety in Autism (Open Pilot Study)",,"Completed","No Results Available","Autism|Autism Spectrum Disorder|Anxiety","Behavioral: CBT for anxiety in autism","functional magnetic resonance imaging (fMRI)|Multidimensional anxiety scale for children (MASC)|Pediatric Anxiety Rating Scale (PARS)","Yale University","All","8 Years to 14 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1211011144","August 2014","December 2016","December 2016","August 26, 2014",,"January 14, 2020","Yale School of Medicine, Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02225808"
588,"NCT00787111","Extended Management and Measurement of Autism","EMMA","Terminated","No Results Available","Autistic Disorder","Drug: Fluoxetine (prozac)","Safety Outcomes: Laboratory determinations, Urine drugs of abuse tests,Vital Signs,Physical Examinations, Adverse Events/Serious Adverse Events, Clinical Global Impression of Severity (CGI-S AD)","Neuropharm|Autism Speaks","All","5 Years to 18 Years   (Child, Adult)","Phase 3","128","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPL-2008-4-AUTUS-005","November 2008","April 2009","April 2009","November 7, 2008",,"February 23, 2010","Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00787111"
589,"NCT01977248","Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12","SMART","Completed","No Results Available","Autism Spectrum Disorder|Autistic Disorder","Behavioral: Sensorimotor Affect Relationship-based Therapy (SMART)","Pervasive Developmental Disorder Behavior Inventory (PDDBI)","Nationwide Children's Hospital","All","2 Years to 12 Years   (Child)","Not Applicable","37","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB13-00460","October 2013","December 2014","December 2014","November 6, 2013",,"February 4, 2015","Nationwide Children's Hospital Hilliard Close to Home, Hilliard, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01977248"
590,"NCT03982888","DBS in Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Self-Injurious Behavior","Procedure: Deep Brain Stimulation|Device: DBS","Changes in repetitive behaviour|Changes in self-injurious behaviour|Changes in abberant behaviour|Changes in obsessive-compulsive thoughts|Changes in quality of life|Changes in physical brain abnormalities|Changes in metabolic brain abnormalities|Changes in activity|Type of adverse events reported in caregiver logs|Changes in number of complications pre and post intervention will be compared.","The Hospital for Sick Children","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB1000060282","August 14, 2019","August 14, 2021","August 14, 2022","June 12, 2019",,"March 1, 2021","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03982888"
591,"NCT00954213","A Study of a Developmental,Individual-Difference,Relationship-Bases/Floortime Intervention for Children With Autistic","DIR","Completed","No Results Available","Autism Spectrum Disorders","Behavioral: DIR/Floortime parent intervention","The Functional Emotional Assessment Scale (FEAS) Ratings (the child part)|The Childhood Autism Rating Scale (CARS) Clinical rating of the children (6 point scale related to Greenspan's six Functional Development Level -FDL) Satisfaction of the effectiveness of the intervention of their child (Six-point Likert scale)","Mahidol University","All","2 Years to 6 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206/2551(EC1)","May 2008","March 2010","June 2010","August 7, 2009",,"July 26, 2010","Kingkaew Pajareya, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00954213"
592,"NCT00161135","Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders",,"Completed","No Results Available","Autism|Developmental Disabilities",,,"UMC Utrecht","All","7 Years to 24 Years   (Child, Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","WOM 98/261","January 1999",,,"September 12, 2005",,"April 20, 2007","Dept. of Child and Adolescent Psychiatry, UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00161135"
593,"NCT02423499","Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder (REMBAU)","REMBAU","Recruiting","No Results Available","Autism Spectrum Disorder|Bipolar Disorder",,"Physiological emotional response during emotion elicitation in a laboratory session (Pupil size measured by eye tracking, heart rate, electrodermal response, breath rate) during emotion elicitation in a laboratory session|Subjective emotional response during emotion elicitation in a laboratory session|Facial emotional response during emotion elicitation in a laboratory session|Experience sampling method in real life during a week (emotions, activities, social context, burden)|Physiological emotional response in real life (heart rate, electrodermal response, breath rate, actimetry)","University Hospital, Tours","All","18 Years to 50 Years   (Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PHAO13-ML/REMBAU|2014-A00431-46","May 19, 2015","May 26, 2021","May 26, 2021","April 22, 2015",,"May 12, 2021","LEMAIRE, Tours, France",,"https://ClinicalTrials.gov/show/NCT02423499"
594,"NCT01535508","Open Label Clinical Trial of Vitamin D in Children With Autism",,"Completed","No Results Available","Autism|Vitamin D Deficiency","Drug: Liquid Vitamin D","Clinical Global Impression Scale - Improvement (CGI-I)","University of California, San Francisco","All","3 Years to 8 Years   (Child)","Phase 2|Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VitD11-06899","February 2012","September 2015","December 2015","February 17, 2012",,"October 9, 2019","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01535508"
595,"NCT00198107","Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism",,"Completed","Has Results","Autistic Disorder","Drug: Aripiprazole|Drug: Placebo|Drug: D-cycloserine","Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase|Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase|Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8|Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8|Mean Social Reciprocity Scale (SRS) Total Score, Week 8","Indiana University|National Institute of Mental Health (NIMH)","All","5 Years to 17 Years   (Child)","Phase 3","81","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH072961|DSIR 82-SEDR","September 2005","September 2011","September 2011","September 20, 2005","March 29, 2019","April 9, 2019","Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00198107"
596,"NCT03162445","Bone Mass Accrual in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Bone Diseases, Developmental",,"Bone Mineral Density","Massachusetts General Hospital","Male","8 Years to 17 Years   (Child)",,"49","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2009P002422","January 11, 2010","January 2016","January 2016","May 22, 2017",,"May 22, 2017",,,"https://ClinicalTrials.gov/show/NCT03162445"
597,"NCT04980677","A Smart Toy for Motor Function and Early Assessment of Children With Possible Autism","Tangiball","Not yet recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Device: Tangiball","Accelerometer outputs|User Experience Questionnaire|""Hands-On"" assessment tool","Sussex Community NHS Foundation Trust|National Institute for Health Research, United Kingdom|Brighton & Sussex Medical School|Nottingham Trent University|University of Cambridge|Council for Disabled Children|Autistica","All","2 Years to 5 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","SCFT v1.0_Tangiball_29/04/2021","November 1, 2021","August 2022","August 2022","July 28, 2021",,"September 22, 2021","Sussex Community NHS Foundation Trust, Brighton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04980677"
598,"NCT02300597","Internet-based Support for Young People With ADHD and Autism - a Controlled Study",,"Completed","No Results Available","ADHD|Autism Spectrum Disorders","Other: Internet based support and coaching","QoL|Self esteem|Sense of coherence|Anxiety and depressive symptoms|Depressive symptoms","Göteborg University|Södra Älvsborg Hospital|Habilitation Services in Skaraborg, Skövde","All","15 Years to 30 Years   (Child, Adult)","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBSC-2","September 2010","June 2015","June 2015","November 25, 2014",,"May 21, 2019","Department of Psychiatry and Neurochemistry, Institute of Neurosceince and Physiology, Gothenburg, Sweden",,"https://ClinicalTrials.gov/show/NCT02300597"
599,"NCT02222285","An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Autistic Disorder","Other: Medical Food : Vayarin_005|Other: Placebo","Aberrant Behavior Checklist will be used to asses Autism spectrum symptoms|Clinical Global Impression of Severity assesment|Clinical Global Impression of Improvement assesment|Conners Rating Scale questionnaire|Behavior Rating Inventory of Executive function|Child Health Questionnaire|Caregiver Strain Questionnaire|Adverse events monitoring","Enzymotec","All","6 Years to 17 Years   (Child)","Not Applicable","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Vayarin_005","August 2014","May 2017","October 2017","August 21, 2014",,"April 11, 2018","Institute of Neurology and Neurosurgery at St. Barnabas, Livingston, New Jersey, United States|Spectrum Neuroscience and Treatment Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02222285"
600,"NCT04450641","Piloting a Mobile Game for Behavioral Therapy",,"Completed","No Results Available","Autism Spectrum Disorder|Autism","Other: GuessWhat Mobile Application","Change in parent reported social responsiveness from week 0 to week 4|Change in parent reported socialization subscale scores of the Vineland Adaptive Behavior Scales,2nd Edition (VABS-II) from baseline to week 4|GuessWhat App Usage Data|Parent reported feedback|Change in parent reported communication subscale scores of the Vineland Adaptive Behavior Scales,2nd Edition (VABS-II) from baseline to week 4","Stanford University","All","3 Years to 12 Years   (Child)","Not Applicable","186","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","39562","October 1, 2019","December 1, 2020","December 31, 2020","June 29, 2020",,"February 3, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04450641"
601,"NCT04326231","Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: Usability assessment of Cognoa ASD Therapeutic Device","Usability assessment of Cognoa ASD Therapeutic Device","Cognoa, Inc.","All","3 Years to 8 Years   (Child)","Not Applicable","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO-003","March 17, 2020","July 31, 2020","July 31, 2020","March 30, 2020",,"March 31, 2020","Cognoa, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04326231"
602,"NCT01230359","Early Nutritional Intervention in Patients With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders|Stable Clinical Condition in the Last 3 Months","Dietary Supplement: Pyridoxine hydrochloride|Other: Tang orange powder","Measurement of improvement in blood parameters|Developmental assessments for ASD","Hamad Medical Corporation|Qatar University|Heidelberg University","All","2 Years to 10 Years   (Child)","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","8225/08","April 2010","July 2011","July 2011","October 29, 2010",,"July 19, 2011","Rumailah Hospital, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT01230359"
603,"NCT04319640","Cognitive Behaviour Therapy for Sleep Problems in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder|Cognitive Behaviour Therapy","Behavioral: Cognitive behaviour therapy for insomnia|Behavioral: psychoeducation for ASD","congnitive-neural outcomes|ADOS-2|Sleep diaries by using Actigraphy","Shanghai Jiao Tong University School of Medicine","All","24 Months to 59 Months   (Child)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SCMCIRB-K2018040","March 1, 2019","September 1, 2020","December 31, 2020","March 24, 2020",,"March 24, 2020","shanghai children's medicial center affiliated shanghai jiaotong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04319640"
604,"NCT04675580","Telehealth Language Intervention for Children With Autism Ages 2-4 Years",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Toy Talk","Change in number of unique combinations of subjects and verbs - caregiver|Change in number of unique combinations of subjects and verbs - child|Change in caregiver mean length of utterance|Change in child mean length of utterance|Change in Brief Observation of Social Communication Change (BOSCC) scores|Change in scores on the Observation of Spontaneous Expressive Language (OSEL) - baseline|Change in scores on the Vineland-3","Weill Medical College of Cornell University","All","2 Years to 4 Years   (Child)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","21-03023432|19-07020518","December 23, 2020","January 1, 2022","January 1, 2022","December 19, 2020",,"July 22, 2021","Center for Autism and the Developing Brain/New York-Presbyterian Hospital, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT04675580"
605,"NCT02903030","Probiotics for Quality of Life in Autism Spectrum Disorders",,"Completed","Has Results","Autism Spectrum Disorders|Anxiety","Drug: Maltose (placebo)|Drug: Visbiome Extra Strength","Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8|Change in Target Symptom Rating From Baseline at Week 8|Change in Parent Anxiety Checklist--ASD From Baseline at Week 8|Change in The Aberrant Behavior Checklist (ABC) From Baseline at Week 8|Change in Social Responsiveness Scale (SRS) From Baseline at Week 8|Children's Sleep Habits Questionnaire (CSHQ) at Week 8|Change in The Parenting Stress Index Short Form (PSI)","Ohio State University|Autism Treatment Network|Autism Speaks","All","3 Years to 12 Years   (Child)","Early Phase 1","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016H0174","August 2016","December 1, 2017","December 1, 2017","September 16, 2016","February 5, 2020","February 5, 2020","Ohio State University Wexner Medical Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02903030/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02903030"
606,"NCT03323931","The Efficacy of Robot-enhanced Therapy for Children With Autism Spectrum Disorders","DREAM-RCT","Completed","No Results Available","Autistic Disorders Spectrum","Behavioral: (2) robot--enhanced intervention|Behavioral: (1) discrete trial training / cognitive-behavior therapy","Changes in Imitation skills ratings|Changes in Joint-attention skills ratings|Changes in Turn-taking skills ratings|Changes in Engagement in the task ratings|Changes in Verbal utterances ratings|Changes in Performance in sharing information task|Changes in Performance in sorting in categories task|Performance in continuing repetitive patterns task","Babes-Bolyai University|University of Skövde|Vrije Universiteit Brussel|University of Plymouth|University of Portsmouth|De Montfort University|SoftBank Robotics","All","3 Years to 6 Years   (Child)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","30664/10.02.2017","March 1, 2017","December 31, 2018","December 31, 2018","October 27, 2017",,"May 14, 2019","Babes-Bolyai University Psychological Clinic, Cluj-Napoca, Romania",,"https://ClinicalTrials.gov/show/NCT03323931"
607,"NCT03279471","Specifying and Treating Anxiety in Autism Research","STAAR","Recruiting","No Results Available","Autism Spectrum Disorder|Anxiety","Drug: Sertraline|Behavioral: CBT/BIACA|Drug: Placebo","Change in Pediatric Anxiety Rating Scale","University of California, Davis","All","8 Years to 14 Years   (Child)","Phase 2","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","1097281","October 1, 2017","February 15, 2022","September 14, 2022","September 12, 2017",,"January 13, 2021","UC Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03279471"
608,"NCT00027404","Study of Fluoxetine in Adults With Autistic Disorder",,"Completed","No Results Available","Autistic Disorder","Drug: Fluoxetine",,"Icahn School of Medicine at Mount Sinai|FDA Office of Orphan Products Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","FD-R-2026-01|FD-R-002026-01","September 2001",,"August 2005","December 7, 2001",,"March 25, 2015","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00027404"
609,"NCT03099239","hCT-MSCs for Children With Autism Spectrum Disorder (ASD)","hCT-MSCs","Completed","No Results Available","Autism|Autism Spectrum Disorder|ASD","Biological: hCT-MSC infusion","Incidence of Infusion reactions|Incidence of Infections","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","2 Years to 11 Years   (Child)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00079421","June 6, 2017","June 10, 2019","June 10, 2019","April 4, 2017",,"December 3, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03099239"
610,"NCT02813564","Cognitive Training in Children With ASD",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Cognitive Assessment & Video-game INtervention Solutions (CAVINS)","The Dimensional Change Card Sorting task (DCCS): Measuring change in mental flexibility|The Go/NoGo task: Measuring change in inhibitory control|The preschool version of the Behavior Rating Inventory of Executive Function (BRIEF-P): Measuring change in everyday executive functions|Flanker Test: Measuring change in selective attention|Aberrant Behaviour Checklist (ABC): Measuring change in behaviour|Tower of Hanoi: Measuring change in planning ability|The Stroop-like day-night: Measuring change in inhibitory control|Sequential Order (SO): Measuring change in reasoning ability|The Peabody Picture Vocabulary Test (PPVT): Measuring change in communication abilities","McMaster University","All","3 Years to 7 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0323","March 2, 2018","March 1, 2019","March 1, 2020","June 27, 2016",,"August 21, 2018","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02813564"
611,"NCT05017779","A Hybrid Effectiveness-implementation Trial of a School Based Executive Function Treatment for Transition Age Youth With Autism",,"Not yet recruiting","No Results Available","Executive Dysfunction|Autism Spectrum Disorder|Adolescent Behavior","Behavioral: Unstuck & On Target: High School|Other: Treatment as Usual","Classroom Behavior|Adaptive Behavior","Children's National Research Institute","All","14 Years to 22 Years   (Child, Adult)","Not Applicable","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH124772","August 27, 2021","October 30, 2024","November 30, 2024","August 24, 2021",,"August 24, 2021",,,"https://ClinicalTrials.gov/show/NCT05017779"
612,"NCT04049981","Investigation of Mechanisms of Action in Superpower Glass",,"Suspended","No Results Available","Autism Spectrum Disorder|Autism","Device: Superpower Glass","Change in socialization subscale scores of the Vineland Adaptive Behavior Scales,3rd Edition (VABS-III) from baseline to week 4.|Change in Parent Rated Social Responsiveness Scale 2 (SRS-2) from baseline to week 4|Changes in Parent Self Agency Measure scores from Baseline to Week 4|Change in ASD symptoms as measured by Brief Observation of Social Communication Change (BOSCC) from baseline to week 4","Stanford University","All","4 Years to 8 Years   (Child)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","34059|PHIND Dream Team Award|SPARK Pilot Program","September 4, 2019","October 1, 2021","December 1, 2021","August 8, 2019",,"February 4, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04049981"
613,"NCT02725619","CBT for Anxiety in Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Anxiety","Behavioral: CBT|Behavioral: PST","Pediatric Anxiety Rating Scale (PARS)|Clinical Global Impression - Improvement (CGI-I) scale|blood oxygenation level dependent signal (BOLD) during down-regulation versus passive viewing of affective images.|blood oxygenation level dependent signal (BOLD) during emotional face perception task","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 14 Years   (Child)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1211011144B|1R01HD083881-01A1","April 2016","December 2021","December 2021","April 1, 2016",,"March 2, 2021","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02725619"
614,"NCT04166591","Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Overheard Speech|Behavioral: Addressed Speech","Number of children who select the target object by touching, pointing, or grasping on each trial|Number of children who select the target object by touching, pointing, or grasping|Proportion of time during which children's eye gaze is directed toward the target object","New York University|Emerson College","All","18 Months to 71 Months   (Child)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","R01DC017131","December 1, 2020","February 2025","February 2025","November 18, 2019",,"March 3, 2021","Emerson College, Boston, Massachusetts, United States|New York University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04166591"
615,"NCT02591446","Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder|Intellectual Disability",,"Motor Evoked Potential","Rhode Island Hospital|Nancy Lurie Marks Family Foundation|Bradley Hospital","All","6 Years to 45 Years   (Child, Adult)",,"48","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","413114","October 2014","August 7, 2017","August 7, 2017","October 29, 2015",,"August 10, 2017","Bradley Hospital, East Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02591446"
616,"NCT01661855","A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD","RILISE","Completed","No Results Available","Autism Spectrum Disorders","Drug: Riluzole|Drug: Placebo","Efficacy of riluzole vs. placebo on measures of social function|Efficacy of riluzole vs. placebo on measures of repetitive behaviors|Safety and tolerability of riluzole in children and adolescents with ASD","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|The Hospital for Sick Children|University of Western Ontario, Canada|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.","All","6 Years to 17 Years   (Child)","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RILISE-07-2013","September 2013","September 2015","October 2015","August 10, 2012",,"March 20, 2017","Offord Centre for Child Studies, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01661855"
617,"NCT03592654","Pilot Study: A Telehealth Intervention for Caregivers of Infants With Early Signs of Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Developmental Delay","Behavioral: infant telehelp","Child Behaviors Targeted by Intervention|Autism Observation Scale for Infants|Ages and Stages Questionnaires, 3rd Edition|Individual Growth and Development Indices|Vineland Adaptive Behavior Scales, 2nd edition|Parent Satisfaction Rating|Working Alliance Scale for Interventions with Children|Caregiver Fidelity of Treatment Implementation","University of California, Davis","All","5 Months to 12 Months   (Child)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1249018","July 1, 2018","September 18, 2019","October 1, 2019","July 19, 2018",,"September 4, 2020","MIND institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03592654"
618,"NCT03984513","Daily Living Skills Intervention for 9th and 10th Graders With Autism Spectrum Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Surviving and Thriving in the Real World|Behavioral: Program for the Education and Enrichment of Relational Skills","Vineland Adaptive Behavior Scales, 3rd Edition","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CIN-DUNCAN-2018-5606|1K23HD094855-01A1","September 25, 2018","February 28, 2022","December 31, 2022","June 13, 2019",,"June 23, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03984513"
619,"NCT02278328","MEG Study of Acute STX209 Effects in ASD",,"Completed","Has Results","Autism Disorder","Drug: STX209 (15mg)|Drug: placebo|Drug: STX209 (30mg)","M50 Latency (Left Hemisphere)|M50 Latency (Right Hemisphere)|Steady State Inter Trial Coherence (Left Hemisphere)|Steady State Inter Trial Coherence (Right Hemisphere)|GABA (Left Hemisphere)","Timothy Roberts|Simons Foundation|Clinical Research Associates, LLC|Children's Hospital of Philadelphia","Male","14 Years to 17 Years   (Child)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14-010857","February 2016","July 30, 2018","September 27, 2019","October 30, 2014","October 21, 2019","October 21, 2019","Children's Hospital of Phladelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02278328/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02278328"
620,"NCT03883139","PRISM Intervention Study",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: JASPER|Behavioral: DTT (Discrete Trial Training)","Change of spontaneous utterances (SCU) from the Language Sample throughout the study.|Change in Joint Engagement on the Caregiver-Child Play Interaction (CCX) over the course of the study.|Change in receptive language using the Preschool Language Scales-5 (PLS-5) throughout the study.|Presence of word combinations in the Language Sample over the course of the study.","University of California, Los Angeles","All","42 Months to 59 Months   (Child)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19-000193","March 1, 2021","June 30, 2024","June 30, 2025","March 20, 2019",,"September 27, 2021","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03883139"
621,"NCT02995564","The Multi-Media Social Skills Project for Adults",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: social skills therapy","Social Responsiveness Scale - Adult|Video recording of Social Interaction|Achenbach Adult Behavior Checklist|Social and Emotional Loneliness Scale for Adults (SELSA)|Social Skills Inventory (SSI)|Social Phobia Inventory (SPIN)|Empathy Quotient|Achenbach Adult Behavior Checklist - Self Report|Social Fluency Assessment","Milton S. Hershey Medical Center|Pennsylvania Bureau of Autism Services","All","18 Years to 35 Years   (Adult)","Not Applicable","199","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","41078EP","July 2013","April 9, 2018","April 9, 2018","December 16, 2016",,"March 13, 2019","The Pennsylvania Psychiatric Institute Northeast Drive Clinic, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02995564"
622,"NCT01985022","Changing Developmental Trajectories Through Early Treatment",,"Recruiting","No Results Available","Autism Spectrum Disorders","Behavioral: PII with IES|Behavioral: IES","Child's social communication|Child's Autism Symptoms|Child's Developmental Level|Child's Adaptive Behavior|Parent Report","Emory University|National Institute of Mental Health (NIMH)","All","9 Months to 24 Months   (Child)","Not Applicable","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00064779|P50MH100029-02","May 2013","July 2022","December 2022","November 15, 2013",,"June 10, 2021","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01985022"
623,"NCT00760812","Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders",,"Completed","No Results Available","Autistic Disorder","Behavioral: Early Social Interaction Project- PII|Behavioral: Early Social Interaction Project- IES","Child measures of autism symptoms, social communication, developmental level, and adaptive behavior|Parent report measures of family functioning, daily hassles, and treatment satisfaction","Florida State University|National Institute of Mental Health (NIMH)","All","16 Months to 20 Months   (Child)","Not Applicable","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH077730|1R01MH077730-01A2|1R01MH078165-01A2|DDTR B2-MBA","April 2007","May 2013","January 2014","September 26, 2008",,"February 20, 2014","Florida State University, Tallahassee, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00760812"
624,"NCT03721913","Participation-based Intervention on Community Participation and Parent Empowerment for Children With ASD","PBI-ASD","Completed","No Results Available","Autism Spectrum Disorder","Other: participation-based intervention","Change in the Canadian Occupational Performance Measure (COPM) performance and satisfaction scores|Change in the Goal Attainment Scaling (GAS) scores|Parent Empowerment and Efficacy Measure (PEEM)|Family Quality of Life (FaQoL)|Chinese version of Family-Professional Partnership Scale (FPPS-P-C)","Chang Gung University|Chang Gung Memorial Hospital","All","6 Years to 10 Years   (Child)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201800429A3","October 23, 2018","December 30, 2020","December 30, 2020","October 26, 2018",,"August 4, 2021","Chang Gung University, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03721913"
625,"NCT03337035","Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children",,"Completed","No Results Available","Autism Spectrum Disorder","Drug: intranasal oxytocin|Dietary Supplement: oral probiotics|Dietary Supplement: oral placebo","Social Responsiveness Scale (SRS) Edition 2|Aberrant Behavior Checklist (ABC) Edition 2|Neuroinflammation and Oxytocin levels|structural MRI|Functional MRI (resting state)|Functional MRI (task based)|Autonomic indices 1|Autonomic indices 2|Autonomic indices 3|Autonomic indices 4|Autonomic indices 5|Microbiome|Eye tracking and Behavioral task (joint attention)|Eye tracking and behavioral task (emotion response)|Eye tracking and behavioral task (eye behavior)","Massachusetts General Hospital","All","3 Years to 25 Years   (Child, Adult)","Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2017P001667","December 1, 2018","October 2, 2019","October 2, 2019","November 8, 2017",,"March 4, 2020","Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03337035"
626,"NCT02719951","Glutaminergic Transmission in Autism : Molecular Imaging Exploration","TANGAU","Completed","No Results Available","Autism|Fragile-X Syndrome (FXS)|Healthy Volunteers","Drug: [18F]FPEB PET imaging|Other: Biological samples|Other: MRI","cerebral glutaminergic activity assessed by binding potential of [18F]FPEB|distribution volume of [18F]FPEB","University Hospital, Tours","Male","18 Years to 45 Years   (Adult)","Phase 1","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PRIA 14 FBB / TANGAU","April 2016","November 15, 2018","May 2019","March 25, 2016",,"June 11, 2019","CHU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02719951"
627,"NCT02361762","Gaming for Autism to Mold Executive Skills Project","GAMES","Completed","Has Results","Autism Spectrum Disorders","Behavioral: Computerized executive control training","Change Task - Stop Signal Reaction Time|Stroop Task (Difference in Percentage of Correct Responses for Congruent Minus Incongruent Trials)|Event-related Potentials Assessed During Child Attention Network Flanker Task|BRIEF Parent Survey (Global Executive Composite)|Backward Digit Span (Scaled Score)|Social Attribution Task (SAT) - Problem Solving Scale|Theory of Mind Composite: Perception Knowledge, Location Change False Belief, Unexpected-contents False Belief|TOM Test (Theory of Mind Test)|Social Skills Improvement System-Parent (SSIS) - Social Standard Score|Narrative Language Task|Performance on Hungry Donkey Task Assessed as Ratio of Safe to Risky Selections|Event-related Potentials Assessed During Cued Go/Nogo Task","Boston Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 11 Years   (Child)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P00014188|R00HD071966","February 2015","November 2017","November 2017","February 12, 2015","February 20, 2019","July 28, 2021","Boston Children's Hospital: Labs of Cognitive Neuroscience- Faja Lab, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02361762/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02361762"
628,"NCT03196713","Early Intervention, Supervision, Quality and Outcome in ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Early Intensive Behavioral Intervention","York Measure of Quality of Behavioural Intensive Intervention (YMQI)|Vineland Adaptive Behavior Scales (VABS)|Social Responsiveness Scale (SRS)","Karolinska Institutet","All","2 Years to 6 Years   (Child)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","EIBI Quality","April 1, 2013","August 31, 2017","October 27, 2017","June 23, 2017",,"August 15, 2018","KIND, CAP Research Center, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03196713"
629,"NCT02812368","Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder",,"Withdrawn","No Results Available","Autism Spectrum Disorder","Drug: Clonidine|Drug: Placebo (for clonidine)","Change in Children's Sleep Habits Questionnaire (CSHQ) Total Score","Ohio State University|Autism Treatment Network|Autism Intervention Research Network on Physical Health","All","6 Years to 14 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016H0181","August 2016","January 2017","January 2017","June 24, 2016",,"February 2, 2017","Ohio State University Nisonger Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02812368"
630,"NCT00352352","Use of Acupuncture In Children With Autistic Spectrum Disorder",,"Completed","No Results Available","Autism|Autistic Disorder","Procedure: Tongue Acupuncture (Procedure)","Ritvo-Freeman Real Life Scale (RFRLS) was conducted on both groups before (Week 0) and after (Week 8) acupuncture.|Functional Independence Measure for children (WeeFIM) consists of 18 questions concerning on the Functional Independence Measure for children, which was conducted on both groups before (Week 0) and after (Week 8) acupuncture.|Parental Stress Index (PSI) consists of child domain, parent domain and a total domain, which was conducted on both groups before (Week 0) and after (Week 8) acupuncture.|Clinical Global Impression Scale (CGIS) is a measure in a Likert scale of 0 - 7, which was conducted on both groups before (Week 0) and after (Week 8) acupuncture.","The University of Hong Kong","All","3 Years to 15 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","3469296479554546",,,,"July 14, 2006",,"July 14, 2006","Duchess of Kent of Children Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00352352"
631,"NCT00505830","Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ",,"Unknown status","No Results Available","Asperger Syndrome|Autism","Other: questionnaires",,"Groupe Francais d'Epidemiologie Psychiatrique|Joint Clinical Research Center","All","12 Years to 18 Years   (Child, Adult)",,"450","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","Autisme AQ","July 2007",,"July 2009","July 25, 2007",,"July 25, 2007","Centre Hospitalier Saint Jean de Dieu, Lyon, France",,"https://ClinicalTrials.gov/show/NCT00505830"
632,"NCT03020927","Therapist and Parent Delivered Reciprocal Imitation Training for Young Children With Autism Spectrum Disorder","ParentRIT","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Reciprocal Imitation Training (Therapist-Delivered)|Behavioral: Reciprocal Imitation Training (Therapist + Parent Delivered)","Unstructured Imitation Assessment (UIA)|Percentage of parent acts imitated during Parent-Child Play Interaction|Parenting Stress Index, 4th Edition|Motor Imitation Scales|Early Social Communication Scales|Proportion of time spent jointly engaged during Parent-Child Play Interaction","Ohio State University","All","24 Months to 60 Months   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015B0475","April 2016","December 2023","December 2023","January 13, 2017",,"January 14, 2021","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03020927"
633,"NCT00325572","Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism",,"Terminated","Has Results","Autism|Pervasive Developmental Disorder","Drug: oral zinc and vitamin C supplements|Other: oral Placebo","Copper/Zinc Ratio of Children With Autism Compared to Typically Developing Children Phase 2: Change in Copper/Zinc Ratio With Supplementation of Zinc and Vitamin C","Milton S. Hershey Medical Center|Thrasher Research Fund","All","3 Years to 8 Years   (Child)","Phase 1","89","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","23275","November 2006","December 2010","December 2011","May 15, 2006","July 17, 2019","July 17, 2019","Penn State Children's Hospital, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00325572"
634,"NCT00346736","Use of Acupuncture In Children With Autistic Spectrum Disorder",,"Completed","No Results Available","Autistic Disorder|Autism","Procedure: Acupuncture (Procedure)","Aberrant Behavioral Checklist (ABC) will be completed by parents and teachers at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Ritvo-Freeman Real LIfe Scale (RFRLS) will be completed by parents and teachers at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Functional Independence Measure for Children (WeeFIM) will be conducted by trained Research Assistant at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Pediatric Evaluation Disability Inventory (PEDI) will be completed by parents and teachers at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Leiter International Performance Scale-Revised will be conducted on patient by trained Research Assistant at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Reynell Language Developmental Scale will be conducted on patient by trained Research Assistant at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Symbolic Play Test will be conducted on patient by trained Research Assistant at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.|Clinical Global Impression Scale (CGIS) will be self administered by parent and by trained Research Assistant at Week 0, once during Week 6 to Week 7, and once during Week 14 to Week 15.","The University of Hong Kong","All","3 Years to 18 Years   (Child, Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","UW 04-096 T/418","May 2005","June 2006","March 2007","June 30, 2006",,"September 3, 2008","TWGHs Tung Wah Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00346736"
635,"NCT04218331","Boosting Language Outcomes of Minimally Verbal Children With ASD (BLOOM)","BLOOM","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: JASPER|Behavioral: PROMPT","Change in spontaneous socially communicative utterances (SCU) using the Elicitation of Language Samples for Analysis (ELSA).|Change in number of novel and distinct word root (NDWR), and presence of word combinations at age six based on the ELSA language sample.|Change in number of novel and distinct word root (NDWR) based on the Preschool Language Scales-5 (PLS-5).|Presence of word combinations at age six based on the Preschool Language Scales-5 (PLS-5)","University of California, Los Angeles|National Institutes of Health (NIH)","All","48 Months to 66 Months   (Child)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-000806","April 29, 2021","June 30, 2024","June 30, 2024","January 6, 2020",,"September 28, 2021","UCLA Semel Institute, Los Angeles, California, United States|UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04218331"
636,"NCT01745497","Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Insomnia","Drug: Ferrous sulfate|Drug: Placebo","Improvement in sleep onset|Changes inDay time behavior|Improvements in sleep maintenance insomnia","University of Colorado, Denver|Autism Treatment Network|Massachusetts General Hospital|The Emmes Company, LLC|Health Resources and Services Administration (HRSA)","All","2 Years to 10 Years   (Child)","Phase 2","24","Other|Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-0466","December 2012","August 2015","August 2015","December 10, 2012",,"August 3, 2020","Childrens Hospital Colorado, Aurora, Colorado, United States|University of Rochester, Rochester, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01745497"
637,"NCT04955093","Heart Rate Variability Biofeedback in Young People With Autism",,"Completed","No Results Available","Autistic Disorders Spectrum","Device: Biofeedback","Reduction in Anxiety Scale using Beck Youth Inventory|Any change in Heart rate variability (ideally key metrics increased)","University of Ulster|South Eastern Health and Social Care Trust","All","13 Years to 24 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRAS139122|15/NI/0255","May 30, 2016","August 9, 2017","August 9, 2017","July 8, 2021",,"July 8, 2021","South Eastern Health Trust, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04955093"
638,"NCT02707939","Observational Prospective Study on Behavioral Outcomes of Children With Autism Spectrum Disorder (ASD) in Comparison to Those Without Neurodevelopmental Diagnoses",,"Recruiting","No Results Available","Autism Spectrum Disorder|Anesthesia","Other: Observation","Incidence of postoperative behavioral changes in the participants","Boston Children's Hospital","All","2 Years to 17 Years   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00021473","February 2016","December 2021","May 2022","March 14, 2016",,"January 28, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02707939"
639,"NCT01541033","Biomarker of Children With Familial Autoimmune History",,"Completed","No Results Available","Autism|Children",,"Number of autistic participants with autoimmune markers|Identification of neuronal protein autoimmunity","Le Bonheur Children's Hospital|University of Tennessee Health Science Center","All","4 Years to 17 Years   (Child)",,"58","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","08-00206-XP","November 2009","May 2016","August 2016","February 29, 2012",,"August 19, 2016","LeBonheur Children's Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01541033"
640,"NCT01340092","Use of a Family Navigator in Families With Children Newly Diagnosed With Autism Spectrum Disorder",,"Completed","No Results Available","Autistic Disorder","Other: Family Navigator","Hours of Services|Receipt of adequate services|Time to Receipt of Services|Family Psychological Functioning","Boston Medical Center","All","15 Years to 64 Years   (Child, Adult)","Not Applicable","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","29964|HRSA R40MC19928-01-00","April 2011","May 2014","May 2014","April 22, 2011",,"April 25, 2016","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01340092"
641,"NCT05066906","Videogame-based Tool for Job Search and Executive Function Improvement in Adults With ASD",,"Withdrawn","No Results Available","Autism Spectrum Disorder","Device: Use of Identifor assessment tool and Companion app|Other: Referral to employment agencies","Rate of securing internship, part-time, or full-time positions|Level of satisfaction|Behavior Rating Inventory of Executive Function for Adults (BRIEF-A)","Stanford University","All","18 Years to 55 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","IRB-52313","May 2021","June 2021","July 2021","October 4, 2021",,"October 4, 2021",,,"https://ClinicalTrials.gov/show/NCT05066906"
642,"NCT04942522","Application of Probiotic PS128 in Children With ASD",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder","Biological: probiotics PS128|Drug: placebo (Microcrystalline cellulose )","change in Autism Diagnostic Observation Scale (ADOS)|change in Social Responsiveness Scale (SRS)|Change in Social Communication Questionnaire (SCQ)|Change in the Autism Behavior Checklist (ABC)|Change in the Childhood Autism Rating Scale (CARS)|Change in Gesell developmental scale|Change in frequency of child behavioral problems|Change in frequency of ASD symptoms|change in gastrointestinal symptoms among children with ASD|Cytokine Analysis|Evaluate changes of type, number and structural composition of gut microorganisms in children with ASD.","Yan Hao|Tongji Hospital","All","2 Years to 5 Years   (Child)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S313","June 6, 2021","June 6, 2023","October 6, 2023","June 28, 2021",,"June 28, 2021","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04942522"
643,"NCT05015439","Cannabidiol (CBD) in Adults With ASD",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: Cannabidiol|Drug: Placebo","Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist|Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale|Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Change in Clinical Global Impression Scale-Improvement (CGI)|Change in neuropsychiatric symptomatology as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Change in Waisman Activities of Daily Living scale|Change in Social Communication Questionnaire|Change in Mini Mental State Examination (MMSE)|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Subjective|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Informant|Change in Adverse Effects- Medication Side-Effects Questionnaire","Johns Hopkins University|Canopy Growth Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00267739","December 2021","May 2023","August 2023","August 20, 2021",,"September 16, 2021",,,"https://ClinicalTrials.gov/show/NCT05015439"
644,"NCT00355329","Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation",,"Completed","No Results Available","Autism|Autistic Disorder","Procedure: Tongue Acupuncture (Procedure)","Autism Treatment Evaluation Checklist (ATEC) consisting of 4 subscales before (Week 0) and after (Week 8) acupuncture|Reynell Language Developmental Scale (RLDS) before (Week 0) and after (Week 8) acupuncture|Symbolic Play Test (SPT) before (Week 0) and after (Week 8) acupuncture|Functional Independence Measure for children (WeeFIM) with 3 domains before (Week 0) and after (Week 8) acupuncture|Clinical Global Impression Scale (CGIS) before (Week 0) and after (Week 8) acupuncture|18F-fluorodeoxyglucose Positron Emission Tomography (PET) before (Week 0) and after (Week 8) acupuncture","The University of Hong Kong","All","3 Years to 16 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PET-001",,,,"July 21, 2006",,"October 20, 2006","Duchess of Kent of Children Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00355329"
645,"NCT04869540","Improving Transition Outcomes for Youth With ASD in a Medicaid Accountable Care Organization",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Other: Usual care|Other: 'Got Transition' toolkit and resources|Behavioral: PSE intervention","Baseline Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) ASD|6 months PEDI-CAT ASD|Social skills|Cognition|Parent Functioning and Depressive Symptoms assessed by SAS-SR|Parent Functioning and Depressive Symptoms assessed by QIDS|Family Empowerment|Perceived parental stress|Parental stress|Perceived youth stress|Parental coping strategies|Youth coping strategies|Vocational and Educational Activities|Health Care Transition Readiness and Family Perception of Health Care Integration using TRAQ|Health Care Transition Readiness and Family Perception of Health Care Integration using the Pediatric Integrated Care Survey (PICS)","Boston Medical Center|National Institute of Mental Health (NIMH)","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","H-41693|5K18MH120457","November 2021","June 2022","June 2022","May 3, 2021",,"August 25, 2021",,,"https://ClinicalTrials.gov/show/NCT04869540"
646,"NCT02548442","Children's Autism Metabolome Project","CAMP-01","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Developmental Disorder",,"Metabolites in plasma indicative of autism spectrum disorder.|Metabolites in plasma that are specific for subtypes of autism spectrum disorder","Stemina Biomarker Discovery, Inc.|National Institute of Mental Health (NIMH)|Nancy Lurie Marks Family Foundation","All","18 Months to 48 Months   (Child)",,"1102","Industry|NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAMP-01|R44MH107124-01","August 2015","January 2023","August 2023","September 14, 2015",,"June 29, 2020","Melmed Center, Scottsdale, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|UC David MIND Institute, Sacramento, California, United States|Lurie Center for Autism, Lexington, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02548442"
647,"NCT01078714","Efficiency of Bumetanide in Autistic Children","BUMEA","Completed","No Results Available","Autistics Children","Drug: bumetanide","Child Autism Rating Scale score|Clinical global impressions score|Repetitive end restricted behavior score|GRAM score","University Hospital, Brest","All","3 Years to 10 Years   (Child)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RB09-017","March 2010","June 2011","June 2011","March 2, 2010",,"December 21, 2011","Lemonnier, Brest, France|Chevreuil, Rennes, France|DUPIN, Vannes, France",,"https://ClinicalTrials.gov/show/NCT01078714"
648,"NCT02276534","SENSE Theatre Intervention for Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: SENSE Theatre|Behavioral: Delayed Intervention","NEPSY Memory for faces|Measurement of Salivary Cortisol levels|Event Related Potentials (ERP) incidental memory task|Social Responsiveness Scale|Peer Interaction Playground Paradigm|Adaptive Behavior Assessment System|Parenting Stress Index|Clinical Evaluation of Fundamentals Recalling Sentences subtest|Peabody Picture Vocabulary Test","Vanderbilt University|National Institute of Mental Health (NIMH)|Vanderbilt University Medical Center","All","8 Years to 16 Years   (Child)","Not Applicable","136","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110082","August 2014","May 2017","May 2017","October 28, 2014",,"June 14, 2017","Vanderbilt Kennedy Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02276534"
649,"NCT04729127","A Trial of Project ImPACT in Early Intervention",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Project ImPACT","Vineland Adaptive Behavior Scales 3rd Edition|Brief Observation of Social Communication Change (BOSCC)|Early Intervention Parenting Self-Efficacy Scale (EIPSES)|Parenting Interactions with Children: Checklist of Observations Linked to Outcomes (PICCOLO)|Project ImPACT Intervention Fidelity Checklist|Project ImPACT Coaching Fidelity Checklist","University of Pennsylvania|Michigan State University","All","up to 30 Months   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842506","June 11, 2020","February 2022","August 2022","January 28, 2021",,"October 6, 2021","Center for Mental Health, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04729127"
650,"NCT03700190","The Predictors for Activity and Participation in Children With ASD: A Follow-up Study",,"Recruiting","No Results Available","Autism Spectrum Disorder",,"Change from baseline of general developmental for Healthy child and patients with Autism Spectrum Disorder in 6 months and 12 months|Change from baseline of body function & structures in 6 months and 12 months|Change from baseline of Sensory and Perceptual function in 6 months and 12 months|Change from baseline of Participation in 6 months and 12 months|Change from baseline of Visual Perception in 6 months and 12 months|Change from baseline of lower extremity function & structures in 6 months and 12 months|Change from baseline of activities in 6 months and 12 months|Change from baseline of Quality of Life in 6 months and 12 months|Change from baseline of Personal & Environment factor in 6 months and 12 months|Change from baseline of Rehabilitation & community service factor in 6 months and 12 months|Change from baseline of Social Responsiveness Scale in 6 months and 12 months|Change from baseline of facial expression in 6 months and 12 months|Change from baseline of Clancy Behavior Scale in 6 months and 12 months|Change from baseline of Theory of Mind Inventory-2 in 6 months and 12 months|Change from baseline of Childhood Autism Rating Scale II in 6 months and 12 months|Change from baseline of Childhood Asperger Syndrome Test in 6 months and 12 months","Chang Gung Memorial Hospital","All","2 Years to 18 Years   (Child, Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201601949B0","August 1, 2017","July 31, 2022","October 31, 2022","October 9, 2018",,"November 27, 2020","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03700190"
651,"NCT00352248","Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder",,"Completed","No Results Available","Autistic Disorder|Autism","Procedure: Tongue Acupuncture (Procedure)","Griffiths Mental Developmental Scale (GMDS) was conducted before (at Week 0) and after (at Week 9) acupuncture.|Ritvo-Freeman Real Life Scale (RFRLS) was conducted before (at Week 0) and after (at Week 9) acupuncture.|Reynell Language Developmental Scale (RLDS) was conducted before (at Week 0) and after (at Week 9) acupuncture.|Symbolic Play Test (SPT) was conducted before (at Week 0) and after (at Week 9) acupuncture.|Functional Independence Measure for children (WeeFIM) was conducted before (at Week 0) and after (at Week 9) acupuncture.","The University of Hong Kong","All","3 Years to 11 Years   (Child)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","9608944339555027",,,,"July 14, 2006",,"July 14, 2006","Duchess of Kent of Children Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00352248"
652,"NCT04467073","Stepped-care Telehealth for Young Children With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Online RIT","Change from Baseline RIT Parent Fidelity Form (RIT-PFF) Score at 15 weeks|Change from Baseline Unstructured Imitation Assessment (UIA) Score at 15 weeks|Change from Baseline Early Intervention Parenting Self-Efficacy Scale (EIPSES) Score at 15 weeks|Change from Baseline Social Communication Checklist (SCC) Score at 15 weeks|Change from Baseline Beach Center Family Quality of Life Scale (FQOL) Score at 15 weeks","Rush University Medical Center","All","16 Months to 60 Months   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15100203","January 10, 2016","August 30, 2017","August 30, 2017","July 10, 2020",,"July 10, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04467073"
653,"NCT00549731","Participant Database for Autism Research Studies",,"Recruiting","No Results Available","Autism Spectrum Disorder",,,"Massachusetts General Hospital|National Institute of Mental Health (NIMH)|National Institutes of Health (NIH)","All","14 Years to 32 Years   (Child, Adult)",,"120","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","2007-P-000062|5R01MH117998","June 2013","June 2023","June 2023","October 26, 2007",,"September 18, 2020","Martinos Center of Biomedical Imaging, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00549731"
654,"NCT02457169","Addressing Systemic Health Disparities in Early Identification and Treatment of Autism Spectrum Disorder (ASD): ABCD Project",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Parent Preschool Engagement intervention|Behavioral: Attention Control","parental school involvement|parent-teacher relationship quality|parent-special education engagement","University of Massachusetts, Boston|Tufts Medical Center|Northeastern University|National Institute of Mental Health (NIMH)","All","14 Months to 3 Years   (Child)","Not Applicable","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UMassBoston|1R01MH104400-01","September 2014","April 2018","April 2018","May 29, 2015",,"December 4, 2018",,,"https://ClinicalTrials.gov/show/NCT02457169"
655,"NCT01784263","Schema, Emotion, and Behavior Therapy for Children","SEBASTIEN","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Individual Cognitive Behavioral Therapy|Behavioral: Standard Community Treatment","Playground Observation of Peer Engagement scale","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","9 Years to 13 Years   (Child)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","11-002061|1R01MH094391-01A1","March 1, 2012","February 1, 2017","September 1, 2017","February 5, 2013",,"September 7, 2018","Jeffrey Wood, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01784263"
656,"NCT04312932","Fatty Acid Supplementation in Children With ASD (Study 2)","Omega Heroes","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo","Pervasive Developmental Disorder Behavior Inventory (PDDBI) - Autism Composite|Vineland Adaptive Behavior Scales 2nd ed. (modified timeframe of 90 days)|Pervasive Developmental Disorder (PDD) Behavior Inventory (PDDBI) - Aggressiveness Problems|Preschool Language Scales - 5 (PLS-5)|Childhood Autism Rating Scale (CARS2) (2nd ed.)|Autism Impact Measure","Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital","All","2 Years to 6 Years   (Child)","Phase 2","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB17-00517-2","October 15, 2021","October 31, 2023","January 31, 2024","March 18, 2020",,"September 9, 2021","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04312932"
657,"NCT02139514","Virtual Reality Social Cognition Training for Adults With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Virtual Reality Social Cognition Training","functional magnetic resonance imaging (MRI)","Yale University|University of Texas","Male","18 Years to 40 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1211011083","January 2013","June 2016","June 2016","May 15, 2014",,"October 26, 2016","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02139514"
658,"NCT04545606","Targeting Insomnia in School Aged Children With Autism Spectrum Disorder","RECHArge","Recruiting","No Results Available","Insomnia Chronic|Autism Spectrum Disorder","Behavioral: In-Person CBT for insomnia in children with autism|Behavioral: Remote CBT for insomnia in children with autism|Behavioral: Remote sleep hygiene and related education (SHARE) for insomnia in children with autism","Baseline Average Objective Sleep Efficiency for the child|Change in Average Objective Sleep Efficiency for the child from baseline to immediately after the intervention|Change in Average Objective Sleep Efficiency for the child from baseline to 6 months|Change in Average Objective Sleep Efficiency for the child from baseline to 12 months|Baseline Average Bed/Waketime Variability for the child|Change in Average Bed/Waketime Variability for the child from baseline to immediately after the intervention|Change in Average Bed/Waketime Variability for the child from baseline to 6 months|Change in Average Bed/Waketime Variability for the child from baseline to 12 months|Baseline Average RMSDNN (root mean squared st. dev. of N-N intervals) for the child|Change in Average RMSDNN (root mean squared st. dev. of N-N intervals) for the child from baseline to immediately after the intervention|Change in Average RMSDNN (root mean squared st. dev. of N-N intervals) for the child from baseline to 6 months|Change in Average RMSDNN (root mean squared st. dev. of N-N intervals) for the child from baseline to 12 months|Baseline Average Objective Total Sleep Time for the parent|Change in Average Objective Total Sleep Time for the parent from baseline to immediately after the intervention|Change in Average Objective Total Sleep Time for the parent from baseline to 6 months|Change in Average Objective Total Sleep Time for the parent from baseline to 12 months|Baseline Aberrant Behavior Checklist (ABC) for the child|Aberrant Behavior Checklist (ABC) for the child immediately after the intervention|Aberrant Behavior Checklist (ABC) for the child at 6 months|Aberrant Behavior Checklist (ABC) for the child at 12 months|Baseline Conners' Continuous Performance Test - 3rd Edition (CCPT-3) for a child (ages 8+)|Conners' Continuous Performance Test - 3rd Edition (CCPT-3) for a child (ages 8+) immediately after the intervention|Conners' Continuous Performance Test - 3rd Edition (CCPT-3) for a child (ages 8+) at 6 months|Conners' Continuous Performance Test - 3rd Edition (CCPT-3) for a child (ages 8+) at 12 months|Baseline Conners' Kiddie Continuous Performance Test (K-CPT) for a child (ages 6-7)|Conners' Kiddie Continuous Performance Test (K-CPT) for a child (ages 6-7) immediately after the intervention|Conners' Kiddie Continuous Performance Test (K-CPT) for a child (ages 6-7) at 6 months|Conners' Kiddie Continuous Performance Test (K-CPT) for a child (ages 6-7) at 12 months|Baseline Behavior Rating Inventory of Executive Function - 2nd Edition (BRIEF-2) for the child|Behavior Rating Inventory of Executive Function - 2nd Edition (BRIEF-2) for the child immediately after the intervention|Behavior Rating Inventory of Executive Function - 2nd Edition (BRIEF-2) for the child at 6 months|Behavior Rating Inventory of Executive Function - 2nd Edition (BRIEF-2) for the child at 12 months|Baseline Child and Adolescent Symptom Inventory - 4th Edition Revised (CASI-4R) for the child|Child and Adolescent Symptom Inventory - 4th Edition Revised (CASI-4R) for the child immediately after the intervention|Child and Adolescent Symptom Inventory - 4th Edition Revised (CASI-4R) for the child at 6 months|Child and Adolescent Symptom Inventory - 4th Edition Revised (CASI-4R) for the child at 12 months|Baseline Child Quality of Life: PedsQL Child Form for the child|Child Quality of Life: PedsQL Child Form for the child immediately after the intervention|Child Quality of Life: PedsQL Child Form for the child at 6 months|Child Quality of Life: PedsQL Child Form for the child at 12 months|Baseline Child Quality of Life: PedsQL Parent Form for the child|Child Quality of Life: PedsQL Parent Form for the child immediately after the intervention|Child Quality of Life: PedsQL Parent Form for the child at 6 months|Child Quality of Life: PedsQL Parent Form for the child at 12 months|Baseline Average Subjective Sleep Onset Latency for the child|Change in Average Subjective Sleep Onset Latency for the child from baseline to immediately after the intervention|Change in Average Subjective Sleep Onset Latency for the child from baseline to 6 months|Change in Average Subjective Sleep Onset Latency for the child from baseline to 12 months|Baseline Average Subjective Total Wake Time for the child|Change in Average Subjective Total Wake Time for the child from baseline to immediately after the intervention|Change in Average Subjective Total Wake Time for the child from baseline to 6 months|Change in Average Subjective Total Wake Time for the child from baseline to 12 months|Baseline Average Subjective Total Sleep Time for the child|Change in Average Subjective Total Sleep Time for the child from baseline to immediately after the intervention|Change in Average Subjective Total Sleep Time for the child from baseline to 6 months|Change in Average Subjective Total Sleep Time for the child from baseline to 12 months|Baseline Average Subjective Sleep Efficiency for the child|Change in Average Subjective Sleep Efficiency for the child from baseline to immediately after the intervention|Change in Average Subjective Sleep Efficiency for the child from baseline to 6 months|Change in Average Subjective Sleep Efficiency for the child from baseline to 12 months|Baseline Average LF/HF ratio for the child|Change in Average LF/HF ratio for the child from baseline to immediately after the intervention|Change in Average LF/HF ratio for the child from baseline to 6 months|Change in Average LF/HF ratio for the child from baseline to 12 months|Baseline Average pNN50 (% of N-N intervals > 50 ms) for the child|Change in Average pNN50 (% of N-N intervals > 50 ms) for the child from baseline to immediately after the intervention|Change in Average pNN50 (% of N-N intervals > 50 ms) for the child from baseline to 6 months|Change in Average pNN50 (% of N-N intervals > 50 ms) for the child from baseline to 12 months|Baseline State-Trait Anxiety Inventory (STAI-Y1) for the parent|State-Trait Anxiety Inventory (STAI-Y1) for the parent immediately after the intervention|State-Trait Anxiety Inventory (STAI-Y1) for the parent at 6 months|State-Trait Anxiety Inventory (STAI-Y1) for the parent at 12 months|Baseline Beck Depression Inventory (BDI-II) for the parent|Beck Depression Inventory (BDI-II) for the parent immediately after the intervention|Beck Depression Inventory (BDI-II) for the parent at 6 months|Beck Depression Inventory (BDI-II) for the parent at 12 months|Baseline Fatigue Severity Scale for the parent|Fatigue Severity Scale for the parent immediately after the intervention|Fatigue Severity Scale for the parent at 6 months|Fatigue Severity Scale for the parent at 12 months|Baseline Daily Fatigue for the parent|Daily Fatigue for the parent immediately after the intervention|Daily Fatigue for the parent at 6 months|Daily Fatigue for the parent at 12 months|Baseline Caregiver Strain Index (CSI) for the parent|Caregiver Strain Index (CSI) for the parent immediately after the intervention|Caregiver Strain Index (CSI) for the parent at 6 months|Caregiver Strain Index (CSI) for the parent at 12 months|Baseline Average Subjective Sleep Onset Latency for the parent|Change in Average Subjective Sleep Onset Latency for the parent from baseline to immediately after the intervention|Change in Average Subjective Sleep Onset Latency for the parent from baseline to 6 months|Change in Average Subjective Sleep Onset Latency for the parent from baseline to 12 months|Baseline Average Subjective Total Wake Time for the parent|Change in Average Subjective Total Wake Time for the parent from baseline to immediately after the intervention|Change in Average Subjective Total Wake Time for the parent from baseline to 6 months|Change in Average Subjective Total Wake Time for the parent from baseline to 12 months|Baseline Average Subjective Total Sleep Time for the parent|Change in Average Subjective Total Sleep Time for the parent from baseline to immediately after the intervention|Change in Average Subjective Total Sleep Time for the parent from baseline to 6 months|Change in Average Subjective Total Sleep Time for the parent from baseline to 12 months|Baseline Average Subjective Sleep Efficiency for the parent|Change in Average Subjective Sleep Efficiency for the parent from baseline to immediately after the intervention|Change in Average Subjective Sleep Efficiency for the parent from baseline to 6 months|Change in Average Subjective Sleep Efficiency for the parent from baseline to 12 months","University of Missouri-Columbia|United States Department of Defense","All","6 Years to 12 Years   (Child)","Not Applicable","180","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019182|W81XW-H2010399","September 15, 2020","August 2025","August 2030","September 11, 2020",,"June 30, 2021","Thompson Center for Autism and Neurodevelopmental Disorders, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04545606"
659,"NCT00298246","Clinical and Immunological Investigations of Subtypes of Autism",,"Completed","No Results Available","Autism Spectrum Disorders|Seizures",,"Behavioral profiles|Immune markers|Sleep/EEG findings|Neuroimaging findings|Other laboratory findings|Genetic abnormalities","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","1 Year to 7 Years   (Child)",,"557","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","060102|06-M-0102","February 22, 2006",,"March 15, 2017","March 1, 2006",,"October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00298246"
660,"NCT04016701","VR for Joint Attention Support in ASD",,"Withdrawn","No Results Available","Autism Spectrum Disorder","Device: Floreo Joint Attention Module|Behavioral: Regularly Scheduled Therapy","Change from Baseline Joint Attention Protocol score at 12 weeks|Change from Baseline Joint Attention Assessment score at 12 weeks|Change from Baseline Vineland Adaptive Behavior Scales, Third Edition total score","Floreo, Inc.","All","7 Years to 17 Years   (Child)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Floreo Salus Protocol 1","July 20, 2018","July 16, 2019","July 16, 2019","July 11, 2019",,"July 17, 2019","Children's SPOT, Columbia, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04016701"
661,"NCT01908686","Pivotal Response Treatment for Children With Autism Spectrum Disorders","PRT","Completed","No Results Available","Autism Spectrum Disorders","Behavioral: Pivotal Response Training","Social Responsiveness Scale (SRS) Total Score|Clinical Global Impressions Scale (CGI-I)|Autism Diagnostic Observation Schedule (ADOS) Comparison Score|Aberrant Behavior Checklist (ABC)|Vineland Domain Scores|Change in Eye Tracking (ET) patterns|Change in neural response to social stimuli using fMRI","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)","All","4 Years to 35 Years   (Child, Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1106008625|2R01NS035193-18","May 2012","December 1, 2019","March 1, 2020","July 26, 2013",,"August 14, 2020","Yale Child Study Center - Autism Program, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01908686"
662,"NCT04147988","Characterizing ASD Adult Population Asking for a Diagnosis","ASSORT","Recruiting","No Results Available","Autism Spectrum Disorder","Other: screening and diagnostic assessment DONALD T unit list","Autism Diagnostic Observation Schedule (ADOS-2)|Adult Asperger's Assessment (AAA)|Vineland Adaptative Behavior Scale (VABS-2)|Hospital Anxiety and Depression Scale (HADS)|Liebowitz Social Anxiety Scale (LSAS)|Yale-Brown Scale(Y-BOCS)","Hôpital le Vinatier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2019-A01130-57","September 27, 2019","July 31, 2021","September 30, 2021","November 1, 2019",,"November 18, 2020","Centre hospitalier Le Vinatier, Bron, Aura, France",,"https://ClinicalTrials.gov/show/NCT04147988"
663,"NCT03840642","Examining an Adaptive Telehealth Intervention",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Mirror Me|Behavioral: Remote Coaching","Change in Unstructured Imitation Assessment (UIA)|Change in Early Intervention Parenting Self Efficacy Scale|Change in Parent Fidelity|Change in Vineland Scales of Adaptive Functioning (3rd edition, survey form)|Change in Social Communication Checklist Revised|Change in Brief Observation of Social Communication Change","Rush University Medical Center|University of Chicago|National Institutes of Health (NIH)|Eotvos Lorand University","All","16 Months to 5 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ORA 16122005|KL2TR002387","January 1, 2018","January 1, 2022","April 1, 2022","February 15, 2019",,"August 25, 2021","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03840642"
664,"NCT00956579","Sensory and Connectivity Abnormalities in Autism Spectrum Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder",,"Saliency of Sensory Stimuli in Developmental Disorders","Massachusetts General Hospital|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)","All","14 Years to 32 Years   (Child, Adult)",,"120","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","2005P001768|5R01MH117998","June 2013","June 2023","June 2023","August 11, 2009",,"September 18, 2020","Martinos Center or Biomedical Imaging, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00956579"
665,"NCT03432065","A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Anxiety","Drug: Buspirone","Reduction in Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) Score","Massachusetts General Hospital","All","6 Years to 17 Years   (Child)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-P-002731","December 2021","August 2022","August 2023","February 13, 2018",,"September 23, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03432065"
666,"NCT04233502","Efficacy and Safety of Slenyto for Insomnia in Children With ASD","ASD","Withdrawn","No Results Available","Autism Spectrum Disorder","Drug: Melatonin|Drug: Placebo","Total Sleep Time (TST)|Sleep Latency (SL)|Longest Sleep Episode (LSE)","Neurim Pharmaceuticals Ltd.","All","2 Years to 18 Years   (Child, Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NEU_CH_7913","September 2020","September 2022","December 2022","January 18, 2020",,"March 12, 2021",,,"https://ClinicalTrials.gov/show/NCT04233502"
667,"NCT03859336","High-Frequency Transdermal Neuromodulation to Decrease Anxiety and Improve Sleep in ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder","Device: Transdermal Neuromodulation Stimulation","Change in physiological response measure of heart rate variability in the time-domain as measured by the standard deviation of the normal-to-normal heart beat (SDNN)|Change in physiological response measure of heart rate variability in the frequency-domain as measured by the power of the low frequency (LF) band|Change in physiological response measure of heart rate variability in the frequency-domain as measured by the power of the high frequency (HF) band|Change in physiological response measure of galvanic skin response (GSR)|Change in the Screen for Child Anxiety Related Disorders (SCARED) score|Change in the Parent Reported Anxiety Scale (PRAS) score|Change in amylase and cortisol levels|Change in the Children's Sleep Habits Questionnaire (CSHQ) score","Phoenix Children's Hospital","All","10 Years to 25 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TENS_ASD","May 21, 2019","April 2022","April 2022","March 1, 2019",,"August 12, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03859336"
668,"NCT03963479","Vitamin B6 and Magnesium- A Clinical Trial on ASD Patients",,"Unknown status","No Results Available","Autism Spectrum Disorder","Combination Product: Magnesium and Vitamin B6","Autism Spectrum Disorder","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","2 Years to 12 Years   (Child)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","BSMMU/2018/14607","January 1, 2019","July 31, 2019","July 31, 2019","May 24, 2019",,"July 31, 2019","Farhana Khan, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03963479"
669,"NCT04060030","Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Language Disorders","Drug: Levoleucovorin Calcium|Other: Placebo","Evaluate the change in social communication symptoms|Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD|Evaluate the safety of L-leucovorin calcium in young children with ASD|Examine the change in measures of Expressive and Receptive Language|Evaluate the change in effects of autism symptoms on family members|Evaluate the change in stereotypical autism symptoms|Evaluate change in overall autism severity|Evaluate the change in overall cognitive ability|Evaluate the change in adaptive functioning|Evaluate the overall change in core ASD symptoms of social communication","Phoenix Children's Hospital|Autism Speaks|State University of New York - Downstate Medical Center|University of Arizona|New York State Institute for Basic Research","All","30 Months to 60 Months   (Child)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AS Leucovorin","October 8, 2020","December 2022","December 2022","August 16, 2019",,"March 10, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|State University of New York, Downstate, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04060030"
670,"NCT03972254","Feasibility of Using Telepractice to Provide Modified Interaction Guidance.",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Modified Interaction Guidance","Parenting Interactions with Children Checklist of Observations Linked to Outcomes (PICCOLO)|Goal Attainment Scale (GAS)","University of Manitoba","All","10 Months to 35 Years   (Child, Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H2019:105","November 1, 2020","March 1, 2021","September 1, 2021","June 3, 2019",,"February 4, 2021","College of Rehabilitation Sciences, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03972254"
671,"NCT01170325","A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG",,"Withdrawn","No Results Available","Autism|Autism Spectrum Disorders","Drug: Divalproex Sodium|Drug: Placebo Comparator","epileptiform EEG discharges|Improvement in behavior","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","3 Years to 10 Years   (Child)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","100157|10-M-0157","June 30, 2010","January 28, 2011","January 28, 2011","July 27, 2010",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01170325"
672,"NCT03550209","Fatty Acid Supplementation in Children With ASD","Omega Heroes","Completed","Has Results","Autism Spectrum Disorder","Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo","Bioavailability|Safety (Adverse Events)|Biological Signatures","Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital","All","2 Years to 6 Years   (Child)","Phase 2","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB17-00517|R61AT009632","June 28, 2018","January 10, 2020","January 10, 2020","June 8, 2018","April 2, 2021","August 3, 2021","Nationwide Children's Hospital, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03550209"
673,"NCT04145076","Brain Response to Serotonergic Medications in ASD",,"Unknown status","No Results Available","Autism Spectrum Disorder","Drug: Placebo|Drug: Citalopram|Drug: Tianeptine","Brain excitation and inhibition response to pharmacological stimulation as assessed by magnetic resonance spectroscopy|Brain activation response to pharmacological stimulation as assessed by functional magnetic resonance imaging|Brain connectivity response to pharmacological stimulation as assessed by resting-state functional magnetic resonance imaging","King's College London","Male","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14/LO/0663","December 15, 2014","June 2020","July 2020","October 30, 2019",,"October 30, 2019","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04145076"
674,"NCT04931043","Feasibility of Competent Learner Model With Families of Children With ASD",,"Completed","No Results Available","Autism Spectrum Disorder",,"Session Attendance|Homework Completion|Parenting Stress Index Fourth Edition|Parent Sense of Competence Scale","West Virginia University","All","Child, Adult, Older Adult",,"5","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1803052856","November 26, 2018","June 12, 2019","June 12, 2019","June 18, 2021",,"June 18, 2021","West Virginia University Medicine University Behavioral Medicine and Psychiatry, Martinsburg, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04931043"
675,"NCT02836405","TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorder|Intellectual Disability","Device: Transcranial Magnetic Stimulation","Percent of baseline TMS-induced measures of human synaptic plasticity","Boston Children's Hospital|Beth Israel Deaconess Medical Center|National Institute of Mental Health (NIMH)","All","6 Years to 65 Years   (Child, Adult, Older Adult)",,"164","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","00014965|1R01MH100186-01A1","May 2015","April 2020","July 2020","July 19, 2016",,"December 4, 2020","Boston Children's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02836405"
676,"NCT02996708","Assessment of the Benefit of Teleconsultations for Children With Autism Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorder|Child Autism",,"Composite score: CARS, VABS evaluated once a year and ADI-R at least once in the lifetime","Assistance Publique - Hôpitaux de Paris","All","up to 18 Years   (Child, Adult)",,"102","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TLM Prometted","January 2014","December 2017","December 2017","December 19, 2016",,"December 19, 2016","IME notre Ecole, Carrieres sur Poissy, France|Association Agir et Vivre l'Autisme, Chambourcy, France|IME Eclair, Collegien, France|Association UNI-TEDS, Dammarie les Lys, France|Hôpital Sainte Anne, Paris, France|IME Le Reverdi, Vert saint denis, France",,"https://ClinicalTrials.gov/show/NCT02996708"
677,"NCT00178503","Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children",,"Completed","Has Results","Autism|Attention Deficit Disorder With Hyperactivity","Drug: Methylphenidate-extended release|Drug: Methylphenidate-immediate release|Other: Placebo","Mean Conners' Teacher ADHD Index T Score by Dose|Mean Continuous Performance Test (CPT)-Commission Errors by Dose|Mean Conners' Parent ADHD Index T Score by Week","The University of Texas Health Science Center, Houston|National Institute of Mental Health (NIMH)","All","7 Years to 12 Years   (Child)","Phase 2|Phase 3","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH072263|DDTR B2-NDA","September 2005","May 2011","May 2011","September 15, 2005","May 7, 2013","May 9, 2013","University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00178503"
678,"NCT01847521","Effects of the Anti-inflammatory Flavonoid Luteolin on Behavior in Children With Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders","Dietary Supplement: Luteolin, Quercetin and Rutin combined in a capsule","Change in Age-Equivalent scores of the Vineland Adaptive Behavior Scales domains from baseline at 26 weeks|Change in Aberrant Behavior Checklist subscales from baseline at 18th week and at 26th week|Change in Autism Treatment Evaluation Checklist from baseline at 18th week and at 26th week|Clinical Global Impression-Improvement score at 18th week and at 26th week","Attikon Hospital","All","4 Years to 10 Years   (Child)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NeuroproteckOpenLabel","December 2011","February 2013","March 2013","May 7, 2013",,"May 7, 2013","Attikon Hospital, Chaidari, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT01847521"
679,"NCT02755051","Targeting Sleep in Kids With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Chronic Insomnia","Behavioral: Cognitive Behavioral Therapy","Change from Baseline Subjective Sleep at 12 weeks|Change from Baseline Objective Sleep at 12 weeks|Change from Baseline Subjective Sleep at 18 weeks|Change from Baseline Objective Sleep at 18 weeks|Child Behavior at Baseline|Child Behavior at Post-treatment|Child Behavior at Follow-up|Change in subjective Parent Sleep from Baseline at 12 weeks|Change in subjective Parent Sleep from Baseline at 18 weeks|Change in objective Parent Sleep from Baseline at 12 weeks|Change in objective Parent Sleep from Baseline at 18 weeks","University of Missouri-Columbia","All","6 Years to 12 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004675","July 2016","March 2018","March 2018","April 28, 2016",,"July 20, 2018","Department of Health Psychology, University of Missouri-Columbia, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02755051"
680,"NCT03980366","Use of Electroconvulsive Therapy to Treat Self-Injurious Behavior in Adults With Autism Spectrum Disorders",,"Terminated","No Results Available","Autism Spectrum Disorder|Self-Injurious Behavior","Device: Electroconvulsive Therapy (ECT)","Changes in Self-Injury Trauma Scale (SIT) across time|Changes in Daily Diary Card across time|Changes in Repetitive Behavior Scale-Revised (RBS-R) across time|Changes in Aberrant Behavior Checklist (ABC) across time|Changes in ASD Diagnostic Checklist (ADC) across time","Eastern Virginia Medical School|Sentara Norfolk General Hospital","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECT4ASD","March 15, 2019","September 9, 2020","September 9, 2020","June 10, 2019",,"June 24, 2021","Eastern Virginia Medical School, Norfolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03980366/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03980366/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03980366"
681,"NCT02010086","Schema, Emotion and Behavior-Based Therapy for School Children","SEBASTIEN JR","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Individual Cognitive Behavioral Therapy|Behavioral: Standard Community Treatment","Playground Observation of Peer Engagement scale","University of California, Los Angeles","All","6 Years to 10 Years   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","12000556|Autism Speaks 7552","December 2011","November 2015","June 2016","December 12, 2013",,"September 7, 2018","Jeffrey Wood, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02010086"
682,"NCT03812068","Parent-mediated Developmental Behavioral Intervention","PDBI","Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Long-distance developmental behavioral intervention|Behavioral: Developmental behavioral intervention","The Autism Diagnostic Observation Schedule|Child Behavior Checklist Ages 1.5-5|Pediatric Evaluation of Disability Inventory|Mullen Scale of Early Learning|Movement Assessment Battery for Children|3D Gait Assessment Foot-worn Inertial Sensor|Peabody Developmental Motor Scales, Second Edition|Parenting Stress Index|Parenting Sense of Competence Scale","National Taiwan University Hospital","All","30 Months and older   (Child, Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201809001RINC","September 30, 2018","August 31, 2021","August 31, 2021","January 22, 2019",,"January 22, 2019","School and Graduate Institute of Physical Therapy, National Taiwan University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03812068"
683,"NCT03362840","Integrating the ESDM in ASD Preschools in Israel","ESDM-ISR","Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model|Behavioral: Eclectic preschool intervention","Change from baseline Mullen Scales of Early Learning (MSEL)|Change from baseline Vineland Adaptive Behavior Scales, Second Edition (VABS-II)|Change from baseline Parent Sense of Competence Scale (PSOC)|Change from baseline Parenting Stress Index - Short Form (PSI\SF)|Change from baseline parent-child interaction paradigm|Change from baseline child-staff member interaction paradigm","Bar-Ilan University, Israel|Association for Children at Risk","All","3 Years to 6 Years   (Child)","Not Applicable","59","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BarIlanU","November 1, 2016","September 30, 2017","September 30, 2018","December 5, 2017",,"December 5, 2017","Bar Ilan University, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03362840"
684,"NCT03274622","Efficacy of IMPACT in Infant Siblings of Children With ASD","IMPACT","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Impact Parent Training|Behavioral: No Impact","Growth in communication|Growth in play|Motor imitation|Autism social affect symptomatology|Language delay|language level|parent implementation of ImPACT treatment","Vanderbilt University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","12 Months to 18 Months   (Child)","Not Applicable","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","140924|1R01DC013767-01","February 16, 2016","August 30, 2019","August 30, 2019","September 7, 2017",,"October 2, 2019","Vanderbilt University, Nashville, Tennessee, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03274622"
685,"NCT04926090","Developing Mental Health Supports for Autistic Students",,"Recruiting","No Results Available","Autism Spectrum Disorder|Depression, Anxiety","Behavioral: Emotional Support Plan - Clinician Guided (ESP-C)|Behavioral: Emotional Support Plan - Self Guided (ESP-S)","Change in distress on Patient Health Questionnaire (PHQ-9)|Change in distress on Ecological Momentary Assessment (EMA) reports|Change in anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Change in Adult Self Report|Change in Adult Behavior Checklist|Change in Emotion Dysregulation Inventory|Change Young Adult Coping Orientation for Problem Experience (YA-COPE)","Rutgers, The State University of New Jersey|Organization for Autism Research","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2021000076","July 26, 2021","January 2022","January 2022","June 14, 2021",,"August 5, 2021","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04926090"
686,"NCT04820998","Living in a Precarious Situation With an Autistic Child: What Are the Issues at Stake for Support in Care","HaSPrEA","Not yet recruiting","No Results Available","Autistic Disorder","Other: Families|Other: professionals","living conditions of children with Autism Spectrum Disorders (ASD)|Precarity","Centre Hospitalier Universitaire de Saint Etienne","All","up to 18 Years   (Child, Adult)",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20CH029","September 2021","April 1, 2022","January 1, 2023","March 29, 2021",,"August 19, 2021","Chu St Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04820998"
687,"NCT03372421","The Use of Social Stories to Reduce Negative Affect and Improve Satisfaction in Adults Attending an ASD Assessment",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Social Story|Other: Standard Information","Positive and Negative Affect Schedule|Assessment Satisfaction|Predictability","University of Sheffield","All","18 Years and older   (Adult, Older Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","rjenkinson001","May 26, 2018","April 30, 2019","April 30, 2019","December 13, 2017",,"August 30, 2019","Sheffield Adult Autism and Neurodevelopmental Service, Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03372421"
688,"NCT02818205","Electrodermal Patterns of Arousal in Children",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Sensory Challenge Protocol","Electrodermal Activity in response to sensation: tonic and phasic skin conductance in MicroSiemens","Barpak Geriatric Health Services, Inc. d/b/a Barpak Occupational Therapy","Male","4 Years to 11 Years   (Child)",,"32","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Barpak-02-EDA","January 2013","April 2014","May 2014","June 29, 2016",,"June 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02818205"
689,"NCT04301141","Using Virtual Reality to Treat Social Anxiety in Autistic Adolescents",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Social Anxiety","Other: Virtual Reality Assisted Cognitive Behavioural Therapy","VR session completion rate.|Rate of participant identification.|Recruitment rate.|Rate of participant retention.|Therapy attendance.|Frequency and number of sessions.|Adverse effects.|Experience and opinions on the intervention.|Data completion rates.|Homework compliance.|Change in progress with attaining therapy goals.|Change in anxiety (including social anxiety) and depression levels.|Change in Global Outcome Ratings of Severity of Illness.","King's College London|South London and Maudsley NHS Foundation Trust|National Institute for Health Research, United Kingdom|Guy's and St Thomas' NHS Foundation Trust","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0c Valmaggia","January 2021","September 2021","September 2021","March 10, 2020",,"September 9, 2020","St Thomas Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College London, London, United Kingdom|Maudsley Hospital, South London and Maudsley NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04301141"
690,"NCT04339153","Feasibility Study on Parents Skill Training Program for Reducing Parental Distress and Disruptive Behavior of Their Children With Autism Spectrum Disorder (ASD)",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Disruptive Behaviours","Behavioral: Parent Training for Disruptive Behaviours","Aberrant Behavior Checklist-Community (ABC-C; Aman & Singh, 1994)|Parenting Stress Index, Fourth Edition Short Form (PSI-4; Abidin, 1995)|Symptom Checklist-90 (SCL-90, Derogatis, Rickels, Rock, 1976)|Vineland Adaptive Behavior Scales (Vineland-II; Sparrow, Cicchetti, & Balla, 2005)|Home Situations Questionnaire Disorder (HSQ; Chowdhury et al, 2016)|Clinical Global Impressions - Improvement Scale (CGI; Guy 1976)","Foundation University Islamabad","All","3 Years to 10 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FUI/CTR/2020/2","April 2, 2020","September 2, 2021","September 2, 2021","April 9, 2020",,"April 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04339153"
691,"NCT04312152","Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.","Q10ASD","Enrolling by invitation","No Results Available","Autism Spectrum Disorder|Phelan-McDermid Syndrome","Dietary Supplement: Q10 Ubiquinol|Dietary Supplement: Vitamin E|Dietary Supplement: Multi-Vitamin B complex","Change in Vineland Adaptive Behavior Scales scores|Change in Childhood Autism Rating Scale score|Change in Clinical Global Impression of Improvement scale scores between experimental and active comparator arms.|Change in Visual Analog Scales scores|Children's Global Assessment Scale|Social Responsiveness Scale|Repetitive Behaviors Scale - Revised|Aberrant Behavior Checklist|Short Sensory Profile|Conners' Parent Rating Scale-Revised|Child Behavior Checklist|Intellectual Quotient|The Quality of Life in Autism Questionnaire|The World Health Organization's Quality of Life Questionnaire|Measurement of protein carbonylation level as a marker of oxidative stress in leukocytes.|Measurement of the activity of mitochondrial respiratory chain complexes.|Measurement of expression levels of mitochondrial respiratory chain complexes.","Antonio Persico|Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM)|University of Bari|University of Messina","All","2 Years to 40 Years   (Child, Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Q10_study_ASD","March 9, 2019","December 31, 2022","August 31, 2023","March 18, 2020",,"March 18, 2020","Interdipartimental Program ""Autismo 0-90"" at ""G. Martino"" Universitary Hospital, Messina, ME, Italy",,"https://ClinicalTrials.gov/show/NCT04312152"
692,"NCT03682978","Arbaclofen in Children and Adolescents With ASD","AIMS2-CT1","Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Arbaclofen|Drug: Placebo","Effect of Arbaclofen vs. placebo on social function|Effect of Arbaclofen vs. placebo on measures of global function|Effect of Arbaclofen vs. placebo on other adaptive domains|Effect of Arbaclofen on measures of social abilities and responsiveness|Effect of Arbaclofen on measures of social abilities and responsiveness through BOSCC|Effect of Arbaclofen on measures of social abilities and responsiveness through SRS-2-P|Effect of Arbaclofen on measures of social abilities and responsiveness through SRS-2-T|Effect of Arbaclofen on measures of problem behaviours|Effect of Arbaclofen on other measures of core symptoms|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the SMURF|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the ESS-CHAD|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the C-SSRS|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a pulse rate measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a body temperature measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a blood pressure measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by measuring weight|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by measuring height|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the Tanner scale|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with blood tests|To explore the use and feasibility of digital biomarkers","Celso Arango, MD, PhD|UMC Utrecht","All","5 Years to 17 Years   (Child)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AIMS2-CT-01|2018-000942-21","September 19, 2019","August 31, 2022","August 31, 2022","September 25, 2018",,"September 28, 2021","Robert Debré Hospital, Paris, France|Hospital Clínic de Barcelona, Barcelona, Spain|Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, SERMAS, Madrid, Spain|University of Salamanca & Complejo asistencial de Zamora, Salamanca, Spain|University of Glasgow, Glasgow, United Kingdom|King's College London, London, United Kingdom|University of Newcastle upon Tyne, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03682978"
693,"NCT03818490","Aromatherapy for Anxiety Among Children With Autism Spectrum Disorder",,"Completed","No Results Available","Anxiety|Autism Spectrum Disorder","Other: Bergamot Aromatherapy","Change from baseline State Trait Anxiety Inventory for Children|Change from baseline in Blood Pressure|Change from baseline in Heart Rate","Franklin School of Integrative Health Sciences","All","6 Years to 11 Years   (Child)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-1200","June 24, 2016","March 9, 2018","March 30, 2018","January 28, 2019",,"January 28, 2019","Franklin Institute of Wellness, Franklin, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03818490"
694,"NCT00183339","Early Intervention With Fluoxetine in Autism",,"Completed","Has Results","Autistic Disorder","Drug: Fluoxetine|Drug: Placebo","Rate of Recruitment|Rate of Attrition|Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire|Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I)","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","All","30 Months to 58 Months   (Child)","Phase 2","18","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U54MH066418","July 2005","February 2008","February 2008","September 16, 2005","March 26, 2014","March 26, 2014","Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00183339"
695,"NCT03255837","tDCS on Working Memory (WM) in Adults With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Device: Transcranial direct current stimulation (tDCS)","Working memory accuracy score compared to typically developed controls scores.|Difference in working memory accuracy score between adults with ASD and healthy controls","NHS Greater Glasgow and Clyde|University of Glasgow","Male","18 Years to 35 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","GN17MH365","February 26, 2018","December 21, 2018","December 21, 2018","August 21, 2017",,"January 25, 2019","University of Glasgow, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03255837"
696,"NCT02747459","Sensory Supported Swimming for Children With ASD","SSS","Enrolling by invitation","No Results Available","Autism Spectrum Disorders","Behavioral: Sensory Supported Swimming","Skill Acquisition Form|Instructor Survey|Parent Survey|Program Records","University of Kansas Medical Center","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","13124","March 2012","September 2022","September 2022","April 21, 2016",,"October 4, 2021","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02747459"
697,"NCT03715166","Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Drug: Bumetanide Oral Solution|Drug: Placebo","Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Sales, Second Edition (VABS II) subscores|Adverse events and Paediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|the Columbia Suicide Severity Rating Scale Children's version (C-SSRS-C)|Tanner stage|Acceptability and palatability questionnaire|Paediatric Quality of Life Inventory (PedsQL) questionnaire","Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier","All","7 Years to 17 Years   (Child)","Phase 3","211","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL3-95008-001|2017-004419-38","September 24, 2018","December 8, 2021","December 8, 2021","October 23, 2018",,"January 20, 2021","Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de Psiquiatria, São Paulo, Brazil|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Il De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Universitätsklinikum Freiburg, Zentrum für Psychische Erkrankungen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Freiburg, Baden-Württemberg, Germany|Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und, Dresden, Saxony (Sachsen), Germany|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Unità Semplice di Psichiatria Infantile Policlinico Universitario di Napoli - Università Federico II, Napoli, Campania, Italy|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale ""Autismo 0-90"" A.O.U. Policlinico ""Gaetano Martino"", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|Accare Groningen, Groningen, Netherlands|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Wojewodztwo Lodzkie, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Wojewodztwo Mazowieckie, Poland|Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Wojewodztwo Pomorskie, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Forward Thinking Birmingham_Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03715166"
698,"NCT04416360","Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak","CLIECO","Recruiting","No Results Available","Autism Spectrum Disorder|Attention-deficit Hyperactivity Disorder","Other: Interview by psychologists","Interview of the parents : contextual data|Interview of the children/adolescents/ parents : Experience of the confinement in general|Interview of the referring caregiver : data relating to disease and management of care","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","6 Years to 17 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC31/20/0151","May 5, 2020","July 2020","January 2021","June 4, 2020",,"June 4, 2020","University hospital of Toulouse, Toulouse, Occitanie, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Esquirol, Limoges, France|Hôpital Robert-Debré (AP-HP), Paris, France|Maison de Solenn (Hôpital Cochin AP-HP), Paris, France",,"https://ClinicalTrials.gov/show/NCT04416360"
699,"NCT01205282","Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO)",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Pioglitazone|Drug: Placebo","Safety of pioglitazone in children with ASD ages 5-12 years|Efficacy of outcome measure to be used in a follow-up multisite randomized control trial of pioglitazone in children with ASD|Maximum tolerated dose to be used in the follow-up multisite randomized controlled trial|Efficacy of pioglitazone on markers of inflammation (cytokine levels) and oxidative stress (superoxide dismutase, malonyl aldehydes)|Relationship between different doses and response to treatment","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|Anagnostou, Evdokia, M.D.","All","5 Years to 12 Years   (Child)","Phase 2","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","10-002","April 2013","September 2015","September 2015","September 20, 2010",,"March 20, 2017","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01205282"
700,"NCT02555241","Emergence of Generative Language",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Mand Training|Behavioral: Matrix|Behavioral: Stimulus Equivalence Training","Change in Mean Length of Utterances (MLU) during manding|Acquisition of noun-verb and color-shape combinations during tacting|Emergence of intraverbal responses|Change in Macarthur Bates-Communicative Development Inventory (CDI) Score|Observe overall improvements in pragmatic language within social/play interactions with parents/caregivers, as measured on the Direct Observation of Spoken Language (DOSL).","Emory University","All","4 Years to 6 Years   (Child)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00080641","September 2015","November 2016","November 2016","September 21, 2015",,"December 5, 2016",,,"https://ClinicalTrials.gov/show/NCT02555241"
701,"NCT02296502","Comparison of DSM-IV-TR and DSM-5 for ASD",,"Completed","Has Results","Autism Spectrum Disorder","Other: DSM","Clinical Features of Concordant vs Discordant Groups|Sensitivity and Specificity of DSM-5 Criteria for ASD Relative to DSM-IV Criteria","University of Pittsburgh|University of Missouri-Columbia|Children's Hospital Los Angeles|Nationwide Children's Hospital|Children's Hospital Medical Center, Cincinnati|Vanderbilt University","All","2 Years to 17 Years   (Child)",,"439","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DSM5 and ASD","November 2014","November 2016","November 2016","November 20, 2014","March 11, 2019","March 11, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of Missouri, Columbia, Missouri, United States|Children's Hospital of Cincinnati, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02296502"
702,"NCT04746027","Empathy, Psychopathy and Autism: Behavioural Associations and the Role of an Oxytocin Receptor Polymorphism in a Non-clinical Adult Population",,"Completed","No Results Available","Empathy|Autism|Psychopathy",,"31-item Questionnaire for Cognitive and Affective Empathy (QCAE)|36-item 'Reading the Mind in the Eyes' behavioural task (RMET)|26-item Levenson's Self-Report for Psychopathy (LSRP)|50-item Autism Quotient (AQ)|OXTR rs53576 genotype","St Mary's University College","All","18 Years and older   (Adult, Older Adult)",,"126","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SMEC_2016-17_092","July 1, 2017","March 31, 2018","November 1, 2018","February 9, 2021",,"February 9, 2021","St Mary's University, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04746027"
703,"NCT03757585","Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)",,"Recruiting","No Results Available","Non-verbal Learning Disorder|Autism Spectrum Disorder|Autism","Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol|Drug: Open-label Treatment with N-acetylcysteine","Mean Change in the Parent-Young Mania Rating Scale (P-YMRS) Score|Mean Change in the Parent-completed Children's Depression Inventory (CDI)|Mean Change in the NIMH Clinical Global Improvement scale (CGI)","Massachusetts General Hospital|Demarest Lloyd Jr. Foundation","All","5 Years to 17 Years   (Child)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002261","May 20, 2019","December 2021","December 2021","November 29, 2018",,"February 24, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03757585"
704,"NCT03123146","Cognitive Behavioural Therapy for Children With Autism Spectrum Disorder and Obsessive Compulsive Behaviour",,"Completed","No Results Available","Autism Spectrum Disorder|Obsessive-Compulsive Behavior","Behavioral: Functional Behavior-Based Cognitive Behavioral Therapy","Change in Repetitive Behavior Scale (RBS_SCR)|Change in Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)|Change in Repetitive Behavior Scale 100 (RBS_100)|Change in The child Obsessive-Compulsive Impact Scale-Revised (COIS-R)|Parent OCB Rating Scale.","Tricia Vause|Ontario Mental Health Foundation|Ontario Ministry of Health and Long Term Care|Brock University","All","7 Years to 13 Years   (Child)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","09-066-VAUSE","June 1, 2010","February 1, 2014","February 1, 2014","April 21, 2017",,"April 21, 2017","Brock University, St Catharines, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03123146"
705,"NCT01250938","Effectiveness of Early Intervention in an Underserved Population","ESI-CO","Unknown status","No Results Available","Autism Spectrum Disorders","Behavioral: ESI - Community Outreach","Caregiver Transactional Support|Child Outcome|Caregiver Outcome","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)|Autism Speaks|Florida State University","All","24 Months to 54 Months   (Child)","Not Applicable","44","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1108011843|Autism Speaks 5766|R01MH078165","July 2009","May 2019","May 2019","December 1, 2010",,"July 23, 2018","Florida State University, Tallahassee, Florida, United States|Weill Cornell Medical College, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT01250938"
706,"NCT04944901","28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder",,"Recruiting","No Results Available","Autistic Disorder","Drug: SB-121|Drug: Placebo","Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESIs), and adverse events (AEs) leading to discontinuation from the study|Incidence of presence of L. reuteri and Sephadex® microspheres in the stool|Incidence of symptomatic bacteremia with positive L. reuteri identification|Change from baseline in Clinical Global Impressions Severity (CGI-S) Subscales|Change from baseline in Clinical Global Impressions Improvement (CGI-I) Subscales|Change from baseline in Vineland Adaptive Behavior Scales (3rd edition)|Change from baseline in Aberrant Behavior Checklist (ABC)|Change from baseline in Woodcock Johnson 3rd Edition (WJ-III)|Change from baseline in Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline in Test of Attentional Performance for Children (KiTap)|Change from baseline in Neurophysiology Measures: electroencephalogram (EEG) resting state|Change from baseline in Neurophysiology Measures: auditory habituation|Change from baseline in Neurophysiology Measures: chirp modulated sweep auditory evoked response|Change from baseline in eye tracking|Change from baseline in Biomarkers: plasma oxytocin|Change from baseline in Biomarkers: plasma vasopressin|Change from baseline in Biomarkers: serum high-sensitivity C-reactive protein (hs-CRP)|Change from baseline in Biomarkers: tumor necrosis factor-α|Change from baseline in Biomarkers: stool biomarkers","Scioto Biosciences, Inc.","All","15 Years to 45 Years   (Child, Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SBI-SB121-20-01","August 3, 2021","November 29, 2021","November 29, 2021","June 30, 2021",,"September 22, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04944901"
707,"NCT02464527","Stimulus-Stimulus Pairing Study",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Stimulus-stimulus pairing|Other: Vocal recorder","Feasibility of intervention assessed by a change in frequency of target vocalizations and/or approximations during sessions|Change in frequency of target vocalizations and/or approximations at home|Change in parent-reported vocalizations|Feasibility of intervention assessed by reliability of delivery by therapists|Acceptability of stimulus-stimulus pairing (SSP) by parents|Feasibility of intervention assessed by compliance of the vocal recorder|Feasibility of the vocal recorder assessed by the utility of vocal recorder","Emory University","All","24 Months to 47 Months   (Child)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00073588","June 2014","May 2015","May 2015","June 8, 2015",,"July 15, 2016","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02464527"
708,"NCT02758496","A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD",,"Completed","No Results Available","Autistic Disorder","Other: MeRT Efficacy Chart Review","Childhood Autism Rating Scale (CARS)|Electrophysiological","Wave Neuroscience","All","2 Years to 20 Years   (Child, Adult)",,"141","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MeRT-016","April 2016","April 2017","April 2017","May 2, 2016",,"May 9, 2017","Brain Treatment Center, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02758496"
709,"NCT02359084","Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children",,"Active, not recruiting","No Results Available","Autism|Developmental Delay Disorders","Behavioral: Family Navigation|Behavioral: Conventional Care Management","Diagnostic interval (Number of days defined as beginning the day of the positive confirmatory screen and ending the day when the family receives a determination (yes/no) of ASD diagnosis)|Time to receipt of ASD services/recommended services|Determination of ASD diagnosis (based on DSM V criteria made by a Board Certified DBP Pediatrician. Assessments are based on site protocols; all use standardized, validated measures appropriate for very young children.)|Satisfaction with Family Navigator (Patient Satisfaction with Interpersonal Relationship with Navigator (PSN-I))","Boston University|Yale University|Children's Hospital of Philadelphia|National Institute of Mental Health (NIMH)|Developmental Behavioral Pediatrics Research Network","All","15 Months to 27 Months   (Child)","Not Applicable","340","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","H-33008|1R01MH104355","February 2015","December 2021","December 2021","February 9, 2015",,"June 30, 2021","Yale University School of Medicine, New Haven, Connecticut, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston University School of Public Health, Boston, Massachusetts, United States|South End Community Health Center, Boston, Massachusetts, United States|Dorchester House Multi-Service Center, Boston, Massachusetts, United States|Codman Square Health Center, Boston, Massachusetts, United States|East Boston Neighborhood Health Center, Boston, Massachusetts, United States|MGH Chelsea, Chelsea, Massachusetts, United States|Lowell Community Health Center, Lowell, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02359084"
710,"NCT02483910","Direct Instruction Language for Learning in Autism Spectrum Disorder","DILLASD","Completed","No Results Available","Autism Spectrum Disorder|Moderate Language Delay","Behavioral: Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|Behavioral: Standard of care delivered via telehealth (e.g., Zoom or WebEx)","Change in the Clinical Evaluation of Language Fundamentals-4 (CELF-4) Score|Change in Clinical Evaluation of Language Fundamentals-Preschool 2 (CELF-P) Score|Improvement item of the Clinical Global Impression scale (CGI-I)","Emory University","All","4 Years to 7 Years   (Child)","Not Applicable","137","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00081144|AR140208","October 2015","November 24, 2020","November 24, 2020","June 29, 2015",,"January 6, 2021","Marcus Autism Center - Children's Healthcare of Atlanta, Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02483910/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02483910"
711,"NCT01179841","Intervention for Toddlers at Risk for Autism Spectrum Disorders (ASD)",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Playgroup|Behavioral: Parent Training","Developmental Level|Communication|Presence and Severity of Autism","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Autism Speaks","All","11 Months to 21 Months   (Child)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00006553","January 2008","December 2011","December 2011","August 11, 2010",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01179841"
712,"NCT02797379","The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders","MANAGE","Completed","No Results Available","Autism Spectrum Disorders|Anxiety","Other: Psychoeducation","Knowledge about anxiety in ASD|Anxiety symptoms|Acceptability, usefulness and appropriateness of the guide","King's College London|South London and Maudsley NHS Foundation Trust|Guy's and St Thomas' NHS Foundation Trust","All","8 Years to 25 Years   (Child, Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200774","September 1, 2016","August 31, 2017","August 31, 2017","June 13, 2016",,"September 13, 2019","South London and the Maudsley, London, United Kingdom|Guy's and St Thomas' NHS trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02797379"
713,"NCT02348125","Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?","MitoASD","Unknown status","No Results Available","Autism Spectrum Disorders|Mitochondrial Diseases","Drug: Mitochondrial Cocktail","Change in features of Autistic behavior phenotype assessed using the Social Responsiveness Scale (SRS)|Change in Executive Function assessed using the Behavior Rating Inventory of Executive Function (BRIEF)|Changes in mitochondrial enzyme specific activities biochemically evaluated using buccal swab analysis|Change in buccal oxidative stress markers and mitochondrial DNA (mtDNA) damage","Drexel University","All","3 Years to 12 Years   (Child)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DrexelMitoApp","March 2016","June 2017","June 2017","January 28, 2015",,"April 14, 2017","St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02348125"
714,"NCT01177969","Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents",,"Completed","Has Results","Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified","Behavioral: Cognitive-Behavioral Therapy|Behavioral: Wait-list","Pediatric Anxiety Rating Scale.|Anxiety Disorders Interview Schedule: Child and Parent Versions","University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, Los Angeles|University of Miami","All","11 Years to 14 Years   (Child)","Phase 1|Phase 2","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R34HD065274-01","November 2009","April 2014","April 2014","August 9, 2010","July 1, 2014","July 1, 2014","Univeristy of California at Los Angeles, Los Angeles, California, United States|University of South Florida, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01177969"
715,"NCT04587557","Storytelling With or Without Social Contextual Information in Children With Autistic Spectrum Disorder and Typical Development",,"Completed","No Results Available","Autism Spectrum Disorder|Healthy","Behavioral: Storytelling with social contextual information|Behavioral: Storytelling without social contextual information|Other: Children with ASD|Other: Children with TD","Eye gaze on the eye tracker|Trail Making Test","The Hong Kong Polytechnic University","All","6 Years to 12 Years   (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HSEARS20160427001","June 2016","December 2018","December 2018","October 14, 2020",,"October 14, 2020","The Hong Kong Polytechnic University, Department of Rehabilitation Sciences, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04587557"
716,"NCT04638452","Evaluation of Behavioural Psycho & Physiological Responses in People With ASD During a Blood Test in Routine Care Practice","AUTICOPP","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Video & movements recording|Behavioral: Questionnaires","Facial expression during blood sample|Body movement during blood sample|Evaluation of emotion felt by participants during blood sample","Centre Hospitalier Charles Perrens, Bordeaux","All","6 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020-A00693-36","February 8, 2021","November 30, 2023","February 28, 2024","November 20, 2020",,"August 18, 2021","Centre Hospitalier Charles PERRENS, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04638452"
717,"NCT04095741","Characteristics of Autism Spectrum Disorder in Minors With Anorexia Nervosa in Remission",,"Unknown status","No Results Available","Anorexia Nervosa|Autism Spectrum Disorder","Diagnostic Test: Questionnaires","Symptoms of autism spectrum disorder|Global functioning|Symptoms of anorexia nervosa","Universitair Ziekenhuis Brussel|University Ghent","All","up to 18 Years   (Child, Adult)",,"34","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PAIKA2019STUDIE01","October 1, 2019","March 31, 2020","March 31, 2020","September 19, 2019",,"September 19, 2019","UZ Brussel, Brussel, Belgium",,"https://ClinicalTrials.gov/show/NCT04095741"
718,"NCT04972136","rTMS for Depression in Young Adults With Autism","rTMS-MDD","Recruiting","No Results Available","Autism Spectrum Disorder|Major Depressive Disorder","Device: Active Bilateral Theta Burst Stimulation|Device: Sham Bilateral Theta Burst Stimulation","Change in scores on the 17-item Hamilton Rating Scale for Depression (HRSD-17)|Change in scores on the Beck Scale for Suicide Ideation (BSI)","Centre for Addiction and Mental Health","All","16 Years to 29 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","141/2019","January 14, 2021","January 14, 2024","January 14, 2024","July 22, 2021",,"July 22, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04972136"
719,"NCT04779632","Fish Oil Affects Cognition and ADHD Symptoms in Adults With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Dietary Supplement: Experimental: Fish Oil|Dietary Supplement: Comparator: Safflower Oil","Change in short-term spatial working memory|Change in attention|Cognitive flexibility and inhibition|ADHD symptoms|Executive function|ASD symptoms","University of Copenhagen","All","18 Years to 45 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D227","December 10, 2019","February 13, 2020","February 13, 2020","March 3, 2021",,"March 3, 2021","University of Copenhagen - Department of Nutrition & Exercise, Copenhagen, Frederiksberg, Denmark",,"https://ClinicalTrials.gov/show/NCT04779632"
720,"NCT01882153","Evaluating Parent Delivered Interventions for Children With Autism",,"Recruiting","No Results Available","Autistic Disorder|Developmental Disabilities","Behavioral: Pivotal Response Training (PRT)|Behavioral: PACE Therapy|Behavioral: PACE and PRT Hybrid","Change in CGI-S (Clinical Global Impression - Severity)|Change in SRS (Social Responsiveness Scale)|Change in CDI (Communicative Development Survey) Score|Change in social and communication behaviors as assessed by standardized laboratory observations|Change in VABS (Vineland Adaptive Behavior Scale) Score|Change in social and communication behaviors as assessed from home videos|Change in PSI (Parenting Stress Index) Score|Change in FES (Family Empowerment Scale) Score|Change in frequency and duration of investigation therapy|Change in demographics data","Stanford University","All","18 Months to 17 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-11232011-8727","February 2010","March 2023","December 2023","June 20, 2013",,"March 10, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01882153"
721,"NCT04869930","Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome",,"Recruiting","No Results Available","Autism Spectrum Disorder|Fra(X) Syndrome","Other: specimen collection","microbial diversity profile|differences in serotonin levels|differential expression of serotonin-related signaling molecules","Nova Mentis Life Science Corp|Microbiome Insights|FourthWall Testing","All","6 Months to 21 Years   (Child, Adult)",,"300","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","NM101","May 3, 2021","May 2022","December 2022","May 3, 2021",,"May 3, 2021","Broward Health Medical Center, Fort Lauderdale, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04869930"
722,"NCT00927030","Melatonin for Sleep in Children With Autism","NICHD","Completed","No Results Available","Autistic Disorder|Insomnia","Drug: supplemental liquid melatonin|Drug: flavored liquid or liquid supplemental melatonin","Determine dose-response, tolerability, and adverse effects of melatonin in 30 children with autism.|A sub-set of 12 children will be studied to characterize the pharmacokinetic profile of orally administered melatonin.|A group of behavioral and parental stress measures will be piloted for the participants in this study.","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 10 Years   (Child)","Phase 1","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","071269","January 2008","April 2010","October 2010","June 24, 2009",,"July 2, 2012","Vanderbilt Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00927030"
723,"NCT01734941","TSO in Pediatric Autistic Spectrum Disorders","TSO","Terminated","No Results Available","Autistic Spectrum Disorders","Drug: TSO|Drug: Placebo","Aberrant Behavior Checklist (ABC) subscale scores|Secondary assessments of efficacy will be assessed via: The change from baseline in the CY-BOCS, CGI-I, SRS, SCQ.","Hadassah Medical Organization","All","6 Years to 17 Years   (Child)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0522-12-HMO","April 2014","May 2015","May 2015","November 28, 2012",,"February 2, 2016","The Neuro-Cognitive Center, Pediatric Division, Hadassah-Hebrew University Medical Center, Jerusalem, Mount Scopus, Israel",,"https://ClinicalTrials.gov/show/NCT01734941"
724,"NCT00277407","Treatment of Autistic Children Using NAET Procedures",,"Completed","No Results Available","Autism|Food Allergies","Procedure: NAET with acupressure and/or chiropractic procedures","Improvement in verbal and norverbal communication|Reduction of commonly seen autistic traits","Nambudripad's Allergy Research Foundation|Anonymous","All","3 Years to 10 Years   (Child)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MulticlinicalAutism Study|NARFoundationAutismStudy2006","June 2006",,"May 2007","January 16, 2006",,"May 7, 2007","NAET Pain Clinic, Buena Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00277407"
725,"NCT01929642","Rapalogues for Autism Phenotype in TSC: A Feasibility Study","RAPT","Completed","Has Results","Tuberous Sclerosis Complex|Self-injury|Autism","Drug: Sirolimus|Drug: Everolimus","Number of Participants With Compliance to the Treatment Protocol.|Caregiver Burden|Feasibility Measurements of Parental Stress|Total Number of Aggressions or Self-injuries|Cognitive Function as Assessed by the Capute Scale|Repetitive Behavior|Self-Injury Trauma Scale--SIT Scale|Frequency of Seizures Assessed by Total Number of Seizures","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","All","2 Years to 30 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AM00037881","July 2013","July 2016","August 2016","August 28, 2013","March 29, 2021","March 29, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01929642"
726,"NCT01513629","Structural Connectivity as Imaging Endophenotypes of Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders",,,"National Taiwan University Hospital|National Science Council, Taiwan","Male","10 Years to 15 Years   (Child)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201006032R","October 1, 2010","September 30, 2012","September 30, 2012","January 20, 2012",,"September 2, 2021","Center for Optoelectronic Biomedicine, National Taiwan University College of Medicine, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01513629"
727,"NCT01694667","Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder",,"Completed","Has Results","Autism Spectrum Disorders|Hyperactivity","Drug: Omega-3 Fatty Acids|Other: Placebo","Change in Aberrant Behavior Checklist - Hyperactivity Subscale (ABC-H) Score|Change in Aberrant Behavior Checklist - Lethargy Subscale Score|Change in Aberrant Behavior Checklist - Stereotypy Subscale Score|Aberrant Behavior Checklist - Irritability Subscale Score|Aberrant Behavior Checklist - Inappropriate Speech Subscale Score|Change in Social Responsiveness Scale (SRS) Score|Change in Clinical Global Impression - Improvement (CGI-I) Score","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|University of California, San Francisco","All","5 Years to 8 Years   (Child)","Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00068694","September 2012","December 2012","May 2013","September 27, 2012","June 16, 2014","August 31, 2020","This study is open to continental USA, Multiple Locations, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01694667"
728,"NCT00808782","The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder",,"Completed","No Results Available","Autistic Disorder|Asperger's Disorder","Device: Deep rTMS|Device: Sham rTMS","Theory of Mind Neurobehavioural Battery|Autism Spectrum Quotient","Bayside Health","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","277/07","December 2008","October 2012","October 2012","December 16, 2008",,"February 7, 2013","Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00808782"
729,"NCT01558180","Telephone Care Management to Address Sleep Problems in Young Children With Autism",,"Completed","No Results Available","Autism Spectrum Disorders|Insomnia","Behavioral: Telephone Care Management|Behavioral: Usual Care","Children's Sleep Habits Questionnaire|Actigraphy (Activity Monitoring)","Nationwide Children's Hospital|The Ingram Foundation is funding this work.","All","3 Years to 6 Years   (Child)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB11-00719","April 2012","December 2013","December 2013","March 20, 2012",,"February 3, 2015","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01558180"
730,"NCT04569058","Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD",,"Recruiting","No Results Available","Autism|Attention Deficit Hyperactivity Disorder","Device: Transcranial Photobiomodulation","Efficacy-Attention Deficit Hyperactivity Disorder (Attention Deficit Hyperactivity Disorder Symptom Checklist)|Efficacy-Autism Spectrum Disorder (Social Responsiveness Scale-2)|Safety (The Transcranial Photobiomodulation Self-Report Questionnaire)|Number of Participants that Report Adverse Events (Clinician-Rated Treatment Emergent Adverse Events Log)","Massachusetts General Hospital","All","9 Years to 17 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-P-002352","January 14, 2021","October 2022","October 2023","September 29, 2020",,"August 2, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04569058"
731,"NCT04060017","Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium",,"Recruiting","No Results Available","Autism Spectrum Disorder|Language Disorders","Drug: Levoleucovorin Calcium|Other: Placebo","Evaluate the change in measures of expressive language|Evaluate the change in measures of language|Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD|Evaluate the safety of L-leucovorin calcium in young children with ASD|Evaluate the overall change in core autism symptoms of social communication|Evaluate the change in stereotypical autism symptoms|Evaluate the change in social withdrawal autism symptoms|Evaluate the change in effects of autism symptoms most problematic to family members|Evaluate change in overall autism severity|Evaluate the change in overall cognitive ability|Evaluate the change in adaptive functioning","Phoenix Children's Hospital|State University of New York - Downstate Medical Center|United States Department of Defense|University of Arizona|New York State Institute for Basic Research","All","30 Months to 60 Months   (Child)","Phase 2","80","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DOD Leucovorin","September 22, 2020","December 2022","December 2022","August 16, 2019",,"March 10, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|State University of New York, Downstate, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04060017"
732,"NCT04324099","Investigating the Specificity of Neural Correlates for Emotion Processing Deficits in Conduct Disorder and Autism Spectrum Disorders",,"Recruiting","No Results Available","Autism-Spectrum Disorder|Conduct Disorder","Other: neuroimaging session (with simultaneously acquired eye-tracking)|Other: Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|Other: Social and Health Assessment (SAHA) questionnaire (for children)|Other: Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|Other: Interpersonal Reactivity Index (IRI) (for children)|Other: Youth Psychopathic Traits Inventory (YPI) (for children)|Other: Reactive Proactive Questionnaire (RPQ) (for children)|Other: Emotion Regulation Questionnaire (for children)|Other: Basic Empathy Scale (BES) (for children)|Other: Pubertal Development Scale (PDS) (for children)|Other: Alabama Parenting Questionnaire (APQ) (for parents)|Other: Inventory of Callous Unemotional Traits (ICU) (for parents)|Other: Child Behavior Checklist (CBCL) (for parents)|Other: Griffith Empathy Measure (GEM) (for parents)|Other: Social Responsiveness Scale (SRS) (for parents)","difference between groups (children and adolescents with CD, ASD and typically developing adolescents) in neural activity|Emotion processing task (fMRI)","University Hospital, Basel, Switzerland|Swiss National Science Foundation","All","10 Years to 18 Years   (Child, Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2019-02386;pk17Stadler","July 16, 2020","April 2023","June 2023","March 27, 2020",,"August 13, 2020","Department of Child and Adolescent Psychiatry, KJPK (UPK), Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04324099"
733,"NCT03379662","An Evaluation of Low Level Laser Light Therapy for Autistic Disorder",,"Completed","Has Results","Autistic Disorder","Device: Erchonia HLS Laser|Device: Placebo Laser","Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score.","Erchonia Corporation","All","5 Years to 17 Years   (Child)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC_AUT_001","July 2, 2017","October 28, 2017","November 28, 2017","December 20, 2017","May 27, 2021","May 27, 2021","Institute for Brain and Rehabilitation Sciences, Nazareth, Israel","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03379662/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03379662"
734,"NCT01850355","An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders|Anxiety","Drug: Buspirone","Reduction in Pediatric Anxiety Rating Scale (PARS) score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score","Massachusetts General Hospital","All","6 Years to 17 Years   (Child)","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-P-000661","July 2013","December 2021","December 2021","May 9, 2013",,"July 9, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01850355"
735,"NCT03668873","Telehealth Delivery of Treatment for Sleep Disturbances in Young Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder|Sleep Disturbance","Behavioral: Sleep Parent Training|Behavioral: Sleep Parent Education","Improvement in Sleep Disturbances|Parental Quality of Life: PSOC","The Cleveland Clinic|United States Department of Defense","All","2 Years to 7 Years   (Child)","Not Applicable","90","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AR170155","November 1, 2018","January 1, 2023","January 1, 2023","September 13, 2018",,"July 28, 2021","Cleveland Clinic Lerner School for Autism, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03668873/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03668873"
736,"NCT02008396","Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",,"Completed","Has Results","Social Anxiety in Autistic Adults","Drug: Placebo|Drug: 75 mg to 125 mg MDMA|Behavioral: Psychotherapy","Liebowitz Social Anxiety Scale (LSAS) Total Score at Baseline|Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2|Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2","Multidisciplinary Association for Psychedelic Studies|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAA-1","February 2014","August 2017","August 2017","December 11, 2013","October 14, 2020","June 22, 2021","Los Angeles Biomedical Research Institute, Torrance, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02008396/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02008396/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02008396"
737,"NCT02757066","Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders","NPC-15-5","Completed","No Results Available","Sleep Disorders|Autism Spectrum Disorder","Drug: NPC-15 Granules Lower Dose|Drug: NPC-15 Granules Higher Dose|Drug: NPC-15 Placebo Granule","Sleep latency with electronic sleep diary|Sleep latency measured by actigraphy|Abnormal behavior checklist Japanese version|Adverse events|Electro cardiogram","Nobelpharma","All","6 Years to 15 Years   (Child)","Phase 2|Phase 3","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPC-15-5","June 16, 2016","September 2018","September 14, 2018","April 29, 2016",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT02757066"
738,"NCT01154894","Dietary Fatty Acids Improve Social Impairment in Autism Spectrum Disorders","Fatty acid","Completed","No Results Available","Autism Spectrum Disorders","Other: Aravita including arachidonic acid and docosaheaenoic acid","Aberrant Behavior Checklist-community (ABC)|Social Responsiveness Scale (SRS)","Ashiya University","All","6 Years to 29 Years   (Child, Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KunioYui","February 2009","February 2009","December 2009","July 1, 2010",,"June 23, 2011",,,"https://ClinicalTrials.gov/show/NCT01154894"
739,"NCT03071120","Parent-Mediated Intervention for Families With Children With Autism and Feeding Challenges",,"Recruiting","No Results Available","Parent-Child Relations|Meals|Autism Spectrum Disorder","Behavioral: Parent-Mediated Intervention","Change in Brief Autism Mealtime Behavior Inventory (BAMBIC)|Change in Sensory Experiences Questionnaire (SEQ 3.0)|Change in Behavioral Pediatric Feeding Assessment Scale (BPFAS)|Change in Goal Attainment Scaling (GAS).|Beck Depression Inventory-II (BDI)|Parenting Stress Index-Short Form (PSI-SF)|Change in the Caregiver Involvement Scale Score","University of Wisconsin, Madison","All","2 Years to 7 Years   (Child)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-1428|A176000|EDUC\KINESIOLOGY\KINESIO","February 3, 2017","December 31, 2021","December 31, 2021","March 6, 2017",,"March 8, 2021","Waisman Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03071120"
740,"NCT02911194","a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)","A2MT","Completed","No Results Available","Autism|Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder","Dietary Supplement: a2 milk|Dietary Supplement: a1 containing milk","Change in Childhood Autism Rating Scale (CARS2-HF) Value during intervention|Change in Conners' Rating Scale - Revised (L) value during intervention.|Amino acid analysis of urine samples by mass spectroscopy.|Metabolomic analysis of blood spot samples by mass spectroscopy.|Changes to the gut microbiome profile.|Changes to stool appearance measured using the Bristol Stool Chart.","Northumbria University|ESPA Research|a2 Milk Company Ltd.","Male","5 Years to 10 Years   (Child)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SUB017_Lodge_031115","September 2016","September 2018","September 2018","September 22, 2016",,"September 5, 2018","ESPA Research, Sunderland, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02911194"
741,"NCT01825798","Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)","MET","Completed","Has Results","Overweight|Autism Spectrum Disorder","Drug: Metformin|Drug: Placebo","Change in Body Mass Index Z-score|Changes in Additional Body Composition Parameters (Absolute Change in Weight)|Changes in Additional Body Composition Parameters (Relative Change in Weight)|Changes in Additional Body Composition Parameters (Absolute BMI)|Changes in Additional Body Composition Parameters (Abdominal Circumference)|Changes in Additional Body Composition Parameters (Hip Circumference)|Changes in Fasting Metabolic Parameters (Total Cholesterol)|Changes in Fasting Metabolic Parameters (LDL)|Changes in Fasting Metabolic Parameters (HDL)|Changes in Fasting Metabolic Parameters (Triglycerides)|Changes in Fasting Metabolic Parameters (Glucose)|Changes in Fasting Metabolic Parameters (Insulin)","Evdokia Anagnostou|Massachusetts General Hospital|Vanderbilt University|University of Pittsburgh|Nationwide Children's Hospital|Ohio State University|Anagnostou, Evdokia, M.D.","All","6 Years to 17 Years   (Child)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MET-10-2012","April 2013","June 2015","October 2015","April 8, 2013","February 22, 2018","February 22, 2018","Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01825798"
742,"NCT03718923","FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.",,"Recruiting","No Results Available","FOXP1|Mental Retardation With Language Impairment and With or Without Autistic Features|Autism Spectrum Disorder",,"Autism Diagnostic Observation Schedule (ADOS)|Autism Diagnostic Interview - Revised (ADI-R)|Stanford-Binet Intelligence Scales|Differential Ability Scales (DAS)|Mullen Scales of Early Learning","Icahn School of Medicine at Mount Sinai|The Seaver Foundation|Autism Science Foundation|Research Foundation for Mental Hygiene, Inc.","All","2 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GCO 98-436 - A","March 28, 2016","March 2023","March 2023","October 25, 2018",,"January 22, 2021","The Seaver Autism Center for Research and Treatment, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03718923"
743,"NCT00047697","Donepezil HCl & Cognitive Deficits in Autism",,"Completed","Has Results","Autistic Disorder","Drug: Donepezil HCl|Drug: Placebo","Cognitive Assessment: TMT|Cognitive Assessment: EOWVT Standard Score|Cognitive Assessment: CVLT","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","8 Years to 17 Years   (Child)","Phase 2","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21MH064941|DSIR CT-M3","October 2002","August 2006","August 2006","October 16, 2002","October 5, 2017","October 5, 2017","Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00047697"
744,"NCT02795611","Family Centered Occupational Therapy on Play Skills and Participation of Children With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Family-centered occupational therapy|Behavioral: regular occupational therapy|Other: intervention done outside our hospital","Goal Attainment Scale (GAS)|Revised Knox Preschool Play Scale (RKPPS)|Vineland Adaptive Behavior Scale-Chinese version (VABS-C)|Parenting Stress Index Short Form (PSI/SF)|Family Outcomes Survey (FOS)|Family Empowerment Scale (FES)|Home Observation for Measurement of the Environment (HOME)","National Taiwan University Hospital","All","2 Years to 6 Years   (Child)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","201509008RINC","May 2016","December 2017","December 2017","June 10, 2016",,"December 28, 2017","National Taiwan University Hospital, Taipei, Zhongzheng, Taiwan",,"https://ClinicalTrials.gov/show/NCT02795611"
745,"NCT01978210","Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism",,"Completed","No Results Available","Autism|Enuresis|Incontinence","Device: Wireless Moisture Pager (WMP)","Total number of participants successfully recruited|Percentage of participants retained across the life of the study|Treatment Fidelity (Interventionists)|Fidelity of Parent Implementation|Rate of toileting accidents|Participants' Daily Rate of Toilet Use for Urination|Parent Satisfaction with Toilet Training Intervention","University of Rochester|Autism Treatment Network","All","3 Years to 6 Years   (Child)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Moisture Pager Intervention","September 2013","June 2015","June 2015","November 7, 2013",,"February 24, 2017","University of Rochester Medical Center, Rochester, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Whitney Loring, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01978210"
746,"NCT02568631","Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls",,"Completed","No Results Available","Autistic Disorder","Other: serious game JeStiMulE|Other: control video game","Change of Emotion recognition|Change of Social cognition|Change of impact on quality of life|Impact on the verbal fluency of emotional words (number of words emitted perminute)|Feedback from JeStiMulE players","Fondation Lenval","All","18 Years to 40 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","15-HPNCL-01","September 22, 2015","September 20, 2016","September 20, 2017","October 6, 2015",,"July 31, 2018","Fondation Lenval, Nice, France|Hôpital Pasteur - CHU de Nice, Nice, France|Hôpital psychiatrique de Sainte marie, Nice, France",,"https://ClinicalTrials.gov/show/NCT02568631"
747,"NCT02874690","Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD","SAT","Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Drug: Methylphenidate|Drug: Placebo","Change in Eye-Tracking: Microsaccades and pupil size using Tobii eye tracker|Change in Short Interval IntraCortical Inhibition (SICI) using Transcranial Magnetic Stimulation (TMS)|Change in Resting State Electroencephalogram (EEG)","Children's Hospital Medical Center, Cincinnati","All","8 Years to 21 Years   (Child, Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2015-4401","February 19, 2016","August 3, 2017","August 3, 2017","August 22, 2016",,"January 15, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02874690/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02874690"
748,"NCT01059201","Exome Sequencing in Autistic Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Autism|Autistic Disorder",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"322","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","100022|10-CH-0022","January 21, 2010",,"May 15, 2017","January 29, 2010",,"December 17, 2019","Kennedy Krieger Institute, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01059201"
749,"NCT01816178","Using a Voice Output Communication Aid to Facilitate Language Development in Young Children With ASD",,"Completed","No Results Available","Autistic Disorder","Behavioral: communication training","Improved Communication|Review of text output from the VOCA","University of South Alabama","All","2 Years to 5 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASUIRB-1","February 2004","August 2005","August 2005","March 22, 2013",,"March 22, 2013","Arkansas State University, State University, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01816178"
750,"NCT05009095","The Listening Program® With Bone Conduction Headphones Changes Hypersensitivity to Sound and Behavioral Responses",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Device: The Listening Program® with bone conduction headphones","Change from Baseline Adaptive Behavior Assessment System, Third Edition (ABAS-3) Score at 41 Weeks (Immediately Post-Treatment)|Change from 41 Weeks (Immediately Post-Treatment) Adaptive Behavior Assessment, Third Edition (ABAS-3) Score After 3 months of No Treatment|Pediatric Evaluation of Disability Inventory Computer Adaptive Test with ASD Scales (PEDI-CAT (ASD))","Children's Health","All","5 Years to 10 Years   (Child)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2019-1698","September 1, 2021","May 1, 2023","May 1, 2023","August 17, 2021",,"August 17, 2021",,,"https://ClinicalTrials.gov/show/NCT05009095"
751,"NCT01474278","A Study of RO5028442 in Adult Male High-Functioning Autistic Patients",,"Completed","No Results Available","Autistic Disorder","Drug: Placebo|Drug: RO5028442","Efficacy: Behavior assessments|Safety: Incidence of adverse events","Hoffmann-La Roche","Male","18 Years to 45 Years   (Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","BP27801","December 2011","March 2013","March 2013","November 18, 2011",,"November 2, 2016","Los Ageles, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01474278"
752,"NCT01655173","Cognitive Behavioural Therapy (CBT) and Recreational Activity for Autism Spectrum Disorders (ASD)",,"Completed","No Results Available","Asperger Syndrome|Autistic Disorder|Atypical Autism","Behavioral: Cognitive behaviour therapy|Behavioral: Recreational activity intervention","The Quality of Life Inventory (QOLI, Frisch et al. 1992)|Sense of Coherence (SoC, Antonovsky 1993)|The ten-item Rosenberg Self Esteem Scale (RSES, Rosenberg 1962)|The patient versions of the Clinical Global Impression scale - Severity (patient CGI-S)|Clinical Global Impression scale - Improvement (patient CGI-I)|Autism Quotient (AQ, Baron-Cohen et al. 2001)|Adult ADHD Self-Report Scale (ASRS, Kessler et al. 2005)|Beck Depression Inventory (BDI, Beck et al. 1996)|Symptom Checklist 90 (SCL-90, Derogatis & Cleary 1977)","Karolinska Institutet|Ministry of Health and Social Affairs, Sweden","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Dnr 52-6104","August 2005","September 2011","September 2011","August 1, 2012",,"October 22, 2020","Northern Stockholm psychiatry, St. Göran hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01655173"
753,"NCT00914030","Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorders|Schizophrenia","Other: Neuropsychological evaluation",,"University Hospital, Strasbourg, France","All","7 Years to 55 Years   (Child, Adult)",,"140","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2008-A01459-46","June 2009","December 2016","December 2016","June 4, 2009",,"August 26, 2016","Pôle départemental du Centre de Ressources Autisme pour adultes (67) - Etablissement public de santé Alsace-Nord (site de Brumath), Brumath, France|Centre de Ressources Autisme Pôle adultes (68) - Espace Autisme 68, Colmar, France|Clinique Lautréamont, Loos, France|Pôle régional du Centre de Ressources Autisme pour enfants et adolescents - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - Pôle de Psychiatrie - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - HUS, Strasbourg, France|INSERM U666 ; Pôle de Psychiatrie - Service de Psychiatrie Adulte- HUS, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT00914030"
754,"NCT02945423","Improving the Understanding of Catatonia in Autism","A-CAT","Withdrawn","No Results Available","Autistic Disorder|Catatonia",,"Psychiatric, cognitive and biological identification of catatonia in psychiatric illness","University of Michigan","All","10 Years to 30 Years   (Child, Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","HUM00113776","March 2020","October 2021","October 2023","October 26, 2016",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT02945423"
755,"NCT03115671","Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Dietary Supplement: Vayarin","Conners 3rd Edition - Parent|Social Responsiveness Scale (SRS)|Aberrant Behaviour Checklist (ABC)|Physical examination and safety evaluation (PAERS)","Institute of Mental Health, Singapore","All","6 Years to 12 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DSRB A/16/01120|CTC 1600529","November 30, 2016","December 31, 2018","December 31, 2018","April 14, 2017",,"August 14, 2019","Child Guidance Clinic, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03115671"
756,"NCT03337646","Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism",,"Recruiting","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder","Drug: Lisdexamfetamine Dimesylate","ADHD Symptoms|Health Related Quality of Life|Executive Function|Severity of illness|Improvement of Subjects|Safety-Adverse events|Safety - suicidality","JPM van Stralen Medicine Professional|Shire","All","6 Years to 12 Years   (Child)","Phase 4","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RES 16-002","September 26, 2018","October 2021","October 2021","November 9, 2017",,"May 21, 2021","Center for Pediatric Excellence, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03337646"
757,"NCT02384486","Efficacy of Training Programme to Reduce Stress",,"Completed","No Results Available","Autism Spectrum Disorder (ASD)","Behavioral: Training to Reduce Stress in Mothers of Children with (ASD)|Other: Nothing (treatment as usual)","Parent Stress Index Short From (PSI-SF)","University of Nottingham","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","OVS12022015 SA SoM PAPsych PhD","April 2015","December 2015","December 2015","March 10, 2015",,"May 17, 2016","Voluntary sector ASD organization no.1, Jeddah, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02384486"
758,"NCT02918864","Oxytocin and Social Cognitive Skills Groups","ION-ASD","Completed","No Results Available","Autism Spectrum Disorder","Drug: Oxytocin and social cognitive skills group|Behavioral: Facilitated Play Therapy","Change from Baseline in Social Behavior Composite|Change from Baseline in Social Cognition Composite|Change from Baseline in Global Functioning|Change from Baseline in Social Functioning|Change from Baseline in Quality of Life","Rush University Medical Center|University of Illinois at Chicago|University of Chicago|Northwestern University|Eotvos Lorand University","All","8 Years to 11 Years   (Child)","Phase 2","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","14062403","June 15, 2016","September 2021","September 2021","September 29, 2016",,"October 6, 2021","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02918864"
759,"NCT02301195","Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Child Development Disorders, Pervasive","Other: Therapeutic horseback riding|Other: Barn Activity Intervention","Change in Aberrant Behavior Checklist-Community (Irritability subscale)|Change in Aberrant Behavior Checklist-Community (Hyperactivity, Lethargy, Stereotypy subscale)|Change in Social Responsiveness|Change in Systematic Analysis of Language Transcript|Change in Peabody Picture Vocabulary Test-4|Change in Bruininks-Oseretsky Test of Motor Proficiency-2nd Ed. (Short form)|Change In Sensory Integration and Praxis Test (Praxis on verbal command & Postural Praxis subtests)|Change in Vineland Adaptive Behavior Scales Interview 2nd Ed.","University of Colorado, Denver|National Institute of Nursing Research (NINR)","All","6 Years to 16 Years   (Child)","Not Applicable","209","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","07-1148|1R01NR012736","October 2010","June 19, 2014","June 19, 2014","November 25, 2014",,"March 15, 2021",,,"https://ClinicalTrials.gov/show/NCT02301195"
760,"NCT01247662","Psychometric Studies of the Chinese Versions of the SRS, CAST, and AQ",,"Completed","No Results Available","Autism Spectrum Disorder",,,"National Taiwan University Hospital","All","6 Years to 16 Years   (Child)",,"2460","Other","Observational",,"201005041R","January 2011",,"December 2011","November 24, 2010",,"November 15, 2012","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01247662"
761,"NCT03718936","ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.",,"Recruiting","No Results Available","ADNP|Helsmoortel-Van Der Aa Syndrome|Autism Spectrum Disorder",,"Autism Diagnostic Observation Schedule (ADOS)|Autism Diagnostic Interview - Revised (ADI-R)|Stanford-Binet Intelligence Scales|Differential Ability Scales (DAS)|Mullen Scales of Early Learning","Icahn School of Medicine at Mount Sinai|The Seaver Foundation|Autism Science Foundation|Research Foundation for Mental Hygiene, Inc.","All","2 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GCO 98-436","November 14, 2017","January 2023","January 2023","October 25, 2018",,"October 30, 2020","The Seaver Autism Center for Research and Treatment, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03718936"
762,"NCT02552147","Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism",,"Completed","Has Results","Autism Spectrum Disorder|Aggression|Irritability","Drug: Transdermal nicotine|Other: Transdermal placebo","Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)|Change in Social Responsiveness Scale-Adults (SRS-A)|Change in Qualitative Description of Irritability and Aggression Symptoms|Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task|Change in State/Trait Anxiety Inventory (STAI) Score|Nightly Sleep Quality","Yale University|Autism Speaks","All","18 Years to 60 Years   (Adult)","Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1502015384","September 2015","November 17, 2017","November 17, 2017","September 16, 2015","March 14, 2019","March 14, 2019","Yale University, New Haven, Connecticut, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02552147"
763,"NCT01190917","Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Autism|Autism Spectrum Disorder","Behavioral: Cognitive Behavioral Therapy (CBT)|Behavioral: Play Therapy","Diagnostic Analysis of Nonverbal Accuracy-2* (DANVA2)|Reading the Mind in the Eyes Task - Child Version|Functional Magnetic Resonance Imaging (fMRI)|Social Responsiveness Scale (SRS)|Strange Stories Task|Vineland Adaptive Behavior Scales, Second Edition (Vineland II)|Autism Diagnostic Observation Schedule (ADOS)|Direct Observation|Peer generalization assessment","Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)","All","8 Years to 11 Years   (Child)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GCO #09-0859|R21MH089236","September 2009","September 2012","September 2012","August 30, 2010",,"October 2, 2012","Mount Sinai School of Medicine - Seaver Autism Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01190917"
764,"NCT02677051","Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism",,"Recruiting","No Results Available","Autism|Autistic Disorder|Autism Spectrum Disorder|Autistic Behavior","Drug: Sulforaphane|Drug: Placebo","Change in Aberrant Behavior Checklist (ABC) scores.|Change in Social Responsiveness Scale (SRS) scores.|Clinical Global Impression Severity Scale (CGI-S).|Clinical Global Impression Improvement Scale (CGI-I) to measure change from baseline CGI-S scores.|Liver Function Tests as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.|Renal Function Tests as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.|Thyroid Stimulating Hormone (TSH) as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.","Rutgers, The State University of New Jersey|Rowan University","Male","13 Years to 30 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro20120001884|CAUT15APL013","February 2016","December 2021","July 2022","February 9, 2016",,"July 14, 2021","Rutgers University - Staged Research Building, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02677051"
765,"NCT00245778","fMRI Study of Grasping in Autistic Patients",,"Terminated","No Results Available","Autistic Disorder",,,"University Hospital, Tours","Male","18 Years to 35 Years   (Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","PHRC-R-2003-INCA","March 2004",,"February 2007","October 28, 2005",,"May 28, 2007","University hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT00245778"
766,"NCT03408886","Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders","MTT-ASD","Recruiting","No Results Available","Autism Spectrum Disorder|Gastrointestinal Disorder","Drug: Vancomycin|Drug: MoviPrep|Biological: Full Spectrum Microbiota","Change in Childhood Autism Rating Scale (CARS) from baseline to 10 weeks|Change in Daily Stool Log (DSL) from baseline to 10 weeks|Change in Social Responsiveness Scale - 2 from baseline to 10 weeks of treatment|Change in Aberrant Behavior Checklist from baseline to 10 weeks","Arizona State University","All","18 Years to 60 Years   (Adult)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MTT-Adults-1|Wi1XWH-16-1-0492","January 4, 2018","October 4, 2022","September 1, 2023","January 24, 2018",,"September 2, 2020","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03408886"
767,"NCT01256060","Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)",,"Completed","Has Results","Autism Spectrum Disorder","Drug: Intranasal Oxytocin","Maximum Tolerated Dose (MTD)|Number of Participants With Serious Adverse Events|Baseline Levels of Oxytocin in Relation to Either Safety or Treatment Response|Blood Levels of Oxytocin During the Trial in Relation to Safety or Treatment Response","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|The Hospital for Sick Children|University of Illinois at Chicago|Anagnostou, Evdokia, M.D.","All","10 Years to 17 Years   (Child)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-001","November 2010","March 2013","March 2013","December 8, 2010","April 15, 2015","August 12, 2016","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01256060"
768,"NCT02826148","Validation of the French Adaptation of the RAADS-R Scale : Scale of Asperger Syndrome Diagnosis","RAADS-R","Completed","No Results Available","Autism Spectrum Disorder","Other: RAADS-R scale","score at the RAADS-R scale","University Hospital, Montpellier|Fondation Orange","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","324","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","8747","December 2011","December 2015","December 2015","July 7, 2016",,"July 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02826148"
769,"NCT00916851","Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and ADHD",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder",,,"National Taiwan University Hospital","All","8 Years to 17 Years   (Child)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","200903062R","August 1, 2010","July 31, 2013","July 31, 2013","June 10, 2009",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00916851"
770,"NCT00670891","A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children","VPH","Completed","No Results Available","Autistic Disorder","Procedure: oxygen (Hyperbaric Oxygen Therapy)","Developmental and Skill training assessment, Rajanukul Hospital 5th edition","Vachira Phuket Hospital","All","5 Years to 9 Years   (Child)","Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VP 000001","July 2007","April 2008","April 2008","May 2, 2008",,"May 29, 2008","Vachira Phuket Hospital, Phuket, Thailand",,"https://ClinicalTrials.gov/show/NCT00670891"
771,"NCT01617460","A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder",,"Completed","Has Results","Autistic Disorder","Drug: Aripiprazole","Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score","Otsuka Pharmaceutical Co., Ltd.","All","6 Years to 17 Years   (Child)","Phase 3","86","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","031-11-003","September 2012","October 2016","October 2016","June 12, 2012","October 20, 2017","October 20, 2017","Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan",,"https://ClinicalTrials.gov/show/NCT01617460"
772,"NCT00693953","Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism",,"Withdrawn","No Results Available","Autistic Disorder|Autism, Early Infantile|Autism, Infantile|Asperger Syndrome",,,"Yellen & Associates, Inc.","All","5 Years to 25 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Case-Control","PA-06-278","January 2010","January 2011","December 2012","June 9, 2008",,"October 2, 2009","Yellen & Associates, Inc., Northridge, California, United States",,"https://ClinicalTrials.gov/show/NCT00693953"
773,"NCT04243382","Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study",,"Recruiting","No Results Available","Autistic Spectrum Disorder","Biological: Autologous umbilical cord blood|Biological: Placebo","Improvement of social communication skills|Functional assessment","Sheba Medical Center","All","18 Months to 12 Years   (Child)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHEBA-18-5105-OBY-CTIL","February 27, 2020","December 2024","December 2024","January 28, 2020",,"January 20, 2021","Chaim Seba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04243382"
774,"NCT04879303","Robotic Intervention Framework for Children With Autism Spectrum Disorder to Enhance Social Engagement and Participation",,"Recruiting","No Results Available","Autism Spectrum Disorder|Social Engagement|Robotic Intervention","Behavioral: Robot-assisted social skill intervention|Behavioral: Human-only instruction programme on social skill training","The Autism Diagnostic Observation Schedule|Social Responsiveness Scale|The Canadian Occupational Performance Measure|Short sensory profile","Education University of Hong Kong","All","5 Years to 11 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1230","May 3, 2021","October 2021","June 30, 2022","May 10, 2021",,"August 18, 2021","The Education University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04879303"
775,"NCT01984944","Characterisation of Circadian Rhythm in Autistic Spectrum Disorder",,"Completed","No Results Available","Autistic Disorder","Other: Autistic functional exploration|Other: Control functional exploration","Urinary sulfatoxymelatonin secretion|Core body temperature rhythm|Circadian rhythms assessed with actometer","Assistance Publique - Hôpitaux de Paris|Henri Mondor University Hospital|Albert Chenevier Hospital (Department of Psychiatry)|Robert Debré Hospital|Pasteur Institute (Cognitive Function and Human Genetic)|Fondation FondaMental","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","P081103|2009-011842-24","October 2009","August 2013","August 2013","November 15, 2013",,"November 7, 2014","Henri Mondor Hospital, Creteil, France",,"https://ClinicalTrials.gov/show/NCT01984944"
776,"NCT00332241","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)",,"Completed","Has Results","Autistic Disorder","Drug: Aripiprazole|Drug: Placebo","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","6 Years to 17 Years   (Child)","Phase 3","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-178","June 2006","April 2008","April 2008","June 1, 2006","July 23, 2009","December 2, 2013","Marsella, Gregory, Boca Raton, Florida, United States|Child Neurology Associates, Pc, Atlanta, Georgia, United States|University Of Louisville, Louisville, Kentucky, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Las Vegas, Nevada, United States|Suny - Stony Brook School Of Medicine, Stony Brook, New York, United States|Univ Of Nc, Chapel Hill, North Carolina, United States|Ut Medical Group, Memphis, Tennessee, United States|Red Oak Psychiatry Associates, Pa, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00332241"
777,"NCT01617447","A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder",,"Completed","Has Results","Autistic Disorder","Drug: Placebo of Aripiprazole|Drug: Aripiprazole","Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score","Otsuka Pharmaceutical Co., Ltd.","All","6 Years to 17 Years   (Child)","Phase 3","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","031-11-002","July 2012","June 2015","June 2015","June 12, 2012","April 11, 2017","April 11, 2017","Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan",,"https://ClinicalTrials.gov/show/NCT01617447"
778,"NCT00926471","Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders",,"Completed","No Results Available","Autistic Disorder|Child Development Disorders, Pervasive","Behavioral: Cognitive Behavioral Therapy (CBT) Program","Child and Adolescent Symptom Inventory 20-Item Anxiety Subscale (CASI-20)","Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH)","All","12 Years to 17 Years   (Child)","Phase 1","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","K01MH079945|DDTR B2-MBA","September 2008","May 2011","January 2013","June 23, 2009",,"November 7, 2013","Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00926471"
779,"NCT02746445","A Longitudinal Study on the Safety and Efficacy for Subjects With ASD Who Received MeRT",,"Completed","No Results Available","Autistic Disorder","Other: No intervention","Change in Childhood Autism Rating Scale (CARS)|Childhood Autism Rating Scale (CARS)","Wave Neuroscience","All","6 Years to 15 Years   (Child)",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MeRT-015","April 2016","April 2017","April 2017","April 21, 2016",,"May 9, 2017","Brain Treatment Center, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02746445"
780,"NCT02491645","Comparison of Effectiveness of Home Based Sensory Interventions Along With Standard Therapy Versus Standard Therapy Alone in Autistic Children With Sensory Processing Abnormalities",,"Completed","No Results Available","Autistic Children With Sensory Processing Abnormalities","Other: Sensory interventions","1. Comparison of change in total score on 10 item Likert scale (as rated by parents)|1. Comparison of change in health related quality of life using PedsQL ( Pediatric quality of life inventory) questionnaire|2. Comparison of change in overall functional outcome using CGAS (Children's global assessment scale) questionnaire","Postgraduate Institute of Medical Education and Research","All","3 Years to 12 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PGIMER-HS","February 2015","June 2017","December 2017","July 8, 2015",,"August 1, 2018","Dr Hansashree P, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02491645"
781,"NCT01983189","Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism",,"Terminated","No Results Available","Autism|Asperger Disorder|Other Developmental Pervasive Disorder","Procedure: transcranial magnetic stimulation","clinical improvement based on repetitive behavior scale.|clinical improvement based on the social responsiveness scale.","New York State Psychiatric Institute","All","18 Years to 55 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","5594","November 2008","November 2010","November 2010","November 13, 2013",,"March 24, 2017","New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01983189"
782,"NCT03889821","Mindfulness Training and Parent-coaching Interventions for Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Parents|Stress","Behavioral: Parent-implemented Early Start Denver Model|Behavioral: Mindfulness Based Stress Reduction","Change in parental stress|Change in parental depression|Change in parental anxiety|Change in parental mindfulness|Change in parent relationship quality|Change in parental life satisfaction|Change in parental sleep quality|Change in child autism symptom severity|Change in child cognitive functioning|Change in child adaptive behavior|Change in child problem behaviors|Change in child communication behaviors","Vanderbilt University Medical Center","All","12 Months and older   (Child, Adult, Older Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MBSR and P-ESDM|R40MC30769","March 11, 2015","March 23, 2018","March 23, 2018","March 26, 2019",,"March 26, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03889821"
783,"NCT05029375","Parental Insightfulness and the Acquisition of Social Skills in Children With ASD.","ASD","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: PEERS® for Preschoolers","Behavioral peer interaction measurement|Insightfulness Assessment|Social Responsiveness Scale-second edition (Constantino & Gruber, 2012)|The Social Skills Improvement System (SSIS; Gresham & Elliott, 2008)|Quality of Play Questionnaire (QPQ; Frankel & Mintz, 2011).|The Parental Reflective Functioning Questionnaire (PRFQ; Luyten, Mayes, Nijssens & Fonagy, 2017).","Bar-Ilan University, Israel|Israel Science Foundation","All","4 Years to 8 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","205698","August 2021","August 2023","October 2023","August 31, 2021",,"August 31, 2021","Bar-Ilan University, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT05029375"
784,"NCT04358484","Implementation of Incredible Years for Autism and Language Delay Program in Spain","FS","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Language Delay|Prematurity","Behavioral: Incredible Years - ASD and Language Delay®","Autism Program Parent Final Satisfaction Questionnaire|Register sheet of attendance|Autism Program Parent Weekly Evaluation.|Incredible Years® Parent Strategies Questionnaire for Children with Autism (2-5 years)|Parental Stress Index (PSI-SF) by Abidin.|Beck Depression Inventory (BDI)|Autism Specify Five Minutes Speech Sample - ASFMSS|Alabama Parenting Questionnaire Preschool revision (APQ-Pr).","Fundació Sant Joan de Déu","All","24 Months to 71 Months   (Child)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PIC-220-19","January 2, 2020","May 2021","May 2021","April 24, 2020",,"February 8, 2021","Fundació Sant Joan de Déu, Esplugues de Llobregat, Spain",,"https://ClinicalTrials.gov/show/NCT04358484"
785,"NCT02847182","Cord Blood Infusion for Children With Autism Spectrum Disorder","Duke ACT","Completed","Has Results","Autism Spectrum Disorder|ASD|Autism|PDD","Biological: Cord Blood Infusion|Biological: Placebo","Change in Social Communication as Measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3)|Change in Vineland Socialization Domain Raw Score|Change in Vineland Socialization Domain Age Equivalent|Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Composite Standard Score (Parent Questionnaire)|Change in Clinical Global Impressions - Severity of Illness (CGI-S) Score, Clinician Assessment|Clinical Global Impressions - Global Improvement (CGI-I) Score, Clinician Assessment|Change in Expressive One-Word Picture Vocabulary Test (Clinician Assessment)|Change in Vineland Adaptive Behavior Scales II (VABS-II) Communication Subscale Standard Score|Change in Vineland Adaptive Behavior Scales II (VABS-II) Daily Living Subscale Standard Score|Change in Vineland Adaptive Behavior Scales II (VABS-II) Composite Score|Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Repetitive, Ritualistic and Pragmatic Problems T-Score|Change in PDD-BI Approach/Withdrawal Problems T-Score|Change in PDD-BI Sensory/Perceptual Approach Behaviors T-Score|Change in PDD-BI Ritualisms/Resistance to Change T-Score|Change in PDD-BI Social Pragmatic Problems T-Score|Change in PDD-BI Semantic/Pragmatic Problems T-Score|Change in PDD-BI Arousal Regulation Problems T-Score|Change in PDD-BI Specific Fears T-Score|Change in PDD-BI Aggressiveness T-Score|Change in PDD-BI Expressive Social Communication Abilities T-Score|Change in PDD-BI Receptive/Expressive Social Communication Ability T-Score|Change in PDD-BI Social Approach Behaviors T-Score|Change in PDD-BI Expressive Language T-Score|Change in PDD-BI Learning, Memory, and Receptive Language T-Score|Number of Participants With Infusion Reactions|Severity of Infusion Reactions|Number of Participants With Product-related Infections|Severity of Product-related Infections|Evidence of Alloimmunization Via Anti-HLA (Human Leukocyte Antigen) and Anti-RBC (Red Blood Cell) Antibodies and Nonspecific Markers of Systemic Inflammation (ESR, CRP)|Incidence of Graft vs. Host Disease|Severity of Graft vs. Host Disease|Incidence of Unexpected Adverse Events, by Relation to Study Product|Severity of Unexpected Adverse Events, by Relation to Study Product","Joanne Kurtzberg, MD|Duke University","All","2 Years to 7 Years   (Child)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00070514","September 2016","August 19, 2018","May 2019","July 28, 2016","December 26, 2019","June 9, 2020","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02847182/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02847182"
786,"NCT02265094","Associative Memory in Autism Spectrum Disorder","MEM-TA","Unknown status","No Results Available","Autistic Disorder","Other: Electroencephalography|Behavioral: Neuropsychological assessment","Index of discrimination obtained with the task of associative memory","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|Amiens University Hospital","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2014- A00481-46","December 22, 2015","December 2018","December 2019","October 15, 2014",,"February 20, 2018","Caen University Hospital, Caen, France",,"https://ClinicalTrials.gov/show/NCT02265094"
787,"NCT04376151","Guided ACT and for Adults With ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Other: Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'","Comprehensive Assessment of Acceptance and Commitment Therapy Process (CompACT) repeated measure of change|Comprehensive Assessment of Acceptance and Commitment Therapy Process (CompACT short form) repeated measure of change|The Depression, Anxiety and Stress Scale (DASS-21) repeated measure of change|Personal Questionnaire (PQ) repeated measure of change|World Health Organisation Quality of Life Questionnaire (WHO-QoL- BRIEF) repeated measure of change","University of Lincoln|Nottinghamshire Healthcare NHS Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","245597","September 1, 2020","January 20, 2022","August 20, 2022","May 6, 2020",,"May 5, 2021","Nottingham City Autisum Service, Nottingham, Nottinghamshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT04376151/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04376151"
788,"NCT00619190","Study of Aripiprazole to Treat Children and Adolescents With Autism","PAIRS","Completed","Has Results","Autistic Disorder|Asperger Syndrome|Autism Spectrum Disorder","Drug: aripiprazole","Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks|Clinical Global Impressions Scale - Severity Score (CGI-S)|Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks","University of North Carolina, Chapel Hill|Bristol-Myers Squibb","All","30 Months to 17 Years   (Child)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-1792 GCRC-2491","January 2006","June 2012","June 2012","February 20, 2008","March 26, 2014","March 26, 2014","University of North Carolina, Department of Psychiatry, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00619190"
789,"NCT03947086","Neurostimulation for Cognitive Rehabilitation in Autistic Spectrum Disorders",,"Unknown status","No Results Available","Autistic Disorders Spectrum","Device: Transcranial Direct Current Stimulation (TDCS)- Active|Device: Transcranial Direct Current Stimulation (TDCS)- Sham|Behavioral: Cognitive Training","Facial emotion recognition|Theory of mind- Verbal task|Theory of mind- Contextual task|Memory for Digit Span|Trail Making Test A e B|Seven Errors Test","Federal University of Paraíba","Male","8 Years to 12 Years   (Child)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","U1111-1221-6178","April 30, 2018","September 30, 2018","May 30, 2019","May 13, 2019",,"May 15, 2019","Gabriela Medeiros, João Pessoa, Paraíba, Brazil",,"https://ClinicalTrials.gov/show/NCT03947086"
790,"NCT03814083","Transcranial Direct Current Stimulation in Autism Spectrum Disorder",,"Recruiting","No Results Available","Transcranial Direct Current Stimulation|Autistic Disorders Spectrum|Electroencephalography","Device: Active-tDCS|Device: Sham-tDCS|Other: Wait-list","Change in behavioral measures - Early Adolescent Temperament Questionnaire - Revised - Effortful control subscale (EATQ-R-EC)|Change in behavioral measures - Autism Quotient (AQ)|Change in behavioral measures - Social Responsiveness Scales (SRS)|Change in CANTAB® cognitive test - Stop Signal Task (SST)|Change in CANTAB® cognitive test - Reaction Time (RTI)|Change in CANTAB® cognitive test - One Touch Stockings of Cambridge (OTS)|Change in CANTAB® cognitive test - Multitasking Test (MTT)|Change in CANTAB® cognitive test - Emotion Recognition Task (ERT)|Change in n-back task|Change in the Attention Network Task (ANT)|Change in Electroencephalography (EEG) coherence measure|Change in functional near-infrared spectroscopy (fNIRS) recording","The Hong Kong Polytechnic University|Chinese University of Hong Kong","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSEARS20171230001","July 23, 2019","December 2022","June 2023","January 23, 2019",,"July 22, 2021","The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03814083"
791,"NCT01227668","Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder",,"Completed","Has Results","Irritability Associated With Autistic Disorder","Drug: Aripiprazole|Drug: Placebo","Percentage of Patients Relapsing by Week 16|Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])|Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])|Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1","Bristol-Myers Squibb","All","6 Years to 17 Years   (Child)","Phase 4","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN138-603","March 2011","June 2012","June 2012","October 25, 2010","May 2, 2014","May 2, 2014","Harmonex Neuroscience Research, Inc, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Costa Mesa, California, United States|Behavioral Research Specialists, Llc, Glendale, California, United States|Abbey Neuropsychology Clinic, Palo Alto, California, United States|Ucsf - Lppi, San Francisco, California, United States|Stanford University School Of Medicine, Stanford, California, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Florida Clinical Research Center, Llc, Maitland, Florida, United States|Miami Children'S Hospital, Miami, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Llc, Smyrna, Georgia, United States|Kootenai Behavioral Health Center, Coeur D'Alene, Idaho, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|Lsu Health Sciences Center, Shreveport, Louisiana, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Inc, Las Vegas, Nevada, United States|Clinical Research Center Of New Jersey, Gibbsboro, New Jersey, United States|Children'S Specialized Hosp, Toms River, New Jersey, United States|Stony Brook University School Of Medicine, Stony Brook, New York, United States|Unc Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Ou Physician'S Child Study Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Kingsport, Tennessee, United States|Insite Clinical Research, Desoto, Texas, United States|Ericksen Research And Development, Clinton, Utah, United States|Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01227668"
792,"NCT03887676","Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)","ARBA","Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Arbaclofen|Other: Placebo","Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Social Domain|Clinical Global Impressions - Impression Scale - Improvement (CGI-I)|Aberrant Behavior Checklist (ABC) - Social Withdrawal Subscale|Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Communication Domain|Safety Monitoring Uniform Report Form (SMURF)|Clinical Global Impressions - Impression Scale - Global (CGI-I-Global)|Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD)|Suicidality assessment using the Columbia-Suicide Severity Rating Scale (C-SSRS)","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|University of Western Ontario, Canada|Queen's University|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.","All","5 Years to 17 Years   (Child)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARB-05-2018","March 18, 2019","May 15, 2022","May 15, 2022","March 25, 2019",,"August 13, 2021","McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada|Queen's Universtiy, Kingston, Ontario, Canada|University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03887676"
793,"NCT03348982","Examining the Association Between Physical Activity and Sleep Quality in Children With Autism Spectrum Disorder",,"Unknown status","No Results Available","Physical Activity|Sleep Apnea|Autism Spectrum Disorder","Behavioral: Jogging program","Sleep onset latency|Sleep efficiency|Wake after sleep onset|Sleep duration|Parental-assessed sleep quality|Melatonin","The Hong Kong Polytechnic University","All","9 Years to 12 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","28602517","January 2018","June 2019","June 2019","November 21, 2017",,"December 6, 2017",,,"https://ClinicalTrials.gov/show/NCT03348982"
794,"NCT01337700","Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism",,"Completed","Has Results","Autism Spectrum Disorder|Asperger Syndrome|Aspergers Syndrome","Drug: Milnacipran|Drug: Placebo","Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale|Change in Hyperactivity as Measured by Aberrant Behavior Checklist - Hyperactivity Scale|Change in Autism Severity Levels Based on the Clinical Global Impressions Scale|Change in Repetitive Behaviors Using YBOCS-Compulsion and Rigidity Subscale|Change in Diagnostic Analysis of Nonverbal Activity-2 ADULT FACIAL EXPRESSIONS: (DANVA2-AF)","Montefiore Medical Center|Forest Laboratories","All","18 Years to 50 Years   (Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-09-299","February 2011","July 2014","July 2014","April 19, 2011","February 27, 2020","February 27, 2020","Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01337700"
795,"NCT01031511","Effect of Cognitive Behavioural Therapy (CBT) for Children With Autistic Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorder|Anxiety","Behavioral: Cognitive Behavioural Therapy|Other: Social Recreational","Anxiety level of child|Parent Stress Level","National Healthcare Group, Singapore|Nanyang Technological University|Autism Resource Centre, Singapore","All","9 Years to 16 Years   (Child)","Early Phase 1","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DSRB Ref Code: A/05/091|NMRC/1002/2005|130/2005","June 2005","January 2010","February 2011","December 14, 2009",,"December 14, 2009","Institute of Mental Health, Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01031511"
796,"NCT01805128","Exploration of the Social Cognition in Adolescents With a Dissociative Disorder or Autism Spectrum",,"Completed","No Results Available","Schizophrenia|Autistic Disorder","Other: Facial recognition of emotions|Other: understanding metaphors|Other: Attribution of intentionality to others in social situations depending on the type of situation","Compare cognitive profiles in clinical adolescents with a schizophrenic disorder, autistic or healthy in the three areas of social cognition|Compare the cognitive profiles within the clinical group of schizophrenic|Cognitive profiles compare clinical results between the different types of schizophrenia and autism patients.","Centre Hospitalier Universitaire de Nice|Centre Hospitalier d'Antibes Juans les Pins|Centre Hospitalier de Cannes","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","12-AOI-04","January 2013","April 2013","May 2013","March 6, 2013",,"May 29, 2013","Centre Hospitalier d'Antibes Juans les Pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT01805128"
797,"NCT04460677","ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19",,"Recruiting","No Results Available","Psychological Distress|Stress, Psychological|Autism Spectrum Disorder","Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring","Decreased distress on Patient Health Questionnaire (PHQ-9)|Decreased distress on EMA reports|Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Adult Self Report (ASR)","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020001593","August 12, 2020","December 31, 2021","December 31, 2021","July 7, 2020",,"July 12, 2021","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04460677"
798,"NCT00773812","Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders",,"Completed","No Results Available","Autistic Disorder|Pervasive Developmental Disorder","Drug: mecamylamine|Drug: placebo","The primary measure will be a global composite derived by calculating the z scores on each measure other than CGI from published norms (or from the baseline descriptives, then averaging the z scores of the various outcome measures for each individual.|OSU Autism Rating Scale-DSM-IV|Repetitive Behavior Questionnaire|Aberrant Behavior Checklist|Ohio Autism Clinical Impressions Scale|Social Responsiveness Scale|Expressive Vocabulary test-Second Edition|Adverse Experience checklist and AE log|Cognitive Battery","Ohio State University|Autism Speaks","All","4 Years to 12 Years   (Child)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007H0096","July 2007","November 2012","November 2012","October 16, 2008",,"January 13, 2017","Nisonger Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00773812"
799,"NCT01078844","Memantine in Adult Autism Spectrum Disorder",,"Terminated","Has Results","Autism|Asperger's Disorder|Pervasive Developmental Disorder NOS","Drug: memantine|Drug: Placebo","Clinical Global Impression-Scale(CGI-S)","Johns Hopkins University|Forest Laboratories","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00015760","February 2010","July 2010","July 2010","March 2, 2010","July 26, 2017","July 26, 2017","Johns Hopkins Bayview, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01078844"
800,"NCT04235543","Occurrence of Traumatic Dental Injury in a Group of Egyptian Autistic Children Compared to Normal Children: (A Cohort Study)",,"Not yet recruiting","No Results Available","Traumatic Dental Injury|Autism Spectrum Disorder|Dental Trauma",,"occurrence of Traumatic Dental Injury|Risk factor of Traumatic dental injury|oral habits that contribute to TDI","Cairo University","All","6 Years to 12 Years   (Child)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Cairo University Egypt","March 2020","November 2020","February 2021","January 22, 2020",,"March 24, 2020","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04235543"
801,"NCT02461459","Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)",,"Recruiting","No Results Available","Tuberous Sclerosis|Autism Disorder|Intellectual Disability",,"Change in ADOS-2 scores at end of study|Change in SBIS-5 scores or Mullen Scales of Early Learning (MSEL) at end of study|Change in Fractional anisotropy (FA) at 12 months|Change in fractional anisotropy (FA) at 24 months|Change in radial diffusivity (RD) at 12 months|Change in radial diffusivity (RD) at 24 months|Change in mean diffusivity (MD) of cerebellar fascicles at 12 months|Change in mean diffusivity (MD) of cerebellar fascicles at 24 months|Change in axial diffusivity (AD) at 12 months|Change in axial diffusivity (AD) at 24 months","Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance|National Center for Advancing Translational Science (NCATS)|Office of Rare Diseases (ORD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Months and older   (Child, Adult, Older Adult)",,"195","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00013585|1U54NS092090","May 2015","December 2024","December 2025","June 3, 2015",,"August 2, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California at Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Texas at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02461459"
802,"NCT00308074","An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders",,"Completed","Has Results","Autism|Asperger's Disorder|Pervasive Developmental Disorder","Drug: Aripiprazole","Clinical Global Impressions-Improvement|Aberrant Behavior Checklist-Irritability Subscale|Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Brief Psychiatric Rating Scale for Children (BPRS-C)","Cambridge Health Alliance|Bristol-Myers Squibb","All","6 Years to 17 Years   (Child)","Phase 2","14","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHA-IRB-0119/06/05","February 2006","December 2008","February 2009","March 29, 2006","January 2, 2017","February 15, 2017","Cambridge Health Alliance, Medford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00308074"
803,"NCT04788537","Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder|Autistic Disorder|Asperger Syndrome|Pervasive Developmental Disorder","Behavioral: Training to Understand and Navigate Emotions and Interactions (TUNE In)","reduction in Social Responsiveness Scale, Second Edition (SRS-2) - Adult (relative/other report)","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","820694","February 16, 2021","December 22, 2022","December 22, 2022","March 9, 2021",,"March 9, 2021","Perelman School of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04788537"
804,"NCT04418492","An Intervention Targeting Daily Adaptive Skills Through Executive Function Training for Adults With ASD",,"Completed","No Results Available","Autism Spectrum Disorder|High-functioning Autism|Autism","Behavioral: Skills for Adaptive Functioning through Executive training (SAFE; tentative title)","The change in the Korean version of Barkley Deficits in Executive Functioning Scale (K-BDEFS)|The change in the Korean version of Vineland Adaptive Behavior Scale-II (K-Vineland-II)|The change in the Community Integration Skills Assessment-2 (CISA-2)|The change in the Cognitive Flexibility Inventory (CFI)","Seoul National University Hospital","All","18 Years to 35 Years   (Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B-1904/537-302","December 11, 2019","March 11, 2020","March 11, 2020","June 5, 2020",,"June 9, 2020","Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04418492"
805,"NCT04994613","Use of an Adaptive Sensory Environment in Autism Spectrum Disorder (ASD) Patients in the Perioperative Environment",,"Recruiting","No Results Available","Autism Spectrum Disorder|Anesthesia|Procedural Anxiety|Sensory Processing Disorder","Other: Sensory adaptive environment","Examine the preoperative anxiety scores of ASD patients in an adaptive sensory environment.|2. Determine the relationship of severity of sensory integration in ASD patients and their preoperative anxiety scores.|3. Explore family satisfaction with tailored care of their ASD child in the peri-operative environment.","Dayton Children's Hospital|Robert C. Cohn Memorial Research Grant","All","3 Years to 12 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","21-037","September 20, 2021","July 1, 2022","July 1, 2022","August 6, 2021",,"September 27, 2021","Dayton Children's Hospital, Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04994613"
806,"NCT04007224","Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder",,"Recruiting","No Results Available","Autistic Spectrum Disorder","Drug: Intranasal oxytocin|Biological: Autologous umbilical cord blood","Improvement in behaviour, interaction with family and peers|Improvement in behavior and social interaction|Improvement in overall functioning of the child","Fundatia Bio-Forum|Spitalul Angiomedica","All","3 Years to 7 Years   (Child)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CORDUS","January 17, 2019","November 30, 2021","December 30, 2021","July 5, 2019",,"June 24, 2021","Spitalul Angiomedica, Bucharest, Bucuresti, Romania|Medicover Hospital, Bucharest, Romania|Ponderas Academic Hospital, Bucharest, Romania","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04007224/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04007224"
807,"NCT02828332","Developmental Trajectories in ASD Until Adulthood: A 15 Years Follow-up Study","EpiTED","Completed","No Results Available","Autism Spectrum Disorders","Other: Vineland II (VABS -II)|Other: Quality of life","Vineland II (VABS -II)|Quality of life|comorbidities","University Hospital, Montpellier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","8878","October 2012","September 2015","September 2015","July 11, 2016",,"July 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02828332"
808,"NCT01624675","A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder",,"Completed","No Results Available","Autistic Disorder in Children and Adolescents","Drug: Risperidone|Drug: Placebo","The change from baseline in the Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale scores|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the double-blind phase|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the open-label phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the double-blind phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of the double-blind phase and open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of open-label-phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the double-blind phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the open label-phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the double-blind phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the open label-phase","Janssen Pharmaceutical K.K.","All","5 Years to 17 Years   (Child)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR100877|RIS-AUT-JPN-01","September 2012","October 2014","October 2014","June 21, 2012",,"October 15, 2015","Fuchu, Japan|Fukui, Japan|Hirakata, Japan|Ichikawa, Japan|Kanzaki, Japan|Kobe, Japan|Kodaira, Japan|Kurashiki, Japan|Neyagawa, Japan|Okayama, Japan|Sakai, Japan|Shimotsuke, Japan|Tokyo, Japan|Toyama, Japan|Tsuyama, Japan|Tsu, Japan|Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT01624675"
809,"NCT02000284","Mitochondrial Dysfunction in Autism Spectrum Disorder","Mito","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Autism|Mitochondrial Disease|Developmental Delay",,"Mitochondrial Reserve Capacity measured using the Seahorse XR Flux Analyzer","University of Arkansas|Jane Botsford Johnson Foundation|Arkansas Biosciences Institute|The University of Texas Health Science Center at San Antonio|St. Christopher's Hospital for Children","All","up to 17 Years   (Child)",,"450","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","137162","October 2012","January 2022","January 2022","December 4, 2013",,"March 2, 2021","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02000284/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02000284"
810,"NCT04909710","Feasibility of Mobile Game System for Potential Treatment of Developmental Delays",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Autism","Other: Mobile Game System for Potential Treatment of Developmental Delays","Preliminary change in parent/caregiver reported socialization on the Vineland Adaptive Behavior Scales,2nd Edition (VABS-2) from baseline to week 12|Mobile Application Usage|Change in parent/caregiver reported social responsiveness from week 0 to week 12|Change in mobile autism risk assessment score from week 0 to week 12|Video Based Feature Analysis|Change in Parent/Caregiver Confidence and Resources from baseline to week 12|Change in Parent Stress Index - Short Form (PSI-SF) from baseline to week 12|Engagement in gameplay across the 12 week period|Change in Emotion Recognition from baseline to week 12|Changes in parent/caregiver reported eye contact and joint attention from week 0 to week 12|Change in NIH-Emotion Toolbox from baseline to Week 12","Stanford University","All","2 Years to 8 Years   (Child)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB 39562","November 1, 2022","November 1, 2023","January 31, 2024","June 2, 2021",,"June 2, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04909710"
811,"NCT01452061","Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit/Hyperactivity Disorder|Developmental Delay",,"Autism Spectrum Disorder clinical diagnosis","Thomas W. Frazier, Ph.D|IntegraGen SA|The Cleveland Clinic","All","1 Year to 12 Years   (Child)",,"456","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CCF 11-949","January 2012","December 2013","December 2013","October 14, 2011",,"January 29, 2014","Cleveland Clinic Center for Autism, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01452061"
812,"NCT01031823","Adolescent Social Skills Training Program","ASST","Completed","No Results Available","Asperger's Disorder|High-functioning Autism","Behavioral: Multi-Media Social Skills Training Program","Social Fluency|Loneliness Scale (Asher & Wheeler, 1985)|Social Responsiveness Scale (SRS; Constantino, 2002)|Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997)","Milton S. Hershey Medical Center","All","13 Years to 17 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","32300","November 2009","October 2012","July 10, 2013","December 15, 2009",,"June 6, 2019","Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01031823"
813,"NCT02680015","Understanding the Effects of Intervention on the Brain in Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Asperger Disorder|PDD-NOS|Autism","Behavioral: PEERS","Social Responsiveness Scale (SRS: Constantino, 2005)|Test of Adolescent Social SKills (TASSK: Laugeson & Frankel, 2010)","Marquette University","All","4 Years to 28 Years   (Child, Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HR 2020","August 2010","December 2025","December 2025","February 11, 2016",,"December 10, 2018","Marquette University, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02680015"
814,"NCT04313283","Translating Peer-to-Peer Support Into a Clinical Setting",,"Active, not recruiting","No Results Available","Development Delay|Neurodevelopmental Disorders|Autism","Behavioral: Parents Taking Action","Changes in parenting stress|Changes in depression|Changes in family functioning|Fidelity|Changes in child behavior","University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00090447","September 16, 2020","November 1, 2021","November 1, 2021","March 18, 2020",,"August 12, 2021","University of Maryland, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04313283"
815,"NCT03718910","DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.",,"Recruiting","No Results Available","DDX3X|Mental Retardation, X-linked 102|Autism Spectrum Disorder",,"Autism Diagnostic Observation Schedule (ADOS)|Autism Diagnostic Interview - Revised (ADI-R)|Stanford-Binet Intelligence Scales|Differential Ability Scales (DAS)|Mullen Scales of Early Learning","Icahn School of Medicine at Mount Sinai","All","2 Years and older   (Child, Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GCO 98-436 - B","May 22, 2018","August 2024","August 2024","October 25, 2018",,"August 17, 2021","The Seaver Autism Center for Research and Treatment, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03718910"
816,"NCT03536351","Building Social Skills With Interdisciplinary Process Drama in ASD",,"Completed","No Results Available","Autistic Disorder","Behavioral: Interdisciplinary process drama","Social Skills Improvement Scale|Theory of Mind Battery & Inventory|recruitment|retention|Structured Play Assessment|Brain activity during ToM tasks|Parental perceptions of social skills|Changes in social skills during program|modifications needed to program","University of Utah","All","3 Years to 4 Years   (Child)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_0091961","July 1, 2018","January 15, 2019","January 15, 2019","May 24, 2018",,"August 19, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03536351"
817,"NCT04865198","Role of Neuralized1 and RGS14 Genes With ASD Patients",,"Completed","No Results Available","Autism Spectrum Disorder|High-functioning Autism|Healthy","Diagnostic Test: Neurl1 gene expression|Diagnostic Test: RGS14 gene expression","NEURL1 gene expression levels|RGS14 gene expression levels|Age|Gender|Intellectual disability (ID)|Consanguinity|Presence of Neurological Disease in Relatives|Corelation tests","TC Erciyes University","All","2 Years to 16 Years   (Child)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","NEURL1RGS14","January 10, 2013","August 30, 2014","August 30, 2014","April 29, 2021",,"April 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04865198"
818,"NCT02444117","Clinical and Neurophysiological Evolutions Through a Functional Rehabilitation of Social Communication in ASD",,"Unknown status","No Results Available","Autistic Disorder","Other: functional rehabilitation of social communication","Clinical changes between Baseline and Two years|neurophysiological evaluations at baseline|neurophysiological evaluations at 1 year|neurophysiological évaluations at 2 years|Social and cognitive evaluations at baseline|Social and cognitive évaluations at 1 year|Social and cognitive évaluations at 2 years|Repetitive behaviors évaluations at baseline|Repetitive behaviors évaluations at one year|Repetitive behaviors at two years","University Hospital, Tours","All","12 Months to 12 Years   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013-A012740-45","February 2015","February 2021","February 2021","May 14, 2015",,"May 14, 2015","University hospital Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02444117"
819,"NCT03711799","Mind the Gap (AIR-B3)","MtG","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Access to services via peer coaching","Change in Service Access Form from month to month|Family Empowerment Scale (Koren, DeChillo & Friesen, 1992)|Caregiver Agency Questionnaire (adapted from Kuhn & Carter, 2006)|Caregiver Autism Knowledge Questionnaire (adapted, Kuhn & Carter, 2006)|Caregiver Stigma Scale (McKay & Cavaleri, 2009)|Satisfaction Survey|Community Capital Scale|Social Dynamics of Intervention_ASD (Autism Spectrum Disorder)-SoDI","Health Resources and Services Administration (HRSA)|University of Rochester|University of Pennsylvania|University of California, Davis|Drexel University","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","156","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-000029","April 1, 2018","August 1, 2020","December 1, 2021","October 18, 2018",,"February 9, 2021","UC Davis, Davis, California, United States|University of Rochester, Rochester, New York, United States|UPENN, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03711799"
820,"NCT00376194","Mercury Chelation to Treat Autism",,"Withdrawn","No Results Available","Autism|Asperger's Disorder|Child Development Disorders, Pervasive","Drug: DMSA","Improvement in social reciprocity.|Improvement in language skills, decrease in blood mercury levels.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","4 Years to 10 Years   (Child)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","060238|06-M-0238","September 2006",,"March 2007","September 14, 2006",,"September 18, 2013","National Institute of Mental Health (NIMH), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00376194"
821,"NCT02442115","Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress",,"Unknown status","No Results Available","Autistic Disorder|Constipation|Gastrointestinal Diseases","Other: Treatment of Functional Constipation by","Reduction in F2-IsoProstanes (IsoPs) oxidative stress biomarker|Reduction in T-score from Social Responsiveness Scale (SRS-2) (Teacher questionnaire)","Children's Hospital Los Angeles","All","5 Years to 17 Years   (Child)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-00212","September 2009","December 2019","December 2019","May 13, 2015",,"January 10, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|The Center for Autism & Neurodevelopmental Disorders, Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT02442115"
822,"NCT03665363","Evaluating the Efficacy and Effectiveness of SCOPE - RCT","SCOPERCT","Unknown status","No Results Available","Autism Spectrum Disorder|Transition","Other: SCOPE|Other: Self-study","Change in scores on the ASD Knowledge Quiz|Hospital Anxiety and Depression Scale|Acceptance and Action Questionnaire (AAQ-II)|Brunnsviken Brief Quality of Life Inventory (BBQ)","Karolinska Institutet|Stiftelsen Promobilia|Stiftelsen Sunnerdahls Handikappfond|Stiftelsen Sven Jerrings fond|L.J. Boëthius stiftelse|Stiftelsen Frimurarna Barnhuset|Stockholm County Council ALF/PPG","All","16 Years to 25 Years   (Child, Adult)","Not Applicable","175","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SCOPERCT","September 1, 2016","August 31, 2020","November 30, 2020","September 11, 2018",,"September 11, 2018","Habilitering & Hälsa, Stockholm, Stockholm County, Sweden",,"https://ClinicalTrials.gov/show/NCT03665363"
823,"NCT03992118","Project LEaH: Learning to Eat at Home",,"Completed","No Results Available","Autism Spectrum Disorder|Feeding Behavior","Behavioral: Parent coaching","Parent Treatment Adherence Scale|Parent Satisfaction Scale|Treatment Fidelity Scale|Change in number of foods eaten from baseline to week 12 (or end of intervention whichever comes first)|Change from baseline in performance scores on the COPM scale at 12 weeks","Holland Bloorview Kids Rehabilitation Hospital","All","2 Years to 5 Years   (Child)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-786","August 7, 2018","April 23, 2020","July 23, 2020","June 20, 2019",,"November 20, 2020","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03992118"
824,"NCT00518804","Functional Behavioural Skill Training for Young Children With Severe Autism",,"Unknown status","No Results Available","Autistic Disorder","Behavioral: Functional Behavioural Skills Group and Parent Training","Parenting Sense of Competence|Child Behavioural Skills Assessment|Child Intellectual Functioning|Child Language Functioning|Child Adaptive Behaviour|Child Maladaptive Behaviour|Caregiver Strain|Parent Behaviour Skills Assessment","Hamilton Health Sciences Corporation|McMaster University","All","3 Years to 10 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Reitzel 2007","August 2007",,"August 2009","August 21, 2007",,"December 5, 2008","McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00518804"
825,"NCT03900923","Cannabidiol for ASD Open Trial",,"Recruiting","No Results Available","ASD|Autism Spectrum Disorder","Drug: 98% pure CBD","Clinical Global Impression Scale -Improvement (CGI-I)|Repetitive Behavior Scale-Revised (RBS-R)|Social Responsiveness Scale, 2nd Edition (SRS-2), School-Age Form|Aberrant Behavior Checklist (ABC) - Irritability and Social Withdrawal Subscales|Anxiety, Depression and Mood Scale (ADAMS)|Screen for Child Anxiety Related Disorders (SCARED), Parent Version|Sleep Disturbance Scale for Children (SDSC)|Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Parent/Caregiver Form|Clinical Global Impression-Severity (CGI-S):|Autism Family Experience Questionnaire (AFEQ)|Anxiety Scale for Children - Autism Spectrum Disorder - Parent Versions (ASC-ASD-P)|Anxiety Scale for Children - Autism Spectrum Disorder (ASC-ASD-C) - Child Versions|OSU Autism Clinical Global Impressions: Severity|OSU Autism Clinical Global Impressions: Improvement|Behavioral Inflexibility Scale (BIS)|Home Situations Questionnaire - Modified for ASD (HSQ-ASD)|16. Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder Symptoms and Normal Behavior (SWAN)","NYU Langone Health","All","7 Years to 17 Years   (Child)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-00250","March 12, 2019","December 31, 2022","December 31, 2022","April 3, 2019",,"September 27, 2021","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03900923"
826,"NCT04436432","Phenomenology of Anxiety in Preschool Children With ASD",,"Recruiting","No Results Available","Anxiety|Autism Spectrum Disorder",,"Anxiety diagnostic status as measured by Anxiety Disorders Interview Schedule with Autism Addendum|Attention to threat behavioral paradigms|Child Behavior Checklist|Preschool Anxiety Scale - Revised|Screen for Child Anxiety Related Disorders|Response to Uncertainty and Low Environmental Stability Scale|Social Responsiveness Scale|Emotion Regulation Checklist|The Children's Sleep Habits Questionnaire|Hospital Anxiety and Depression scale|Intolerance of Uncertainty Scale|Family Accommodation Scale|Burden Assessment Scale|Broader Autism Phenotype","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","All","36 Months to 71 Months   (Child)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00173329","October 25, 2018","December 31, 2022","December 31, 2022","June 18, 2020",,"September 3, 2020","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04436432"
827,"NCT02199925","An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum",,"Unknown status","No Results Available","Autism|Autistic Disorder|Asperger's Disorder|PDD|Pervasive Developmental Disorder","Drug: Gammaplex 5%","The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction.|The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation.","Isaac Melamed|Bio Products Laboratory|IMMUNOe Research Centers","All","4 Years to 12 Years   (Child)","Phase 4","30","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMXAUT01","June 2013","April 2015","July 2015","July 25, 2014",,"April 16, 2015","IMMUNOe International Research Centers, Centennial, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02199925"
828,"NCT04511767","Reliability and Validity of CCISO for Diagnosis of Autism Spectrum Disorder",,"Recruiting","No Results Available","Autism Spectrum Disorder|Global Developmental Delay|Language Disorder","Other: Do not take any interventions","The scores of CCSIO for ASD/GDD/ID children|The scores of CCSIO for ASD/GDD/ID children (One quarter)","Children's Hospital of Fudan University","All","18 Months to 48 Months   (Child)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CCIOS2020","September 1, 2019","July 30, 2021","September 30, 2021","August 13, 2020",,"February 2, 2021","Children's hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04511767"
829,"NCT04768816","Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder",,"Recruiting","No Results Available","Safety Issues;Effect of Drugs","Drug: 0.9% Sodium Chloride|Biological: Autologous Umbilical Cord Blood","ABC|CARS","Guangdong Women and Children Hospital","All","2 Years and older   (Child, Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GuangdongWCHASD","July 1, 2019","December 31, 2022","December 31, 2024","February 24, 2021",,"February 24, 2021","Guangdong Women and Children's Hospital and Health Institute, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04768816"
830,"NCT04903353","Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole",,"Recruiting","No Results Available","Weight Gain|Autism Spectrum Disorder|Medication Side Effect","Drug: Comparison of Risperidone and Aripiprazole","weight gain","Vanderbilt University Medical Center","All","up to 17 Years   (Child)","Phase 4","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","210757","November 1, 2021","July 1, 2024","July 1, 2025","May 26, 2021",,"September 21, 2021","Division of Developmental Medicine, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04903353"
831,"NCT01917864","iPad Application to Treat Prosodic Deficits in Students With Communication Disorders",,"Completed","No Results Available","Autism|Communication Disorders","Behavioral: iPad Application","Effectiveness of software|Usability of software|Student engagement in treatment|Improvement in peer acceptance","Yale University|Handhold Adaptive","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1306012259|ED-IES-13-R-0005","July 2013","May 2016","May 2016","August 7, 2013",,"June 14, 2016","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01917864"
832,"NCT04505488","Efficacy of the ASPEN Intervention Program in Low-Resource Communities","ASPEN","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: ASD Screening Parent ENgagement Intervention Program (ASPEN)","Adaptive Behavior|Child Cognition|Parenting Stress|Parent Empowerment|Child Challenging Behavior|Family Quality of Life","Texas State University, San Marcos|National Institute on Disability, Independent Living, and Rehabilitation Research","All","18 Months to 6 Years   (Child)","Not Applicable","320","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","90IFST0004","July 7, 2020","June 30, 2022","June 30, 2022","August 10, 2020",,"October 7, 2021","Texas State University, San Marcos, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04505488"
833,"NCT01160783","Genetic Contributions to Autism Spectrum Disorders",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder|Autism|Asperger's Syndrome|Pervasive Developmental Disorder",,"Gene expression levels","Boston Children's Hospital","All","18 Months and older   (Child, Adult, Older Adult)",,"240","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","07-04-0136","April 2007","December 2022","February 2024","July 12, 2010",,"August 3, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01160783"
834,"NCT02275715","Treatment of Feeding Problems in Children With Autism","PT-F","Completed","No Results Available","Treatment of Feeding Problems in Children With ASD","Behavioral: Parent Training Program","Number of Subjects with Complete Data|Treatment Fidelity|Parent Adherence|Brief Autism Mealtime Behavior Inventory (BAMBI)","University of Florida|University of Rochester|National Institute of Mental Health (NIMH)","All","2 Years to 7 Years   (Child)","Not Applicable","54","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB201400831-N","February 2015","January 25, 2017","June 25, 2017","October 27, 2014",,"April 5, 2018","University of Florida, Gainesville, Florida, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02275715"
835,"NCT05035511","A Machine Learning Approach for Predicting tDCS Treatment Outcomes of Adolescents With Autism Spectrum Disorders",,"Not yet recruiting","No Results Available","Transcranial Direct Current Stimulation|Autistic Disorders Spectrum|Electroencephalography|Machine Learning","Device: tDCS","Change in behavioral measures (social communication and restricted repetitive behavior) - Social Responsiveness Scale-2nd edition (SRS-2)|ASD symptomatology - The Autism Diagnostic Interview-Revised (ADI-R)|Change in CANTAB® cognitive tests - Multitasking Test (MTT)|Change in CANTAB® cognitive tests - Stop Signal Task (SST)|Change in CANTAB® cognitive tests - Emotion Recognition Task (ERT)|Change in Neurophysiological measures","The Hong Kong Polytechnic University|Chinese University of Hong Kong","All","16 Years to 22 Years   (Child, Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSEAR20201118003-01","September 2021","September 2024","December 2024","September 5, 2021",,"September 9, 2021","The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05035511"
836,"NCT01187784","Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety",,"Completed","No Results Available","Autism Spectrum Disorder|Autism|Asperger Syndrome|PDD-NOS","Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth","Anxiety Disorders Interview Schedule - Child/Parent Version|Multidimensional Anxiety Scale for Children|Spence Children's Anxiety Scale (Child and Parent Versions)","Alliant International University|National Foundation for Autism Research|Autism Society of America - San Diego Chapter","All","7 Years to 14 Years   (Child)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","McNallyKeehn","May 2009","August 2010","August 2010","August 24, 2010",,"August 24, 2010","Alliant International University, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01187784"
837,"NCT04146428","Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial","EBJ","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: clinician-mediated JASPER|Behavioral: parent-mediated JASPER","Change in frequency of language utterances and number of conversation turns using the Elicitation of Language Samples for Analysis- Toddlers (ELSA-T)|Change in social communication using the Brief Observation of Social Communication Change (BOSCC)","University of California, Los Angeles|Simons Foundation","All","18 Months to 5 Years   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-001638","April 27, 2021","April 1, 2022","August 31, 2022","October 31, 2019",,"April 28, 2021","UCLA, Los Angeles, California, United States|Semel Institute, Los Angeles, California, United States|Boston University, Boston, Massachusetts, United States|Weill Cornell Medical College/New York Presbyterian Hospital, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT04146428"
838,"NCT04930471","Steroid and Behaviour Changes Under Metformin",,"Not yet recruiting","No Results Available","Autistic Disorder","Drug: Metformin","Changes in GC-MS measured urinary androgen metabolite levels.|Changes in GC-MS measured urinary oestrogen metabolite levels.|Changes in GC-MS measured urinary progesterone metabolite levels.|Changes in GC-MS measured urinary aldosterone metabolite levels.|Changes in GC-MS measured urinary corticosterone metabolite levels.|Changes in GC-MS measured urinary cortisone metabolite levels.|Changes in GC-MS measured urinary cortisol metabolite levels.|Behavioral Changes|Correlation between urinary steroid hormone level changes (metabolites of androgen, oestrogen, progesterone, aldosterone, corticosterone, cortisone and cortisol) and behavioral changes measured with pearson correlation coefficient.","University Hospital Inselspital, Berne|Lindenhofstiftung","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Steroid Changes Metformin","June 2021","August 2023","December 2023","June 18, 2021",,"June 18, 2021","Lindenhofgruppe, Berne, Switzerland",,"https://ClinicalTrials.gov/show/NCT04930471"
839,"NCT04001790","Effect of a 9-Month Internship Intervention for Military Dependents With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Project Search plus ASD Supports","Change in Competitive Integrated Employment rates|Change in Number of hours worked|Change in hourly Wage earned|Change in Social responsiveness|Quality of Life of Individual with ASD|Change in anxiety|Change in Depression","Virginia Commonwealth University|United States Department of Defense","All","18 Years to 21 Years   (Adult)","Not Applicable","38","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20008778|CDMRP AR150172","May 11, 2017","May 19, 2021","May 19, 2021","June 28, 2019",,"June 3, 2021","Virginia Commonwealth University, Richmond, Virginia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04001790/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04001790"
840,"NCT04764539","Video Assisted Speech Technology to Enhance Motor Planning for Speech","VAST","Completed","No Results Available","Autism Spectrum Disorder|Apraxia of Speech","Behavioral: Video Assisted Speech Therapy (VAST)","Increased mean length of utterance (MLU)|percentage of correctly transcribed words using automatic speech recognition|change speech intelligibility|Generalization of skills","iTherapy, LLC|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","4 Years to 8 Years   (Child)","Phase 1","6","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R43DC018447-01","December 1, 2019","November 30, 2020","November 30, 2020","February 21, 2021",,"February 21, 2021","All research was conducted via tele-research due to COVID-19, Vallejo, California, United States",,"https://ClinicalTrials.gov/show/NCT04764539"
841,"NCT01553240","Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies",,"Terminated","Has Results","Autism Spectrum Disorder|Asperger Disorder|Pervasive Developmental Disorder","Device: TMS and functional MRI (Magstim)","Repetitive Behavior Scale-revised|Vineland Maladaptive Behavior Scale","New York State Psychiatric Institute","All","18 Years to 55 Years   (Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","5438","June 2007","June 2010","June 2010","March 14, 2012","January 13, 2017","January 13, 2017","New York state Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01553240"
842,"NCT04422483","A Realist Evaluation of Autism ServiCe Delivery (RE-ASCeD)","Re-ASCed","Recruiting","No Results Available","Autism|Children|Family|Diagnoses, Syndromes, and Conditions|Patient Satisfaction","Other: Realist evaluation","Case Study: Case Note Review - Pathway completion time taken|Questionnaire: Reported Challenges|Questionnaire: Reported Type of Service|Questionnaire: Reported New Models of Services|Questionnaire: Reported Geographical Area|Questionnaire: Reported Activity Levels|Questionnaire: Reported Resources Available|Questionnaire: Reported Age Range of Service|Questionnaire: Reported Clinical Remit|Questionnaire: Reported Clinical Team Competencies for Clinical Remit|Case Study - Diagnostic Team Realist Interviews|Case Study: Child and Family Interviews|Case Study: Case Note Review - Dates of Meetings|Case Study: Case Note Review - Duration of Meetings|Case Study: Case Note Review - Purpose of Clinical Meeting|Case Study: Case Note Review - Test results|Case Study: Case Note Review Pathway completion final diagnosis|Case Study: Case Note Review Pathway Completion Co-Morbidities|Case Study: Case Note Review Pathway Completion- type of professional involved","Sussex Community NHS Foundation Trust|University of Kent|University of Surrey|Newcastle University|Council for Disabled Children|Autistica|West Sussex Parent Carer Forum|Northumberland, Tyne and Wear NHS Foundation Trust|Cambridgeshire and Peterborough NHS Foundation Trust|Brighton & Sussex Medical School|National Health Service, United Kingdom","All","Child, Adult, Older Adult",,"520","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","Re-ASCed Protocol IM 17-4-20","November 30, 2019","June 30, 2022","December 30, 2022","June 9, 2020",,"May 6, 2021","Nightingale Primary Care Centre, Haywards Heath, West Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04422483"
843,"NCT04769011","Motor Impairments in Children With Autism Spectrum Disorder: a Multimodal Approach","MOSAICO","Recruiting","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Intellectual Disability","Diagnostic Test: Clinical evaluation|Diagnostic Test: Neuropsychological evaluation|Diagnostic Test: Neurophysiological evaluation|Diagnostic Test: Genetic evaluation","Movement Assessment Battery for Children 2 (MABC2)|Developmental Coordination Disorder Questionnaire (DCDQ)|kinematic analysis of a reach-to-drop task|Magnetic Resonance (MRI)|Diffusion Tensor Imaging (DTI)|Exome sequencing","IRCCS Eugenio Medea","All","1 Year to 14 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","510","January 2, 2018","December 2021","December 2021","February 24, 2021",,"February 24, 2021","IRCCS E. Medea, Bosisio Parini, Lecco, Italy",,"https://ClinicalTrials.gov/show/NCT04769011"
844,"NCT03333629","Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder","Behavioral: Enhanced early detection","Change in ASD Symptom Severity|Change in Cognitive Functioning|Adaptive Functioning|ASD Symptoms - secondary measure1|Kindergarten Readiness|Social Engagement|Long-term change in Cognitive Functioning|Parent-Child Social Engagement|ASD symptoms - secondary measure2|ASD symptoms - secondary measure3|Long-term change in Cognitive Functioning (alternative)","Drexel University|University of California, Davis|University of Connecticut","All","16 Months to 58 Months   (Child)","Phase 4","3450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","R01MH115715","November 29, 2017","May 31, 2023","May 31, 2023","November 7, 2017",,"September 24, 2021","University of California, Davis, Sacramento, California, United States|University of Connecticut, Storrs, Connecticut, United States|Drexel University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03333629"
845,"NCT02383758","An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders",,"Completed","Has Results","Encopresis|Autistic Disorder","Drug: Glycerin Suppository|Drug: Bisacodyl suppository|Drug: Senna","Percent Continent|Percent Independence|Mean Clinical Global Impression for Severity (CGI-S) Score|Mean Clinical Global Impression for Improvement (CGI-I) Score","Emory University|Organization for Autism Research","All","5 Years to 21 Years   (Child, Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00076608","February 1, 2015","January 1, 2017","January 1, 2017","March 9, 2015","January 11, 2018","July 2, 2018","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02383758"
846,"NCT01552460","Brain Genomics Superstruct Project",,"Completed","No Results Available","Autism Spectrum Disorders",,"Neuroimaging phenotype","Massachusetts General Hospital|Harvard University","All","13 Years and older   (Child, Adult, Older Adult)",,"61","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2011P000375","April 2011","January 2015","January 2015","March 13, 2012",,"July 9, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01552460"
847,"NCT01631851","Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism|Autism Spectrum Disorder (ASD|Asperger's Disorder|Pervasive Developmental Disorder (PDD-NOS)","Behavioral: Cognitive-Behavioral Therapy (CBT) for Irritability","ABC Irritability Scale","Yale University","All","9 Years to 16 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0102012121-B","May 2011","December 2021","December 2021","June 29, 2012",,"March 1, 2021","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01631851"
848,"NCT00954083","A Pilot Trial of a Developmental, Individual-Difference, Relationship-Bases (DIR)/Floortime for Children With Autistic Spectrum Disorders","DIR","Completed","No Results Available","Autistic Spectrum Disorders","Behavioral: DIR/Floortime|Behavioral: Routine care","The Functional Emotional Assessment Scale (FEAS) Ratings (the child part)|The Childhood Autism Rating Scale (CARS) Clinical rating of the children (6 point scale related to Greenspan's six Functional Development Level -FDL) Satisfaction of the effectiveness of the intervention of their child (Six-point Likert scale)","Mahidol University","All","2 Years to 6 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","194/2550 (EC2)","June 2007","October 2008","April 2009","August 6, 2009",,"August 6, 2009",,,"https://ClinicalTrials.gov/show/NCT00954083"
849,"NCT03380078","Translating Evidence-based Interventions for ASD: Multi-Level Implementation Strategy","TEAMS","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Teams Leadership Institute (TLI)|Behavioral: Motivational Enhancement (TIPS for Training)|Behavioral: Classroom Pivotal Response Teaching (CPRT)|Behavioral: An Individualized Mental Health Intervention for ASD (AIM HI)","Provider Training Completion / Certification|Child Improvements on The Eyberg Child Behavior Inventory (ECBI)|Child Improvements on the PDD Behavior Inventory, Parent Extended Version (PDDBI-PX)","University of California, Davis|University of California, San Diego|University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","990914|R01MH1198101|RO1MH1195001","October 20, 2017","June 30, 2021","December 2021","December 20, 2017",,"September 16, 2021","University of California, Davis, Sacramento, California, United States|University of California, San Diego, San Diego, California, United States|University of California, Los Angeles, Westwood, California, United States",,"https://ClinicalTrials.gov/show/NCT03380078"
850,"NCT01352611","Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen",,"Withdrawn","No Results Available","Autism Spectrum Disorder","Drug: baclofen, intrathecal","Modified Short Sensory Profile.|Clinical Global Impression of Change in Autism Symptoms","University of Missouri-Columbia","All","10 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1109397","September 2014","April 2015","April 2015","May 12, 2011",,"October 6, 2016","University Hospital/University of Missouri Health Care, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01352611"
851,"NCT04972838","AIR-B4: Remaking Recess (RR)","RR","Recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Behavioral: Remaking Recess (RR)","Stages of Implementation Completion (SIC)|School Implementation Climate Scale|Social Network Survey- participants of survey will name key personnel that can be participants of the UNITED team for this intervention|Teacher Perceptions Scale|Clinical Global Rating (CGI)","Health Resources and Services Administration (HRSA)|University of California, Davis|University of Kansas|University of Washington|University of Pennsylvania|University of Rochester|Drexel University","All","5 Years to 12 Years   (Child)","Not Applicable","264","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-001993","August 15, 2021","August 31, 2025","December 1, 2025","July 22, 2021",,"July 22, 2021","University of Rochester, Rochester, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04972838"
852,"NCT02739321","Examining the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD",,"Completed","Has Results","Autism Spectrum Disorders","Device: Sound to Sleep System","Compare Percentage of Participants Who Drop Out of Study as a Measure of Toleration of Mattress Technology|Parent Reported Quality of Sleep Across Treatment Conditions|Total Time Asleep Recorded by Actigraphy Watch|Total Time to Fall Asleep (Sleep Latency) Recorded by Actigraphy Watch|Total Time Awake During Night Recorded by Actigraphy Watch|Percentage of Time in Bed That the Participant Spent Sleeping (Sleep Efficiency) Recorded by Actigraphy Watch.|Caregiver-Rated Severity of Social Deficits as Measured by the Social Responsiveness Scale 2 (SRS-2)|Caregiver-Rated Severity Problem Behaviors as Measured by the Aberrant Behavior Checklist (ABC)|Caregiver-Rated Communication Problems as Measured by the CCC-2|Caregiver-Rated Problems With Sleep Habits as Measured by the FISH|Caregiver-Rated Sleep Disturbance as Measured by the Children's Sleep Habits Questionnaire (CSHQ)|Caregiver-Rated Sensory Issues Across Domains as Measured by the SSPQ|Caregiver-Rated of Quality of Life as Measured by the CFQL-2 Questionnaire|Caregiver-Rated Measure of Challenging Behavior/Task Compliance as Measured by the Daily Sleep Diary|Caregiver-Rated Measure of Tolerance of Mattress Technology as Measured by the Daily Sleep Diary|Caregiver-Rated Measure of Tolerance of the Actigraph Watch as Measured by the Daily Sleep Diary|Caregiver-Rated Measure of Ease of Mattress Technology Use as Measured by the Daily Sleep Diary|Caregiver-Rated Measure of Sleep Resistance as Measured by the Daily Sleep Diary","The Cleveland Clinic|Kugona LLC","All","30 Months to 13 Years   (Child)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","14-066","May 2014","December 2015","February 2016","April 15, 2016","November 6, 2017","November 6, 2017","Cleveland Clinic Center for Autism, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02739321"
853,"NCT04972825","AIR-B4: Mind the Gap","MTG","Recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Behavioral: Mind the Gap","Stages of Implementation Completion (SIC)|School Implementation Climate Scale (SICS)|Change in Coaching Session Data Form from month to month|Family Empowerment Scale (Koren, DeChillo & Friesen, 1992)|WHOQOL scale|Social Network Survey|Caregiver Satisfaction Survey","Health Resources and Services Administration (HRSA)|University of Rochester|University of Kansas|University of Pennsylvania|Drexel University|University of California, Davis|University of Washington","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","308","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-001403","June 29, 2021","August 1, 2025","August 31, 2025","July 22, 2021",,"July 22, 2021","UC Davis MIND Institute, Davis, California, United States|University of Kansas, Lawrence, Kansas, United States|University of Rochester, Rochester, New York, United States|UPENN, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04972825"
854,"NCT03170453","Confirmatory Efficacy Trial of Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder","PerspectivesII","Active, not recruiting","No Results Available","Autistic Disorder|Autism Spectrum Disorder|Asperger Syndrome|Pervasive Developmental Disorder","Behavioral: Cognitive Enhancement Therapy|Behavioral: Enriched Supportive Therapy","Change in Neurocognition|Change in Social cognition|Change in Functional outcome","University of Pittsburgh","All","16 Years to 45 Years   (Child, Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MH106450","June 1, 2015","March 31, 2022","March 31, 2023","May 31, 2017",,"March 3, 2021","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03170453"
855,"NCT02435407","The Sequential Oral Sensory Approach for Limited Food Repertoire in Children With Autism Spectrum Disorder","SOS","Unknown status","No Results Available","Autism Spectrum Disorder|Feeding Disorder|Restricted Diet","Behavioral: SOS|Other: Education","Change in the number of foods eaten after 12 weeks of intervention as determined by the 3 day food diary|Change in the level of parental stress around meal times after 12 weeks of intervention as determined by the Parent Stress Index questionnaire|Description of the sensory profiles of participants as determined by the Short Sensory Profile- short form Questionnaire","Holland Bloorview Kids Rehabilitation Hospital|The Hospital for Sick Children","All","4 Years to 8 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB file # 14-511","January 2015","September 2015","December 2015","May 6, 2015",,"September 29, 2015","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02435407"
856,"NCT04593576","Impact of Sports Activity on Pragmatic Skills of Children",,"Completed","No Results Available","Autistic Disorder of Childhood Onset With Full Syndrome","Other: Physical activity protocol/out door sports|Other: Intensive table teaching speech therapy","Social Interaction tasks ABLLS-R (Assessment of basic language learning Skills-Revised)","Riphah International University","All","5 Years to 7 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC/00807 Saman Javaid","October 20, 2020","April 10, 2021","April 10, 2021","October 20, 2020",,"June 29, 2021","Profiles, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT04593576"
857,"NCT04972851","AIRB-4: Self-Determined Learning Model of Instruction","SDLMI","Recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Behavioral: Self-Determined Learning Model of Instruction (SDLMI)","Stages of Implementation Completion (SIC)|School Implementation Climate Scale|Self-Determination Inventory (SDI-SR)|Goal Attainment Scaling (GAS)|Social Network Survey","Health Resources and Services Administration (HRSA)|University of California, Davis|University of Kansas|University of Washington|University of Pennsylvania|University of Rochester|Drexel University","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","358","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-002001","August 15, 2021","August 31, 2025","December 1, 2025","July 22, 2021",,"July 22, 2021","UC Davis MIND Institute, Davis, California, United States|University of Kansas, Lawrence, Kansas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04972851"
858,"NCT01506232","Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study",,"Terminated","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Bipolar Disorder",,"Agreement between clinical diagnoses and the results of brain activity flow pattern analysis (BAFPA).","Massachusetts General Hospital|ElMindA Ltd","All","6 Years to 17 Years   (Child)",,"1","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2010P000547","March 2011","November 2012","November 2012","January 9, 2012",,"July 9, 2021","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01506232"
859,"NCT02721381","Comparative Efficacy of Self-directed & Therapist-assisted Telehealth Parent Training Intervention for Children With ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: ImPACT Online","ImPACT Online Fidelity Change Scale|Parent Sense of Competence Change Scale|Mullen Scales of Early Learning Change Score|MacArthur-Bates Child Developmental Inventory Change Score|Parent-child Interaction Change|ImPACT Online electronic tracking system|Intervention Log Change|Vineland Adaptive Behavior Scales Change Score","Michigan State University","All","18 Months to 95 Months   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R40MC27704","March 2015","September 2022","December 2023","March 29, 2016",,"March 25, 2021","Michigan State University Autism Lab, East Lansing, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02721381"
860,"NCT05025553","Oral Administration of Polyethylene Glycol (PEG) for 6 Months in Chronically Constipated Autistic Children",,"Completed","No Results Available","Autistic Spectrum Disorder|Constipation","Dietary Supplement: Gut mobilization","Change in stool quality|Change from baseline urinary concentrations of total p-cresol|Change in Childhood Autism Rating Scale (CARS)|Change in Repetitive Behavior Scale-Revised (RBS-R)|Change in Conners' Parent Rating Scale - Revised (CPRS-R)|Change in Social Responsiveness Scale (SRS)","University of Messina","All","2 Years to 8 Years   (Child)","Not Applicable","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PEG_study_ASD","January 1, 2018","January 1, 2021","February 1, 2021","August 27, 2021",,"August 27, 2021","Interdipartimental Program ""Autismo 0-90"" at ""G. Martino"" University Hospital, Messina, ME, Italy",,"https://ClinicalTrials.gov/show/NCT05025553"
861,"NCT02827279","Study of the Visual Perception During Emotional States on Subjects With an Intrusive Disorder of the Development","VisioTED","Unknown status","No Results Available","Autism Spectrum Disorder","Other: emotional induction","Ratio corresponding to the relative change in visual orientation","University Hospital, Montpellier","All","8 Years to 12 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","8991","March 2013","June 2017","June 2018","July 11, 2016",,"May 21, 2018","Montpellier University Hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02827279"
862,"NCT03369769","Wellness Effects of Animal-assisted Activities With Autism Spectrum Disorder Youth in a Specialized Psychiatric Hospital",,"Completed","No Results Available","Child Behavior|Autism Spectrum Disorder|Psychiatric Hospitalization|Veterinary Therapeutics","Other: Activity","Change in physiological measurements with the wristband device from baseline through 90 minutes.|Observation of Human Animal Interaction for Research (OHAIRE-modified)","University of Colorado, Denver|Human Animal Bond Institute for Research|Purdue University","All","4 Years to 16 Years   (Child)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","15-1227","August 6, 2015","February 27, 2017","March 13, 2019","December 12, 2017",,"May 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03369769"
863,"NCT02409303","An SRT Model for Early Access to ASD Intervention",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: Screen-Refer-Treat Intervention","Change in rates of ASD screening by PCPs at the 18-month Well-Child visit from baseline (pre-SRT intervention) to post-SRT intervention|Change in rates of referral for early intervention services by PCPs at the 18-month Well-Child visit from baseline (pre-SRT intervention) to post-SRT intervention|Change in percent of toddlers at risk for ASD recieving ASD-specialized behavioral intervention before 24 months from baseline (pre-SRT intervention) to post-SRT intervention|Change in average age at which children receive an ASD diagnosis from baseline (pre-SRT intervention) to post-SRT intervention|Change in levels of parenting stress, parenting efficacy, health quality of life, and satisfaction with the healthcare system from baseline (pre-SRT intervention) to post-SRT intervention|Change in levels of pivotal social-communicative behaviors in toddlers at risk for ASD from baseline (pre-SRT intervention) to post-SRT intervention","University of Washington|Seattle Children's Hospital|National Institute of Mental Health (NIMH)","All","16 Months and older   (Child, Adult, Older Adult)","Not Applicable","555","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","47892|R01MH104302-01","July 2015","June 2019","June 2019","April 6, 2015",,"October 30, 2017","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02409303"
864,"NCT01686685","Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months","ASD-CXCR4","Completed","No Results Available","Autism Spectrum Disorder|Complication of Prematurity",,"Diagnosis of ASD at 24 months corrected age|Language or cognitive delay at 24 months corrected age","Hadassah Medical Organization","All","up to 1 Day   (Child)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","begin1HMO-CTIL","September 2013","April 2018","April 1, 2018","September 18, 2012",,"April 12, 2018","Hadassah Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01686685"
865,"NCT04805957","Validation Digital Bio-markers During Sulforaphane Treatment.",,"Not yet recruiting","No Results Available","Autism|Autism Spectrum Disorder|Autistic Disorder","Dietary Supplement: Sulforaphane","Aberrant Behavior Checklist (ABC)|Social Responsiveness Scale (SRS)|Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)|Digital Biomarkers|EEG|EKG|Electrophysiological recordings.","Rutgers, The State University of New Jersey","Male","13 Years to 30 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2019001854","April 1, 2021","June 30, 2021","June 30, 2022","March 18, 2021",,"March 18, 2021","Rutgers-RWJMS Department of Neurology, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04805957"
866,"NCT04208425","Promoting Resilience in Teens With ASD","PRITA","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Project Personality|Behavioral: Sharing Feelings Intervention","Children's Depression Inventory-2 (CDI-2)|Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2)|Brief Symptom Inventory 18 (BSI-18)|Multidimensional Anxiety Scale for Children-2 (MASC-2)|Primary Control Scale for Children (PCSC)|Secondary Control Scale for Children (SCSC)|Social Responsiveness Scale-2 (SRS-2)|The Self Perception Profile for Children/ Adolescents (SPPC/A) self-report|Implicit Personality Theory Questionnaire (ITPQ)","Stony Brook University|Society of Clinical Child & Adolescent Psychology|Autism Research Institute","All","11 Years to 16 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB2019-00280|AWD00001042|AWD00001244","January 7, 2019","December 2021","March 2022","December 23, 2019",,"March 18, 2020","Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04208425"
867,"NCT01643343","Measurement of Joint Attention Fluency",,"Unknown status","No Results Available","Autism Spectrum Disorders|Autism",,,"The Vista School|Penn State University","All","8 Months to 6 Years   (Child)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","33060","October 2011","October 2013","October 2014","July 18, 2012",,"July 18, 2012","The Vista School, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01643343"
868,"NCT02939560","TMS for Adults With Autism and Depression","TAD","Completed","Has Results","Autism Spectrum Disorder|Depression|Depressive Disorder|Major Depressive Disorder","Device: NeuroStar® TMS device (Neuronetics, Atlanta, GA)","Change From Baseline in Hamilton Depression Rating Scale|Change From Baseline in Aberrant Behavior Checklist|Change From Baseline in Social Responsiveness Scale-2|Change From Baseline in Ritvo Autism-Aspergers Diagnostic Scale|Change From Baseline in Repetitive Behavior Scale-Revised|Change From Baseline in Functional MRI Scanning During Cognitive Processing Tasks","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00056546","September 2016","June 1, 2018","September 20, 2018","October 20, 2016","October 1, 2019","October 1, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02939560/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02939560"
869,"NCT03499262","Group Social ABCs: Early Intervention for Toddlers With Suspected ASD",,"Completed","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Group Social ABCs","Vocal Responsivity|Vocal Initiations|Social Orienting|Caregiver Fidelity of Implementation","Holland Bloorview Kids Rehabilitation Hospital","All","12 Months to 36 Months   (Child)","Not Applicable","93","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-745","March 26, 2018","December 23, 2020","December 23, 2020","April 17, 2018",,"July 23, 2021","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03499262"
870,"NCT04005547","Health Education and Relationships Through Theater: An RCT of Promoting Awareness Through Live Movement and Sound for Youth With Autism Spectrum Disorder (PALMS-ASD)","HEART","Unknown status","No Results Available","Sexual Health|Education, Health","Behavioral: Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder","unsafe sex self-report survey item|sexual health knowledge self-report survey scale|adult-teen communication youth-report survey scale|sexual health empowerment self-report survey scale|self-protective boundary knowledge self-report survey scale|sexual health efficacy self-report survey, item or scale","Public Health Management Corporation|Temple University","All","14 Years to 19 Years   (Child, Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PublicHMC|90AP2690-01-00","September 15, 2017","February 2021","February 2021","July 2, 2019",,"July 2, 2019","Public Health Management Corporation, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04005547"
871,"NCT01591707","Evaluating a Social and Communication Intervention for Preschoolers",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: ISC+PRT Intervention","Change in educator instruction to meet fidelity of intervention.|Change in Baseline Autism Diagnostic Observation Schedule|Change in Baseline Mullen Scales of Early Learning|Change in Child's Baseline Spontaneous Imitation Task|Change in Child Classroom-based Social Communication Performance|Change in parent perception of child behavior as recorded by the Autism Composite score of the PDDBI (parent version)","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|U.S. Department of Education","All","3 Years to 6 Years   (Child)","Not Applicable","700","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA_00073501","July 2012","January 2022","January 2022","May 4, 2012",,"March 10, 2021","Brennen School, Newark, Delaware, United States|Kennedy Krieger Institute/Howard County Public Schools, Baltimore, Maryland, United States|Elwyn Early Childhood Services, Media, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01591707"
872,"NCT04845243","Effectiveness of a Short Computer-based Emotion Recognition Training in Different Patient Groups",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Conduct Disorder","Behavioral: Emotionen Verstehen und Ausdrücken (E.V.A.)","Change in performance accuracy in Geneva Emotion Recognition Test (GERT)|Change in performance response times in Geneva Emotion Recognition Test (GERT)|Change in performance reaction times in Social decision-making task|Change in choices in Social decision-making task","Prof. Christina Stadler|University Psychiatric Clinics Basel","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EmoRecTraining_EVA","April 15, 2021","November 30, 2021","November 30, 2021","April 14, 2021",,"April 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04845243"
873,"NCT03197922","Encopresis & MIE (DoD #2)",,"Recruiting","No Results Available","Encopresis|Autism Spectrum Disorder","Combination Product: MIE Treatment","Change in Continence|Clinical Global Impression Scale - Improvement (CGI-I) Score|Caregiver Strain Questionnaire","Emory University|United States Department of Defense","All","5 Years to 12 Years   (Child)","Phase 3","112","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00095849","October 25, 2017","October 1, 2021","October 1, 2021","June 23, 2017",,"December 30, 2020","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03197922"
874,"NCT01730209","Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex","RAPIT","Unknown status","No Results Available","Tuberous Sclerosis Complex|TSC Related Cognitive Disability|TSC Related Autism|TSC Related Learning Problems","Drug: Everolimus|Drug: Placebo","Cognitive ability measured by IQ|Autistic features|Social and communicational skills|Working memory and attention, information processing|Visual-motor integration|Child behavior|Executive functioning|Sleeping problems|Child health|Sensory related difficulties|Epilepsy","Erasmus Medical Center|Utrecht University","All","4 Years to 15 Years   (Child)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL38619.078.11","November 2012","November 2015","November 2016","November 21, 2012",,"May 5, 2015","Erasmus Medical Center, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01730209"
875,"NCT03560453","Facilitating Employment for Youth With Autism",,"Completed","No Results Available","Autism Spectrum Disorder|Autism|Asperger Syndrome|Pervasive Developmental Disorder|Adolescent Development","Behavioral: Project SEARCH Plus ASD Supports","Change in Employment Outcomes Survey from Graduation to 12 months follow-up|Change in the Support Intensity Scale (SIS; Thompson, et al., 2004) from Graduation to 12 months follow-up|Change in Social Responsiveness Scale, Second Edition (Constantino & Gruber, 2012) from Graduation to 12 months follow-up|Change in The ARC's Self-Determination Scale (Wehmeyer, 1996) from from Graduation to 12 months follow-up|Change in The Short Form 36 Version 2 (SF-36v2, Maurish & Turner-Bowker, 2009) from from Graduation to 12 months follow-up","Virginia Commonwealth University|National Institute on Disability, Independent Living, and Rehabilitation Research","All","18 Years to 22 Years   (Adult)","Not Applicable","162","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM15031|NIDILRRDRRP13-16","August 1, 2013","March 15, 2018","March 15, 2018","June 18, 2018",,"July 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03560453"
876,"NCT00902798","Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder","Perspectives","Completed","No Results Available","Autistic Disorder|Autism Spectrum Disorder|Asperger's Syndrome|Pervasive Developmental Disorder","Behavioral: Cognitive Enhancement Therapy|Behavioral: Enriched Supportive Therapy","Neurocognition|Social cognition|Functional outcome","University of Pittsburgh|National Institute of Mental Health (NIMH)|Autism Speaks|United States Department of Defense|Pennsylvania Department of Health","All","16 Years to 45 Years   (Child, Adult)","Not Applicable","54","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MH085851|R33MH085851|R21MH085851|AR100344|05381|2008NF-Autism|ARI2014","August 2010","April 2016","June 2017","May 15, 2009",,"April 13, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00902798"
877,"NCT03814902","A Pilot Study to Characterize the Household Impact of Locating Devices for Children With ASD Who Wander","CHILD","Completed","No Results Available","Autism Spectrum Disorder|Wandering Behavior","Device: Electronic Tracking Device","Rates of participant retention|Rates of questionnaire completion|Adherence to the intervention|Changes from baseline in Caregiver Strain Questionnaire (CGSQ) scores|Changes from baseline in GAD-7 scores|Changes from baseline in BFDS scores|Changes from baseline in the frequency of wandering-related disruptions to the household.|Perceived impact of the intervention","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18-0314_A","January 15, 2019","November 11, 2019","November 11, 2019","January 24, 2019",,"January 5, 2021","Cohen Children's Medical Center of New York, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT03814902"
878,"NCT01008800","A Randomized Clinical Trial for Toddlers With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Social Communication|Behavioral: Social communication","Communication and Symbolic Behavior Scales|Mullen Scales of Early Learning","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|HRSA/Maternal and Child Health Bureau","All","22 Months to 33 Months   (Child)","Not Applicable","196","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R40 MC 15594-01|NA_00030329","September 2009","February 2013","February 2013","November 6, 2009",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01008800"
879,"NCT00337571","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)",,"Completed","Has Results","Behavioral Symptoms|Autistic Disorder","Drug: Aripiprazole|Drug: Placebo","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","6 Years to 17 Years   (Child)","Phase 3","218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-179","June 2006","June 2008","June 2008","June 16, 2006","July 23, 2009","December 2, 2013","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Huntington Beach, California, United States|University Of California-Davis Medical Center, Sacramento, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children'S Hospital, Aurora, Colorado, United States|Marsella, Gregory, Boca Raton, Florida, United States|University Of Florida, Gainesville, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Cambridge Health Alliance, Medford, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Children'S Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children'S Mercy Hospital, Kansas City, Missouri, United States|Munroe-Meyer Institute, Omaha, Nebraska, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver And New York Autism Center Of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Mission Hospitals, Asheville, North Carolina, United States|Duke Child And Family Study Center, Durham, North Carolina, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Children'S National Medical Center, Fairfax, Virginia, United States|Pacific Institute Of Medical Sciences, Bothell, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00337571"
880,"NCT01092208","Studies of Autistic Patients: Gene Networks and Clinical Subtypes",,"Terminated","No Results Available","Autism|Tuberous Sclerosis",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","4 Years to 18 Years   (Child, Adult)",,"11","NIH","Observational","Time Perspective: Retrospective","100084|10-CH-0084","March 17, 2010",,"September 24, 2013","March 24, 2010",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01092208"
881,"NCT01187940","Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder",,"Unknown status","No Results Available","Efficacy of PEGASUS","Behavioral: PEGASUS","Autism Knowledge Questionnaire|Child Behaviour Checklist|Vineland-II, Rosenburg Self-Esteem Scale|Parenting Stress index|Qualitative interview conducted at baseline and termination.","Institute of Child Health","All","9 Years to 14 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09BS22","September 2010","September 2012",,"August 24, 2010",,"August 24, 2010","Institute of Child Health, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01187940"
882,"NCT04369417","Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD)","SibChat","Active, not recruiting","No Results Available","Stress","Behavioral: Relaxation Response Resiliency Program for Siblings of Children with ASD","Feasibility assessed by the number participants enrolled.|Feasibility assessed by the number SibChat-3RP of sessions attended|Feasibility assessed by the survey retention post intervention.|Acceptability assessed using the participant feedback survey|Acceptability assessed by relaxation response adherence|Effectiveness of trial on improving stress coping ability (assessed using Measure of Current Status-A)|Effectiveness of trial on improving resiliency (assessed using Current Experiences Scale)|Pre-post intervention changes as measured by change in primary outcome scores of resiliency and stress coping.|Sustained improvements in primary outcomes of resiliency and stress coping as measured by sustained change in primary outcome scores.","Massachusetts General Hospital|Health Resources and Services Administration (HRSA)","All","14 Years to 17 Years   (Child)","Not Applicable","40","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019P003218","January 28, 2020","January 20, 2021","February 1, 2021","April 30, 2020",,"January 14, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04369417"
883,"NCT01854333","The Swedish Versions of ADOS and ADI-R: Psychometric Validation",,"Completed","No Results Available","Autism Spectrum Disorders","Other: ADOS module 1-4 or ADI-R","Diagnosis of Autism Spectrum Disorders","Karolinska Institutet","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","EvaluationADOS&ADI-R","January 2011","October 2014","November 2014","May 15, 2013",,"June 24, 2015","Karolinska Institute Center for Neurodevelopmental Disorders, Stockholm, Stockholms län, Sweden",,"https://ClinicalTrials.gov/show/NCT01854333"
884,"NCT04053036","Effects of Drugs on Responses to Brain and Emotional Processes","MAT","Completed","No Results Available","Autism Spectrum Disorder|Healthy","Drug: MDMA|Drug: Placebo oral tablet","Change in responses to affective touch","University of Chicago","All","21 Years to 40 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB19-0174","August 8, 2019","April 12, 2021","April 12, 2021","August 12, 2019",,"June 9, 2021","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04053036"
885,"NCT03199937","Executive Function Intervention for High School Students With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Flexible Futures|Other: Current standard of care","Change in Behavior Rating Inventory of Executive Function (BRIEF)- Self-Report Form (Gioia, Isquith, Guy & Kenworthy, 2000).|Change in Challenge Task (CT) scores|Change in Wechsler Abbreviated Scale of Intelligence- Second Edition (WASI-II, Wechsler, 2011), block design subtest|Change in Delis-Kaplan Executive Functioning System (DKEFS; Delis, Kaplan, and Kramer, 2001), Sorting subtest|Change in Tower of London-Drexel (TOL-DX; Culbertson & Zillmer, 2000) scores|Change in Adaptive Behavior Assessment System-Second Edition (ABAS-2)|Social Responsiveness Scale-Second Edition (SRS-2; Constantino and Gruber 2012)|Change in Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2)- Parent Form (Gioia, Isquith, Guy & Kenworthy, 2015).|Flexibility and Planning Interference Scale|The Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP, Swanson, 1992)|Classroom Observations|Cognitive Flexibility Task","Children's National Research Institute|Georgetown University","All","14 Years to 22 Years   (Child, Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1K23MH110612-01|OAR Innovative Research Award","July 11, 2015","April 23, 2019","June 30, 2019","June 27, 2017",,"April 10, 2020","Children's Research Institute, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03199937"
886,"NCT00380692","Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder",,"Completed","Has Results","Autistic Disorder|Attention Deficit Disorder With Hyperactivity","Drug: Atomoxetine|Drug: Placebo","ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score|Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)|Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)|ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score|Sleep Measure Scale|Aberrant Behavior Checklist (ABC)|Children's Social Behavior Questionnaire (CSBQ) Total Score|General Health Questionnaire (GHQ) Total Score|Nijmeegse Ouderlijke Stress Index (NOSI) Total Score|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement|Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times|Cytochrome P450 2D6 Genotype","Eli Lilly and Company","All","6 Years to 17 Years   (Child)","Phase 4","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10483|B4Z-UT-S017","October 2006","May 2008","October 2008","September 26, 2006","July 8, 2009","May 11, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoorn, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oosterhout, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00380692"
887,"NCT02956226","Cannabinoids for Behavioral Problems in Children With ASD","CBA","Completed","No Results Available","Autistic Disorder","Drug: Cannabinoids - 99% pure cannabinoids mix|Drug: Placebo|Drug: Cannabinoids - whole plant extract","Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition.|Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition.|Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject differences between the placebo condition and the pure cannabinoids condition and between the whole plant extract condition and the pure cannabinoids condition.|Change in Social Responsiveness Scale scores-2 (SRS-2, parent and teacher rated) at three months|Change in Autism Parenting Stress Index (APSI) score, at three months|Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months.","Shaare Zedek Medical Center","All","5 Years to 21 Years   (Child, Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBA","January 2017","October 2018","December 2018","November 6, 2016",,"December 27, 2018","Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02956226"
888,"NCT03047018","Open Trial Obesity CHANGE Program ASD",,"Completed","No Results Available","Autism Spectrum Disorder|Obesity","Behavioral: The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program","Willingness to Participate|Attendance Rate|Percent Homework Adherence|Percent Demonstration of Skills|Attrition Rate|Percent Satisfaction|Therapist Fidelity to the Treatment Manual|Difference in Body Mass Index (BMI) Percentile|Change in Food Preference Inventory (FPI) Score|Change in physical activity|Change in Parenting Stress Index- Short Form (PSI-SF) Score","Emory University","All","5 Years to 12 Years   (Child)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00090911","October 6, 2017","March 20, 2020","March 20, 2020","February 8, 2017",,"December 4, 2020","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03047018"
889,"NCT03225651","Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism","ASPRA","Completed","No Results Available","Stem Cell Transplantation","Biological: Stem cell transplantation|Behavioral: Psychological therapy and Rehabilitation","Assess the change in autism level by using tools|Evaluate the safety of therapy by record number of adverse events","Vinmec Research Institute of Stem Cell and Gene Technology","All","3 Years to 7 Years   (Child)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecRISCGT69","July 18, 2017","August 30, 2019","August 30, 2019","July 21, 2017",,"September 6, 2019","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03225651"
890,"NCT00227487","Intestinal Inflammation and Carbohydrate Digestion in Autistic Children",,"Unknown status","No Results Available","Autism|Inflammation","Other: Stool collection|Other: Administration of carbohydrate solution during clinically indicated endoscopy|Other: Questionnaires",,"Massachusetts General Hospital|Autism Speaks","All","18 Months to 17 Years   (Child)","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KRPP1","October 2005","May 2011","December 2017","September 28, 2005",,"September 30, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Newton Wellesley Hospital, Newton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00227487"
891,"NCT02995408","Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder","ASD","Unknown status","No Results Available","Stress","Behavioral: Relaxation Response Resiliency Program for Parents of Children with ASD","Distress Tolerance|Stress Reactivity","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P002037","December 2016","January 2018","January 2018","December 16, 2016",,"September 20, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02995408"
892,"NCT02339935","Improving Hospitalizations for Children With ASD",,"Completed","No Results Available","Autism Spectrum Disorder|Autistic Disorder","Behavioral: Brief Analogue Functional Analysis|Other: No Brief AFA","Aberrant Behavior Checklist|Decrease in Length of Hospitalization|Clinical Global Impression Scales of Severity|Blinded Observational Ratings|Physician/Nurse/Family Perception of Care","Vanderbilt University","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","141265","January 2015","November 2015","November 2015","January 16, 2015",,"April 27, 2016","Vanderbilt University Medical Center - MEND Clinic, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02339935"
893,"NCT00844753","Atomoxetine, Placebo and Parent Management Training in Autism","Strattera","Completed","Has Results","Autism|Pervasive Development Disorder|Asperger's Disorder|Attention Deficit Hyperactivity Disorder","Drug: atomoxetine|Drug: Placebo|Behavioral: Parent Management Training","Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents|Percentage of Participants Who Were Autism Spectrum Disorder Respondents","University of Rochester|University of Pittsburgh|Ohio State University","All","5 Years to 14 Years   (Child)","Phase 4","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1R01MH079082-01A2","October 2008","April 2014","April 2014","February 16, 2009","February 4, 2016","February 4, 2016","University of Rochester Medical Center, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00844753"
894,"NCT04953793","High School SUCCESS: Vocational Soft Skills Program for Transition-Age ASD Youth","TAY SUCCESS","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: TAY SUCCESS|Other: Usual Care","Behavior Rating Inventory of Executive Function (BRIEF-2/BRIEF-A)|Delis Kaplan Executive Function Scale (DKEFS)|Social Responsiveness Scale 2 (SRS-2)","Rady Children's Hospital, San Diego","All","15 Years to 22 Years   (Child, Adult)","Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R34MH111491","November 6, 2017","January 20, 2020","December 31, 2020","July 8, 2021",,"July 8, 2021","Rady Children's Hospital San Diego, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04953793/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04953793"
895,"NCT04820647","KF STRIDE to Improve Job Interview Skills",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: KF-STRIDE","Mock Job Interview|employment status (yes=1, no=0)|time-to-reach-employment (assessed as weeks since intervention completion).","Kessler Foundation","All","16 Years to 21 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","E-1139-21","March 29, 2021","March 2023","March 2023","March 29, 2021",,"April 22, 2021","Kessler Foundation, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04820647"
896,"NCT02909959","Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder",,"Completed","Has Results","Autism Spectrum Disorder|Autistic Disorder|Neurodevelopmental Disorder|Childhood Developmental Disorders, Pervasive","Drug: Sulforaphane|Drug: Placebo","Social Responsiveness Scale-2 (SRS-2) Total Score at Baseline|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 4|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 8|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 12|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 16|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Awareness)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Cognition)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Communication)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Motivation)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Restricted Interests/Repetitive Behaviors)|Aberrant Behavior Checklist (ABC) Subscale Score (Social Withdrawal)|Aberrant Behavior Checklist (ABC) Subscale Scores (Hyperactivity)|Aberrant Behavior Checklist (ABC) Subscale Score (Inappropriate Speech)|Aberrant Behavior Checklist (ABC) Subscale Score (Stereotypy)|Aberrant Behavior Checklist (ABC) Subscale Score (Irritability)|Clinical Global Impression-Severity (CGI-S) Score|Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score of Much Improved or Very Much Improved|Repetitive Behavior Scale-Revised (RBSR) Total Score|Mean Red Blood Cell Value|Mean White Blood Cell Value|Mean Hemoglobin Value|Mean Hematocrit Value|Mean Corpuscular Volume Value|Mean Corpuscular Hemoglobin Value|Mean Corpuscular Hemoglobin Concentration Value|Mean Red Blood Cell Distribution Width Value|Mean Platelets Value|Mean Absolute Neutrophils Value|Mean Absolute Lymphocytes Value|Mean Absolute Monocytes Value|Mean Absolute Eosinophils Value|Mean Absolute Basophils Value|Mean Serum Chemistries (Sodium)|Mean Serum Chemistries (Potassium)|Mean Serum Chemistries (Chloride)|Mean Serum Chemistries (Bicarbonate)|Mean Serum Chemistries (Blood Urea Nitrogen)|Mean Serum Chemistries (Creatinine)|Mean Serum Chemistries (Glucose)|Mean Liver Function Tests Values (Alanine Transaminase)|Mean Liver Function Tests Values (Aspartate Transaminase)|Mean Liver Function Tests Values (Total Bilirubin)|Mean Value of Thyroid Stimulating Hormone (TSH)|Least Squares Mean of Vital Signs (Weight)|Least Squares Mean of Vital Signs (Height)|Least Squares Mean of Vital Signs (Blood Pressure)|Least Squares Mean of Vital Signs (Heart Rate)","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","Male","13 Years to 30 Years   (Child, Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16-2059|5KL2TR001109-05","March 1, 2017","May 30, 2019","May 30, 2019","September 21, 2016","May 15, 2020","June 4, 2020","Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Carrboro, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02909959/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02909959"
897,"NCT04714606","Feasibility Controlled Trial of an 8-session Group Intervention for Siblings of Children Who Have ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Sibling support group|Other: None - control condition","Change in Strengths & Difficulties Questionnaire (SDQ, Goodman et al., 2009) scores|Change in Paediatric Quality of Life Inventory (PedsQL V4.0; Varni, Seid & Kurtin, 2001) scores|Change in Knowledge of Autism Questionnaire (KAS; Ross & Cuskelly, 2006) scores|Change in Goal Based Outcomes (GBOs, Law & Jacob, 2015) scores Goal Based Outcomes (GBOs, Law & Jacob, 2015)|Experience of Service Questionnaire (ESQ, Attride-Stirling, 2002)","University of Surrey","All","7 Years to 11 Years   (Child)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","260159","December 14, 2020","April 30, 2021","April 30, 2021","January 19, 2021",,"June 16, 2021","The Howard Partnership Multi-Academy Trust, Leatherhead, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04714606"
898,"NCT01669889","A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome",,"Completed","No Results Available","Healthy Volunteer, Autistic Disorder, Asperger's Syndrome",,"Behavior assessment ratings|Cognition assessment ratings","Hoffmann-La Roche","Male","18 Years to 45 Years   (Adult)",,"38","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BP28421","January 2013","December 2013","December 2013","August 21, 2012",,"November 2, 2016","Los Ageles, California, United States|New Haven, Connecticut, United States|New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01669889"
899,"NCT04173663","Advocating for Supports to Improve Service Transitions","ASSIST","Active, not recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: ASSIST","Change in Parental Knowledge about adult services questionnaire|Change in Parental Empowerment Scale|Change in Advocacy Skills and Comfort Scale|Change in Access to Services interview: Number of services the family applied for|Change in Access to Services interview: Number of services the family is receiving|Change in Access to Services interview: Barriers to services|Social Participation Youth Outcomes|Post-Secondary Youth Outcomes|Change in Advocacy Activities Scale|Post-Secondary Youth Outcomes: Employment stability|Post-Secondary Youth Outcomes: Hours spent in activity","Vanderbilt University Medical Center|University of Illinois at Urbana-Champaign|University of Wisconsin, Madison","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","191187","January 3, 2020","May 30, 2024","May 30, 2024","November 22, 2019",,"August 12, 2021","University of Illinois at Urbana-Champaign, Chicago, Illinois, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Waisman Center at University of Madison-Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04173663"
900,"NCT04612231","Examining the Efficacy of the T-STEP",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|Behavioral: Counseling Services Alone","Change in Becker Work Adjustment Profile-2 (BWAP) Scores from Baseline to Post-Intervention|Change in Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A) Scores from Baseline to Post-Intervention|Change in Transition Readiness and Employability Evaluation (TREE) Scores from Baseline to Post-Intervention|Change in The American Institutes for Research Self-Determination Scale (AIR) Scores from Baseline to Post-Intervention|Change in Coping Self-Efficacy Scale (CES) Scores from Baseline to Post-Intervention|Change in Center for Epidemiological Studies - Depression, Revised (CESD-R) Scores|Change in State Trait Anxiety Inventory (STAI) Trait Scale Scores|Student Adaptation to College Questionnaire (SACQ)|Change in Grade Point Average (GPA)|Change in Employment Status Categorizations|Change in Becker Work Adjustment Profile-2 (BWAP) Scores from Post-Intervention to 4 Month Follow Up|Change in Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A) Scores from Post-Intervention to 4 Month Follow Up|Change in The American Institutes for Research Self-Determination Scale (AIR) Scores from Post-Intervention to 4 Month Follow Up|Change in Coping Self-Efficacy Scale (CES) Scores from Post-Intervention to 4 Month Follow Up|Change in Activities of Daily Living (WADL) Scores|Change in Clinical Global Impression Scale (CGI) Scores from Baseline to Post-Intervention","University of North Carolina, Chapel Hill|United States Department of Defense","All","18 Years to 21 Years   (Adult)","Not Applicable","18","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-0627|CDMRP-R180178-A","December 11, 2020","August 2023","August 2023","November 2, 2020",,"February 21, 2021","University of North Carolina, Chapel Hill, North Carolina, United States|Guilford Technical Community College, Greensboro, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04612231"
901,"NCT04316338","Intermittent Theta-Burst Stimulation to Target Irritability in Adults With ASD",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Device: Intermittent theta-burst stimulation (iTBS)","Aberrant Behavior Checklist-irritability subscale (ABC-I)|Irritability Questionnaire|Self-injury questionnaire (SIQ)|THE MODIFIED OVERT AGGRESSION SCALE (MOAS)|Difficulties in Emotion Regulation Scale|The Adult Autism Quotient (AQ)|Repetitive Behavior Scale-Revised (RBS-R)|Montgomery-Åsberg Depression Rating Scale (MADRS)|Functional connectivity between areas involved in negative emotion regulation|EEG recordings|Magnetic resonance spectroscopy (MRS)","Stanford University","All","22 Years to 55 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-41458","May 1, 2022","May 1, 2024","May 1, 2025","March 20, 2020",,"May 10, 2021",,,"https://ClinicalTrials.gov/show/NCT04316338"
902,"NCT04258254","The Effect of Play on Social and Motor Skills of Children With ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Multimodal|Behavioral: General|Behavioral: Standard of Care","Change in cortical activation during the Rhythmic Synchrony task|Change in cortical activation during a building task|Change in joint attention scores|Change in gross-motor performance scores|Change in praxis errors|Change in movement quality and prosocial behaviors|Change in distance covered during walking|Changes in time taken to complete the task|Developmental Coordination Disorder-Questionnaire|Sensory Processing Measure (SPM)","University of Delaware|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)","All","5 Years to 15 Years   (Child)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1539736-1|3P20GM103446-19S1","June 4, 2020","February 28, 2022","February 28, 2022","February 6, 2020",,"January 6, 2021","University of Delaware, Newark, Delaware, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04258254/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04258254"
903,"NCT04156646","A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers",,"Completed","Has Results","Autism Spectrum Disorder","Drug: Balovaptan|Drug: Esomeprazole","Maximum Plasma Concentration (Cmax) of Balovaptan|Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan|Time to Reach Cmax in Plasma (Tmax) of Balovaptan|Last Quantifiable Concentration (Clast) of Balovaptan|Time To the Last Quantifiable Concentration (Tlast) of Balovaptan|Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)|Apparent Clearance (Cl/F) of Balovaptan|Apparent Volume of Distribution (Vd/F) of Balovaptan|Terminal Elimination Phase Half-Life (T1/2) of Balovaptan|Terminal Phase Rate Constant (λz) of Balovaptan|Plasma Concentrations of Balovaptan|Maximum Plasma Concentration (Cmax) of M2 Metabolite|Maximum Plasma Concentration (Cmax) of M3 Metabolite|Maximum Plasma Concentration (Cmax) of Esomeprazole|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole|Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite|Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite|Time to Reach Cmax in Plasma (Tmax) of Esomeprazole|Last Quantifiable Concentration (Clast) of M2 Metabolite|Last Quantifiable Concentration (Clast) of M3 Metabolite|Last Quantifiable Concentration (Clast) of Esomeprazole|Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole|Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole|Percentage of Patricipants With Adverse Events (AEs)|Terminal Phase Rate Constant (λz) of M2 Metabolite|Terminal Phase Rate Constant (λz) of M3 Metabolite|Terminal Phase Rate Constant (λz) of Esomeprazole|Plasma Concentrations of M2 Analyte|Plasma Concentrations of M3 Analyte|Plasma Concentrations of Esomeprazole","Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WP41047","November 19, 2019","December 24, 2019","January 6, 2020","November 7, 2019","March 16, 2021","March 16, 2021","PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04156646/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04156646"
904,"NCT04114942","PEERS© for Careers",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Never Coach|Behavioral: Internship Only Coach|Behavioral: Constant Coach","Change in Employment-related Social Skills Knowledge as Assessed by Test of Employment Social Skills (TESS)|Change in Employment-related Social Skills Knowledge as Assessed by Adapted Contextual Assessment of Social Skills (CASS)|Change in Social Skills Knowledge as Assessed by Social Responsiveness Scale (SRS-2)|Autism Severity as Assessed by Wechsler Abbreviated Scale of Intelligence (WASI-II)","University of California, Los Angeles","All","18 Years to 35 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11934","January 1, 2020","December 2022","December 2022","October 3, 2019",,"September 29, 2021","UCLA CAN Clinic, Los Angeles, California, United States|UCLA PEERS Clinic, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04114942"
905,"NCT04042337","Improving Access to Pivotal Response Treatment (PRT) Via Telehealth Parent Training",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Pivotal Response Treatment","Change in Parent Fidelity of PRT Implementation from Baseline to Week 12|Change in Child Frequency of Functional Utterances from Baseline to Week 12","Stanford University","All","2 Years to 5 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","52597","April 13, 2020","December 31, 2022","December 31, 2024","August 1, 2019",,"November 23, 2020","Department of Psychiatry and Behavioral Sciences, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04042337"
906,"NCT03605368","VR Intervention to Improve Police Safety",,"Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Behavioral: Virtual Reality Intervention|Behavioral: Video Modeling Intervention","Change in Live Police Interaction Assessment Scores from Pre-to-Post treatment|Change in Police Interaction Knowledge|Learned skill improvements - Phase IIb only","Children's Hospital of Philadelphia|Floreo, Inc.|National Institute of Mental Health (NIMH)","All","12 Years to 60 Years   (Child, Adult)","Not Applicable","96","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17-014387|1R42MH115539-01","November 28, 2017","September 2021","September 2021","July 30, 2018",,"September 1, 2021","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03605368"
907,"NCT03912350","The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan",,"Suspended","No Results Available","Autism Spectrum Disorder","Drug: Balovaptan","Plasma concentration of balovaptan|Plasma concentration of M2 metabolite, as applicable|Plasma concentration of M3 metabolite|AUC during the dosing interval on Day 1 of balovaptan|AUC during the dosing interval on Day 1 of M2 metabolite|AUC during the dosing interval on Day 1 of M3 metabolite|AUC during the dosing interval at steady state on Day 14 of balovaptan|AUC during the dosing interval at steady state on Day 14 of M2 metabolite|AUC during the dosing interval at steady state on Day 14 of M3 metabolite|Maximum observed plasma concentration (Cmax) of balovaptan|Maximum observed plasma concentration (Cmax) of M2 metabolite|Maximum observed plasma concentration (Cmax) of M3 metabolite|Time of maximum observed plasma concentration (Tmax) of balovaptan|Time of maximum observed plasma concentration (Tmax) of M2 metabolite|Time of maximum observed plasma concentration (Tmax) of M3 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M2 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M3 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M2 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M3 metabolite|Apparent volume of distribution (V/F) of balovaptan|Apparent volume of distribution (V/F) of M2 metabolite|Apparent volume of distribution (V/F) of M3 metabolite|Terminal phase rate constant (λZ) of balovaptan, when possible|Terminal phase rate constant (λZ) of M2 metabolite, when possible|Terminal phase rate constant (λZ) of M3 metabolite, when possible|Apparent terminal elimination half-life (t½) of balovaptan, when possible|Apparent terminal elimination half-life (t½) of M2 metabolite, when possible|Apparent terminal elimination half-life (t½) of M3 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of balovaptan, when possible|Apparent plasma clearance after oral administration (CLss/F) of M2 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of M3 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of balovaptan, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M2 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M3 metabolite, when possible|Percentage of participants with adverse events","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WP41045","June 26, 2022","September 24, 2022","October 13, 2022","April 11, 2019",,"May 18, 2021","Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03912350"
908,"NCT03899831","Structured Function-Based Elopement Treatment Program","FBET","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Function-Based Elopement Treatment (FBET)|Behavioral: Parent Education Program (PEP)","Change in Aberrant Behavior Checklist - Hyperactivity (ABC-H) Subscale Score|Change in Clinical Global Impression - Improvement (CGI-I) Score|Change in Home Elopement Safety Checklist (HESC) Score|Direct observation of elopement frequency","Emory University|Autism Speaks","All","4 Years to 12 Years   (Child)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00108995","May 9, 2019","January 2023","January 2023","April 2, 2019",,"June 14, 2021","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03899831"
909,"NCT03934879","Physical Exercise and Contributors to Academic Performance Among Adolescents With ASD (Fit Club Study)","FitClub","Completed","No Results Available","Autism Spectrum Disorders","Behavioral: FitClub|Other: Regular School Activities","Change from baseline in Bruininks-Osteretsky Test of Motor Proficiency, Second Edition|Change from baseline in Adolescent and Young Adult Activity Card Sort|Change from baseline in Depression, Anxiety and Stress Scale|Change from baseline in Repetitive Behavior Scale|Change from baseline in Sensory Profile Adolescent/Adult|Change from baseline in Body Mass Indices|Change from baseline in Exercise Heart Rate|Change from baseline in Delis-Kaplan Executive Function System","The University of Texas Medical Branch, Galveston","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","105","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-0185","August 2016","July 2018","December 2020","May 2, 2019",,"February 1, 2021","Gateway Academy, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03934879"
910,"NCT03769571","Generalized Training Program for Caregivers on the ESDM: PEGASE","PEGASE","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Parental coaching program at ESDM (P-ESDM)","effectiveness of a parent's training program (name PEGASE) of young children (aged 2 to 4 years) with Autism Spectrum Disorders.","Assistance Publique Hopitaux De Marseille","All","2 Years to 4 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2018-42","November 8, 2018","November 7, 2021","November 7, 2021","December 7, 2018",,"December 10, 2018","Service de pédopsychiatrie Sainte-Marguerite, Marseille, Marseille Cedex 09, France",,"https://ClinicalTrials.gov/show/NCT03769571"
911,"NCT03685474","Facing Your Fears in Schools: Implementing a CBT Program for Students With ASD or Other Special Learning Needs","FYF-SB","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Facing Your Fears - School Based|Behavioral: Usual Care","Reduction in symptoms of anxiety of the participant as measured by scores from the teacher - completed questionnaire, The School Anxiety Scale (SAS).|Reduction in symptoms of anxiety of participants as measured by scores from the parent-completed questionnaire, Parent-Rated Anxiety Scale for ASD (PRAS-ASD).|Reduction in symptoms of anxiety of participant as measured by scores from parent -, and self - completed questionnaire, Screening for Childhood Anxiety and Related Emotional Disorders (SCARED).|Reduction in symptoms of anxiety of participants as measured by scores from parent - completed questionnaire, The Social Responsiveness Scale, Second Edition (SRS-2).|Reduction in symptoms of anxiety of participants as measured by scores from parent -, and teacher - completed questionnaire, Emotion Regulation Checklist (ERC).|Classroom attendance|Protocol adherence as measured by fidelity checklist.|Emotion Dysregulation Inventory Scores: Dysphoria|Emotion Dysregulation Inventory Scores: Reactivity|Teacher Concern Inventory: Time Management Subscale|Teacher Concern Inventory: Work Stressors|Teacher Concern Inventory: Professional Distress|Teacher Concern Inventory: Discipline and Motivation|Teacher Concern Inventory: Professional Investment","University of Colorado, Denver|Health Resources and Services Administration (HRSA)","All","8 Years to 14 Years   (Child)","Not Applicable","389","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-0114","August 1, 2018","June 1, 2020","June 1, 2020","September 26, 2018",,"September 30, 2021","University of Colorado School of Medicine, Aurora, Colorado, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03685474/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03685474"
912,"NCT03676660","The Evaluation of Care Demand and Intervention Models for Individuals With ASD in Taiwan",,"Completed","No Results Available","Autism Spectrum Disorder",,"Camberwell Assessment of Need (CAN)","National Taiwan University Hospital","All","18 Years to 30 Years   (Adult)",,"1948","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","201707041RINA","August 1, 2017","December 31, 2018","December 31, 2018","September 19, 2018",,"September 9, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03676660"
913,"NCT03670381","Investigation of the HDAC4 Copy Number Variation and Its Effect on Gene and Protein Expression in Patients With ASD",,"Completed","No Results Available","Autism Spectrum Disorder","Other: Psychiatric diagnosis","Copy number variation (CNV) analysis","National Taiwan University Hospital","All","7 Years and older   (Child, Adult, Older Adult)",,"35","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201608089RIN","January 2017","December 2017","December 2017","September 13, 2018",,"September 19, 2018","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03670381"
914,"NCT03560297","SeRenade Parent-Child Music Class Program",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: SeRenade Parent-Child Music Class|Behavioral: Delayed Intervention","Motor Imitation Scale|Actions & Gestures|Parenting Stress Index, 4th edition Short Form|Parenting Efficacy/Quality|Parent-Child Interaction|social visual attention eye-tracking paradigm","Vanderbilt University Medical Center|National Endowment for the Arts, United States","All","20 Months to 72 Months   (Child)","Not Applicable","68","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","160784","May 15, 2018","May 2021","May 2021","June 18, 2018",,"July 21, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03560297"
915,"NCT02985749","A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder|Pervasive Developmental Disorder|ASD|PDD","Drug: Intranasal Oxytocin","Social Responsiveness Scale (SRS-2 School Age form and SRS-2 Adult Self-Report)|Quality of Life Enjoyment and Satisfaction (PQ-LES-Q and Q-LES-Q)","Massachusetts General Hospital","All","12 Years to 55 Years   (Child, Adult)","Phase 3","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P002148","October 9, 2017","September 2022","September 2022","December 7, 2016",,"June 25, 2021","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02985749"
916,"NCT03537261","CPI Training for Parents of Children With ASD",,"Completed","Has Results","Autism Spectrum Disorder","Behavioral: Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)","Change in the Child Adjustment and Parent Efficacy Scale-Developmental Disability Self-Efficacy Scale Total Score|Change in the Parent Stress Index - Short Form Total Score|Change in the Family Quality of Life Scale Total Score","Massachusetts General Hospital|Crisis Prevention Institute","All","5 Years to 12 Years   (Child)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P000119","August 8, 2018","June 15, 2020","June 15, 2020","May 25, 2018","June 29, 2021","June 29, 2021","Lurie Center for Autism, Lexington, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03537261/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03537261"
917,"NCT03514134","Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Virtual Reality Job Interview Training|Behavioral: Services as Usual","Change in Job Interview Skills|Change in Job Interview Self-Efficacy|Change in Job Interview Motivation|Change in Job Interview Anxiety|Change in Employment Outcomes","University of Michigan|University of Wisconsin, Madison|SIMmersion, LLC","All","16 Years to 21 Years   (Child, Adult)","Not Applicable","71","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HUM00129575","October 1, 2018","April 20, 2021","August 28, 2021","May 2, 2018",,"May 6, 2021","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03514134"
918,"NCT03507569","Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513",,"Completed","Has Results","Autism Spectrum Disorder","Drug: RO7017773|Other: [11C] Ro15-4513","Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773|Plasma Concentrations of RO7017773|Number of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","23 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP40257","April 24, 2018","June 22, 2018","June 22, 2018","April 25, 2018","September 30, 2019","September 30, 2019","Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03507569/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03507569"
919,"NCT01931033","An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders",,"Active, not recruiting","No Results Available","Autism Spectrum Disorders|Pervasive Developmental Disorders|ASD|PDD","Drug: Intranasal Oxytocin","Social Responsiveness Scale (SRS-2)|Clinical Global Impression of PDD - Improvement (CGI-I)","Massachusetts General Hospital","All","11 Years to 17 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-P-001548","October 2013","June 2022","June 2022","August 29, 2013",,"July 9, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01931033"
920,"NCT03445520","Building Better Bridges Randomized Control Trial","(AIR-B3)","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Intervention Coaching Group","Transition Evaluation Questionnaire (TEQ)|Engagement vs.Disaffection|Social Dynamics of Intervention_ASD (Autism Spectrum Disorder)- SoDI|Parent Engagement (ESE)|Community Capital|Usability & Acceptability Form|Strategies Survey|Transition Practices|Burnout Measure|School Situations Questionnaire (SSQ)","Health Resources and Services Administration (HRSA)|University of Rochester|University of Pennsylvania|University of California, Davis|Drexel University","All","Child, Adult, Older Adult","Not Applicable","375","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-001459","March 15, 2018","March 31, 2020","December 1, 2021","February 26, 2018",,"February 9, 2021","UC Davis, Davis, California, United States|University of Rochester, Rochester, New York, United States|UPENN, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03445520"
921,"NCT03432832","Emotion Awareness and Skills Enhancement Program","EASE-yes","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: EASE|Behavioral: Supportive Therapy","The Clinical Global Impression Scale- Improvement (CGI-I)|Emotion Dysregulation Inventory Reactivity Scale Short Form (EDI-SF)|Brief Psychiatric Rating Scale (BPRS)","University of Pittsburgh|University of Alabama at Birmingham","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PRO17070496","January 30, 2018","January 15, 2023","June 30, 2023","February 14, 2018",,"July 7, 2021","University of Alabama, Tuscaloosa, Alabama, United States|Shannondora Porton, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03432832/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03432832"
922,"NCT03423160","A Novel Framework for Impaired Imitation in ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder","Other: None--observational","Psychophysical measures of imitation|EEG measures of brain activity during gesture imitation","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","All","8 Years to 12 Years   (Child)",,"148","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00146732","April 24, 2018","December 2021","June 2023","February 6, 2018",,"October 19, 2020","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03423160"
923,"NCT01675414","Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)",,"Completed","No Results Available","Gastrointestinal Disorders|Autism Spectrum Disorders","Other: evaluation visit by a pediatric gastroenterologist","diagnosis of active gastrointestinal disorder/dysfunction based on the medical history reviewed by and the physical examination performed by a pediatric gastroenterologist","Massachusetts General Hospital|Autism Speaks|Columbia University","All","2 Years to 17 Years   (Child)",,"131","Other","Observational","Observational Model: Cohort","Grant 2037","September 2008","June 2010","February 2011","August 30, 2012",,"August 30, 2012","LADDERS, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01675414"
924,"NCT03370510","Translating Neuroprediction Into Precision Medicine Via Brain Priming",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Oxytocin|Behavioral: Pivotal Response Treatment|Drug: Placebo","Social Responsiveness Scale, 2nd edition (SRS-2)|Vineland Adaptive Behavior Scale, 3rd edition (Vineland-III)","Yale University","All","5 Years to 9 Years   (Child)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000021581","December 7, 2018","January 2022","June 2022","December 12, 2017",,"September 5, 2021","Yale School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03370510"
925,"NCT03323918","ImPACT Intervention for Children With ASD",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Other: ImPACT|Other: TAU","Change from baseline in the score of the Early Social Communication Scales (ESCS)|Change from baseline in the score of a semi-structured social imitation task|Change from baseline in the score of the Brief Observation of Social Communication Change (BOSCC)|Change from baseline in electrophysiological event-related potentials in response to voice and non-voice sounds (N1, N2 and P3 effects), measured with EEG|Change from baseline in haemodynamic response function (oxyhaemoglobin and deoxyhaemoglobin concentration in the cerebral cortex) evoked by social attention cues, measured with NIRS (near infrared spectroscopy)|Change from post-test in the score of the Early Social Communication Scales (ESCS)|Change from post-test in the score of a semi-structured social imitation task|Change from post-test in the score of the Brief Observation of Social Communication Change (BOSCC).|Change from post-test in electrophysiological event-related potentials in response to voice and non-voice sounds (N1, N2 and P3 effects), measured with EEG|Change from post-test in haemodynamic response function (oxyhaemoglobin and deoxyhaemoglobin concentration in the cerebral cortex) evoked by social attention cues, measured with NIRS (near infrared spectroscopy)|Change from baseline in the score of the Autism Diagnostic Observational Scale - 2 (ADOS-2)|Change from baseline in the score of the Mullen Scales of Early Learning (M-SEL)|Change from baseline in the score of the Vineland screener questionnaire (0-6 years).|Change from baseline in the score of the Dutch adaptation of the MacArthur Communicative Development Inventories (NCDI - short form)|Change from baseline in the score of the Nijmeegse Ouderlijke Stress Index|Change from post-test in the score of the Vineland screener questionnaire (0-6 years).|Change from post-test in the score of the Dutch adaptation of the MacArthur Communicative Development Inventories (NCDI - short form)|Change from post-test in the score of the Nijmeegse Ouderlijke Stress Index","University Ghent|European Union","All","18 Months to 48 Months   (Child)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRAINVIEW/ESR14","November 2016","November 28, 2021","November 28, 2021","October 27, 2017",,"May 5, 2021","Ghent University, Ghent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT03323918"
926,"NCT03307057","Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Social Communication Growth Charts (SCGC)|Behavioral: Parent-Implemented (P-I) Condition|Behavioral: Clinician-Implemented (C-I) Condition","Measure of Active Engagement and Transactional Supports (MAETS)|Communication and Symbolic Behavior Scales (CSBS) Score|Autism Diagnostic Observation Schedule Score|Mullen Scales of Early Learning Score|Vineland-3 Adaptive Behavior Scales Score|Measure of Active Engagement and Transactional Supports (MAETS) in Parents of Children Showing Signs of ASD|Communication and Symbolic Behavior Scales (CSBS) Score in Children Showing Signs of ASD|Autism Diagnostic Observation Schedule Score in Children Showing Signs of ASD|Mullen Scales of Early Learning Score in Children Showing Signs of ASD|Vineland-3 Adaptive Behavior Scales Score in Children Showing Signs of ASD","Emory University","All","6 Months to 6 Months   (Child)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00098127","February 1, 2018","September 2022","September 2022","October 11, 2017",,"June 16, 2021","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03307057"
927,"NCT00365859","Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)",,"Completed","Has Results","Autistic Disorder|Behavioral Symptoms","Drug: Aripiprazole","Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs|Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint|Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities|Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities|Number of Potentially Clinically Relevant Vital Sign Abnormalities|Mean Change From Baseline in Patient Weight|Mean Change From Baseline by Time Period in Body Weight Z-Score|Mean Change From Baseline in Patient Body Mass Index (BMI)|Mean Change From Baseline By Time Period in BMI Z-Score|Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)|CGI-Improvement Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","6 Years to 17 Years   (Child)","Phase 3","330","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN138-180","September 2006","June 2009","June 2009","August 18, 2006","January 25, 2010","December 2, 2013","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Univ of Arizona, Tuscon, Arizona, United States|Clinical Innovations, Inc, Costa Mesa, California, United States|Peninsula Research Assoc, Rolling Hills Estate, California, United States|University Of California-Davis Health Science Center, Sacramento, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Offices of Gregory Marsella, MD, PA, Boca Raton, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Children's Developmental Center, Winter Park, Florida, United States|Child Neurology Associates, PC, Atlanta, Georgia, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Massachusetts General Hospital, Cambridge, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Children's Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Munroe-Meyer Institute Diagnostic Center, Omaha, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|Children's Specialized Hospital, Toms River, New Jersey, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver and New York Autism Center of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY at Stony Brook - School of Medicine, Stony Brook, New York, United States|Mission Hospitals - Mission Children's Clinics, Asheville, North Carolina, United States|University of NC, Chapel Hill, North Carolina, United States|Duke Child and Family Study Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|UT Medical Group, Department Of Psychiatry, Memphis, Tennessee, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Children's National Medical Center, Fairfax, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Monarch Research Associates, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00365859"
928,"NCT03205475","JASPER Implementation in NFLD",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Alternate Coaching and Video Feedback Phase 1|Behavioral: Weekly Coaching in Phase 1|Behavioral: Weekly Coaching plus Intensive Refresher Course Phase 2|Behavioral: Weekly Coaching plus Peer Coaching Phase 2|Behavioral: Video Feedback Only Phase 2","Change in JASPER Strategy Implementation Fidelity|Change in Children's Joint Engagement|Change in Children's Play Skills and Social Communication Skills","Government of Newfoundland and Labrador","All","24 Months to 97 Months   (Child)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GovernmentNL","May 1, 2018","December 31, 2018","July 30, 2021","July 2, 2017",,"February 2, 2021","Department of Health and Community Services, Government of Newfoundland and Labrador, St. John's, Newfoundland and Labrador, Canada",,"https://ClinicalTrials.gov/show/NCT03205475"
929,"NCT03079765","Training Educators to Conduct Functional Behavior Assessment Via Telehealth",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Behavioral skills training|Behavioral: Protocol Only","Increased functional behavior assessment procedural fidelity","University of Colorado, Denver","All","Child, Adult, Older Adult","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1691","January 1, 2017","May 31, 2019","May 31, 2019","March 14, 2017",,"March 3, 2020","University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03079765"
930,"NCT03045263","Pivotal Response Treatment (PRT) Telemedicine","PRT","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Pivotal Response Treatment","Behavioural Intervention Rating Scale (BIRS)|Client Credibility Questionnaire (CCQ)","Yale University","All","3 Years to 6 Years   (Child)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1504015664","February 2, 2017","May 3, 2018","May 3, 2018","February 7, 2017",,"June 26, 2020","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03045263"
931,"NCT03019978","Person-Centered Assessment and Monitoring Systems","PCAMS","Completed","No Results Available","Autism Spectrum Disorder","Other: PCAMS assessments","Social Responsiveness Scale- 2|Adult Behavior Checklist|Additional PROMIS measures|Community Engagement measure|PROMIS measures|Elected Reporter Community Engagement measure","Milton S. Hershey Medical Center|Pennsylvania Bureau of Autism Services","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","STUDY00004326","July 2016","August 2019","August 2019","January 13, 2017",,"April 8, 2020","The Penn State College of Medicine, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03019978"
932,"NCT03019952","Effectiveness of the Care Coordination, Assessment, and Responsive Engagement Program for Transition-aged Adolescents (t-CARE) With ASD","t-CARE","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Care Coordination Visit","Holmes and Rahe Stress Scale|SRS-2|Waisman Activities of Daily Living Scale|Intolerance of Uncertainty|PROMIS Multi-Domain 49|Temple University Community Participation (TUCP) measure|PROMIS proxy measures|PROMIS SF measures|Self-Determination Scale|Closure Survey","Milton S. Hershey Medical Center|Pennsylvania Bureau of Autism Services","All","14 Years to 19 Years   (Child, Adult)","Not Applicable","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","STUDY00003849","January 2016","April 9, 2018","April 9, 2018","January 13, 2017",,"March 13, 2019","The Penn State College of Medicine, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03019952"
933,"NCT02255786","""ACT"" for Parents of Children With Autism Spectrum Disorder",,"Completed","No Results Available","Stress","Behavioral: Acceptance and Commitment Therapy","Change in Acceptance and Action Questionnaire-II Score","Massachusetts General Hospital|Organization for Autism Research","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014P001563","October 2014","December 2016","December 2016","October 3, 2014",,"August 13, 2019","Lurie Center   Massachusetts General Hospital, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02255786"
934,"NCT02856061","Tracking Intervention Effects With Eye Tracking",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Pivotal Response Treatment","Laboratory Eye Tracking Measuring Longitudinal Change|Home-Based Eye Tracking|Longitudinal Change in Autism Symptom Severity","Yale University|Simons Foundation","All","4 Years to 7 Years   (Child)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1106008625a|383661","January 2016","March 2018","March 2018","August 4, 2016",,"March 9, 2020","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02856061"
935,"NCT02720939","ASD-specific Induced Pluripotent Stem Cells for Disease Modeling",,"Completed","No Results Available","Autism Spectrum Disorder",,"iPSC derivation and characterization","National Taiwan University Hospital","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201507086RINA","January 1, 2016","December 31, 2016","December 31, 2016","March 28, 2016",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02720939"
936,"NCT02700113","Investigating Phenotypic Profiles of Children and Adolescents With ASD","Phenotyping","Completed","No Results Available","Autism Spectrum Disorders","Other: No intervention","Autism Spectrum Diagnosis|Adaptive Abilities|Cognitive Abilities|Language|Social Behavior|Repetitive Behavior|Sensory Behaviors|Atypical Behavior|Psychopathology|Emotion Regulation|Handedness|Electrophysiological Measures and Neural Oscillatory Patterns of Perception, Organization, and Analysis of Auditory scenes|Indices of social attention deployment measured by unobtrusively recording participants' eye-movements during the passive viewing of brief realistic video-clips.|Indices of electrodermal activity (EDA) measured wirelessly with the Q sensor (a small wearable device designed to work in real-world environments in an untethered, unobtrusive way).","Boston University Charles River Campus|National Institutes of Health (NIH)|Northeastern University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","4 Years to 18 Years   (Child, Adult)",,"72","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","3646E|P50DC013027","November 2014","June 2019","August 30, 2019","March 7, 2016",,"January 27, 2020","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02700113"
937,"NCT02574741","Combination Treatment for Augmenting Language in Children With ASD","PIII","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Behavioral Therapy|Drug: Aripiprazole|Drug: Placebo","Number of words as assessed in a naturalistic language assessment","University of California, Los Angeles","All","5 Years to 11 Years   (Child)","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-000726","June 2012","December 2019","December 2019","October 14, 2015",,"April 29, 2020","University of California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02574741"
938,"NCT01505270","The Prevalence of Psychological and Medical Comorbidities Among Children Suffering From Autistic Spectrum Disorder and the Differences Between Ethnic Groups in Israel",,"Unknown status","No Results Available","Autism","Other: Retrospective case study","Percentage of autistic children with comorbidities","Hillel Yaffe Medical Center","All","1 Year to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","0103-11-HYMC","March 2012","March 2013","March 2013","January 6, 2012",,"January 6, 2012","Hillel Yaffe Medical Center, Hadera, Israel",,"https://ClinicalTrials.gov/show/NCT01505270"
939,"NCT02500771","Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1",,"Unknown status","No Results Available","Autism Spectrum Disorder","Behavioral: ABA therapy enhanced with V-Motive software","Feasibility of V-Motive software's ability to positively impact a child's performance within 4 weeks|Amount of time required to construct a fully-indexed video repository from therapy footage using V-Motive|Accuracy of V-Motive software in suggesting and cueing up appropriate video for playback on demand","Experiad LLC|northwest behavioral associates","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VMOTIVE-1","June 2017","December 2020","December 2020","July 17, 2015",,"July 17, 2015","Northwest Behavioral Associates, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02500771"
940,"NCT02468505","STEPS: Stepped Transition in Education Program for Students With ASD","STEPS","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: STEPS","Questionnaire to measure feasibility and program acceptability","Virginia Polytechnic Institute and State University|University of Alabama at Birmingham","All","16 Years to 25 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","R34MH104337","September 2014","July 1, 2018","October 1, 2018","June 11, 2015",,"July 12, 2019","Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02468505"
941,"NCT02463422","Detection of ASD at the 1st Birthday as Standard of Care: The Get SET Early Model",,"Recruiting","No Results Available","Autism Spectrum Disorder",,"Rate of screening per pediatric office|Rate of referral for developmental evaluation per pediatric office|Age at screen|Age at developmental evaluation|Age at treatment start|Number of ASD toddlers detected by program|Changes in parent and pediatrician screening perceptions from baseline to Year 4","University of California, San Diego|Southwest Autism Research and Resource Center (SARRC)|National Institute of Mental Health (NIMH)","All","12 Months to 36 Months   (Child)",,"12000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01MH104446","August 2014","June 2020","June 2020","June 4, 2015",,"March 2, 2020","Southwest Autism Research & Resource Center (Sarrc), Phoenix, Arizona, United States|Autism Center of Excellence, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02463422"
942,"NCT02440451","Rt-fMRI NF Intervention Study in ASD","NF-ASD","Completed","Has Results","Autism Spectrum Disorder","Device: Neurofeedback using BCI","FEEST - Facial Expression of Emotion: Stimuli and Tests|ATEC - Autism Treatment Evaluation Checklist|VABS - Vineland Adaptive Behaviour Scale","University of Coimbra","All","16 Years to 30 Years   (Child, Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBILI-VB-2015-02","February 2016","September 2017","September 2018","May 12, 2015","November 13, 2018","February 20, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02440451/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02440451/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02440451"
943,"NCT02416323","Effectiveness and Implementation of a Mental Health Intervention for ASD","AIM HI","Completed","No Results Available","Autism Spectrum Disorder","Other: AIM HI Training","Change since baseline in child behaviors on the Eyberg Child Behavior Inventory (ECBI)|Change since baseline in child behaviors on the Social Skills Improvement System (SSIS) Competing Behavior Scale","University of California, San Diego|National Institute of Mental Health (NIMH)","All","5 Years to 13 Years   (Child)","Not Applicable","609","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","2011-4131|R01MH094317","April 2012","February 2018","February 2018","April 15, 2015",,"July 9, 2018","Child and Adolescent Services Research Center, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02416323"
944,"NCT02065193","Prevalence of Autism Spectrum Conditions in Mainland China","China SCORE","Unknown status","No Results Available","Autism Spectrum Conditions/Disorders","Behavioral: ADOS/ADI-R/Clinical assessment","Three-staged consensus diagnosis","University of Cambridge|China Disabled Persons Federation|Chinese University of Hong Kong","All","6 Years to 11 Years   (Child)",,"280000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","China SCORE study","April 2013","January 2015",,"February 17, 2014",,"February 17, 2014","Fujian CDPF, Fuzhou, Fujian, China|Shenzhen CDPF, Shenzhen, Guangdong, China|Heilongjiang CDPF, Jiamusi, Heilongjiang, China|Luoyang CDPF, Luoyang, Henan, China|Hengyang CDPF, Hengyang, Hunan, China|Jilin Mingzhi Centre, Jilin, Jilin, China|Liaoning CDPF, Benxi, Liaoning, China|Shanxi CDPF, Changzhi, Shanxi, China|Shanxi CDPF, Xian, Shanxi, China|Beijing CDPF, Beijing, China|Guangdong CDPF, Guangzhou, China|Zhejiang CDPF, Hangzhou, China|Hubei CDPF, Wuhan, China|Jiangsu CDPF, Yangzhou, China",,"https://ClinicalTrials.gov/show/NCT02065193"
945,"NCT05030610","Adaptation of a Behavioral Activation Treatment to Treat Depression in Autistic Adults",,"Recruiting","No Results Available","Autism Spectrum Disorder|Depression|Depressive Symptoms","Behavioral: BeatIt-ASD","Change in distress on Patient Health Questionnaire (PHQ-9)|Change in distress on Glasgow Depression Scale (GDS)|Change in distress on Anxiety Depression and Mood Scale (ADAMS)|Change on Adult Behavior Checklist (ABCL)|Change on Adult Self Report (ASR)|Change in frequency of activities on Index of Community Involvement (ICI)|Change in frequency of activities on Index of Participation in Domestic Life (IPDL)|Change in behavioral activation on Behavioral Activation for Depression Scale (BADS)|Change in adaptive behavior on Vineland Adaptive Behavior Scale, 3rd edition (VABS-3)|Change in quality of life on Shalock Quality of Life Questionnaire","Rutgers, The State University of New Jersey|Governor's Council for Medical Research and Treatment of Autism","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2021001254","August 25, 2021","June 2022","June 2022","September 1, 2021",,"September 1, 2021","Rutgers University - New Brunswick, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05030610"
946,"NCT02400177","Parents Workgroup About Emotion Regulation",,"Completed","No Results Available","Autism Spectrum Disorders","Behavioral: emotion regulation training","Mentalization level|Relationship coherence level","Stanford University","All","3 Years to 18 Years   (Child, Adult)","Not Applicable","96","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB32455","March 2015","November 2016","November 2016","March 26, 2015",,"June 1, 2018","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02400177"
947,"NCT03829878","Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)","SPROUT","Withdrawn","No Results Available","Autism Spectrum Disorder|Autism|ASD|Autistic Thinking|Autistic Behavior|Finch|FMT|Fecal Microbiota Transplant|CP101|SPROUT|Fecal Transplant","Drug: CP101|Drug: Placebo","Childhoood Autism Rating Scales-2 (CARS-2)|Aberrant Behavior Checklist-2 (ABC-2)|Social Responsiveness Scale-2 (SRS-2)|Parent Global Impressions-III (PGI-III)|Gastrointestinal Symptom Rating Scale (GSRS)|Gastrointestinal Stool & Symptom Questionnaire for Autism (GSSQA)|Reynolds Intellectual Assessment Scales-2-Nonverbal (RIAS-2-NV)|Autism Diagnostic Interview-Revised (ADI-R)","Finch Research and Development LLC.","All","5 Years to 17 Years   (Child)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP101-ASD-203","May 2020","May 2020","December 2021","February 4, 2019",,"April 8, 2021",,,"https://ClinicalTrials.gov/show/NCT03829878"
948,"NCT01784276","Dental Fear Among Children With Autism Spectrum Disorders",,"Completed","No Results Available","Dental Fear","Behavioral: Video","Anxiety|Uncooperative behavior","Boston Children's Hospital","All","7 Years to 17 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB-CRX10-09-0486-2","September 2010","August 2012","August 2012","February 5, 2013",,"February 5, 2013","Boston Children'S Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01784276"
949,"NCT02574559","CBCT for Parents of Children With Autism",,"Completed","No Results Available","Stress","Behavioral: Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Behavioral: Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Behavioral: Cognitive Based Compassion Training Session: Self-compassion|Behavioral: Cognitive Based Compassion Training Session: Cultivating Equanimity|Behavioral: Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Behavioral: Cognitive Based Compassion Training Session: Developing Affection and Empathy|Behavioral: Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Behavioral: Cognitive Based Compassion Training Session: Realizing Active Compassion|Behavioral: Meditation Session","Change in Aberrant Behavior Checklist (ABC) Score|Change in Parenting Stress Index/Short Form (PSI/SF) Score|Change in Perceived Stress Scale (PSS) Score|Change in Acceptance and Action Questionnaire (AAQ) Score|Change in Interpersonal Reactivity Index (IRI) Score|Change in Mindful Attention Awareness Scale (MAAS) Score|Change in Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A) Score|Change in Parenting Sense of Competence Scale Score","Emory University","All","Child, Adult, Older Adult","Not Applicable","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00074454","June 2014","February 11, 2016","February 11, 2016","October 14, 2015",,"January 31, 2020","Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02574559"
950,"NCT00453180","A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders",,"Completed","Has Results","Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive","Drug: N-acetylcysteine|Drug: Placebo","Clinical Global Impression - Severity|Clinical Global Impression - Improvement|Aberrant Behavior Checklist|Social Responsiveness Scale|Pervasive Developmental Disorder Behavior Index|Vineland Adaptive Behavior Scales-II (VABS-II)","Indiana University School of Medicine|National Alliance for Autism Research|Indiana University","All","4 Years to 12 Years   (Child)","Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0611-10","March 2007","August 2009","November 2009","March 28, 2007","June 14, 2017","June 14, 2017","Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00453180"
951,"NCT03206996","Exposure Therapy for Auditory Sensitivity in Autism",,"Completed","No Results Available","Sensory Disorders|Autism|Autism Spectrum Disorder|Autism With High Cognitive Abilities|Autistic Behavior|Hyperacusis","Behavioral: Exposure therapy|Behavioral: Psycho-education|Behavioral: Caregiver education/home program development","Participant Subjective Unit of Distress (SUD) Level|Parent Stress Index|Spence Child Anxiety Scale|Modified Khalfa Hyperacusis Questionnaire|Autism Symptoms|Sensory Profile","University of Florida","All","5 Years to 17 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201601664","September 30, 2017","May 31, 2019","May 31, 2019","July 2, 2017",,"June 18, 2019","UF Health Child and Adolescent Psychiatry/Medical Psychology, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03206996"
952,"NCT04606966","Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth",,"Recruiting","No Results Available","Autism Spectrum Disorder|Mental Disorders","Other: Therapeutic Horseback Riding|Other: Barn Activity|Other: Hybrid","Change in Aberrant Behavior Checklist-Community (ABC-C)|Change in Social Responsiveness Scale™, Second Edition|Change in Emotion Dysregulation Inventory (EDI)|Change in World Health Organization's Quality of Life Instrument (WHOQOL-BREF)|Change in Systematic Analysis of Language Transcripts (SALT)","University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Maine Health/Spriing Harbor Hospital|Northeastern University|Colorado State University|Riding To The Top Therapeutic Riding Center|Hearts and Horses Therapeutic Riding Center|Salimetrics, LLC","All","6 Years to 16 Years   (Child)","Not Applicable","192","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","19-1962|1R01HD097693-01A1","December 22, 2020","November 2024","January 2026","October 28, 2020",,"May 28, 2021","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Maine Health, Portland, Maine, United States",,"https://ClinicalTrials.gov/show/NCT04606966"
953,"NCT01854346","Social Skills Group Training (""KONTAKT"") for Children and Adolescent With High-functioning Autism Spectrum Disorders","KONTAKT-RCT","Completed","No Results Available","Autism Spectrum Disorder (ASD)|Attention Deficit Hyperactivity Disorder (ADHD)|Anxiety|Depression","Behavioral: Social skills group training, KONTAKT","Social Responsiveness Scale (SRS)|Adaptive Behavior Assessment System II (ABAS II)|Developmental Disabilities Modification of the Children's Global Assessment Scale (DD-CGAS)|Clinical Global Impression-Improvement/Severity (CGI)|Samples With DNA","Karolinska Institutet|Child and Adolescent Psychiatry, Stockholm|Region Stockholm|Stiftelsen Sunnerdahls Handikappfond|The Swedish Research Council|The Pediatric Research Foundation at Astrid Lindgren Children's Hospital|Majblomman","All","8 Years to 17 Years   (Child)","Not Applicable","296","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","KONTAKT","August 2012","March 2016","March 2016","May 15, 2013",,"August 22, 2017","Child & Adolescent Psychiatry Research Center, KIND, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01854346"
954,"NCT04432077","Anxiety Intervention for Preschool Children With ASD",,"Recruiting","No Results Available","Anxiety Disorder|Autism Spectrum Disorder","Behavioral: DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)","Change in child anxiety diagnostic status on Anxiety Disorders Interview Schedule, Autism Spectrum Disorder Addendum (ADIS-ASA) after 12-week waitlist and 12-week intervention|Improvement in child anxiety symptoms on Clinical Global Impressions Scale-Improvement following 12-week intervention|Change in child anxiety symptoms on Preschool Anxiety Scale - Revised following 12-week waitlist and 12-week intervention|Change in child anxiety symptoms on the Screen for Child Anxiety Related Disorders following 12-week waitlist and 12-week intervention|Change in severity of anxiety and other psychiatric symptoms on Child Behavior Checklist following 12-week waitlist and 12-week intervention|Change in child's tolerance of uncertainty on Response to Uncertainty and Low Environmental Stability Scale following 12-week waitlist and 12-week intervention|Change in child ASD symptoms on Social Responsiveness Scale following 12-week waitlist and 12-week intervention|Change in child repetitive behaviors on Repetitive Behavior Scale-Revised following 12-week waitlist and 12-week intervention|Change in parental anxiety and depression symptoms on Hospital Anxiety and Depression Scale following 12-week waitlist and 12-week intervention|Change in parental tolerance of uncertainty on Intolerance of Uncertainty Scale following 12-week waitlist and 12-week intervention|Change on parental accommodating behaviors on Family Accommodation Scale following 12-week waitlist and 12-week intervention|Change in child attention bias to threat on Behavioral Paradigms following 12-week waitlist and 12-week intervention","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Organization for Autism Research","All","48 Months to 83 Months   (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019A06","October 12, 2020","December 2021","March 2022","June 16, 2020",,"September 17, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04432077"
955,"NCT02090491","MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation",,"Completed","No Results Available","Autism",,"Self-Report","Northeastern University","All","5 Years to 20 Years   (Child, Adult)",,"20","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Janssen Research & Development","November 2013","October 2014","October 2014","March 18, 2014",,"April 7, 2017","Center for Discovery, Harris, New York, United States",,"https://ClinicalTrials.gov/show/NCT02090491"
956,"NCT04860986","A Repeatability and Reproducibility Study of the EarliPoint™ Device","RnR","Not yet recruiting","No Results Available","Autism Spectrum Disorder (ASD)","Device: EarliPoint","The EarliPoint Device repeatability|The EarliPoint Device reproducibility|The repeatability variance of the underlying EarliPoint Device|The reproducibility variance of the underlying EarliPoint Device","EarliTec Diagnostics, Inc","All","16 Months to 30 Months   (Child)",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CLN-1001-001","April 30, 2021","September 30, 2021","October 30, 2021","April 27, 2021",,"April 27, 2021","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04860986"
957,"NCT04639141","Combined Gut-brain Therapy for Children With Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Functional Gastrointestinal Disorders|Neurodevelopmental Disorders|Anxiety","Combination Product: Synbiotic|Behavioral: Gut-directed Hypnotherapy","GI symptom severity|ASD severity/behaviour|Anxiety|Gut microbiome","The University of Queensland","All","5 Years to 10 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASD-MGB-RCT2020","December 1, 2020","February 28, 2022","May 31, 2022","November 20, 2020",,"April 5, 2021","University of Queensland, Child Health Research Centre, Faculty of Medicine, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT04639141"
958,"NCT01921244","Shared Decision Making to Improve Care and Outcomes for Children With Autism",,"Completed","No Results Available","Autistic Disorder|Pervasive Developmental Disorder|Child Development Disorders, Pervasive|Asperger Syndrome|Autism Spectrum Disorder|Autism","Other: Decision Aid","Decisional Conflict|Parent-physician interaction","Children's Hospital Medical Center, Cincinnati","All","4 Years to 15 Years   (Child)","Not Applicable","142","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","FP00005038","August 2013","July 2015","July 2015","August 13, 2013",,"February 5, 2016","Cincinnati Children's Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01921244"
959,"NCT01012076","Promoting Development in Toddlers With Communication Delays",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Active Control vs Experimental Treatment","Maternal Synchronization|Early Social Communication Scale","Autism Speaks","All","15 Months to 30 Months   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","G07-02-055-03","April 2007","October 2011","October 2011","November 11, 2009",,"June 14, 2012","University of California, Los Angeles, Los Angeles, California, United States|Hunter College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01012076"
960,"NCT01339767","Study of Toddlers With Language Delay",,"Completed","No Results Available","Autism|Language Acquisition|Language Development|Toddlers",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","9 Months to 21 Months   (Child)",,"77","NIH","Observational","Time Perspective: Prospective","110144|11-M-0144","April 18, 2011",,"June 30, 2017","April 21, 2011",,"December 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01339767"
961,"NCT04564170","Eating Disorders and Autism Spectrum Disorders",,"Recruiting","No Results Available","Eating Disorders",,"Autism Spectrum Quotient|Eating Disorders Inventory|Bulimic Investigatory Test Edinburgh|Quality of Life Enjoyment and Satisfaction Questionnaire|Beck Depression Inventory|Scale Unawareness of Mental Disorders.|Body Shape Questionnaire|Rosenberg Self -Esteem Scale|State Trait Anxiety Inventory|Inventory of interpersonal problems personality disorder","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years and older   (Adult, Older Adult)",,"135","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IIBSP-TCA-2020-11","April 1, 2020","September 1, 2021","December 2025","September 25, 2020",,"October 5, 2020","Cristina Carmona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04564170"
962,"NCT04983667","Zinc-AA Supplementation During Pregnancy & Lactation to Assess Effects on ASD Prevalence in Offspring",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Zinc Deficiency|Pregnancy Related","Dietary Supplement: Zn-AA","Autism spectrum disorder|Microbiota modification associated to maternal zinc supplementation or placebo during pregnancy|Immune phenotype","Instituto Tecnologico y de Estudios Superiores de Monterey","Female","18 Years to 35 Years   (Adult)","Not Applicable","3840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","Zinc-Autismo","August 1, 2021","September 2025","December 2025","July 30, 2021",,"July 30, 2021",,,"https://ClinicalTrials.gov/show/NCT04983667"
963,"NCT02046889","A Bicycle Training Intervention",,"Completed","No Results Available","Autism Spectrum Disorder|Down Syndrome","Behavioral: Bicycle Training Intervention","Independent bicycle riding ability|Bicycle riding effects on physical activity|Bicycle riding effects on leg strength|Bicycle riding effects on static balance ability|Participation following learning to ride a two-wheeled bicycle|Bicycle riding effects on sleep behavior","University of Michigan|National Institutes of Health (NIH)","All","9 Years to 18 Years   (Child, Adult)","Not Applicable","155","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMBDS2012|H133G090006","June 2010","August 2012","December 2012","January 28, 2014",,"January 28, 2014","Southbend, Indiana, United States|Ann Arbor, Michigan, United States|Grand Rapids, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02046889"
964,"NCT00374764","Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone",,"Completed","No Results Available","Autistic Disorder","Drug: Risperidone|Behavioral: ABA",,"Washington University School of Medicine","All","30 Months to 5 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IND #58033","July 2000",,"June 2002","September 11, 2006",,"February 16, 2007","Early Emotional Development Program, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00374764"
965,"NCT02461446","Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations",,"Recruiting","No Results Available","PTEN|ASD|Autism|Macrocephaly|PTEN Hamartoma Tumor Syndrome",,"Change in verbal abilities at 12 months|Change in communication ability at 12 months|Change in verbal abilities at 24 months|Change in visual perception at 12 months|Change in working memory at 12 months|Change in processing speed at 12 months|Change in working memory at 24 months|Change in processing speed at 24 months|Change in visual perception at 24 months|Change in communication ability at 24 months","Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Months and older   (Child, Adult, Older Adult)",,"170","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00013150|1U54NS092090-01","May 2015","December 2024","December 2025","June 3, 2015",,"August 2, 2021","University of California at Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02461446"
966,"NCT04788212","Transdiagnostic Group Behavioral Activation for Autistic Adults","GBAT","Completed","No Results Available","Autism Spectrum Disorder|Depression, Anxiety|Anxiety|Anger","Behavioral: Group Behavioral Activation Therapy for Autism Spectrum Disorder","Change in symptoms on the Adult Self Report (ASR)|Change in Clinician Global Impairment rating|Change in symptoms on the Depression Anxiety Stress Scales-21|Change in distress on Patient Health Questionnaire (PHQ-9)|Change in anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Change in Adaptive Behavior Assessment System - 3 (ABAS-3)|Change in Behavioral Activation for Depression Scale|Change in Idiographic target goals","Rutgers, The State University of New Jersey","All","18 Years to 40 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020001634","February 16, 2021","July 8, 2021","July 8, 2021","March 9, 2021",,"August 5, 2021","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04788212"
967,"NCT02165410","MRI Study of Cerebral Blood Flow in Development Disorders in Children","IRM-Aut","Unknown status","No Results Available","Autism","Procedure: ASL-MRI|Procedure: Diffusion tensor imaging (diffusion MRI)|Procedure: Eye-tracking|Procedure: Cognitive profile","CBF|anatomical connectivity|eye-tracking method","Assistance Publique - Hôpitaux de Paris","All","18 Months to 18 Years   (Child, Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P120204|2012-A01695-38","November 13, 2013","November 12, 2019","December 2019","June 17, 2014",,"May 29, 2019","Hôpital Necker-Enfants Malades Service de Radiologie Pédiatrique, Paris, France",,"https://ClinicalTrials.gov/show/NCT02165410"
968,"NCT04308915","Mobile-based Games for Cognitive Training in Children With Neurodevelopmental Disorders",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Game-based cognitive training","Corsi Task Block Span|Corsi Task Total Score|Autism Treatment Evaluation Checklist Total Score","Indian Institute of Technology Kanpur","All","5 Years to 16 Years   (Child)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IITK/IEC/2017-18II/2","September 6, 2018","October 31, 2018","October 31, 2018","March 16, 2020",,"March 17, 2020","Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT04308915"
969,"NCT03724136","Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study","ACIST","Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Vascular Dementia|Lewy Body Disease|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia, Mixed|Parkinson-Dementia Syndrome|Chronic Traumatic Encephalopathy|Huntington's Dementia|Wernicke Korsakoff Syndrome|Traumatic Brain Injury|Dementia, Multi-Infarct|Autism|Autism Spectrum Disorder|Autistic Behavior|Autistic Disorder, Current or Active State|Cadasil|LATE Limbic-predominant Age-related TDP-43 Encephalopathy","Procedure: Intravenous Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Near Infrared Light","Mini-Mental Status Exam (MMSE)|Autism Spectrum Quotient Exam|Activities of Daily Living","MD Stem Cells","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDSC-ACIST","October 24, 2018","October 24, 2022","October 24, 2023","October 30, 2018",,"September 10, 2021","MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States|Medcare Orthopaedics & Spine Hospital, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03724136"
970,"NCT00672360","Folate Rechallenge",,"Completed","No Results Available","Autism","Dietary Supplement: Folic acid|Dietary Supplement: Placebo","Behavior as measured with the Aberrant Behavior Checklist (ABC) and the Pervasive Developmental Disorder Behavior Inventory (PDDBI).|Level of folate metabolites in plasma and site-specific DNA methylation.","Baylor College of Medicine","All","Child, Adult, Older Adult","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H-20959","May 2007","February 2015","February 2015","May 6, 2008",,"October 19, 2020","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00672360"
971,"NCT05054829","Establishment of Social Skills Training Group in Adults With Autism Spectrum Disorder and Effectiveness Analysis",,"Recruiting","No Results Available","Social Skill Training Group","Behavioral: PEERS®: program for the education and enrichment of relational skills","Outcome analysis","National Taiwan University Hospital","All","18 Years to 45 Years   (Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201612185RIN","March 8, 2017","December 31, 2018","July 1, 2023","September 23, 2021",,"September 23, 2021","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05054829"
972,"NCT03625609","Sexaffectivity in Autistic Spectrum Disorder",,"Unknown status","No Results Available","Autistic Disorders Spectrum|Sexual Behavior|Adolescent Development|Sexual Inadequacy",,"Sexual Behaivor Scale","Hospital Parc Taulí, Sabadell","All","12 Years to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","2018/509","March 11, 2018","February 11, 2020","July 11, 2020","August 10, 2018",,"August 10, 2018","Jordi Torralbas Ortega, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03625609"
973,"NCT01031407","Cognitive Neuroscience of Autism Spectrum Disorders",,"Recruiting","No Results Available","Asperger's Disorder|Mental Retardation|Children|Adult|Autism Spectrum Disorders",,"Cognitive and neurological phenotypes in ASD and control participants","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","5 Years to 89 Years   (Child, Adult, Older Adult)",,"1550","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","100027|10-M-0027","February 21, 2010",,,"December 14, 2009",,"September 2, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01031407"
974,"NCT03826940","From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1","ASD/NF1inhib","Completed","No Results Available","Autism Spectrum Disorder|Neurofibromatosis 1","Drug: Lovastatin 60 MG|Drug: Placebos","Neurochemical response changes to GABAergic stimulation|Motor evoked potentials changes under motor cortical stimulation|Cortical excitability changes under motor cortical stimulation|Brain oscillations changes under sensory stimulation|Event-related potentials changes under sensory stimulation","University of Coimbra","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CRU2C-ICNAS-001|FLAD Life Science 2020","February 19, 2019","March 31, 2020","August 31, 2020","February 1, 2019",,"April 2, 2021","ICNAS, Coimbra, Portugal",,"https://ClinicalTrials.gov/show/NCT03826940"
975,"NCT03424811","Mobile Health (mHealth) Nutrition Intervention for Children With Autism Spectrum Disorder",,"Completed","No Results Available","Diet Modification","Device: Mobile Health Intervention","Intake of Target Foods|Evaluation of mHealth intervention - Technology Engagement|Evaluation of mHealth intervention - User Evaluation","University of Pennsylvania","All","6 Years to 10 Years   (Child)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","827786","December 10, 2018","August 31, 2020","August 31, 2020","February 7, 2018",,"September 29, 2020","Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03424811"
976,"NCT00110708","Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism",,"Unknown status","No Results Available","Autism|Autistic Disorder|Child Development Disorders, Pervasive|Gastrointestinal Diseases|Signs and Symptoms, Digestive","Drug: Oralgam (human immunoglobulin)","Global improvement in gastrointestinal function|Assessment of behavior (improvement and severity); additional assessments of gastrointestinal conditions","PediaMed Pharmaceuticals","All","2 Years to 18 Years   (Child, Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Protocol 004","April 2005",,"June 2006","May 13, 2005",,"February 22, 2006","Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Center for Autism Research and Education, Phoenix, Arizona, United States|University of California Davis, MIND Institute, Sacramento, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida HSC, Gainesville, Florida, United States|International Child Development Resource Center, Melbourne, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kansas Medical Center, Developmental Disabilities Center, Kansas City, Kansas, United States|Bluegrass Clinical Research, Louisville, Kentucky, United States|Gulf Coast Research, LLC, Baton Rouge, Louisiana, United States|Hardy Health Associates, Hingham, Massachusetts, United States|Pivotal Research Centers - Detroit, Royal Oak, Michigan, United States|Mercy Health Research, St. Louis, Missouri, United States|Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Strong Center for Developmental Disabilities, University of Rochester Medical Center, Rochester, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Nisonger Center Ohio State University, Columbus, Ohio, United States|Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00110708"
977,"NCT04509401","Effects of High Dose of Vitamin B6 With Magnesium in Children With Autism Spectrum Disorder",,"Recruiting","No Results Available","ASD","Drug: Vitamin B 6 with Magnesium|Drug: placebo of vitamin B6 and magnesium","To measure the urinary homovanillic acid Conc in µgm/mg of creatinine in Vitamin B6 with magnesium treated autistic children pre and post supplementation of Vitamin B6 and Magnesium.","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","2 Years to 8 Years   (Child)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BSMMU/2019/12342","January 11, 2020","November 15, 2020","November 15, 2020","August 12, 2020",,"October 6, 2020","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04509401"
978,"NCT01311596","Show Me to Help Me",,"Completed","No Results Available","Autism","Other: Icons","Icons improve understanding, transition and cooperation of the child with Autism/communication delay as measured by improved times for the obtainment of vital signs|Icons improve understanding and cooperation of the child with Autism/communication delay as measured by improved times of lab draws, success of lab draws, and decreased noise level","Akron Children's Hospital","All","4 Years to 18 Years   (Child, Adult)",,"83","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","101201","February 2011","February 2011","February 2011","March 9, 2011",,"June 24, 2014","Akron Children's Hospital, Akron, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01311596"
979,"NCT00965068","Cholesterol in ASD: Characterization and Treatment",,"Completed","No Results Available","Autism|Asperger Disorder|PDD-NOS","Other: Cholesterol","Behavioral Changes","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","4 Years to 12 Years   (Child)","Phase 1|Phase 2","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","090203|09-CH-0203","July 28, 2009",,"November 14, 2013","August 25, 2009",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00965068"
980,"NCT03397719","Parent Video Feedback Intervention Study",,"Active, not recruiting","No Results Available","Autism Spectrum Disorder|Parent-Child Relations","Behavioral: Treatment Condition|Behavioral: Control Group","Change in Brief Observation of Social Communication Change (BOSCC)|Change in Autism Diagnostic Observation Schedule-2 (ADOS-2)|Change in Beck Depression Inventory|Change in Beck Anxiety Inventory|Change in Parent Stress Index|Change in Behavior Rating Inventory of Executive Function-Preschool Version","Weill Medical College of Cornell University","All","1 Year to 4 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1707018416","October 13, 2017","October 13, 2022","October 13, 2022","January 12, 2018",,"October 5, 2020","Weill Cornell Medicine Center for Autism and the Developing Brain, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT03397719"
981,"NCT04047355","Propranolol for Challenging Behaviors in Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder|Developmental Disability|Aggression|Self-Injurious Behavior|Challenging Behavior","Drug: Propranolol","Change in Aberrant Behavior Checklist (ABC-C)|Change in Clinical Global Impression Scale (CGI)|Change in Modified Overt Aggression Scale (IBR-MOAS)|Change in Questions About Behavior Function (QABF)|Change in Side Effects Survey","Rutgers, The State University of New Jersey|New Jersey Governor's Council for Medical Research and Treatment of Autism|New York State Institute for Basic Research","All","12 Years to 30 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro20170001942|CAUT17 APL025","January 1, 2021","January 1, 2023","July 1, 2023","August 6, 2019",,"March 16, 2021","Department of Pediatrics, Division of Pediatric Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04047355"
982,"NCT02830022","Sleep, Autonomic Nervous System and Cardiorespiratory Capacity in Autism Spectrum Disorders Children (APAUTRES)","APAUTRES","Completed","No Results Available","Autonomic Nervous System Diseases|Sleep","Other: physiological explorations","cardiorespiratory evaluation|autonomic nervous system evaluation|sleep evaluation|physical activity|Motor capacities|Behavioural characteristics|biological parameters","University Hospital, Grenoble","All","8 Years to 18 Years   (Child, Adult)","Not Applicable","78","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","38RC14.123","December 11, 2013","June 11, 2017","June 18, 2017","July 12, 2016",,"October 30, 2018","CHU Grenoble, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT02830022"
983,"NCT01322555","A Study of the Association Between Autism and Immune Changes in the Brain",,"Terminated","No Results Available","Autism Spectrum Disorders|Brain Disease|Autism|Healthy Volunteers",,"[11C]PBR28 uptake in brain as measured using VT (volume of distribution) and VT/fp (divided by free fraction in plasma.|Compare VT in autism versus healthy volunteers","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)",,"15","NIH","Observational","Time Perspective: Prospective","110118|11-M-0118","March 4, 2011",,"July 14, 2017","March 24, 2011",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01322555"
984,"NCT02660099","Internet Delivered CBT for OCD in Adolescents With ASD - A Clinical Case Series",,"Completed","No Results Available","Obsessive Compulsive Disorder|Autism Spectrum Disorder","Behavioral: Internet-delivered Cognitive Behavior Therapy","Obsessional Compulsive Inventory - Child version, OCI-CV|Children's Yale Brown Obsessive Compulsive Scale|Mini International Neuropsychiatric Interview for Children and Adolescents, MINI-KID|Clinical Global Impression - Severity, CGI-S|Clinical Global Impression - Improvement, CGI-I|Children's Global Assessment Scale, CGAS|Children´s Depression Inventory - Short version|Strength and difficulties, SDQ|Family Accommodation Scale, Parent-Report, FAS-PR|Patient ICBT Adherence Rating, PIAR|Education, Work and Social Adjustment Scale - child and parent version, EWSAS","Karolinska Institutet","All","12 Years to 17 Years   (Child)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BiP-ASD/OCD","July 2015","April 2016","June 2016","January 21, 2016",,"September 7, 2016","Karolinska Institutet, Stockholm, Sweden|Karolinska insititute, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02660099"
985,"NCT01141595","Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders",,"Completed","Has Results","Autism Spectrum Disorder","Drug: sapropterin dihydrochloride","Preschool Language Scales","The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical","All","2 Years to 6 Years   (Child)","Not Applicable","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-09-0578","July 2010","September 2011","September 2011","June 10, 2010","February 24, 2014","April 1, 2014","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01141595"
986,"NCT02618135","Brain-Computer Interface-based Programme for the Treatment of ASD/ADHD","ASDBCI","Completed","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorders","Other: Intervention Group|Other: Control Group","ADHD Rating Scale (clinicians)|ADHD Rating Scale (parent)|ADHD Rating Scale (clinician and parent)|ADHD Rating Scale|Social Responsiveness Scale|Clinical Global Assessment Scale (C-GAS)|Clinical Global Impression Severity Scale (CGI-S)|Clinical Global Impression Improvement Scale (CGI-I)|Conners' Continuous Performance Test (CPT-II)","Duke-NUS Graduate Medical School|Institute of Mental Health, Singapore|Agency for Science, Technology and Research","All","8 Years to 12 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2015/00841","May 2016","March 2018","October 31, 2018","December 1, 2015",,"July 23, 2020","Institute of Mental Health, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02618135"
987,"NCT01655485","Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder",,"Completed","No Results Available","Anxiety","Other: Patient teaching","Child behaviors|Parent anxiety","Medical College of Wisconsin|Marquette University","All","4 Years to 16 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","255769-1","October 2011","July 2013","July 2013","August 2, 2012",,"August 7, 2013","Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01655485"
988,"NCT02028247","Psychotherapy for Anxiety in Children With Autism Spectrum Disorder","TAASD","Completed","No Results Available","Autism Spectrum Disorders|Autism|Asperger's Syndrome|Pervasive Developmental Disability - Not Otherwise Specified|Obsessive-compulsive Disorder|Social Phobia|Generalized Anxiety Disorder|Specific Phobia|Separation Anxiety Disorder","Behavioral: Personalized Cognitive-behavioral therapy|Behavioral: Standard Practice Cognitive-behavioral therapy","Change from Baseline in anxiety severity on the Pediatric Anxiety Rating Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Clinical Global Impressions Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Child and Adolescent Symptom Inventory after 16 weeks of treatment.|Change from Baseline in anxiety related impairment as measured by the Childhood Anxiety Impact Scale after 16 weeks of treatment.","University of South Florida|Temple University|University of California, Los Angeles","All","8 Years to 13 Years   (Child)","Phase 3","201","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NICHD CBT for ASD","July 2014","October 2018","October 2018","January 7, 2014",,"March 19, 2019","Rothman Center for Neuropsychiatry, University of South Florida, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02028247"
989,"NCT03426826","The Gut-Brain Study",,"Recruiting","No Results Available","Autism Spectrum Disorder (ASD)|Gastro-Intestinal Disorder","Biological: FMT versus placebo","Primary Outcome Measures, safety and tolerability|Secondary Outcome Measures, symptom improvement","Children's Hospital Los Angeles","All","5 Years to 17 Years   (Child)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APP-18-00409","August 15, 2019","March 2022","June 2022","February 8, 2018",,"January 27, 2020","Children's Hospital Los Angles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03426826"
990,"NCT01592773","Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",,"Terminated","Has Results","Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)","Drug: Memantine Hydrochloride (HCl)","Patients With Any Treatment-emergent Adverse Event","Forest Laboratories","All","6 Years to 12 Years   (Child)","Phase 2","747","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEM-MD-69","October 2012","January 2014","March 2014","May 7, 2012","February 16, 2015","February 16, 2015","Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 124, Roanoke, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussels, Belgium|Forest Investigative Site 203, Jette, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 228, Antioquia, Bello, Colombia|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, Rhone, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Tyniec Maly, Poland|Forest Investigative Site 577, Warsaw, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Bellville Cape Town, South Africa|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 728, Sabadell, Spain|Forest Investigative Site 730, Torremolinos, Spain|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT01592773"
991,"NCT01592786","An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",,"Completed","Has Results","Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)","Drug: Memantine Hydrochloride (HCl)","Number of Confirmed Social Responsiveness Scale (SRS) Responders","Forest Laboratories","All","6 Years to 12 Years   (Child)","Phase 2","906","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEM-MD-91","June 2012","July 2013","August 2013","May 7, 2012","August 7, 2014","August 7, 2014","Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 124, Orlando, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 114, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 084, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 074, Owensboro, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 177, Camperdown, New South Wales, Australia|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 202, Hoboken, Belgium|Forest Investigative Site 201, Leuven, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron, Rhone, France|Forest Investigative Site 326, Paris, France|Forest Investigative Site 379, Budapest, Hungary|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 380, Szeged, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 651, Singapore, Singapore|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 730, Torremolinos, Málaga, Spain|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 727, Madrid, Spain|Forest Investigative Site 802, Kherson, Vil. Stepanivka, Ukraine|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odesa, Ukraine",,"https://ClinicalTrials.gov/show/NCT01592786"
992,"NCT02096952","Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD",,"Completed","Has Results","Attention-deficit/Hyperactivity Disorder|Autism Spectrum Disorder","Drug: Methylphenidate extended-release liquid formulation","Change in Adult ADHD Investigator Symptom Report Scale (AISRS) Score","Massachusetts General Hospital","All","18 Years to 40 Years   (Adult)","Phase 4","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014P000501","May 2014","January 2018","January 2018","March 26, 2014","February 23, 2018","February 23, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02096952/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02096952/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02096952"
993,"NCT01751698","Adaptive Interventions for Minimally Verbal Children With ASD in the Community","AIM-ASD","Completed","No Results Available","Autism","Behavioral: JASP-EMT|Behavioral: DTT","Primary Outcome 1: Language Sample|Secondary Aim 1: Joint Engagement|Secondary Outcome 2: Number of Unique Words (Vocabulary)|Secondary Outcome 3: Object Play","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","54 Months to 96 Months   (Child)","Not Applicable","192","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD073975","January 2013","June 2017","December 2017","December 18, 2012",,"October 11, 2018","University of California, Los Angeles, Los Angeles, California, United States|University of Rochester, Rochester, New York, United States|Weill Cornell Medical College, White Plains, New York, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01751698"
994,"NCT04100863","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Autism",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder|Autistic Disorder|Autism, Akinetic|Autism; Atypical|Autism; Psychopathy|Autism Fragile Syndrome X|Autism With High Cognitive Abilities|Autism-Related Speech Delay|Autism, Susceptibility to, 6|Autism Spectrum Disorder High-Functioning|Autistic Thinking|Autism, Susceptibility to, X-Linked 6|Autistic Behavior","Other: No Intervention","Correlation of Microbiome to Autism via Relative Abundance Found in Microbiome Sequencing|Validation of Sequencing Methods","ProgenaBiome","All","6 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRG-006","March 2, 2020","March 2023","June 2023","September 24, 2019",,"September 5, 2021","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04100863"
995,"NCT04257331","Parent Training to Reduce Behavioral Problems in Children With Autism Spectrum Disorder in China","SREIA","Active, not recruiting","No Results Available","Child Behavior Problem|Autism Spectrum Disorder|Parent-Child Relations|Parenting|Mental Health Issue|Child Abuse|Family Relations","Behavioral: Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme","Change in frequency of child ehavioral problems|Change in frequency of ASD symptoms|Change in frequency of parenting style: over-reactivity|Change in frequency of parenting style: supportive behaviors|Change in frequency of parental mental health symptoms|Change in family function|Change in parental knowledge","University of Oxford|Beijing Normal University|Beijing Stars and Rain Education Institute for Autism","All","18 Years and older   (Adult, Older Adult)","Not Applicable","111","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R67619/RE001","September 1, 2020","December 31, 2020","December 2021","February 6, 2020",,"August 10, 2021","Beijing Stars and Rain Education Institute for Autism, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04257331"
996,"NCT01302964","Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders",,"Completed","Has Results","Autism Spectrum Disorders","Drug: Placebo|Drug: Mirtazapine","Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase|Proportion of Participants Who Responded to Treatment at 10 Weeks According to the Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or CGI-I=2)","Massachusetts General Hospital|Autism Speaks","All","5 Years to 17 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012P001009","August 2010","October 10, 2017","October 10, 2017","February 24, 2011","November 7, 2018","November 7, 2018","Riley Child and Adolescent Psychiatry Clinic Riley Hospital, Indianapolis, Indiana, United States|Lurie Center -MassGeneral Hospital, Lexington, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01302964/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01302964"
997,"NCT02088047","The Effects of ProFoveate on Reducing Self-Stimulating Behaviors",,"Terminated","Has Results","Autism Spectrum Disorders|Normal Hearing|Normal Intelligence|Exhibit Self- Stimulating or Ritualistic Behaviors","Device: ProFoveate","Numbers of Self-stimulating Behaviors","University of Arkansas","All","10 Years to 17 Years   (Child)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","202241","August 30, 2014","October 4, 2018","October 4, 2018","March 14, 2014","October 9, 2020","October 9, 2020","University of Arkansas at Little Rock Speech and Hearing Clinic, Little Rock, Arkansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02088047/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02088047"
998,"NCT03613051","Assessment of Movement Skills in Autism Spectrum Disorder",,"Unknown status","No Results Available","Movement Disorders","Behavioral: Movement Assessment Battery for children","assessment of motor skills in autism spectrum disorders through Movement Assessmet Battery for Children test ( M-ABC) , using checklists' method .","Dina Tharwat mohamed ali|Assiut University","All","3 Years to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","movement skills in autism","April 1, 2019","December 1, 2019","April 1, 2020","August 2, 2018",,"February 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03613051"
999,"NCT04243694","Sustainable Mindfulness and Resilience Training (SMART)","SMART","Withdrawn","No Results Available","Caregiver Stress|Autism Spectrum Disorder","Behavioral: Mindfulness training","Acceptance of child's diagnosis: Acceptance of Diagnosis of Autism-modified scale|Acceptance of one's negative experiences (experiential avoidance, negative emotions and thoughts): Acceptance and Action Questionnaire|Acceptance of one's momentary situation as assessed by daily mind states (mind wandering, rejection vs. engagement in current moment): daily diary assessments","University of California, San Francisco","All","20 Years to 60 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19-27771","January 1, 2020","July 1, 2020","July 1, 2020","January 28, 2020",,"January 20, 2021","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04243694"
1000,"NCT03002363","The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance",,"Completed","No Results Available","Autism","Behavioral: Video Modeling Intervention|Behavioral: Placebo Video","Compliance to audiology tests (% of audiology tests completed during an audiology session)|Parent stress","Northwestern University","All","18 Months to 36 Months   (Child)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","STU00203250","September 2016","September 1, 2017","September 1, 2017","December 23, 2016",,"August 21, 2018","Northwestern Clinic for Audiology, Speech, Language, and Learning, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03002363"
1001,"NCT02674022","Screening for Metabolic Problems in Mothers of Children With Autism and Typically Developing Children",,"Completed","No Results Available","Pregnancy|Autistic Disorder|Folic Acid Deficiency","Dietary Supplement: Prenatal supplement","Homocysteine level","Mayo Clinic|Arizona State University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15-006909","January 20, 2016","April 5, 2018","April 5, 2018","February 4, 2016",,"October 19, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02674022"
1002,"NCT04654260","Behavior Therapy for Irritability in Autism","BTIA","Recruiting","No Results Available","Autism Spectrum Disorder|Irritability|Disruptive Behavior|Anger|Aggression|Asperger Syndrome|Pervasive Developmental Disorder","Behavioral: Behavioral Therapy for Irritability in Autism|Behavioral: Psychoeducation and Supportive Therapy (PST)","Modified Overt Aggression Scale (MOAS)|The Clinical Global Impression - Improvement Score (CGI-I)|Irritability subscale - Aberrant Behavioral Checklist|Vineland Adaptive Behavior Scales - Communication Domain Score","Yale University|Congressionally Directed Medical Research Programs","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","126","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","0102012121-5|W81XWH2010718","December 10, 2020","August 30, 2024","December 1, 2024","December 4, 2020",,"March 2, 2021","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04654260"
1003,"NCT05010824","A Brief Parent-based Sleep Intervention for Children With Autism Spectrum Disorder",,"Enrolling by invitation","No Results Available","ASD|Insomnia","Behavioral: Sleep hygiene practices and behavioural intervention","Child: Change of child's sleep|Child: change of insomnia symptoms (bedtime resistance)|Child: change of insomnia symptoms (sleep onset delay)|Child: change of insomnia symptoms (night waking)|Parent: Change of parental self-reported sleep quality|Parent: Change of parental insomnia symptoms|Child: Change of child's behaviour & other clinical symptoms|Child: Change of child's executive functions reported by parents|Parent: Change of parental mood symptoms|Parent: Change of parental stress|Parent: Change of parental sense of competence and satisfactory in parenting|Parent: Parent's satisfaction to the treatment|Parent: Parent's overall health status","The University of Hong Kong","All","3 Years to 6 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW20-204","August 5, 2021","December 31, 2021","December 31, 2021","August 18, 2021",,"August 18, 2021","Department of Clinical Psychology, The Duchess of Kent Children's Hospital at Sandy Bay, HKWC, Hospital Authority, Hong Kong, Hong Kong|Sleep Research Clinic & Laboratory, Department of Psychology, The University of Hong Kong, Hong Kong, Hong Kong","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT05010824/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05010824"
1004,"NCT02035176","Novel Measure of Social Deficits in Children","OATS","Completed","No Results Available","Autism Spectrum Disorders|ADHD",,"Eye gaze in response to animated social situations|Facial expressions in response to animated social situations","Oregon Health and Science University","All","6 Years to 11 Years   (Child)",,"92","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","eIRB 9747","February 2014","December 2018","December 2018","January 14, 2014",,"August 28, 2019","OHSU, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02035176"
1005,"NCT03957044","the Effect of Vestibular Rehabilitation in Autistic Children",,"Completed","No Results Available","Autistic Spectrum Disorder|Vestibular Disorder|Sensory Integration Disorder","Other: The education of sensory integration with vestibular education","sensory profile test|postrotary nystagmus test","Istinye University","All","3 Years to 10 Years   (Child)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","University","March 1, 2013","June 1, 2013","July 1, 2013","May 21, 2019",,"July 30, 2020",,,"https://ClinicalTrials.gov/show/NCT03957044"
1006,"NCT02168868","Immune Tests in Blood Samples From Children With ASD",,"Recruiting","No Results Available","Autistic Disorder","Diagnostic Test: Blood Draw|Diagnostic Test: Stool Sample Collection|Diagnostic Test: Urine Sample Collection","Identification of ASD-specific immunological biomarkers and/or signatures in blood samples collected from ASD children.|Correlative assessment of ASD severity vs. biomarker levels|Correlative assessment of biomarker levels and subject age|Correlative assessment of biomarker levels and subject gender","Cell El Ltd|Assaf-Harofeh Medical Center|Shaare Zedek Medical Center","All","2 Years to 12 Years   (Child)",,"450","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CellEL-920130030","May 2013","December 2022","December 2022","June 20, 2014",,"January 28, 2021","Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02168868"
1007,"NCT01592747","Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine",,"Completed","Has Results","Autistic Disorder|Autism|Asperger's Disorder|Asperger Syndrome|Autism Spectrum Disorders|Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)","Drug: Memantine Hydrochloride (HCl)|Drug: Placebo capsules","Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)|Time to First Loss of Therapeutic (LTR) Response|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12","Forest Laboratories","All","6 Years to 12 Years   (Child)","Phase 2","479","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MEM-MD-68","September 2012","September 2013","October 2013","May 7, 2012","April 24, 2019","April 24, 2019","Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogotá, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson,Vil. Stepanivka, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01592747"
1008,"NCT00631215","Effects of Hyperbaric Oxygen Therapy on Cognitive Function on Autistic Spectrum Disordered Children",,"Unknown status","No Results Available","Cognition","Procedure: Hyperbaric oxygen therapy","CogState touch screen measuring cognitive changes","Pediatric Partners of Ponte Vedra","All","6 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","07.11.0005","January 2008","June 2009","October 2009","March 7, 2008",,"March 7, 2008","Pediatric Partners of Ponte Vedra, Ponte Vedra Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00631215"
1009,"NCT04663022","Influence of the Sensory Profile of Deaf Children With Autism Spectrum Disorders on the Outcome of Cochlear Implantation","PSIC-TSA","Recruiting","No Results Available","Deafness","Other: Dunn's sensory profile questionnaire","determine the sensory profile","University Hospital, Toulouse","All","15 Months to 10 Years   (Child)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RC31/20/0328","December 1, 2020","December 2021","December 2021","December 10, 2020",,"December 10, 2020","University Hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04663022"
1010,"NCT03614000","Early Screening of Emotional, Behavioral and Autism Spectrum Disorders in Children With Functional Constipation.",,"Recruiting","No Results Available","Functional Constipation|Emotional Problems|Behavioural Problems|Developmental Disorder|Autism Spectrum Disorder","Other: Screening Questionnaires","The prevalence of internalizing and externalizing behavioural problems as assessed by the Aseba questionnaires|The prevalence of behavioural and social responsiveness problems as assessed by the Social Responsiveness Scale-2.","Universitair Ziekenhuis Brussel","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","B.U.N. 143201733193","January 12, 2018","August 12, 2021","October 12, 2021","August 3, 2018",,"May 22, 2020","Universitair Kinderziekenhuis Brussel, Jette, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03614000"
1011,"NCT01033565","Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders",,"Terminated","Has Results","Sleep Disorder","Drug: Natrol","Clinical Global Impression-Improvement","University of Nebraska","All","4 Years to 8 Years   (Child)","Phase 4","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","401-09","December 2009","October 2010","October 2010","December 16, 2009","September 9, 2013","September 9, 2013","University of Nebraska Medical Center Munroe Meyer Institute, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01033565"
1012,"NCT02147236","Social Skills in Children With Autism Spectrum Disorders","SSD_ASD","Completed","No Results Available","Pervasive Developmental Disorders","Behavioral: Social Skills Training","Clinical Global Impression for Improvement|Social Competence Inventory","Yale University|Organization of Autism Research|Renfield Foundation","All","8 Years to 11 Years   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","0402026356","July 2003","January 2005","January 2005","May 26, 2014",,"May 26, 2014","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02147236"
1013,"NCT03434080","Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy",,"Recruiting","No Results Available","Autism|Cerebral Palsy",,"Magnitude, extent and location of brain activity recorded by NIRS and/or EEG within tasks across subject groups. We will also quantify changes in brain activation across ages (cross-sectional) and time (longitudinal).|Secondary outcomes include motion and EMG data to help interpret task and group differences and measures of motor abilities. The sameoutcome measures will be compared across ages to examine the development of cortical activation patterns and ...","National Institutes of Health Clinical Center (CC)","All","3 Months to 5 Years   (Child)",,"300","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","180052|18-CC-0052","May 16, 2018","December 1, 2025","December 1, 2025","February 15, 2018",,"December 2, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03434080"
1014,"NCT00464477","Advanced Grandparental Age as a Risk Factor for Autism",,"Completed","No Results Available","Autistic Disorder|Pervasive Developmental Disorder|Asperger Syndrome|Childhood Disintegrative Disorder|Rett Syndrome",,,"University of Mississippi Medical Center","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2007-0023","June 2007",,"October 2007","April 23, 2007",,"November 7, 2007","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00464477"
1015,"NCT04771338","Examining the Effects of a Job Entry Intervention","IMPRESSIVE","Recruiting","No Results Available","Autism Spectrum Disorder|Autism|ASD","Behavioral: VR-JIT/KF-STRIDE","Mock Job Interview Change","Kessler Foundation","All","16 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R-1078-19","September 1, 2019","August 31, 2021","August 31, 2022","February 25, 2021",,"March 29, 2021","Kessler Foundation, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04771338"
1016,"NCT01565629","Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders","CCAL","Completed","No Results Available","Autism|Asperger's Syndrome|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder","Behavioral: Computer assisted cognitive behavioral therapy.","Pediatric Anxiety Rating Scale|Anxiety Disorders Interview Schedule: Parent and Child Versions|Clinical Global Impression - Severity Scale","University of South Florida","All","7 Years to 12 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CCAL-2012","February 2012","October 2016","October 2016","March 28, 2012",,"October 26, 2017","University of South Florida, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01565629"
1017,"NCT01178385","Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders",,"Completed","Has Results","Autism|Asperger's Syndrome|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder","Behavioral: Cognitive-behavioral therapy|Behavioral: Treatment as Usual","Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms)|Anxiety Disorders Interview Schedule Highest Anxiety Clincian Severity Rating (Measures the Severity of the Child's Anxiety Symptoms)|Clinical Global Impression - Severity Scale (This Scale Measures the Severity of the Child's Anxiety Symptoms).","University of South Florida","All","7 Years to 11 Years   (Child)","Phase 2|Phase 3","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ACH-2010","April 2010","December 2012","December 2012","August 10, 2010","April 2, 2013","April 2, 2013","Rothman Center for Neuropsychiatry, University of South Florida, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01178385"
1018,"NCT02543203","Essential Oils for Enhancing QOL in ASD",,"Completed","Has Results","Autism Spectrum Disorder|Quality of Life|Sleep|Anxiety","Biological: Reconnect|Biological: Coconut oil Comparator","Pediatric Quality of Life Inventory|Children's Sleep Habits Questionnaire|Parent-rated Anxiety Scale for Autism Spectrum Disorder PRAS-ASD","Jill Hollway|Young Living Essential Oils|Ohio State University","All","3 Years to 9 Years   (Child)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2015H0005","July 2015","March 16, 2018","March 16, 2018","September 7, 2015","April 1, 2021","April 1, 2021","Ohio State University Nisonger Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02543203/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02543203"
1019,"NCT02153203","Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders",,"Completed","No Results Available","Child Development Disorders, Pervasive","Behavioral: Prevent-Teach-Reinforce Model|Other: Individual Parent Training Session","Change from baseline in parental report of problem behavior at 8 weeks|Change from baseline in quality of life at 8 weeks|Change from baseline in parental report of stress at 20 weeks|Change from baseline in parental report of stress at 8 weeks|Change from baseline in quality of life at 20 weeks|Social validity of the intervention|Change from baseline in parental report of problem behavior at 20 weeks|Change from baseline in parental report of positive social behavior at 20 weeks|Change from baseline in parental report of positive social behavior at 8 weeks","Université de Montréal","All","up to 12 Years   (Child)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CERFAS-2014-15-058-P","October 2014","June 2016","September 2016","June 2, 2014",,"October 25, 2016","West Montreal Readaptation Centre, Lachine, Quebec, Canada|Gold Centre, Montreal, Quebec, Canada|CRDITED de Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02153203"
1020,"NCT03624400","Internet-delivered Cognitive Behaviour Therapy for Sleep Problems in ASD",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder|Sleep Disturbance|Insomnia","Behavioral: Internet-based CBT-I|Behavioral: Internet-based psychoeducation","Change in sleep impairment by using The Insomnia Severity Index (ISI)|Sleep diaries by using Actigraphy|Quality of sleep by using Athens Insomnia Scale (AIS)|Everyday functioning by using Developmental disabilities modification of the Children's Global Assessment scale (DD-CGAS)|Anxiety problems by using Spence Children's Anxiety Scale|Emotion regulation difficulties by using The brief version of Difficulties in Emotion Regulation Scale (DERS-16)","Karolinska Institutet","All","13 Years to 17 Years   (Child)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Sleep Good Autism","February 8, 2021","June 30, 2022","December 30, 2023","August 10, 2018",,"February 23, 2021","Nora Choque Olsson, Stockholm, Sverige, Sweden",,"https://ClinicalTrials.gov/show/NCT03624400"
1021,"NCT02403817","Training Attention and Eye Movement in ASD",,"Completed","Has Results","Autistic Disorder|Autism Spectrum Disorder","Behavioral: Cognitive Training|Behavioral: Eye Motor Training|Behavioral: Hand Motor Training","Spatial Attention Baseline|Saccadic Eye Movements Baseline|Change in Spatial Attention at 8 Weeks|Change in Saccadic Eye Movements at 8 Weeks","University of California, San Diego","All","9 Years to 25 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R33MH096967","November 2015","August 31, 2018","August 31, 2018","March 31, 2015","December 4, 2019","December 4, 2019","University of California San Diego, La Jolla, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02403817/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02403817"
1022,"NCT03919721","Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions",,"Unknown status","No Results Available","Autistic Disorder","Behavioral: Applied Behavioral Analysis","Impact of software on number of updates to programs made by behavior analysts (intervention agility)|Event tracking usability assessed by user ratings|Program editing efficiency as assessed by usage analysis|Impact of software on trial success rate|Impact of software on trials to criterion (number of trials needed to achieve mastery)|Impact of software on total number of targets mastered","Experiad LLC|National Institute of Mental Health (NIMH)|University of Washington|northwest behavioral associates","All","2 Years to 21 Years   (Child, Adult)","Not Applicable","12","Industry|NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Motivity-II|R44MH098476","November 1, 2019","March 31, 2020","March 31, 2020","April 18, 2019",,"April 18, 2019","Northwest Behavioral Associates, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03919721"
1023,"NCT03025646","Feasibility of Implementing a Mental Health Care Program and Home-based Training for Mothers of Children With Autism Spectrum Disorder in an Urban Population in Bangladesh",,"Recruiting","No Results Available","Maternal Depression","Other: Mental Health care services & home based training","Participants who can accept, afford and adapt the implemented program of mental health service and home based training program|Number of mothers with Major Depressive Disorder (MDD)|Number of children with ASD who have improved their skill in terms of communication, behavior and social skills","International Centre for Diarrhoeal Disease Research, Bangladesh|Harvard Medical School|National Institute of Mental Health (NIMH)|National Institute of Neurosciences Hospital (NINS)|Institute of Paediatric Neurodisorder and Autism (IPNA)","Female","18 Years to 50 Years   (Adult)","Not Applicable","78","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PR-16070","April 1, 2017","September 2021","September 2021","January 19, 2017",,"April 26, 2021","Awf, Swac, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03025646"
1024,"NCT02302209","Dyad Oxytocin Study (DOS)","DOS","Completed","No Results Available","Schizophrenia|Autism Spectrum Disorder","Drug: Oxytocin|Other: Placebo Comparator","Change in Negative Expressed Emotion","University of California, San Francisco","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","104","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","10-04286","April 2011","October 2017","October 2017","November 26, 2014",,"May 21, 2019","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02302209"
1025,"NCT05066178","Speech Treatment for Minimally Verbal Children With ASD and CAS","TxMVASD+CAS","Not yet recruiting","No Results Available","Developmental Verbal Dyspraxia|Autism Spectrum Disorder","Behavioral: CAS Treatment for Minimally Verbal Children with Autism","Attempts Correct|Phonemes Correct|Lip aperture movement variability|Phoneme distinctiveness","MGH Institute of Health Professions","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021P002598","January 1, 2022","November 30, 2023","November 30, 2024","October 4, 2021",,"October 4, 2021",,,"https://ClinicalTrials.gov/show/NCT05066178"
1026,"NCT01563003","Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism",,"Completed","Has Results","Autism|Asperger's Syndrome|Pervasive Developmental Disorder Not Otherwise Specified|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder","Other: Cognitive Behavioral Therapy|Other: Treatment as usual","Pediatric Anxiety Rating Scale|Anxiety Disorders Interview Schedule Clinical Severity Rating|Clinical Global Impression - Severity Scale","University of South Florida","All","11 Years to 16 Years   (Child)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AASD-2012","June 2011","April 2015","April 2015","March 26, 2012","April 17, 2015","April 17, 2015","Rothman Center for Neuropsychiatry, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01563003"
1027,"NCT04535817","Xolair Interventional Study in ASD Patients With Comorbid Atopy",,"Withdrawn","No Results Available","Autism Spectrum Disorder|Atopy","Drug: Omalizumab Injection [Xolair]","Change from Baseline to Week 12 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 24 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Week 24 to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 12 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 24 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Week 24 to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 1 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 4 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 8 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 12 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 16 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 20 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 24 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Change from Week 24 to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Inflammatory Marker Levels|Structural MRI|Functional MRI (resting state)|Generalized Anxiety Disorder 7-item (GAD-7)|Epworth Sleepiness Scale (ESS)|Pittsburgh Sleep Quality Index (PSQI)|Asthma Control Test (ACT)|Rhinitis Control Assessment Test (RCAT)|Validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD)","Beth Israel Deaconess Medical Center|Novartis","All","18 Years to 30 Years   (Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P000753","January 1, 2021","January 1, 2022","January 1, 2022","September 2, 2020",,"August 18, 2021","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04535817"
1028,"NCT03553875","Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder|Nonverbal Learning Disability","Drug: Memantine Hydrochloride|Drug: Placebo","Clinical Global Impression-Improvement Scale (CGI-I)","Massachusetts General Hospital","All","8 Years to 18 Years   (Child, Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018P001082","November 13, 2018","June 2022","June 2022","June 12, 2018",,"July 9, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03553875"
1029,"NCT02850666","Social Skills in Children With ASD and Process Drama",,"Completed","No Results Available","Autistic Disorder","Behavioral: Interdisciplinary process drama","Social Skills Improvement Scale|Theory of Mind Battery and Inventory|Structured Play Assessment|Retention Rate|Recruitment|Brain activity during Theory of Mind tasks|Parental perceptions of social skills|Changes in social skills during program|Modifications needed to program","University of Utah","All","3 Years to 4 Years   (Child)","Not Applicable","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00091961","July 2016","September 12, 2017","October 1, 2017","August 1, 2016",,"May 15, 2018","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02850666"
1030,"NCT04047615","The Effects of Exercise on Behavior and Fitness in Children With ASD",,"Unknown status","No Results Available","Autism Spectrum Disorder|Behavior","Other: Exercise","Behavior|Fitness Level","Institute of Technology, Carlow","All","4 Years to 13 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASD Intervention","September 1, 2019","February 2021","February 2021","August 7, 2019",,"August 9, 2019","Institute of Technology, Carlow, Carlow, Ireland",,"https://ClinicalTrials.gov/show/NCT04047615"
1031,"NCT03820869","The Effect Of Occupational Therapy On Sensory-Based Feeding Problems",,"Unknown status","No Results Available","Feeding Disorder|Autism Spectrum Disorder|Sensory Integration Disorder (Disorder)","Other: Family Training|Other: Occupational Therapy","Dunn Sensory Profile|BAMBİ|STEP","Hacettepe University","All","3 Years to 10 Years   (Child)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/454","March 2019","May 2019","July 2019","January 29, 2019",,"January 29, 2019",,,"https://ClinicalTrials.gov/show/NCT03820869"
1032,"NCT03222375","SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism","SQUED™","Recruiting","No Results Available","Autistic Disorder|Autism Spectrum Disorder|Child Development Disorders, Pervasive|Neurodevelopmental Disorders|Mental Disorders|Asperger's Syndrome|Neurobehavioral Manifestations|Nervous System Diseases","Device: SQUED™ series 28.1 home-use","SQUED™ software of patient","American Federation of Medical Synergetics|Clinic of Synergetics, Department of Neurology/Neuropsychology WOMS|Institute of Medical Synergetics, Department of Cognitive Neurology WOMS|Laboratory of Neurocomputational Active Media WOMS|SQUED, Inc., USA|Center of Synergetics, Universität Stuttgart, Germany|Ivan Franko National University of Lviv, Ukraine|Danylo Halytsky Lviv National Medical University|World Organization of Medical Synergetics|World Autism Center, American Federation of Medical Synergetics","All","1 Month to 21 Years   (Child, Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SQUED™ series 28.1 home-use","September 26, 2017","September 2022","December 2027","July 19, 2017",,"November 28, 2017","World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS, Louisville, Kentucky, United States|Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics, Lviv, Solonka Village, Urozayna Street 41, Ukraine",,"https://ClinicalTrials.gov/show/NCT03222375"
1033,"NCT01238250","Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight",,"Recruiting","No Results Available","16P11.2 Deletion Syndrome|16p11.2 Duplications|1Q21.1 Deletion|1Q21.1 Microduplication Syndrome (Disorder)|ACTL6B|ADNP|AHDC1|ANK2|ANKRD11|ARID1B|ASH1L|BCL11A|CHAMP1|CHD2|CHD8|CSNK2A1|CTBP1|CTNNB1 Gene Mutation|CUL3|DDX3X|DNMT3A|DSCAM|DST (Dystonin) Related Epidermolysis Bullosa Simplex|DYRK1A|FOXP1|GRIN2A|GRIN2B|HIVEP2-Related Intellectual Disability|HNRNPH2|KATNAL2|KDM5B|KDM6B|KMT2C Gene Mutation|KMT2E|KMT5B|MBD5|MED13L|PACS1|PBRM1|PPP2R5D-Related Intellectual Disability|PTCHD1|REST|SCN2A Encephalopathy|SETBP1 Gene Mutation|SETD5|SMARCA4 Gene Mutation|SMARCC1|SMARCC2|STXBP1 Encephalopathy With Epilepsy|SYNGAP1-Related Intellectual Disability|TBR1|ARHGEF9|HNRNPU|PPP3CA|PPP2R1A|SLC6A1|2p16.3 Deletions|5q35 Deletions|5q35 Duplications|7q11.23 Duplications|15Q13.3 Deletion Syndrome|16p11.2 Triplications|16P12.2 Microdeletion|16P13.11 Microdeletion Syndrome (Disorder)|17Q12 Microdeletion Syndrome (Disorder)|17Q12 Duplication Syndrome|17Q21.31 Deletion Syndrome|17q21.3 Duplications|ACTB|ADSL|AFF2|ALDH5A1|ANK3|ARX|ATRX Gene Mutation|AUTS2 Syndrome|BAZ2B|BCKDK|BRSK2|CACNA1C|CAPRIN1|CASK|CASZ1|CHD3|CIC|CNOT3|CREBBP Gene Mutation|CSDE1|CTCF|DEAF1|DHCR7|DLG4|DMPK|EBF3|EHMT1|EP300 Gene Mutation|GIGYF1|GIGYF2|GRIN1|GRIN2D|IQSEC2-Related Syndromic Intellectual Disability|IRF2BPL|KANSL1|KCNB1|KDM3B|NEXMIF|KMT2A|MBOAT7|MEIS2|MYT1L|NAA15|NBEA|NCKAP1|NIPBL|NLGN2|NLGN3|NLGN4X|NR4A2|NRXN1|NRXN2|NRXN3|NSD1 Gene Mutation|PHF21A|PHF3|PHIP|POMGNT1|PSMD12|RELN|RERE|RFX3|RIMS1|RORB|SCN1A|SCN8A Encephalopathy|SETD2 Gene Mutation|SHANK2|SIN3A|SLC9A6|SON|SOX5|SPAST|SRCAP|TAOK1|TANC2|TCF20|TLK2|TRIO|TRIP12|TSHZ3|UPF3B|USP9X|VPS13B|WAC|WDFY3|ZBTB20|ZNF292|ZNF462|2Q37 Deletion Syndrome|9q34 Duplications|15q15 Deletions|15Q24 Deletion|NR3C2|SYNCRIP|Additional Genetic Changes Associated With Autism May be Added as Identified|2q34 Duplication|2q37.3 Deletion|6q16 Deletion|15q11.2 BP1-BP2 Deletion|16p13.3 Deletion|17Q11.2 Microduplication Syndrome (Disorder)|17p13.3|Xq28 Duplication|CLCN4|CSNK2B|DYNC1H1|EIF3F|GNB1|MED13|MEF2C|RALGAPB|SCN1B|YY1|Xp11.22 Duplication",,"Baseline comprehensive collection of medical, behavioral, learning, and developmental information of people who have documented gene changes that are associated with features of autism and other neurodevelopmental disorders.|Longitudinal, or long-term, comprehensive collection of medical, behavioral, learning, and developmental information from people who have documented gene changes that are associated with features of autism and other neurodevelopmental disorders.","Simons Searchlight|Geisinger Clinic|Columbia University|Simons Foundation","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","2011-0320|Simons Searchlight|Simons VIP|Simons VIP Connect","October 2010","October 2050","October 2050","November 10, 2010",,"September 27, 2021","CUMC/New York-Presbyterian Morgan Stanley Children's Hospital, New York, New York, United States|Geisinger Health System, Lewisburg, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01238250"
1034,"NCT00324909","Effects of Hyperbaric Oxygen Therapy in Autistic Children: A Pilot Study",,"Completed","No Results Available","Autism|Oxidative Stress|Inflammation","Drug: Hyperbaric Oxygen Therapy","Scores on autism rating scales before and after HBOT|Measure of inflammation before and after HBOT|Measures of oxidative stress before and after HBOT","International Hyperbarics Association","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBA-1",,,,"May 11, 2006",,"April 10, 2007","Blue Ridge Medical Center, Arrington, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00324909"
1035,"NCT01620060","Lurasidone Pediatric Pharmacokinetics Study",,"Completed","Has Results","Schizophrenia|Autism","Drug: Lurasidone","Lurasidone Primary Pharmacokinetic Parameters|Lurasidone Peak Serum Concentration (Cmax)|Number of Participants With Serious Adverse Events and Non-serious Adverse Events","Sunovion","All","6 Years to 17 Years   (Child)","Phase 1","105","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1050300","June 2012","May 2013","May 2013","June 15, 2012","July 31, 2014","April 8, 2016","Woodland International Research Group, Inc., Little Rock, Arkansas, United States|Woodland Northwest Research, LLC, Springdale, Arkansas, United States|World Wide Research Centers Inc., Murrietta, California, United States|Segal Institute for Clinical Research, Ft. Lauderdale, Florida, United States|Miami Children's Hospital, South Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Aspen Clinical Research, Orem, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01620060"
1036,"NCT04204226","Autism and Disruptive Behavior Trial",,"Recruiting","No Results Available","ASD|Child Behavior Problem","Behavioral: Social Worker|Behavioral: Autism Behavioral Health Navigation (ABHN)|Behavioral: Social work + ABHN|Behavioral: Social work + ABHN + CAP","Number of children referred to the study each month meeting eligibility requirements|Number of families successfully contacted by the navigator or social worker|Retention Rate|Number of subjects consented|Changes (or Improvement) with interpersonal relationships|Changes in ABC-irritability subscale|Changes in levels of challenging behavior","Children's Hospital of Philadelphia|Eagles Autism Challenge, Inc|University of Pennsylvania","All","5 Years to 12 Years   (Child)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","19-016364","December 17, 2019","November 2021","November 2021","December 18, 2019",,"January 13, 2021","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04204226"
1037,"NCT01172509","TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers",,"Terminated","No Results Available","Autism","Drug: R-baclofen","percent of baseline TMS-induced measures of (1) human synaptic plasticity (LTD)","Gonzalez-Heydrich, Joseph, M.D.|Boston Children's Hospital|Seaside Therapeutics, Inc.","All","18 Years to 30 Years   (Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TMS_biomarker_Rbac_normals1","October 2010","July 2012","July 2012","July 29, 2010",,"August 21, 2015","Berenson-Allen Center for Noninvansive Brain Stimulation Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01172509"
1038,"NCT02383732","A Study of the Elopement Prevention and Safety Training Program",,"Completed","No Results Available","Elopement|Autism Spectrum Disorder","Behavioral: Universal Safety Measures Module (All participants)|Behavioral: Proximity Training Module (Bolting Prevention Participants)|Behavioral: Check-In Training Module (Wandering Prevention Participants)","Feasibility of intervention, assessed by change in severity on Clinical Global Impression for Severity (CGI-S)|Change in elopement behavior","Emory University","All","4 Years to 12 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00076337","February 2015","January 31, 2017","January 31, 2017","March 9, 2015",,"March 30, 2017","Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02383732"
1039,"NCT04840498","UAB AIM Virtual Magic Camp",,"Active, not recruiting","No Results Available","Autism","Behavioral: Autism Research","Self Esteem|Strengths & Difficulties|Social Anxiety|Social Skills|Social Responses|Parental Stress","Hon K. Yuen, PhD|University of Alabama at Birmingham","All","9 Years to 18 Years   (Child, Adult)",,"18","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","300005328","April 7, 2021","August 31, 2023","August 31, 2023","April 12, 2021",,"September 8, 2021","UAB Alys Sthepens Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04840498"
1040,"NCT03771001","5Minutes4Myself: A Wellness Program for Caregivers",,"Recruiting","No Results Available","Autism|Stress|Autism Spectrum Disorder","Other: Motivational Interviewing coaching and habit-building app","SF-36 Questionnaire|Perceived Stress Scale|Ryff's Psychological Well-Being Scale|Center for Epidemiological Depression Scale-Revised|Five facets of Mindfulness Questionnaire|Modified System Usability Scale|Participant Feedback","University of Wisconsin, Madison","All","Child, Adult, Older Adult","Not Applicable","70","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015-1004","November 2015","August 2025","December 2025","December 10, 2018",,"July 28, 2021","Community Sites, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03771001"
1041,"NCT00691080","Understanding Sleep Problems in Children With Autism Spectrum Disorder","REST","Completed","No Results Available","Sleep Problems",,"Sleep Latency, as measured by actigraphy|Total sleep time, as measured by actigraphy","Baylor College of Medicine|Autism Speaks|Oregon Health and Science University|Columbia University|The Emmes Company, LLC|Autism Treatment Network","All","4 Years to 9 Years   (Child)",,"58","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2003","September 2007","September 2011","November 2011","June 5, 2008",,"January 13, 2016","Columbia University, New York, New York, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00691080"
1042,"NCT03546504","Program to Improve Dental Care: Children With ASD",,"Terminated","No Results Available","Autism","Behavioral: Procedure alteration and occupational therapy","Child's behavior in typical oral hygiene activities|Decayed, Missing, Filled Surfaces (DMFS) Index|Simplified Oral Hygiene Index|Modified Gingival index from the Community Periodontal Index|Assessment of saliva for bacteria content|Number of dental procedures completed|Dental Subscale of the Childrens Fear Survey|Frankl Behavioral Scale|Child's behavior during dental visits|Parent report of burden of oral hygiene activities|Wong-Baker Faces Scale","University of Utah","All","5 Years to 12 Years   (Child)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_0085018","December 1, 2018","December 31, 2019","February 28, 2020","June 6, 2018",,"November 4, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03546504"
1043,"NCT00859664","Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders",,"Unknown status","No Results Available","Autism|Neuroleptic Treatment","Other: Genotyping of Cytochrome P450","Genotyping of the polymorphic cytochrome P450 (CYP) 2D6 gene, in children with autistic spectrum disorder treated with neuroleptics, will improve treatment efficacy and prevent undesired adverse drug reactions.","Assaf-Harofeh Medical Center","All","3 Years to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","145/07","March 2009","July 2011","July 2011","March 11, 2009",,"March 11, 2009","Assaf Harofeh Medical center, Zerifin, Israel",,"https://ClinicalTrials.gov/show/NCT00859664"
1044,"NCT02430051","Sensory Adapted Dental Environments to Enhance Oral Care for Children","SADE-2","Active, not recruiting","No Results Available","Autism","Behavioral: Sensory Adapted Dental Environment","Electrodermal Activity (EDA)|Children's Dental Behavior Rating Scale (CDBRS)|Anxiety and Cooperation Scale|Duration|Number of hands used to restrain child|Faces Pain Scale - Revised|Dental Sensory Sensitivity Scale|Frankl Scale","University of Southern California|Children's Hospital Los Angeles","All","6 Years to 12 Years   (Child)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DE024978-01","May 2015","April 30, 2022","April 30, 2022","April 29, 2015",,"May 11, 2021","Children's Hospital Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02430051"
1045,"NCT02428205","Combined Effects of Early Behavioral Intervention and Propranolol on ASD",,"Recruiting","No Results Available","Autism","Drug: Propranolol|Drug: Placebo","Change in General Social Outcome Measure (GSOM)|Change in Social Responsiveness Scale (SRS)|Change in Preschool Anxiety Scale (PAS)|Change in Clinical Global Impression of Change (CGIC) scale|Change in Clinical Global Impression of Severity (CGIS) scale|Change in Aberrant Behavior Checklist (ABC)|Change in Vineland Adaptive Behavior Scales-II (VABS)|Change in Autism Impact Measure (AIM)|Change in Preschool Language Scale (PLS):","University of Missouri-Columbia|Autism Science Foundation","All","3 Years to 10 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2001935","April 2015","December 2022","December 2022","April 28, 2015",,"April 12, 2021","Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02428205/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02428205"
1046,"NCT04896671","Physical Exercise Training to Enhance Executive and Social Functions",,"Completed","No Results Available","Broad Autism Phenotype","Behavioral: Physical exercise (running on a treadmill)","Demographics|Change from baseline autistic traits at 6 weeks|Change from baseline executive functions at 6 weeks|Change from baseline psychological resilience at 6 weeks|Change from baseline schizotypal personality traits at 6 weeks|Change from baseline aggression at 6 weeks|Change from baseline empathy at 6 weeks","The University of Hong Kong|The Hong Kong Polytechnic University|Griffith University","All","7 Years to 20 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HSEARS20190311003","April 1, 2019","September 30, 2020","September 30, 2020","May 21, 2021",,"May 25, 2021","The Hong Kong Polytechnic University, Hong Kong, Hong Kong","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04896671/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04896671/SAP_004.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04896671/ICF_005.pdf","https://ClinicalTrials.gov/show/NCT04896671"
1047,"NCT03473080","An eHealth Intervention for Obsessive Compulsive Disorder in Youth With Autism Spectrum Disorder",,"Completed","No Results Available","Obsessive-Compulsive Disorder","Behavioral: Internet CBT","Children's Yale-Brown Obsessive Compulsive Scale|Obsessive-compulsive inventory - child version|Autism spectrum quotient (AQ-10)|Education, work and social adjustment scale - child and parent version|Family accommodation scale for obsessive-compulsive disorder|Mood and Feeling Questionnaire - child and parent version|Children's Obsessional Compulsive Inventory Revised - parent rated (ChOCI-R-P)|Mini International Neuropsychiatric Interview for Children and Adolescents|Children's global assessment scale|Children's Assessment Scale for Developmental Disabilities|Clinical global impression - severity|Clinical global impression - improvement|internet intervention Patient Adherence Scale|Client Satisfaction Questionnaire (CSQ-8)|Parent strategies|Patient EX/RP Adherence Scale|Drop-out rate from treatment|Completed treatment modules","Karolinska Institutet","All","7 Years to 17 Years   (Child)","Not Applicable","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIP ASD/OCD pilot","March 9, 2018","February 15, 2021","February 15, 2021","March 22, 2018",,"July 6, 2021","BUP OCD and Related Disorders, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03473080"
1048,"NCT01086475","D-Cycloserine and Social Skills Training in Autism Spectrum Disorders",,"Completed","Has Results","Autistic Disorder|Asperger's Disorder|Pervasive Developmental Disorder NOS","Drug: D-cycloserine|Drug: Placebo","Social Responsiveness Scale (SRS) Change|Social Responsiveness Scale (SRS) at Follow-Up|Clinical Global Impressions Improvement Scale Responder Analysis","Indiana University|United States Department of Defense","All","5 Years to 11 Years   (Child)","Phase 3","68","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0906-09","March 2010","January 2014","January 2014","March 15, 2010","April 14, 2016","April 14, 2016","Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01086475"
1049,"NCT01730079","Near Infrared Spectroscopy in Children With Autism and ADHD",,"Terminated","No Results Available","Attention Deficit Disorder With Hyperactivity|Attention Deficit Disorder|Attention Deficit Hyperactivity Disorder|Autism|Autism Spectrum Disorders",,"Graded changes in blood flow and oxygen, measured with NIRS, in response to different functional tasks.|Differential activity according to region of the frontal cortext and task elements.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","4 Years to 8 Years   (Child)",,"42","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","130007|13-M-0007","October 23, 2012","April 11, 2017","April 11, 2017","November 21, 2012",,"October 18, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01730079"
1050,"NCT04199533","Iterative Redesign of a Behavioral Skills Training Program for Use in Educational Settings",,"Recruiting","No Results Available","Autism Spectrum Disorder|Disruptive Behavior","Behavioral: RUBI|Behavioral: RUBIES","Acceptability of Intervention Measure (AIM): 5-point scale|Intervention Appropriateness Measure (IAM): 5-point scale|Feasibility of Intervention Measure (FIM): 5-point scale|Intervention Usability Scale (IUS)","University of Washington|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult",,"40","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SCH-STUDY00001890|1P50MH115837","September 1, 2019","June 30, 2021","September 30, 2021","December 16, 2019",,"December 3, 2020","Seattle Public Schools, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04199533"
1051,"NCT04557488","Effectiveness of Music Therapy in Social Skill Intervention for Children With ASD/ID",,"Recruiting","No Results Available","Autism Spectrum Disorder|Intellectual Disability","Other: Music therapy|Behavioral: Behavioral-based social skill training","Changes of Childhood Autism Rating Scale-2|Changes of Social Responsiveness Scale second edition|In-session social behavior|Changes of EEG recording","Education University of Hong Kong","All","6 Years to 13 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FHB/H/41/165","October 1, 2020","August 31, 2022","August 31, 2022","September 21, 2020",,"February 3, 2021","The Education University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04557488"
1052,"NCT04518358","Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills",,"Recruiting","No Results Available","Autism Spectrum Disorder|Intellectual Disability","Behavioral: Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges","Fidelity of Treatment Implementation|Independent Completion of Steps|Number of Sessions to Skill Acquisition","John T. Nosek|Guiding Technologies Corporation","All","Child, Adult, Older Adult","Not Applicable","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R43MH121230-01","September 1, 2019","August 31, 2021","August 31, 2021","August 19, 2020",,"August 19, 2020","Chimes Delaware, Newark, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT04518358"
1053,"NCT02800681","Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample",,"Completed","No Results Available","Asperger Syndrome|Autism Spectrum Disorder|Schizotypal Personality Disorder","Other: Expert panel evaluation|Other: Semi-structured psychopathological interviews|Other: Self-administered rating scales|Other: Other general interviewer ratings","Level of altered experiences|Pattern of most occurring altered experiences|Autism Spectrum symptom load|Schizophrenia Spectrum symptom load|Self-reported Autism Spectrum symptom load|Self-reported Schizotypia symptom load|Self-reported well-being","Mental Health Services in the Capital Region, Denmark|The Danish Autism Centre","All","18 Years to 30 Years   (Adult)",,"59","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","E-61120-06","June 2016","December 2018","December 2018","June 15, 2016",,"March 10, 2020","Mental Health Centre Ballerup, Mental Health Services, The Capitol Region, Copenhagen, Ballerup, Copenhagen, Denmark|The Danish Autism Centre, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT02800681"
1054,"NCT02791321","Fragility Assessment in Adults With ADHD and Mental Retardation","EFAAR","Recruiting","No Results Available","Autism Spectrum Disorder|Mental Retardation","Other: ADS severity|Other: Adaptative and intellectual functioning|Other: Psychiatric and somatic comorbidities","Frailty index","University Hospital, Montpellier","All","20 Years to 95 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","9691","September 2016","February 2024","February 2026","June 6, 2016",,"May 21, 2018","CHU Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02791321"
1055,"NCT04532424","Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD","TMS for ASD","Suspended","No Results Available","Autism Spectrum Disorder|Autism|Asperger Syndrome","Device: Transcranial magnetic stimulation","Repetitive Behavior Scale-Revised (RBS-R)|Set-shifting performance (Dimensional Change Card Sort Test score)","Stanford University","All","12 Years to 45 Years   (Child, Adult)","Not Applicable","67","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","57738","January 4, 2021","December 1, 2023","December 1, 2024","August 31, 2020",,"August 3, 2021","Robin Libove, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04532424"
1056,"NCT04119492","DCD & ASD Imaging Intervention Study",,"Recruiting","No Results Available","Motor Skills Disorders|Autism Spectrum Disorder","Behavioral: CO-OP Treatment Group","Canadian Occupational Performance Measure (COPM)|Diffusion Tensor Imaging on MRI|Performance Quality Rating Scale (PQRS)|Bruninks-Oseretsky Test of Motor Proficiency 2nd ed. (BOT-2) short form|Resting-state connectivity on MRI|Voxel-based morphometry","University of British Columbia|Waterloo Foundation","All","8 Years to 12 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H18-02759","February 20, 2019","June 30, 2021","June 30, 2021","October 8, 2019",,"October 12, 2020","University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04119492"
1057,"NCT02054949","Treatment Resistant Epilepsy and N-Acetyl Cysteine","TRE-NAC","Withdrawn","No Results Available","Autistic Disorder|Seizures|Irritability","Drug: N-Acetyl Cysteine (NAC)","Recruitment rate|seizure frequency","Nationwide Children's Hospital","All","6 Years to 21 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB12-00325","April 2013","January 2015","January 2015","February 4, 2014",,"October 9, 2015","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02054949"
1058,"NCT00280670","CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS","BIACA","Completed","No Results Available","Autistic Disorder|Asperger Syndrome|Anxiety Disorders","Behavioral: Cognitive-behavioral therapy","Score on anxiety diagnostic interview after treatment or waitlist|Score on anxiety rating scale after treatment or waitlist|Score on daily living skills rating scale after treatment or waitlist|Score on children's social functioning and service use after treatment or waitlist","University of California, Los Angeles","All","7 Years to 11 Years   (Child)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R03MH075806-01","January 2005","August 2008","August 2009","January 23, 2006",,"April 2, 2012","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00280670"
1059,"NCT01602016","A Folinic Acid Intervention for Autism Spectrum Disorders",,"Terminated","Has Results","Autism Spectrum Disorder|Autistic Disorder|Autism|Asperger's Syndrome|Pervasive Development Disorders","Drug: Folinic Acid and placebo|Drug: Folinic Acid","Language Improvement|Improved Stereotyped Behavior and Improved Social Skills","University of Arkansas|Arkansas Children's Hospital Research Institute","All","3 Years to 14 Years   (Child)","Phase 2","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","136002","May 2012","November 2015","November 2015","May 18, 2012","November 6, 2016","October 17, 2017","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01602016"
1060,"NCT02565524","the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder.","GenAuDiss","Recruiting","No Results Available","Schizophrenia|Dissociative Disorders","Other: genetic and phenotypic profile","characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing standard karyotype|characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing search CGG|characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing whole exome sequencing|Intensity of positive symptoms of schizophrenia|Co-morbid psychiatric diagnosis|Evaluation of executive and attentional by the verbal fluency test|Clinical evaluation of autistic symptoms|Neurocognitive profile|Personality dimensional test","Fondation Lenval","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-HPNCL08","May 18, 2014","May 18, 2023","May 18, 2023","October 1, 2015",,"May 7, 2021","Fondation Lenval, Nice, France",,"https://ClinicalTrials.gov/show/NCT02565524"
1061,"NCT03253081","Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response",,"Recruiting","No Results Available","Children With Autism","Behavioral: PARENT focused intervention|Behavioral: CHILD focused intervention","Change in Joint Engagement on the Caregiver-child interaction (CCX) over the course of the study|Early Social- Communication Scales|The Structured Play Assessment-R|Parenting Stress Index (PSI)|The Broader Autism Phenotype Questionnaire (BAPQ)|Caregiver Expectancies /Belief in the Intervention|BOSCC|Caregiver-child interaction (CCX)","University of California, Los Angeles","All","12 Months to 36 Months   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2P50HD055784-11","June 15, 2018","June 30, 2022","June 30, 2022","August 17, 2017",,"November 3, 2020","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03253081"
1062,"NCT00156221","MR Scanning of Very Young Children With Severe Developmental Disorders",,"Completed","No Results Available","Autism|Mental Retardation|Language Disorder",,,"UMC Utrecht|Netherlands Organisation for Scientific Research|The Dutch Brain Foundation","All","18 Months to 7 Years   (Child)",,,"Other","Observational","Observational Model: Natural History|Time Perspective: Other","METC UMC Utrecht 99/184","September 2000",,"September 2005","September 12, 2005",,"September 12, 2005","UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00156221"
1063,"NCT04460976","Psychoeducation for Adults With Autism and Their Significant Others/Family Members","Prisma","Completed","No Results Available","Treatment Satisfaction|Knowledge Acquisition Disability Nos|Anxiety|Depression|Quality of Life|Relation, Family|Acceptance of Diagnosis|Stigma of Mental Illness|Participation","Behavioral: Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Behavioral: Treatment as usual/standard care","Study 1: Evaluation of session 1|Study 1: Evaluation after session 2|Study 1: Evaluation after session 3|Study 1: Evaluation after session 4|Study 1: Number of individuals that completed the intervention|Study 1: Adverse events during the intervention|Study 1: Adverse events after the intervention|Study 1: Overall treatment satisfaction measured by The Evaluation Questionnaire|Study 1: Open answer questions regarding Treatment satisfaction measured by The Evaluation Questionnaire|Study 1: Well-beining before and after the intervention measures by The Evaluation Questionnaire|Study 1: Credibility measured with the Credibility Scale (TCS: Borkovec & Nau, 1972)|Study 2: Knowledge about autism measured by Autism specific quiz|Study 3: Participation measured by Patient Participation in Rehabilitation Questionnaire.|Study 3: Patient Stigma|Study 3: Affiliate Stigma|All studies: Quality of life: Satisfaction with life scale (SWLS)|All studies: Acceptance of diagnosis measured with ""What I think about my diagnosis""|All studies: Well-being with Hospital Anxiety and Depression Scale (HADS)|Study 1 and 2: The burden of care on significant others measured with Assessment Scale (BAS)|Study 1 and 2: Relation to significant others (QAFM)","Karolinska Institutet|Region Stockholm","All","18 Years and older   (Adult, Older Adult)","Not Applicable","718","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Prisma","September 1, 2017","September 15, 2020","September 15, 2020","July 8, 2020",,"December 14, 2020","Karolinska Institutet, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04460976"
1064,"NCT03957993","OT Intervention Via Telehealth for Children With ASD and ADHD",,"Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Other: Occupational Therapy via Telehealth|Other: Standard of Care Occupational Therapy","Change in Goal Attainment Scale|Change in Canadian Occupational Performance Measure","Children's Hospital Medical Center, Cincinnati","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2017-5623","August 6, 2018","December 30, 2019","December 30, 2019","May 21, 2019",,"July 16, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03957993"
1065,"NCT03388294","Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders","PIE","Completed","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Behavioral: Parents and Infants Engaged","Change in Parent Child Engagement Coding from baseline to posttest 1|Change in Parent Child Engagement Coding from baseline to posttest 2|Change in Parent Responsiveness to Child Sensory Reactivity Cues from baseline to posttest 1|Change in Parent Responsiveness to Child Sensory Reactivity Cues from baseline to posttest 2|Change in Parent Responsiveness to Child Prelinguistic Communication Cues from baseline to posttest 1|Change in Parent Responsiveness to Child Prelinguistic Communication Cues from baseline to posttest 2|Change in infant intentional communication, Baseline to posttest1|Change in infant intentional communication, Baseline to posttest 2|Change in Respiratory sinus arrhythmia from baseline to posttest 2|Change in skin conductance levels from baseline to posttest 2|Change in The Behavioral Observation of Social Communication Change (BOSCC) from baseline to posttest 2|Change in The Attention Following Protocol (AF Protocol) from baseline to posttest 2|Change in Mullen Scales of Early Learning Receptive Language T-Scores from baseline to posttest 2|Change in Mullen Scales of Early Learning Expressive Language T-scores from baseline to posttest 2|Change in Sensory Processing Assessment for Young Children from baseline to posttest 2|Change in The Sensory Experiences Questionnaire version 2.1 from baseline to posttest 1|Change in The Sensory Experiences Questionnaire version 2.1 from baseline to posttest 2","University of North Carolina, Chapel Hill|University of Southern California|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Months to 16 Months   (Child)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17-0292|1R21HD091547-01","March 8, 2018","April 1, 2020","May 30, 2021","January 2, 2018",,"June 15, 2021","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03388294"
1066,"NCT03242772","Impact of Combined Medication and Behavioral Treatment for ASD & ADHD",,"Terminated","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Drug: Amphetamine|Behavioral: ESDM informed parent coaching|Drug: Placebo Oral Tablet","Change in amount and quality of joint engagement between the child and parent during a semi-structured 6 minute parent child interaction task|Change in Mean Socialization and Communication Subscales Standard Scores of the Vineland Adaptive Behavior Scale - 3rd edition, Interview Version (VABS-3)|Change in ADHD Symptoms using Preschool or School age ADHD Rating Scale (ADHD-RS)","Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","36 Months to 131 Months   (Child)","Phase 2","18","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00085179|1P50HD093074-01","December 14, 2018","December 28, 2020","April 19, 2021","August 8, 2017",,"August 23, 2021","Duke Center for Autism and Brain Development, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03242772"
1067,"NCT04126395","An Explorative RVA of the Motor Development of Children With DCD <2y","RVA_DCD","Recruiting","No Results Available","Developmental Coordination Disorder|Autism Spectrum Disorder","Diagnostic Test: Movement Assessment Battery for Children 2(M-ABC-2)|Diagnostic Test: Developmental Coordination Disorder - Questionnaire (DCD-Q)|Diagnostic Test: Social Responsiveness Scale 2 (SRS-2)|Other: Retrospective Video Analysis","Early motor development","University Ghent","All","6 Years to 12 Years   (Child)",,"45","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","B670201941082","November 1, 2019","June 30, 2022","December 30, 2022","October 15, 2019",,"January 18, 2020","Vakgroep Revalidatiewetenschappen, Gent, Oost-Vlaanderen, Belgium|Ghent University, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT04126395"
1068,"NCT02498262","Using Virtual Reality and Robotics Technologies for Vocational Evaluation, Training and Placement","VR4VR","Unknown status","No Results Available","Autism Spectrum Disorder|Traumatic Brain Injury","Other: Virtual Reality System","Improvement in composite score of performing the vocational tasks of shelving, cleaning, environmental awareness, loading back of a truck, money management and social skills.","University of South Florida|Florida Department Of Education","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Ame2_Pro00013008","June 2015","December 2019","December 2020","July 15, 2015",,"July 12, 2019","Rehabilitation Robotics & Prosthetics Testbed (RRT) Laboratory on the campus of the University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02498262"
1069,"NCT03860389","The Effects of Exercise in Anxiety in Children With ASD",,"Unknown status","No Results Available","Autism Spectrum Disorder|Anxiety|Behavior","Other: Exercise","Anxiety|Behaviour|Fitness level","Institute of Technology, Carlow|University of Reading","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASD1","January 7, 2019","June 24, 2019","December 16, 2019","March 1, 2019",,"March 1, 2019","Sharon Kinsella, Carlow, Co. Carlow, Ireland",,"https://ClinicalTrials.gov/show/NCT03860389"
1070,"NCT03525951","Parent-Level Predictors of Early Language Interaction Quality and Intervention Outcomes",,"Recruiting","No Results Available","Language Development Disorders|Autism Spectrum Disorder","Behavioral: Enhanced Milieu Teaching|Other: no intervention comparison group","Parental Language Stimulation Strategies (Study 2; Hybrid)|Parental Language Stimulation Strategies (Study 1; Remote)|Adult-Child Conversational Turns (Study 2; Hybrid)|Adult-Child Conversational Turns (Study 1; Remote)","Temple University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","30 Months and older   (Child, Adult, Older Adult)","Not Applicable","350","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","24997|1K23DC017763-01A1","March 22, 2021","November 30, 2024","November 30, 2024","May 16, 2018",,"April 1, 2021","Temple University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03525951"
1071,"NCT04539990","A Behavioral Intervention for Ameliorating Sleep Problems in Children With ASD",,"Not yet recruiting","No Results Available","Autism|Autism Spectrum Disorder|Sleep","Behavioral: Behavioral treatment for sleep difficulties","Child Sleep Habits Questionnaire|Night time sleep as measured by Fitbit sensor","Soroka University Medical Center","All","18 Months to 5 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sor 0266-20 ctil","October 2020","September 2022","September 2023","September 7, 2020",,"September 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04539990"
1072,"NCT04182633","MTT for Children With ASD Who Have Gastrointestinal Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder|Gastro-Intestinal Disorder|Constipation|Diarrhea","Combination Product: vancomycin, Miralax, intestinal microbiota|Combination Product: placebo vancomycin, Miralax, placebo intestinal microbiota","Childhood Autism Rating Scale (CARS)|Gastrointestinal Symptom Severity Scale (GSRS)|Daily Stool Record|Social Responsiveness Scale 2|Aberrant Behavior Checklist","Arizona State University|Arizona State University Foundation|University of Minnesota|Finch Therapeutics","All","5 Years to 17 Years   (Child)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEIRB#: 120190306","November 15, 2019","June 30, 2022","June 30, 2024","December 2, 2019",,"December 24, 2020","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04182633"
1073,"NCT01780441","Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)",,"Completed","No Results Available","Tuberous Sclerosis Complex",,"ADOS evaluation score at the 36 month visit|MRI biomarkers|EEG biomarkers","Boston Children's Hospital|National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance","All","3 Months to 12 Months   (Child)",,"166","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00005074|1U01NS082320-01","January 2013","December 2019","December 2020","January 31, 2013",,"February 4, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California at Los Angeles, Los Angeles, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Texas at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01780441"
1074,"NCT01233414","Randomized Trial of Parent Training for Young Children With Autism","RUBI","Completed","No Results Available","Child Development Disorders, Pervasive","Behavioral: Parent Training|Other: Psychoeducational Program","Aberrant Behavior Checklist Irritability Subscale|Home Situations Questionnaire|Vineland Adaptive Behavior Scales|Clinical Global Impressions Improvement Scale","Yale University|Emory University|Indiana University|Ohio State University|University of Pittsburgh|University of Rochester|National Institute of Mental Health (NIMH)","All","3 Years to 7 Years   (Child)","Not Applicable","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH081148","September 2010","September 2014","March 2015","November 3, 2010",,"April 8, 2016","Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Rochester, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01233414"
1075,"NCT01300923","Acamprosate in Youth With Fragile X Syndrome",,"Completed","Has Results","Fragile X Syndrome|Autism Spectrum Disorders","Drug: Acamprosate","Clinical Global Impression- Severity Scale (CGI-S)|The Aberrant Behavior Checklist (ABC)|Social Responsiveness Scale|Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD|ADHD Rating Scale 4th Edition|Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain|Peabody Picture Vocabulary|Brain-derived Neurotrophic Factor (BDNF)","Indiana University","All","5 Years to 17 Years   (Child)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1003-26","August 2010","September 2011","September 2011","February 23, 2011","April 28, 2017","July 30, 2019","Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01300923"
1076,"NCT01019967","A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder",,"Terminated","No Results Available","Childhood Obsessive-Compulsive Disorder|Autism Spectrum Disorders",,"Change in brain glutamate after adding riluzole vs. placebo|Correlation between brain glutamate activity and riluzole level","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","7 Years to 17 Years   (Child)",,"17","NIH","Observational","Time Perspective: Prospective","100024|10-M-0024","November 17, 2009",,"September 20, 2012","November 25, 2009",,"October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01019967"
1077,"NCT02803801","Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers",,"Completed","No Results Available","Autism Spectrum Disorder (ASD)|Developmental Disorder","Behavioral: Build Your Parenting Toolkit Program","Relationship Development Assessment|Being a Parent Scale|Cooking Club Feedback Questionnaires|Exit Questionnaire","Rehabilitation Centre for Children, Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BYPT2016","September 2016","December 2016","April 2017","June 17, 2016",,"April 12, 2017","Rehabilitation Centre for Children, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02803801"
1078,"NCT00261508","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)",,"Completed","No Results Available","DCild Development Disorders, Pervasive|Autistic Disorder|Developmental Disabilities|Asperger Syndrome|Rett Syndrome","Drug: risperidone","Change in the Irritability Subscale of the Aberrant Behavior Checklist (ABC) and other ABC subscales at end of treatment compared with baseline|Change from baseline to end of treatment in Nisonger Child Behavior Rating Form (N-CBRF), Visual Analogue Scale (VAS), and Clinical Global Impression (CGI); incidence of adverse events throughout study.","Janssen-Ortho Inc., Canada","All","5 Years to 12 Years   (Child)","Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006106","August 1999",,"December 2001","December 5, 2005",,"January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00261508"
1079,"NCT01980186","Transcranial Ultrasonography Using Linear 2D Imaging of the Brain",,"Unknown status","No Results Available","Autism|Extra-axial Fluid","Device: TUS transcranial 2D ultrasound","Extra-axial fluid as measured at the gyral summit.","Brain Treatment Center","All","6 Months to 21 Years   (Child, Adult)",,"100","Other","Observational",,"BTC-002","November 2013","November 2016",,"November 8, 2013",,"November 11, 2013","Brain Treatment Center, Newport Beach, California, United States|Brain Treatment Center, Buford, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01980186"
1080,"NCT01932515","Diagnostic Instruments for Autism in Deaf Children Study","DIADS","Unknown status","No Results Available","Hearing Loss|ASD","Behavioral: A revised screening instrument for use in Deaf children","A validated Autism Spectrum Disorder screening instrument to identify those in need of further assessment from deaf children suspected of ASD, with both English and BSL versions (for deaf parents).|A modified version of the Autism Diagnostic Interview Revised (ADIR) validated for use in the assessment of deaf young people; accessible in English and BSL (for hearing and deaf parents to fully participate in assessment).","Leeds and York Partnership NHS Foundation Trust|University of Manchester|Newcastle University","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","325","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BH120870","November 2013","April 2017","April 2017","August 30, 2013",,"June 26, 2014","Leeds and York Partnership NHS Foundation Trust, York, North Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01932515"
1081,"NCT04878575","A Multi-dimensional Prospective Study to Discover Gene-microenvironment Interactions in Neurodevelopmental Disorders",,"Recruiting","No Results Available","Attention-Deficit Hyperactivity Disorder, Unspecified Type|Autism Spectrum Disorder","Other: ASD diagnosis|Other: Psychiatric diagnosis","Neuropsychological functions: Continuous Performance Test(CPT)|Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)|Structural neuroimaging: Diffusing spectrum imaging (DSI)|Multi-echo resting-state fMRI (rfMRI)","National Taiwan University Hospital","All","5 Years to 18 Years   (Child, Adult)",,"360","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201903105RINB","January 1, 2021","December 2025","December 2025","May 7, 2021",,"May 7, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04878575"
1082,"NCT03620097","Evaluate the Efficacy and Safety of DHA in the Adjuvant Treatment of Children With ASD.",,"Completed","No Results Available","ASD","Dietary Supplement: EuPoly-3 DHA Infant|Other: Placebo","Plasma and erythrocytic level of DHA","Maimónides Biomedical Research Institute of Córdoba","All","2 Years to 5 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ICI14/00355","January 21, 2015","December 2, 2015","December 2, 2015","August 8, 2018",,"August 8, 2018",,,"https://ClinicalTrials.gov/show/NCT03620097"
1083,"NCT04317118","Ask Suicide-Screening Questions (ASQ) for Youth With Autism Spectrum and Neurodevelopmental Disorders",,"Recruiting","No Results Available","Suicidal Ideation",,"Suicide risk","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","8 Years to 17 Years   (Child)",,"300","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","200066|20-M-0066","October 12, 2021","September 18, 2023","September 18, 2023","March 23, 2020",,"October 7, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04317118"
1084,"NCT03625297","Shelter Cat Adoption in Families of Children With Autism (Feline Friends)",,"Completed","No Results Available","Social Skills|Anxiety","Other: shelter cat","Change in Social Skills of child with autism over time from baseline to 6, to 12 and to 18 weeks|Change in Anxiety of child with autism over time from baseline to 6, to 12 and to 18 weeks|change in parent Human-animal Bonding over time from 2-3 days, to 6, to 12 and 18 weeks|change in child Human-animal Bonding over time from 2-3 days, to 6, to 12 and 18 weeks","University of Missouri-Columbia|Winn Feline Foundation|Human Animal Bond Research Institute (HABRI)","All","6 Years to 17 Years   (Child)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2008460","June 23, 2017","October 1, 2019","October 1, 2019","August 10, 2018",,"November 2, 2020","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03625297"
1085,"NCT00251303","Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders",,"Completed","Has Results","Obsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental Disorder","Drug: Riluzole|Drug: Placebo","Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)|Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","7 Years to 17 Years   (Child)","Phase 2","78","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","050225|05-M-0225","August 2005","February 2012","February 2012","November 9, 2005","July 15, 2014","July 15, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00251303"
1086,"NCT01993251","Does Melatonin Restore Sleep Architecture in Autistic Children","SOMELIA","Completed","No Results Available","Sleep Disorders","Drug: melatonin|Drug: Melatonin|Drug: placebo","To determine the most effective dose of melatonin to improve sleep quality in autistic children.|To assess in autistic children the melatonin effects on sleep characteristics|To assess the effectiveness of treatment on sleep disorders.|To assess the effectiveness of melatonin on daytime autistic behavior|To assess the melatonin safety in autistic children.|Establish whether there is a correlation between sleep quality and melatonin secretion.|To assess in autistic children the melatonin effects on sleep characteristics.","Hospices Civils de Lyon","All","3 Years to 12 Years   (Child)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-732|2013-001230-17","June 2014","June 12, 2018","June 12, 2018","November 25, 2013",,"January 28, 2019","Hôpital Femme Mere Enfant, Bron, France|CHU de Caen, Caen, France|Centre Hospitalier du Chinonais, Chinon, France|CHRU de Strasbourg, Strasbourg, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01993251"
1087,"NCT01021384","Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders",,"Completed","No Results Available","Maternal Depression","Behavioral: Problem Solving Education","Quick Inventory of Depressive Symptoms|Parenting Stress Index|Perceived Stress Scale|Social Problem Solving Inventory|Social Adjustment Scale Self-Report|Patient Activation Measure","Boston Medical Center|HRSA/Maternal and Child Health Bureau","Female","Child, Adult, Older Adult","Phase 3","122","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","H-28799","September 2009","August 2012","March 2013","November 30, 2009",,"April 29, 2013","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01021384"
1088,"NCT00004458","Longitudinal and Biological Study of Childhood Disintegrative Disorder",,"Terminated","No Results Available","Pervasive Child Development Disorders|Autism",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yale University|Office of Rare Diseases (ORD)","All","2 Years to 9 Years   (Child)",,"220","NIH|Other","Observational","Time Perspective: Other","199/13682|YALE-5P01HD0300830|YALE-HIC-5895","May 1997",,,"October 19, 1999",,"June 24, 2005","Yale Child Study Center, New Haven, Connecticut, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00004458"
1089,"NCT00717392","Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder",,"Improving the parameters of autism","Sheba Medical Center","All","5 Years to 17 Years   (Child)",,"40","Other","Observational","Time Perspective: Prospective","SHEBA-08-5327-LG-CTIL","September 2008","June 2011","July 2012","July 17, 2008",,"March 1, 2013","Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00717392"
1090,"NCT02369445","Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention",,"Completed","No Results Available","Autistic Disorder|Enuresis","Behavioral: Moisture Pager Intervention for Toilet Training|Behavioral: Standard of Care","Teacher Satisfaction with Toilet Training Experience (teacher satisfaction survey)|Number of Toileting Accidents/Day and Number of Successful Toilet Use for Urination/Day at End of Treatment (Toileting Data Logs)|Number of Toileting Accidents/Day and Number of Successful Toilet Use (3-Month Follow-Up) (Toileting Data Logs)","University of Rochester|Nationwide Children's Hospital|Vanderbilt University","All","3 Years to 10 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1 R40 MC27705-01-00","September 2014","June 1, 2018","June 1, 2018","February 24, 2015",,"November 21, 2018","University of Rochester Medical Center, Rochester, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Whitney Loring, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02369445"
1091,"NCT00848874","Portable Visual Guidance System Phase II","PVGS-II","Completed","No Results Available","Asperger Syndrome|High Functioning Autism","Behavioral: PVGS","Students who use the PVGS will demonstrate improved classroom social pragmatics and executive functioning.","Minna Levine, PhD|SymTrend Inc.|University of North Carolina, Chapel Hill","All","11 Years to 21 Years   (Child, Adult)","Not Applicable","47","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2R41MH075162|NIHM_2R41MH75162--02A1","September 2008","March 2010","March 2010","February 20, 2009",,"October 9, 2018","SymTrend, Inc., Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00848874"
1092,"NCT02574273","Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)",,"Completed","No Results Available","Anxiety|Attention Deficit Hyperactivity Disorder (ADHD)|Autistic Spectrum Disorder (ASD)","Behavioral: Secret Agent Society (SAS) Program|Other: Waitlist Group / Treatment As Usual","Anxiety Disorders Interview Schedule for DSM-IV-Child Version (ADIS)","Weill Medical College of Cornell University","All","8 Years to 12 Years   (Child)","Not Applicable","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1503015990","October 2015","December 2018","December 2018","October 12, 2015",,"July 30, 2019","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02574273"
1093,"NCT02057809","""Family-centered"" Pediatric Rehabilitation Services in Children With Developmental Disabilities",,"Completed","No Results Available","Developmental Disabilities|Autistic Spectrum Disorder",,"The Measure of Processes of Care-20|Measure of Processes of Care- for Service Providers|Children and Adolescent Factor Inventory|Assessment of Preschool Children's Participation (APCP)|Children's Assessment of Participation and Enjoyment (CAPE)","Chang Gung University","All","2 Years to 12 Years   (Child)",,"130","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","102-3767B","January 2014","December 2014","December 2014","February 7, 2014",,"August 17, 2018","Chang Gung University, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02057809"
1094,"NCT03699527","Medical Cannabis Registry and Pharmacology","Med Can Autism","Completed","No Results Available","Autism|ASD","Behavioral: Multiple questionnaires administered","Number of children with ASD who use medical cannabis|Maximum Cannabinoid concentrations in pediatric patients with ASD|Number of families who complete the educational program to assess epidemiologic outcomes","Children's Hospital of Philadelphia|Zelda Therapeutics","All","up to 21 Years   (Child, Adult)",,"119","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-014628","July 15, 2018","January 15, 2020","January 15, 2020","October 9, 2018",,"January 27, 2020","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03699527"
1095,"NCT02328638","Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity",,"Completed","No Results Available","Autism|Obesity","Behavioral: Parent Education Program|Behavioral: Manual-based Behavioral Treatment","Change in body mass index percentile/ratio|Change in intake of healthy food|Change in physical activity","Emory University","All","3 Years to 10 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00073170","December 2014","August 2015","August 2015","December 31, 2014",,"January 20, 2016","Pediatric Feeding Disorders Program at the Marcus Autism Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02328638"
1096,"NCT04295512","Adaptation and Implementation of an ASD Executive Functioning Intervention in Children's Mental Health Services",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Mental Health Disorder|Executive Dysfunction","Behavioral: Unstuck and on Target (UOT)","Acceptability of Intervention Measure|Intervention Appropriateness Measure|Feasibility of Intervention Measure|Provider Fidelity- Change since baseline in provider fidelity|Eyberg Child Behavior Inventory- Change since baseline in child behaviors","San Diego State University|Rady Children's Hospital, San Diego","All","5 Years to 13 Years   (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","HS-2018-0147","April 1, 2021","April 1, 2022","August 31, 2022","March 4, 2020",,"March 4, 2020","Child and Adolescent Services Research Center, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04295512"
1097,"NCT03003286","Community Based Intervention for Children With ADHD and ASD",,"Completed","No Results Available","Autism Spectrum Disorder|Attention Deficit-Hyperactivity Disorder|Executive Function","Behavioral: Unstuck and on Target (UOT)|Behavioral: Parents and Teachers Supporting Students (PATSS)","Change in Classroom Observation total raw score at termination of intervention|Change in Wechsler Abbreviated Scale of Intelligence--II Block Design- T-score at termination of intervention (post testing) and 1 year later (long-term follow-up)|Change in Delis-Kaplan Executive Function System - Category Fluency and Switching Accuracy scaled scores at termination of intervention (post testing) and 1 year later (long-term follow-up)|Change in Executive Function Challenge Task - Flexibility and Planning raw scores at termination of intervention (post testing) and 1 year later (long-term follow-up)|Change in Flexibility Interference Questions Questionnaire total raw score at termination of intervention (post testing) and 1 year later (long-term follow-up)|Change in Behavior Rating Inventory of Executive Function (BRIEF) - Parent Form - Shift, Plan/Organize, Emotional Control and Global Executive at termination of intervention (post testing) and 1 year later (long-term follow-up)Composite T-scores|Change in The Child Behavior Checklist (CBCL) - Parent Report Externalizing Behaviors T-scores at termination of intervention (post testing) and 1 year later (long-term follow-up)|Parent Feedback Form - Acceptability total raw score|Child Feedback-Acceptability raw score","Lauren Kenworthy|Georgetown University|University of Colorado, Denver|Children's National Research Institute","All","8 Years to 11 Years   (Child)","Not Applicable","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AD-1304-7379","September 13, 2014","August 5, 2017","August 5, 2017","December 28, 2016",,"April 4, 2018","Children's Research Institude, Children's National Heath System, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03003286"
1098,"NCT03404505","Effects of a Short-term Parent Mediated Social Training on Developmental Trajectories in Infants","IA","Recruiting","No Results Available","Younger Sibling of Child With Autism Spectrum Disorder|Signs of Developmental Delay|Signs of Communication Delay|Signs of Social Delay","Behavioral: Infant Achievements|Behavioral: Caregiver Education (CE)","Change in parent behavior during the Parent-Child Play Sample|Change in child communication and social engagement sample during the Parent-Child Play Sample|Change in scores on the Mullen Scales of Early Learning Receptive and Expressive Language Raw Scores|Change in scores on the MacArthur-Bates Communication Development Inventory|Change in scores on the CSBS Behavior Sample","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","8 Months to 12 Months   (Child)","Not Applicable","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00065698|R21DC015846","November 3, 2017","November 2021","November 2021","January 19, 2018",,"March 10, 2021","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03404505"
1099,"NCT02124720","Using Mobile Technology to Reduce Stereotypy",,"Completed","No Results Available","Child Development Disorders, Pervasive","Behavioral: iSTIM","Frequency and duration of stereotypy|Social validity score","Université de Montréal","All","up to 12 Years   (Child)","Not Applicable","39","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CERFAS-2014-15-030-P","December 2014","February 2019","February 2019","April 28, 2014",,"September 26, 2019","Monarch House, Mississauga, Ontario, Canada|CRDITED de Montréal, Montreal, Quebec, Canada|Gold Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02124720"
1100,"NCT01364818","Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment",,"Completed","No Results Available","Autism Spectrum Disorders|Psychosis|Fragile X Syndrome",,"Pre-Post Treatment Differences between Groups","University of North Carolina, Chapel Hill","All","3 Years to 45 Years   (Child, Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","11-0962","September 2011","December 2014","December 2014","June 2, 2011",,"April 18, 2016","University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01364818"
1101,"NCT02316145","Internet-based Coaching for Young Adults With Neuropsychiatric Disorders",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Tourette's Disorder","Behavioral: Habilitation (Internet-based support and coaching)","quality of life (QoL)","Vardalinstitutet The Swedish Institute for Health Sciences",,"Child, Adult, Older Adult","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16611","September 2008","June 2010","December 2010","December 12, 2014",,"December 12, 2014",,,"https://ClinicalTrials.gov/show/NCT02316145"
1102,"NCT00080145","RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders",,"Completed","No Results Available","Child Development Disorders, Pervasive","Drug: Risperidone|Behavioral: Behavior Therapy","Home Situations Questionnaire|Vineland Daily Living Skills Scale|Irritability subscale-Aberrant Behavioral Checklist|Clinical Global Impressions-Improvement (CGI-I)","Yale University|National Institute of Mental Health (NIMH)","All","4 Years to 13 Years   (Child)","Not Applicable","124","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U10MH066764|U10MH066766|U10MH066768|DDTR BD-DD","February 2004","September 2007","September 2007","March 25, 2004",,"August 16, 2013","Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00080145"
1103,"NCT02088905","Efficacy of Parent-Child Interaction Therapy With Autism Spectrum Disorder","PCIT","Completed","Has Results","Noncompliance","Behavioral: Parent Child Interaction Therapy","Eyberg Child Behavior Inventory|Parental Stress Index-4 Short Form|Social Responsiveness Scale 2 Score|Dyadic Parent-Child Interaction Coding System Scores|Parental Stress Index Score","University of Pittsburgh|Autism Speaks","All","30 Months to 83 Months   (Child)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0031588|PRO023120445","April 2014","July 2016","July 2016","March 17, 2014","March 1, 2019","March 22, 2019","Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02088905"
1104,"NCT00496210","Predictors of Caregiver Adaptation to Pervasive Developmental Disorders",,"Completed","No Results Available","Autism|Asperger's Syndrome|Rett's Disorder",,,"National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"324","NIH","Observational","Time Perspective: Other","999907178|07-HG-N178","June 27, 2007",,"December 7, 2015","July 4, 2007",,"November 15, 2019","National Human Genome Research Institute (NHGRI), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00496210"
1105,"NCT03776656","Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency","ADSL","Active, not recruiting","No Results Available","Adenylosuccinate Lyase Deficiency","Drug: Allopurinol","Measurement of adaptive functional improvement : composite total score for Vineland II adaptive behaviour Scale|Evolution of the Scores of different subdomains Vineland II scale from baseline|Evolution of the Psycho-Educative Profile (PEP III/R) from baseline|Evolution of the Score ADI-R (Autism Diagnostic Interview-Revised) from baseline|Evolution of the Score ADOS-2 (Autism Diagnostic Observation Schedule 2) from baseline|Evolution of the Score on Conners hyperactivity Scale|Evolution of the Score on ABC scale (Aberrant Behaviour Checklist)|Evolution of SAICAr levels in the urine|Evolution of S-Ado levels in the urine|Evolution of SAICAr levels in the blood|Evolution of S-Ado levels in the blood|Evolution of the number of seizures from Baseline for epileptic patients|Evolution of antiepileptic treatments from Baseline for epileptic patients|Evolution of electroencephalogram tracing from Baseline for epileptic patients","Assistance Publique - Hôpitaux de Paris|URC-CIC Paris Descartes Necker Cochin","All","18 Months and older   (Child, Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P160902J|2017-002155-28","October 14, 2019","April 2022","April 2022","December 17, 2018",,"August 31, 2021","LA PITIE-SALPETRIERE Hospital, AP-HP, Paris, France|Department of Pediatry. Reference centre of Hereditary diseases of the metabolism of child and adult. Necker - Enfants malades Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03776656"
1106,"NCT04096430","Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders|Cerebral Palsy","Behavioral: ENGAGE approach (child-oriented goal-setting)","Goal performance and satisfaction will be measured using the Canadian Occupational Performance Measure (COPM).|Child engagement in therapy will be measured using the Pediatric Rehabilitation Intervention Measure of Engagement (PRIME-SP).|Perceived confidence will be measured using the Belief in Goal Self-Competence Scale [BiGSS].|Goal related performance will be measured using the Goal Attainment Scaling (GAS).|Participation for young children will be measured using the Participation and Environment Measure for Children & Youth (PEM-CY).|Quality of life for children will be measured using the KIDSCREEN-27.|Caregiver quality of life will be measured with the Caregiver Quality of Life (CarerQol-7D).|Functional abilities will be measured with the Pediatric Evaluation of Disability Inventory (PEDI-CAT).","University of Alberta|Alberta Health Services","All","5 Years to 12 Years   (Child)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00090963","September 2020","January 2022","January 2022","September 19, 2019",,"July 31, 2020","Renfrew Educational Services, Calgary, Alberta, Canada|Society for Treatment of Autism, Calgary, Alberta, Canada|Children's Rehabilitation Services, Alberta Health Services, Camrose, Alberta, Canada|Centre for Autism Services Alberta, Edmonton, Alberta, Canada|Children's Rehabilitation Services, Alberta Health Services, Grande Prairie, Alberta, Canada|Children's Rehabilitation Services, Alberta Health Services, Red Deer, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04096430"
1107,"NCT04475848","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants",,"Recruiting","No Results Available","Autistic Disorder|Autism Spectrum Disorder|Child Development Disorders, Pervasive|Mental Disorders|Neurodevelopmental Disorders","Drug: RO6953958|Drug: Placebo","Percentage of Participants with Adverse Events in Part 1|Percentage of Participants with Adverse Events in Part 2|Part 2: Change in suicide risk assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)|Part 1: Maximum Observed Plasma Concentration (Cmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Last Quantifiable Concentration (Clast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Time To the Last Quantifiable Concentration (Tlast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Terminal Elimination Phase Half-Life (T1/2) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve from Time 0 to 12 hours (AUC(0-12h)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Apparent Clearance (CL/F) of RO6953958 in Fasted and Fed state|Part 1: Apparent Volume of Distribution (V/F) of RO6953958 in Fasted and Fed state|Part 1: Cumulative Amount of Unchanged Drug Excreted into the Urine (Ae) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Fraction of the Administered Drug Excreted into the Urine (Fe) of RO6953958 in Fasted and Fed state|Part 1: Renal Clearance of the Drug from Urine (CLR) of RO6953958 in Fasted and Fed state|Parts 2: Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2: Average Plasma Concentration (Cavg) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Tmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: T1/2 of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: CL/F of RO6953958|Part 2: V/F of RO6953958|Part 2: Ae of RO6953958|Part 2: Fe of RO6953958|Part 2: CLR of RO6953958|Part 2: Trough Plasma Concentration (Ctrough) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio based on AUC (Rauc) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio Based on Cmax (RCmax) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio based on Ctrough (RCtrough) of RO6953958 and its Metabolites RO7021594 and RO7045755","Hoffmann-La Roche","Male","18 Years to 55 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP41695|2019-004486-41","July 15, 2020","November 8, 2021","November 8, 2021","July 17, 2020",,"September 17, 2021","Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04475848"
1108,"NCT03426059","Mapping the Phenotype in Adults With Phelan-McDermid Syndrome",,"Completed","No Results Available","Phelan-McDermid Syndrome|Autism Spectrum Disorder|Intellectual Disability","Other: No Intervention","Global cognitive ability|Measure of Adaptive Behavior|Measure of Overall Language Abilities|Measure of Overall Motor Functioning|Measure of autism symptoms|Measure of Receptive Language Abilities|Measure of Expressive Language Abilities","Boston Children's Hospital|Phelan-McDermid Syndrome Foundation","All","22 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00025776","May 22, 2018","December 31, 2019","December 31, 2020","February 8, 2018",,"April 2, 2021","Stanford University, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|National Institutes of Health, Bethesda, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03426059"
1109,"NCT02461420","Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome",,"Recruiting","No Results Available","Phelan-McDermid Syndrome|Autism Spectrum Disorder|Intellectual Disability",,"Change in global cognitive ability at 12 months|Change in adaptive behavior at 12 months|Change in language abilities at 12 months|Change in motor functioning at 12 months|Change in autism symptoms at 12 months|Change in global cognitive ability at 24 months|Change in adaptive behavior at 24 months|Change is language abilities at 24 months|Change in motor functioning at 24 months|Change in autism symptoms at 24 months","Boston Children's Hospital|National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health (NIH)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Phelan-McDermid Syndrome Foundation","All","18 Months and older   (Child, Adult, Older Adult)",,"190","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00013300|1U54NS092090","May 2015","December 2024","December 2025","June 3, 2015",,"August 2, 2021","Stanford University, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|National Institutes of Health, Bethesda, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02461420"
1110,"NCT01914393","Pediatric Open-Label Extension Study",,"Completed","Has Results","Schizophrenia|Autism|Bipolar Depression","Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed","Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)|Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score|Change From Baseline in PANSS Positive Subscale Score|Change From Baseline in PANSS Negative Subscale Score|Change From Baseline in PANSS General Psychopathology Subscale Score|Change From Baseline in PANSS Excitability Subscale Score|Change From Baseline in the Clinical Global Impression -Severity Score|Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score|Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score|Change From Baseline in Clinical Global Impression (CGI) - Severity Score|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)|Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score|Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score|Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score|Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score|Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score|Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score","Sunovion","All","6 Years to 17 Years   (Child)","Phase 3","702","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1050302|2013-001694-24","September 30, 2013","October 17, 2018","October 17, 2018","August 2, 2013","December 19, 2019","December 19, 2019","Harmonex Neuroscience Research, Dothan, Alabama, United States|Diligent Clinical Trials, Inc, Downey, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|APG Research, LLC, Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida Rothman Center of Neuropychiatry, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|University Of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Neurobehavioral medicine Group, LLC, Bloomfield Hills, Michigan, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|North Shore/Long Island Jewish PRIME, Glen Oaks, New York, United States|Dr. Jeanette Cueva, Mount Kisco, New York, United States|Montefiore Medical Center PRIME, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Clinical Research Partners, LLC, Petersburg, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|MHC - Ruse, EOOD, Ruse, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|MHAT-Targovishte, AD, Targovishte, Bulgaria|DCC ""Mladost M"" - Varna, OOD, Varna, Bulgaria|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|E.S.E. Hospital Mental de Antioquia, Bello, Colombia|Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda, Bogota, Colombia|CHU Nantes - Hôpital Mère-Enfant, Nantes Cedex 1, France|Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert, Budapest, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Seoul National University Hospital, Seoul, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C., Culiacan, Sinaloa, Mexico|Dr. Jessica Rosas Escobar, Durango, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Instituto de Informacion de Investigacion en Salud Mental, Monterrey, Mexico|Av Modesto Arreola #917 Ote. Col Centro, Nuevo León, Mexico|Alexian Brothers Health and Wellness Center, Davao City, Philippines|West Visayas State University Medical Center, Iloilo, Philippines|National Center for Mental Health, Mandaluyong City, Philippines|Veterans Memorial Medical Center, Quezon City, Philippines|NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy, Toruń, Poland|Centro de Investigacion Clinica Psiquiatrica, Caguas, Puerto Rico|Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia, Bucuresti, Romania|Spitalul Clinic de Psihiatrie Socola, Iasi, Romania|Spitalul Clinic de Urgenta pentru Copii ""Louis Turcanu"" Timisoara, Timisoara, Romania|Sverdiovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Russian Federation|GUZ Lipetsk Regional psychoneurological Hospital #1, Lipetsk, Russian Federation|Closed corporation ""Scientific Center of Personalized Psychiatry"", Moscow, Russian Federation|Scientific Center of Personalized Psychiatry, Moscow, Russian Federation|State Healthcare Institution of Nizhniy Novgordo region ""Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"", Nizhny Novgorod, Russian Federation|SHI ""City Psychoneurological dispensary #7 (with Hospital)"", Saint Petersburg, Russian Federation|Center of Recovery Treatment ""Pediatric Psychiatry"" named after S.S. Mnukhin, Saint Petersburg, Russian Federation|Bekhterev Institute, Saint Petersburg, Russian Federation|Regional Clinical Mental Hospital of Saint Sofiya, Saratow, Russian Federation|FSBSI ""Scientific Research Institute of Mental Health"", Tomsk, Russian Federation|State Healthcare Institution of Yaroslavl Rgion ""Yaroslavl Regional clinical Mental Hospital"", Yaroslavl, Russian Federation|Hospital Marítimo de Torremolinos, Torremolinos, Málaga, Spain|RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU, Ivano Frankivsk, Ukraine|SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, Ukraine|SI Institute of Children and Adolescents Healthcare of NAMSU, Kharkiv, Ukraine|TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions, Kyiv, Ukraine|CI Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odesa Regional Psychoneurological Dispensary, Outpatient Dept., Odesa, Ukraine|O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy, Poltava, Ukraine|CI Kherson Regional Psychiatric Hospital of Kherson RC, Stepanivka, Ukraine|Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI, Vinnitsia, Ukraine","""Study Protocol: Final Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01914393"
1111,"NCT01602263","Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing",,"Active, not recruiting","No Results Available","Aphasia|Autism|Schizophrenia","Procedure: Transcranial Direct Current Stimulation (tDCS)","Indices of cognitive function|Persistence of cognitive enhancements following tDCS|Initiation, endurance and cessation of skin sensations caused by tDCS","Johns Hopkins University","All","18 Years to 79 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","NA_00015657|15657","January 2009","January 2025","December 2030","May 18, 2012",,"December 14, 2020","Department of Neurology; Cognitive Neurology/Neuropsychology, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01602263"
1112,"NCT03730194","A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Sleep Disturbance","Dietary Supplement: Melatonin|Behavioral: Bedtime Bank","Actigraphy (total sleep time)|Cleveland Adolescent Sleepiness Questionnaire (CASQ)|Sleep Diary|PROMIS Pediatric Item Bank Sleep Disturbance|PROMIS Pediatric Item Bank Sleep Related Impairment|Dim Light Melatonin Onset (DLMO)|Urinary Melatonin|PROMIS Sleep Disturbance (short form v. 1.0 8b)|PROMIS Sleep Related Impairment (short form v. 1.0 8a)","University of Nebraska|National Institute of Nursing Research (NINR)","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","775-18-FB|1K01NR017465-01A1","May 31, 2019","January 31, 2022","January 31, 2022","November 5, 2018",,"April 27, 2021","University of Nebraska Medical Center, Center for Nursing Science, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03730194"
1113,"NCT04878198","Treatment of Sleep Disturbance in Children With ASD",,"Not yet recruiting","No Results Available","Physical Exercise|Sleep Disturbance|Autism Spectrum Disorder|Melatonin Deficiency","Behavioral: Jogging program|Drug: Melatonin supplement intervention","Sleep onset latency|Sleep efficiency|Wake after sleep onset|Sleep duration|Parental-assessed sleep quality|24-h melatonin level|First morning void melatonin level","Education University of Hong Kong|Chinese University of Hong Kong|Castle Peak Hospital|University of Leicester|United Christian Hospital","All","8 Years to 12 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG 21/2019-2020R","September 1, 2021","June 30, 2023","June 30, 2023","May 7, 2021",,"May 11, 2021",,,"https://ClinicalTrials.gov/show/NCT04878198"
1114,"NCT00445471","A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment",,"Terminated","No Results Available","Child Development Disorders, Pervasive","Behavioral: Mifne Approach to PDD|Behavioral: Treatment as usual","ADOS scores at 3 and 6 months after commencement of treatment|CGI-I score after 3 and 6 months","Rabin Medical Center","All","2 Years to 5 Years   (Child)","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4222","April 2007","December 2012","December 2012","March 9, 2007",,"December 25, 2014","Schneider Children's Medical Center of Israel, Departemnt of Psychological Medicine, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT00445471"
1115,"NCT01778504","Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders",,"Recruiting","No Results Available","Neurological Disorder|Autism|Sleep",,"clinical assessments","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Older Adult)",,"3500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","130028|13-M-0028","December 27, 2012","February 20, 2025","February 20, 2025","January 29, 2013",,"August 31, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01778504"
1116,"NCT02919215","Teacher Help for Children and Youth With Mental Health Disorders","TeacherHelp","Unknown status","No Results Available","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Learning Disabilities","Behavioral: Teacher Help Intervention","Teacher Demographic Questionnaire (author made)|Change in Teacher Attitudes at 3 and 5 months (Kos, 2008)|Willingness to Pay Questionnaire|Change in Strengths and Difficulties Questionnaire at 3 and 5 months (SDQ; Goodman, 2001)|Change in Pediatric Quality of Life Inventory at 3 and 5 months (PedsQL-4; Varni et al., 1999)|Client Satisfaction Questionnaire (Attkisson & Swick, 1990)|Collaborating Psychologist Support Log (author-made)|Youth Satisfaction Measure (author-made)|Parent Demographic Questionnaire (author-made)|Change in Treatment Utilization at 3 and 5 months|Change in The Beach Center Family Quality of Life Scale at 3 and 5 months (Hoffman et al., 2006)","IWK Health Centre","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","348363","January 2017","June 2017","September 2018","September 29, 2016",,"September 29, 2016","Dalhousie University, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT02919215"
1117,"NCT01097720","Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine",,"Unknown status","No Results Available","Autism|Developmental Delay|Birth Defects",,"Adaptive Behavior Scores|Presence/Absence of Major Malformations","Massachusetts General Hospital|GlaxoSmithKline","All","36 Months to 83 Months   (Child)",,"298","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2005P000379","March 2005","January 2010","September 2010","April 2, 2010",,"April 2, 2010","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01097720"
1118,"NCT04443179","Brain Imaging in Babies Study","BIBS","Recruiting","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Neurodevelopmental Conditions|COVID-19",,"Neurodevelopmental Outcomes","King's College London","All","16 Years to 75 Years   (Child, Adult, Older Adult)",,"790","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRAS: 108997, REC 12/LO/2017","April 5, 2013","December 2023","December 2023","June 23, 2020",,"June 24, 2020","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04443179"
1119,"NCT04302818","SKOLKONTAKT - Social Skills Training in a School Setting","SKOLKONTAKT","Recruiting","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Anxiety|Depression","Behavioral: SKOLKONTAKT|Behavioral: Social activity group","Social Skills Group Questionnaire (SSGQ)|Social Responsiveness Scale-2 (SRS-ll)|KIDSCREEN-27 (short version)|Worlds Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0)|Conners 3-F|Negative Effects Questionnaire (NEQ)|Goal Attainment Scaling (GAS)","Karolinska Institutet|Marcus och Amalia Wallenbergs minnesfond","All","15 Years to 20 Years   (Child, Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SKOLKONTAKT","September 2, 2019","March 2022","March 2022","March 10, 2020",,"March 12, 2020","CAP Research Center, Center of Neurodevelopmental disorders at Karolinska Institutet (KIND), Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04302818"
1120,"NCT05056922","Telehealth Rapid Intervention for Externalizing Behaviors in ASD","THRIVE-ASD","Not yet recruiting","No Results Available","Autism Spectrum Disorder|Disruptive Behavior|Externalizing Behavior|Parent-Child Interaction Therapy|Telehealth","Behavioral: Tele-PCIT|Behavioral: Treatment as Usual","Change in Child Behavior Problems as assessed by Eyberg Child Behavior Inventory (ECBI)|Change in Child Behavior Problems as assessed by Sutter-Eyberg Student Behavior Inventory-Revised (SESBI-R)|Change in Child Compliance and Parent Interaction as assessed by Dyadic Parent-Child Interaction Coding System, 4th edition (DPICS-IV)|Change in Parenting Practices as assessed by Parenting Scale (PS)|Change in Parenting Stress as assessed by Parenting Stress Index-Short Form (PSI-SF)|Change in Child Behavior Problems as assessed by Behavior Assessment System for Children-3rd Edition (BASC-3)|Change in Child Behavior Problems as assessed by Disruptive Behavior Disorders Rating Scale (DBD)|Parent Satisfaction with Tele-PCIT as assessed by Therapy Attitude Inventory (TAI)|Impact of Barriers on Treatment Engagement as assessed by Barriers to Treatment Participation Scale (BTPS)","Medical University of South Carolina|Health Resources and Services Administration (HRSA)","All","2 Years to 83 Months   (Child)","Not Applicable","80","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00114600|R41MC42775-01-00","January 3, 2022","August 31, 2024","August 31, 2024","September 27, 2021",,"September 27, 2021",,,"https://ClinicalTrials.gov/show/NCT05056922"
1121,"NCT04026386","A Center Based Early Intervention Program For Preschoolers With Developmental Disorders",,"Recruiting","No Results Available","Development Disorder, Child|Developmental Disability|Development Delay|Autism Spectrum Disorder","Behavioral: Center Based Early Intervention Program","Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.|Change From Baseline in Parent Rated Stanford Social Dimension Scale (SSDS) Scores During Treatment.|Change From Baseline in Parent Rated Vineland Adaptive Behavior Scale- 3 (VABS-3) Scores During Treatment.|Change From Baseline in Parent Rated Short Sensory Profile Questionnaire (SSPQ) Scores During Treatment.|Change From Baseline in Parent Rated General Self Efficacy Scale (GSES) Scores During Treatment.","Stanford University|John & Marcia Goldman Foundation","All","2 Years to 4 Years   (Child)","Not Applicable","75","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-52348","October 19, 2019","December 2024","December 2024","July 19, 2019",,"May 24, 2021","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04026386"
1122,"NCT03282162","The Effects of Oxytocin on Affective Touch",,"Completed","No Results Available","Healthy","Drug: intranasal oxytocin|Drug: intranasal placebo","brain function: neural activity during affective touch as assessed via BOLD fMRI|Brain function: functional connectivity during affective touch as assessed via BOLD fMRI|Perceived affective quality of the touch|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - brain function: activity|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - brain function: functional connectivity|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - behaviour: pleasantness experience|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - brain function: activity|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - brain function: functional connectivity|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - behaviour: pleasantness experience","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UESTC-neuSCAN-40","August 28, 2017","January 31, 2018","July 12, 2018","September 13, 2017",,"October 29, 2018","University of Electronic Science and Technology of China(UESTC), Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03282162"
1123,"NCT03518346","Use of Virtual Reality Game Playing During Venipuncture",,"Completed","No Results Available","Autism|Development Delay|Typical Development","Behavioral: Virtual Reality|Behavioral: Standard of Care","Attempting vs. Refusing Venipuncture|Blood volume|Pain Scale|Satisfaction Survey|Fear Scale|Time to Achieve Optimal Blood Volume","University of California, Davis","All","8 Years to 19 Years   (Child, Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1170355","April 9, 2018","January 15, 2019","January 15, 2019","May 8, 2018",,"May 15, 2019","University of California Davis MIND Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03518346"
1124,"NCT04199299","Sensors for Communication for Persons Who Cannot Communicate Unequivocally",,"Recruiting","No Results Available","Intellectual Disability|Autism|Cerebral Palsy","Device: Heart rate and respiration rate sensors","Caregivers' practice detailed in structured interview|Caregivers' understanding of the user detailed in structured interview","University of Oslo","All","5 Years to 80 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Understand me!","February 1, 2020","December 31, 2030","December 31, 2032","December 13, 2019",,"April 28, 2021","University of Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04199299"
1125,"NCT03423836","Maternal Oral Therapy to Reduce Obstetric Risk Kids","MOTORKids","Completed","No Results Available","Periodontitis|Autism|Premature Infants",,"MCHAT Score","University of North Carolina, Chapel Hill|National Institute of Dental and Craniofacial Research (NIDCR)","All","Child, Adult, Older Adult",,"331","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-0727|3U01DE014577-04S1","April 30, 2007","May 31, 2010","January 11, 2013","February 6, 2018",,"February 14, 2018","University of Alabama at Birmingham Department of Ostetrics and Gynecology, Birmingham, Alabama, United States|Department of Periodontology, UNC School of Dentistry, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Texas Health Science Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03423836"
1126,"NCT02504502","Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients",,"Completed","Has Results","Intellectual Disability|Autism|Multiple Congenital Anomalies","Other: enhanced genomic report","Satisfaction With Genomic Test Report","Geisinger Clinic|Patient-Centered Outcomes Research Institute","All","up to 21 Years   (Child, Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","2013-0594","August 2015","January 1, 2017","January 1, 2017","July 22, 2015","June 15, 2017","February 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02504502"
1127,"NCT04167839","Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement",,"Completed","No Results Available","Sensory Processing Disorder|Special Education|Autism","Other: Sensory diet","Change in frequency of a target behaviors related to psycho-social behaviors|Change in duration of a target behavior related to off-task behaviors.|Change in duration of a target behavior related to sensory seeking behaviors.","Pingale, Vidya, OTR|Tina S. Fletcher, EdD, MFA, OTR|Catherine Candler, PhD, OTR|Noralyn Pickens, PhD, OT|Karen Dunlap, EdD","Male","4 Years to 11 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TWU protocol# 19711","September 6, 2017","February 15, 2018","February 15, 2018","November 19, 2019",,"November 19, 2019","Vidya Pingale, Cliffside Park, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04167839"
1128,"NCT01184235","Multidimensional Measurement of Psychopharmacological Treatment Response",,"Completed","No Results Available","Autism Spectrum Disorders|Mood Disorders|Sleep Disorders|Attention Deficit Disorders","Drug: Pharmacological Intervention","Actigraphic Measurement|Operationally Defined Observations","Child Psychopharmacology Institute","All","6 Months and older   (Child, Adult, Older Adult)",,"44","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Act3","August 2010","August 2011","August 2011","August 18, 2010",,"January 6, 2014","Child Psychopharmacology Institute, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01184235"
1129,"NCT03293511","Oxytocin Modulates Eye Gaze Behavior During Social Processing",,"Unknown status","No Results Available","Healthy","Drug: intranasal oxytocin|Drug: intranasal placebo","Global eye gaze characteristic: differences between oxytocin and placebo treatment|Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment|Global eye gaze characteristic - associations with autism traits|Feature-specific eye gaze characteristics - associations with trait autism","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UESCT_neuSCAN_42","June 9, 2017","July 2019","July 2019","September 26, 2017",,"October 29, 2018","school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China|University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03293511"
1130,"NCT00716235","Characterization of Executive Functions and Patterns of Eye Movements in Children With Developmental Disabilities",,"Unknown status","No Results Available","Attention Deficit Hyperactivity Disorder|Autistic Disorder|Developmental Coordination Disorder",,,"Sheba Medical Center|Bar-Ilan University, Israel","All","4 Years to 10 Years   (Child)",,"160","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SHEBA-08-5185-LG-CTIL","January 2009","December 2009","December 2009","July 16, 2008",,"January 16, 2009","Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00716235"
1131,"NCT04639570","KneuroKnits: Participation and Anxiety in People With Neurological Conditions Participating in a Knitting Group",,"Completed","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders|Acquired Brain Injury|Physical Disability","Other: KneuroKnits","Self-reported Experience of Activity Settings (SEAS)|Symptom Checklist-90 (SCL-90; anxiety subscale; change during program participation)|State-Trait Anxiety Inventory (STAI; change between beginning and end of sessions; change between weeks 1 and 4)","Holland Bloorview Kids Rehabilitation Hospital","All","15 Years to 24 Years   (Child, Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-717","November 3, 2018","February 9, 2019","February 9, 2019","November 20, 2020",,"November 20, 2020","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04639570"
1132,"NCT03610919","Effects of Oxytocin Dose Frequency on Behavioral and Neural Responses",,"Unknown status","No Results Available","Healthy","Drug: Nasal Sprays","Between group differences in the changes between acute and chronic administration effects of oxytocin on amygdala reactivity towards fearful faces as assessed by fMRI.|Between group differences in the changes between acute and chronic administration effects of oxytocin on amygdala resting state connectivity as assessed by fMRI.|Association between trait autism with acute and chronic treatment effects on amygdala activity in response to fearful faces|Association between trait autism with acute and chronic treatment effects on amygdala resting state connectivity|Interaction of acute and chronic treatment effects on amygdala activity with oxytocin receptor genotype.|Interaction of acute and chronic treatment effects on amygdala connectivity with oxytocin receptor genotype.|Treatment effects on arousal will be assessed by subjects rating their arousal on a 9-point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5|Treatment effects on valence will be assessed by subjects rating their valence on a 9 point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5|Treatment effects on intensity will be assessed by subjects rating their intensity on a 9 point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5","University of Electronic Science and Technology of China","Male","17 Years to 30 Years   (Child, Adult)","Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UESTC-neuSCAN-57","March 1, 2018","September 1, 2018","December 1, 2018","August 1, 2018",,"October 29, 2018","school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03610919"
1133,"NCT02342366","Characterization of the Prosocial and Prosexual Effects of GHB",,"Completed","No Results Available","Depressive Disorder, Major|Bipolar Disorder|Autistic Disorder","Drug: GHB 35 mg/kg p.o.|Drug: GHB 20 mg/kg p.o.","Sexual Arousal|Social Cognition and Behavior|Composite measure of Neuroendocrine Parameters|electroencephalography (EEG) activity|fMRI activity","University of Zurich|University of Regensburg|University of Salerno|University of Vienna|University of Freiburg","Male","18 Years to 40 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","PUK-GHB01","February 2012","November 2014","December 2014","January 19, 2015",,"July 29, 2019","Hospital for Psychiatry, University of Zurich, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02342366/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02342366"
1134,"NCT03847402","The Early Integrated Intervention for Child Brain-developmental Disorders in China",,"Recruiting","No Results Available","Brain Developmental Diseases|Autism Spectrum Disorder|Global Developmental Delay|Attention Deficit-Hyperactivity Disorder","Behavioral: The early integrated intervention for GDD|Behavioral: The early integrated intervention for ASD|Behavioral: The early integrated intervention for ADHD|Behavioral: community intervention for ASD|Behavioral: Community intervention for GDD|Behavioral: community intervention for ADHD","Change from baseline development quotient (DQ) in the Griffiths Development Scales-Chinese version at 1 year, 2 years for GDD and ASD|Change from baseline score of the Conners Early Childhood (Conners EC) at 1 year, 2 years for ADHD|Change from baseline score of the Communication and Symbolic Behavior Scales Developmental Profile-Infant Toddler Checklist（CSBS-DP-ITC）at 1 year, 2 years for ASD|Change from baseline intelligence quotient (IQ) in the Wechsler Intelligence Scale at 1 year, 2 years for ADHD","Children's Hospital of Fudan University|National Key Research and Development Program of China","All","3 Months to 3 Years   (Child)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MBDZXGY2018","June 15, 2018","October 30, 2021","December 30, 2021","February 20, 2019",,"February 2, 2021","Children's hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03847402"
1135,"NCT02160886","Effects of a Task Oriented Intervention With Two Goal-setting Approaches",,"Completed","No Results Available","Movement Disorder|Learning Disability|Autism Spectrum Disorder|Children","Behavioral: child-goal|Behavioral: parent-goal","Goal Attainment Scaling (GAS)|Performance scale of the Canadian Occupational Performance Measure|Beck Youth scales, subscale self-concept","Region Gävleborg","All","5 Years to 12 Years   (Child)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RFR-296311","October 2011","January 2014","February 2014","June 11, 2014",,"June 11, 2014","Gävleborg County Council, Gävle, Sweden",,"https://ClinicalTrials.gov/show/NCT02160886"
1136,"NCT01731119","Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychosis NOS|Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive|Bipolar I Disorder|Bipolar II Disorder|Mood Disorder NOS|Severe Major Depression With Psychotic Features|Single Episode Major Depression Without Psychotic Symptoms|Severe Mood Disorder With Psychotic Features","Drug: Latuda©","Change in Weight|Proportion of Participants Completing Treatment|Changes in Efficacy Measures|Number of Participants Experiencing Side Effects|Overall Clinical Improvement","University of North Carolina, Chapel Hill|Foundation of Hope, North Carolina","All","6 Years to 19 Years   (Child, Adult)","Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-2302","December 2012","August 2014","August 2014","November 21, 2012","May 17, 2017","June 14, 2017","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01731119"
1137,"NCT02741063","Oxytocin Effect on Attentional Bias Towards Emotional Expression Faces in Individuals With High and Low Autistic Traits: A Functional Magnetic Resonance Imaging (fMRI) Study",,"Unknown status","No Results Available","Healthy","Behavioral: screen low autistic subjects|Behavioral: screen high autistic subjects|Drug: oxytocin|Drug: placebo","attentional bias toward emotional expression faces|brain activity during RSVP task","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","UESTC-neuSCAN-19","May 2016","June 2019","September 2019","April 18, 2016",,"October 29, 2018","China, Sichuan, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT02741063"
1138,"NCT02660775","Social Cognitive Assessment in Autism and Schizophrenia","(ClaCoS)","Recruiting","No Results Available","Schizophrenia","Behavioral: schizophrenia|Behavioral: Autism|Behavioral: Healthy controls","Change from Baseline in social cognition measures|Change from Baseline in symptoms measure|Change from Baseline in Neurocognitive functioning measures","Hôpital le Vinatier","All","18 Years to 45 Years   (Adult)","Not Applicable","440","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2015-A00580-49","December 4, 2015","March 31, 2021","June 30, 2021","January 21, 2016",,"June 17, 2020","Professeur FRANCK Nicolas, Bron, Rhone-alpes, France",,"https://ClinicalTrials.gov/show/NCT02660775"
1139,"NCT04962659","Telehealth Mindfulness-Based Music and Songwriting for Parents of Children With Intellectual/Developmental Disabilities",,"Recruiting","No Results Available","Parents|Stress|Developmental Disability|Intellectual Disability|Autism Spectrum Disorder","Behavioral: Mindfulness-Based Music and Songwriting","Perceived stress|Parent depression|Parent well-being|Parent mindfulness|Parent positive reappraisal|Parent anxiety|Parent affect regulation to MBMS sessions|Parent social connection to therapist at MBMS sessions|Parent daily momentary affect","Vanderbilt University Medical Center|National Endowment for the Arts, United States","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18632783820","June 29, 2021","June 2022","June 2022","July 15, 2021",,"July 15, 2021","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04962659"
1140,"NCT02097355","Using an Online Patient Monitoring System to Improve Care for Children With Chronic Conditions","TriVoxHealth","Completed","No Results Available","Attention Deficit Hyperactivity Disorder|Asthma|Autism Spectrum Disorder|Depression|Epilepsy","Other: TriVox for clinical care","Change in caregiver-rated disease-specific symptoms|Number of patients with ""red flag"" alerts|Change in caregiver-rated global functioning|Experience of care","Boston Children's Hospital","All","Child, Adult, Older Adult","Not Applicable","946","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","BCH PPQI 52012","December 2014","December 2019","December 2019","March 27, 2014",,"July 14, 2020","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02097355"
1141,"NCT01874327","Biomarkers of Developmental Trajectories and Treatment in Autism Spectrum Disorder (ASD)","BabyJ","Completed","No Results Available","Children at Risk for ASD","Behavioral: Baby JASPER|Behavioral: Standard Baby Classroom","Assessing change in Parent Child Interaction (PCX) throughout the diverse time points.|Autism Diagnostic Observation Schedule Toddler module (ADOS-T)|Imitation Task|Vineland Adaptive Behavior Scales (VABS)|EEG/Event Related Potential (ERP)|Mullen Scales of Early Learning (MSEL)|Early Social Communication Scales (ESCS)|Structured Play Assessment (SPA)","University of California, Los Angeles","All","12 Months to 21 Months   (Child)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","12-000607","January 2013","August 2018","September 2018","June 11, 2013",,"October 10, 2018","UCLA Semel Institue, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01874327"
1142,"NCT01808066","GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs",,"Completed","Has Results","Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Pervasive Developmental Disorder|Asperger's Disorder","Device: Groundskeeper","Number of Participants With an Increase/Improvement in Focusing|Number of Participants Identified as Attentive, Interested and Motivated Via Pre Interview","CogCubed, Corp|Ohio University","All","5 Years to 12 Years   (Child)","Not Applicable","21","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12X226","January 2013","May 2013","May 2013","March 11, 2013","September 9, 2014","October 16, 2019","Ohio University, Athens, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01808066"
1143,"NCT02776215","Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents",,"Unknown status","No Results Available","Circadian Rhythm Sleep Disorders|Non-24 Hour Sleep-Wake Disorder|Autism Spectrum Disorder|Smith-Magenis Syndrome","Drug: tasimelteon","Area under the curver (AUC) of tasimelteon and its metabolites|Maximum concetration (Cmax) of tasimelteon and its metabolites|Steady-state concentration (Css) of tasimelteon and its metabolites|Half-life of tasimelteon and its metabolites|Trough concentration (Ctrough) of tasimelteon and its metabolites|Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)|Safety and tolerability of tasimelteon as measured by Pediatric Adverse Event Reporting System (PAERS)","Vanda Pharmaceuticals","All","3 Years to 17 Years   (Child)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VP-VEC-162-4201","September 2016","December 2018",,"May 18, 2016",,"March 1, 2017","Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02776215"
1144,"NCT00025779","Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders",,"Completed","No Results Available","Attention Deficit Disorder With Hyperactivity|Autistic Disorder|Pervasive Development Disorders","Drug: methylphenidate|Drug: guanfacine","hyperactivity, impulsiveness, and distractibility","National Institute of Mental Health (NIMH)","All","5 Years to 14 Years   (Child)","Not Applicable","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","N01 MH70009|N01 MH80011|N01 MH70010|N01 MH70001|DSIR CT","October 2001","November 2003",,"October 24, 2001",,"July 28, 2009","UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00025779"
1145,"NCT04075552","Healthy Eating ASD",,"Recruiting","No Results Available","Food Selectivity","Behavioral: Pre Meal Presentation|Behavioral: Pre Meal Presentation + Modeling|Behavioral: Pre Meal Presentation + Token Economy","Increased consumption of healthy foods","Penn State University","All","6 Years to 14 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00005814","September 23, 2016","July 21, 2023","July 21, 2023","August 30, 2019",,"September 5, 2021","Hogan Learning Academy, Fleetwood, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04075552"
1146,"NCT02902952","Physical Exercise to Reduce Anxiety in Underserved Children With ASD","PETRA","Recruiting","No Results Available","Physical Exercise Condition|Control Condition","Behavioral: Physical Exercise|Behavioral: Control Intervention","Anxiety rating|Salivary Cortisol","University of California, Irvine|Massachusetts General Hospital|University of Missouri-Columbia","All","6 Years to 12 Years   (Child)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS 2016-2859","October 2016","March 2024","March 2024","September 16, 2016",,"March 29, 2021","2500 Red Hill Avenue, Santa Ana, California, United States|Thompson Center for Autism, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02902952"
1147,"NCT02908321","CBT for Anxiety Disorder in Children With Co-morbid ASD",,"Completed","No Results Available","Randomized Treatment Study","Behavioral: CBT","Anxiety Disorders Interview Schedule for DSM-IV: Parent & Child interview schedule (ADIS/CP).|Spence Children's Anxiety Scale (SCAS),|Children's Anxiety Life Inference Scale (CALIS)|Children's Automatic Thoughts Scale (CATS).","University of Aarhus","All","7 Years to 14 Years   (Child)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-2018","August 2016","September 2019","December 2019","September 20, 2016",,"November 10, 2020","Centre for Child and Adolescent Psychiatry, Risskov, Region Of Midtjylland, Denmark",,"https://ClinicalTrials.gov/show/NCT02908321"
1148,"NCT03826498","Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy",,"Active, not recruiting","No Results Available","Cerebral Palsy","Biological: CP CB-MNC injection|Other: Standard therapy","Number of participants with non-serious and serious adverse events|Changes in Standardized Gross Motor Function 66 (GMFM-66) Score for all child.|Changes in Cognitive Neurodevelopmental Outcome for child before 3yrs|Changes in The Infant Toddler Quality of Life Questionnaire for child above 3yrs.|Changes in Ashworth scale score for all child.|Number of Participants with Chimerism (longevity) of infused cell","State-Financed Health Facility ""Samara Regional Medical Center Dinasty""","All","1 Year to 10 Years   (Child)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12102017","January 12, 2018","December 26, 2021","January 26, 2022","February 1, 2019",,"March 17, 2021","Medical Centre Dinasty, Samara, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03826498"
1149,"NCT00271622","The Neurodevelopmental and Behavioral Phenotyping Screening Protocol",,"Recruiting","No Results Available","Neurologic Disorders|Autism|Neurodegenerative Disease|Neurobehavioral Manifestation",,"Screening evaluations such as a psychiatric interview; a diagnostic interview; developmental and/or cognitive testing; ratings of other psychiatric symptoms","National Institute of Mental Health (NIMH)|National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"5000","NIH","Observational","Observational Model: Other|Time Perspective: Other","060065|06-M-0065","February 27, 2006",,,"January 2, 2006",,"September 21, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00271622"
1150,"NCT04327648","Effect and Mechanism of Social Interaction Treatment on ASD Children",,"Not yet recruiting","No Results Available","ASD","Device: Social interaction treatment|Device: Neuronal cognition treatment|Other: Routine treatment","Childhood Autism Rating Scale, (CARS)|Social responsiveness scale, (SRS)|Autism Diagnostic Observation Schedule, ADOS|Clinical Global Impression, CGI","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","3 Years to 6 Years   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XH-20-004","June 1, 2020","December 30, 2023","December 30, 2023","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327648"
1151,"NCT03354923","Parent-Child Reciprocity and the Effectiveness of PEERS","ISR-PEERS","Unknown status","No Results Available","Social Skills|Parent-Child Relational Problem","Behavioral: PEERS intervention","Change from baseline Parent-Adolescent reciprocity paradigm at 4 and 8 months|Change from baseline Contextual Assessment of Social Skills at 4 and 8 months|Change from baseline Social Responsiveness Scale at 4 and 8 months|Change from baseline The Social Skills Improvement System at 4 and 8 months|Change from baseline Friendship Qualities Scale|Change from baseline Quality of Play Questionnaire at 4 and 8 months|Change from baseline Test of Adolescent Social Skills Knowledge at 4 and 8 months|Change from baseline Vineland Adaptive Behaviors Scales II at 4 and 8 months|Change from baseline Loneliness and Social Dissatisfaction Questionnaire at 4 and 8 months|Change from baseline Beck Depression Inventory II at 4 and 8 months|Change from baseline Autism Spectrum Quotient at 4 and 8 months|Change from baseline Empathy Quotient at 4 and 8 months|Change from baseline Parenting Stress Index Short Form at 4 and 8 months","Bar-Ilan University, Israel","All","12 Years to 17 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BIU121216","January 2016","August 2018","August 2019","November 28, 2017",,"February 26, 2019","Bar Ilan University, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03354923"
1152,"NCT04237870","Effect of rTMS on the Abnormal Executive Function of ASD Children",,"Recruiting","No Results Available","Executive Dysfunction|ASD","Device: Active cTBS|Device: Sham","Change in scores on Behaviour Rating Inventory of Executive Functioning (BRIEF)|Change in scores, reaction time and brain blood flow on the Working Memory Task by fNIRS|Change in size and connections of different parts of the brain to assess brain structure and blood flow by functional magnetic resonance imaging (fMRI)","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","6 Years to 16 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XH-19-013","January 1, 2019","August 31, 2021","September 30, 2021","January 23, 2020",,"January 23, 2020","Fei Li, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04237870"
1153,"NCT01050582","A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children",,"Completed","Has Results","Schizophrenia|Bipolar Disorder|Autistic Disorder|Conduct and Other Disruptive Behavior Disorders","Drug: Risperidone|Drug: Other atypical antipsychotic drugs","Height (cm) Z-score at Study Visit|Age (Years) at Current Tanner Stage|Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","8 Years to 16 Years   (Child)","Phase 4","244","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR016687|RISNAP4022","October 2009","July 2011","July 2011","January 15, 2010","November 27, 2012","November 27, 2012","San Francisco, California, United States|Aurora, Colorado, United States|Altamonte Springs, Florida, United States|Gainesville, Florida, United States|Smyrna, Georgia, United States|Naperville, Illinois, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|Boston, Massachusetts, United States|Cambridge, Massachusetts, United States|Glen Oaks, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Antwerpen, Belgium|Freiburg, Germany|Jena, Germany|Mannheim, Germany|München, Germany|Tübingen, Germany|Ulm, Germany|Würzburg, Germany|Athens, Greece|Nijmegen, Netherlands|Gdansk, Poland|Kielce, Poland|Lódź, Poland|Sosnowiec, Poland|Warszawa N/A, Poland|Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01050582"
1154,"NCT00198055","A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.",,"Completed","No Results Available","Asperger's Disorder|Pervasive Developmental Disorder","Drug: aripiprazole","The Clinical Global Impression(CGI)Improvement Scale.|The Irritability subscale of the Aberrant Behavior Checklist (ABC)|The Clinical Global Impression Severity Scale.|The Compulsion subscale of the Children's Yale-Brown Obsessive-Compulsive(CY-BOCS).|The Vineland Maladaptive Behavior Subscale.","Indiana University School of Medicine|Bristol-Myers Squibb|Indiana University","All","4 Years to 17 Years   (Child)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0302-24","January 2005","September 2007","September 2007","September 20, 2005",,"June 4, 2014","Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00198055"
1155,"NCT01712464","Modulation of Reinforcement Learning",,"Completed","No Results Available","Impact of Oxytocin on Social Learning","Drug: Oxytocin vs. Placebo","Bold Signal in nucleus accumbens|Bold signal in ventral tegmental areal","RWTH Aachen University","Male","18 Years to 26 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","12-033","October 18, 2013","August 7, 2016","August 7, 2016","October 23, 2012",,"May 1, 2018","Universtiy Hospital Aachen, Aachen, Northrhine-Westfalia, Germany",,"https://ClinicalTrials.gov/show/NCT01712464"
1156,"NCT00892580","Biomarker and DNA Collection in Subjects Participating in Protocol 22003",,"Completed","No Results Available","Fragile X Syndrome","Drug: STX209","Biomarker","Seaside Therapeutics, Inc.","All","6 Years to 17 Years   (Child)",,"32","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","22003A","May 2009","June 2010",,"May 4, 2009",,"July 31, 2013","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00892580"
1157,"NCT01804582","The Family VOICE Study",,"Completed","Has Results","Autism|Aggression|Bipolar Disorder|Psychotic Disorders","Other: Family Navigator consultation","Family Empowerment Scale|Duke-UNC (University of North Carolina) Functional Social Support Questionnaire|Youth Services Survey for Families|Child Behavior Checklist - Brief Problem Monitor|Psychosocial Service Utilization|Medication Regimen","University of Maryland, Baltimore","All","2 Years to 15 Years   (Child)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00054913|1300476","May 2013","March 31, 2016","March 31, 2016","March 5, 2013","November 20, 2019","November 20, 2019","University of Maryland, School of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01804582"
1158,"NCT03880383","BRIGHT Coaching Program for Families",,"Active, not recruiting","No Results Available","Mental Health Wellness 1|Parent-Child Relations|Child Developmental Delay|Parenting|Parent-child Problem|Child Development Disorder|Autism Spectrum Disorder","Behavioral: Coaching|Behavioral: Online parent education|Behavioral: Online peer support","Family Empowerment Scale (FES) - change is being assessed.|Parent Sense of Competency (PSOC) Scale - change is being assessed.|36-Item Short Form Survey (SF-36) - change is being assessed.|Parenting Stress Index - 36 (PSI-36) - change is being assessed.|Measure of Process of Care - 20 (MPOC - 20) - change is being assessed.|Resource Utilization Questionnaire - Preschoolers (RUQ-P) - change is being assessed.","McGill University Health Centre/Research Institute of the McGill University Health Centre|Canadian Institutes of Health Research (CIHR)|University of Alberta","All","18 Months to 54 Months   (Child)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2017-3159","August 23, 2018","June 2022","March 2023","March 19, 2019",,"September 8, 2021","Child Health BC, BC Children's Hospital, UBC, Vancouver, British Columbia, Canada|Specialized Services for Children and Youth (SSCY) Centre, Winnipeg, Manitoba, Canada|Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, Canada|Research Institute of McGill University Health Centre, Montreal Children's Hospital, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03880383/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03880383"
1159,"NCT01379443","Rehabilitation of Children With Multiple Disabilities",,"Completed","No Results Available","Cerebral Palsy|Autism|Down's Syndrome|Brain Injury","Other: CTN model of care for children and their families","Parental reports in the Quality of Life of Children and Youth|Integration of teams amongst service providers. Integration was measured at two levels using the Integration of Human Services Measure.","Children's Treatment Network|McMaster University","All","up to 19 Years   (Child, Adult)","Phase 1","445","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","2008H00766","April 2007","December 2009","December 2009","June 23, 2011",,"June 23, 2011","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01379443"
1160,"NCT01431326","Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","PTN_POPS","Completed","No Results Available","Adenovirus|Anesthesia|Anxiety|Anxiolysis|Autism|Autistic Disorder|Bacterial Meningitis|Bacterial Septicemia|Benzodiazepine|Bipolar Disorder|Bone and Joint Infections|Central Nervous System Infections|Convulsions|Cytomegalovirus Retinitis|Early-onset Schizophrenia Spectrum Disorders|Epilepsy|General Anesthesia|Gynecologic Infections|Herpes Simplex Virus|Infantile Hemangioma|Infection|Inflammation|Inflammatory Conditions|Intra-abdominal Infections|Lower Respiratory Tract Infections|Migraines|Pain|Pneumonia|Schizophrenia|Sedation|Seizures|Skeletal Muscle Spasms|Skin and Skin-structure Infections|Treatment-resistant Schizophrenia|Urinary Tract Infections|Withdrawal|Sepsis|Gram-negative Infection|Bradycardia|Cardiac Arrest|Cardiac Arrhythmia|Staphylococcal Infections|Nosocomial Pneumonia|Neuromuscular Blockade|Methicillin Resistant Staphylococcus Aureus|Endocarditis|Neutropenia|Headache|Fibrinolytic Bleeding|Pulmonary Arterial Hypertension|CMV Retinitis|Hypertension|Chronic Kidney Diseases|Hyperaldosteronism|Hypokalemia|Heart Failure|Hemophilia|Heavy Menstrual Bleeding|Insomnia","Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:","Composite of pharmacokinetic outcomes for understudied drugs in children|Composite pharmacodynamic outcomes of understudied drugs in children|Biomarkers associated with understudied drugs in children","Daniel Benjamin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University","All","up to 21 Years   (Child, Adult)",,"3520","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00029638|IND 113645|IND 114369|IND 114531|IND 118358|HHSN20100006|HHSN27500020|HHSN27500027|HHSN27500043|HHSN27500049","November 2011","November 2019","November 2019","September 9, 2011",,"December 20, 2019","Alaska Native Medical Center, Anchorage, Alaska, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California at San Diego Medical Center, La Jolla, California, United States|Axis Clinical Trials, Los Angeles, California, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|The Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Children's Mercy Hospital and Clinics, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|University of Montana, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|UNC Hospital Neonatal-Perinatal Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center (PICU / NICU), Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Akron Children's Hospital, Cleveland, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|Assaf Harofeh Medical Center, Zerifin, Tel Aviv, Israel|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|KK Women's and Children's Hospital Pte Ltd, Singapore, Singapore|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01431326"
1161,"NCT03269110","Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)",,"Enrolling by invitation","No Results Available","Autism Spectrum Disorder|Asthma|Executive Dysfunction|Emotional Problem|Behavioural Problem|Pre-Eclampsia|Death","Diagnostic Test: SRS 2, CBCL, BRIEF-P","Neurocognitive disability|Severe Morbidity","Ottawa Hospital Research Institute","All","4 Years to 6 Years   (Child)",,"2578","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTO 816","July 1, 2017","July 2021","July 2022","August 31, 2017",,"August 6, 2020","Nepean, Penrith, New South Wales, Australia|Townsville, Douglas, Queensland, Australia|Ipswich, Ipswich, Queensland, Australia|Women's and Children's Hospital, Adelaide, South Australia, Australia|Royal Women's, Parkville, Victoria, Australia|Sunshine, St Albans, Victoria, Australia|Calgary Foothills Medical Center, Calgary, Alberta, Canada|Edmonton Lois Hole Hospital for Women, Edmonton, Alberta, Canada|St-Paul's Hospital, Vancouver, British Columbia, Canada|Winnipeg University of Manitoba, Winnipeg, Manitoba, Canada|Fredericton Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada|Moncton Hospital, Moncton, New Brunswick, Canada|St-John's Women's Health Centre, St John's, Newfoundland and Labrador, Canada|Hamilton McMaster University, Hamilton, Ontario, Canada|Kingston, Kingston, Ontario, Canada|London, London, Ontario, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|The Ottawa Hospital, Civic Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences, Toronto, Ontario, Canada|Quebec City (CHUL) Centre Hospitalier Universitaire, Montreal, Quebec, Canada|Sainte-Justine, Montreal, Quebec, Canada|St-Mary's Hospital, Montreal, Quebec, Canada|St-Luc, Montreal, Quebec, Canada|Regina Qu'Appelle Health Region, Regina, Saskatchewan, Canada|University of West Indies, Kingston 7, Jamaica|Jubilee, Kingston, Jamaica|Spanishtown, Kingston, Jamaica|Hinchingbrooke, Huntingdon, Cambridgeshire, United Kingdom|Leighton, Crewe, Cheshire, United Kingdom|Darlington Memorial Hospital, Darlington, County Durham, United Kingdom|Fairfield, Bury, Lancashire, United Kingdom|Rochdale, Rochdale, Lancashire, United Kingdom|Lincolnshire, Lincoln, Lincolnshire, United Kingdom|West Middlesex University Hospital, Isleworth, Middlesex, United Kingdom|Wansbeck General Hospital, Ashington, Northumberland, United Kingdom|St George's Hospital, London, Tooting, United Kingdom|Gateshead Queen Elizabeth Hospital, Gateshead, Tyne And Wear, United Kingdom|South Tyneside Distrcit Hospital, South Shields, Tyne And Wear, United Kingdom|Blackburn, Blackburn, United Kingdom|Burnley, Burnley, United Kingdom|Cumberland Infirmary Carlisle, Carlisle, United Kingdom|North Manchester, Crumpsall, United Kingdom|North Durham, Durham, United Kingdom|Guy's and St. Thomas, London, United Kingdom|South Tees Hospital, Middlesbrough, United Kingdom|Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Norfolk & Norwich, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Nottingham Queens Medical Centre, Nottingham, United Kingdom|Oldham, Oldham, United Kingdom|North Tees Hospital, Stockton, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom|Hillingdon Hospital, Uxbridge, United Kingdom|Warrington Hospital, Warrington, United Kingdom|West Cumberland Hospital, Whitehaven, United Kingdom|49 Marine Avenue, Whitley Bay, United Kingdom|Royal Wolverhampton - New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03269110"
1162,"NCT03852550","READYorNot[TM] Brain-Based Disabilities Trial",,"Recruiting","No Results Available","Autism Spectrum Disorder|Cerebral Palsy|Epilepsy|Fetal Alcohol Spectrum Disorders|Spina Bifida","Other: e-health application","Transition Readiness Assessment Questionnaire (TRAQ) Change|Canadian Occupational Performance Measure (COPM) Change|TRANSITION-Q Change|Pediatric Quality of Life Instrument (PedsQL[TM]) Change|Measure of Process of Care (MPOC) Change|Health Utilities Index® (Hui2/3) Proxy-Assessed Change|Resource Use Questionnaire (RUQ) Change|System Usability Scale (SUS)","McMaster University|Canadian Institutes of Health Research (CIHR)|McGill University Health Centre/Research Institute of the McGill University Health Centre|The Montreal Children's Hospital Foundation|McMaster Children's Hospital Foundation|Hamilton Health Sciences Corporation|New Brunswick Health Research Foundation|The Hospital for Sick Children|Harvard Medical School|Oregon Health and Science University","All","15 Years to 17 Years   (Child)","Not Applicable","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1666","June 22, 2020","November 2021","December 2021","February 25, 2019",,"January 22, 2021","Alberta Health Services and The Governors of the University of Alberta, Edmonton, Alberta, Canada|McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Children's Hospital of Eastern Ontario Research Institute Inc., Ottawa, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03852550"
1163,"NCT03217110","Cerebellar Stimulation and Cognitive Control",,"Recruiting","No Results Available","Schizophrenia|Autism Spectrum Disorder|Bipolar Disorder|Depression|Parkinson Disease","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)","Change in disease-specific symptom rating scale, one scale identified for each group (MADRS for bipolar group; PANSS for schizophrenia group; UPDRS in Parkinson's patient group).|Change in brain rhythms|Change in cognitive function|Changes in functional MRI|Change in NIH Toolbox emotion battery|Change in motor function|Schizophrenia group: Change in Calgary depression scale.|Bipolar group: Change in Young Mania Rating Scale.|Bipolar group: Change in Columbia Suicide Severity Rating Scale.|Change in PHQ9 score.|Change in CGI.|Change in cognitive function.|Changes in structural MRI.|Changes in MRI-based timing task.|Changes in DTI.|Changes in T1 rho MRI signal.","Krystal Parker, PhD|University of Iowa","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","201610712","November 30, 2017","August 1, 2021","August 1, 2021","July 13, 2017",,"November 6, 2020","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03217110"
1164,"NCT02769949","Pediatric Patients With Metabolic or Other Genetic Disorders",,"Recruiting","No Results Available","Genetic Disorder|Asperger Disorder|Autism Spectrum Disorder|Fragile X Syndrome|Developmental Delay",,"Recruit Patients with Suspected or diagnosed genetic diseases","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"5000","NIH","Observational","Observational Model: Other|Time Perspective: Other","160103|16-CH-0103","May 3, 2016","January 1, 2029","January 1, 2029","May 12, 2016",,"August 25, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02769949"
1165,"NCT00391261","An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar Disorder|Autism Spectrum Disorders","Drug: Metformin","BMI|MOSES","Cambridge Health Alliance|American Psychiatric Association","All","10 Years to 18 Years   (Child, Adult)","Phase 4","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHA-IRB-0143/12/05","July 2006","October 2007","October 2007","October 23, 2006",,"March 25, 2010","Cambridge Health Alliance, Medford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00391261"
1166,"NCT00318162","Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)",,"Unknown status","No Results Available","Pervasive Developmental Disorder","Drug: low dose naltrexone","play observation|Autism Behavior Checklist (ABC) questionnaire","Hadassah Medical Organization|Jerusalem Institute for Child Development","All","3 Years to 6 Years   (Child)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","PDDLDN-HMO-CTIL",,,,"April 26, 2006",,"May 3, 2006","Jerusalem Institute for Child Development, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00318162"
1167,"NCT03892798","Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene","IRF2BPL","Recruiting","No Results Available","Autism Spectrum Disorder|Movement Disorders|Seizures|Dystonia|NEDAMSS","Other: No interventions are planned","Questionnaire|Genotype-phenotype correlations","Children's Hospital Medical Center, Cincinnati","All","2 Months to 80 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2018-6357","November 27, 2018","December 2038","December 2039","March 27, 2019",,"August 2, 2021","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03892798"
1168,"NCT00166595","Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)",,"Completed","No Results Available","Child Development Disorders, Pervasive","Drug: Risperidone",,"Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","100","Other|NIH","Interventional","Primary Purpose: Treatment","PPRU 10545s","February 2003",,"March 2005","September 14, 2005",,"January 28, 2014","Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00166595"
1169,"NCT00531830","Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy",,"Unknown status","No Results Available","Pervasive Developmental Disorder",,,"BeerYaakov Mental Health Center","All","2 Years to 6 Years   (Child)",,"60","Other","Observational","Observational Model: Defined Population|Time Perspective: Retrospective","Children with PDD -31CTIL","September 2007",,"September 2011","September 19, 2007",,"September 26, 2007",,,"https://ClinicalTrials.gov/show/NCT00531830"
1170,"NCT03327467","Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries",,"Available","No Results Available","Autism Spectrum Disorder|Autism|Cerebral Palsy|Hydrocephalus|Apraxia of Speech|Hypoxia Ischemia, Cerebral|Drowning; Anoxia","Biological: Cord Blood Infusion",,"Joanne Kurtzberg, MD|Duke University","All","up to 26 Years   (Child, Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"Pro00083888",,,,"October 31, 2017",,"November 24, 2020","Duke University Medical Center, Durham, North Carolina, United States|MD Anderson, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03327467"
1171,"NCT02766101","Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges","MM","Completed","No Results Available","Autistic Disorder|Attention Deficit and Disruptive Behavior Disorders|Anxiety Disorders|Mood Disorders|Conduct Disorder|Oppositional Defiant Disorder","Behavioral: Aerobic Exergaming PE Curriculum|Behavioral: Standard PE","Change in Minutes and Number of Disciplinary Time Out of Class Events (classroom functioning)|Change in Conners Abbreviated Teacher Rating Scale score (behavioral dysregulation: impulsivity/emotional lability)","Harvard School of Public Health|Judge Baker Children's Center","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","103","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB14-2312","October 2014","April 2015","April 2015","May 9, 2016",,"May 9, 2016","Judge Baker Children's Center, Manville School, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02766101"
1172,"NCT04158960","Motor Skill Proficiency After Equine-assisted Activities and Brain-building Tasks",,"Completed","No Results Available","Motor Delay|Motor Skills Disorders|Autism Spectrum Disorder|Attention Deficit Hyper Activity|Intellectual Disability|Sensory Disorders","Behavioral: Equine-assisted activities|Behavioral: GaitWay program","Fine motor precision|Fine motor integration|Manual dexterity|Bilateral coordination|Balance|Running speed and agility|Upper-limb coordination|Strength|Overall Motor Skill Scores|Caregiver reports","Texas Woman's University","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","17959","February 1, 2015","May 31, 2018","May 31, 2018","November 12, 2019",,"November 12, 2019",,,"https://ClinicalTrials.gov/show/NCT04158960"
1173,"NCT00485849","A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine Hydrochloride","Test whether atomoxetine is effective in reducing symptoms of inattention and overactivity/impulsivity as measured by the AHDHRS-IV-Parent:Inv scale in pediatric outpatients with ASD accompanied by ADHD behavior problems|To assess whether atomoxetine will be effective in reducing symptoms of inattention and overactivity/impulsivity|To assess whether atomoxetine will be effective for improving social functioning and personal sufficiency in children and adolescents with ASD+ADHD|To assess whether atomoxetine has a positive or negative effect on frequently associated symptoms as impulsive aggression, agitation, self-injurious behavior, troublesome repetitive behavior and poor motor coordination|To assess whether atomoxetine has a positive or negative effect on neuropsychological functioning|To assess the overall influence on functioning and burden on the family|To monitor clinical safety and side effects as assessed by adverse events elicited during open-ended questioning","Eli Lilly and Company","All","6 Years to 17 Years   (Child)","Phase 4","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6639|B4Z-UT-S003","February 2004",,"October 2004","June 13, 2007",,"June 13, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00485849"
1174,"NCT01919970","Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety",,"Completed","Has Results","Autism|Asperger's Syndrome|Pervasive Developmental Disorder Not Otherwise Specified|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder|Specific Phobia","Other: Cognitive Behavioral Therapy|Other: Treatment as usual","Pediatric Anxiety Rating Scale|Clinical Global Impression - Severity Scale","University of South Florida","All","6 Years to 12 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ASD-FET 2013","August 2013","August 2016","August 2017","August 9, 2013","June 14, 2019","June 14, 2019","Rothman Center for Neuropsychiatry, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01919970"
1175,"NCT00147394","Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)",,"Completed","No Results Available","Child Development Disorders, Pervasive","Drug: Risperidone","Quantify the variability of clearance and volume of distribution among AE rating, weight gain and ABC responder status.|Exploratory analysis will be performed to examine the relationship of other factors to risperidone and metabolite concentrations for PK/PD assessment.","Children's Hospital Medical Center, Cincinnati","All","5 Years to 16 Years   (Child)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPRU 10544","December 2001",,"June 2004","September 7, 2005",,"October 29, 2012","Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00147394"
1176,"NCT04322734","Mitochondrial Disease and Dysfunction in Neurological and Neurodevelopmental Disorders",,"Recruiting","No Results Available","Autism Spectrum Disorder|Mitochondrial Pathology|Epilepsy|Brain Tumor|Psychiatric Disorder|Mitochondrial Diseases",,"Mitochondrial Reserve Capacity measured using the Seahorse XR Flux Analyzer","Phoenix Children's Hospital","All","up to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mito Tissue","January 1, 2020","January 1, 2024","January 1, 2025","March 26, 2020",,"August 17, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04322734"
1177,"NCT04255472","Effectiveness of the WHO Caregivers Skills Training Program",,"Recruiting","No Results Available","Autism Spectrum Disorder|Development Delay|Developmental Disorder|Language Delay|Behavioral Problem|Emotional Problem|Maternal Distress","Behavioral: WHO Caregiver skills training (CST) program|Behavioral: Treatment as usual","Play-based caregiver-child interaction|Adaptive functioning behaviors|Child emotional and behavioral problems|Parental health related quality of life|Health services utilization|Communication and Symbolic Behavior","Human Development Research Foundation, Pakistan|World Health Organization|University of Liverpool|WHO Collaborating Center for mental health research, Institute of Psychiatry, Rawalpindi, Pakistan","All","2 Years to 9 Years   (Child)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WHO CST-RCT","February 11, 2020","December 31, 2020","January 31, 2021","February 5, 2020",,"February 25, 2020","Human Development Research Foundation, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT04255472"
1178,"NCT03292848","Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders",,"Completed","No Results Available","ADHD|Autism|Bipolar I Disorder|Conduct Disorder|Oppositional Defiant Disorder","Drug: Brexpiprazole","Maximum Plasma Concentration (Cmax) [PK]|Area under concentration-time curve (AUC) calculated from time zero to time t (AUCt) [PK]|AUC from time zero to infinity [PK]|Time of maximum plasma concentration (tmax) [PK]|Terminal-phase elimination half-life (t½,z) [PK]|Apparent clearance of drug from plasma after extravascular administration (CL/F) [PK]|Treatment-Emergent Adverse Events (TEAES) [Safety]|Clinical laboratory tests [Safety]|Vital signs observed and change from baseline data (systolic and diastolic blood pressure) [Safety]|Vital signs observed and change from baseline data (heart rate) [Safety]|Vital signs observed and change from baseline data (respiratory rate) [Safety]|Vital signs observed and change from baseline data (body temperature) [Safety]|12-lead electrocardiogram (ECGs) [Safety]|Physical examinations (height) [Safety]|Physical examinations (weight) [Safety]|Physical examinations- Body Mass Index (BMI) [Safety]|Physical examinations- review of body systems [Safety]|Simpson-Angus Scale (SAS) rating scale [Safety]|Abnormal Involuntary Movement Scale (AIMS) [Safety]|Barnes Akathisia Rating Scale (BARS) [Safety]|Columbia-Suicide Severity Rating Scale (C-SSRS) [Safety]","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","6 Years to 12 Years   (Child)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-201-00103","October 10, 2017","May 21, 2018","May 21, 2018","September 26, 2017",,"June 12, 2018","Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Alliance for Wellness dba Alliance for Research, Long Beach, California, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Road Runner Research Ltd., San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03292848"
1179,"NCT04689282","Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders",,"Recruiting","No Results Available","Language Delay|Language; Developmental Disorder, Expressive|Language; Developmental Disorder, Receptive|Autism Spectrum Disorder|Attention Deficit-Hyperactivity Disorder|Speech Disorders in Children","Biological: Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).","Change in the severity of speech disorders according to Speech Assessment Scale (SAS)|The number of patients with adverse events","Russian Academy of Medical Sciences","All","3 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFCI-23/06/2017","February 1, 2020","December 1, 2021","July 1, 2022","December 30, 2020",,"December 30, 2020","Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04689282"
1180,"NCT05056415","Effect and Cost-effectiveness of the Everyday Life Rehabilitation Intervention","ELR","Recruiting","No Results Available","Psychiatric or Mood Diseases or Conditions|Neuropsychiatric Syndrome|Psychosis|Autism|Severe Mental Disorder","Other: Everyday Life Rehabilitation (ELR)|Other: Treatment as usual (TAU)","Change from baseline 'Recovering quality of life score' at 6 months|Change from baseline 'Total Recovery score' at 6 months","Umeå University|Swedish Council for Working Life and Social Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","330210302 - FORTE 2021-2024, M","September 15, 2021","March 15, 2023","March 15, 2023","September 24, 2021",,"September 30, 2021","Umeå university, Umeå, Sweden",,"https://ClinicalTrials.gov/show/NCT05056415"
1181,"NCT04293120","Training Balance Among People With Neurodevelopmental Disabilities","TAPAS","Terminated","No Results Available","Posture|Balance|Cerebral Palsy|Autism|Down Syndrome","Other: Training with weighted ball","Muscle activation timing|Muscle amplitude response","University of Hartford|Universita di Verona","All","8 Years to 25 Years   (Child, Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO19020012","February 10, 2020","August 31, 2020","August 31, 2020","March 3, 2020",,"June 1, 2021","University of Hartford, West Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04293120"
1182,"NCT02149823","Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations",,"Suspended","No Results Available","Borderline Personality Disorder|BPD|Schizotypal Personality Disorder|SPD|Autism Spectrum Disorder|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder","Drug: Syntocinon 24 Intranasal Units (IU)|Drug: Syntocinon 40 Intranasal Units (IU)|Drug: Intranasal Placebo","Movie for the Assessment of Social Cognition (MASC)|Reading of the Mind in the Eyes|Resting-state functional connectivity","Maria de las Mercedes Perez Rodriguez|James J. Peters Veterans Affairs Medical Center|VISN 3 Mental Illness Research, Education and Clinical Center|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","165","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","GCO 13-0340|UL1TR000067","September 2013","August 2021","August 2021","May 29, 2014",,"October 8, 2020","James J Peters VA Medical Center, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02149823"
1183,"NCT00870974","A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions","FPEB","Completed","No Results Available","Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment","Drug: [18F]FPEB","Does FPEB reliably represent the known distribution of MGLUR5 in the brain?","Institute for Neurodegenerative Disorders","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","FPEB","March 2009","October 2016","November 2016","March 27, 2009",,"January 6, 2017","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00870974"
1184,"NCT02714868","Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)","ProjectTEAM","Completed","Has Results","Transition-age Youth|Developmental Disabilities|Cerebral Palsy|Autism|Intellectual Disability","Behavioral: Project TEAM|Behavioral: Matched Comparison","Goal Attainment Scaling (GAS)|Project TEAM Knowledge Test|AIR Self-Determination Scale (American Institutes on Research- AIR)|Generalized Self Efficacy Scale (GSES)|Participation and Environment Measure for Children and Youth (PEM-CY)|Readiness for Advocacy","Boston University Charles River Campus|Wayne State University","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","82","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H133G120091|90IF0032-01-00","October 2012","September 2016","July 31, 2017","March 22, 2016","November 25, 2019","November 25, 2019",,,"https://ClinicalTrials.gov/show/NCT02714868"
1185,"NCT01269710","Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study","SATIETY","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychotic Disorder, Not Otherwise Specified|Prodromal Schizophrenia|Mood Disorder|Bipolar Disorder|Major Depressive Disorder|Depressive Disorder, Not Otherwise Specified|Mood Disorder, Not Otherwise Specified|Autism Spectrum Disorder",,"Change in Weight (in Lbs.)|Change in Glucose Levels (mg/dL)|Change in Total Cholesterol (mg/dL)|Change in Triglycerides (mg/dL)|Change in LDL (mg/dL)","University of North Carolina, Chapel Hill","All","3 Years to 19 Years   (Child, Adult)",,"4","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-1734","October 2009","March 2011","March 2011","January 4, 2011","February 22, 2013","February 22, 2013","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01269710"
1186,"NCT01313325","Hippotherapy to Improve the Balance of Children With Movement Disorders","HPOT","Completed","No Results Available","Neuromuscular Diseases|Cerebral Palsy|Down Syndrome|Autism|Developmental Coordination Disorder","Other: Hippotherapy","Pediatric Balance Scale|Activities Scale for Kids","Central Michigan University","All","5 Years to 17 Years   (Child)","Not Applicable","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","09/14/2006","September 2006","December 2007","December 2007","March 11, 2011",,"March 11, 2011","CHUM Therapeutic Riding Center, Dansville, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01313325"
1187,"NCT04111874","Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD",,"Recruiting","No Results Available","Cognitive Behavioral Therapy|Autism Spectrum Disorder|Anxiety Disorders|Obsessive-Compulsive Disorder|Social Anxiety Disorder|Generalized Anxiety Disorder|Specific Phobia","Behavioral: Cognitive Behavioral Teletherapy LTA|Behavioral: Cognitive Behavioral Teletherapy STA","6-item Pediatric Anxiety Rating Scale|Clinical Global Impression-Improvement|Clinical Global Impression-Severity","Baylor College of Medicine","All","7 Years to 13 Years   (Child)","Not Applicable","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H45203","July 30, 2019","December 31, 2021","December 31, 2021","October 1, 2019",,"May 6, 2021","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04111874"
1188,"NCT03720795","Stepped-Care Cognitive-Behavioral Treatment for Youth With ASD and Anxiety",,"Active, not recruiting","No Results Available","Cognitive Behavioral Therapy|Autism Spectrum Disorder|Anxiety Disorders|Obsessive-Compulsive Disorder|Social Anxiety Disorder|Generalized Anxiety Disorder|Specific Phobia","Behavioral: Stepped Care CBT","6-item Pediatric Anxiety Rating Scale|Clinical Global Impression-Improvement|Clinical Global Impression-Severity","Baylor College of Medicine","All","4 Years to 14 Years   (Child)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCM SC-CBT001","February 1, 2019","December 30, 2021","December 31, 2021","October 25, 2018",,"May 6, 2021","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03720795"
1189,"NCT01243905","Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders",,"Unknown status","No Results Available","Pervasive Developmental Disorder","Other: Family psychoeducational therapy plus TAU|Other: Treatment as usual","Change from baseline in the total score of the General Health Questionaire 28(GHQ28) at 21 weeks|Change from baseline in the total score of the General Health Questionaire 28(GHQ28) at 7 weeks|Change from baseline in the total score of the Abnormal Behavior Checklist at 7 weeks","Nagoya City University","Female","Child, Adult, Older Adult","Phase 2|Phase 3","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCUPsychiatry003","September 2010","December 2011","March 2012","November 19, 2010",,"January 19, 2011","Nagoya City University Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan",,"https://ClinicalTrials.gov/show/NCT01243905"
1190,"NCT00870727","Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders",,"Completed","Has Results","Pervasive Developmental Disorder","Drug: Aripiprazole oral product|Drug: Placebo oral capsule","Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Subscale Score, Parent Report, Double-blind Phase","Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb","All","5 Years to 17 Years   (Child)","Phase 3","33","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0805-26|MH 082119","February 2009","March 2015","May 2015","March 27, 2009","November 28, 2018","January 2, 2019","Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00870727"
1191,"NCT00709202","Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar I Disorder|Bipolar II|Bipolar NOS(Not Otherwise Specified)|Psychotic Disorder Not Otherwise Specified|Autism Spectrum Disorder","Drug: Betahistine|Drug: Placebo Oral Tablet","Change in Weight|Change in Body Mass Index (BMI)|Change in Waist Circumference|Change in Hip Circumference|Change in Glucose|Change in Cholesterol|Change in LDL|Change in HDL|Change in Triglycerides|Change in Appetite Hunger|Change in Appetite Fullness","Nathan Kline Institute for Psychiatric Research|Stanley Medical Research Institute","All","18 Years to 59 Years   (Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07TGF-1112","July 2008","May 2016","December 2016","July 3, 2008","January 25, 2019","January 25, 2019","Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States",,"https://ClinicalTrials.gov/show/NCT00709202"
1192,"NCT03886753","Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products","Ilera","Terminated","No Results Available","ALS|Autism Spectrum Disorder|Cancer|Spasticity, Muscle|Dyskinetic Syndrome|Epilepsy|Glaucoma|Huntington Disease|Inflammatory Bowel Disease (IBD)|Multiple Sclerosis|Neuropathy|Opioid Use|Parkinson Disease|HIV/AIDS|Ptsd|Intractable Pain|Sickle Cell Disease|Terminal Illness","Other: Registry|Other: PK microsampling of blood","Change in symptoms|Description and incidence of patient or caregiver reported side effects|Changes in drug concentrations|Rate of bioavailabilty|Volume of distribution|Report area under the plasma concentration versus time curve (AUC)|Report half-life|Assess therapeutic range","Children's Hospital of Philadelphia|Ilera Healthcare","All","2 Years and older   (Child, Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-015787","May 15, 2019","June 30, 2020","June 30, 2020","March 22, 2019",,"July 30, 2020","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03886753"
1193,"NCT03508583","Turkish Version of The Measure of Processes of Care (MPOC)",,"Unknown status","No Results Available","Cerebral Palsy|Muscular Dystrophies|Autism Spectrum Disorder|Traumatic Brain Injury|Down Syndrome|Disability, Developmental|Disability Physical","Other: Participation","The Measure of Processes of Care (MPOC- 56)|The Measure of Processes of Care 20 (MPOC- 20)|The Measure of Processes of Care for services providers (MPOC- SP)|Child Health Questionnaire - Parent Form 50","Hacettepe University","All","5 Years to 25 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","46418926","May 1, 2018","June 1, 2018","August 1, 2019","April 26, 2018",,"April 27, 2018",,,"https://ClinicalTrials.gov/show/NCT03508583"
1194,"NCT03602378","QoL and Stress in Parents of Children With Developmental Disabilities and Chronic Disease",,"Enrolling by invitation","No Results Available","Developmental Disability|Chronic Disease|Down Syndrome|Autism Spectrum Disorder|Pervasive Developmental Disorder|Cerebral Palsy|Diabetes Mellitus, Type 1|Epilepsy|Asthma|Stress","Diagnostic Test: salivary cortisol|Device: Holter Medilog AR12 Plus|Device: Polar V800|Device: AGE reader","Quality of life in parents of children with developmental disability and chronic disease, and healthy children.|Stress in parents of children with developmental disability and chronic disease, and healthy children.|Family quality of life|Perceived Stress Scale|Salivary cortisol concentration in parents of children with developmental disability, chronic disease and parents of healthy children.|Heart rate variability in parents of children with developmental disability, chronic disease and parents of healthy children|Advanced glycation end products in parents of children with developmental disability, chronic disease and parents of healthy children.","University of Split, School of Medicine|General Hospital Zadar","All","20 Years to 50 Years   (Adult)",,"592","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2181-198-03-04-18-0014","April 2, 2018","April 2, 2021","May 2, 2021","July 26, 2018",,"March 26, 2020","University Hospital Split, Split, Croatia|Ivana Kolcic, Split, Croatia",,"https://ClinicalTrials.gov/show/NCT03602378"
1195,"NCT03492060","A Natural History Study of hnRNP-related Disorders",,"Recruiting","No Results Available","Neurodevelopmental Disorders|Intellectual Disability|Developmental Delay|Autism Spectrum Disorder|Seizures|Hypertonia, Muscle|Hypotonia",,"Medical abnormalities associated with a mutation in any hnRNP gene|Education-based impairments associated with a mutation in any hnRNP gene|Repetitive Behavior|Sleep Habits|Sensory Issues|Social Interaction and Communication SRS-II Score|Anxiety|Receptive Language Skills|Executive Functioning|Autism|Adaptive Behavior|Social Interaction and Communication SCQ Score|Emotional Regulation|Motor Performance|Function in Daily Activities, Mobility, Social and Cognitive, and Responsibility|Functional Balance|Functional Capability and Mobility|Coordination and Gait","Columbia University|Simons Foundation","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAR7203","June 13, 2018","April 2024","April 2024","April 10, 2018",,"October 5, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03492060"
1196,"NCT02205658","Sensory Processing Difficulties in Adults and Adolescents",,"Unknown status","No Results Available","Sensory Processing Dysfunction",,"Sensory processing difficulties","The Spiral Foundation at OTA Watertown|Maxwell Hurston Charitable Foundation","All","13 Years to 95 Years   (Child, Adult, Older Adult)",,"1300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","1027","January 2014","September 2014","December 2014","July 31, 2014",,"July 31, 2014","The Spiral Foundation, Newton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02205658"
1197,"NCT01894958","A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome",,"Completed","No Results Available","Fragile X Syndrome","Drug: NNZ-2566|Drug: Placebo","Adverse events|Physiological changes|Behavior|Global and Functional outcome Measures","Neuren Pharmaceuticals Limited","Male","12 Years to 45 Years   (Child, Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Neu-2566-FXS-001","January 2014","September 2015","October 2015","July 10, 2013",,"February 5, 2018","UC Davis MIND Institute, Sacramento, California, United States|Children's Hospital Colorado, Denver, Colorado, United States|Children's National Hospital, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nebraska, Omaha, Nebraska, United States|Mount Sinai School of Medicine, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Autism & Developmental Medicine Institute Geisinger Health System, Lewisburg, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01894958"
1198,"NCT03548779","North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2","NCGENES2","Enrolling by invitation","No Results Available","Epilepsy; Seizure|Neuromuscular Diseases|Brain Malformation|Intellectual Disability|Autism Spectrum Disorder|Hypotonia|Inborn Errors of Metabolism|Movement Disorders|Genetic Disease|Development Delay|Chromosome Abnormality|Hearing Loss|Dysmorphic Features|Skeletal Dysplasia|Congenital Abnormality|Microcephaly|Macrocephaly","Behavioral: Pre-visit prep|Diagnostic Test: usual care + exome seq","Number of in-patient hospital admissions 1 year prior to return of results|Number of in-patient hospital admissions 1 year after return of results|Number of in-patient hospital days 1 year prior to return of results|Number of in-patient hospital days 1 year after return of results|Number of long-term care admissions 1 year prior to return of results|Number of long-term care admissions 1 year after return of results|Number of long-term care days 1 year prior to return of results|Number of long-term care days 1 year after return of results|Number of ER visits 1 year prior to return of results|Number of ER visits 1 year after return of results|Number of specialists visits 1 year prior to return of results|Number of specialists visits 1 year after return of results|Initial Patient Pediatric Quality of Life (Peds QL) score|Intermediate Patient Pediatric Quality of Life (Peds QL) score|Final Patient Pediatric Quality of Life (Peds QL) score|Initial Caregiver QoL score|Intermediate Caregiver QoL score|Final Caregiver QoL score|Post-Clinic Visit 1 Mean Patient Centeredness Score|Post-Return of Results Mean Patient Centeredness Score|Number of questions caregiver asks in Clinic Visit 1|Initial Average Peds QL score for ""missing school for not feeling well""|Intermediate Average Peds QL score for ""missing school for not feeling well""|Final Average Peds QL score for ""missing school for not feeling well""|Initial Average Peds QL score for ""missing school for doctors visit""|Intermediate Average Peds QL score for ""missing school for doctors visit""|Final Average Peds QL score for ""missing school for doctors visit""|Initial Amount of work missed because of child's condition or treatments score|Intermediate Amount of work missed because of child's condition or treatments score|Final Amount of work missed because of child's condition or treatments score|Initial Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Intermediate Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Final Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Vital status at final f/u|Child causes of death related to the primary condition|Percent concordance of caregiver and provider reports of genetic or genomic test results|Mean Baseline Self Efficacy Score|Mean Pre-Clinic Visit 1 Self Efficacy Score|Post-Return of Results Mean FACToR Uncertainty Subscale Score","University of North Carolina, Chapel Hill|National Human Genome Research Institute (NHGRI)|East Carolina University|Mission Health System, Asheville, NC","All","Child, Adult, Older Adult","Not Applicable","1700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","17-0816|U01HG006487","September 28, 2018","August 31, 2022","August 31, 2023","June 7, 2018",,"March 26, 2021","Mission Health, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States","""Informed Consent Form: 7-14 Assent Form 1 Randomization to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_000.pdf|""Informed Consent Form: 7-14 Assent Form 2 Assent to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_001.pdf|""Informed Consent Form: 15-17 Assent Form 1 Randomization to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_002.pdf|""Informed Consent Form: 15-17 Assent Form 2 Assent to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_003.pdf|""Informed Consent Form: Consent Form 1 Randomization to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_004.pdf|""Informed Consent Form: Consent Form 2 Assent to Research"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_005.pdf","https://ClinicalTrials.gov/show/NCT03548779"
1199,"NCT03342495","Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial","TNT","Active, not recruiting","No Results Available","Diabetes|Endocrine System Diseases|Gastro-Intestinal Disorder|Neuro-Degenerative Disease|Epilepsy|Autoimmune Diseases|Renal Disease|Cardiac Disease|Metabolic Disease|Genetic Diseases, Inborn|Respiratory Disease|Hematologic Diseases|Autism Spectrum Disorder|Fetal Alcohol Spectrum Disorders|Traumatic Brain Injury|Stroke","Other: Patient Navigator|Other: Usual Care","Health services utilization|cost analysis|Variation in TRAQ (Transition Readiness Questionnaire) scores|Variation in SF-12 Scores","University of Calgary|Alberta Health Services|University of Alberta","All","16 Years to 21 Years   (Child, Adult)","Not Applicable","337","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","REB16-2561","February 6, 2018","August 31, 2021","December 31, 2022","November 17, 2017",,"September 24, 2021","Alberta Children's Hospital, Calgary, Alberta, Canada|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|Stollery Childrens Hospital, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03342495"
1200,"NCT03672266","Studies of Brain and Body Interaction",,"Unknown status","No Results Available","Autistic Disorders Spectrum|Adhd|Asperger Syndrome|Alzheimer Disease|Parkinson|Tremor Essential|Dementia, Alzheimer Type|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia With Lewy Bodies|Dementia Frontal",,"Unitless Stochastic Signatures of Biophysiological Signals, consisting of the Empirically Estimated Shape and Dispersion (scale) Parameters of Probability Distribution Functions|Brain and Body Connectivity metrics and Derived Geometric and Topological Indexes from the Network Connectivity Model and Inverse Kinematic Model|Information theoretic metric","Rutgers University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BrainBody","August 1, 2018","July 1, 2019","July 1, 2019","September 14, 2018",,"September 14, 2018","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03672266"
1201,"NCT01282268","Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome","Harbor-A","Completed","No Results Available","Fragile X Syndrome","Drug: arbaclofen|Drug: placebo","Aberrant Behavior Checklist - FXS Social Avoidance Subscale","Seaside Therapeutics, Inc.","All","12 Years to 50 Years   (Child, Adult)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","209FX301","May 2011","December 2012",,"January 24, 2011",,"July 31, 2013","Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Miller Children's Hospital Research Administration, Long Beach, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Psychiatric Centers at San Diego, San Diego, California, United States|University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States|University of Miami, Mailman Center for Child Development, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Emory University School of Medicine, Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|Duke University Clinical Research Unit, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|University of Oklahoma, Physician's Child Study Center, Oklahoma City, Oklahoma, United States|Suburban Research Associates/Elwyn Genetics, Media, Pennsylvania, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01282268"
1202,"NCT03325946","The FBRI VTC Neuromotor Research Clinic",,"Recruiting","No Results Available","Neuromotor Impairments|Cerebral Palsy|Microcephaly|Autism|Trauma, Brain|Acquired Brain Injury","Behavioral: ACQUIRE Therapy","Emerging Behaviors Scale|Assisting Hand Assessment|Pediatric Motor Activity Log|Peabody Developmental Motor Scales 2|The Bayley Motor Scales of Infant Development -III","Virginia Polytechnic Institute and State University","All","3 Months to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-196","January 1, 2013","December 31, 2027","December 31, 2027","October 30, 2017",,"April 8, 2021","Fralin Biomedical Research Institute - VTC, Roanoke, Virginia, United States|Fralin Biomedical Research Institute - VTC, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03325946"
1203,"NCT03522337","Oral Health Promotion Among Preschool Children With Special Needs",,"Completed","No Results Available","Intellectual Disability|Cerebral Palsy|Developmental Disorders|Developmental Delay|Autistic Spectrum Disorders|Down Syndrome|Epilepsy|Developmental Disability|Learning Disorders","Other: Visual pedagogy (social stories)|Other: Conventional leaflets","Change in carious tooth surfaces over course of the trial|Change in the prevalence of dental caries|Change in oral hygiene status|Change in gingival status|Change in children's tooth-brushing performance|Change in children's eating habits|Change in children's dental-visit experience|The amount of toothpaste|Toothbrush wear","The University of Hong Kong","All","2 Years to 6 Years   (Child)","Not Applicable","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","SCCC2016to2018|HKUCTR-2015","April 12, 2016","September 28, 2018","September 30, 2018","May 11, 2018",,"April 18, 2019","Dental Faculty, The University of Hong Kong, Hong Kong, Hong Kong, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03522337/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03522337/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03522337"
1204,"NCT01238575","Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder",,"Completed","Has Results","Pervasive Development Disorders","Other: placebo|Drug: extended-release guanfacine","Aberrant Behavior Checklist Hyperactivity Subscale|ADHD Rating Scale - Total|Aberrant Behavior Checklist Irritability Subscale|Aberrant Behavior Checklist Social Withdrawal Subscale|Aberrant Behavior Checklist Sterotypy Subscale|Aberrant Behavior Checklist Inappropriate Speech Subscale|ADHD Rating Scale - Inattention Subscale|ADHD Rating Scale - Hyperactivity Subscale","Yale University|Emory University|Massachusetts General Hospital|Seattle Children's Hospital|University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","5 Years to 14 Years   (Child)","Phase 4","62","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1001006172|R01MH083707","December 2011","March 2014","March 2014","November 10, 2010","December 7, 2015","March 31, 2020","University of California, Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01238575"
1205,"NCT01903681","Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances",,"Completed","No Results Available","Sleep Problems","Drug: Circadin 2 mg|Drug: Circadin 10 mg","baseline profile of endogenous saliva melatonin concentrations and urine 6-SMT excretion|concentration-time profile of saliva melatonin concentrations and 24 hour 6-SMT urine excretion after 2 and 10 mg Circadin® mini-tablets single dose administration|adverse event profile after a single dose of 2 or 10 mg Circadin® mini-tablets","Neurim Pharmaceuticals Ltd.","All","2 Years to 17 Years   (Child)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHDR1219","March 2013","February 2014","April 2014","July 19, 2013",,"April 4, 2014","Centre for Human Drug Research, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01903681"
1206,"NCT01430845","Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay",,"Completed","No Results Available","Global Developmental Delay|Cerebral Palsy|Mental Retardation|Pervasive Developmental Disorders",,"level of Mental retardation in older age","Sheba Medical Center","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SHEBA-11-8458-LG-CTIL","September 1, 2011","December 1, 2015","December 1, 2015","September 8, 2011",,"June 29, 2018","Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT01430845"
1207,"NCT01525901","Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)",,"Recruiting","No Results Available","22q13 Deletion Syndrome|Phelan-McDermid Syndrome","Drug: Insulin-Like Growth Factor-1 (IGF-1)|Drug: Normal saline","Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) subscale|Repetitive Behavior Scale|CGI-Improvement and Severity Scales|Caregiver Strain Index|Exploratory outcomes","Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)","All","5 Years to 12 Years   (Child)","Phase 2","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 12-0929|IF# 1358648|1R34MH100276-01|GCO 11-1555|R34MH100276","February 2012","April 2023","April 2023","February 3, 2012",,"March 15, 2021","Seaver Austin Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01525901"
1208,"NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation",,"Recruiting","No Results Available","Crohn Disease|Ulcerative Colitis|Celiac Disease|Irritable Bowel Syndrome|Functional Dysphonia|Constipation|Clostridium Difficile Infection|Diabetes Mellitus|Obesity|Multidrug -Resistant Infection|Hepatic Encephalopathy|Multiple Sclerosis|Pseudo-Obstruction|Carbapenem-Resistant Enterobacteriaceae Infection|Vancomycin Resistant Enterococci Infection|Multiple Organ Dysfunction Syndrome|Dysbiotic Bowel Syndrome|MRSA Enteritis|Pseudomembranous Enterocolitis|Alopecia|Autism|Graft-versus-host Disease|Idiopathic Thrombocytopenic Purpura|Atopy or Allergy|Liver Disease|Alcohol Dependence|Psoriatic Arthropathy","Procedure: Fecal Microbiota Transplantation","The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome)|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","Chinese University of Hong Kong","All","Child, Adult, Older Adult","Not Applicable","450","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMT-Pilot","July 15, 2019","October 31, 2023","October 31, 2024","July 10, 2019",,"April 22, 2020","The Chinese University of Hong Kong, Hong Kong, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04014413"
1209,"NCT03944447","Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19","OMNI-Can","Recruiting","No Results Available","Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus","Drug: Cannabis, Medical","Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events","OMNI Medical Services, LLC|OMNI Medical Services Inc","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2","200000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00033337","December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"December 9, 2020","OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03944447"
1210,"NCT02453763","In Vivo Imaging of Therapeutic Electric Current Flow","tDCS","Completed","No Results Available","Parkinson Disease|Epilepsy|Alzheimer's Disease|Stroke|Autism|Depression|Schizophrenia","Device: Transcranial direct current stimulation|Procedure: MRI","Magnetic Resonance Imaging (MRI) of therapeutic current flow","University of Florida|Arizona State University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 30 Years   (Adult)",,"17","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","506-2012-N|1R21NS081646-01A1","June 2015","July 6, 2017","July 6, 2017","May 25, 2015",,"April 5, 2018","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02453763"
1211,"NCT02396576","Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas",,"Completed","No Results Available","Developmental, Behavioral and Mental Health|Adhd|Depression|Anxiety|Developmental Delay|Autism|Behavioral Problems","Behavioral: Telehealth Intervention","Access to specialty services- Referral time|Access to specialty services- Travel|Access to specialty services- Missed school/work|Access to specialty services- Out of pocket cost|Access to specialty services- Visits|Quality of care measures|Child Behavior measures|Provider coordination- Communication|Provider coordination- Comfort level","University of California, Los Angeles|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","359","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IH-12-11-4168","April 7, 2015","June 15, 2017","June 15, 2017","March 24, 2015",,"August 10, 2017","Northeast Valley Health Corporation- Canoga Park, Canoga Park, California, United States|Northeast Valley Health Corporation- Pacoima, Pacoima, California, United States|Northeast Valley Health Corporation- San Fernando, San Fernando, California, United States|Northeast Valley Health Corporation- Santa Clarita, Santa Clarita, California, United States|Northeast Valley Health Corporation- Valencia, Valencia, California, United States|Northeast Valley Health Corporation- Van Nuys, Van Nuys, California, United States",,"https://ClinicalTrials.gov/show/NCT02396576"
1212,"NCT02250339","A Prospective Observational Study of Family-based Interventions for Children With Neuropsychiatric and/or Psychiatric Disorders",,"Unknown status","No Results Available","ADHD|Asperger Syndrome|Child Behavior Disorders","Other: LAKU family program|Other: Etä-LAKU family program|Other: Family therapy","Child's Health Related Quality of Life questionnaire (HRQOL) - (KINDL-R)|Multisource Assessment of Children's Socioemotional Competence Scale (MASCS)|Parenting Self-Efficacy (PSE)|Finnish version of the Peer Network and Dyadic Loneliness Scale (PNDL)|Mental Health Inventory (MHI-5)","Social Insurance Institution, Finland|Turku University Hospital|University of Turku","All","5 Years to 12 Years   (Child)",,"230","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Perhe14|Kela","December 2013","June 2018","December 2018","September 26, 2014",,"January 26, 2016","Social Insurance Institution, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT02250339"
1213,"NCT00352196","Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study",,"Completed","No Results Available","Asperger's Disorder","Drug: Risperidone|Other: Magnetic Resonance Spectroscopy","Chang in the Scale for the Assessment of Negative Symptoms (SANS)|Change in Positive and Negative Symptom Scale (PANNS)|Change in Brief Psychiatric Rating Scale (BPRS)|Change in Montgomery Asberg Rating Scale (MADRS)|Change in Global Assessment Scale (GAS)|Change in Abnormal Involuntary Movement Scale (AIMS)|Change in Neurocognitive test battery","Augusta University|Ortho-McNeil Janssen Scientific Affairs, LLC","All","6 Years and older   (Child, Adult, Older Adult)","Phase 4","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIS-EMR-4026|MCG HAC File #01-09-063","November 2001","May 2007","May 2007","July 14, 2006",,"January 14, 2015","Medical College of Georgia, Dept. of Psychiatry, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00352196"
1214,"NCT00600717","Clinical Applications of High-Frequency Oscillations","HFOs","Enrolling by invitation","No Results Available","Healthy|Epilepsy|Migraine|Headache|Pain|Autism|Cerebral Palsy",,"epileptic foci","Children's Hospital Medical Center, Cincinnati|University of Cincinnati","All","6 Years to 18 Years   (Child, Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB 06-04-23; 2012-0866|2008-1439","November 1, 2006","July 1, 2022","July 1, 2022","January 25, 2008",,"August 2, 2021","MEG, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00600717"
1215,"NCT01166152","Development of a New Diagnosis and Intervention Method for Developmental Disorders","DIDD","Unknown status","No Results Available","Developmental Disabilities","Behavioral: social skills training","thermogram of head|view direction","Tokyo University of Agriculture and Technology|Ashiya University|Saitama Medical University","All","up to 50 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","TokyoUAT_21_11","August 2010","November 2011","March 2013","July 20, 2010",,"July 21, 2011","Ashiya University Graduate School of Clinical Education, Ashiya, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT01166152"
1216,"NCT02922400","Social Cognition Assessment in Young Adults",,"Completed","No Results Available","Cognitive Function 1, Social","Behavioral: Social Cognition Assessment and Training","Brain Activation Change: Social Cognitive Network|Change in Neuropsychological Scores: Recognizing Emotion|Change in Neuropsychological Scores: Theory of Mind|Change in Neuropsychological Scores: Social Behavior|Change in Neuropsychological Scores: Social Functioning","The University of Texas at Dallas|University of Texas Southwestern Medical Center|Yale University","All","17 Years to 40 Years   (Child, Adult)","Not Applicable","153","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STU 042011-021","November 2006","September 2016","January 2018","October 4, 2016",,"May 8, 2018","Center for BrainHealth University of Texas at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02922400"
1217,"NCT02680379","Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome","LovaMiX","Completed","No Results Available","Fragile X Syndrome","Drug: Minocycline, then Minocycline/Lovastatin|Drug: Lovastatin, then Minocycline/Lovastatin","Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks|Clinical Global Impression Scale improvement (CGI-I)|Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks|Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks|Behavior Rating Inventory of Executive Function (BRIEF)|Change from baseline Vineland II; adaptive behaviour scale at 20 weeks","Université de Sherbrooke|FRAXA Research Foundation","All","8 Years to 45 Years   (Child, Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-1177","March 2016","October 2017","November 2017","February 11, 2016",,"October 15, 2018","Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02680379"
1218,"NCT00879515","Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes",,"Completed","No Results Available","Anxiety Disorders|Child Developmental Disorders, Pervasive",,"Fear-potentiated startle reflex","University of California, Davis|National Institute of Mental Health (NIMH)","All","5 Years to 25 Years   (Child, Adult)",,"511","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","200210645|K23MH077554|DDTR B2-MBA","October 2005","September 2010","September 2010","April 10, 2009",,"May 30, 2017","M.I.N.D. Institute, University of California, Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00879515"
1219,"NCT01474746","Trial of Sertraline to Treat Children With Fragile X Syndrome",,"Completed","Has Results","Fragile X Syndrome","Drug: Sertraline|Drug: Placebo","Change in Mullen Scales of Early Learning - Expressive Language Raw Score|Clinical Global Impression - Improvement|Change in Mullen Scales of Early Learning - Expressive Language Standard T Score|Autism Diagnostic Observation Schedule|Visual Analog Scale|Eye Tracking|Preschool Language Scale-fifth Edition (PLS-5): AC+EC Total Raw Score|Sensory Processing Measure - Preschool (SPM-P) Social Participation: Raw Score|Sensory Profile - Sensation Seeking Subscale Raw Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) - Adaptive Behavior Composite Standard Score|Mullen Scales of Early Learning - Visual Reception Raw Score|Mullen Scales of Early Learning - Fine Motor Raw Score|The Autism Diagnostic Observation Schedule (ADOS-2)|The Visual Analog Scale|Sensory Processing Measure-Preschool (SPM-P) Social Participation: Raw Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score|Mullen Scales of Early Learning - Visual Reception Age-equivalent Score|Mullen Scales of Early Learning - Fine Motor Age-equivalent Score|Mullen Scales of Early Learning - Cognitive T Score Sum|Mullen Scales of Early Learning - Summary Age-equivalent Score","Randi J. Hagerman, MD|University of California, Davis","All","24 Months to 68 Months   (Child)","Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","271070|R40MC22641","January 2012","August 2015","September 2015","November 18, 2011","September 25, 2017","September 25, 2017","UC Davis M.I.N.D. Institute, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01474746"
1220,"NCT01867554","Research and Characterization of New Genes Involved in Intellectual Disability","GeneDefi","Recruiting","No Results Available","Intellectual Disability","Genetic: gene analysis","Number of participants with genetic cause identified|genotype-phenotype correlations","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"8500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C12-06|2012-A00936-37","December 2012","December 2022","December 2022","June 4, 2013",,"December 7, 2016","CRICM - UPMC/Inserm UMR_S975/CNRS UMR7225, Groupe Hospitalier de la Pitié-Salpêtrière,, Paris, France",,"https://ClinicalTrials.gov/show/NCT01867554"
1221,"NCT01777542","Treatment of Rett Syndrome With Recombinant Human IGF-1",,"Completed","Has Results","Rett Syndrome","Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Drug: Placebo","Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale|Anxiety, Depression, and Mood Scale (ADAMS) - Social Avoidance Subscale|Clinical Global Impression - Severity (CGI-S)|Clinical Global Impression - Improvement (CGI-I)|Parental Global Impression - Severity (PGI-S)|Parental Global Impression - Improvement (PGI-I)|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 1|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 2|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 3|Kerr Clinical Severity Scale|Rett Syndrome Behavior Questionnaire (RSBQ)|Anxiety, Depression, and Mood Scale (ADAMS)|Mullen Scales of Early Learning (MSEL)|Vineland Adaptive Behavior Scales, Second Edition (VABS-II)|Communication and Symbolic Behavior Scales - Developmental Profile (CSBS-DP)|Aberrant Behavior Checklist - Community Edition (ABC-C)|Quantitative Measures of Respiration: Apnea Index","Boston Children's Hospital|International Rett Syndrome Foundation","Female","2 Years to 10 Years   (Child)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB-P00005610","January 2013","July 2016","November 2016","January 29, 2013","March 26, 2018","March 26, 2018","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01777542"
1222,"NCT04668716","Brain Involvement in Dystrophinopathies Part 2",,"Not yet recruiting","No Results Available","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy",,"CNS Comorbidity Phenotyping","University College London Hospitals|Newcastle-upon-Tyne Hospitals NHS Trust|Leiden University Medical Center|Stichting Kempenhaeghe|Region Hovedstadens Apotek|Institut Necker Enfants Malades|Catholic University of the Sacred Heart|Università degli Studi di Ferrara|Universidad Complutense de Madrid","Male","5 Years to 50 Years   (Child, Adult)",,"270","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20NM35","December 2021","May 2024","May 2024","December 16, 2020",,"October 6, 2021",,,"https://ClinicalTrials.gov/show/NCT04668716"
1223,"NCT02715115","A Safety Study of NNZ-2566 in Pediatric Rett Syndrome",,"Completed","No Results Available","Rett Syndrome","Drug: NNZ-2566|Drug: Placebo","Adverse events|Motor Behaviour Assessment Scale (MBA)|Clinical Global Impression of Improvement (CGI-I)|Caregiver Top 3 Concerns via a Visual Analogue Scale (VAS)","Neuren Pharmaceuticals Limited|rettsyndrome.org","Female","5 Years to 15 Years   (Child)","Phase 2","82","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Neu-2566-RETT-002","March 2016","January 5, 2017","January 5, 2017","March 22, 2016",,"August 14, 2020","University of Alabama, Birmingham, Alabama, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of California, San Diego, San Diego, California, United States|Children's Hosptial Colorado, Aurora, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02715115"
1224,"NCT00205699","Metabolic Effects of Antipsychotics in Children","MEAC","Completed","Has Results","Aggression|Attention Deficit-Hyperactivity|Oppositional Defiant Disorder|Pervasive Development Disorders|Bipolar Disorder","Drug: risperidone|Drug: olanzapine|Drug: aripiprazole","Change in DEXA % Body Fat|Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)|Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)|Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)|Change in MRI-measured Visceral Abdominal Fat|Change in MRI-measured Subcutaneous Abdominal Fat","Washington University School of Medicine|National Institute of Mental Health (NIMH)","All","6 Years to 18 Years   (Child, Adult)","Phase 4","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NIMH|R01MH072912","April 2006","March 2011","July 2011","September 20, 2005","June 15, 2018","June 15, 2018","Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States","""Informed Consent Form: Child and Adult Consent"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_000.pdf|""Informed Consent Form: Genetics Consent"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT00205699"
1225,"NCT01703533","A Safety Study of NNZ-2566 in Patients With Rett Syndrome",,"Completed","No Results Available","Rett Syndrome","Drug: NNZ-2566|Drug: Placebo","Adverse events|Change in EEG activity|Behavior|Physiological changes|Global and Functional outcome Measures","Neuren Pharmaceuticals Limited|Baylor College of Medicine|International Rett Syndrome Foundation","Female","16 Years to 45 Years   (Child, Adult)","Phase 2","67","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Neu-2566-RETT-001","March 2013","September 2014","September 2014","October 10, 2012",,"February 5, 2018","University of Alabama, Birmingham, Alabama, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Baylor School of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01703533"
1226,"NCT04003207","Growth Hormone Treatment in Children With Phelan McDermid Syndrome",,"Completed","No Results Available","Phelan McDermid Syndrome","Drug: Recombinant human Growth hormone","ABC - Social Withdrawal subscale|Repetitive Behavior Scale-Revised (RBS-R)|The Sensory Profile|The Sensory Assessment for Neurodevelopmental Disorders (SAND)|Visual evoked potentials (VEP)|Change in Auditory event related potentials (AERP)","Swathi Sethuram|Icahn School of Medicine at Mount Sinai","All","2 Years to 12 Years   (Child)","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 18-2549","September 13, 2019","June 5, 2020","June 5, 2020","July 1, 2019",,"June 12, 2020","Seaver Autism Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04003207"
1227,"NCT02003170","Etiology and Early Diagnosis of Neurodevelopmental Disorders",,"Active, not recruiting","No Results Available","Neurodevelopmental Disorders",,"Medical abnormalities associated with specific neurodevelopmental disorders|Biomarkers associated with neurodevelopmental disorders|Treatments associated with neurodevelopmental disorders","University of Arkansas|Arkansas Children's Hospital Research Institute","All","up to 99 Years   (Child, Adult, Older Adult)",,"576","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","136272","May 2012","June 2022","June 2022","December 6, 2013",,"June 8, 2021","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02003170"
1228,"NCT04812119","Genotype-phenotype Correlations in Children and Adults With CTNNB1 Mutation","Gen-Phe CTNNB1","Recruiting","No Results Available","CTNNB1 Gene Mutation","Diagnostic Test: The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|Diagnostic Test: The Autism Spectrum Quotient-Children's Version (AQ-Child)|Diagnostic Test: The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|Diagnostic Test: The Viking's Speech Scale|Diagnostic Test: The Functional Communication Classification System (FCCS)|Diagnostic Test: Brief Infant Sleeping Questionnaire (BISQ)|Diagnostic Test: Pediatric Sleep Questionnaire (PSQ)|Diagnostic Test: The Eating and Drinking Ability Classification System (EDACS)|Diagnostic Test: Mini Manual Ability Classification System (Mini-MACS)|Diagnostic Test: Manual Ability Classification System (MACS)|Diagnostic Test: The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|Diagnostic Test: The Visual Function Classification System (VFCS)|Diagnostic Test: The Early Childhood Oral Health Impact Scale (ECOHIS)|Diagnostic Test: The Family Impact Scale (FIS)|Diagnostic Test: The Achenbach System of Empirically Based Assessment (ASEBA)|Diagnostic Test: Adaptive Behavior Assessment System Third Edition (ABAS-3)","Baseline comprehensive collection of medical, behavioral, learning, and developmental information of patients who have documented CTNNB1 gene changes.","University Medical Centre Ljubljana|University of Ljubljana, Faculty of Medicine|National Institute of Chemistry, Ljubljana, Slovenia|Children's Medical Research Institute, Westmead, Australia|The University of Sydney, Sydney, Australia","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","0120-80/2021/3","March 1, 2021","December 31, 2021","December 31, 2031","March 23, 2021",,"April 5, 2021","The University of Sydney, Sydney, Australia|Children's Medical Research Institute, Westmead, Australia|University Medical Centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04812119"
1229,"NCT01013545","Developmental and Augmented Intervention for Facilitating Expressive Language","CCNIA","Completed","No Results Available","Joint Engagement + Enhanced Milieu Training|Joint Engagement + Enhanced Milieu Training+Augmentative Communication (AAC)","Behavioral: JAE Intervention","Number of words used spontaneously during language sample","Autism Speaks|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Vanderbilt University|University of California, Los Angeles","All","5 Years to 8 Years   (Child)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","G09-04-013-01|5666","July 2009","July 2012","December 2012","November 13, 2009",,"July 11, 2013","University of California, Los Angeles, Los Angeles, California, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01013545"
1230,"NCT03858816","Efficacy of Multiple Strain Probiotics Reduces the Neurobehavioral Disorder in Premature Very Low Birth Weight Infants",,"Unknown status","No Results Available","Very Low Birth Weight Infants","Other: Mixture probiotics|Other: Placebo","Incidence rate of death or ADHD and ASD|Incidence rate of NEC ≧ stage 2, sepsis, severe (grade 3-4) IVH, BPD, liver function and adverse effects or intolerance and neurodevelopment impairment.","China Medical University Hospital","All","Child, Adult, Older Adult","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMUH106-REC2-102","June 14, 2018","June 30, 2020","June 30, 2021","March 1, 2019",,"March 6, 2019","Department of Pediatrics, Children Hospital, China Medical University, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03858816"
1231,"NCT00579267","Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)",,"Completed","No Results Available","Major Depression|Mania|Anxiety Disorders|Psychotic Disorder|Alcohol Dependence|Drug Dependence|Eating Disorders|Suicidality|Dysthymia|ADHD|Tourettes Disorder|Conduct Disorder|Oppositional Defiant Disorder|Pervasive Developmental Disorder","Other: MINI-KID","Kappa scores between MINI Kid and K-SADS","University of South Florida","All","6 Years to 17 Years   (Child)",,"230","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MINI-KID Validation Study","February 2004","January 2008","January 2008","December 24, 2007",,"February 16, 2009","University of South Florida College of Medicine, Department of Psychiatry, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00579267"
1232,"NCT00399698","Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.",,"Completed","No Results Available","Oppositional Defiant Disorder|Conduct Disorder|Attention Deficit/Hyperactivity Disorder (ADHD)|Intermittent Explosive Disorder|Impulse-Control Disorders|Adjustment Disorder|Bipolar Disorder|Pervasive Developmental Disorder","Drug: Risperdal","Short Term Recognition Memory task (accuracy)|Titrated Delayed Matching-to-Sample task (accuracy)|Continuous Performance task (omission errors)|Seat Activity|Graduated Holes task (errors and error times)","Ohio State University","All","4 Years to 14 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Diagnostic","1998H0298","May 1999",,"June 2005","November 15, 2006",,"June 23, 2016","Ohio State University Nisonger Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00399698"
1233,"NCT00597948","Healthy Lifestyles for People With Intellectual Disabilities","HLID","Completed","No Results Available","Mental Retardation|Developmental Disabilities|Intellectual Disabilities","Behavioral: Healthy Lifestyles Curriculum","Health Promoting Lifestyles Profile II|Body Mass Index (BMI)|waist circumference|Community Integration Questionnaire|Healthy Lifestyles Knowledge Test|Starting and Continuing Healthy Behaviors|Self-Efficacy and Social Support for Activity for Persons with Intellectual Disabilities|Living Well with a Disability Evaluation|General Health Survey|Healthy Lifestyles Goal Tracking Form","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","131","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R21HD055189-01","April 2007","January 2010","March 2010","January 18, 2008",,"February 27, 2012","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00597948"
1234,"NCT00919906","My Scrivener® - Measuring Effectiveness and Dose Response in Children",,"Completed","No Results Available","Asperger's Syndrome|Dyslexia|Cerebral Palsy|Attention Deficit Disorder|ADHD|Traumatic Brain Injury|Stroke","Device: My Scrivener(R)","Beery Motor Coordination Subtest|Print Tool and Cursive Tool|Deviations from desired 3-D writing path|Brief Assessment of Fine Motor Skills","Obslap Research LLC","All","5 Years to 19 Years   (Child, Adult)","Phase 1|Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","002|#H133S070082","April 2009","September 2010","September 2010","June 12, 2009",,"October 28, 2010","Susan Palsbo, Eugene, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00919906"
1235,"NCT03569631","A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome",,"Completed","No Results Available","Fragile X Syndrome|FXS|Fra(X) Syndrome","Drug: BPN14770|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","Tetra Discovery Partners","Male","18 Years to 45 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-203","July 9, 2018","July 31, 2020","July 31, 2020","June 26, 2018",,"December 3, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03569631"
1236,"NCT04922684","Can Mimic Emotional Expression Training Help Improve Emotion Processing",,"Recruiting","No Results Available","Healthy","Behavioral: Mimic facial expressions","Intensity score of subjects' mimic facial emotions|Valence score of subjects' mimic facial emotions|Arousal score of subjects' mimic facial emotions|Task-dependent functional MRI data","University of Electronic Science and Technology of China","Male","17 Years to 30 Years   (Child, Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UESTC-neuSCAN-66","March 30, 2020","December 30, 2021","March 30, 2022","June 11, 2021",,"June 11, 2021","University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04922684"
1237,"NCT00783783","CYP2D6 Pharmacogenetics in Risperidone-Treated Children",,"Completed","No Results Available","Psychiatric Disorders|Neurodevelopmental Disorders",,"association of common CYP2D6 polymorphisms with risperidone area under the curve","Children's Hospital Medical Center, Cincinnati|Ohio State University|Rainbow Babies and Children's Hospital","All","3 Years to 18 Years   (Child, Adult)",,"47","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008-0659|SPR104683","November 2008","June 2011","June 2011","November 2, 2008",,"December 11, 2012","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00783783"
1238,"NCT02694003","Better Nights, Better Days for Children With Neurodevelopment Disorders","BNBD-NDD","Active, not recruiting","No Results Available","Nonorganic Insomnia|Neurodevelopmental Disorders|Primary Insomnia","Behavioral: BNBD-NDD Intervention","Disorder of Initiating and Maintaining Sleep (DIMS) Score|Sleep Diary|Actigraphy|Child Behavior Checklist (CBCL) to assess Child Psychosocial Health|Pediatric Quality of Life (Peds-QL)|Single Item Fatigue Impact Scale (SIFIS) to assess Caregiver Fatigue|Parenting Scale (PS) to assess Parenting Practices|Depression Anxiety Stress Scale (DASS-21) to assess Caregiver Psychological Health","IWK Health Centre","All","4 Years to 12 Years   (Child)","Not Applicable","218","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1024081","June 10, 2019","January 2022","April 2022","February 29, 2016",,"September 22, 2021","Dalhousie University, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT02694003"
1239,"NCT03422367","JASPER Early Intervention for Tuberous Sclerosis","JETS","Recruiting","No Results Available","Tuberous Sclerosis","Behavioral: JASPER","ESCS (Early Social Communication Scales) Assessment.|Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine.|Structured Play Assessment (SPA)|SPA|Mullen Scales of Early Learning (MSEL)|Mullen|Social communication","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Boston Children's Hospital|Massachusetts General Hospital","All","6 Months to 40 Months   (Child)","Not Applicable","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB #17-000262|1R01HD090138-01A1","October 24, 2017","June 15, 2022","June 15, 2022","February 5, 2018",,"November 6, 2020","University of California Los Angeles, Los Angeles, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03422367"
1240,"NCT01289912","Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)","TSC","Completed","Has Results","Tuberous Sclerosis Complex","Drug: RAD001|Drug: Placebo","Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC.|Evaluation of the Efficacy of RAD001 on Neurocognition in Patients With TSC Compared With Placebo.|Evaluation of the Efficacy of RAD001 on Neurocognition (Cambridge Neuropsychological Test Automated Battery) in Patients With TSC Compared With Placebo.|Comparison of Absolute Change From Baseline in Frequency of Epileptiform Events Between Patients Taking RAD001 vs. Placebo|Comparison of Sleep Disturbances Between Patients Taking RAD001 vs. Placebo|Comparison of Autism Spectrum Disorders Features Between Patients Taking RAD001 vs. Placebo|Comparison of Academic Skills Between Patients Taking RAD001 vs. Placebo|Comparison of Behavioral Problems Between Patients Taking RAD001 vs Placebo","Mustafa Sahin|Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children's Hospital","All","6 Years to 21 Years   (Child, Adult)","Phase 2","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10-06-0247","January 2011","December 2014","December 2014","February 4, 2011","January 25, 2018","January 25, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01289912"
1241,"NCT02567357","Parents Resources for Decreasing the Incidence of Change Triggered Temper Outbursts","PREDICTORS","Completed","No Results Available","Child Behavior","Behavioral: Visual Scheduling|Behavioral: signalling change","Change in frequency of temper outbursts between baseline and intervention|Change in percentage of changes to routines/plans experienced by children that are followed by temper outbursts between baseline and intervention|Change in cost of services with which the child engages - Cost of Services Receipt Inventory|Process information on how the intervention strategies are being implemented by caregivers","Queen's University, Belfast|University of Warwick|University of Birmingham","All","7 Years to 16 Years   (Child)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R2149PSY","January 2015","May 2017","June 2017","October 5, 2015",,"February 17, 2020","Queen's University Belfast, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02567357"
1242,"NCT02991807","RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome",,"Active, not recruiting","No Results Available","PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome","Drug: RAD001|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Change in Working Memory at 6 Months|Change in Processing Speed at 6 Months|Change in Fine Motor Skills at 6 Months|Change in Attention at 6 Months|Change in Impulsivity at 6 Months|Change in Global Cognitive Ability at 6 Months|Change in Motor Functioning at 6 Months|Change in Communication Ability at 6 Months","Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 45 Years   (Child, Adult)","Phase 1|Phase 2","40","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB-P00020332|1U54NS092090","June 12, 2017","September 2021","December 2021","December 14, 2016",,"February 4, 2021","Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02991807"
1243,"NCT02792894","Family Networks (FaNs) for Children With Developmental Disorders and Delays","FaNs","Completed","No Results Available","Neurodevelopmental Disorders|Developmental Disabilities","Behavioral: Family networks program","Developmental Disorders- Children Disability Assessment Schedule (DD-CDAS)|Caregiver-Child Interaction|Strengths and Difficulties Questionnaire (SDQ)|Family Empowerment Scale (FES)|Inventory of Stigmatizing Experiences (Family version)|Pediatric Quality of Life (PedsQL) family impact module|Client Services Receipt Inventory (CSRI)|Clinical Global Impression (CGI)","Human Development Research Foundation, Pakistan|Grand Challenges Canada|Autism Speaks|World Health Organization|Institute of Psychiatry, Benazir Bhutto Hospital, Rawalpindi, Pakistan|University of Liverpool","All","2 Years to 12 Years   (Child)","Not Applicable","540","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","746-05","April 2016","December 2017","April 2018","June 8, 2016",,"January 27, 2021","Human Development Research Foundation, Gujar Khan, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT02792894"
1244,"NCT03694275","A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)",,"Completed","Has Results","15q Duplication Syndrome|CDKL5 Deficiency Disease","Drug: Soticlestat","Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period|Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Treatment Period|Percentage of Participants Considered as Treatment Responders During the Maintenance Period|Percent Change From Baseline in Frequency of Motor Seizures Longer Than 5 Minutes in Participants With CDD|Proportion of Motor Seizure-free Days in Participants During the Maintenance Period|Change From Baseline in Clinician's Global Impression of Severity (CGI-S) Responses of Investigator|Percentage of Participants With Clinical Global Impression of Change (CGI-C) Responses as Per the Investigator Reported Impression|Percentage of Participants With Care Clinical Global Impression of Change (CGI-C) Responses of Parent/Family|Change From Baseline of Plasma 24S-hydroxycholesterol (24HC) Levels|Change From Baseline in Seizure Frequency in Participants Treated With TAK-935 as an Adjunctive Therapy","Takeda|Ovid Therapeutics Inc.","All","2 Years to 55 Years   (Child, Adult)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-935-18-002 (OV935)|U1111-1219-5787","September 10, 2018","July 13, 2020","July 31, 2020","October 3, 2018","April 20, 2021","April 20, 2021","UCLA, Los Angeles, California, United States|Research Institute Children's Hospital Colorado, Aurora, Colorado, United States|Center for Rare Neurological Diseases, Norcross, Georgia, United States|Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital Translational Neuroscience Center, Boston, Massachusetts, United States|Minnesota Epilepsy Group, P.A., Saint Paul, Minnesota, United States|New York University (NYU), New York, New York, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03694275"
1245,"NCT01741051","A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community",,"Completed","No Results Available","Fetal Growth Restriction","Device: HEPA Filter","Gestational-age adjusted birthweight|Birthweight|Gestational age|Head circumference|Small for gestational age|Birth length|Child body mass index|Child wheeze|Child behavioural development|Child neurocognitive development|Child social development|Blood pressure|C-reactive protein|Stratified Analyses","Simon Fraser University|Canadian Institutes of Health Research (CIHR)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","540","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","275997","January 2014","December 2019","December 2019","December 4, 2012",,"January 23, 2020","Mongolia National University of Medical Sciences, Ulaanbaatar, Mongolia",,"https://ClinicalTrials.gov/show/NCT01741051"
1246,"NCT01329770","Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome","SXF-TRA152","Completed","No Results Available","Fragile X Syndrome","Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|Dietary Supplement: Placebo","Changes in the baseline Conner's Parent and Teacher Scales at 12 and 24 weeks|Change in the baseline measure of the Inventory of behaviour development (DBC-P24) at 12 and 24 weeks|Wechsler Intelligence Scale for children|Composite measure of blood and urine.","Yolanda de Diego Otero|The Mediterranean Institute for the Advance of Biotechnology and Health Research","Male","6 Years to 18 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-017837-23","December 2010","April 2015","April 2015","April 6, 2011",,"April 14, 2015","Psychiatric Service. Hospital Carlos Haya, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT01329770"
1247,"NCT00305305","Brain Development Research Program",,"Recruiting","No Results Available","Brain Disorders|Aicardi Syndrome",,,"University of California, San Francisco|University of Washington|California Institute of Technology","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UCSF-PCRC #2206","August 2003","January 2025","January 2025","March 21, 2006",,"June 10, 2021","University of California, San francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00305305"
1248,"NCT00161109","Genetics and Psychopathology in the 22q11 Deletion Syndrome",,"Unknown status","No Results Available","Chromosome 22q11.2 Deletion Syndrome",,,"UMC Utrecht|Netherlands Brain Foundation|Children's Hospital of Philadelphia","All","8 Years to 20 Years   (Child, Adult)",,"175","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","P03.0377C","October 2002",,"October 2012","September 12, 2005",,"October 13, 2006","Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry, Philadelphia, Pennsylvania, United States|UMC Utrecht, Dpt of Child and Adolescent Psychiatry, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00161109"
1249,"NCT03218462","Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities",,"Completed","No Results Available","Developmental Disability|Intellectual Disability|Dental Anxiety","Behavioral: Sensory Adapted Dental Environment (SADE)","Behavior during initial dental exam|Behavior during recall exam|Physiologic outcomes (oxygen saturation) during initial exam|Physiologic outcomes (oxygen saturation) during recall exam|Physiologic outcomes (hearts rate) during initial exam|Patient cooperation during initial exam|Patient cooperation during recall exam","Virginia Commonwealth University","All","6 Years to 21 Years   (Child, Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HM20009272","July 10, 2017","March 30, 2018","March 30, 2018","July 14, 2017",,"April 18, 2018","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03218462"
1250,"NCT04665453","Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children","MeloDex","Recruiting","No Results Available","Electroencephalography|Child|Dexmedetomidine|Melatonin|Sleep|Epilepsy","Diagnostic Test: Electroencephalography|Diagnostic Test: Monitoring of vital functions|Drug: Melatonin 0,1mg/kg oral syrup|Drug: Dexmedetomidine 3 mcg/kg sublingually|Drug: Dexmedetomidine 3 mcg/kg intranasally","Comparison of the three medical interventions on sleep initiation|Comparison of the three medical interventions on the depth of sleep and the most prominent sleep stage on EEG|Comparison of the three medical interventions on respiratory rate|Comparison of the three medical interventions on heart rate|Comparison of the three medical interventions on oxygene saturation|Comparison of the three medical interventions on blood pressure","University Medical Centre Ljubljana","All","1 Year to 20 Years   (Child, Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0120-597/2019/16","September 1, 2020","December 31, 2021","December 31, 2021","December 11, 2020",,"December 16, 2020","University Medical Centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04665453"
1251,"NCT04979182","Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders","MONOGENETND","Recruiting","No Results Available","Neurodevelopmental Disorders",,"Study of clinical profiles associated to different monogenic form of NDD","University Hospital, Strasbourg, France","All","4 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","8209","May 15, 2021","March 2024","May 2024","July 28, 2021",,"July 28, 2021","Service de Génétique Moléculaire Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04979182"
1252,"NCT01906866","Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities",,"Completed","Has Results","Sleep Disorders","Drug: Circadin 2/5/10 mg|Drug: Placebo","The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.|Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of Wake After Sleep Onset Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Number of Awakenings During the Night Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of the Longest Sleep Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Children's Social Functioning at Home, in School, and Community Settings Will be Measured for the Circadin 2/5 mg and Placebo by the Children Global Assessment Scale (CGAS) Questionnaire After 13 Weeks of Double-blind Treatment.|The Children's Behavior at Home, in School, and Community Will be Measured for the Circadin 2/5 mg and Placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire Filled Out by the Parents After 13 Weeks of Double-blind Treatment.|The Number of Dropouts Between Circadin 2/5 mg to That of Placebo Will be Compared During the 13 Weeks of Double-blind Treatment.|Sleep Parameters (Rest/Activity Cycles) Will be Measured for the Circadin 2/5 mg and Placebo as Measured by Actigraphy After 13 Weeks of Double-blind Treatment.|Safety and Tolerability Throughout the Study Will be Measured for the Circadin 2/5 mg and Placebo Throughout the Study Using AE Eliciting Method Treatment Emergent Signs and Symptoms (TESS)|The Following Vital Signs Will be Measured: Blood Pressure, Pulse, Breathing and Body Temperature. They Will be Compared Between the Circadin and Placebo Groups.","Neurim Pharmaceuticals Ltd.","All","2 Years to 17 Years   (Child)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NEU_CH_7911","October 2013","March 27, 2018","March 27, 2018","July 24, 2013","October 30, 2018","May 21, 2019","Southwest Autism Research and Resource Center (SARRC), Phoenix, Arizona, United States|Crystal BioMedical Research, LLC, Miami Lakes, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Mate Lazlo, West Palm Beach, Florida, United States|Attalla Consultants LLC, dba Institue for Behabiovral medicine, Smyrna, Georgia, United States|AMR Baber research INC, Naperville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Child Neurology Specialists/ CRCN, Henderson, Nevada, United States|Clinical research center of New Jersey, LLC, Voorhees, New Jersey, United States|Geinsinger Clinic, Danville, Pennsylvania, United States|The children's hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|INSITE Clinical Research, DeSoto, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Sleep Therapy & Research Center, San Antonio, Texas, United States|Road Runner Research, Ltd, San Antonio, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|Pacific institute of medical science, Bothell, Washington, United States|Helsinki Sleep Clinic Vitalmed OY, Helsinki, Finland|Hospital Raymond Poincare, Garches, France|Strasbourg University Hospital Depatment of Child Psychiatry & Neurology, Strasbourg,, France|Yulius Mental Health Organization, Dordrecht, Netherlands|Hospital Gelderse Vallei, Ede, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Birmingham Childrens Hospital NHS FOUNDATION TRUST, Birmingham, United Kingdom|Blackpool Victoria Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital, London, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT01906866"
